{"data": [{"Element": "<div class=\"WordSection1\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX I</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image001.gif\" width=\"21\"/>This medicinal product is subject to additional monitoring.\nThis will allow quick identification of new safety information. Healthcare\nprofessionals are asked to report any suspected adverse reactions. See\nsection\u00a04.8\u00a0for how to report adverse reactions.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nconcentrate for solution for infusion.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">One vial of\u00a04\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">One vial of\u00a010\u00a0mL contains\u00a0100\u00a0mg\nof nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is produced in Chinese hamster\novary cells by recombinant DNA technology.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipient\nwith known effect</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a00.1\u00a0mmol\n(or\u00a02.5\u00a0mg) sodium.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Concentrate for solution for infusion\n(sterile concentrate).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Clear to opalescent, colourless to pale\nyellow liquid that may contain few light particles. The solution has a pH of approximately\u00a06.0\nand an osmolality of approximately\u00a0340\u00a0mOsm/kg.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is indicated for the\ntreatment of locally advanced or metastatic squamous non-small cell lung cancer\n(NSCLC) after prior chemotherapy</span><span lang=\"EN-GB\" style=\"color:black;\nbackground:white\"> in adults</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and\nmethod of administration</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Treatment must be initiated and\nsupervised by physicians experienced in the treatment of cancer.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The recommended dose of Nivolumab\u00a0BMS\nis\u00a03\u00a0mg/kg administered intravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks.\nTreatment should be continued as long as clinical benefit is observed or until treatment\nis no longer tolerated by the patient. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Dose escalation or reduction is not\nrecommended. Dosing delay or discontinuation may be required based on\nindividual safety and tolerability. </span><span lang=\"EN-GB\">Guidelines for\npermanent discontinuation or withholding of doses are described in\nTable\u00a01. Detailed guidelines for the management of immune\u2011related\nadverse reactions are described in section\u00a04.4.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<thead>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\"><span lang=\"EN-GB\">Immune-related adverse reaction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Severity</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Treatment modification</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related pneumonitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related colitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related hepatitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Immune</span><span lang=\"EN-GB\">\u2011</span><span lang=\"FR-BE\">related rash</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a03 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\">Withhold dose until symptoms resolve and management\n  with corticosteroids is complete</p>\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a04 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Permanently discontinue </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Note: Toxicity grades are in accordance\nwith National Cancer Institute Common Terminology Criteria for Adverse Events\nVersion\u00a04.0\u00a0(NCI\u2011CTCAE v4).</span></p>\n<p align=\"left\" class=\"BMSBodyText\" style=\"margin-bottom:0in;text-align:left;\nline-height:normal\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendation for the\nuse of hormone replacement therapy is provided in section 4.4.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS should also be\npermanently discontinued for Grade\u00a02\u00a0or\u00a03\u00a0immune\u2011related\nadverse reactions that persist despite treatment modifications (see\nsection\u00a04.4) or for inability to reduce corticosteroid dose\nto\u00a010\u00a0mg prednisone or equivalent per day.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patients treated with Nivolumab\u00a0BMS\nmust be given the patient alert card and be informed about the risks of\nNivolumab\u00a0BMS (see also package leaflet).</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of\nNivolumab\u00a0BMS in children below\u00a018\u00a0years of age have not been\nestablished. No data are available.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly\n</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dose adjustment is required for elderly\npatients (\u2265\u00a065\u00a0years) (see sections\u00a05.1 and\u00a05.2). Data\nfrom patients 75\u00a0years of age or older are too limited to draw conclusions\non this population.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\nimpairment</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on the population pharmacokinetic\n(PK) results, no dose adjustment is required in patients with mild or moderate renal\nimpairment (see section\u00a05.2). Data from patients with severe renal\nimpairment are too limited to draw conclusions on this population.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic\nimpairment</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on the population PK results, no\ndose adjustment is required in patients with mild hepatic impairment (see\nsection\u00a05.2). </span><span lang=\"EN-GB\">Data from patients with moderate or\nsevere hepatic impairment are too limited to draw conclusions on these\npopulations. </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\" style=\"font-size:11.5pt\"> must be administered with caution in patients with\nmoderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0the\nupper limit of normal [ULN] and any AST) or severe (total\nbilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN and any AST) hepatic\nimpairment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Method\nof administration </span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is for intravenous\nuse only. It is to be administered as an intravenous infusion over a period of\u00a060\u00a0minutes.\nThe infusion must be administered through a sterile, non\u2011pyrogenic, low\nprotein binding in\u2011line filter with a pore size of\u00a00.2\u20111.2\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">m.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS must not be\nadministered as an intravenous push or bolus injection.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The total dose of Nivolumab\u00a0BMS required\ncan be infused directly as a\u00a010\u00a0mg/mL solution or can be diluted to\nas low as\u00a01\u00a0mg/mL with sodium chloride\u00a09\u00a0mg/mL (0.9%)\nsolution for injection or\u00a0glucose 50\u00a0mg/mL (5%) solution for\ninjection. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For instructions on the handling of the\nmedicinal product before administration, see section\u00a06.6.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Hypersensitivity to the active substance\nor to any of the excipients listed in section\u00a06.1.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is associated with immune\u2011related\nadverse reactions. Patients should be monitored continuously (at least up to\n5\u00a0months after the last dose) as an adverse reaction with nivolumab may\noccur at any time during or after discontinuation of nivolumab therapy. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For suspected immune-related adverse\nreactions, adequate evaluation should be performed to confirm aetiology or\nexclude other causes. Based on the severity of the adverse reaction, nivolumab\nshould be withheld and corticosteroids administered. If immunosuppression with\ncorticosteroids is used to treat an adverse reaction, a taper of at\nleast\u00a01\u00a0month duration should be initiated upon improvement. Rapid\ntapering may lead to worsening of the adverse reaction. Non\u2011corticosteroid\nimmunosuppressive therapy should be added if there is worsening or no\nimprovement despite corticosteroid use. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab should not be resumed while\nthe patient is receiving immunosuppressive doses of corticosteroids or other\nimmunosuppressive therapy. Prophylactic antibiotics should be used to prevent\nopportunistic infections in patients receiving immunosuppressive therapy.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab must be permanently discontinued\nfor any severe immune related adverse reaction that recurs and for any life\nthreatening immune related adverse reaction.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\npneumonitis</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe pneumonitis or interstitial lung\ndisease, including fatal cases, has been observed with nivolumab treatment (see\nsection\u00a04.8). Patients should be monitored for signs and symptoms of\npneumonitis such as radiographic changes (e.g., focal ground glass opacities,\npatchy filtrates), dyspnoea, and hypoxia. Infectious and disease\u2011related\naetiologies should be ruled out.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0pneumonitis, nivolumab must be permanently\ndiscontinued, and corticosteroids should be initiated at a dose\nof\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone equivalents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0(symptomatic)\npneumonitis, nivolumab should be withheld and corticosteroids initiated at a\ndose of\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement,\nnivolumab may be resumed after corticosteroid taper. If worsening or no\nimprovement occurs despite initiation of corticosteroids, corticosteroid dose\nshould be increased to\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone\nequivalents and nivolumab must be permanently discontinued.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe diarrhoea or colitis has been\nobserved with nivolumab treatment (see section\u00a04.8). Patients should be monitored\nfor diarrhoea and additional symptoms of colitis, such as abdominal pain and\nmucus or blood in stool. Infectious and disease\u2011related aetiologies\nshould be ruled out. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a04\u00a0diarrhoea or\ncolitis, nivolumab must be permanently discontinued, and corticosteroids should\nbe initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a03\u00a0diarrhoea or\ncolitis, nivolumab should be withheld and corticosteroids initiated at a dose\nof\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, nivolumab must\nbe permanently discontinued.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0diarrhoea or\ncolitis, nivolumab should be withheld. Persistent diarrhoea or colitis should\nbe managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe hepatitis has been observed with\nnivolumab treatment. Patients should be monitored for signs and symptoms of\nhepatitis such as transaminase and total bilirubin elevations. Infectious and\ndisease\u2011related aetiologies should be ruled out.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0transaminase or total bilirubin elevation, nivolumab\nmust be permanently discontinued, and corticosteroids should be initiated at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0transaminase or\ntotal bilirubin elevation, nivolumab should be withheld. Persistent elevations\nin these laboratory values should be managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nnephritis or renal dysfunction</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe nephritis or renal dysfunction\nhas been observed with nivolumab treatment (see section\u00a04.8). Patients\nshould be monitored for signs and symptoms of nephritis and renal dysfunction.\nMost patients present with asymptomatic increases in serum creatinine. Disease\u2011related\naetiologies should be ruled out.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a04\u00a0serum creatinine\nelevation, nivolumab must be permanently discontinued, and corticosteroids\nshould be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a02\u00a0or\u00a03\u00a0serum creatinine elevation, nivolumab should\nbe withheld, and corticosteroids should be initiated at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, corticosteroid\ndose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents, and nivolumab must be permanently discontinued.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nendocrinopathies</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe endocrinopathies, including\nhypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes\nmellitus, and diabetic ketoacidosis have been observed with nivolumab treatment.\n</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\">Patients should be monitored for clinical signs and\nsymptoms of endocrinopathies and for changes in thyroid function (at the start\nof treatment, periodically during treatment, and as indicated based on clinical\nevaluation). Patients may present with fatigue, headache, mental status\nchanges, abdominal pain, unusual bowel habits, and hypotension, or nonspecific\nsymptoms which may resemble other causes such as brain metastasis or underlying\ndisease. Unless an alternate etiology has been identified, signs or symptoms of\nendocrinopathies should be considered immune-related.</p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic hypothyroidism,\nnivolumab should be withheld, and thyroid hormone replacement should be\ninitiated as needed. For symptomatic hyperthyroidism, nivolumab should be\nwithheld and methimazole should be initiated as needed. Corticosteroids at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents\nshould also be considered if acute inflammation of the thyroid is suspected.\nUpon improvement, nivolumab may be resumed after corticosteroid taper, if\nneeded. Monitoring of thyroid function should continue to ensure appropriate\nhormone replacement is utilised.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic adrenal insufficiency,\nnivolumab should be withheld, and physiologic corticosteroid replacement should\nbe initiated as needed. Monitoring of adrenal function and hormone levels\nshould continue to ensure appropriate corticosteroid replacement is utilised.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic hypophysitis, nivolumab\nshould be withheld, and hormone replacement should be initiated as needed.\nCorticosteroids at a dose of 1\u00a0to 2\u00a0mg/kg/day methylprednisolone\nequivalents should also be considered if acute inflammation of the pituitary\ngland is suspected. Upon improvement, nivolumab may be resumed after\ncorticosteroid taper, if needed. Monitoring of pituitary function and hormone\nlevels should continue to ensure appropriate hormone replacement is utilised.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic diabetes, nivolumab\nshould be withheld, and insulin replacement should be initiated as needed.\nMonitoring of blood sugar should continue to ensure appropriate insulin\nreplacement is utilised. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Immune-related rash</span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Severe\nrash has been observed with nivolumab treatment that may be immune-related (see\nsection\u00a04.8). Nivolumab should be withheld for Grade\u00a03 rash and\ndiscontinued for Grade\u00a04 rash. Severe rash should be managed with\nhigh-dose corticosteroid at a dose of 1\u00a0to 2\u00a0mg/kg/day prednisone\nequivalents. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\">Caution should be used when considering the use of nivolumab\nin a patient who has previously experienced a severe or life-threatening skin\nadverse reaction on prior treatment with other immune-stimulatory anticancer\nagents.</p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Other\nimmune\u2011related adverse reactions</span></u></p>\n<p class=\"BMSBodyText\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following immune-related adverse\nreactions were reported in less than 1% of patients treated with nivolumab in\nclinical trials across doses and tumour types: pancreatitis, uveitis,\ndemyelination, autoimmune neuropathy (including facial and abducens nerve\nparesis), Guillain\u2011Barr\u00e9 syndrome, hypopituitarism, and</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">myasthenic\nsyndrome</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For suspected immune\u2011related\nadverse reactions, adequate evaluation should be performed to confirm aetiology\nor exclude other causes. Based on the severity of the adverse reaction,\nnivolumab should be withheld and corticosteroids administered. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. Nivolumab\nmust be permanently discontinued for any severe immune\u2011related adverse\nreaction that recurs and for any life\u2011threatening immune\u2011related\nadverse reaction.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe infusion reactions have been\nreported in clinical trials (see section\u00a04.8). In case of a severe\ninfusion reaction, nivolumab infusion must be discontinued and appropriate medical\ntherapy administered. Patients with mild or moderate infusion reaction may\nreceive nivolumab with close monitoring.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations </span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patients with a baseline performance\nscore\u00a0\u2265\u00a02, active brain metastases or autoimmune disease,\nsymptomatic interstitial lung disease, and patients who had been receiving\nsystemic immunosuppressants prior to study entry were excluded from the clinical\ntrials of NSCLC (see sections 4.5 and\u00a05.1).</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">In the absence of data, nivolumab should be used with caution in\nthese populations after careful consideration of the potential risk-benefit on\nan individual basis.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients\non controlled sodium diet</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of this medicinal product\ncontains\u00a00.1\u00a0mmol (or\u00a02.5\u00a0mg) sodium. To be taken into\nconsideration when treating patients on a controlled sodium diet.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patient Alert Card</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">All prescribers of Nivolumab\u00a0BMS\nmust be familiar with the Physician Information and Management Guidelines. The\nprescriber must discuss the risks of Nivolumab\u00a0BMS therapy with the\npatient. The patient will be provided with the Patient Alert Card with each\nprescription.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is a human monoclonal\nantibody,</span><span lang=\"EN-GB\"> as such pharmacokinetic interaction studies\nhave not been conducted. As monoclonal antibodies are not metabolised by\ncytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or\ninduction of these enzymes by co\u2011administered medicinal products is not\nanticipated to affect the pharmacokinetics of nivolumab. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Other\nforms of interaction </span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Systemic\nimmunosuppression</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The use of systemic corticosteroids and\nother immunosuppressants at baseline, before starting nivolumab, should be\navoided because of their potential interference with the pharmacodynamic\nactivity. However, systemic corticosteroids and other immunosuppressants can be\nused after starting nivolumab to treat immune\u2011related adverse reactions.\nThe preliminary results show that systemic immunosuppression after starting\nnivolumab treatment does not appear to preclude the response on nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There are no data on the use of\nnivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity\n(see section\u00a05.3). Human IgG4 is known to cross the placental barrier and\nnivolumab is an IgG4; therefore nivolumab has the potential to be transmitted\nfrom the mother to the developing foetus. Nivolumab is not recommended during\npregnancy and in women of childbearing potential not using effective contraception\n</span><span lang=\"EN-GB\">unless the clinical benefit outweighs the potential\nrisk</span><span lang=\"EN-GB\">. Effective contraception should be used for at\nleast 5\u00a0months following the last dose of Nivolumab\u00a0BMS.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether nivolumab is\nsecreted in human milk. </span><span lang=\"EN-GB\" style=\"color:black\">Because many\nmedicinal products, including antibodies, can be secreted in human milk, a</span><span lang=\"EN-GB\"> risk to the ne</span><span lang=\"EN-GB\">wborns/infants cannot be\nexcluded. A decision must be made whether to discontinue breast\u2011feeding\nor to discontinue from nivolumab therapy taking into account the benefit of breast\u2011feeding\nfor the child and the benefit of therapy for the woman.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies to evaluate the effect of\nnivolumab on fertility have not been performed. Thus, the effect of nivolumab\non male and female fertility is unknown.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on\nability to drive and use machines</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\nnivolumab is unlikely to affect the ability to drive and use machines. Because\nof potential adverse reactions such as fatigue (see section\u00a04.8), patients\nshould be advised to use caution when driving or operating machinery until they\nare certain that nivolumab does not adversely affect them.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable\neffects</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is most commonly associated\nwith immune-related adverse reactions. Most of these, including severe\nreactions, resolved following initiation of appropriate medical therapy or\nwithdrawal of nivolumab (see \u201cDescription of selected adverse\nreactions\u201d below).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In the pooled dataset of two studies in squamous\nNSCLC (CA209017 and CA209063), the most frequent adverse reactions\n(\u2265\u00a010%\u00a0of patients) were fatigue (33%), decreased appetite\n(15%), and nausea (12%). </span><span lang=\"EN-GB\">The majority of adverse\nreactions were mild to moderate (Grade\u00a01\u00a0or\u00a02)</span><span lang=\"EN-GB\">. </span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nsummary of adverse reactions</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions reported in the pooled\ndataset (n=248) of CA209017 and CA209063 are presented in Table\u00a02. These\nreactions are presented by system organ class and by frequency. Frequencies are\ndefined as: very common (\u2265\u00a01/10); common (\u2265\u00a01/100\u00a0to\u00a0&lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000\u00a0to\u00a0&lt;\u00a01/100);\nrare\u00a0(\u2265\u00a01/10,000\u00a0to\u00a0&lt;\u00a01/1,000); very\nrare\u00a0(&lt;\u00a01/10,000). </span><span lang=\"EN-GB\">Within each frequency\ngrouping, adverse reactions are presented in the order of decreasing\nseriousness.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:467.8pt;margin-left:5.4pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"height:29.4pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:29.4pt\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n  2: </span></b><b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span></p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\">a</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Musculoskeletal\npain is a composite term which includes back pain, bone pain, musculoskeletal\nchest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity,\npain in jaw, spinal pain.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\">b</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Frequencies\nreflect the proportion of patients who experienced a worsening from baseline in\nlaboratory measurements. See \u201cDescription of selected adverse reactions;\nlaboratory abnormalities\u201d below.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Data for the following immune\u2011related\nadverse reactions are based on patients who received\nnivolumab\u00a03\u00a0mg/kg in two NSCLC studies (CA209017 and CA209063, see\nsection\u00a05.1). The management guidelines for these adverse reactions are\ndescribed in section\u00a04.4.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune-related\npneumonitis</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof pneumonitis, including interstitial lung disease, was 5.2%\u00a0(13/248).\nGrade 2\u00a0and Grade\u00a03 cases were reported in 2.8% (7/248) and 1.6% (4/248)\nof patients, respectively. No Grade\u00a04 or\u00a05 cases reported in these\nstudies. In the phase 1 study MDX1106-03, pneumonitis, including a Grade 4 case\nin 1 patient, was reported in 3/37 patients (8.1%) with NSCLC receiving\nnivolumab </span><span lang=\"EN-GB\">3\u00a0mg/kg.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 11.6\u00a0weeks\n(range: 2.6-85.1). Eleven patients received high-dose corticosteroids (at least\n40\u00a0mg prednisone equivalents) at a median initial dose of 1.1\u00a0mg/kg\n(range:\u00a00.5-4.0) for a median total duration of 4.3 weeks (range:\u00a00.6-13.1).\nEight patients, including the 4 patients with a Grade 3 case, required\npermanent discontinuation of nivolumab due to pneumonitis. Resolution occurred\nin all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof diarrhoea or colitis was\u00a09.3% (23/248). Grade\u00a02 and Grade\u00a03\u00a0cases\nwere reported in\u00a02% (5/248) and 1.6% (4/248)\u00a0of patients,\nrespectively. No Grade\u00a04\u00a0or\u00a05\u00a0cases were reported in these\nstudies.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was\u00a05.6\u00a0weeks\n(range:\u00a00.1\u201191.0). Three patients, </span><span lang=\"EN-GB\">including\u00a02\u00a0patients\nwith a Grade\u00a03\u00a0case,</span><span lang=\"EN-GB\"> received high\u2011dose\ncorticosteroids (at least\u00a040\u00a0mg prednisone equivalents) at a median\ninitial dose of 0.6\u00a0mg/kg (range: 0.4-1.3) for a median duration of 2.0\u00a0weeks\n(range: 1.4-14.1). One patient required permanent discontinuation of nivolumab\ndue to Grade 3 diarrhoea. Resolution occurred in 19\u00a0patients (83%) with a\nmedian time to resolution of 2.0\u00a0weeks (range:\u00a00.1\u201131.0).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof liver function test abnormalities was 1.2% (3/248). Grade\u00a02 cases were\nreported in 0.4% (1/248) of patients. No Grade\u00a03-5 cases were reported in\nthese studies. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 25.1 weeks\n(range: 4.1-31.1). None of these patients received high-dose corticosteroids. One\npatient required permanent discontinuation of nivolumab due to Grade 2 increases\nin transaminases. Resolution occurred in 2\u00a0patients (67%) with a median\ntime to resolution of 4.1\u00a0weeks (range:\u00a02.9\u201122.3<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>\n<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\nnephritis and renal dysfunction</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof nephritis or renal dysfunction was 3.2%\u00a0(8/248). Grade\u00a02 and Grade\u00a03\ncases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively.\nNo Grade\u00a04\u00a0or\u00a05 nephritis or renal dysfunction was reported in\nthese studies.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was\u00a010.5 weeks\n(range:\u00a02.1\u201127.0). Two patients, including the one patient with a Grade\u00a03\u00a0case\n(tubulointerstitial nephritis), received high\u2011dose corticosteroids (at\nleast 40\u00a0mg prednisone equivalents) at a median initial dose of 0.8\u00a0mg/kg\n(range: 0.5-1.2) for a median duration of 5.3\u00a0weeks (range: 0.9-9.7).\nResolution occurred in 5 patients (71%), including the Grade\u00a03 case, with\na median time to resolution of 5.9\u00a0weeks (range: 0.7- 37.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune-related\nendocrinopathies</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof thyroid disorders, including hypothyroidism or thyroiditis, was\u00a04.4%\u00a0(11/248).\nGrade\u00a02 cases were reported in 3.6% (9/248) of patients. No Grade 3\u20115\nthyroid disorders were reported. The incidence of adrenal insufficiency was 0.4%\n(1/248; Grade\u00a03). There were no reports of hypophysitis, diabetes\nmellitus, or diabetic ketoacidosis in these studies.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset of these\nendocrinopathies was\u00a017.8\u00a0weeks (range: 6.1\u201133.1). Three\npatients, including the one patient with Grade\u00a03 adrenal insufficiency,\nreceived high\u2011dose corticosteroids (at least 40\u00a0mg prednisone\nequivalents) at a median initial dose of 1.1\u00a0mg/kg (range: 0.5-1.3) for 2.7\u00a0weeks\n(range: 0.6-4.6). The Grade\u00a03 case required permanent discontinuation of\nnivolumab. Resolution occurred in 6\u00a0patients (50%) with a median time to\nresolution of 20.6\u00a0weeks (0.4-47.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\">Immune-related rash </span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof rash was 12.1%\u00a0(30/248). Grade\u00a02 and Grade\u00a03 cases were\nreported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively. No\nGrade\u00a04\u00a0or\u00a05 rash was reported in these studies.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 8.1\u00a0weeks\n(range:\u00a00.3\u201151.9). None of these patients received high-dose\ncorticosteroids. Two patients (1 with Grade\u00a02 rash and 1 with Grade\u00a03\nrash) required permanent discontinuation of nivolumab. Resolution occurred in\n24\u00a0patients (83%), including the 2\u00a0patients with a Grade\u00a03 case,\nwith a median time to resolution of 5.7\u00a0weeks (range: 0.1- 46.9<sup>+</sup>);\n<span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>\n<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nreactions</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof hypersensitivity/infusion reactions was 1.6% (4/248). Grade\u00a03\nanaphylactic reaction and Grade\u00a04 hypersensitivity were each reported in 1\u00a0patient;\nboth of these cases led to discontinuation and resolved with treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Laboratory\nabnormalities</span></u></i></p>\n<p align=\"left\" class=\"BMSBodyText\" style=\"margin-bottom:0in;text-align:left;\nline-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">In\nCA209017 and CA209063, the proportion of patients who experienced a shift from\nbaseline to a Grade\u00a03\u00a0or\u00a04 laboratory abnormality was as\nfollows: 13.2% for decreased lymphocytes, 9% for hyponatraemia, 2.9% for\nhypercalcaemia and hyperkalaemia, 2.5% for decreased haemoglobin (all\nGrade\u00a03), 2.0% for hypokalaemia, 1.6% for decreased neutrophil count, 1.3%\nfor hypomagnesaemia, 1.2% for hypocalcaemia, 0.8% for increased total bilirubin,\nand 0.4% for increased AST, decreased platelet, hypermagnesaemia, and\nhypernatraemia. There was no worsening to Grade\u00a03\u00a0or\u00a04 in increased\nALT, increased alkaline phosphatase, and increased creatinine</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:windowtext\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In study CA209017, hypercalcaemia was more\nfrequently reported in the nivolumab group (31/130, 24%) than in the docetaxel\ngroup (9/124, 7%). The exact cause is not known. Although hyperparathyroidism\nwas not reported in CA209017, immune-related hyperparathyroidism might be\nconsidered especially if associated with hypophosphataemia (reported in\n6\u00a0hypercalcemic patients in this study).</span></p>\n<p class=\"EMEABodyText\">\u00a0</p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immunogenicity</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with all therapeutic proteins, there\nis a potential for an immune response to nivolumab. Of the 497\u00a0patients\nwho were treated with nivolumab 3\u00a0mg/kg every 2\u00a0weeks and evaluable\nfor the presence of anti\u2011product\u2011antibodies, 51\u00a0(10.3%)\npatients tested positive for treatment-emergent anti-product antibodies by an\nelectrochemiluminescent (ECL) assay. Only 4\u00a0(0.8%)\u00a0patients were\npersistent positive. Neutralising antibodies were detected in only 5\u00a0(1.0%\nof the total) of the positive anti\u2011product\u2011antibody patients. There\nwas no evidence of altered pharmacokinetic or toxicity profile associated with\nanti\u2011product\u2011antibody development.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting\nof suspected adverse reactions</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\nafter authorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\" style=\"background:silver\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span><span lang=\"EN-GB\" style=\"background:silver\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No cases of overdose have been reported\nin clinical trials. In case of overdose, patients should be closely monitored\nfor signs or symptoms of adverse reactions, and appropriate symptomatic\ntreatment instituted immediately.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1 \u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Antineoplastic\nagents, monoclonal antibodies. ATC code: </span><span lang=\"EN-GB\">L01XC17.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is a human immunoglobulin G4\n(IgG4) monoclonal antibody (HuMAb), which binds to the programmed death\u20111\n(PD\u20111) receptor and blocks its interaction with PD\u2011L1 and PD\u2011L2.\nThe PD\u20111 receptor is a negative regulator of T\u2011cell activity that\nhas been shown to be involved in the control of T\u2011cell immune responses.\nEngagement of PD\u20111 with the ligands PD\u2011L1 and PD\u2011L2, which are\nexpressed in antigen presenting cells and may be expressed by tumours or other\ncells in the tumour microenvironment, results in inhibition of T\u2011cell\nproliferation and cytokine secretion. Nivolumab potentiates T\u2011cell\nresponses, including anti-tumour responses, through blockade of PD\u20111\nbinding to PD\u2011L1 and PD\u2011L2 ligands. In syngeneic mouse models,\nblocking PD\u20111 activity resulted in decreased tumour growth.</span></p>\n<p class=\"EMEABodyText\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Randomised\nphase\u00a03 study vs. docetaxel (CA209017)</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of\nnivolumab\u00a03\u00a0mg/kg as a single agent for the treatment of advanced or\nmetastatic squamous NSCLC were evaluated in a phase\u00a03, randomised,\nopen-label study (CA209017). The study included patients (18\u00a0years or\nolder) who have experienced disease progression during or after one prior\nplatinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology\nGroup (ECOG) performance status score of 0 or 1. Patients were enrolled\nregardless of their PD-L1 status. Patients with active autoimmune disease,\nsymptomatic interstitial lung disease, or untreated brain metastasis were\nexcluded from the study. Patients with treated brain metastases were eligible\nif neurologically returned to baseline at least 2\u00a0weeks prior to\nenrolment, and either off corticosteroids, or on a stable or decreasing dose of\n&lt;10 mg daily prednisone equivalents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">A total of 272 patients were randomised\nto receive either nivolumab 3\u00a0mg/kg (N\u00a0=\u00a0135) administered\nintravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks or docetaxel (n\u00a0=\u00a0137)\n75\u00a0mg/m<sup>2</sup> every 3\u00a0weeks. Treatment was continued as long as\nclinical benefit was observed or until treatment was no longer tolerated. </span><span lang=\"EN-GB\">T</span><span lang=\"EN-GB\">umour assessments,</span><span lang=\"EN-GB\"> according\nto the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, </span><span lang=\"EN-GB\">were conducted\u00a09 weeks after randomisation and continued every\u00a06\u00a0weeks\nthereafter. The primary efficacy outcome measure was overall survival (OS). Key\nsecondary efficacy outcome measures were investigator-assessed objective\nresponse rate (ORR) and progression-free survival (PFS). In addition, symptom\nimprovement and overall health status were assessed using the Lung Cancer\nSymptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue\nScale (EQ-VAS), respectively. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Baseline characteristics were generally balanced\nbetween the two groups. The median age was\u00a063\u00a0years (range:\u00a039\u201185)\nwith 44% </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">65\u00a0years of age and 11% </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">75\u00a0years of age. The\nmajority of patients were white (93%) and male (76%). Thirty-one percent had\nprogressive disease reported as the best response to their most recent prior\nregimen and 45% received nivolumab within 3\u00a0months of completing their\nmost recent prior regimen. Baseline ECOG performance status score was 0\u00a0(24%)\nor 1\u00a0(76%). </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The Kaplan-Meier curves for OS are shown\nin Figure\u00a01.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b>Figure 1:\u00a0\u00a0\u00a0 Kaplan-Meier\ncurves of OS (CA209017) </b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center;page-break-after:\navoid\"><span style=\"position:absolute;z-index:251657728;left:0px;margin-left:\n1px;margin-top:17px;width:39px;height:336px\"><img alt=\"Text Box: Probability of Survival\" height=\"336\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image002.gif\" width=\"39\"/></span><span lang=\"EN-GB\"><img border=\"0\" height=\"377\" id=\"Picture 4\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image003.jpg\" width=\"527\"/></span></p>\n<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center;page-break-after:\navoid\"><span lang=\"EN-GB\">Overall Survival (Months)</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\nSubjects at Risk</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse\" width=\"567\">\n<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">135</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">113</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">86</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">69</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Docetaxel</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">137</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">103</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">45</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">30</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image004.jpg\" width=\"49\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nivolumab\n3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image005.jpg\" width=\"45\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Docetaxel\n(events : 113/137), median and 95% CI : 6.01 (5.13, 7.33)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The observed OS benefit was consistently\ndemonstrated across subgroups of patients. Survival benefit was observed\nregardless of whether patients had tumours that were designated PD-L1 negative\nor PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%).\nHowever, the role of this biomarker (PD-L1 expression) has not been fully\nelucidated.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Study CA209017 included a limited number\nof patients \u2265 75\u00a0years (11\u00a0in the nivolumab group and 18\u00a0in\nthe docetaxel group). Nivolumab showed numerically less effect on OS (HR\u00a01.85;\n95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05 ) and ORR (9.1% vs\n16.7%). Because of the small sample size, no definitive conclusions can be\ndrawn from these data.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Efficacy results are shown in Table\u00a03.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n3</span></b><span lang=\"EN-GB\">:\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Efficacy\nresults (CA209017)</b></span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr>\n<td style=\"width:151.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b></p>\n</td>\n<td style=\"width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p class=\"BMSTableText\">9.23 (7.33, 13.27)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p class=\"BMSTableText\">6.01 (5.13, 7.33)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">3.48 (2.14, 4.86)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">2.83 (2.10, 3.52)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\">20.8 (14.0, 28.4)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"margin-top:0in\">6.4 (2.9, 11.8)</p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The rate of disease-related symptom\nimprovement, as measured by LCSS, was similar between the nivolumab group\n(18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time\nfor both treatment groups, indicating better overall health status for patients\nremaining on treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Single-arm\nphase\u00a02\u00a0study (CA209063)</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Study CA209063 was a single-arm, open-label\nstudy conducted in 117\u00a0patients with locally advanced or metastatic\nsquamous-NSCLC after two or more lines of therapy; otherwise similar inclusion\ncriteria as study CA209017 were applied. Nivolumab 3\u00a0mg/kg showed an\noverall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of\n8.21\u00a0months (95% CI: 6.05-10.9\u00a0months ), and a median PFS of 1.87\u00a0months\n(95% CI 1.77-3.15\u00a0months. The PFS was measured by RECIST version 1.1. The\nestimated 1-year survival rate was 41%.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u>Safety and efficacy in\nelderly patients</u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No overall differences in safety or\nefficacy were reported between elderly (\u2265\u00a065\u00a0years) and younger\npatients (&lt;\u00a065\u00a0years). </span><span lang=\"EN-GB\">Data from patients\n75\u00a0years of age or older are too limited to draw conclusions on this\npopulation.</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The European Medicines Agency has\ndeferred the obligation to submit the results of studies with nivolumab in all\nsubsets of the paediatric population in the treatment of malignant solid\ntumours (see section\u00a04.2 for information on paediatric use).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics (PK) of nivolumab\nis linear in the dose range of\u00a00.1\u00a0to\u00a010\u00a0mg/kg. The\ngeometric mean clearance (CL), terminal half\u2011life, and average exposure\nat steady state at 3\u00a0mg/kg every\u00a02\u00a0weeks of nivolumab\nwere\u00a09.5\u00a0mL/h,\u00a026.7\u00a0days, and 75.3\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/mL,\nrespectively, based on a population PK analysis.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab CL increased with increasing\nbody weight. Body weight normalised dosing produced approximately uniform\nsteady\u2011state trough concentration over a wide range of body weights (34\u2011162\u00a0kg).\n</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The metabolic pathway of nivolumab has\nnot been characterised. Nivolumab is expected to be degraded into small\npeptides and amino acids via catabolic pathways in the same manner as\nendogenous IgG.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">A population PK analysis suggested no difference\nin CL of nivolumab based on age, gender, race, tumour type, tumour size, and\nhepatic impairment. Although ECOG status, baseline glomerular filtration rate\n(GFR), albumin, body weight, and mild hepatic impairment had an effect on\nnivolumab CL, the effect was not clinically meaningful.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Renal\nimpairment</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The effect of renal impairment on the CL\nof nivolumab was evaluated in patients with mild (GFR\u00a0&lt;\u00a090\nand\u00a0\u2265\u00a060\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0379), moderate (GFR\u00a0&lt;\u00a060\nand\u00a0\u2265\u00a030\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0179), or severe (GFR\u00a0&lt;\u00a030\nand\u00a0\u2265\u00a015\u00a0mL/min/1.73\u00a0m<sup>2</sup>; n\u00a0=\u00a02)\nrenal impairment compared to patients with normal renal function\n(GFR\u00a0\u2265\u00a090\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0342) in population PK analyses. No clinically important\ndifferences in the CL of nivolumab were found between patients with mild or\nmoderate renal impairment and patients with normal renal function. Data from\npatients with severe renal impairment are too limited to draw conclusions on\nthis population (see section\u00a04.2). </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Hepatic\nimpairment</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The effect of hepatic impairment on the\nCL of nivolumab was evaluated in patients with mild hepatic impairment (total\nbilirubin\u00a01.0\u00a0\u00d7\u00a0to\u00a01.5\u00a0\u00d7\u00a0ULN or AST\u00a0&gt;\u00a0ULN\nas defined using the National Cancer Institute criteria of hepatic dysfunction;\nn\u00a0=\u00a092) compared to patients with normal hepatic function (total\nbilirubin and AST\u00a0\u2264\u00a0ULN; n\u00a0=\u00a0804) in the population\nPK analyses. No clinically important differences in the CL of nivolumab were\nfound between patients with mild hepatic impairment and normal hepatic\nfunction. Nivolumab has not been studied in patients with moderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) or severe hepatic impairment (total bilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) (see section\u00a04.2).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.5pt;color:black\">Blockade\nof PD\u2011L1 signalling has been shown in murine models of pregnancy to\ndisrupt tolerance to the foetus and to increase foetal loss. </span><span lang=\"EN-GB\">The effects of nivolumab on prenatal and postnatal development were\nevaluated in monkeys that received nivolumab twice weekly from the onset of\norganogenesis in the first trimester through delivery, at exposure levels\neither\u00a08\u00a0or\u00a035\u00a0times higher than those observed at the\nclinical dose of\u00a03\u00a0mg/kg of nivolumab (based on AUC). </span><span lang=\"EN-GB\">There was a </span><span lang=\"EN-GB\">dose\u2011dependent increase in\nfoetal losses and increased neonatal mortality </span><span lang=\"EN-GB\">beginning\nin the third trimester</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The remaining offspring of nivolumab\u2011treated\nfemales survived to scheduled termination, with no treatment\u2011related\nclinical signs, alterations to normal development, organ\u2011weight effects,\nor gross and microscopic pathology changes. Results for growth indices, as well\nas teratogenic, neurobehavioral, immunological, and clinical pathology\nparameters throughout the 6\u2011month postnatal period were comparable to the\ncontrol group. However, b</span><span lang=\"EN-GB\" style=\"font-size:11.5pt;\ncolor:black\">ased on its mechanism of action, foetal exposure to nivolumab may\nincrease the risk of developing immune\u2011related disorders or altering the\nnormal immune response and immune\u2011related disorders have been reported in\nPD\u20111 knockout mice.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility studies have not been\nperformed with </span><span lang=\"EN-GB\">nivolumab</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of\nexcipients</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium citrate dihydrate</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium chloride</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mannitol (E421)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pentetic acid (diethylenetriaminepentaacetic\nacid)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Polysorbate\u00a080</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Water for injections</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products. Nivolumab\u00a0BMS\nshould not be infused concomitantly in the same intravenous line with other\nmedicinal products.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened\nvial</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">2\u00a0years.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">After opening</span></u></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">From a microbiological point of view, once opened, the medicinal\nproduct should be infused or diluted and infused immediately.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:0in;text-indent:0in\"><u><span lang=\"EN-GB\">After preparation of infusion</span></u><span lang=\"EN-GB\"> </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">From a microbiological point of view,\nthe product should be used immediately.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If not used immediately, chemical and\nphysical in-use stability of Nivolumab\u00a0BMS has been demonstrated for\n24\u00a0hours at\u00a02\u00baC to\u00a08\u00baC protected from light and a\nmaximum of 4\u00a0hours at 20\u00b0C-25\u00b0C and room light (this 4-hour period\nof the total 24\u00a0hours should be inclusive of the product administration\nperiod).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C\u20118\u00b0C).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For storage conditions after preparation\nof the infusion, see section\u00a06.3.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and\ncontents of container</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">4\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a dark\nblue flip\u2011off seal (aluminium). Pack size of\u00a01\u00a0vial.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">10\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a grey flip\u2011off\nseal (aluminium). Pack size of 1\u00a0vial.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><a name=\"OLE_LINK1\"><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</span></a></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparation\nand administration</span></u></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Calculating\nthe dose</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The prescribed dose for the patient is\ngiven in mg/kg. Based on this prescribed dose, calculate the total dose to be\ngiven. More than one vial of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">concentrate may be needed to give the total dose for the patient.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">The\ntotal nivolumab dose in mg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">The\nvolume of Nivolumab\u00a0BMS concentrate to prepare the dose (mL)\u00a0=\u00a0the\ntotal dose in mg, divided by\u00a010 (the Nivolumab\u00a0BMS concentrate\nstrength is\u00a010\u00a0mg/mL). </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Preparing\nthe infusion</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Take care to ensure aseptic handling\nwhen you prepare the infusion. The infusion should be prepared in a laminar\nflow hood or safety cabinet using standard precautions for the safe handling of\nintravenous agents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> can be used for intravenous administration either:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:27.0pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">without\ndilution, after transfer to an infusion container using an appropriate sterile\nsyringe;</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">or</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\n</span></span><span lang=\"EN-GB\">after diluting to concentrations as low as\u00a01\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">. The final infusion concentration should\nrange between\u00a01\u00a0and\u00a010\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">. </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">concentrate may be diluted with either:</span><span lang=\"EN-GB\"> </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">sodium\nchloride\u00a09\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">\n(0.9%) solution for injection; or</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">50\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\"> (5%) glucose solution for injection.</span><span lang=\"EN-GB\"> </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">STEP 1</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Inspect\nthe Nivolumab\u00a0BMS concentrate for particulate matter or discoloration. Do\nnot shake the vial. Nivolumab\u00a0BMS concentrate is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles. </span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Withdraw\nthe required volume of Nivolumab\u00a0BMS concentrate using an appropriate\nsterile syringe. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">STEP 2</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Transfer\nthe concentrate into a sterile, evacuated glass bottle or intravenous container\n(PVC or polyolefin). </span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">If\napplicable, dilute with the required volume of sodium chloride\u00a09\u00a0mg/mL\n(0.9%) solution for injection or\u00a050\u00a0mg/mL (5%) glucose solution for\ninjection. Gently mix the infusion by manual rotation. Do not shake.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Administration</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion must not be administered as an intravenous push or bolus\ninjection.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS infusion\nintravenously over a period of\u00a060\u00a0minutes.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm to\u00a01.2 \u03bcm).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion is compatible with PVC and polyolefin containers, glass\nbottles, PVC</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">infusion sets and\nin-line filters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to 1.2\u00a0\u00b5m.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">After administration of the nivolumab dose,\nflush the line with sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for\ninjection or\u00a050\u00a0mg/mL (5%) glucose solution for injection.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Disposal</span></u></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. </span><span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG<br/>\nUxbridge Business Park<br/>\nSanderson Road<br/>\nUxbridge UB8\u00a01DH<br/>\nUnited Kingdom<br/>\n<br/>\n</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EU/1/15/1026/001-002</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF\nREVISION OF THE TEXT</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\nproduct is available on the website of the European Medicines Agency </span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>\n<span class=\"MsoHyperlink\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span></b></span>\n<p class=\"EMEATitle\"><a name=\"_GoBack\"></a><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX II</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER\n</span><span lang=\"EN-GB\">OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Name and address of the manufacturer of\nthe biological active substance</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lonza\nBiologics, Inc.</span></p>\n<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">101\nInternational Drive</span></p>\n<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Portsmouth,\nNew Hampshire</span></p>\n<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">03801</span></p>\n<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">USA</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Loc. Fontana del Ceraso</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">03012\u00a0Anagni (FR)</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Italy</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">B.</span></a><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic safety update reports</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The marketing authorisation holder shall\nsubmit the first periodic safety update report for this product within 6 months\nfollowing authorisation. Subsequently, the marketing authorisation holder shall\nsubmit periodic safety update reports for this product in accordance with the\nrequirements set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and published on the European\nmedicines web-portal.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If the dates for submission of a PSUR\nand the update of a RMP coincide, they can be submitted at the same time.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Additional risk minimisation measures </span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Prior to launch of Nivolumab\u00a0BMS in\neach Member State the Marketing Authorisation Holder (MAH) must agree about the\ncontent and format of the educational programme, including communication media,\ndistribution modalities, and any other aspects of the programme, with the\nNational Competent Authority. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The educational programme is aimed at\nincreasing the awareness about the potential immune mediated adverse events\nassociated with Nivolumab\u00a0BMS use, how to manage them and to enhance the awareness\nof patients or their caregivers on the signs and symptoms relevant to the early\nthose adverse events.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The MAH shall ensure that in each Member\nState where Nivolumab\u00a0BMS is marketed, all healthcare professionals and\npatients/carers who are expected to prescribe and use Nivolumab\u00a0BMS have\naccess to/are provided with the following educational package:</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Physician educational material</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patient alert card</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">The physician educational material</span></b><span lang=\"EN-GB\"> should contain:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The Summary of Product Characteristics</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Adverse Reaction Management Guide</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The </span><span lang=\"EN-GB\">Adverse\nReaction Management Guide shall contain the following key elements:</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:#1D1B11\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Relevant information (e.g. seriousness,\nseverity, frequency, time to onset, reversibility of the AE as applicable) for\nthe following safety concerns:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related pneumonitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related colitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related hepatitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related endocrinopathies </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune related rash</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other immune-related ARs</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Details on how to minimise the safety concern\nthrough appropriate monitoring and management</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The patient alert card</span></b><span lang=\"EN-GB\"> shall contain the following key messages: </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">That Nivolumab\u00a0BMS treatment may increase\nthe risk of: </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related pneumonitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related colitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related hepatitis</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related endocrinopathies </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune related rash</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other immune-related ARs</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Signs or symptoms of the safety concern and when\nto seek attention from a HCP</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Contact details of the Nivolumab\u00a0BMS prescriber\n</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Obligation to conduct post-authorisation\nmeasures </span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The MAH\nshall complete, within the stated timeframe, the below measures:</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:1.2pt;border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:21.5pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;background:white;\n  padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"462\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:106.3pt;border:solid black 1.0pt;border-left:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Due date</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:63.25pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">1. </span><span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span><span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span><span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span><span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:303.7pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2015</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> March 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> December 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>\n<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\n\"Times New Roman\",serif;color:black'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span></span>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">III</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">LABELLING</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">AND</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">PACKAGE</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">LEAFLET</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">A. LABELLING</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\nPACKAGING</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">nivolumab</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each vial of 4\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">Each vial of\n10\u00a0mL contains\u00a0100\u00a0mg of nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Excipients: sodium citrate dihydrate,\nsodium chloride, mannitol\u00a0(E421), pentetic acid, polysorbate\u00a080,\nsodium hydroxide, hydrochloric acid, water for injections.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">See leaflet\nfor further information.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">Concentrate\nfor solution for infusion.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">1\u00a0vial</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Intravenous use.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE\nMEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For single use only.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND\nADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uxbridge Business Park</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sanderson Road</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">United Kingdom<i><br/>\n<br/>\n</i></span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\">EU/1/15/1026/001\u00a0<span style=\"background:silver\">40\u00a0mg\nvial</span></p>\n<p class=\"EMEABodyText\"><span style=\"background:silver\">EU/1/15/1026/002\u00a0100\u00a0mg\nvial</span></p>\n<p class=\"EMEABodyText\">\u00a0</p>\n<p class=\"EMEABodyText\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></p>\n</div>\n<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></p>\n</div>\n<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification\nfor not including Braille accepted</span><span lang=\"EN-GB\" style=\"color:black;\nbackground:#CCCCCC\">.</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;text-transform:uppercase;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">minimum PARTICULARS TO APPEAR ON small\nIMMEDIATE PACKAGING units</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">VIAL LABEL</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nsterile concentrate</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">nivolumab</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">IV use</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></p>\n</div>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For single use only.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">Package leaflet: Information for the user</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitle\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span></p>\n<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><span lang=\"EN-GB\">nivolumab</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image006.gif\" width=\"21\"/></span><span lang=\"EN-GB\">This medicine is subject to\nadditional monitoring. This will allow quick identification of new safety\ninformation. You can help by reporting any side effects you may get. See the\nend of section\u00a04 for how to report side effects.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start using this medicine because it contains important information\nfor you.</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this leaflet. You may need to read\nit again. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is important that you keep the Alert\nCard with you during treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions, ask\nyour doctor.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\nyour doctor.</span><span lang=\"EN-GB\"> This includes any possible side effects\nnot listed in this leaflet. See section\u00a04.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nis in this leaflet</span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto use Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is a medicine used to\ntreat advanced non-small cell lung cancer (a type of lung cancer) in adults. It\ncontains the active substance nivolumab, which is a monoclonal antibody, a type\nof protein designed to recognise and attach to a specific target substance in\nthe body. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab attaches to a target protein\ncalled programmed death\u20111 receptor (PD\u20111) that can switch off the\nactivity of T cells (a type of white blood cell that forms part of the immune\nsystem, the body\u2019s natural defences). By attaching to PD-1, nivolumab\nblocks its action and prevents it from switching off your T cells. This helps\nincrease their activity against the lung cancer cells.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You\nshould not be given Nivolumab\u00a0BMS</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you are <b>allergic</b> to nivolumab or any\nof the other ingredients of this medicine (listed in section\u00a06\n\"Contents of the pack and other information\"). <b>Talk to your doctor</b>\nif you are not sure.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Talk to your doctor before using\nNivolumab\u00a0BMS as it may cause:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Problems with your lungs</span></b><span lang=\"EN-GB\"> such as breathing difficulties or cough. These may be signs of\ninflammation of the lungs (pneumonitis <span style=\"color:black\">or\ninterstitial lung disease).</span></span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Diarrhoea</span></b><span lang=\"EN-GB\">\n(watery, loose or soft stools) or any symptoms of <b>inflammation of the\nintestines</b> (colitis), such as stomach pain and mucus or blood in stool.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation of the liver (hepatitis).</span></b><span lang=\"EN-GB\"> Signs and symptoms of hepatitis may include abnormal liver function\ntests, eye or skin yellowing (jaundice), pain on the right side of your stomach\narea, or tiredness.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation or problems with your kidneys. </span></b><span lang=\"EN-GB\">Signs and symptoms may include abnormal kidney function tests, or\ndecreased volume of urine.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Problems with your hormone producing glands</span></b><span lang=\"EN-GB\"> (including the pituitary, the thyroid and adrenal glands) that may\naffect how these glands work. Signs and symptoms that these glands are not\nworking properly may include fatigue (extreme tiredness), weight change or\nheadache and visual disturbances.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Diabetes </span></b><span lang=\"EN-GB\">(symptoms\ninclude excessive thirst, the passing of a greatly increased amount of urine,\nincrease in appetite with a loss of weight, feeling tired, drowsy, weak,\ndepressed, irritable and generally unwell) or <b>diabetic ketoacidosis </b>(acid\nin the blood produced from diabetes).</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation of the skin </span></b><span lang=\"EN-GB\">that can lead to rash and itching.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor\nimmediately</span></b><span lang=\"EN-GB\" style=\"color:black\"> if you have any of\nthese signs or symptoms or if they get worse. <b>Do not try to treat your\nsymptoms with other medicines on your own. </b>Your doctor may</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">give you other medicines in order to prevent complications\nand reduce your symptoms,</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">withhold the next dose of Nivolumab\u00a0BMS,</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">or stop your treatment with Nivolumab\u00a0BMS\naltogether.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Please note that\nthese signs and symptoms are <b>sometimes delayed</b>, and may develop weeks or\nmonths after your last dose. Before treatment, your doctor will check your\ngeneral health. You will also have <b>blood tests</b> during your treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Check\nwith your doctor or nurse before you are given Nivolumab\u00a0BMS if:</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have been told that your <b>cancer has\nspread to your brain</b></span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have an <b>autoimmune disease</b> (a\ncondition where the body attacks its own cells);</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have any history of <b>inflammation of the\nlungs</b>;</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have been taken <b>medicines to suppress\nyour immune system.</b></span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Children\nand adolescents</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS should not be used in\nchildren and adolescents below\u00a018\u00a0years of age.</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Nivolumab\u00a0BMS</span></b></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Before you are given </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b><b><span lang=\"EN-GB\">, tell your doctor </span></b><span lang=\"EN-GB\">if you are taking any medicines that suppress your immune system,\nsuch as corticosteroids, since these medicines may interfere with the effect of\n</span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. However,\nonce you are treated with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">, your doctor may give you corticosteroids to reduce any possible\nside\u2011effects that you may have during your treatment and this will not\nimpact the effect of the medicine.</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor </span></b><span lang=\"EN-GB\">if you are taking or have recently taken any other medicines. </span><b><span lang=\"EN-GB\">Do not take any other medicines </span></b><span lang=\"EN-GB\">during\nyour treatment without talking to your doctor first.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast\u2011feeding</span></b></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor</span></b><span lang=\"EN-GB\"> if you are pregnant or think you might be, if you are planning to\nbecome pregnant, or if you are breast\u2011feeding.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS if you\nare pregnant</span></b><span lang=\"EN-GB\"> unless your doctor specifically tells\nyou to. The effects of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> in pregnant women are not known, but it is possible that the active\nsubstance, nivolumab, could harm an unborn baby.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You must use <b>effective contraception</b>\nwhile you are being treated with Nivolumab\u00a0BMS and for at least 5\u00a0months\nfollowing the last dose of Nivolumab\u00a0BMS, if you are a woman who could\nbecome pregnant.</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you become pregnant while using Nivolumab\u00a0BMS\n<b>tell your doctor</b>.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is not known whether nivolumab gets\ninto breast milk. A risk to the breast\u2011fed infant cannot be excluded. <b>Ask\nyour doctor</b> if you can breast\u2011feed during or after treatment with Nivolumab\u00a0BMS.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is unlikely to affect your\nability to drive or use machines; however, use caution when performing these\nactivities until you are sure that nivolumab does not adversely affect you.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> contains sodium</span></b></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor </span></b><span lang=\"EN-GB\">if you are on a low\u2011sodium (low\u2011salt) diet before you\nare given </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. This\nmedicine contains\u00a02.5\u00a0mg sodium per </span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\"> of concentrate.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">You will also find this information in\nthe Patient Alert Card you have been given by your doctor. It is important that\nyou keep this Alert Card and show it to your partner or caregivers.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 H</span><span lang=\"EN-GB\">ow to use Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nmuch </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b><b><span lang=\"EN-GB\">\nis given</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The amount of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> you will be given will be calculated based on your body weight. The\n</span><span lang=\"EN-GB\">recommended</span><span lang=\"EN-GB\"> dose\nis\u00a03\u00a0mg of nivolumab per kilogram of your body weight.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Depending on your dose, the appropriate\namount of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> will\nbe diluted with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for\ninjection or\u00a0glucose 50\u00a0mg/mL\u00a0(5%) solution for injection before\nuse. More than one vial of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> may be necessary to obtain the required dose.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nNivolumab\u00a0BMS is given</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">You will receive treatment with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> in a hospital or clinic,\nunder the supervision of an experienced doctor.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> will be given to you as an infusion (a drip) into a vein\n(intravenously) over a period of\u00a060\u00a0minutes, every\u00a02\u00a0weeks.\nYour doctor will continue giving you </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> for as long as you keep benefitting from it or until you no longer\ntolerate the treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nmiss a dose of Nivolumab\u00a0BMS</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is very important for you to keep all\nyour appointments to receive </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. If you miss an appointment, ask your doctor when to schedule your\nnext dose.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nstop using Nivolumab\u00a0BMS</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Stopping your treatment may stop the\neffect of the medicine. Do not stop treatment with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> unless you have discussed this with your doctor.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions about\nyour treatment or on the use of this medicine, ask your doctor.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\ncause side effects, although not everybody gets them. Your doctor will discuss\nthese with you and will explain the risks and benefits of your treatment.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Be aware of important symptoms of\ninflammation.</span></b><span lang=\"EN-GB\"> Nivolumab\u00a0BMS acts on your\nimmune system and may cause inflammation in parts of your body. Inflammation\nmay cause serious damage to your body and some inflammatory conditions may be\nlife\u2011threatening and need treatment or withdrawal of nivolumab.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following side effects have been\nreported in clinical trials with nivolumab:</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon (may affect more than\u00a01\u00a0in\u00a010\u00a0people)</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Decreased appetite</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Nausea</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling tired or weak</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Common\n(may affect up to\u00a01\u00a0in\u00a010\u00a0people)</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Underactive thyroid gland which can cause\ntiredness or weight gain</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the nerves causing numbness,\nweakness, tingling or burning pain of the arms and legs, headache, dizziness</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the lungs (pneumonitis),\ncharacterised by coughing and difficulty breathing, shortness of breath\n(dyspnoea), cough</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Diarrhoea (watery, loose or soft stools), mouth\nulcers and cold sores (stomatitis), vomiting, stomach pain, constipation, dry\nmouth</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Skin rash, itching</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;letter-spacing:.15pt\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Pain in the muscles, bones and joints</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Fever, oedema\n(swelling)</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon\n(may affect up to\u00a01\u00a0in\u00a0100\u00a0people)</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bronchitis, infections of the upper respiratory\ntract</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A disease causing the inflammation or\nenlargement of a lymph node (Kikuchi lymphadenitis)</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Allergic reaction, reactions related to the\nadministration of the medicine </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Adrenal glands not working properly,\ninflammation of the thyroid gland</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A condition in which the muscles become weak and\ntire easily (myasthenic syndrome), damage to the nerves in different parts of\nthe body that can cause decreased feeling or affect movement</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fast heart rate</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of blood vessels</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid in the lungs</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the intestines (colitis), ulcer\nof the small intestines</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hives (itchy, bumpy rash)</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of muscles causing pain or\nstiffness</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney disease, kidney failure.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor immediately</span></b><span lang=\"EN-GB\"> if you get any of the side effects listed above. Do not try to\ntreat your symptoms with other medicines on your own.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Changes\nin test results</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> may cause changes in the results of tests carried out by your\ndoctor. These include:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A decreased number of red blood cells (which\ncarry oxygen), white blood cells (which are important in fighting infection) or\nplatelets (cells which help the blood to clot)</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal liver function tests (increased amounts\nof the liver enzymes aspartate aminotransferase, alanine aminotransferase or\nalkaline phosphatase in your blood, higher blood levels of bilirubin)</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal kidney function tests (increased\namounts of creatinine in your blood)</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal levels of calcium, potassium,\nmagnesium, or sodium in your blood</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">An increased level of the enzyme that breaks\ndown lipids and of the enzyme that breaks down starch.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, <b>talk to\nyour doctor</b>.</span><span lang=\"EN-GB\"> This includes any possible side\neffects not listed in this leaflet. You can also report side effects directly\nvia <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>. By reporting side effects you\ncan help provide more information on the safety of this medicine.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\nreach of children.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\nexpiry date which is stated on the carton and the vial label </span><span lang=\"EN-GB\">after EXP. The expiry date refers to the last day of that month.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator\n(2\u00b0C\u00a0to\u00a08\u00b0C).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS contains</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is nivolumab.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Each mL of\nconcentrate for solution for infusion contains\u00a010\u00a0mg of nivolumab.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Each vial\ncontains either\u00a040\u00a0mg (in\u00a04\u00a0mL) or\u00a0100\u00a0mg\n(in\u00a010\u00a0mL) of nivolumab.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are sodium citrate\ndihydrate, sodium chloride (see section\u00a02\u00a0\"</span><span lang=\"EN-GB\"> Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> contains sodium\"),\nmannitol\u00a0(E421), pentetic acid, polysorbate\u00a080, sodium hydroxide,\nhydrochloric acid and water for injections.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS looks like and contents of the pack</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS concentrate for\nsolution for infusion (sterile concentrate) is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is available in packs containing\neither\u00a01\u00a0vial of\u00a04\u00a0mL or\u00a01\u00a0vial of\u00a010\u00a0mL.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Uxbridge Business Park</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Sanderson Road</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">United Kingdom</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span></p>\n<p class=\"EMEAAddress\"><span lang=\"ES\">Loc. Fontana del Ceraso</span></p>\n<p class=\"EMEAAddress\"><span lang=\"ES\">03012\u00a0Anagni (FR)</span></p>\n<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Italy</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For </span><span lang=\"EN-GB\">any</span><span lang=\"EN-GB\"> information about this medicine, please\ncontact the local representative of the Marketing Authorisation Holder.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.4pt;border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.0pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 372 6827 400</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:47.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:55.55pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"ES\">Portugal</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Vistor\n  hf.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"EN-GB\">: + 354 535 7000</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:38.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:60.95pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\navailable on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">-------------------------------------------------------------------------------------------------------------------------</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">The\nfollowing information is intended for healthcare professionals only:</span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Preparation\nand administration of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></u></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Calculating\nthe dose</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The <b>prescribed dose</b> for the\npatient is given in mg/kg. Based on this prescribed dose, calculate the total\ndose to be given. More than one vial of Nivolumab\u00a0BMS concentrate may be\nneeded to give the total dose for the patient.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The <b>total nivolumab dose</b> in\nmg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The <b>volume of Nivolumab\u00a0BMS concentrate</b>\nto prepare the dose (mL)\u00a0=\u00a0the total dose in mg, divided by\u00a010\n(the Nivolumab\u00a0BMS concentrate strength is\u00a010\u00a0mg/mL). </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Preparing\nthe infusion</span></b></p>\n<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Take care to ensure aseptic handling</span></b><span lang=\"EN-GB\"> when you prepare the infusion. The infusion should be prepared in a\nlaminar flow hood or safety cabinet using standard precautions for the safe\nhandling of intravenous agents.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> can be used for intravenous administration either:</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">without dilution,</span></b><span lang=\"EN-GB\">\nafter transfer to an infusion container using an appropriate sterile syringe;</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">or</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">after diluting</span></b><span lang=\"EN-GB\"> to\nconcentrations as low as\u00a01\u00a0mg/mL. The final infusion concentration\nshould range between\u00a01\u00a0and\u00a010\u00a0mg/mL. Nivolumab\u00a0BMS\nconcentrate may be diluted with either: </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:85.05pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection; or</span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:85.05pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">50\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">STEP 1</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inspect the Nivolumab\u00a0BMS concentrate for\nparticulate matter or discoloration. Do not shake the vial. Nivolumab\u00a0BMS\nconcentrate is a clear to opalescent, colourless to pale yellow liquid that may\ncontain few light particles. </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw the required volume of Nivolumab\u00a0BMS\nconcentrate using an appropriate sterile syringe. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">STEP 2</span></b></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Transfer the concentrate into a sterile,\nevacuated glass bottle or intravenous container (PVC or polyolefin). </span></p>\n<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If applicable, dilute with the required volume\nof sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection\nor\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for injection. Gently mix the\ninfusion by manual rotation. Do not shake.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Administration</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion must not be administered as an intravenous push or bolus\ninjection.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS\ninfusion <b>intravenously over a period of 60\u00a0minutes</b>.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm\u00a0to\u00a01.2\u00a0\u03bcm).</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion is compatible with:</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">PVC\ncontainers</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Polyolefin\ncontainers</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Glass\nbottles</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">PVC\ninfusion sets</span></p>\n<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">In\u2011line\nfilters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to\u00a01.2\u00a0\u00b5m.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">After administration of the nivolumab\ndose, flush the line with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection or\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Storage\nconditions and shelf life</span></b></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened\nvial</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> must be <b>stored in a refrigerator</b>\n(2\u00b0C\u00a0to\u00a08\u00b0C). The vials must be kept in the original package\nin order to protect from light. Nivolumab\u00a0BMS should not be frozen.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS after the\nexpiry date which is stated on the carton and on the vial label after EXP. The\nexpiry date refers to the last day of that month.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nivolumab\u00a0BMS\ninfusion</span></u></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion must be completed within\u00a024\u00a0hours of\npreparation. If not used immediately, the solution may be stored under\nrefrigeration conditions (2\u00b0C\u20118\u00b0C) and protected from light for\nup to\u00a024\u00a0hours [a maximum of\u00a04\u00a0hours of the\ntotal\u00a024\u00a0hours can be at room temperature (20\u00b0C\u201125\u00b0C)\nand room light]. Other in\u2011use storage time and conditions are the\nresponsibility of the user.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disposal</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span></p>\n</div>", "ID": "a320bbc2-23bc-44fe-8c66-044859926d59", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ", "ParentId": "9a27487d-8083-4e62-aafb-c317184a8785"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9ec3316-5f70-47a4-91f6-b9728124b1d9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "abcb5ec2-4ab9-42bc-93e0-f3e51a3462eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9ec3316-5f70-47a4-91f6-b9728124b1d9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd5ca149-ce19-4759-95ed-7d469ae08a41", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfcc3311-2d77-4f16-a85a-44bb9c49901b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd5ca149-ce19-4759-95ed-7d469ae08a41"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85a35df0-e3a5-4fac-9c3d-2af38dafeaa8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f897f6cd-c4a5-4c8d-8ad8-c699edef155f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85a35df0-e3a5-4fac-9c3d-2af38dafeaa8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "24c1cd57-ffdf-4c8a-83db-2c7dcead26f3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bae15e09-71d3-4177-b441-5c8082532b8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24c1cd57-ffdf-4c8a-83db-2c7dcead26f3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "84de8a3a-3296-4e60-87f6-cf4ab1a2f22f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2308173-e9ac-42b2-bdf4-1e459e7a6099", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84de8a3a-3296-4e60-87f6-cf4ab1a2f22f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ebc432ca-00e8-4ced-b925-a1d744d031e7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64d35a88-72ff-46e6-b70d-434912eb4c26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ebc432ca-00e8-4ced-b925-a1d744d031e7"}, {"Element": "<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>", "ID": "97b0877d-80fc-4760-9a13-cd7c59786c18", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "7bcfda72-42eb-4c86-ba33-3f4331dbac31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "97b0877d-80fc-4760-9a13-cd7c59786c18"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "13e7fd8b-4f71-4f72-9412-027aae441e98", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7bcfda72-42eb-4c86-ba33-3f4331dbac31"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "41691095-3e6f-42eb-b8d3-aabda9b94de5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13e7fd8b-4f71-4f72-9412-027aae441e98"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "934c6d18-389e-4925-be46-3f6d5e6987b1", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "41691095-3e6f-42eb-b8d3-aabda9b94de5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d887761e-4d4d-486b-a9ce-44dfd77dd34d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "044bed9f-8eff-456b-917d-753bfcdd66f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d887761e-4d4d-486b-a9ce-44dfd77dd34d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8b3602f2-12c3-4724-9c6b-d497644a533c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eeb5be04-2ab6-456e-86d5-89f4e98e4d07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8b3602f2-12c3-4724-9c6b-d497644a533c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "082a515e-beef-4b49-ba46-2a8d5b12d7e3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a651032-6de6-456e-a758-b1ee8650a2c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "082a515e-beef-4b49-ba46-2a8d5b12d7e3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9956b450-6b7e-4f7b-97d6-e330d15deb3e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "267e2d58-5cb8-4234-8ba4-e0c86ac8722a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9956b450-6b7e-4f7b-97d6-e330d15deb3e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e91f84ea-3651-43df-afa4-7c2337b941c2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8717fe3-a817-4ce4-904f-f5151949f949", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e91f84ea-3651-43df-afa4-7c2337b941c2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a83e0cda-2221-42ff-a306-72be3fe081c0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55433a31-28eb-47b5-bf45-62e6b93155cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a83e0cda-2221-42ff-a306-72be3fe081c0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "186b988f-408e-4655-af0a-1f21be54df69", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f77656d8-037f-426e-bc02-7ab52a45d55c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "186b988f-408e-4655-af0a-1f21be54df69"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6dd2df98-d03d-445b-9541-161b0c5ab729", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc024dda-d3a6-4e0a-85bb-dc384988037c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6dd2df98-d03d-445b-9541-161b0c5ab729"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9efc083f-5e2a-4956-9880-d422be64b658", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf70f431-5cd0-4750-aa95-b5a81401ef53", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9efc083f-5e2a-4956-9880-d422be64b658"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc5e87ed-df13-4b8c-9381-b93b297670f1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "342bdd92-d2d9-42e3-80e5-b53970c6622f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc5e87ed-df13-4b8c-9381-b93b297670f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9269b21-6812-48d3-8843-36d7aa8bac10", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ad1992a-ead0-44ac-b891-c1fec8cb0f73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9269b21-6812-48d3-8843-36d7aa8bac10"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "70079ef2-4986-4709-b649-855346a5cc5c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea9e6d12-24e8-49bb-9b19-68f56ba0bcfb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "70079ef2-4986-4709-b649-855346a5cc5c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d8e0c2df-e81f-414e-a09c-56a1782bd35e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fcddd43-26a7-4855-81f5-6e65f964c3e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8e0c2df-e81f-414e-a09c-56a1782bd35e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a0df77d1-4f37-4a6f-9832-87ee8e33e080", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1cc048c8-a228-4b80-8f46-a2303e4a5694", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a0df77d1-4f37-4a6f-9832-87ee8e33e080"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "653ad29a-818a-4cd8-86ef-32c75208d29b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "54f2be4c-5c2d-41ad-9269-a8d42504dba6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "653ad29a-818a-4cd8-86ef-32c75208d29b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9eedc0d-3b6c-45b6-920a-f191310ba9e9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c261b90-b19b-4c15-b3c4-5a78ba9638d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9eedc0d-3b6c-45b6-920a-f191310ba9e9"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX I</span></p>", "ID": "884fce4d-787c-47aa-b44b-6f6944cefcab", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">ANNEX I</span>", "ID": "c6410ed1-d1c1-4cae-9a23-c604d198b3fc", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "884fce4d-787c-47aa-b44b-6f6944cefcab"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d8f473d2-e669-464f-8614-74c0cac10bb0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c4a8ff04-f370-4d4a-aae4-c6866503e460", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8f473d2-e669-464f-8614-74c0cac10bb0"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>", "ID": "a7e076ab-3955-4a45-b74d-c218beed471f", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span>", "ID": "dcfec1cb-a788-4b71-8fcb-fb8e4a8fea3c", "Styles": "None", "Classes": "None", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "a7e076ab-3955-4a45-b74d-c218beed471f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2152aba2-52bf-4ece-a580-e37200b8a1a3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6f770c79-d272-42f5-bf77-11036a560226", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2152aba2-52bf-4ece-a580-e37200b8a1a3"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "cb61ee6f-46e4-4cff-a264-7ea2ae98c661", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "2d2d86ce-faf0-4ffc-b310-974361c582e0", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "cb61ee6f-46e4-4cff-a264-7ea2ae98c661"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image001.gif\" width=\"21\"/>This medicinal product is subject to additional monitoring.\nThis will allow quick identification of new safety information. Healthcare\nprofessionals are asked to report any suspected adverse reactions. See\nsection\u00a04.8\u00a0for how to report adverse reactions.</span></p>", "ID": "c08fca59-9eba-42d8-b225-fc786d9c76ee", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image001.gif\" width=\"21\"/>This medicinal product is subject to additional monitoring.\nThis will allow quick identification of new safety information. Healthcare\nprofessionals are asked to report any suspected adverse reactions. See\nsection\u00a04.8\u00a0for how to report adverse reactions.</span>", "ID": "b0afc7d6-88fd-4f0c-9b97-eb6c1259580a", "Styles": "None", "Classes": "None", "Text": "This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section\u00a04.8\u00a0for how to report adverse reactions.", "ParentId": "c08fca59-9eba-42d8-b225-fc786d9c76ee"}, {"Element": "<img alt=\"BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image001.gif\" width=\"21\"/>", "ID": "8ee2e033-dd93-4b8b-8f6d-ba93102f96d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0afc7d6-88fd-4f0c-9b97-eb6c1259580a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b792d4a4-f591-48f0-a27f-bac3d3b2aa71", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb2f8828-aa7d-468c-b175-816cb20dad89", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b792d4a4-f591-48f0-a27f-bac3d3b2aa71"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0615bf65-48cc-46e0-be74-6ac2c3dfae8d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "03d8a120-80af-43e4-bd47-7baf5036f303", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0615bf65-48cc-46e0-be74-6ac2c3dfae8d"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></p>", "ID": "35756dde-57d5-4aaa-a7c1-fb959cfbb37c", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "8cfc154b-653b-459b-bac6-88f2c81795ec", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "35756dde-57d5-4aaa-a7c1-fb959cfbb37c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b021802-947a-4aa0-b050-8b112813ffd8", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37cc5469-1043-40d1-8df9-1c3a3c7c24f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b021802-947a-4aa0-b050-8b112813ffd8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nconcentrate for solution for infusion.</span></p>", "ID": "555b40c2-d959-4429-abd6-3bd8235142e1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nconcentrate for solution for infusion.</span>", "ID": "2bb9f8aa-3e09-4114-a09a-e28b3f8e3d2e", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate for solution for infusion.", "ParentId": "555b40c2-d959-4429-abd6-3bd8235142e1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "abc37f64-2899-4e94-93aa-c7dc7ea4fc04", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf85936e-d83f-4911-a27a-eb4a9a6c3d83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "abc37f64-2899-4e94-93aa-c7dc7ea4fc04"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "83348ca2-3d55-4622-8bd1-19667355c371", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa52e349-db8b-4e01-b7ec-166d3acf40ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83348ca2-3d55-4622-8bd1-19667355c371"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span></p>", "ID": "2309cb2f-a8bc-4686-807a-08de1400f691", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span>", "ID": "7474e7e7-5980-4389-907c-9ae5bbe80ccf", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "2309cb2f-a8bc-4686-807a-08de1400f691"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ef7831d-5d0a-47fd-a3f7-23a98f3757d0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c4ebbc72-30fc-4b53-943f-dd88c139b9b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ef7831d-5d0a-47fd-a3f7-23a98f3757d0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span></p>", "ID": "34176c9c-ff86-409e-9574-e5ae50f5d1bc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span>", "ID": "7038dfd0-99d6-40bb-a331-cd5ca95ac999", "Styles": "None", "Classes": "None", "Text": "Each mL of concentrate contains\u00a010\u00a0mg of nivolumab.", "ParentId": "34176c9c-ff86-409e-9574-e5ae50f5d1bc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">One vial of\u00a04\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span></p>", "ID": "7c2b45f8-e82c-4e4a-9667-f3334c20dda0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">One vial of\u00a04\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span>", "ID": "b4e1ee80-1099-4c0a-8100-185a1cbc5962", "Styles": "None", "Classes": "None", "Text": "One vial of\u00a04\u00a0mL contains\u00a040\u00a0mg of nivolumab.", "ParentId": "7c2b45f8-e82c-4e4a-9667-f3334c20dda0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">One vial of\u00a010\u00a0mL contains\u00a0100\u00a0mg\nof nivolumab.</span></p>", "ID": "fc94fd58-c30a-4c51-ab5e-0cb22863c955", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">One vial of\u00a010\u00a0mL contains\u00a0100\u00a0mg\nof nivolumab.</span>", "ID": "9c037b23-2417-414a-bb32-b1417239d660", "Styles": "None", "Classes": "None", "Text": "One vial of\u00a010\u00a0mL contains\u00a0100\u00a0mg of nivolumab.", "ParentId": "fc94fd58-c30a-4c51-ab5e-0cb22863c955"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ab2b135-27f6-4fee-b79f-1a15764ef071", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2015bf6-5c30-42e0-b8a2-4f699ebe6759", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ab2b135-27f6-4fee-b79f-1a15764ef071"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is produced in Chinese hamster\novary cells by recombinant DNA technology.</span></p>", "ID": "40d8b6a5-1697-4239-bc09-86df1439571e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is produced in Chinese hamster\novary cells by recombinant DNA technology.</span>", "ID": "2ffcd09e-f8c6-4a78-a6a1-9381c7f4e340", "Styles": "None", "Classes": "None", "Text": "Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology.", "ParentId": "40d8b6a5-1697-4239-bc09-86df1439571e"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "5b9a0e94-5e17-490e-9b57-96a1e87a93d7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "7123e133-699e-4cdd-9fbf-66888091aa8e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b9a0e94-5e17-490e-9b57-96a1e87a93d7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "f2f07e85-8ae4-4910-904d-26055926405f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7123e133-699e-4cdd-9fbf-66888091aa8e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "7f6022ab-31f4-48f9-8e6c-5f05fab4bf7d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "f2f07e85-8ae4-4910-904d-26055926405f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipient\nwith known effect</span></u></p>", "ID": "225256e9-82c7-4921-aea6-ca5a217d6afd", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Excipient\nwith known effect</span></u>", "ID": "fe8f6ca6-803a-41c7-80f9-e4c893614cba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "225256e9-82c7-4921-aea6-ca5a217d6afd"}, {"Element": "<span lang=\"EN-GB\">Excipient\nwith known effect</span>", "ID": "1bdb1092-1718-4d01-a62a-a092c48202fb", "Styles": "None", "Classes": "None", "Text": "Excipient with known effect", "ParentId": "fe8f6ca6-803a-41c7-80f9-e4c893614cba"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a00.1\u00a0mmol\n(or\u00a02.5\u00a0mg) sodium.</span></p>", "ID": "5e987ad4-2e3c-4527-88a0-5990eb7f2936", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each mL of concentrate contains\u00a00.1\u00a0mmol\n(or\u00a02.5\u00a0mg) sodium.</span>", "ID": "0da03c22-6f32-4192-9025-9ef2c693b3ee", "Styles": "None", "Classes": "None", "Text": "Each mL of concentrate contains\u00a00.1\u00a0mmol (or\u00a02.5\u00a0mg) sodium.", "ParentId": "5e987ad4-2e3c-4527-88a0-5990eb7f2936"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "200e7791-0516-4b39-a165-92dc60bb0d81", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d43667a4-36db-442a-8741-e85ba8a1596c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "200e7791-0516-4b39-a165-92dc60bb0d81"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span></p>", "ID": "5ab30164-2823-41bd-99c9-076de18b169e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span>", "ID": "6b4797f6-fd65-429e-b3db-b5e0de9398b5", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section\u00a06.1.", "ParentId": "5ab30164-2823-41bd-99c9-076de18b169e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e39e9cd0-d05a-4aeb-8bb8-b52a67f8f986", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77de56cd-a1bd-4470-92ad-828e706137e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e39e9cd0-d05a-4aeb-8bb8-b52a67f8f986"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a63d4cbd-2636-4a40-8b7c-511cc5cd42a8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea1b8cf8-4099-4bb7-9511-52fd9f29eedb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a63d4cbd-2636-4a40-8b7c-511cc5cd42a8"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span></p>", "ID": "95bc5da8-fb6a-424c-aada-78a0e7d07179", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span>", "ID": "81782bce-af1e-45fb-b36f-5a18d698174c", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM", "ParentId": "95bc5da8-fb6a-424c-aada-78a0e7d07179"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f57ba6be-bbb4-4e5c-b10f-821d1c355fad", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0a9a7adf-c771-4f84-bd34-c27f17951ac2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f57ba6be-bbb4-4e5c-b10f-821d1c355fad"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Concentrate for solution for infusion\n(sterile concentrate).</span></p>", "ID": "0faf978e-63c8-43be-a852-eb5ce5f21136", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Concentrate for solution for infusion\n(sterile concentrate).</span>", "ID": "c235d7ce-a30e-41a6-81d7-14dad7638cd9", "Styles": "None", "Classes": "None", "Text": "Concentrate for solution for infusion (sterile concentrate).", "ParentId": "0faf978e-63c8-43be-a852-eb5ce5f21136"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ae63990-7f53-414c-a53f-c6a1cf76fff6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8878731a-a755-4bda-b688-2dca0ba197d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ae63990-7f53-414c-a53f-c6a1cf76fff6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Clear to opalescent, colourless to pale\nyellow liquid that may contain few light particles. The solution has a pH of approximately\u00a06.0\nand an osmolality of approximately\u00a0340\u00a0mOsm/kg.</span></p>", "ID": "11d7b158-899a-4124-99b4-473b49702e9e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Clear to opalescent, colourless to pale\nyellow liquid that may contain few light particles. The solution has a pH of approximately\u00a06.0\nand an osmolality of approximately\u00a0340\u00a0mOsm/kg.</span>", "ID": "910de985-9843-4abe-a0f7-b5a5ee367960", "Styles": "None", "Classes": "None", "Text": "Clear to opalescent, colourless to pale yellow liquid that may contain few light particles. The solution has a pH of approximately\u00a06.0 and an osmolality of approximately\u00a0340\u00a0mOsm/kg.", "ParentId": "11d7b158-899a-4124-99b4-473b49702e9e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33d030f1-b92a-4e8c-be79-f10550db52d6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65d8309a-5c92-44cc-a76a-0e378be0c10b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33d030f1-b92a-4e8c-be79-f10550db52d6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ed99192-aba8-41ad-82f3-2811e37ea3df", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7ba04dc-65ad-43ff-8f54-60b4678099eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ed99192-aba8-41ad-82f3-2811e37ea3df"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span></p>", "ID": "4b578a93-bc48-4013-80aa-8aa08886707f", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span>", "ID": "cc819fad-45ab-42f2-b749-606d56297f62", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS", "ParentId": "4b578a93-bc48-4013-80aa-8aa08886707f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "958ccc06-b96a-4648-b6c3-ddfe641df7aa", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75df07f2-c3c1-45d3-aabf-29c258eb9dfd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "958ccc06-b96a-4648-b6c3-ddfe641df7aa"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span></p>", "ID": "4d3f8e94-9824-46cb-a714-dbbbd006c508", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span>", "ID": "14501326-e8ea-4957-ba93-dda1b6178ca8", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "4d3f8e94-9824-46cb-a714-dbbbd006c508"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0b6e3ce8-a53f-4f94-963c-adc3a524b2ca", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f68ce498-a9f7-4b24-9c5e-412610c198e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0b6e3ce8-a53f-4f94-963c-adc3a524b2ca"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is indicated for the\ntreatment of locally advanced or metastatic squamous non-small cell lung cancer\n(NSCLC) after prior chemotherapy</span><span lang=\"EN-GB\" style=\"color:black;\nbackground:white\"> in adults</span><span lang=\"EN-GB\">.</span></p>", "ID": "59e37ed5-01cf-442b-9812-ef1243b2d549", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS is indicated for the\ntreatment of locally advanced or metastatic squamous non-small cell lung cancer\n(NSCLC) after prior chemotherapy</span>", "ID": "102c29e6-7d54-4403-8d8b-d29e31d1efb0", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy", "ParentId": "59e37ed5-01cf-442b-9812-ef1243b2d549"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;\nbackground:white\"> in adults</span>", "ID": "304bdc7d-536b-465d-baec-78ad51d02ff2", "Styles": "color:black;\nbackground:white", "Classes": "None", "Text": " in adults", "ParentId": "59e37ed5-01cf-442b-9812-ef1243b2d549"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f57ab492-12fa-4123-a01a-dd86df1c469c", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "59e37ed5-01cf-442b-9812-ef1243b2d549"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "284ca2d4-8b55-41aa-a29b-76a7f266b18e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "439c9a8a-8647-41d4-9543-5073a658ffea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "284ca2d4-8b55-41aa-a29b-76a7f266b18e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c25b9b9b-c4f6-4915-832e-d5df0616d327", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ecb56c2-fc9b-415c-953e-ccf64c64060a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c25b9b9b-c4f6-4915-832e-d5df0616d327"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and\nmethod of administration</span></p>", "ID": "73d5a3d5-db64-4783-a758-5d9cb0870892", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and\nmethod of administration</span>", "ID": "7407f734-1931-440d-a70a-b0dbec0fac70", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "73d5a3d5-db64-4783-a758-5d9cb0870892"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "394abf5a-051d-4ca4-b719-f5d62f14ade5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "796f34d0-afe9-4f87-8637-0c61a2e23396", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "394abf5a-051d-4ca4-b719-f5d62f14ade5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Treatment must be initiated and\nsupervised by physicians experienced in the treatment of cancer.</span></p>", "ID": "ee01e39f-9a9d-4c4d-aada-2a96b4ae016c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Treatment must be initiated and\nsupervised by physicians experienced in the treatment of cancer.</span>", "ID": "5b123a2b-d630-45c9-acdd-aa968e580f15", "Styles": "None", "Classes": "None", "Text": "Treatment must be initiated and supervised by physicians experienced in the treatment of cancer.", "ParentId": "ee01e39f-9a9d-4c4d-aada-2a96b4ae016c"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "7c626326-8393-4b23-89e4-a50ca8142fae", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "dd8c18dc-d47d-4bbb-9c06-7951a42f82f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c626326-8393-4b23-89e4-a50ca8142fae"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "667b780d-45f0-440d-a680-31607ce58e01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dd8c18dc-d47d-4bbb-9c06-7951a42f82f4"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "678ca25d-cab5-4f26-8ca2-01d2c29a0757", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "667b780d-45f0-440d-a680-31607ce58e01"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p>", "ID": "000a4185-3f17-404e-879a-abff72dabf82", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Posology</span></u>", "ID": "681caf67-fa13-4f31-baa8-86b174ddc836", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "000a4185-3f17-404e-879a-abff72dabf82"}, {"Element": "<span lang=\"EN-GB\">Posology</span>", "ID": "90011ab3-e433-469e-9b5b-0dcb67ad7f76", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "681caf67-fa13-4f31-baa8-86b174ddc836"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The recommended dose of Nivolumab\u00a0BMS\nis\u00a03\u00a0mg/kg administered intravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks.\nTreatment should be continued as long as clinical benefit is observed or until treatment\nis no longer tolerated by the patient. </span></p>", "ID": "795aa1a2-9973-48f2-bcf6-eff58e0ac279", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The recommended dose of Nivolumab\u00a0BMS\nis\u00a03\u00a0mg/kg administered intravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks.\nTreatment should be continued as long as clinical benefit is observed or until treatment\nis no longer tolerated by the patient. </span>", "ID": "256d8877-0a07-4aff-a506-632af1f59b8b", "Styles": "None", "Classes": "None", "Text": "The recommended dose of Nivolumab\u00a0BMS is\u00a03\u00a0mg/kg administered intravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient. ", "ParentId": "795aa1a2-9973-48f2-bcf6-eff58e0ac279"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba49b431-313a-432f-b33f-85b0af86c3f1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be62e541-0c69-43df-8ff5-cb9e1bc29a0a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba49b431-313a-432f-b33f-85b0af86c3f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Dose escalation or reduction is not\nrecommended. Dosing delay or discontinuation may be required based on\nindividual safety and tolerability. </span><span lang=\"EN-GB\">Guidelines for\npermanent discontinuation or withholding of doses are described in\nTable\u00a01. Detailed guidelines for the management of immune\u2011related\nadverse reactions are described in section\u00a04.4.</span></p>", "ID": "8abb6c9d-4599-4553-846f-ac49bb8f3051", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Dose escalation or reduction is not\nrecommended. Dosing delay or discontinuation may be required based on\nindividual safety and tolerability. </span>", "ID": "aaba6323-8fa1-4893-81a3-e8b4f25592ba", "Styles": "None", "Classes": "None", "Text": "Dose escalation or reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability. ", "ParentId": "8abb6c9d-4599-4553-846f-ac49bb8f3051"}, {"Element": "<span lang=\"EN-GB\">Guidelines for\npermanent discontinuation or withholding of doses are described in\nTable\u00a01. Detailed guidelines for the management of immune\u2011related\nadverse reactions are described in section\u00a04.4.</span>", "ID": "8e3af4dc-8b1d-40e3-8e03-eddce851a76c", "Styles": "None", "Classes": "None", "Text": "Guidelines for permanent discontinuation or withholding of doses are described in Table\u00a01. Detailed guidelines for the management of immune\u2011related adverse reactions are described in section\u00a04.4.", "ParentId": "8abb6c9d-4599-4553-846f-ac49bb8f3051"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fdd72f79-1dba-40d0-accc-b7e61d3175a7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16df69be-5e0c-4eaf-b5af-54326e6e143f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fdd72f79-1dba-40d0-accc-b7e61d3175a7"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<thead>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\"><span lang=\"EN-GB\">Immune-related adverse reaction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Severity</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Treatment modification</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related pneumonitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related colitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related hepatitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Immune</span><span lang=\"EN-GB\">\u2011</span><span lang=\"FR-BE\">related rash</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a03 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\">Withhold dose until symptoms resolve and management\n  with corticosteroids is complete</p>\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a04 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Permanently discontinue </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n</table>", "ID": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "              ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<thead>\n<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>\n</thead>", "ID": "9ce6f655-207f-450e-8522-a3d951842367", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>", "ID": "d2013755-57dd-4e99-bb3d-6e7752734172", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "9ce6f655-207f-450e-8522-a3d951842367"}, {"Element": "<td colspan=\"3\" style=\"width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>\n</td>", "ID": "473d907e-5e3d-47e9-a370-a3f820b33e49", "Styles": "width:464.35pt;border:none;\n   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d2013755-57dd-4e99-bb3d-6e7752734172"}, {"Element": "<p class=\"BMSTableTitle\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span></p>", "ID": "fdb2162c-7f0e-4704-ae17-7539838fca7d", "Styles": "None", "Classes": "['BMSTableTitle']", "Text": "", "ParentId": "473d907e-5e3d-47e9-a370-a3f820b33e49"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended\n   treatment modifications for Nivolumab\u00a0BMS</span>", "ID": "37eb3a3a-119a-459a-80b0-d2729ee2bd9d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Table 1:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommended    treatment modifications for Nivolumab\u00a0BMS", "ParentId": "fdb2162c-7f0e-4704-ae17-7539838fca7d"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\"><span lang=\"EN-GB\">Immune-related adverse reaction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Severity</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Treatment modification</span></p>\n</td>\n</tr>", "ID": "c46ccbed-0238-466b-b795-97bac6c38c1f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\"><span lang=\"EN-GB\">Immune-related adverse reaction</span></p>\n</td>", "ID": "c580a4c9-18f8-4762-b1f5-2e3ac700137e", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c46ccbed-0238-466b-b795-97bac6c38c1f"}, {"Element": "<p align=\"left\" class=\"BMSTableHeader\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\"><span lang=\"EN-GB\">Immune-related adverse reaction</span></p>", "ID": "76b961e7-2952-4db9-88e5-c6858493093a", "Styles": "margin:0in;text-align:left;\n  page-break-after:avoid", "Classes": "['BMSTableHeader']", "Text": "", "ParentId": "c580a4c9-18f8-4762-b1f5-2e3ac700137e"}, {"Element": "<span lang=\"EN-GB\">Immune-related adverse reaction</span>", "ID": "e3a56b1b-272f-44a3-acb6-6a94840d3557", "Styles": "None", "Classes": "None", "Text": "Immune-related adverse reaction", "ParentId": "76b961e7-2952-4db9-88e5-c6858493093a"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Severity</span></p>\n</td>", "ID": "65703157-7605-4028-b6af-8e19b6eb8b58", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c46ccbed-0238-466b-b795-97bac6c38c1f"}, {"Element": "<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Severity</span></p>", "ID": "5c2fdd0f-7b87-4177-8589-ba6473fd2ee4", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableHeader']", "Text": "", "ParentId": "65703157-7605-4028-b6af-8e19b6eb8b58"}, {"Element": "<span lang=\"EN-GB\">Severity</span>", "ID": "882898dd-4643-4a12-b8f5-8bec799a840f", "Styles": "None", "Classes": "None", "Text": "Severity", "ParentId": "5c2fdd0f-7b87-4177-8589-ba6473fd2ee4"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Treatment modification</span></p>\n</td>", "ID": "34772391-2e0e-434e-9e34-2131534c39e0", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c46ccbed-0238-466b-b795-97bac6c38c1f"}, {"Element": "<p align=\"left\" class=\"BMSTableHeader\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Treatment modification</span></p>", "ID": "0b5809fb-ad97-4f91-9b4f-c079c4111834", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableHeader']", "Text": "", "ParentId": "34772391-2e0e-434e-9e34-2131534c39e0"}, {"Element": "<span lang=\"EN-GB\">Treatment modification</span>", "ID": "074ae73b-5933-412d-bb48-8559a0ed4910", "Styles": "None", "Classes": "None", "Text": "Treatment modification", "ParentId": "0b5809fb-ad97-4f91-9b4f-c079c4111834"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related pneumonitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span></p>\n</td>\n</tr>", "ID": "7134eed4-cc0e-406d-a72a-a52f1a2a6c5e", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related pneumonitis</span></p>\n</td>", "ID": "dad95045-4199-405d-85cd-8d234cbd9b99", "Styles": "width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7134eed4-cc0e-406d-a72a-a52f1a2a6c5e"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related pneumonitis</span></p>", "ID": "7a488d9f-edee-4fcd-9477-fefa242540fd", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "dad95045-4199-405d-85cd-8d234cbd9b99"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related pneumonitis</span>", "ID": "7fc51840-f969-435b-8780-2c365defc0ab", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related pneumonitis", "ParentId": "7a488d9f-edee-4fcd-9477-fefa242540fd"}, {"Element": "<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span></p>\n</td>", "ID": "bdf334d0-ddec-4bb1-99b9-681fbc1077b6", "Styles": "width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7134eed4-cc0e-406d-a72a-a52f1a2a6c5e"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span></p>", "ID": "381ca5ce-5be2-4292-bb48-03bab1e7b94f", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "bdf334d0-ddec-4bb1-99b9-681fbc1077b6"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a02\u00a0pneumonitis </span>", "ID": "ea2a9e3c-935e-4294-81fd-ac54892b3ee6", "Styles": "None", "Classes": "None", "Text": "Grade\u00a02\u00a0pneumonitis ", "ParentId": "381ca5ce-5be2-4292-bb48-03bab1e7b94f"}, {"Element": "<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span></p>\n</td>", "ID": "bec00aa7-8608-49cd-8cd8-49899e4bdf29", "Styles": "width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7134eed4-cc0e-406d-a72a-a52f1a2a6c5e"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span></p>", "ID": "b1924af0-64c6-4332-9a2c-6de44b386906", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "bec00aa7-8608-49cd-8cd8-49899e4bdf29"}, {"Element": "<span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic\n  abnormalities improve, and management with corticosteroids is complete<a name=\"PlaceHolderTableNotes\"></a></span>", "ID": "d1419dda-9ca5-48cf-b8b1-0c2fd560e88a", "Styles": "None", "Classes": "None", "Text": "Withhold Nivolumab\u00a0BMS until symptoms resolve, radiographic   abnormalities improve, and management with corticosteroids is complete", "ParentId": "b1924af0-64c6-4332-9a2c-6de44b386906"}, {"Element": "<a name=\"PlaceHolderTableNotes\"></a>", "ID": "628511c9-666c-413e-b436-d90e7948f1ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1419dda-9ca5-48cf-b8b1-0c2fd560e88a"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span></p>\n</td>\n</tr>", "ID": "54d807a3-37fe-45c4-ad0c-1a1ef71a79ef", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "2e54583f-6624-45e7-b0bd-c0e3011c3b2f", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54d807a3-37fe-45c4-ad0c-1a1ef71a79ef"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "508bfc26-8b1b-4e39-80cc-acdca860fba7", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "2e54583f-6624-45e7-b0bd-c0e3011c3b2f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5954c4a-102f-44b5-a849-547cfc7db706", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "508bfc26-8b1b-4e39-80cc-acdca860fba7"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span></p>\n</td>", "ID": "c764b6a0-b1f8-4b3e-abf6-51ef6fa209f3", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54d807a3-37fe-45c4-ad0c-1a1ef71a79ef"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span></p>", "ID": "28ebc330-9459-4bdd-9f9a-dc035aa3d207", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "c764b6a0-b1f8-4b3e-abf6-51ef6fa209f3"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis</span>", "ID": "387ddfb9-c847-4cbc-9dd7-f18c2538c9a9", "Styles": "None", "Classes": "None", "Text": "Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis", "ParentId": "28ebc330-9459-4bdd-9f9a-dc035aa3d207"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span></p>\n</td>", "ID": "77a21bfe-962f-49d9-be87-fa6f3fd49906", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54d807a3-37fe-45c4-ad0c-1a1ef71a79ef"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span></p>", "ID": "8cc0cba6-1ef7-45a2-9098-00fa23a4c992", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "77a21bfe-962f-49d9-be87-fa6f3fd49906"}, {"Element": "<span lang=\"EN-GB\">Permanently discontinue Nivolumab BMS</span>", "ID": "d7617be7-6c36-4031-b917-d58769f44230", "Styles": "None", "Classes": "None", "Text": "Permanently discontinue Nivolumab BMS", "ParentId": "8cc0cba6-1ef7-45a2-9098-00fa23a4c992"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related colitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span></p>\n</td>\n</tr>", "ID": "c56aad7e-7c72-4a2d-ac99-81500e8f6a43", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related colitis</span></p>\n</td>", "ID": "7432a162-a2d1-4f95-857c-f4d8e435b2c5", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c56aad7e-7c72-4a2d-ac99-81500e8f6a43"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related colitis</span></p>", "ID": "ee942e94-440c-4397-89f3-17a690acd2ef", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "7432a162-a2d1-4f95-857c-f4d8e435b2c5"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related colitis</span>", "ID": "90c5949c-cd16-42b0-a6c9-971132d2bdc1", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related colitis", "ParentId": "ee942e94-440c-4397-89f3-17a690acd2ef"}, {"Element": "<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span></p>\n</td>", "ID": "a07fcb9b-c45b-4ea9-89f5-bdc8fabdf209", "Styles": "width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c56aad7e-7c72-4a2d-ac99-81500e8f6a43"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span></p>", "ID": "160d108e-e51c-4d4e-9678-05393ab3d7d0", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "a07fcb9b-c45b-4ea9-89f5-bdc8fabdf209"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis</span>", "ID": "20988a6d-2c1f-4e49-99da-a88ec4d74089", "Styles": "None", "Classes": "None", "Text": "Grade\u00a02\u00a0or\u00a03\u00a0diarrhoea or colitis", "ParentId": "160d108e-e51c-4d4e-9678-05393ab3d7d0"}, {"Element": "<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span></p>\n</td>", "ID": "9cf1407a-f50f-4ffc-bb7b-1ae860b6dc6e", "Styles": "width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c56aad7e-7c72-4a2d-ac99-81500e8f6a43"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span></p>", "ID": "f8288fed-e66e-4df0-b78d-5a6993f6092e", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "9cf1407a-f50f-4ffc-bb7b-1ae860b6dc6e"}, {"Element": "<span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids, if needed, is complete</span>", "ID": "5c0c8f09-d6ae-45a0-9bbe-8deb72869673", "Styles": "None", "Classes": "None", "Text": "Withhold Nivolumab\u00a0BMS until symptoms resolve   and management with corticosteroids, if needed, is complete", "ParentId": "f8288fed-e66e-4df0-b78d-5a6993f6092e"}, {"Element": "<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>", "ID": "085c247b-1d0d-41c9-9813-a45552a66f03", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span></p>\n</td>", "ID": "fe2c3204-1aeb-400d-ac6c-5376c90fc38c", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "085c247b-1d0d-41c9-9813-a45552a66f03"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span></p>", "ID": "53257d49-72c7-4802-baff-0056f976183a", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "fe2c3204-1aeb-400d-ac6c-5376c90fc38c"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a04\u00a0diarrhoea or colitis</span>", "ID": "9e0d4fa9-316f-4d7e-91b5-407bc2411656", "Styles": "None", "Classes": "None", "Text": "Grade\u00a04\u00a0diarrhoea or colitis", "ParentId": "53257d49-72c7-4802-baff-0056f976183a"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>", "ID": "7500392b-e7bc-49bc-b21e-177013817bdb", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "085c247b-1d0d-41c9-9813-a45552a66f03"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>", "ID": "3e98ffe4-c074-45be-be33-3d183c365a5a", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "7500392b-e7bc-49bc-b21e-177013817bdb"}, {"Element": "<span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span>", "ID": "132d39f3-7921-4941-ba7a-8f8ac4a1068f", "Styles": "None", "Classes": "None", "Text": "Permanently discontinue Nivolumab\u00a0BMS", "ParentId": "3e98ffe4-c074-45be-be33-3d183c365a5a"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related hepatitis</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span></p>\n</td>\n</tr>", "ID": "6dab81a9-0005-42f3-a3f6-e31942be4949", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related hepatitis</span></p>\n</td>", "ID": "7faf4d7f-69f5-457c-b130-575883ceba53", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6dab81a9-0005-42f3-a3f6-e31942be4949"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related hepatitis</span></p>", "ID": "539be185-5abd-44ca-aebc-ed591d5fd4d8", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "7faf4d7f-69f5-457c-b130-575883ceba53"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related hepatitis</span>", "ID": "65e59e50-26fe-4006-b346-d2beeffc32aa", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related hepatitis", "ParentId": "539be185-5abd-44ca-aebc-ed591d5fd4d8"}, {"Element": "<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>\n</td>", "ID": "59fe1d3a-2953-43f2-bbff-7dca42a2e2ce", "Styles": "width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6dab81a9-0005-42f3-a3f6-e31942be4949"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>", "ID": "8f31d3d6-4cb4-4d06-97ac-0cc1a8241468", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "59fe1d3a-2953-43f2-bbff-7dca42a2e2ce"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a02\u00a0elevation in aspartate\n  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span>", "ID": "f086d4b9-3edb-40d7-826f-59a13422fddb", "Styles": "None", "Classes": "None", "Text": "Grade\u00a02\u00a0elevation in aspartate   aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin ", "ParentId": "8f31d3d6-4cb4-4d06-97ac-0cc1a8241468"}, {"Element": "<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span></p>\n</td>", "ID": "a854a2ba-8ec7-44c7-8005-a94b4f0a3ed3", "Styles": "width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6dab81a9-0005-42f3-a3f6-e31942be4949"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span></p>", "ID": "0fbaaa0b-12f8-4fb5-8d4b-ff33a758f35c", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "a854a2ba-8ec7-44c7-8005-a94b4f0a3ed3"}, {"Element": "<span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until laboratory values\n  return to baseline and management with corticosteroids, if needed, is\n  complete</span>", "ID": "0c123505-d32e-49b2-a699-59dec2953fbe", "Styles": "None", "Classes": "None", "Text": "Withhold Nivolumab\u00a0BMS until laboratory values   return to baseline and management with corticosteroids, if needed, is   complete", "ParentId": "0fbaaa0b-12f8-4fb5-8d4b-ff33a758f35c"}, {"Element": "<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>", "ID": "7db7838e-6c8d-4183-ae07-08e2e9938e2c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span></p>\n</td>", "ID": "9253e8cd-7c41-451a-8519-af04c5ed14eb", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7db7838e-6c8d-4183-ae07-08e2e9938e2c"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span></p>", "ID": "28dbbf98-e089-4af9-95f6-c4c76255bc78", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "9253e8cd-7c41-451a-8519-af04c5ed14eb"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,\n  ALT, or total bilirubin </span>", "ID": "993b8d0e-2a41-4df9-a074-1043c9742e20", "Styles": "None", "Classes": "None", "Text": "Grade\u00a03\u00a0or\u00a04\u00a0elevation in AST,   ALT, or total bilirubin ", "ParentId": "28dbbf98-e089-4af9-95f6-c4c76255bc78"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>", "ID": "d5e19959-227a-4659-b5dc-bf32f0f193c1", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7db7838e-6c8d-4183-ae07-08e2e9938e2c"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>", "ID": "098c87a0-0ebc-487b-8680-a4d22f999668", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "d5e19959-227a-4659-b5dc-bf32f0f193c1"}, {"Element": "<span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span>", "ID": "6e8e2897-173e-454e-8ab3-dbc0564fd9f1", "Styles": "None", "Classes": "None", "Text": "Permanently discontinue Nivolumab\u00a0BMS", "ParentId": "098c87a0-0ebc-487b-8680-a4d22f999668"}, {"Element": "<tr>\n<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span></p>\n</td>\n</tr>", "ID": "ae6df10e-da82-4399-9eb5-d6ae6a176f41", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td rowspan=\"2\" style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span></p>\n</td>", "ID": "ffc03da1-f8a7-43ce-9557-b83b176f7aa5", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ae6df10e-da82-4399-9eb5-d6ae6a176f41"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span></p>", "ID": "36ec5196-a853-4022-a215-2ce60eecf726", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "ffc03da1-f8a7-43ce-9557-b83b176f7aa5"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related nephritis and renal dysfunction</span>", "ID": "8508c2cc-0d8f-4e5a-8e35-9ba205735487", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related nephritis and renal dysfunction", "ParentId": "36ec5196-a853-4022-a215-2ce60eecf726"}, {"Element": "<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span></p>\n</td>", "ID": "c2f3c926-e0ca-4cde-95e5-ee9240193dbb", "Styles": "width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ae6df10e-da82-4399-9eb5-d6ae6a176f41"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span></p>", "ID": "492ae528-283d-4e8b-afb6-39a7f9ba8266", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "c2f3c926-e0ca-4cde-95e5-ee9240193dbb"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation\n  </span>", "ID": "49bc75ed-f442-4edd-bcc9-6e9057715d50", "Styles": "None", "Classes": "None", "Text": "Grade\u00a02\u00a0or\u00a03\u00a0creatinine elevation   ", "ParentId": "492ae528-283d-4e8b-afb6-39a7f9ba8266"}, {"Element": "<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span></p>\n</td>", "ID": "4ed54fb2-a225-49e1-9725-2136428a34dc", "Styles": "width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ae6df10e-da82-4399-9eb5-d6ae6a176f41"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span></p>", "ID": "5ac72106-eaa4-417c-b28d-9ed58fe266f7", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "4ed54fb2-a225-49e1-9725-2136428a34dc"}, {"Element": "<span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until creatinine returns\n  to baseline and management with corticosteroids is complete</span>", "ID": "eca7d273-12aa-4a6c-8549-d2b8fd8b2904", "Styles": "None", "Classes": "None", "Text": "Withhold Nivolumab\u00a0BMS until creatinine returns   to baseline and management with corticosteroids is complete", "ParentId": "5ac72106-eaa4-417c-b28d-9ed58fe266f7"}, {"Element": "<tr>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>", "ID": "6b1ee1d1-5155-4778-ab5c-25409f6667f3", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span></p>\n</td>", "ID": "6979e52a-17fb-4d6d-b4bf-1d7701ba7e6e", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6b1ee1d1-5155-4778-ab5c-25409f6667f3"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span></p>", "ID": "187fb680-cb3f-4d46-a739-1981c4f3c58f", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "6979e52a-17fb-4d6d-b4bf-1d7701ba7e6e"}, {"Element": "<span lang=\"EN-GB\">Grade\u00a04\u00a0creatinine elevation</span>", "ID": "47ac1f71-f0be-4de9-b5ad-7e4a547694f4", "Styles": "None", "Classes": "None", "Text": "Grade\u00a04\u00a0creatinine elevation", "ParentId": "187fb680-cb3f-4d46-a739-1981c4f3c58f"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>\n</td>", "ID": "be64da21-90a0-44f4-8b9d-05ac7ada0466", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6b1ee1d1-5155-4778-ab5c-25409f6667f3"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span></p>", "ID": "f7a1e85a-349d-4cd2-a9d0-2fd2ef47ea46", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "be64da21-90a0-44f4-8b9d-05ac7ada0466"}, {"Element": "<span lang=\"EN-GB\">Permanently discontinue Nivolumab\u00a0BMS</span>", "ID": "d7ea6d18-e9a9-4a33-b980-94b76e431771", "Styles": "None", "Classes": "None", "Text": "Permanently discontinue Nivolumab\u00a0BMS", "ParentId": "f7a1e85a-349d-4cd2-a9d0-2fd2ef47ea46"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span></p>\n</td>\n</tr>", "ID": "39f2b8b6-3e26-4524-84a1-bc0724ae7ab0", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span></p>\n</td>", "ID": "b08d5b74-c5be-4c64-a9b4-900dc31a432b", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39f2b8b6-3e26-4524-84a1-bc0724ae7ab0"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span></p>", "ID": "b403be0f-079f-4aa0-a9ac-048cb8b4c362", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "b08d5b74-c5be-4c64-a9b4-900dc31a432b"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related endocrinopathies</span>", "ID": "34d91046-03ce-4f76-9ede-92e0bc95e1a7", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related endocrinopathies", "ParentId": "b403be0f-079f-4aa0-a9ac-048cb8b4c362"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span></p>\n</td>", "ID": "55515b15-a367-42ca-b30c-a944ce6f2227", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39f2b8b6-3e26-4524-84a1-bc0724ae7ab0"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span></p>", "ID": "870fe9b1-f0e6-43fa-b3ad-f0224663b7f8", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "55515b15-a367-42ca-b30c-a944ce6f2227"}, {"Element": "<span lang=\"EN-GB\">Symptomatic endocrinopathies (including\n  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and\n  diabetes)</span>", "ID": "25437ce7-ec9a-4309-a7b0-b364ac14fe5b", "Styles": "None", "Classes": "None", "Text": "Symptomatic endocrinopathies (including   hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and   diabetes)", "ParentId": "870fe9b1-f0e6-43fa-b3ad-f0224663b7f8"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span></p>\n</td>", "ID": "5481065d-809a-460d-a7fa-9510c8fd6203", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39f2b8b6-3e26-4524-84a1-bc0724ae7ab0"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span></p>", "ID": "8a02e420-e746-433c-873d-7c1bcde6d28a", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "5481065d-809a-460d-a7fa-9510c8fd6203"}, {"Element": "<span lang=\"EN-GB\">Withhold Nivolumab\u00a0BMS until symptoms resolve\n  and management with corticosteroids (if needed for symptoms of acute\n  inflammation) is complete. Nivolumab\u00a0BMS should be continued in the\n  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms\n  are present</span>", "ID": "9ea7cb20-808f-488a-9bd7-3b768df1ac00", "Styles": "None", "Classes": "None", "Text": "Withhold Nivolumab\u00a0BMS until symptoms resolve   and management with corticosteroids (if needed for symptoms of acute   inflammation) is complete. Nivolumab\u00a0BMS should be continued in the   presence of hormone replacement therapy as long as no symptoms   are present", "ParentId": "8a02e420-e746-433c-873d-7c1bcde6d28a"}, {"Element": "<sup>a</sup>", "ID": "de902f76-bf52-42c8-b7de-60783ec40f25", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "9ea7cb20-808f-488a-9bd7-3b768df1ac00"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Immune</span><span lang=\"EN-GB\">\u2011</span><span lang=\"FR-BE\">related rash</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a03 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\">Withhold dose until symptoms resolve and management\n  with corticosteroids is complete</p>\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "13eeb93f-83bf-4c8a-b7df-3be82b33228a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Immune</span><span lang=\"EN-GB\">\u2011</span><span lang=\"FR-BE\">related rash</span></p>\n</td>", "ID": "b16d943d-6cfa-4475-aae0-f2442ce7cadd", "Styles": "width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13eeb93f-83bf-4c8a-b7df-3be82b33228a"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Immune</span><span lang=\"EN-GB\">\u2011</span><span lang=\"FR-BE\">related rash</span></p>", "ID": "7aee512f-e113-4b4c-8182-360cc75465ea", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "b16d943d-6cfa-4475-aae0-f2442ce7cadd"}, {"Element": "<span lang=\"FR-BE\">Immune</span>", "ID": "7ea456f9-c903-4536-88db-657820d75e9f", "Styles": "None", "Classes": "None", "Text": "Immune", "ParentId": "7aee512f-e113-4b4c-8182-360cc75465ea"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "a82f4dc8-f267-4fdd-99f3-b8900dca78ea", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "7aee512f-e113-4b4c-8182-360cc75465ea"}, {"Element": "<span lang=\"FR-BE\">related rash</span>", "ID": "9a217d5b-bc06-4e36-b02b-e08bb7c9ebf3", "Styles": "None", "Classes": "None", "Text": "related rash", "ParentId": "7aee512f-e113-4b4c-8182-360cc75465ea"}, {"Element": "<td style=\"width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a03 rash</span></p>\n</td>", "ID": "4d0a8801-b816-433f-bde6-b68ce3c7b7a1", "Styles": "width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13eeb93f-83bf-4c8a-b7df-3be82b33228a"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a03 rash</span></p>", "ID": "16f1747f-5ffb-42eb-8bd9-0262eee2b7de", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "4d0a8801-b816-433f-bde6-b68ce3c7b7a1"}, {"Element": "<span lang=\"FR-BE\">Grade\u00a03 rash</span>", "ID": "10cc705e-d8b9-4434-a94a-bb674590e278", "Styles": "None", "Classes": "None", "Text": "Grade\u00a03 rash", "ParentId": "16f1747f-5ffb-42eb-8bd9-0262eee2b7de"}, {"Element": "<td style=\"width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\">Withhold dose until symptoms resolve and management\n  with corticosteroids is complete</p>\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "31ad66a5-fd87-4264-8dff-018d98027ed6", "Styles": "width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "13eeb93f-83bf-4c8a-b7df-3be82b33228a"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"margin:0in;text-align:left;\n  page-break-after:avoid\">Withhold dose until symptoms resolve and management\n  with corticosteroids is complete</p>", "ID": "a3745985-2596-45fe-8612-e87432ee76e3", "Styles": "margin:0in;text-align:left;\n  page-break-after:avoid", "Classes": "['BMSTableText']", "Text": "Withhold dose until symptoms resolve and management   with corticosteroids is complete", "ParentId": "31ad66a5-fd87-4264-8dff-018d98027ed6"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b851aa2-1da0-4440-92d9-2d7a80e1308b", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "31ad66a5-fd87-4264-8dff-018d98027ed6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d30b69be-9c4c-48fa-bd0c-a2b627273c01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b851aa2-1da0-4440-92d9-2d7a80e1308b"}, {"Element": "<tr>\n<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a04 rash</span></p>\n</td>\n<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Permanently discontinue </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></p>\n</td>\n</tr>", "ID": "c791e591-82d1-46d5-868a-3a53aa2e600b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2fa2cfbf-8da3-41a5-9faf-475f23243b3d"}, {"Element": "<td style=\"width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"148\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "38b92742-7f32-44cf-b43a-ad8488139ccb", "Styles": "width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c791e591-82d1-46d5-868a-3a53aa2e600b"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3297ebed-1b3d-435a-a3a8-c75c7b333b7e", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "38b92742-7f32-44cf-b43a-ad8488139ccb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "45825e52-9393-44bd-9044-441abbbd3d34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3297ebed-1b3d-435a-a3a8-c75c7b333b7e"}, {"Element": "<td style=\"width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a04 rash</span></p>\n</td>", "ID": "6dffdb08-611e-4471-9791-e1d63dec73f5", "Styles": "width:177.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c791e591-82d1-46d5-868a-3a53aa2e600b"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Grade\u00a04 rash</span></p>", "ID": "f822d180-342b-40e5-8099-9b2f0ee67193", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "6dffdb08-611e-4471-9791-e1d63dec73f5"}, {"Element": "<span lang=\"FR-BE\">Grade\u00a04 rash</span>", "ID": "a472d473-cc57-487e-8fd5-cb003b3e4f19", "Styles": "None", "Classes": "None", "Text": "Grade\u00a04 rash", "ParentId": "f822d180-342b-40e5-8099-9b2f0ee67193"}, {"Element": "<td style=\"width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Permanently discontinue </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></p>\n</td>", "ID": "b94f6ef2-ff5b-45c5-90d5-2ca0c8dc0fd6", "Styles": "width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c791e591-82d1-46d5-868a-3a53aa2e600b"}, {"Element": "<p align=\"left\" class=\"BMSTableText\" style=\"text-align:left;page-break-after:\n  avoid\"><span lang=\"FR-BE\">Permanently discontinue </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></p>", "ID": "3ab1d1c0-14f9-490a-887f-3bd65587b11f", "Styles": "text-align:left;page-break-after:\n  avoid", "Classes": "['BMSTableText']", "Text": "", "ParentId": "b94f6ef2-ff5b-45c5-90d5-2ca0c8dc0fd6"}, {"Element": "<span lang=\"FR-BE\">Permanently discontinue </span>", "ID": "878ee87e-2354-4930-8dc8-0b87df5c3008", "Styles": "None", "Classes": "None", "Text": "Permanently discontinue ", "ParentId": "3ab1d1c0-14f9-490a-887f-3bd65587b11f"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "e5d17023-468e-4558-ad7f-b17346dc7fbd", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "3ab1d1c0-14f9-490a-887f-3bd65587b11f"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Note: Toxicity grades are in accordance\nwith National Cancer Institute Common Terminology Criteria for Adverse Events\nVersion\u00a04.0\u00a0(NCI\u2011CTCAE v4).</span></p>", "ID": "f7116fe3-3000-48a4-870b-45412cb5314d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Note: Toxicity grades are in accordance\nwith National Cancer Institute Common Terminology Criteria for Adverse Events\nVersion\u00a04.0\u00a0(NCI\u2011CTCAE v4).</span>", "ID": "5af7d056-cf16-4a0f-812f-3032b2754295", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version\u00a04.0\u00a0(NCI\u2011CTCAE v4).", "ParentId": "f7116fe3-3000-48a4-870b-45412cb5314d"}, {"Element": "<p align=\"left\" class=\"BMSBodyText\" style=\"margin-bottom:0in;text-align:left;\nline-height:normal\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendation for the\nuse of hormone replacement therapy is provided in section 4.4.</span></p>", "ID": "7d1f0bdb-550d-40a0-a60b-7b64d3b2371d", "Styles": "margin-bottom:0in;text-align:left;\nline-height:normal", "Classes": "['BMSBodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a</span></span>", "ID": "5325d57d-7e6b-4401-9fb2-d4dc3e0a363f", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "7d1f0bdb-550d-40a0-a60b-7b64d3b2371d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">a</span>", "ID": "5a77e853-d1dc-4549-86a3-e8d8c2de74a4", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "a", "ParentId": "5325d57d-7e6b-4401-9fb2-d4dc3e0a363f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendation for the\nuse of hormone replacement therapy is provided in section 4.4.</span>", "ID": "b575a84f-054c-4004-8075-91283cf4e395", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Recommendation for the use of hormone replacement therapy is provided in section 4.4.", "ParentId": "7d1f0bdb-550d-40a0-a60b-7b64d3b2371d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb726dd9-353f-40cb-82e0-bf73b7c1da10", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b5cf1f0-a396-455d-a026-a1d9f7a49c46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb726dd9-353f-40cb-82e0-bf73b7c1da10"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS should also be\npermanently discontinued for Grade\u00a02\u00a0or\u00a03\u00a0immune\u2011related\nadverse reactions that persist despite treatment modifications (see\nsection\u00a04.4) or for inability to reduce corticosteroid dose\nto\u00a010\u00a0mg prednisone or equivalent per day.</span></p>", "ID": "54a00a38-29ec-439e-afe8-fa01215c0349", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS should also be\npermanently discontinued for Grade\u00a02\u00a0or\u00a03\u00a0immune\u2011related\nadverse reactions that persist despite treatment modifications (see\nsection\u00a04.4) or for inability to reduce corticosteroid dose\nto\u00a010\u00a0mg prednisone or equivalent per day.</span>", "ID": "e388b008-cc1b-4ba4-80d9-1b6904be9ca9", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS should also be permanently discontinued for Grade\u00a02\u00a0or\u00a03\u00a0immune\u2011related adverse reactions that persist despite treatment modifications (see section\u00a04.4) or for inability to reduce corticosteroid dose to\u00a010\u00a0mg prednisone or equivalent per day.", "ParentId": "54a00a38-29ec-439e-afe8-fa01215c0349"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1447c742-3b61-46f1-802d-0069302c730a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25ba269d-586f-4624-b4e7-39a1d1bc33fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1447c742-3b61-46f1-802d-0069302c730a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patients treated with Nivolumab\u00a0BMS\nmust be given the patient alert card and be informed about the risks of\nNivolumab\u00a0BMS (see also package leaflet).</span></p>", "ID": "dce9325b-fa31-4e5f-8509-f50354bc0c47", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Patients treated with Nivolumab\u00a0BMS\nmust be given the patient alert card and be informed about the risks of\nNivolumab\u00a0BMS (see also package leaflet).</span>", "ID": "d94643cf-7fa7-4e35-9fdc-e4a768c4a8c0", "Styles": "None", "Classes": "None", "Text": "Patients treated with Nivolumab\u00a0BMS must be given the patient alert card and be informed about the risks of Nivolumab\u00a0BMS (see also package leaflet).", "ParentId": "dce9325b-fa31-4e5f-8509-f50354bc0c47"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i></p>", "ID": "f3a1f5a2-97b6-44e7-8f8f-5e5ec4a39c65", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i>", "ID": "db0a6960-bcca-4e24-9f82-a3b07a5ae13c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3a1f5a2-97b6-44e7-8f8f-5e5ec4a39c65"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations</span></u>", "ID": "3ae8d92b-d306-4798-894d-c780a493cdb5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db0a6960-bcca-4e24-9f82-a3b07a5ae13c"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations</span>", "ID": "8df60f35-1fc7-4865-8f2c-07a4a15dfb3d", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "3ae8d92b-d306-4798-894d-c780a493cdb5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "a3a741c7-9e50-4956-a844-ac61a39d511d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "9ea66006-803b-427a-b247-a3104a4cf734", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a3a741c7-9e50-4956-a844-ac61a39d511d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "894058dd-b8d4-4b4a-88c2-b73d9a6253d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ea66006-803b-427a-b247-a3104a4cf734"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>", "ID": "52a9fed5-c6b0-4f6e-bfd5-59d6c19a980b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation</span></i>", "ID": "cf875821-3b8a-4535-8723-2a6b7dc779ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "52a9fed5-c6b0-4f6e-bfd5-59d6c19a980b"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "5d70f1c4-aab8-4d1d-a12d-8586fbc82e01", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "cf875821-3b8a-4535-8723-2a6b7dc779ad"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of\nNivolumab\u00a0BMS in children below\u00a018\u00a0years of age have not been\nestablished. No data are available.</span></p>", "ID": "0a8cdfaa-f72c-4643-baa0-1f49f6bc1d7b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of\nNivolumab\u00a0BMS in children below\u00a018\u00a0years of age have not been\nestablished. No data are available.</span>", "ID": "90993e41-9e97-4c79-8313-72cc638bd336", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Nivolumab\u00a0BMS in children below\u00a018\u00a0years of age have not been established. No data are available.", "ParentId": "0a8cdfaa-f72c-4643-baa0-1f49f6bc1d7b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "871110cd-3bb8-4ca7-bace-a509a23cfe70", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5cb3f329-2e7a-40c4-b929-62ff7526ed80", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "871110cd-3bb8-4ca7-bace-a509a23cfe70"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly\n</span></i></p>", "ID": "206f6cea-9037-4d49-8946-dddedaf1c7bf", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">Elderly\n</span></i>", "ID": "a24179c8-ba3e-4124-9a21-b2070fb515e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "206f6cea-9037-4d49-8946-dddedaf1c7bf"}, {"Element": "<span lang=\"EN-GB\">Elderly\n</span>", "ID": "83677bcc-1145-472e-a061-e576b8c102ec", "Styles": "None", "Classes": "None", "Text": "Elderly ", "ParentId": "a24179c8-ba3e-4124-9a21-b2070fb515e0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dose adjustment is required for elderly\npatients (\u2265\u00a065\u00a0years) (see sections\u00a05.1 and\u00a05.2). Data\nfrom patients 75\u00a0years of age or older are too limited to draw conclusions\non this population.</span></p>", "ID": "7513a27a-9214-4dce-8c25-af0b014077e2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment is required for elderly\npatients (\u2265\u00a065\u00a0years) (see sections\u00a05.1 and\u00a05.2). Data\nfrom patients 75\u00a0years of age or older are too limited to draw conclusions\non this population.</span>", "ID": "3daf67dc-72b7-487c-ba90-bd1519b84033", "Styles": "None", "Classes": "None", "Text": "No dose adjustment is required for elderly patients (\u2265\u00a065\u00a0years) (see sections\u00a05.1 and\u00a05.2). Data from patients 75\u00a0years of age or older are too limited to draw conclusions on this population.", "ParentId": "7513a27a-9214-4dce-8c25-af0b014077e2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "541b0ccc-886e-401d-a7ef-e1fdb4936988", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3fe3b943-5432-42bd-8a96-3af3b270136a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "541b0ccc-886e-401d-a7ef-e1fdb4936988"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\nimpairment</span></i></p>", "ID": "06cc73fd-6c33-4693-81cb-e899df5376e5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">Renal\nimpairment</span></i>", "ID": "7f26838f-905a-4202-bc0a-4946b818ed6c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06cc73fd-6c33-4693-81cb-e899df5376e5"}, {"Element": "<span lang=\"EN-GB\">Renal\nimpairment</span>", "ID": "12e4bd68-737a-44f2-91c0-194dbd57397a", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "7f26838f-905a-4202-bc0a-4946b818ed6c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on the population pharmacokinetic\n(PK) results, no dose adjustment is required in patients with mild or moderate renal\nimpairment (see section\u00a05.2). Data from patients with severe renal\nimpairment are too limited to draw conclusions on this population.</span></p>", "ID": "227d1a4d-8faf-4b9f-91e3-ce7796c1a508", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Based on the population pharmacokinetic\n(PK) results, no dose adjustment is required in patients with mild or moderate renal\nimpairment (see section\u00a05.2). Data from patients with severe renal\nimpairment are too limited to draw conclusions on this population.</span>", "ID": "c44ed2b9-6ffc-410d-8721-5ef5010401e3", "Styles": "None", "Classes": "None", "Text": "Based on the population pharmacokinetic (PK) results, no dose adjustment is required in patients with mild or moderate renal impairment (see section\u00a05.2). Data from patients with severe renal impairment are too limited to draw conclusions on this population.", "ParentId": "227d1a4d-8faf-4b9f-91e3-ce7796c1a508"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7aaa37b0-9f26-419e-a3c4-e65aed438d50", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6385d462-168c-4828-9197-a63d2da6de7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7aaa37b0-9f26-419e-a3c4-e65aed438d50"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic\nimpairment</span></i></p>", "ID": "703f58d4-5b24-4a3f-849d-fb72a7fbe7ef", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic\nimpairment</span></i>", "ID": "45ca9a80-6fc8-407a-a591-3ae3e94d7a31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "703f58d4-5b24-4a3f-849d-fb72a7fbe7ef"}, {"Element": "<span lang=\"EN-GB\">Hepatic\nimpairment</span>", "ID": "3522fa8b-c4ac-47b4-87a8-43b770a49f94", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "45ca9a80-6fc8-407a-a591-3ae3e94d7a31"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on the population PK results, no\ndose adjustment is required in patients with mild hepatic impairment (see\nsection\u00a05.2). </span><span lang=\"EN-GB\">Data from patients with moderate or\nsevere hepatic impairment are too limited to draw conclusions on these\npopulations. </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\" style=\"font-size:11.5pt\"> must be administered with caution in patients with\nmoderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0the\nupper limit of normal [ULN] and any AST) or severe (total\nbilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN and any AST) hepatic\nimpairment.</span></p>", "ID": "a8f2816b-e558-4db6-b836-2a34579b503d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Based on the population PK results, no\ndose adjustment is required in patients with mild hepatic impairment (see\nsection\u00a05.2). </span>", "ID": "3a3ed624-31e3-4a6b-a10b-c185001cd6e4", "Styles": "None", "Classes": "None", "Text": "Based on the population PK results, no dose adjustment is required in patients with mild hepatic impairment (see section\u00a05.2). ", "ParentId": "a8f2816b-e558-4db6-b836-2a34579b503d"}, {"Element": "<span lang=\"EN-GB\">Data from patients with moderate or\nsevere hepatic impairment are too limited to draw conclusions on these\npopulations. </span>", "ID": "f164f285-1758-484f-80ec-f13563220ed0", "Styles": "None", "Classes": "None", "Text": "Data from patients with moderate or severe hepatic impairment are too limited to draw conclusions on these populations. ", "ParentId": "a8f2816b-e558-4db6-b836-2a34579b503d"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "55a85c5f-ddb8-482e-ac5a-9aa032f675b2", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "a8f2816b-e558-4db6-b836-2a34579b503d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.5pt\"> must be administered with caution in patients with\nmoderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0the\nupper limit of normal [ULN] and any AST) or severe (total\nbilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN and any AST) hepatic\nimpairment.</span>", "ID": "d7307c31-e85d-4ec6-9b3c-2ee11832ae00", "Styles": "font-size:11.5pt", "Classes": "None", "Text": " must be administered with caution in patients with moderate (total bilirubin\u00a0>\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0the upper limit of normal [ULN] and any AST) or severe (total bilirubin\u00a0>\u00a03\u00a0\u00d7\u00a0ULN and any AST) hepatic impairment.", "ParentId": "a8f2816b-e558-4db6-b836-2a34579b503d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4791c290-f839-46e9-86c3-47349ad98687", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a45e875a-bf18-4214-a4be-36a3a4c78538", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4791c290-f839-46e9-86c3-47349ad98687"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Method\nof administration </span></u></p>", "ID": "449131a2-e94a-48fc-afb7-f0b94fea58f9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Method\nof administration </span></u>", "ID": "72b34fa2-176e-423f-a882-e58322b5a67d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "449131a2-e94a-48fc-afb7-f0b94fea58f9"}, {"Element": "<span lang=\"EN-GB\">Method\nof administration </span>", "ID": "f03e53e6-341c-4bac-88f4-a59bd9ddff6b", "Styles": "None", "Classes": "None", "Text": "Method of administration ", "ParentId": "72b34fa2-176e-423f-a882-e58322b5a67d"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aad3556d-35e1-466a-ad61-8728144e6a04", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39692533-0320-44d9-b2a0-0ab2e34fd19e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aad3556d-35e1-466a-ad61-8728144e6a04"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is for intravenous\nuse only. It is to be administered as an intravenous infusion over a period of\u00a060\u00a0minutes.\nThe infusion must be administered through a sterile, non\u2011pyrogenic, low\nprotein binding in\u2011line filter with a pore size of\u00a00.2\u20111.2\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">m.</span></p>", "ID": "b21ea266-7509-434a-a124-6c929327b54e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS is for intravenous\nuse only. It is to be administered as an intravenous infusion over a period of\u00a060\u00a0minutes.\nThe infusion must be administered through a sterile, non\u2011pyrogenic, low\nprotein binding in\u2011line filter with a pore size of\u00a00.2\u20111.2\u00a0</span>", "ID": "8cbf90f6-1e7c-41b4-9cc2-d90df855eb9d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS is for intravenous use only. It is to be administered as an intravenous infusion over a period of\u00a060\u00a0minutes. The infusion must be administered through a sterile, non\u2011pyrogenic, low protein binding in\u2011line filter with a pore size of\u00a00.2\u20111.2\u00a0", "ParentId": "b21ea266-7509-434a-a124-6c929327b54e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span>", "ID": "4fdca66f-ae4d-4929-a8f4-e2ba7e22cf97", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "b21ea266-7509-434a-a124-6c929327b54e"}, {"Element": "<span lang=\"EN-GB\">m.</span>", "ID": "0847dbee-f6bc-4ff9-9fa7-531a6013b5e0", "Styles": "None", "Classes": "None", "Text": "m.", "ParentId": "b21ea266-7509-434a-a124-6c929327b54e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f660cc5-692f-4277-82c0-c35f4aa5eae2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ea42ff8-c1a5-4754-9deb-68d063412108", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f660cc5-692f-4277-82c0-c35f4aa5eae2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS must not be\nadministered as an intravenous push or bolus injection.</span></p>", "ID": "96e8004b-0975-4e61-8bea-196a1a96d394", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS must not be\nadministered as an intravenous push or bolus injection.</span>", "ID": "77a3675d-cbeb-4e6f-bb51-ea4db82322b1", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS must not be administered as an intravenous push or bolus injection.", "ParentId": "96e8004b-0975-4e61-8bea-196a1a96d394"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db19aac5-3368-42e4-9cee-bd9fd4c29f63", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8d9b933-85e1-427d-ac7e-933df12989b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db19aac5-3368-42e4-9cee-bd9fd4c29f63"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The total dose of Nivolumab\u00a0BMS required\ncan be infused directly as a\u00a010\u00a0mg/mL solution or can be diluted to\nas low as\u00a01\u00a0mg/mL with sodium chloride\u00a09\u00a0mg/mL (0.9%)\nsolution for injection or\u00a0glucose 50\u00a0mg/mL (5%) solution for\ninjection. </span></p>", "ID": "cb360f74-6953-49c7-9469-7056c6444d5c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The total dose of Nivolumab\u00a0BMS required\ncan be infused directly as a\u00a010\u00a0mg/mL solution or can be diluted to\nas low as\u00a01\u00a0mg/mL with sodium chloride\u00a09\u00a0mg/mL (0.9%)\nsolution for injection or\u00a0glucose 50\u00a0mg/mL (5%) solution for\ninjection. </span>", "ID": "214b805f-c6e4-42bd-a4ed-bbff04f71415", "Styles": "None", "Classes": "None", "Text": "The total dose of Nivolumab\u00a0BMS required can be infused directly as a\u00a010\u00a0mg/mL solution or can be diluted to as low as\u00a01\u00a0mg/mL with sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for injection or\u00a0glucose 50\u00a0mg/mL (5%) solution for injection. ", "ParentId": "cb360f74-6953-49c7-9469-7056c6444d5c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "071434fe-0ecc-4a16-ba0e-0ab741c67ece", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7aa9452-1465-4582-9ad4-b67fce52b780", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "071434fe-0ecc-4a16-ba0e-0ab741c67ece"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For instructions on the handling of the\nmedicinal product before administration, see section\u00a06.6.</span></p>", "ID": "d2c86476-6fd8-4bf9-98d4-778c9ce344e2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For instructions on the handling of the\nmedicinal product before administration, see section\u00a06.6.</span>", "ID": "3001df72-f53e-42d9-913a-c18543ceb3da", "Styles": "None", "Classes": "None", "Text": "For instructions on the handling of the medicinal product before administration, see section\u00a06.6.", "ParentId": "d2c86476-6fd8-4bf9-98d4-778c9ce344e2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a027977e-3114-4721-9cf0-0f178975d34c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d845b718-569f-41a8-bd75-5895e2cdf4f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a027977e-3114-4721-9cf0-0f178975d34c"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></p>", "ID": "73066577-6ec3-4151-9408-5ac67f65bdf5", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span>", "ID": "e9ae4321-c5e7-4410-a810-037eb5d07145", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "73066577-6ec3-4151-9408-5ac67f65bdf5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c1a030a4-7609-452b-899d-251d415594b0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "53f8ac5d-0130-48dd-8741-91cad42113f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1a030a4-7609-452b-899d-251d415594b0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Hypersensitivity to the active substance\nor to any of the excipients listed in section\u00a06.1.</span></p>", "ID": "46428c44-7797-4901-8107-3bc3e29414e2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity to the active substance\nor to any of the excipients listed in section\u00a06.1.</span>", "ID": "5a6fb649-35f1-40be-b417-aa6791f50ed7", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity to the active substance or to any of the excipients listed in section\u00a06.1.", "ParentId": "46428c44-7797-4901-8107-3bc3e29414e2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "31ca2c9a-ccb4-4360-9b19-f13a33e4a520", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61aa2e44-97e6-4ff7-8910-446d9d24ce09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "31ca2c9a-ccb4-4360-9b19-f13a33e4a520"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span></p>", "ID": "c5b7eaa6-af2a-4be3-931f-6bc91593b904", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</span>", "ID": "debdee23-aeb8-46cd-b3d3-0a81f7bada0c", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "c5b7eaa6-af2a-4be3-931f-6bc91593b904"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a3f2254-5bbe-4d9f-9afe-8f9d240050f3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6cc95407-5f5b-411b-9fa2-245701225e83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a3f2254-5bbe-4d9f-9afe-8f9d240050f3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is associated with immune\u2011related\nadverse reactions. Patients should be monitored continuously (at least up to\n5\u00a0months after the last dose) as an adverse reaction with nivolumab may\noccur at any time during or after discontinuation of nivolumab therapy. </span></p>", "ID": "9fe5b0a9-7b93-4af4-8ee9-0dc3d569cf1e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is associated with immune\u2011related\nadverse reactions. Patients should be monitored continuously (at least up to\n5\u00a0months after the last dose) as an adverse reaction with nivolumab may\noccur at any time during or after discontinuation of nivolumab therapy. </span>", "ID": "20c9311a-8f4f-431c-a207-4f2e3dc2dfa4", "Styles": "None", "Classes": "None", "Text": "Nivolumab is associated with immune\u2011related adverse reactions. Patients should be monitored continuously (at least up to 5\u00a0months after the last dose) as an adverse reaction with nivolumab may occur at any time during or after discontinuation of nivolumab therapy. ", "ParentId": "9fe5b0a9-7b93-4af4-8ee9-0dc3d569cf1e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "593ecbbd-0baf-4dd0-bc22-ebec757727fa", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91098522-093c-4212-941d-09d2b119108a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "593ecbbd-0baf-4dd0-bc22-ebec757727fa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For suspected immune-related adverse\nreactions, adequate evaluation should be performed to confirm aetiology or\nexclude other causes. Based on the severity of the adverse reaction, nivolumab\nshould be withheld and corticosteroids administered. If immunosuppression with\ncorticosteroids is used to treat an adverse reaction, a taper of at\nleast\u00a01\u00a0month duration should be initiated upon improvement. Rapid\ntapering may lead to worsening of the adverse reaction. Non\u2011corticosteroid\nimmunosuppressive therapy should be added if there is worsening or no\nimprovement despite corticosteroid use. </span></p>", "ID": "aa385e57-4ec1-4b11-b15c-08f824cb0b6c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For suspected immune-related adverse\nreactions, adequate evaluation should be performed to confirm aetiology or\nexclude other causes. Based on the severity of the adverse reaction, nivolumab\nshould be withheld and corticosteroids administered. If immunosuppression with\ncorticosteroids is used to treat an adverse reaction, a taper of at\nleast\u00a01\u00a0month duration should be initiated upon improvement. Rapid\ntapering may lead to worsening of the adverse reaction. Non\u2011corticosteroid\nimmunosuppressive therapy should be added if there is worsening or no\nimprovement despite corticosteroid use. </span>", "ID": "e46e88d2-2f0c-4eed-8798-21ba7962e5da", "Styles": "None", "Classes": "None", "Text": "For suspected immune-related adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, nivolumab should be withheld and corticosteroids administered. If immunosuppression with corticosteroids is used to treat an adverse reaction, a taper of at least\u00a01\u00a0month duration should be initiated upon improvement. Rapid tapering may lead to worsening of the adverse reaction. Non\u2011corticosteroid immunosuppressive therapy should be added if there is worsening or no improvement despite corticosteroid use. ", "ParentId": "aa385e57-4ec1-4b11-b15c-08f824cb0b6c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab should not be resumed while\nthe patient is receiving immunosuppressive doses of corticosteroids or other\nimmunosuppressive therapy. Prophylactic antibiotics should be used to prevent\nopportunistic infections in patients receiving immunosuppressive therapy.</span></p>", "ID": "4faddcb6-8cf3-4065-97eb-d8a19ab87e5d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab should not be resumed while\nthe patient is receiving immunosuppressive doses of corticosteroids or other\nimmunosuppressive therapy. Prophylactic antibiotics should be used to prevent\nopportunistic infections in patients receiving immunosuppressive therapy.</span>", "ID": "a03a624e-7d95-44f0-af9c-19aec1fce966", "Styles": "None", "Classes": "None", "Text": "Nivolumab should not be resumed while the patient is receiving immunosuppressive doses of corticosteroids or other immunosuppressive therapy. Prophylactic antibiotics should be used to prevent opportunistic infections in patients receiving immunosuppressive therapy.", "ParentId": "4faddcb6-8cf3-4065-97eb-d8a19ab87e5d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3ebba48-7960-462c-8d87-8755f987481a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "10da9101-2ccc-43e3-ad19-971a43522ad6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3ebba48-7960-462c-8d87-8755f987481a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab must be permanently discontinued\nfor any severe immune related adverse reaction that recurs and for any life\nthreatening immune related adverse reaction.</span></p>", "ID": "68f77de7-e37b-4945-b5fc-5e7f74ff0db8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab must be permanently discontinued\nfor any severe immune related adverse reaction that recurs and for any life\nthreatening immune related adverse reaction.</span>", "ID": "be4bafc4-3183-400b-8122-95cfecf11add", "Styles": "None", "Classes": "None", "Text": "Nivolumab must be permanently discontinued for any severe immune related adverse reaction that recurs and for any life threatening immune related adverse reaction.", "ParentId": "68f77de7-e37b-4945-b5fc-5e7f74ff0db8"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "69192ede-1ec1-4924-af70-9d02eb7e7b35", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "ebe84fce-4995-4f09-8185-c4b7b478b096", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69192ede-1ec1-4924-af70-9d02eb7e7b35"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "6722445a-e51b-4fa8-aff8-a77b57de0533", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ebe84fce-4995-4f09-8185-c4b7b478b096"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "8b346dd8-3980-4961-9fd9-13bc867d97bf", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6722445a-e51b-4fa8-aff8-a77b57de0533"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\npneumonitis</span></u></p>", "ID": "84ac0033-c800-4873-ae2c-1a8f25f125af", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\npneumonitis</span></u>", "ID": "59e0a1d7-6f64-4dd3-910b-dd528a19de16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "84ac0033-c800-4873-ae2c-1a8f25f125af"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\npneumonitis</span>", "ID": "203924af-88dc-450c-9166-62884e9e8bfd", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related pneumonitis", "ParentId": "59e0a1d7-6f64-4dd3-910b-dd528a19de16"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe pneumonitis or interstitial lung\ndisease, including fatal cases, has been observed with nivolumab treatment (see\nsection\u00a04.8). Patients should be monitored for signs and symptoms of\npneumonitis such as radiographic changes (e.g., focal ground glass opacities,\npatchy filtrates), dyspnoea, and hypoxia. Infectious and disease\u2011related\naetiologies should be ruled out.</span></p>", "ID": "fe08717c-2b12-47b0-bc12-433f898d7a67", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe pneumonitis or interstitial lung\ndisease, including fatal cases, has been observed with nivolumab treatment (see\nsection\u00a04.8). Patients should be monitored for signs and symptoms of\npneumonitis such as radiographic changes (e.g., focal ground glass opacities,\npatchy filtrates), dyspnoea, and hypoxia. Infectious and disease\u2011related\naetiologies should be ruled out.</span>", "ID": "acf822a1-27c6-4d51-853c-c2919d3cd2de", "Styles": "None", "Classes": "None", "Text": "Severe pneumonitis or interstitial lung disease, including fatal cases, has been observed with nivolumab treatment (see section\u00a04.8). Patients should be monitored for signs and symptoms of pneumonitis such as radiographic changes (e.g., focal ground glass opacities, patchy filtrates), dyspnoea, and hypoxia. Infectious and disease\u2011related aetiologies should be ruled out.", "ParentId": "fe08717c-2b12-47b0-bc12-433f898d7a67"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b7339487-a728-4fd6-90c3-09c7dada67f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4cf73a7-3f76-44fa-b4da-f93003b42ce8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b7339487-a728-4fd6-90c3-09c7dada67f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0pneumonitis, nivolumab must be permanently\ndiscontinued, and corticosteroids should be initiated at a dose\nof\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone equivalents.</span></p>", "ID": "0242a3a4-0f1e-4f5d-91a3-55aeab3130ca", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0pneumonitis, nivolumab must be permanently\ndiscontinued, and corticosteroids should be initiated at a dose\nof\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone equivalents.</span>", "ID": "64cf88e5-6063-4f15-9a6f-202e48b8b418", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a03\u00a0or\u00a04\u00a0pneumonitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone equivalents.", "ParentId": "0242a3a4-0f1e-4f5d-91a3-55aeab3130ca"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc7f9bb1-b71a-4894-9ec3-b0afc09af33a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1de168e-dfe7-4a0b-9d0d-0e06533e57b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc7f9bb1-b71a-4894-9ec3-b0afc09af33a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0(symptomatic)\npneumonitis, nivolumab should be withheld and corticosteroids initiated at a\ndose of\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement,\nnivolumab may be resumed after corticosteroid taper. If worsening or no\nimprovement occurs despite initiation of corticosteroids, corticosteroid dose\nshould be increased to\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone\nequivalents and nivolumab must be permanently discontinued.</span></p>", "ID": "31b686e4-d2ad-4a6a-af96-809e9a9e53db", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a02\u00a0(symptomatic)\npneumonitis, nivolumab should be withheld and corticosteroids initiated at a\ndose of\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement,\nnivolumab may be resumed after corticosteroid taper. If worsening or no\nimprovement occurs despite initiation of corticosteroids, corticosteroid dose\nshould be increased to\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone\nequivalents and nivolumab must be permanently discontinued.</span>", "ID": "651ef7fe-7e32-436e-b702-8782979ef113", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a02\u00a0(symptomatic) pneumonitis, nivolumab should be withheld and corticosteroids initiated at a dose of\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to\u00a02\u00a0to\u00a04\u00a0mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.", "ParentId": "31b686e4-d2ad-4a6a-af96-809e9a9e53db"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "64ac0d68-75b7-4d61-be0a-042d7dec18dc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "34a9a808-7194-4823-8332-8835b4d7d0bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64ac0d68-75b7-4d61-be0a-042d7dec18dc"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "b9811d73-182a-41e3-bf0c-7fec916df81f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34a9a808-7194-4823-8332-8835b4d7d0bb"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "3b2d01e2-e478-491b-b192-d32b652aaab0", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b9811d73-182a-41e3-bf0c-7fec916df81f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u></p>", "ID": "ada5322a-7eb5-42eb-98c7-9c92ef18bd42", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u>", "ID": "50ed7246-fceb-4ed0-93a5-03b8134b8acd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ada5322a-7eb5-42eb-98c7-9c92ef18bd42"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\ncolitis</span>", "ID": "ab8f573b-b9a0-4ace-b59c-6cd43330752a", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related colitis", "ParentId": "50ed7246-fceb-4ed0-93a5-03b8134b8acd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe diarrhoea or colitis has been\nobserved with nivolumab treatment (see section\u00a04.8). Patients should be monitored\nfor diarrhoea and additional symptoms of colitis, such as abdominal pain and\nmucus or blood in stool. Infectious and disease\u2011related aetiologies\nshould be ruled out. </span></p>", "ID": "c6c2eb44-6817-4e11-8f6b-7b5d1a507a83", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe diarrhoea or colitis has been\nobserved with nivolumab treatment (see section\u00a04.8). Patients should be monitored\nfor diarrhoea and additional symptoms of colitis, such as abdominal pain and\nmucus or blood in stool. Infectious and disease\u2011related aetiologies\nshould be ruled out. </span>", "ID": "b235c387-e430-41cc-bb24-badcb0793a02", "Styles": "None", "Classes": "None", "Text": "Severe diarrhoea or colitis has been observed with nivolumab treatment (see section\u00a04.8). Patients should be monitored for diarrhoea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Infectious and disease\u2011related aetiologies should be ruled out. ", "ParentId": "c6c2eb44-6817-4e11-8f6b-7b5d1a507a83"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eba51c6a-84bf-4338-9335-a0256b8ef0d9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "17de3fb4-7627-43a0-875b-7c38fbfa621c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eba51c6a-84bf-4338-9335-a0256b8ef0d9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a04\u00a0diarrhoea or\ncolitis, nivolumab must be permanently discontinued, and corticosteroids should\nbe initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span></p>", "ID": "465e38ba-b5f3-4ca5-ac6d-007bc7cc3817", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a04\u00a0diarrhoea or\ncolitis, nivolumab must be permanently discontinued, and corticosteroids should\nbe initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span>", "ID": "bcfda466-22ac-4759-b4f7-5dc371f704a8", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a04\u00a0diarrhoea or colitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.", "ParentId": "465e38ba-b5f3-4ca5-ac6d-007bc7cc3817"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f55fcb0c-5cef-4fed-bbee-ba7735342774", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88f3e040-97fe-4933-9b40-5a97fefceb6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f55fcb0c-5cef-4fed-bbee-ba7735342774"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a03\u00a0diarrhoea or\ncolitis, nivolumab should be withheld and corticosteroids initiated at a dose\nof\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, nivolumab must\nbe permanently discontinued.</span></p>", "ID": "70d30f48-5f6f-4579-bc88-19f69368634a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a03\u00a0diarrhoea or\ncolitis, nivolumab should be withheld and corticosteroids initiated at a dose\nof\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, nivolumab must\nbe permanently discontinued.</span>", "ID": "ee30940d-50fe-472a-bb88-17b9c0a461d4", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a03\u00a0diarrhoea or colitis, nivolumab should be withheld and corticosteroids initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, nivolumab must be permanently discontinued.", "ParentId": "70d30f48-5f6f-4579-bc88-19f69368634a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "973f010d-591d-4be2-a1d4-543e606f9b32", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b222b1cb-371a-4c74-ba98-0bb3cb0fc1ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "973f010d-591d-4be2-a1d4-543e606f9b32"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0diarrhoea or\ncolitis, nivolumab should be withheld. Persistent diarrhoea or colitis should\nbe managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>", "ID": "4dc7b037-7ab8-4d1e-915c-ea1c480fa753", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a02\u00a0diarrhoea or\ncolitis, nivolumab should be withheld. Persistent diarrhoea or colitis should\nbe managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span>", "ID": "a7b5e160-2df6-4de1-a973-3caed666410c", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a02\u00a0diarrhoea or colitis, nivolumab should be withheld. Persistent diarrhoea or colitis should be managed with corticosteroids at a dose of\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.", "ParentId": "4dc7b037-7ab8-4d1e-915c-ea1c480fa753"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12f90eea-17d3-4523-934d-41dcc50b2b55", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0035e719-04dd-419c-9259-b29f771d4312", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12f90eea-17d3-4523-934d-41dcc50b2b55"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u></p>", "ID": "ad14d3b3-8225-46c2-bf25-978a4981acb0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u>", "ID": "5263dcb3-e97f-41d9-b24f-6b0423842219", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad14d3b3-8225-46c2-bf25-978a4981acb0"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span>", "ID": "3454732f-56e2-4192-92f8-43d7fa143560", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related hepatitis", "ParentId": "5263dcb3-e97f-41d9-b24f-6b0423842219"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe hepatitis has been observed with\nnivolumab treatment. Patients should be monitored for signs and symptoms of\nhepatitis such as transaminase and total bilirubin elevations. Infectious and\ndisease\u2011related aetiologies should be ruled out.</span></p>", "ID": "e51c41e4-c0db-4840-af10-10ca5561b0f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe hepatitis has been observed with\nnivolumab treatment. Patients should be monitored for signs and symptoms of\nhepatitis such as transaminase and total bilirubin elevations. Infectious and\ndisease\u2011related aetiologies should be ruled out.</span>", "ID": "51db4518-6ad9-4a72-9578-d3cb96b96af0", "Styles": "None", "Classes": "None", "Text": "Severe hepatitis has been observed with nivolumab treatment. Patients should be monitored for signs and symptoms of hepatitis such as transaminase and total bilirubin elevations. Infectious and disease\u2011related aetiologies should be ruled out.", "ParentId": "e51c41e4-c0db-4840-af10-10ca5561b0f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7937266-59f8-4888-b27a-21db625772b8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aecf2cef-d7cd-42c6-bbf3-7b0e68196e9e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7937266-59f8-4888-b27a-21db625772b8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0transaminase or total bilirubin elevation, nivolumab\nmust be permanently discontinued, and corticosteroids should be initiated at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.</span></p>", "ID": "eb30222e-79f7-4203-a3dc-931250345604", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For\nGrade\u00a03\u00a0or\u00a04\u00a0transaminase or total bilirubin elevation, nivolumab\nmust be permanently discontinued, and corticosteroids should be initiated at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.</span>", "ID": "dd49c621-3b11-4697-855c-e2bc7a75b0a0", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a03\u00a0or\u00a04\u00a0transaminase or total bilirubin elevation, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.", "ParentId": "eb30222e-79f7-4203-a3dc-931250345604"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d5b10d5-ea8e-4d8a-9d81-4007f18f67aa", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e7ffd75-2904-4924-bcc5-122ac98be9ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d5b10d5-ea8e-4d8a-9d81-4007f18f67aa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a02\u00a0transaminase or\ntotal bilirubin elevation, nivolumab should be withheld. Persistent elevations\nin these laboratory values should be managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>", "ID": "e0ade7ca-49c9-4bd4-8f58-cbe573849f21", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a02\u00a0transaminase or\ntotal bilirubin elevation, nivolumab should be withheld. Persistent elevations\nin these laboratory values should be managed with corticosteroids at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper, if needed. If\nworsening or no improvement occurs despite initiation of corticosteroids,\ncorticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents and nivolumab must be permanently discontinued.</span>", "ID": "6401d761-1654-4cb4-9f13-bd3029de1d92", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a02\u00a0transaminase or total bilirubin elevation, nivolumab should be withheld. Persistent elevations in these laboratory values should be managed with corticosteroids at a dose of\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.", "ParentId": "e0ade7ca-49c9-4bd4-8f58-cbe573849f21"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "7a7ab3a2-24ac-4447-a537-ca0c5c7e72a8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "8c3c6622-19d1-420d-8dbf-84cbb8e83dd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a7ab3a2-24ac-4447-a537-ca0c5c7e72a8"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "9fe85af6-3cc1-469e-9799-e26648e9f532", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c3c6622-19d1-420d-8dbf-84cbb8e83dd2"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "3d5f66b0-9be5-499d-b155-8bf7f6658d2b", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "9fe85af6-3cc1-469e-9799-e26648e9f532"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nnephritis or renal dysfunction</span></u></p>", "ID": "822c6f9f-9a19-4963-940a-2d31f43b4608", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\nnephritis or renal dysfunction</span></u>", "ID": "2b802959-7642-43b3-865b-fd9de52e6a4a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "822c6f9f-9a19-4963-940a-2d31f43b4608"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\nnephritis or renal dysfunction</span>", "ID": "8bbaf5f5-5025-44f2-a241-a89740ee215e", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related nephritis or renal dysfunction", "ParentId": "2b802959-7642-43b3-865b-fd9de52e6a4a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe nephritis or renal dysfunction\nhas been observed with nivolumab treatment (see section\u00a04.8). Patients\nshould be monitored for signs and symptoms of nephritis and renal dysfunction.\nMost patients present with asymptomatic increases in serum creatinine. Disease\u2011related\naetiologies should be ruled out.</span></p>", "ID": "6786e733-592b-4990-b175-4929771d5f93", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe nephritis or renal dysfunction\nhas been observed with nivolumab treatment (see section\u00a04.8). Patients\nshould be monitored for signs and symptoms of nephritis and renal dysfunction.\nMost patients present with asymptomatic increases in serum creatinine. Disease\u2011related\naetiologies should be ruled out.</span>", "ID": "433142c2-4295-4fd9-a69f-93c9d1154725", "Styles": "None", "Classes": "None", "Text": "Severe nephritis or renal dysfunction has been observed with nivolumab treatment (see section\u00a04.8). Patients should be monitored for signs and symptoms of nephritis and renal dysfunction. Most patients present with asymptomatic increases in serum creatinine. Disease\u2011related aetiologies should be ruled out.", "ParentId": "6786e733-592b-4990-b175-4929771d5f93"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f668a9c6-51cd-451b-8e87-ab7b079e35e3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2f877204-9b65-4fc9-88f3-d1c789caa6d5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f668a9c6-51cd-451b-8e87-ab7b079e35e3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For Grade\u00a04\u00a0serum creatinine\nelevation, nivolumab must be permanently discontinued, and corticosteroids\nshould be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span></p>", "ID": "2f286051-fc35-437a-b3c9-6a82a485f1b2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For Grade\u00a04\u00a0serum creatinine\nelevation, nivolumab must be permanently discontinued, and corticosteroids\nshould be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents.</span>", "ID": "78b00792-157a-474b-8140-88177dea6c10", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a04\u00a0serum creatinine elevation, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents.", "ParentId": "2f286051-fc35-437a-b3c9-6a82a485f1b2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e25f07b-8ba0-493d-b76d-33d13f4b6623", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3affd08-9c09-420e-9ab5-3ab33f4b5384", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e25f07b-8ba0-493d-b76d-33d13f4b6623"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For\nGrade\u00a02\u00a0or\u00a03\u00a0serum creatinine elevation, nivolumab should\nbe withheld, and corticosteroids should be initiated at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, corticosteroid\ndose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents, and nivolumab must be permanently discontinued.</span></p>", "ID": "fce27940-c165-4a2b-972f-3d3e7b5c30ac", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For\nGrade\u00a02\u00a0or\u00a03\u00a0serum creatinine elevation, nivolumab should\nbe withheld, and corticosteroids should be initiated at a dose\nof\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. If worsening\nor no improvement occurs despite initiation of corticosteroids, corticosteroid\ndose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day\nmethylprednisolone equivalents, and nivolumab must be permanently discontinued.</span>", "ID": "3c675ef3-fc36-4845-ad93-1d074c5a1453", "Styles": "None", "Classes": "None", "Text": "For Grade\u00a02\u00a0or\u00a03\u00a0serum creatinine elevation, nivolumab should be withheld, and corticosteroids should be initiated at a dose of\u00a00.5\u00a0to\u00a01\u00a0mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents, and nivolumab must be permanently discontinued.", "ParentId": "fce27940-c165-4a2b-972f-3d3e7b5c30ac"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3efa8084-83f0-4a88-a091-4e68a60e3a96", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d150246-e7b1-4467-bb94-f0c9a38530e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3efa8084-83f0-4a88-a091-4e68a60e3a96"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\u2011related\nendocrinopathies</span></u></p>", "ID": "3f90bd34-6a3b-4556-a6f9-b67852bcdda4", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\nendocrinopathies</span></u>", "ID": "e75cf0b7-b8e9-4d4a-a7a3-9a772a4a6b76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f90bd34-6a3b-4556-a6f9-b67852bcdda4"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\nendocrinopathies</span>", "ID": "62dc7327-1cda-42ee-a5cb-dfad589f1254", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related endocrinopathies", "ParentId": "e75cf0b7-b8e9-4d4a-a7a3-9a772a4a6b76"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe endocrinopathies, including\nhypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes\nmellitus, and diabetic ketoacidosis have been observed with nivolumab treatment.\n</span></p>", "ID": "3701e052-a784-41e9-8918-b132b25ba61f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe endocrinopathies, including\nhypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes\nmellitus, and diabetic ketoacidosis have been observed with nivolumab treatment.\n</span>", "ID": "007f5195-3174-4b2a-a828-f2af91e490e7", "Styles": "None", "Classes": "None", "Text": "Severe endocrinopathies, including hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes mellitus, and diabetic ketoacidosis have been observed with nivolumab treatment. ", "ParentId": "3701e052-a784-41e9-8918-b132b25ba61f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2050c389-66c8-44b1-b6b9-f1f02a6903c7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "450468a6-987d-4418-806b-51673f86154d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2050c389-66c8-44b1-b6b9-f1f02a6903c7"}, {"Element": "<p class=\"EMEABodyText\">Patients should be monitored for clinical signs and\nsymptoms of endocrinopathies and for changes in thyroid function (at the start\nof treatment, periodically during treatment, and as indicated based on clinical\nevaluation). Patients may present with fatigue, headache, mental status\nchanges, abdominal pain, unusual bowel habits, and hypotension, or nonspecific\nsymptoms which may resemble other causes such as brain metastasis or underlying\ndisease. Unless an alternate etiology has been identified, signs or symptoms of\nendocrinopathies should be considered immune-related.</p>", "ID": "d3db1007-9085-4de3-966c-6c850f854d0e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "Patients should be monitored for clinical signs and symptoms of endocrinopathies and for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation). Patients may present with fatigue, headache, mental status changes, abdominal pain, unusual bowel habits, and hypotension, or nonspecific symptoms which may resemble other causes such as brain metastasis or underlying disease. Unless an alternate etiology has been identified, signs or symptoms of endocrinopathies should be considered immune-related.", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "beb88802-9f10-4941-abbf-98afaa692774", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "2ec08c02-6905-4342-82d9-fcb10c84aaad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "beb88802-9f10-4941-abbf-98afaa692774"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "cd1388b5-0bf9-4ebd-8b8d-b1b14e774997", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ec08c02-6905-4342-82d9-fcb10c84aaad"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "bab738df-69d6-4df6-8655-99d5833e3faa", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "cd1388b5-0bf9-4ebd-8b8d-b1b14e774997"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic hypothyroidism,\nnivolumab should be withheld, and thyroid hormone replacement should be\ninitiated as needed. For symptomatic hyperthyroidism, nivolumab should be\nwithheld and methimazole should be initiated as needed. Corticosteroids at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents\nshould also be considered if acute inflammation of the thyroid is suspected.\nUpon improvement, nivolumab may be resumed after corticosteroid taper, if\nneeded. Monitoring of thyroid function should continue to ensure appropriate\nhormone replacement is utilised.</span></p>", "ID": "965e6841-622c-406f-9ce3-8ca94860d8a1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For symptomatic hypothyroidism,\nnivolumab should be withheld, and thyroid hormone replacement should be\ninitiated as needed. For symptomatic hyperthyroidism, nivolumab should be\nwithheld and methimazole should be initiated as needed. Corticosteroids at a\ndose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents\nshould also be considered if acute inflammation of the thyroid is suspected.\nUpon improvement, nivolumab may be resumed after corticosteroid taper, if\nneeded. Monitoring of thyroid function should continue to ensure appropriate\nhormone replacement is utilised.</span>", "ID": "afb4ce1d-707d-4c85-9b4b-4334a8e81019", "Styles": "None", "Classes": "None", "Text": "For symptomatic hypothyroidism, nivolumab should be withheld, and thyroid hormone replacement should be initiated as needed. For symptomatic hyperthyroidism, nivolumab should be withheld and methimazole should be initiated as needed. Corticosteroids at a dose of\u00a01\u00a0to\u00a02\u00a0mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the thyroid is suspected. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. Monitoring of thyroid function should continue to ensure appropriate hormone replacement is utilised.", "ParentId": "965e6841-622c-406f-9ce3-8ca94860d8a1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9a6438f-e138-4235-969e-5cd3f8e2d41e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39fe1167-c9b0-451d-8bbe-c1ffb1ff7b3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9a6438f-e138-4235-969e-5cd3f8e2d41e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic adrenal insufficiency,\nnivolumab should be withheld, and physiologic corticosteroid replacement should\nbe initiated as needed. Monitoring of adrenal function and hormone levels\nshould continue to ensure appropriate corticosteroid replacement is utilised.</span></p>", "ID": "06fce9f3-dab5-4cb3-a43d-f84cac7ec756", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For symptomatic adrenal insufficiency,\nnivolumab should be withheld, and physiologic corticosteroid replacement should\nbe initiated as needed. Monitoring of adrenal function and hormone levels\nshould continue to ensure appropriate corticosteroid replacement is utilised.</span>", "ID": "e450f52a-095b-452a-8bc1-09660ceca75e", "Styles": "None", "Classes": "None", "Text": "For symptomatic adrenal insufficiency, nivolumab should be withheld, and physiologic corticosteroid replacement should be initiated as needed. Monitoring of adrenal function and hormone levels should continue to ensure appropriate corticosteroid replacement is utilised.", "ParentId": "06fce9f3-dab5-4cb3-a43d-f84cac7ec756"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "43c5dcc1-a740-48d0-944a-9dce3e053892", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f330ae39-c2f0-425c-ac50-f759b04d5f2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "43c5dcc1-a740-48d0-944a-9dce3e053892"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic hypophysitis, nivolumab\nshould be withheld, and hormone replacement should be initiated as needed.\nCorticosteroids at a dose of 1\u00a0to 2\u00a0mg/kg/day methylprednisolone\nequivalents should also be considered if acute inflammation of the pituitary\ngland is suspected. Upon improvement, nivolumab may be resumed after\ncorticosteroid taper, if needed. Monitoring of pituitary function and hormone\nlevels should continue to ensure appropriate hormone replacement is utilised.</span></p>", "ID": "71e7ccc9-84bf-4931-84d1-188072e43eea", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For symptomatic hypophysitis, nivolumab\nshould be withheld, and hormone replacement should be initiated as needed.\nCorticosteroids at a dose of 1\u00a0to 2\u00a0mg/kg/day methylprednisolone\nequivalents should also be considered if acute inflammation of the pituitary\ngland is suspected. Upon improvement, nivolumab may be resumed after\ncorticosteroid taper, if needed. Monitoring of pituitary function and hormone\nlevels should continue to ensure appropriate hormone replacement is utilised.</span>", "ID": "4da35f99-2f61-443f-a931-6e5966dd121e", "Styles": "None", "Classes": "None", "Text": "For symptomatic hypophysitis, nivolumab should be withheld, and hormone replacement should be initiated as needed. Corticosteroids at a dose of 1\u00a0to 2\u00a0mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the pituitary gland is suspected. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. Monitoring of pituitary function and hormone levels should continue to ensure appropriate hormone replacement is utilised.", "ParentId": "71e7ccc9-84bf-4931-84d1-188072e43eea"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb093d58-bd5c-4d3d-8bca-f2200e24037c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1b4ded9-aa33-4e7f-9ed4-942bbef5a168", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb093d58-bd5c-4d3d-8bca-f2200e24037c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For symptomatic diabetes, nivolumab\nshould be withheld, and insulin replacement should be initiated as needed.\nMonitoring of blood sugar should continue to ensure appropriate insulin\nreplacement is utilised. </span></p>", "ID": "8d791f6e-8c38-42b1-b0b1-db124ccd02e3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For symptomatic diabetes, nivolumab\nshould be withheld, and insulin replacement should be initiated as needed.\nMonitoring of blood sugar should continue to ensure appropriate insulin\nreplacement is utilised. </span>", "ID": "5f87a2c9-65f1-46b3-9b41-04dfe3b32610", "Styles": "None", "Classes": "None", "Text": "For symptomatic diabetes, nivolumab should be withheld, and insulin replacement should be initiated as needed. Monitoring of blood sugar should continue to ensure appropriate insulin replacement is utilised. ", "ParentId": "8d791f6e-8c38-42b1-b0b1-db124ccd02e3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e6e1b73a-169c-4a66-8aea-62e4f5617cc1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "82613426-1ab4-4c6b-bcc9-66757627090f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6e1b73a-169c-4a66-8aea-62e4f5617cc1"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Immune-related rash</span></u></p>", "ID": "34c78168-b8f2-40e3-8803-90d09073825a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Immune-related rash</span></u>", "ID": "f25ae7ae-3c29-43ba-b688-5a1fd47d97d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34c78168-b8f2-40e3-8803-90d09073825a"}, {"Element": "<span lang=\"EN-GB\">Immune-related rash</span>", "ID": "ee329f49-144d-46c4-a99e-b2c666daf1eb", "Styles": "None", "Classes": "None", "Text": "Immune-related rash", "ParentId": "f25ae7ae-3c29-43ba-b688-5a1fd47d97d9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Severe\nrash has been observed with nivolumab treatment that may be immune-related (see\nsection\u00a04.8). Nivolumab should be withheld for Grade\u00a03 rash and\ndiscontinued for Grade\u00a04 rash. Severe rash should be managed with\nhigh-dose corticosteroid at a dose of 1\u00a0to 2\u00a0mg/kg/day prednisone\nequivalents. </span></p>", "ID": "b71b4930-014f-4530-8acb-71080d7fc661", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe\nrash has been observed with nivolumab treatment that may be immune-related (see\nsection\u00a04.8). Nivolumab should be withheld for Grade\u00a03 rash and\ndiscontinued for Grade\u00a04 rash. Severe rash should be managed with\nhigh-dose corticosteroid at a dose of 1\u00a0to 2\u00a0mg/kg/day prednisone\nequivalents. </span>", "ID": "d40d78c2-b5ca-4702-8cf2-4ee35970849b", "Styles": "None", "Classes": "None", "Text": "Severe rash has been observed with nivolumab treatment that may be immune-related (see section\u00a04.8). Nivolumab should be withheld for Grade\u00a03 rash and discontinued for Grade\u00a04 rash. Severe rash should be managed with high-dose corticosteroid at a dose of 1\u00a0to 2\u00a0mg/kg/day prednisone equivalents. ", "ParentId": "b71b4930-014f-4530-8acb-71080d7fc661"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b36d1e7-6cd3-44c1-9cdc-8c72d03cf027", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fdc4368-cba8-4e3d-ad82-2aeb3756de49", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b36d1e7-6cd3-44c1-9cdc-8c72d03cf027"}, {"Element": "<p class=\"EMEABodyText\">Caution should be used when considering the use of nivolumab\nin a patient who has previously experienced a severe or life-threatening skin\nadverse reaction on prior treatment with other immune-stimulatory anticancer\nagents.</p>", "ID": "1590a3d8-cfd7-4880-b6a8-5e95a9066e94", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "Caution should be used when considering the use of nivolumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents.", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53731ba6-70ba-4df0-a1fa-7ac6377c3acf", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a95e35e8-3339-4cd0-950f-b33b2524fd28", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53731ba6-70ba-4df0-a1fa-7ac6377c3acf"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Other\nimmune\u2011related adverse reactions</span></u></p>", "ID": "d7004ac8-5389-4f6f-add9-7e40d6e1d12c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Other\nimmune\u2011related adverse reactions</span></u>", "ID": "e685a7c5-92dc-4ad4-9507-6e1b47dda247", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7004ac8-5389-4f6f-add9-7e40d6e1d12c"}, {"Element": "<span lang=\"EN-GB\">Other\nimmune\u2011related adverse reactions</span>", "ID": "8a44c505-c8e7-4239-9c63-59d00957c086", "Styles": "None", "Classes": "None", "Text": "Other immune\u2011related adverse reactions", "ParentId": "e685a7c5-92dc-4ad4-9507-6e1b47dda247"}, {"Element": "<p class=\"BMSBodyText\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following immune-related adverse\nreactions were reported in less than 1% of patients treated with nivolumab in\nclinical trials across doses and tumour types: pancreatitis, uveitis,\ndemyelination, autoimmune neuropathy (including facial and abducens nerve\nparesis), Guillain\u2011Barr\u00e9 syndrome, hypopituitarism, and</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">myasthenic\nsyndrome</span><span lang=\"EN-GB\">.</span></p>", "ID": "950d3022-1438-4528-8ef1-8f31b9241613", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BMSBodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">The following immune-related adverse\nreactions were reported in less than 1% of patients treated with nivolumab in\nclinical trials across doses and tumour types: pancreatitis, uveitis,\ndemyelination, autoimmune neuropathy (including facial and abducens nerve\nparesis), Guillain\u2011Barr\u00e9 syndrome, hypopituitarism, and</span>", "ID": "23ef3668-250a-457e-b1cf-9763de37582e", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "The following immune-related adverse reactions were reported in less than 1% of patients treated with nivolumab in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), Guillain\u2011Barr\u00e9 syndrome, hypopituitarism, and", "ParentId": "950d3022-1438-4528-8ef1-8f31b9241613"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "3d072579-2b31-43ba-8b90-d15abf2c78d6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "950d3022-1438-4528-8ef1-8f31b9241613"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">myasthenic\nsyndrome</span>", "ID": "df1851a1-f194-4c82-a316-6b76e143942d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "myasthenic syndrome", "ParentId": "950d3022-1438-4528-8ef1-8f31b9241613"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "18825eff-f339-4ab4-90a9-5179302cc2c8", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "950d3022-1438-4528-8ef1-8f31b9241613"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f83315e0-a322-4d41-ac58-be4756ecaa5b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "17ae95f5-c96c-4205-9561-fd160f573d13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f83315e0-a322-4d41-ac58-be4756ecaa5b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For suspected immune\u2011related\nadverse reactions, adequate evaluation should be performed to confirm aetiology\nor exclude other causes. Based on the severity of the adverse reaction,\nnivolumab should be withheld and corticosteroids administered. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. Nivolumab\nmust be permanently discontinued for any severe immune\u2011related adverse\nreaction that recurs and for any life\u2011threatening immune\u2011related\nadverse reaction.</span></p>", "ID": "c8f3d48a-f0fc-42a1-9b69-375903369aae", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For suspected immune\u2011related\nadverse reactions, adequate evaluation should be performed to confirm aetiology\nor exclude other causes. Based on the severity of the adverse reaction,\nnivolumab should be withheld and corticosteroids administered. Upon\nimprovement, nivolumab may be resumed after corticosteroid taper. Nivolumab\nmust be permanently discontinued for any severe immune\u2011related adverse\nreaction that recurs and for any life\u2011threatening immune\u2011related\nadverse reaction.</span>", "ID": "060a6350-313f-424d-a94e-148de19a8f95", "Styles": "None", "Classes": "None", "Text": "For suspected immune\u2011related adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, nivolumab should be withheld and corticosteroids administered. Upon improvement, nivolumab may be resumed after corticosteroid taper. Nivolumab must be permanently discontinued for any severe immune\u2011related adverse reaction that recurs and for any life\u2011threatening immune\u2011related adverse reaction.", "ParentId": "c8f3d48a-f0fc-42a1-9b69-375903369aae"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ce2cbd8-e24e-459f-a073-ae3b29ca5125", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d770fe86-ef60-47f8-a46c-f08f0720852c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ce2cbd8-e24e-459f-a073-ae3b29ca5125"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions</span></u></p>", "ID": "d89453d2-fb0e-4d54-8e68-fa6f62b6a2ca", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nreactions</span></u>", "ID": "4d3be3b0-1107-47b1-9a74-f986151d04c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d89453d2-fb0e-4d54-8e68-fa6f62b6a2ca"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions</span>", "ID": "79804d1d-4f09-4990-8c68-3c3f409aa079", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "4d3be3b0-1107-47b1-9a74-f986151d04c8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Severe infusion reactions have been\nreported in clinical trials (see section\u00a04.8). In case of a severe\ninfusion reaction, nivolumab infusion must be discontinued and appropriate medical\ntherapy administered. Patients with mild or moderate infusion reaction may\nreceive nivolumab with close monitoring.</span></p>", "ID": "a4219630-f1aa-4b2f-a3a9-551d1b72d192", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Severe infusion reactions have been\nreported in clinical trials (see section\u00a04.8). In case of a severe\ninfusion reaction, nivolumab infusion must be discontinued and appropriate medical\ntherapy administered. Patients with mild or moderate infusion reaction may\nreceive nivolumab with close monitoring.</span>", "ID": "3d5c38e1-8f5e-406e-b32b-89fa38e6813f", "Styles": "None", "Classes": "None", "Text": "Severe infusion reactions have been reported in clinical trials (see section\u00a04.8). In case of a severe infusion reaction, nivolumab infusion must be discontinued and appropriate medical therapy administered. Patients with mild or moderate infusion reaction may receive nivolumab with close monitoring.", "ParentId": "a4219630-f1aa-4b2f-a3a9-551d1b72d192"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f5a7fd54-d43f-4586-adf9-b61ac64321dd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "247dd4b7-34c7-4c3b-a1d8-f47ae19609dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f5a7fd54-d43f-4586-adf9-b61ac64321dd"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations </span></u></p>", "ID": "8dce67c8-def4-4b96-a167-a1430147559a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations </span></u>", "ID": "78e6f9ef-5d0a-4137-9d89-fcaa621557f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8dce67c8-def4-4b96-a167-a1430147559a"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations </span>", "ID": "f3855e4e-723b-4457-86a4-b85fa9d1b658", "Styles": "None", "Classes": "None", "Text": "Special populations ", "ParentId": "78e6f9ef-5d0a-4137-9d89-fcaa621557f4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patients with a baseline performance\nscore\u00a0\u2265\u00a02, active brain metastases or autoimmune disease,\nsymptomatic interstitial lung disease, and patients who had been receiving\nsystemic immunosuppressants prior to study entry were excluded from the clinical\ntrials of NSCLC (see sections 4.5 and\u00a05.1).</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">In the absence of data, nivolumab should be used with caution in\nthese populations after careful consideration of the potential risk-benefit on\nan individual basis.</span></p>", "ID": "b915e05c-7ecf-4272-b3af-5870577b1071", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Patients with a baseline performance\nscore\u00a0\u2265\u00a02, active brain metastases or autoimmune disease,\nsymptomatic interstitial lung disease, and patients who had been receiving\nsystemic immunosuppressants prior to study entry were excluded from the clinical\ntrials of NSCLC (see sections 4.5 and\u00a05.1).</span>", "ID": "13ce95ba-4635-46cb-b913-cbbcb2b60c10", "Styles": "None", "Classes": "None", "Text": "Patients with a baseline performance score\u00a0\u2265\u00a02, active brain metastases or autoimmune disease, symptomatic interstitial lung disease, and patients who had been receiving systemic immunosuppressants prior to study entry were excluded from the clinical trials of NSCLC (see sections 4.5 and\u00a05.1).", "ParentId": "b915e05c-7ecf-4272-b3af-5870577b1071"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "7cb2a956-6a55-4d1f-bc8a-b38a024ecdb1", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "b915e05c-7ecf-4272-b3af-5870577b1071"}, {"Element": "<span lang=\"EN-GB\">In the absence of data, nivolumab should be used with caution in\nthese populations after careful consideration of the potential risk-benefit on\nan individual basis.</span>", "ID": "cca3b513-0d4a-49fe-91e6-0d3b1fbfec09", "Styles": "None", "Classes": "None", "Text": "In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential risk-benefit on an individual basis.", "ParentId": "b915e05c-7ecf-4272-b3af-5870577b1071"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c7438471-e3e2-4d4c-af54-a8fa9210e322", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7fe1e45-ccaf-454c-9bfd-41d0acc8b9d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c7438471-e3e2-4d4c-af54-a8fa9210e322"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients\non controlled sodium diet</span></u></p>", "ID": "69fe1bfc-bd8b-4621-a30f-734dd0ab7a0f", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Patients\non controlled sodium diet</span></u>", "ID": "dfc9a765-f3af-49c2-a960-5800c49889fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69fe1bfc-bd8b-4621-a30f-734dd0ab7a0f"}, {"Element": "<span lang=\"EN-GB\">Patients\non controlled sodium diet</span>", "ID": "47283473-f4f5-4796-9e84-056bd815fe64", "Styles": "None", "Classes": "None", "Text": "Patients on controlled sodium diet", "ParentId": "dfc9a765-f3af-49c2-a960-5800c49889fc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of this medicinal product\ncontains\u00a00.1\u00a0mmol (or\u00a02.5\u00a0mg) sodium. To be taken into\nconsideration when treating patients on a controlled sodium diet.</span></p>", "ID": "5101702d-5b5b-45f3-970e-60cf6aa7724f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each mL of this medicinal product\ncontains\u00a00.1\u00a0mmol (or\u00a02.5\u00a0mg) sodium. To be taken into\nconsideration when treating patients on a controlled sodium diet.</span>", "ID": "150d18c9-4762-4e11-babb-a9e5943a2a4b", "Styles": "None", "Classes": "None", "Text": "Each mL of this medicinal product contains\u00a00.1\u00a0mmol (or\u00a02.5\u00a0mg) sodium. To be taken into consideration when treating patients on a controlled sodium diet.", "ParentId": "5101702d-5b5b-45f3-970e-60cf6aa7724f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8614281f-b94b-45a0-994f-2515d9f34106", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0761ba82-49a7-46e3-b06e-c3ed1b2999c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8614281f-b94b-45a0-994f-2515d9f34106"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Patient Alert Card</span></p>", "ID": "338d0f96-524a-4a8f-9c94-5a6dcb710c99", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Patient Alert Card</span>", "ID": "b7d62735-ba99-4a40-bbfb-3af9ca4d1e68", "Styles": "None", "Classes": "None", "Text": "Patient Alert Card", "ParentId": "338d0f96-524a-4a8f-9c94-5a6dcb710c99"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">All prescribers of Nivolumab\u00a0BMS\nmust be familiar with the Physician Information and Management Guidelines. The\nprescriber must discuss the risks of Nivolumab\u00a0BMS therapy with the\npatient. The patient will be provided with the Patient Alert Card with each\nprescription.</span></p>", "ID": "23762e57-8f0e-4b89-a50b-fa1105a76b46", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">All prescribers of Nivolumab\u00a0BMS\nmust be familiar with the Physician Information and Management Guidelines. The\nprescriber must discuss the risks of Nivolumab\u00a0BMS therapy with the\npatient. The patient will be provided with the Patient Alert Card with each\nprescription.</span>", "ID": "389c756a-f0f9-4628-9682-ca9062da930b", "Styles": "None", "Classes": "None", "Text": "All prescribers of Nivolumab\u00a0BMS must be familiar with the Physician Information and Management Guidelines. The prescriber must discuss the risks of Nivolumab\u00a0BMS therapy with the patient. The patient will be provided with the Patient Alert Card with each prescription.", "ParentId": "23762e57-8f0e-4b89-a50b-fa1105a76b46"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37a953d7-7a7a-49ec-a700-4d4ff026142f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "32d5249a-a7d6-4196-8866-c796ff63b722", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37a953d7-7a7a-49ec-a700-4d4ff026142f"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</span></p>", "ID": "323bdd25-18d8-483f-9bc8-ed41b7f753e8", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</span>", "ID": "2f32a597-ba4d-42be-aa76-d8d0a18ffe71", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "323bdd25-18d8-483f-9bc8-ed41b7f753e8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0d7ef0c-3431-4f40-9d46-a4cf66268c96", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ef9c6a2-f7ac-4d2a-957d-4c540f43b135", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0d7ef0c-3431-4f40-9d46-a4cf66268c96"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is a human monoclonal\nantibody,</span><span lang=\"EN-GB\"> as such pharmacokinetic interaction studies\nhave not been conducted. As monoclonal antibodies are not metabolised by\ncytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or\ninduction of these enzymes by co\u2011administered medicinal products is not\nanticipated to affect the pharmacokinetics of nivolumab. </span></p>", "ID": "b723dc99-3fb8-4314-af4c-15deaa87bb04", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is a human monoclonal\nantibody,</span>", "ID": "58392b92-8702-46aa-a852-b65be7fed555", "Styles": "None", "Classes": "None", "Text": "Nivolumab is a human monoclonal antibody,", "ParentId": "b723dc99-3fb8-4314-af4c-15deaa87bb04"}, {"Element": "<span lang=\"EN-GB\"> as such pharmacokinetic interaction studies\nhave not been conducted. As monoclonal antibodies are not metabolised by\ncytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or\ninduction of these enzymes by co\u2011administered medicinal products is not\nanticipated to affect the pharmacokinetics of nivolumab. </span>", "ID": "a86e29a5-d0bc-4623-94c5-cf088f7082c2", "Styles": "None", "Classes": "None", "Text": " as such pharmacokinetic interaction studies have not been conducted. As monoclonal antibodies are not metabolised by cytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or induction of these enzymes by co\u2011administered medicinal products is not anticipated to affect the pharmacokinetics of nivolumab. ", "ParentId": "b723dc99-3fb8-4314-af4c-15deaa87bb04"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ec92848-2968-4689-b679-4c89eddbe1da", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aad857b9-0bac-4b34-85bb-cb6c7e07aeb8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ec92848-2968-4689-b679-4c89eddbe1da"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Other\nforms of interaction </span></u></p>", "ID": "fd520228-e806-4069-aeed-63fb19171c04", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Other\nforms of interaction </span></u>", "ID": "371c5b75-e504-4585-a895-39a3855ed9b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fd520228-e806-4069-aeed-63fb19171c04"}, {"Element": "<span lang=\"EN-GB\">Other\nforms of interaction </span>", "ID": "68fe0f14-cf2b-4068-888a-07e0b070e255", "Styles": "None", "Classes": "None", "Text": "Other forms of interaction ", "ParentId": "371c5b75-e504-4585-a895-39a3855ed9b2"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "48f2629d-f549-49af-acdf-2e5db5ca8bb0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b05c5e2-8251-4b77-9195-74b54825c515", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48f2629d-f549-49af-acdf-2e5db5ca8bb0"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Systemic\nimmunosuppression</span></u></i></p>", "ID": "718c0242-d527-49a9-aa72-6811c50e3cad", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Systemic\nimmunosuppression</span></u></i>", "ID": "291a1aa6-c7f7-4669-b058-c816105b7af2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "718c0242-d527-49a9-aa72-6811c50e3cad"}, {"Element": "<u><span lang=\"EN-GB\">Systemic\nimmunosuppression</span></u>", "ID": "99db0382-5bd3-4777-8c71-ece286e1584b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "291a1aa6-c7f7-4669-b058-c816105b7af2"}, {"Element": "<span lang=\"EN-GB\">Systemic\nimmunosuppression</span>", "ID": "d8b8a740-3c62-4918-b2ca-73dddd10af5f", "Styles": "None", "Classes": "None", "Text": "Systemic immunosuppression", "ParentId": "99db0382-5bd3-4777-8c71-ece286e1584b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The use of systemic corticosteroids and\nother immunosuppressants at baseline, before starting nivolumab, should be\navoided because of their potential interference with the pharmacodynamic\nactivity. However, systemic corticosteroids and other immunosuppressants can be\nused after starting nivolumab to treat immune\u2011related adverse reactions.\nThe preliminary results show that systemic immunosuppression after starting\nnivolumab treatment does not appear to preclude the response on nivolumab.</span></p>", "ID": "0a55ec14-9004-4f86-98b5-c51511734909", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The use of systemic corticosteroids and\nother immunosuppressants at baseline, before starting nivolumab, should be\navoided because of their potential interference with the pharmacodynamic\nactivity. However, systemic corticosteroids and other immunosuppressants can be\nused after starting nivolumab to treat immune\u2011related adverse reactions.\nThe preliminary results show that systemic immunosuppression after starting\nnivolumab treatment does not appear to preclude the response on nivolumab.</span>", "ID": "c58a2e2d-44de-43a7-8c08-c6ce334183a7", "Styles": "None", "Classes": "None", "Text": "The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity. However, systemic corticosteroids and other immunosuppressants can be used after starting nivolumab to treat immune\u2011related adverse reactions. The preliminary results show that systemic immunosuppression after starting nivolumab treatment does not appear to preclude the response on nivolumab.", "ParentId": "0a55ec14-9004-4f86-98b5-c51511734909"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "827425c5-9e8b-4c17-be78-7b9dafdb251c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "086a0cef-c2d2-4059-a712-c17b7589b0bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "827425c5-9e8b-4c17-be78-7b9dafdb251c"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</span></p>", "ID": "4155ee41-a01c-4b30-8634-a3393dbc1ba8", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</span>", "ID": "4a4c7980-061f-4046-9adf-11e71d4e80d0", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and lactation", "ParentId": "4155ee41-a01c-4b30-8634-a3393dbc1ba8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff8054f2-2637-4755-9c7b-5f3842cbd1c3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7db4f6d2-d6d3-4722-b3db-ccedc9564dd8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff8054f2-2637-4755-9c7b-5f3842cbd1c3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>", "ID": "ee6b8ecf-81fe-4476-a72c-d164b73a8957", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Pregnancy</span></u>", "ID": "aa3f4f05-9e19-4947-bd22-8b1a882fee0f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ee6b8ecf-81fe-4476-a72c-d164b73a8957"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "90e32aac-ba98-4a56-b20c-2b16995636da", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "aa3f4f05-9e19-4947-bd22-8b1a882fee0f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There are no data on the use of\nnivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity\n(see section\u00a05.3). Human IgG4 is known to cross the placental barrier and\nnivolumab is an IgG4; therefore nivolumab has the potential to be transmitted\nfrom the mother to the developing foetus. Nivolumab is not recommended during\npregnancy and in women of childbearing potential not using effective contraception\n</span><span lang=\"EN-GB\">unless the clinical benefit outweighs the potential\nrisk</span><span lang=\"EN-GB\">. Effective contraception should be used for at\nleast 5\u00a0months following the last dose of Nivolumab\u00a0BMS.</span></p>", "ID": "82299b50-0cd7-4c9d-b3e7-60c03cfa5efc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">There are no data on the use of\nnivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity\n(see section\u00a05.3). Human IgG4 is known to cross the placental barrier and\nnivolumab is an IgG4; therefore nivolumab has the potential to be transmitted\nfrom the mother to the developing foetus. Nivolumab is not recommended during\npregnancy and in women of childbearing potential not using effective contraception\n</span>", "ID": "d6ad7cc1-4378-4505-a293-0ad80ca16695", "Styles": "None", "Classes": "None", "Text": "There are no data on the use of nivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity (see section\u00a05.3). Human IgG4 is known to cross the placental barrier and nivolumab is an IgG4; therefore nivolumab has the potential to be transmitted from the mother to the developing foetus. Nivolumab is not recommended during pregnancy and in women of childbearing potential not using effective contraception ", "ParentId": "82299b50-0cd7-4c9d-b3e7-60c03cfa5efc"}, {"Element": "<span lang=\"EN-GB\">unless the clinical benefit outweighs the potential\nrisk</span>", "ID": "2be1b466-5dd7-42c7-ae9e-75ff6275dea2", "Styles": "None", "Classes": "None", "Text": "unless the clinical benefit outweighs the potential risk", "ParentId": "82299b50-0cd7-4c9d-b3e7-60c03cfa5efc"}, {"Element": "<span lang=\"EN-GB\">. Effective contraception should be used for at\nleast 5\u00a0months following the last dose of Nivolumab\u00a0BMS.</span>", "ID": "a2cdbaef-f54c-4dc2-8906-e03243d5c4b6", "Styles": "None", "Classes": "None", "Text": ". Effective contraception should be used for at least 5\u00a0months following the last dose of Nivolumab\u00a0BMS.", "ParentId": "82299b50-0cd7-4c9d-b3e7-60c03cfa5efc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "facd6bf9-9e07-4504-aa02-4cca3ce11aec", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04628d6f-5dcb-444a-afd9-e67ea52fa293", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "facd6bf9-9e07-4504-aa02-4cca3ce11aec"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p>", "ID": "87c6f7b0-b4f6-4f77-acad-dc1164c90381", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Breast\u2011feeding</span></u>", "ID": "2a3a8d13-cd76-4aac-a3ad-95c12713510e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87c6f7b0-b4f6-4f77-acad-dc1164c90381"}, {"Element": "<span lang=\"EN-GB\">Breast\u2011feeding</span>", "ID": "736f891b-a551-405f-886d-7ab6281a2d4c", "Styles": "None", "Classes": "None", "Text": "Breast\u2011feeding", "ParentId": "2a3a8d13-cd76-4aac-a3ad-95c12713510e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether nivolumab is\nsecreted in human milk. </span><span lang=\"EN-GB\" style=\"color:black\">Because many\nmedicinal products, including antibodies, can be secreted in human milk, a</span><span lang=\"EN-GB\"> risk to the ne</span><span lang=\"EN-GB\">wborns/infants cannot be\nexcluded. A decision must be made whether to discontinue breast\u2011feeding\nor to discontinue from nivolumab therapy taking into account the benefit of breast\u2011feeding\nfor the child and the benefit of therapy for the woman.</span></p>", "ID": "05794d70-8ed6-48c9-b929-2774a545d07f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">It is unknown whether nivolumab is\nsecreted in human milk. </span>", "ID": "f2692c1c-c769-4070-bb20-bc089db49c66", "Styles": "None", "Classes": "None", "Text": "It is unknown whether nivolumab is secreted in human milk. ", "ParentId": "05794d70-8ed6-48c9-b929-2774a545d07f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Because many\nmedicinal products, including antibodies, can be secreted in human milk, a</span>", "ID": "d91f0652-19e6-4e1a-bf19-6ca3eb68a0cf", "Styles": "color:black", "Classes": "None", "Text": "Because many medicinal products, including antibodies, can be secreted in human milk, a", "ParentId": "05794d70-8ed6-48c9-b929-2774a545d07f"}, {"Element": "<span lang=\"EN-GB\"> risk to the ne</span>", "ID": "d5d141ef-35e6-4449-90a4-32b373d20527", "Styles": "None", "Classes": "None", "Text": " risk to the ne", "ParentId": "05794d70-8ed6-48c9-b929-2774a545d07f"}, {"Element": "<span lang=\"EN-GB\">wborns/infants cannot be\nexcluded. A decision must be made whether to discontinue breast\u2011feeding\nor to discontinue from nivolumab therapy taking into account the benefit of breast\u2011feeding\nfor the child and the benefit of therapy for the woman.</span>", "ID": "836773b5-b837-4c09-8f46-3ffcaeffd655", "Styles": "None", "Classes": "None", "Text": "wborns/infants cannot be excluded. A decision must be made whether to discontinue breast\u2011feeding or to discontinue from nivolumab therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.", "ParentId": "05794d70-8ed6-48c9-b929-2774a545d07f"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "708bff25-53c4-485e-98fd-a6ad68331e37", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "d2308106-26a4-4c02-94ff-0040875346ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "708bff25-53c4-485e-98fd-a6ad68331e37"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "6bd18984-c9f5-4398-ba2d-66f453205c69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2308106-26a4-4c02-94ff-0040875346ee"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "4c529da9-67d3-4837-bb42-601a43d8a90e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6bd18984-c9f5-4398-ba2d-66f453205c69"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>", "ID": "ccf306c0-6f9d-4afa-8fe8-5393a72881ef", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Fertility</span></u>", "ID": "48d12535-ef4b-472d-9a93-959f26ae0b40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ccf306c0-6f9d-4afa-8fe8-5393a72881ef"}, {"Element": "<span lang=\"EN-GB\">Fertility</span>", "ID": "ad955021-7e00-4f3c-87be-b0222467f30e", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "48d12535-ef4b-472d-9a93-959f26ae0b40"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies to evaluate the effect of\nnivolumab on fertility have not been performed. Thus, the effect of nivolumab\non male and female fertility is unknown.</span></p>", "ID": "277594f6-038d-439d-935d-93f45ca561fb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Studies to evaluate the effect of\nnivolumab on fertility have not been performed. Thus, the effect of nivolumab\non male and female fertility is unknown.</span>", "ID": "f6fd08c4-0bd6-4ad9-8552-c20b1f7c4dae", "Styles": "None", "Classes": "None", "Text": "Studies to evaluate the effect of nivolumab on fertility have not been performed. Thus, the effect of nivolumab on male and female fertility is unknown.", "ParentId": "277594f6-038d-439d-935d-93f45ca561fb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81487cad-40d1-4ac8-b517-9de79b206433", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01c8471d-0455-4712-9cb4-9fc3e4cc039b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81487cad-40d1-4ac8-b517-9de79b206433"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on\nability to drive and use machines</span></p>", "ID": "81b43774-fa45-4c63-a947-8680510c8dae", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on\nability to drive and use machines</span>", "ID": "e57bb0c7-4111-4ad4-92cc-3de99c2816fe", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "81b43774-fa45-4c63-a947-8680510c8dae"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "693fbcf3-b2fe-46ef-be63-f1db1e78c81d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ea6ddf5-8091-4681-a971-af3832414d6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "693fbcf3-b2fe-46ef-be63-f1db1e78c81d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\nnivolumab is unlikely to affect the ability to drive and use machines. Because\nof potential adverse reactions such as fatigue (see section\u00a04.8), patients\nshould be advised to use caution when driving or operating machinery until they\nare certain that nivolumab does not adversely affect them.</span></p>", "ID": "90dea4d4-c0b5-4a8c-b060-e84b696fdb76", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Based on its pharmacodynamic properties,\nnivolumab is unlikely to affect the ability to drive and use machines. Because\nof potential adverse reactions such as fatigue (see section\u00a04.8), patients\nshould be advised to use caution when driving or operating machinery until they\nare certain that nivolumab does not adversely affect them.</span>", "ID": "87855ec4-0f78-483d-8d8a-f80a4a7575aa", "Styles": "None", "Classes": "None", "Text": "Based on its pharmacodynamic properties, nivolumab is unlikely to affect the ability to drive and use machines. Because of potential adverse reactions such as fatigue (see section\u00a04.8), patients should be advised to use caution when driving or operating machinery until they are certain that nivolumab does not adversely affect them.", "ParentId": "90dea4d4-c0b5-4a8c-b060-e84b696fdb76"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71cbf030-3a36-4db0-99d5-cec1a11fc089", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3be29c69-448f-4fd7-bb8b-1d5daf373218", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71cbf030-3a36-4db0-99d5-cec1a11fc089"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable\neffects</span></p>", "ID": "d1c19d76-89d9-4c01-9fb4-33761c393420", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable\neffects</span>", "ID": "a6ea478f-4c41-425a-ac08-9d809e2b08ad", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "d1c19d76-89d9-4c01-9fb4-33761c393420"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5eb6c8d-f343-4bba-9106-88e423a6cd1a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67b383c5-7a4b-423e-adfe-3ea664882975", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5eb6c8d-f343-4bba-9106-88e423a6cd1a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u></p>", "ID": "d8531fd0-38de-42a5-beb9-f008860168ee", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Summary\nof the safety profile</span></u>", "ID": "98e31c0f-300d-4c2b-b426-002d32b53eca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8531fd0-38de-42a5-beb9-f008860168ee"}, {"Element": "<span lang=\"EN-GB\">Summary\nof the safety profile</span>", "ID": "1e4e6e61-e679-42bf-806b-2c91172a5f3a", "Styles": "None", "Classes": "None", "Text": "Summary of the safety profile", "ParentId": "98e31c0f-300d-4c2b-b426-002d32b53eca"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is most commonly associated\nwith immune-related adverse reactions. Most of these, including severe\nreactions, resolved following initiation of appropriate medical therapy or\nwithdrawal of nivolumab (see \u201cDescription of selected adverse\nreactions\u201d below).</span></p>", "ID": "8bd8270d-76c1-48e9-a225-f27a5a75ebbc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is most commonly associated\nwith immune-related adverse reactions. Most of these, including severe\nreactions, resolved following initiation of appropriate medical therapy or\nwithdrawal of nivolumab (see \u201cDescription of selected adverse\nreactions\u201d below).</span>", "ID": "ca0b31c0-81f5-4232-ae5b-7014076dece6", "Styles": "None", "Classes": "None", "Text": "Nivolumab is most commonly associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of nivolumab (see \u201cDescription of selected adverse reactions\u201d below).", "ParentId": "8bd8270d-76c1-48e9-a225-f27a5a75ebbc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37e5ca15-c5e3-48c5-9503-f70e661bd122", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "635f7567-8209-4140-8bf3-08dae6899522", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37e5ca15-c5e3-48c5-9503-f70e661bd122"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In the pooled dataset of two studies in squamous\nNSCLC (CA209017 and CA209063), the most frequent adverse reactions\n(\u2265\u00a010%\u00a0of patients) were fatigue (33%), decreased appetite\n(15%), and nausea (12%). </span><span lang=\"EN-GB\">The majority of adverse\nreactions were mild to moderate (Grade\u00a01\u00a0or\u00a02)</span><span lang=\"EN-GB\">. </span></p>", "ID": "83593342-759b-4f23-b2b4-d2c4b7436a30", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In the pooled dataset of two studies in squamous\nNSCLC (CA209017 and CA209063), the most frequent adverse reactions\n(\u2265\u00a010%\u00a0of patients) were fatigue (33%), decreased appetite\n(15%), and nausea (12%). </span>", "ID": "d2823e76-c410-462f-aace-1d4bf5f74bcc", "Styles": "None", "Classes": "None", "Text": "In the pooled dataset of two studies in squamous NSCLC (CA209017 and CA209063), the most frequent adverse reactions (\u2265\u00a010%\u00a0of patients) were fatigue (33%), decreased appetite (15%), and nausea (12%). ", "ParentId": "83593342-759b-4f23-b2b4-d2c4b7436a30"}, {"Element": "<span lang=\"EN-GB\">The majority of adverse\nreactions were mild to moderate (Grade\u00a01\u00a0or\u00a02)</span>", "ID": "24f02eab-1feb-40f9-97af-634bbdba30b9", "Styles": "None", "Classes": "None", "Text": "The majority of adverse reactions were mild to moderate (Grade\u00a01\u00a0or\u00a02)", "ParentId": "83593342-759b-4f23-b2b4-d2c4b7436a30"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "45c1952a-8f12-462a-aca1-919a61252939", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "83593342-759b-4f23-b2b4-d2c4b7436a30"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "295d2da8-3ed3-4e4e-8f82-41bd8175b369", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "86c4874a-1b8a-4a84-b1a0-902020fdaf12", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "295d2da8-3ed3-4e4e-8f82-41bd8175b369"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "102ffa8e-bd76-4e1c-8c41-517ad674813b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86c4874a-1b8a-4a84-b1a0-902020fdaf12"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "a13fe66d-0351-4b16-9c8a-359b89585040", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "102ffa8e-bd76-4e1c-8c41-517ad674813b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\nsummary of adverse reactions</span></u></p>", "ID": "e57d8a49-a997-4f62-a815-babddb8077b7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Tabulated\nsummary of adverse reactions</span></u>", "ID": "c46bf351-8910-49f6-b010-1b76997bd4e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e57d8a49-a997-4f62-a815-babddb8077b7"}, {"Element": "<span lang=\"EN-GB\">Tabulated\nsummary of adverse reactions</span>", "ID": "22d89c80-fe40-4e61-8508-a2d60f6ff150", "Styles": "None", "Classes": "None", "Text": "Tabulated summary of adverse reactions", "ParentId": "c46bf351-8910-49f6-b010-1b76997bd4e3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions reported in the pooled\ndataset (n=248) of CA209017 and CA209063 are presented in Table\u00a02. These\nreactions are presented by system organ class and by frequency. Frequencies are\ndefined as: very common (\u2265\u00a01/10); common (\u2265\u00a01/100\u00a0to\u00a0&lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000\u00a0to\u00a0&lt;\u00a01/100);\nrare\u00a0(\u2265\u00a01/10,000\u00a0to\u00a0&lt;\u00a01/1,000); very\nrare\u00a0(&lt;\u00a01/10,000). </span><span lang=\"EN-GB\">Within each frequency\ngrouping, adverse reactions are presented in the order of decreasing\nseriousness.</span></p>", "ID": "4077da64-e6ec-425a-96cb-b86fca780269", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Adverse reactions reported in the pooled\ndataset (n=248) of CA209017 and CA209063 are presented in Table\u00a02. These\nreactions are presented by system organ class and by frequency. Frequencies are\ndefined as: very common (\u2265\u00a01/10); common (\u2265\u00a01/100\u00a0to\u00a0&lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000\u00a0to\u00a0&lt;\u00a01/100);\nrare\u00a0(\u2265\u00a01/10,000\u00a0to\u00a0&lt;\u00a01/1,000); very\nrare\u00a0(&lt;\u00a01/10,000). </span>", "ID": "748a273f-a6e5-4a87-a681-dbafb7cac136", "Styles": "None", "Classes": "None", "Text": "Adverse reactions reported in the pooled dataset (n=248) of CA209017 and CA209063 are presented in Table\u00a02. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (\u2265\u00a01/10); common (\u2265\u00a01/100\u00a0to\u00a0<\u00a01/10); uncommon\u00a0(\u2265\u00a01/1,000\u00a0to\u00a0<\u00a01/100); rare\u00a0(\u2265\u00a01/10,000\u00a0to\u00a0<\u00a01/1,000); very rare\u00a0(<\u00a01/10,000). ", "ParentId": "4077da64-e6ec-425a-96cb-b86fca780269"}, {"Element": "<span lang=\"EN-GB\">Within each frequency\ngrouping, adverse reactions are presented in the order of decreasing\nseriousness.</span>", "ID": "e23bbce8-ea4e-4003-8733-73f73f99f280", "Styles": "None", "Classes": "None", "Text": "Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.", "ParentId": "4077da64-e6ec-425a-96cb-b86fca780269"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f2160ec5-c3ea-4e70-8dcc-4ceb7a969b83", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0bf90c56-888c-4f57-85e4-9912fff6abc0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f2160ec5-c3ea-4e70-8dcc-4ceb7a969b83"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:467.8pt;margin-left:5.4pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"height:29.4pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:29.4pt\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n  2: </span></b><b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span></p>\n</td>\n</tr>\n<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span></p>\n</td>\n</tr>\n</table>", "ID": "a3601124-59bd-4de9-ba79-eb73c6fae9a1", "Styles": "width:467.8pt;margin-left:5.4pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                                          ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<tr style=\"height:29.4pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:29.4pt\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n  2: </span></b><b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b></p>\n</td>\n</tr>", "ID": "1355d51a-6b0a-4bf4-9bef-0751cc888875", "Styles": "height:29.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:29.4pt\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n  2: </span></b><b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b></p>\n</td>", "ID": "9a911ed8-e886-41f6-abae-2d660fdf9723", "Styles": "width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:29.4pt", "Classes": "None", "Text": "  ", "ParentId": "1355d51a-6b0a-4bf4-9bef-0751cc888875"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n  2: </span></b><b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b></p>", "ID": "e3ddcad7-a4ff-48d9-8436-348a1f1cdd6a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9a911ed8-e886-41f6-abae-2d660fdf9723"}, {"Element": "<b><span lang=\"EN-GB\">Table\n  2: </span></b>", "ID": "27f254d2-c82f-4152-98ba-c0f98af2adfb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3ddcad7-a4ff-48d9-8436-348a1f1cdd6a"}, {"Element": "<span lang=\"EN-GB\">Table\n  2: </span>", "ID": "130074fc-7ee6-4e40-b520-72a0d23cdcfb", "Styles": "None", "Classes": "None", "Text": "Table   2: ", "ParentId": "27f254d2-c82f-4152-98ba-c0f98af2adfb"}, {"Element": "<b><span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span></b>", "ID": "d0875841-3ed0-4761-af16-5df862e4b6f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3ddcad7-a4ff-48d9-8436-348a1f1cdd6a"}, {"Element": "<span lang=\"EN-GB\">Adverse reactions in patients with squamous\n  NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)</span>", "ID": "560b550f-b46a-41a2-a44d-0341f996af3a", "Styles": "None", "Classes": "None", "Text": "Adverse reactions in patients with squamous   NSCLC treated with nivolumab\u00a03\u00a0mg/kg (CA209017 and CA209063)", "ParentId": "d0875841-3ed0-4761-af16-5df862e4b6f9"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b></p>\n</td>\n</tr>", "ID": "25687074-eb4c-4eaf-9fba-a8581af99f59", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b></p>\n</td>", "ID": "2716ec4f-a269-4887-b9fe-0d441f0e92e4", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "25687074-eb4c-4eaf-9fba-a8581af99f59"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b></p>", "ID": "d0e5aa33-3cd5-4c0a-aabe-5bb5c4a26adc", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "2716ec4f-a269-4887-b9fe-0d441f0e92e4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span></b>", "ID": "54e3f267-2e08-41a0-a8ab-2ac9bb0a0469", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0e5aa33-3cd5-4c0a-aabe-5bb5c4a26adc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Infections and infestations</span>", "ID": "8c55d3b7-d8ba-4ee6-b691-843e4a693804", "Styles": "color:black", "Classes": "None", "Text": "Infections and infestations", "ParentId": "54e3f267-2e08-41a0-a8ab-2ac9bb0a0469"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span></p>\n</td>\n</tr>", "ID": "6ecce521-0b51-4405-a663-37c371e09175", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "3f643b54-b625-434e-bba6-d029c0ce8b85", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "6ecce521-0b51-4405-a663-37c371e09175"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "96666b74-b8de-409e-9bee-f1952714a7ac", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3f643b54-b625-434e-bba6-d029c0ce8b85"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "42b96fd5-457f-4ed1-84ba-6fe58d1f6ca5", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "96666b74-b8de-409e-9bee-f1952714a7ac"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span></p>\n</td>", "ID": "ad3b4435-ca08-4336-9e61-81f704a608d7", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "6ecce521-0b51-4405-a663-37c371e09175"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span></p>", "ID": "9c20ca85-363f-4a16-ad75-2476daeef72f", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "ad3b4435-ca08-4336-9e61-81f704a608d7"}, {"Element": "<span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">bronchitis, upper respiratory tract infection</span>", "ID": "edfe0e15-4ba7-455b-b3a6-3c69b19c7292", "Styles": "letter-spacing:.15pt", "Classes": "None", "Text": "bronchitis, upper respiratory tract infection", "ParentId": "9c20ca85-363f-4a16-ad75-2476daeef72f"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b></p>\n</td>\n</tr>", "ID": "1f426ec2-99c5-459e-9470-280e45fdebe3", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b></p>\n</td>", "ID": "1850e80f-0fe4-4d7d-bc63-f02e0efed400", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "1f426ec2-99c5-459e-9470-280e45fdebe3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b></p>", "ID": "751311b8-4ffe-4d5b-91a5-06564ef6ffdd", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "1850e80f-0fe4-4d7d-bc63-f02e0efed400"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span></b>", "ID": "1429d90a-2400-415f-8ded-e2a10246515c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "751311b8-4ffe-4d5b-91a5-06564ef6ffdd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Neoplasms benign, malignant and unspecified (including\n  cysts and polyps)</span>", "ID": "78672771-08f6-45fd-896a-fd87db7e3284", "Styles": "color:black", "Classes": "None", "Text": "Neoplasms benign, malignant and unspecified (including   cysts and polyps)", "ParentId": "1429d90a-2400-415f-8ded-e2a10246515c"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span></p>\n</td>\n</tr>", "ID": "b51b1ea3-c552-4667-a9a4-647e4c324176", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "e8fd744d-66f4-44e3-9f25-bd39aea22348", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "b51b1ea3-c552-4667-a9a4-647e4c324176"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "4fe685ff-c7c3-4a92-b21c-dd8fb3765e36", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e8fd744d-66f4-44e3-9f25-bd39aea22348"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "e757594c-34bc-4367-8275-411bc12d3a17", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "4fe685ff-c7c3-4a92-b21c-dd8fb3765e36"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span></p>\n</td>", "ID": "66db3143-989c-4739-9e12-3e8958029389", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "b51b1ea3-c552-4667-a9a4-647e4c324176"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span></p>", "ID": "91580b51-d160-485e-9378-cac09ebabfd9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "66db3143-989c-4739-9e12-3e8958029389"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">histocytic necrotising lymphadenitis (Kikuchi\n  lymphadenitis)</span>", "ID": "0603be3e-1041-454f-bfdc-71ddfaeaed02", "Styles": "color:black", "Classes": "None", "Text": "histocytic necrotising lymphadenitis (Kikuchi   lymphadenitis)", "ParentId": "91580b51-d160-485e-9378-cac09ebabfd9"}, {"Element": "<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b></p>\n</td>\n</tr>", "ID": "190ea91a-3300-4b83-b3a5-1baeecdc2d82", "Styles": "height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b></p>\n</td>", "ID": "48b65b3f-a182-4444-99b6-ee14a7cc2795", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "190ea91a-3300-4b83-b3a5-1baeecdc2d82"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b></p>", "ID": "b859b9c0-0942-4d2f-830a-6501e664467c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "48b65b3f-a182-4444-99b6-ee14a7cc2795"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span></b>", "ID": "233bb89b-3de2-460e-9f65-b789d84cce50", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b859b9c0-0942-4d2f-830a-6501e664467c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Immune system disorders</span>", "ID": "88f70cde-b5ca-4917-ba6c-5ea43184b246", "Styles": "color:black", "Classes": "None", "Text": "Immune system disorders", "ParentId": "233bb89b-3de2-460e-9f65-b789d84cce50"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span></p>\n</td>\n</tr>", "ID": "519a20bf-79c6-4e71-a771-1fe5d2131b88", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "c2eb9af3-0535-4a1f-b3f7-9595c3a29700", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "519a20bf-79c6-4e71-a771-1fe5d2131b88"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "eed39268-fcca-4ce2-aaf9-1e33700ae7fb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c2eb9af3-0535-4a1f-b3f7-9595c3a29700"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "34a1972a-84e5-4cef-a53b-eb0cbbead539", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "eed39268-fcca-4ce2-aaf9-1e33700ae7fb"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span></p>\n</td>", "ID": "cbd83132-8e70-4fa3-a998-769c290e04ee", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "519a20bf-79c6-4e71-a771-1fe5d2131b88"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span></p>", "ID": "eebb2548-136c-4487-b99f-6774bcdcc090", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "cbd83132-8e70-4fa3-a998-769c290e04ee"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">anaphylactic reaction, hypersensitivity,\n  infusion related reaction </span>", "ID": "66b5bfb3-1cf1-4e99-ab57-9487023dc8d4", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "anaphylactic reaction, hypersensitivity,   infusion related reaction ", "ParentId": "eebb2548-136c-4487-b99f-6774bcdcc090"}, {"Element": "<tr style=\"height:13.45pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b></p>\n</td>\n</tr>", "ID": "e5a926d1-9b21-49a8-8c17-398282e0b26e", "Styles": "height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b></p>\n</td>", "ID": "aee1225b-559e-4638-a9ee-e77d8a56ebeb", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "e5a926d1-9b21-49a8-8c17-398282e0b26e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b></p>", "ID": "5228c9cd-1564-41e1-b046-1f0d3537818e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "aee1225b-559e-4638-a9ee-e77d8a56ebeb"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span></b>", "ID": "6ff152ba-3720-44e5-a40c-93a111308355", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5228c9cd-1564-41e1-b046-1f0d3537818e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders</span>", "ID": "749b5a97-efcb-4265-aef7-8c6616c39f83", "Styles": "color:black", "Classes": "None", "Text": "Endocrine disorders", "ParentId": "6ff152ba-3720-44e5-a40c-93a111308355"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span></p>\n</td>\n</tr>", "ID": "df3398e0-8160-483c-b4b5-a61629cddbe3", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "bbe917fa-bb58-4abb-ae60-11f320d922bb", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "df3398e0-8160-483c-b4b5-a61629cddbe3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "25ac48a1-1f3c-4c3e-9278-771f9885ba40", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "bbe917fa-bb58-4abb-ae60-11f320d922bb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "2c7cc902-06b0-436a-bc57-dd66dfc5989f", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "25ac48a1-1f3c-4c3e-9278-771f9885ba40"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span></p>\n</td>", "ID": "82930ff7-ea0b-48b5-895b-fe38daad4cf8", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "df3398e0-8160-483c-b4b5-a61629cddbe3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span></p>", "ID": "8e5142bf-d624-48fc-a354-5723cc92ddad", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "82930ff7-ea0b-48b5-895b-fe38daad4cf8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">hypothyroidism</span>", "ID": "f4c39548-6b38-4826-b6f2-236e2cbc0a00", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "hypothyroidism", "ParentId": "8e5142bf-d624-48fc-a354-5723cc92ddad"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span></p>\n</td>\n</tr>", "ID": "34630c6c-d7ed-4fc3-a80f-275da4d1449f", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "23270a40-3d58-4b40-9984-dc47c2ea322a", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "34630c6c-d7ed-4fc3-a80f-275da4d1449f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "e7600ad8-72bc-448d-922e-d6b3d9164e0f", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "23270a40-3d58-4b40-9984-dc47c2ea322a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "94d24c6b-e63d-4413-913b-1e4530f6d558", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "e7600ad8-72bc-448d-922e-d6b3d9164e0f"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span></p>\n</td>", "ID": "bc6259ac-4227-4f2c-9056-d1842eeac955", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "34630c6c-d7ed-4fc3-a80f-275da4d1449f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span></p>", "ID": "33d94e0e-8866-486a-a646-eb2a87f79375", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "bc6259ac-4227-4f2c-9056-d1842eeac955"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">adrenal insufficiency, thyroiditis </span>", "ID": "2e1df9b3-7c54-4583-8b21-023cdd81da4c", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "adrenal insufficiency, thyroiditis ", "ParentId": "33d94e0e-8866-486a-a646-eb2a87f79375"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b></p>\n</td>\n</tr>", "ID": "7f4ecc7b-9b5f-46b2-ad82-fc231a361ce8", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b></p>\n</td>", "ID": "9deea1f0-7cb1-4566-b465-33533cdd3e92", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "7f4ecc7b-9b5f-46b2-ad82-fc231a361ce8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b></p>", "ID": "fcdb3423-f5f8-4926-8679-b048a1ff4ad9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9deea1f0-7cb1-4566-b465-33533cdd3e92"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span></b>", "ID": "e01c5962-1174-4c6f-891c-211594ea55cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fcdb3423-f5f8-4926-8679-b048a1ff4ad9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders</span>", "ID": "bbab88d3-7f7c-4443-b58f-e3dc0d44ed2d", "Styles": "color:black", "Classes": "None", "Text": "Metabolism and nutrition disorders", "ParentId": "e01c5962-1174-4c6f-891c-211594ea55cd"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span></p>\n</td>\n</tr>", "ID": "5d09224e-3cd4-4cea-afbb-565eeb73b108", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>", "ID": "8f13f2d4-2254-4216-91b9-a6cff1225ecd", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5d09224e-3cd4-4cea-afbb-565eeb73b108"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>", "ID": "4cdee49a-feb3-421a-b9a4-d679744a6a27", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8f13f2d4-2254-4216-91b9-a6cff1225ecd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common</span>", "ID": "9bbfceae-5d97-4b27-9bac-09013e7b7248", "Styles": "color:black", "Classes": "None", "Text": "Very common", "ParentId": "4cdee49a-feb3-421a-b9a4-d679744a6a27"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span></p>\n</td>", "ID": "88bfa6b9-80c8-48db-a76c-19a8e451fdb0", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5d09224e-3cd4-4cea-afbb-565eeb73b108"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span></p>", "ID": "5777b388-0b84-4ca0-b4eb-ff726239a7eb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "88bfa6b9-80c8-48db-a76c-19a8e451fdb0"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">decreased appetite</span>", "ID": "58e3e209-47be-45d5-8265-73f407dcbdb6", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "decreased appetite", "ParentId": "5777b388-0b84-4ca0-b4eb-ff726239a7eb"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span></p>\n</td>\n</tr>", "ID": "9c73e33f-8e86-48ec-9ed9-6df445ce0dad", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span></p>\n</td>", "ID": "80135068-dd32-4bdc-9621-377628846474", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "9c73e33f-8e86-48ec-9ed9-6df445ce0dad"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span></p>", "ID": "2a319671-a47b-4f40-bdfd-ba4fd97422de", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "80135068-dd32-4bdc-9621-377628846474"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span></b>", "ID": "53dd6364-9627-4ce7-bc6a-04ab4ae1397d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a319671-a47b-4f40-bdfd-ba4fd97422de"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders</span>", "ID": "3ea0e1a8-f157-4d59-9c52-59799300fbbe", "Styles": "color:black", "Classes": "None", "Text": "Nervous system disorders", "ParentId": "53dd6364-9627-4ce7-bc6a-04ab4ae1397d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span>", "ID": "a0e1fbad-d3e2-48f5-8a3b-0089f890f4dd", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": " ", "ParentId": "2a319671-a47b-4f40-bdfd-ba4fd97422de"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span></p>\n</td>\n</tr>", "ID": "5a303100-c630-452d-901e-1f765581341e", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "b2b7576a-3b36-482d-a12b-e5e77bc8f65d", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5a303100-c630-452d-901e-1f765581341e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "6e257144-7c00-49d5-b4cb-2c4cba0d6b20", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b2b7576a-3b36-482d-a12b-e5e77bc8f65d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "ae218f4b-f872-4f6c-ba8b-40a1c9ef9ac1", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "6e257144-7c00-49d5-b4cb-2c4cba0d6b20"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span></p>\n</td>", "ID": "33af0528-765d-4df5-b8e6-7fa544dd3312", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5a303100-c630-452d-901e-1f765581341e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span></p>", "ID": "1eb5d331-8085-4953-b889-5da899471180", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "33af0528-765d-4df5-b8e6-7fa544dd3312"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">peripheral neuropathy, headache,\n  dizziness</span>", "ID": "4abe1d85-4ef0-4a4f-a5a1-cb792805c401", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "peripheral neuropathy, headache,   dizziness", "ParentId": "1eb5d331-8085-4953-b889-5da899471180"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span></p>\n</td>\n</tr>", "ID": "9a476b04-4e28-49ec-8d01-6f601f67b7bf", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "f8ef395a-aa93-4b80-bfb5-4691e1bc25d8", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "9a476b04-4e28-49ec-8d01-6f601f67b7bf"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "0337e1f2-a1a7-4b56-bfc2-d1240176ed14", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f8ef395a-aa93-4b80-bfb5-4691e1bc25d8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "f814e993-7cfd-4de7-8c81-e43901fd3a0c", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "0337e1f2-a1a7-4b56-bfc2-d1240176ed14"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span></p>\n</td>", "ID": "dbba2757-ff80-4cd4-aaee-333574669622", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "9a476b04-4e28-49ec-8d01-6f601f67b7bf"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span></p>", "ID": "df6375a4-62d5-4bbf-a041-5c75134dbe15", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "dbba2757-ff80-4cd4-aaee-333574669622"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">myasthenic syndrome, polyneuropathy</span>", "ID": "ad271419-1b6f-47ed-868c-50b38791a56f", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "myasthenic syndrome, polyneuropathy", "ParentId": "df6375a4-62d5-4bbf-a041-5c75134dbe15"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b></p>\n</td>\n</tr>", "ID": "42d2cc0d-6ae9-46c5-ac4e-00803f35718e", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b></p>\n</td>", "ID": "bb4d7356-ae49-45a7-a543-5785a4329af0", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "42d2cc0d-6ae9-46c5-ac4e-00803f35718e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b></p>", "ID": "278a8129-9c3e-4d22-a75f-77ca43bf049c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "bb4d7356-ae49-45a7-a543-5785a4329af0"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span></b>", "ID": "f647058c-fd54-4a95-b122-41f556ced274", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "278a8129-9c3e-4d22-a75f-77ca43bf049c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders</span>", "ID": "3210950f-f0ca-4c74-a18c-4bd03927ed9a", "Styles": "color:black", "Classes": "None", "Text": "Cardiac disorders", "ParentId": "f647058c-fd54-4a95-b122-41f556ced274"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span></p>\n</td>\n</tr>", "ID": "27a39195-4bbd-43c9-a958-7d3932418bef", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "1aea9bb7-d692-4071-a557-4d39376ae8b9", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "27a39195-4bbd-43c9-a958-7d3932418bef"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "d114b038-f6bf-47ec-8489-1c1c0f35fcad", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "1aea9bb7-d692-4071-a557-4d39376ae8b9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "8cad15f3-0d45-4198-a6a3-80963818a4c7", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "d114b038-f6bf-47ec-8489-1c1c0f35fcad"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span></p>\n</td>", "ID": "e850cb4f-c96e-4f35-8ef0-963978f38a3f", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "27a39195-4bbd-43c9-a958-7d3932418bef"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span></p>", "ID": "78c79996-07ad-48d7-a063-c7d28132d125", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e850cb4f-c96e-4f35-8ef0-963978f38a3f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tachycardia</span>", "ID": "b8ac90f5-4ec2-44aa-acf8-9cc8a7ec1da7", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "tachycardia", "ParentId": "78c79996-07ad-48d7-a063-c7d28132d125"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b></p>\n</td>\n</tr>", "ID": "845c0457-1633-4c10-b31b-aa5616a35885", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b></p>\n</td>", "ID": "84194965-41d7-42f8-ae84-35d502d8d77c", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "845c0457-1633-4c10-b31b-aa5616a35885"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b></p>", "ID": "56b2d858-d28e-4a11-97b0-bf13c7b4c3dd", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "84194965-41d7-42f8-ae84-35d502d8d77c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span></b>", "ID": "9ae7e0a8-f032-4db1-a990-000c02e9f910", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56b2d858-d28e-4a11-97b0-bf13c7b4c3dd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Vascular disorders</span>", "ID": "c32747bc-bd67-4893-977a-744e7491a53c", "Styles": "color:black", "Classes": "None", "Text": "Vascular disorders", "ParentId": "9ae7e0a8-f032-4db1-a990-000c02e9f910"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span></p>\n</td>\n</tr>", "ID": "0fce150b-8d50-44e7-8ae1-2d46ce30411c", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "b2bd685c-95c0-401f-9f51-bb6f226b5745", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "0fce150b-8d50-44e7-8ae1-2d46ce30411c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "e9a6f891-ef64-4db3-9d72-ce9b84b17b1a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b2bd685c-95c0-401f-9f51-bb6f226b5745"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "a9f59f62-d575-4528-a29f-c885892c896e", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "e9a6f891-ef64-4db3-9d72-ce9b84b17b1a"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span></p>\n</td>", "ID": "9e8bc13f-e442-48dd-b777-93fc3757562a", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "0fce150b-8d50-44e7-8ae1-2d46ce30411c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span></p>", "ID": "ea3c31fe-75b7-4e68-bc08-f9cc61cff891", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9e8bc13f-e442-48dd-b777-93fc3757562a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">vasculitis</span>", "ID": "3dd3a8df-e2ef-4e46-a7b8-668bb13fc05d", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "vasculitis", "ParentId": "ea3c31fe-75b7-4e68-bc08-f9cc61cff891"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b></p>\n</td>\n</tr>", "ID": "d5dde6b3-1f4c-43e7-af01-afc41e7220e2", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b></p>\n</td>", "ID": "f9b84555-6773-488e-9901-008d117bfe9c", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "d5dde6b3-1f4c-43e7-af01-afc41e7220e2"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b></p>", "ID": "b95d410f-7952-47e2-a29c-56ab2b6d1094", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f9b84555-6773-488e-9901-008d117bfe9c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span></b>", "ID": "83b3a7b0-ab4a-4ae2-9740-d130a1d8dd71", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b95d410f-7952-47e2-a29c-56ab2b6d1094"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders</span>", "ID": "5b240ae5-e509-4de4-9aba-1666ce8fe0b6", "Styles": "color:black", "Classes": "None", "Text": "Respiratory, thoracic and mediastinal disorders", "ParentId": "83b3a7b0-ab4a-4ae2-9740-d130a1d8dd71"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span></p>\n</td>\n</tr>", "ID": "38930f68-83a0-4ded-bcfd-1c3ce0653f8f", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "7db00b5f-cb60-4df4-b719-155503eff639", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "38930f68-83a0-4ded-bcfd-1c3ce0653f8f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "146cd4ea-d4ee-4a96-a453-8ae875a669c0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "7db00b5f-cb60-4df4-b719-155503eff639"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "d879ba47-4571-406a-93e7-198a5a0c19d3", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "146cd4ea-d4ee-4a96-a453-8ae875a669c0"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span></p>\n</td>", "ID": "0f597357-576a-4cb7-8037-0c6e6b9a9747", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "38930f68-83a0-4ded-bcfd-1c3ce0653f8f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span></p>", "ID": "027dac13-5109-4e21-be14-2a2aa22721f9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "0f597357-576a-4cb7-8037-0c6e6b9a9747"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pneumonitis, dyspnoea, cough</span>", "ID": "8026fd5c-ab58-4cfa-bd5e-c2f30c304a56", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "pneumonitis, dyspnoea, cough", "ParentId": "027dac13-5109-4e21-be14-2a2aa22721f9"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span></p>\n</td>\n</tr>", "ID": "80d338ac-ab6c-4f09-92e9-c6951525f145", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "dc8602f8-ab75-47c4-9fd1-905cdb0e8cc5", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "80d338ac-ab6c-4f09-92e9-c6951525f145"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "e0cfe3c7-f2dc-4b3b-95e8-2fcb86bcb8d7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "dc8602f8-ab75-47c4-9fd1-905cdb0e8cc5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "3215023d-8b70-4fda-991f-14f9105c001f", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "e0cfe3c7-f2dc-4b3b-95e8-2fcb86bcb8d7"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span></p>\n</td>", "ID": "b45ffccb-2cee-4f2b-b816-65aa327d4ea9", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "80d338ac-ab6c-4f09-92e9-c6951525f145"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span></p>", "ID": "62f6816e-b2c0-4c8e-ab01-221123a2ba18", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b45ffccb-2cee-4f2b-b816-65aa327d4ea9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">lung infiltration</span>", "ID": "7d7fb1c8-f008-4c0f-bc8e-0bacf237a048", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "lung infiltration", "ParentId": "62f6816e-b2c0-4c8e-ab01-221123a2ba18"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b></p>\n</td>\n</tr>", "ID": "dd0a437a-d9f0-4680-b6a7-7f7952c83b2b", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b></p>\n</td>", "ID": "9f1a4e86-dbfc-4f96-8bf4-11bc8bdf287b", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "dd0a437a-d9f0-4680-b6a7-7f7952c83b2b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b></p>", "ID": "32ba82cf-073c-4acd-b423-87e0fcf6a35c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9f1a4e86-dbfc-4f96-8bf4-11bc8bdf287b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span></b>", "ID": "c545b47f-4a15-498d-b08e-3a631a71efab", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32ba82cf-073c-4acd-b423-87e0fcf6a35c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders</span>", "ID": "66e3f375-c2d0-43ac-bc9c-4be80bb56fa2", "Styles": "color:black", "Classes": "None", "Text": "Gastrointestinal disorders", "ParentId": "c545b47f-4a15-498d-b08e-3a631a71efab"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span></p>\n</td>\n</tr>", "ID": "264f0f55-caa7-4cfe-a5d8-109a86fcabf9", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>", "ID": "f05d1839-8ba0-44a9-9c1f-150df146c9a6", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "264f0f55-caa7-4cfe-a5d8-109a86fcabf9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>", "ID": "f5af9501-5f0a-4152-be91-c488149451eb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f05d1839-8ba0-44a9-9c1f-150df146c9a6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common</span>", "ID": "b89c67b8-48a9-4fd8-9300-dfbe1ac04dba", "Styles": "color:black", "Classes": "None", "Text": "Very common", "ParentId": "f5af9501-5f0a-4152-be91-c488149451eb"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span></p>\n</td>", "ID": "1cbef49b-f1a7-4d18-85d2-301430e4be13", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "264f0f55-caa7-4cfe-a5d8-109a86fcabf9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span></p>", "ID": "9d8a00bb-c2b0-4869-be98-2f834c14f59a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "1cbef49b-f1a7-4d18-85d2-301430e4be13"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">nausea</span>", "ID": "8b71243b-c548-4900-9882-4584fa5228ea", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "nausea", "ParentId": "9d8a00bb-c2b0-4869-be98-2f834c14f59a"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span></p>\n</td>\n</tr>", "ID": "5c73fe18-9bc3-4eae-a685-ad12a3c93879", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "1fed2aca-ad6c-4a10-ad41-86d18bbdbc31", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5c73fe18-9bc3-4eae-a685-ad12a3c93879"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "920ae75f-a2f7-4e0e-80b2-438c530fed30", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "1fed2aca-ad6c-4a10-ad41-86d18bbdbc31"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "0c302f82-4c4b-490d-9914-a270e9da3492", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "920ae75f-a2f7-4e0e-80b2-438c530fed30"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span></p>\n</td>", "ID": "e22027d3-7487-423e-8dfa-317f632fa7ca", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "5c73fe18-9bc3-4eae-a685-ad12a3c93879"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span></p>", "ID": "90dcf08a-8ba2-43a0-887f-020baec73968", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e22027d3-7487-423e-8dfa-317f632fa7ca"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">diarrhoea, stomatitis, vomiting, abdominal\n  pain, constipation, dry mouth</span>", "ID": "fad1b5b1-02ab-4dfd-ad91-8fb5f3a7c715", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "diarrhoea, stomatitis, vomiting, abdominal   pain, constipation, dry mouth", "ParentId": "90dcf08a-8ba2-43a0-887f-020baec73968"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span></p>\n</td>\n</tr>", "ID": "f840369c-e758-4e40-add4-f3d28da23d1f", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "f719079e-dcfa-418d-b0aa-98acc86e58ce", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "f840369c-e758-4e40-add4-f3d28da23d1f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "40dbee32-a139-4c5e-9a82-721ecc405088", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f719079e-dcfa-418d-b0aa-98acc86e58ce"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "fa320df0-e61d-4081-9386-90830ef13f99", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "40dbee32-a139-4c5e-9a82-721ecc405088"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span></p>\n</td>", "ID": "c44e0f21-f7c5-4e2f-9e80-69f362620daa", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "f840369c-e758-4e40-add4-f3d28da23d1f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span></p>", "ID": "42a6388b-9d3f-4f6b-8853-50ae0402287d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c44e0f21-f7c5-4e2f-9e80-69f362620daa"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">colitis, duodenal ulcer</span>", "ID": "3ce977e0-13c4-469c-baae-1707b7c102a1", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "colitis, duodenal ulcer", "ParentId": "42a6388b-9d3f-4f6b-8853-50ae0402287d"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b></p>\n</td>\n</tr>", "ID": "484b98be-0bc7-4616-8403-3e8ee45340e5", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b></p>\n</td>", "ID": "6a2f88b7-5e91-417f-addc-7b2204056484", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "484b98be-0bc7-4616-8403-3e8ee45340e5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b></p>", "ID": "c42f9e1e-ed54-4b3a-9240-6bd8cfefdf46", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "6a2f88b7-5e91-417f-addc-7b2204056484"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span></b>", "ID": "49ba2387-0326-4229-8595-dd3a63506bb0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c42f9e1e-ed54-4b3a-9240-6bd8cfefdf46"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders</span>", "ID": "37b79be6-7687-403f-a170-c1fa28d5466d", "Styles": "color:black", "Classes": "None", "Text": "Skin and subcutaneous tissue disorders", "ParentId": "49ba2387-0326-4229-8595-dd3a63506bb0"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span></p>\n</td>\n</tr>", "ID": "cd84c0ba-b04b-4ea9-a739-e8e49eb18e38", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "4324925b-ea32-4260-92f2-d5e4b5e5b46b", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "cd84c0ba-b04b-4ea9-a739-e8e49eb18e38"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "a1e5ac57-6f5d-44a7-bb50-f1b2fbaa6b0b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "4324925b-ea32-4260-92f2-d5e4b5e5b46b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "0095f612-e70c-4764-95ad-f7c584eded2f", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "a1e5ac57-6f5d-44a7-bb50-f1b2fbaa6b0b"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span></p>\n</td>", "ID": "3c9e738c-a684-4922-9be4-9b3dd9ccc97e", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "cd84c0ba-b04b-4ea9-a739-e8e49eb18e38"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span></p>", "ID": "d76e3aaa-8991-40fd-81e4-f991827b1ce3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3c9e738c-a684-4922-9be4-9b3dd9ccc97e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">rash, pruritus</span>", "ID": "5f491ee5-ec81-483e-a852-ad37576e34cc", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "rash, pruritus", "ParentId": "d76e3aaa-8991-40fd-81e4-f991827b1ce3"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span></p>\n</td>\n</tr>", "ID": "300766e2-16dc-43ea-ad4b-71cfeb8550db", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "007badef-e114-49ae-9757-e704ae8b384f", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "300766e2-16dc-43ea-ad4b-71cfeb8550db"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "f8212362-26b8-4595-8a8f-0b42405a76bc", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "007badef-e114-49ae-9757-e704ae8b384f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "8c88d869-c1bf-4d12-8c8e-57b9959cfe4f", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "f8212362-26b8-4595-8a8f-0b42405a76bc"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span></p>\n</td>", "ID": "b2bc1197-973c-41c1-a651-b44765d0e877", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "300766e2-16dc-43ea-ad4b-71cfeb8550db"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span></p>", "ID": "8928cea6-e8a6-47d4-95fe-df9ee821c932", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b2bc1197-973c-41c1-a651-b44765d0e877"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">urticaria</span>", "ID": "b3d13dfd-d9c2-4c2d-862c-32ec6c5d4760", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "urticaria", "ParentId": "8928cea6-e8a6-47d4-95fe-df9ee821c932"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b></p>\n</td>\n</tr>", "ID": "0c0b8d85-265b-4336-97c2-a593f8b45cb8", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b></p>\n</td>", "ID": "4403dcf4-fbc0-4bc5-b320-94653bd42857", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "0c0b8d85-265b-4336-97c2-a593f8b45cb8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b></p>", "ID": "add54218-d98e-4117-bb5b-70c128199a0e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "4403dcf4-fbc0-4bc5-b320-94653bd42857"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span></b>", "ID": "f5e29d24-af88-4195-bb61-f416c87ae1fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "add54218-d98e-4117-bb5b-70c128199a0e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue disorders</span>", "ID": "dcfd0e66-1ece-4e00-85f7-2f6c61da2baa", "Styles": "color:black", "Classes": "None", "Text": "Musculoskeletal and connective tissue disorders", "ParentId": "f5e29d24-af88-4195-bb61-f416c87ae1fd"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span></p>\n</td>\n</tr>", "ID": "867de3ee-7e77-4b4b-80ac-c9157d521690", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "2b492dd6-b9e1-4ef5-9914-d7cf9c7b02ba", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "867de3ee-7e77-4b4b-80ac-c9157d521690"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "db2849a0-74f6-4144-a4ac-7dd2781280e7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "2b492dd6-b9e1-4ef5-9914-d7cf9c7b02ba"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "0c0e65ed-4bd0-47e6-8585-95672615aa1d", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "db2849a0-74f6-4144-a4ac-7dd2781280e7"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span></p>\n</td>", "ID": "712748ec-2c2b-4717-b80b-5538cb055e24", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "867de3ee-7e77-4b4b-80ac-c9157d521690"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span></p>", "ID": "da001f02-6b12-441d-9bbd-7fd92c687ce7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "712748ec-2c2b-4717-b80b-5538cb055e24"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">musculoskeletal pain,<sup>a</sup>\n  arthralgia</span>", "ID": "a28728fb-ae0d-4092-8e63-fd6934d0733f", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "musculoskeletal pain,   arthralgia", "ParentId": "da001f02-6b12-441d-9bbd-7fd92c687ce7"}, {"Element": "<sup>a</sup>", "ID": "6a321d61-4d4e-484b-99b9-b361314825f1", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "a28728fb-ae0d-4092-8e63-fd6934d0733f"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span></p>\n</td>\n</tr>", "ID": "9aba4b64-4622-4e15-b118-eebb128f8e8a", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "b850976f-fae3-4b1b-aa97-813184419caf", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "9aba4b64-4622-4e15-b118-eebb128f8e8a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "3e229e6d-3c0f-479d-b716-f1b737f3ede9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b850976f-fae3-4b1b-aa97-813184419caf"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "5d99a65a-b58e-48c0-a22f-3b7db45c83ab", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "3e229e6d-3c0f-479d-b716-f1b737f3ede9"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span></p>\n</td>", "ID": "c06cb7a9-1b1e-403b-aa9b-e82b41298659", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "9aba4b64-4622-4e15-b118-eebb128f8e8a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span></p>", "ID": "e428a6d0-7c5e-417a-abb4-ef387e5fefe5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c06cb7a9-1b1e-403b-aa9b-e82b41298659"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">polymyalgia rheumatica</span>", "ID": "39d28769-8eda-4943-8a1b-5b4c74e684fb", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "polymyalgia rheumatica", "ParentId": "e428a6d0-7c5e-417a-abb4-ef387e5fefe5"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b></p>\n</td>\n</tr>", "ID": "8b4e8571-6e9e-4962-a9ad-b65599ab3795", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b></p>\n</td>", "ID": "12c5540b-8db1-4032-aeac-05ad405bf17b", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "8b4e8571-6e9e-4962-a9ad-b65599ab3795"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b></p>", "ID": "4008d20c-0c56-45cc-8ca1-d2adb47da901", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "12c5540b-8db1-4032-aeac-05ad405bf17b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span></b>", "ID": "06932b5c-91ec-4d7d-a52b-4bf26f50ddc4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4008d20c-0c56-45cc-8ca1-d2adb47da901"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders</span>", "ID": "fe732f68-6561-4367-a63d-60bb24de4691", "Styles": "color:black", "Classes": "None", "Text": "Renal and urinary disorders", "ParentId": "06932b5c-91ec-4d7d-a52b-4bf26f50ddc4"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span></p>\n</td>\n</tr>", "ID": "f83423e3-18f1-420f-a060-955603a0507a", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "8a64e9c0-d82c-4210-9441-912f883cef00", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "f83423e3-18f1-420f-a060-955603a0507a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "e05e8acd-3a4f-40cf-a124-52d65dad1bc9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a64e9c0-d82c-4210-9441-912f883cef00"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "511a9a72-aedc-4a12-82c3-36b09d717b92", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "e05e8acd-3a4f-40cf-a124-52d65dad1bc9"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span></p>\n</td>", "ID": "c58e16fe-149f-4ed0-9ecb-4eebcb6a7c35", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "f83423e3-18f1-420f-a060-955603a0507a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span></p>", "ID": "3f10c841-8456-41f6-8aae-926167c07eca", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c58e16fe-149f-4ed0-9ecb-4eebcb6a7c35"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">tubulointerstitial nephritis, renal\n  failure</span>", "ID": "1fa293b7-8e4d-40b9-b41f-2d0f5eff0aa9", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "tubulointerstitial nephritis, renal   failure", "ParentId": "3f10c841-8456-41f6-8aae-926167c07eca"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b></p>\n</td>\n</tr>", "ID": "3983fd97-6891-4f85-a1ce-e817df1934f8", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b></p>\n</td>", "ID": "b1843d73-15d9-410b-bd6f-fa39d136fdc0", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "3983fd97-6891-4f85-a1ce-e817df1934f8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b></p>", "ID": "b82bcf26-bfc4-4c99-8308-7cfe4a122a1d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b1843d73-15d9-410b-bd6f-fa39d136fdc0"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span></b>", "ID": "cbae7649-5649-44b8-b208-dc8b748dd75f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b82bcf26-bfc4-4c99-8308-7cfe4a122a1d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site conditions</span>", "ID": "17380e03-1dc9-48ad-a15d-008101f3979a", "Styles": "color:black", "Classes": "None", "Text": "General disorders and administration site conditions", "ParentId": "cbae7649-5649-44b8-b208-dc8b748dd75f"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span></p>\n</td>\n</tr>", "ID": "3394125c-09c3-4d2d-8fd4-e10f4bf2fc39", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>", "ID": "038ce17a-89ba-4756-af71-7d1912fa4657", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "3394125c-09c3-4d2d-8fd4-e10f4bf2fc39"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>", "ID": "34d8982f-7bc9-4303-8d16-f8b5e9e638a6", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "038ce17a-89ba-4756-af71-7d1912fa4657"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common</span>", "ID": "724a3eba-3431-42c9-ab08-7b864d2e0c19", "Styles": "color:black", "Classes": "None", "Text": "Very common", "ParentId": "34d8982f-7bc9-4303-8d16-f8b5e9e638a6"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span></p>\n</td>", "ID": "c9c8ed19-16bc-4ad0-8d32-4c949ca11d66", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "3394125c-09c3-4d2d-8fd4-e10f4bf2fc39"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span></p>", "ID": "0a9421ab-cc39-4a33-98b7-6c86d08c9e41", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c9c8ed19-16bc-4ad0-8d32-4c949ca11d66"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">fatigue</span>", "ID": "779078db-e130-4676-8d24-6a2be1e45c79", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "fatigue", "ParentId": "0a9421ab-cc39-4a33-98b7-6c86d08c9e41"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span></p>\n</td>\n</tr>", "ID": "1a5e80c2-2c26-46c9-92b8-ad4c5c368b74", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "3c754a82-0cdc-4c9e-a04f-c058dc139d3c", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a5e80c2-2c26-46c9-92b8-ad4c5c368b74"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "20425138-2c2c-4f9e-bc60-4768d432eaa5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3c754a82-0cdc-4c9e-a04f-c058dc139d3c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "4820a613-dea9-405f-9dfa-8b45708fc714", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "20425138-2c2c-4f9e-bc60-4768d432eaa5"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span></p>\n</td>", "ID": "e7b8c336-23d3-4515-809b-e8a7452ff2e5", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "1a5e80c2-2c26-46c9-92b8-ad4c5c368b74"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span></p>", "ID": "2c3eb10e-bd90-4f11-a573-cc35b9f337d9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e7b8c336-23d3-4515-809b-e8a7452ff2e5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">pyrexia, oedema</span>", "ID": "de93ccba-a5ca-4635-bb1d-3f2b635a43bb", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "pyrexia, oedema", "ParentId": "2c3eb10e-bd90-4f11-a573-cc35b9f337d9"}, {"Element": "<tr style=\"height:14.15pt\">\n<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b></p>\n</td>\n</tr>", "ID": "2686ca45-6c3f-4e0a-a8ea-82d539c19517", "Styles": "height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td colspan=\"2\" style=\"width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt\" valign=\"top\" width=\"624\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b></p>\n</td>", "ID": "db4c5324-30d2-4cc2-9a06-3b981ea13ad8", "Styles": "width:467.8pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt", "Classes": "None", "Text": "  ", "ParentId": "2686ca45-6c3f-4e0a-a8ea-82d539c19517"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b></p>", "ID": "84e6e88a-6b08-4c94-a6c5-33b70195c57f", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "db4c5324-30d2-4cc2-9a06-3b981ea13ad8"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Investigations</span></b>", "ID": "91dbffca-cf9f-43a6-917a-1fd75d05723f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "84e6e88a-6b08-4c94-a6c5-33b70195c57f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Investigations</span>", "ID": "1654d583-935d-4af2-8b29-eb9b713111da", "Styles": "color:black", "Classes": "None", "Text": "Investigations", "ParentId": "91dbffca-cf9f-43a6-917a-1fd75d05723f"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>\n</td>\n</tr>", "ID": "583ec53a-3a50-4cf7-98af-c4d227ed89a5", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>\n</td>", "ID": "9d6c08d2-ed9c-4380-afab-4b9615744de6", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "583ec53a-3a50-4cf7-98af-c4d227ed89a5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common</span></p>", "ID": "ef8bb1b9-8ea9-4a1d-a068-cf72f9e53d74", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9d6c08d2-ed9c-4380-afab-4b9615744de6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Very common</span>", "ID": "69ab5c11-1483-4d1b-ac86-ae0a69d5e2bb", "Styles": "color:black", "Classes": "None", "Text": "Very common", "ParentId": "ef8bb1b9-8ea9-4a1d-a068-cf72f9e53d74"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>\n</td>", "ID": "5ff882b8-a6ad-4673-b9cb-2d6b28ee7ec6", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "583ec53a-3a50-4cf7-98af-c4d227ed89a5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>", "ID": "bf5b8931-0b43-456f-a732-3e01f14e31fb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "5ff882b8-a6ad-4673-b9cb-2d6b28ee7ec6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">increased AST,<sup>b</sup>increased ALT,<sup>b</sup>\n  increased alkaline phosphatase,<sup>b </sup></span>", "ID": "cb6ed510-a382-49f6-9a62-67eefd1b37bd", "Styles": "color:black", "Classes": "None", "Text": "increased AST,increased ALT,   increased alkaline phosphatase,", "ParentId": "bf5b8931-0b43-456f-a732-3e01f14e31fb"}, {"Element": "<sup>b</sup>", "ID": "3ae3e274-bfa1-4552-ac1b-9dca74a14668", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "cb6ed510-a382-49f6-9a62-67eefd1b37bd"}, {"Element": "<sup>b</sup>", "ID": "ba29895a-2a3a-4bbe-9cd9-d1a542439afa", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "cb6ed510-a382-49f6-9a62-67eefd1b37bd"}, {"Element": "<sup>b </sup>", "ID": "f082ca72-5a6f-48e8-952e-006951d31a48", "Styles": "None", "Classes": "None", "Text": "b ", "ParentId": "cb6ed510-a382-49f6-9a62-67eefd1b37bd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased creatinine,</span>", "ID": "fa523332-add6-48da-accb-ab86efd438fc", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "increased creatinine,", "ParentId": "bf5b8931-0b43-456f-a732-3e01f14e31fb"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup>", "ID": "68acb5ed-ed7a-4c38-83ce-ff1fb143bac4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bf5b8931-0b43-456f-a732-3e01f14e31fb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">b</span>", "ID": "11cf8f4b-2460-492a-902b-3aaa0da20233", "Styles": "color:black", "Classes": "None", "Text": "b", "ParentId": "68acb5ed-ed7a-4c38-83ce-ff1fb143bac4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span>", "ID": "a486a066-276e-46ff-8555-8ddcd567a649", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": " ", "ParentId": "bf5b8931-0b43-456f-a732-3e01f14e31fb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">decreased lymphocytes,<sup>b</sup> decreased platelet\n  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>\n  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>\n  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span>", "ID": "9e60cbc1-1975-4547-b3e2-7760c5fb5261", "Styles": "color:black", "Classes": "None", "Text": "decreased lymphocytes, decreased platelet   count, decreased haemoglobin,hypercalcaemia,   hypocalcaemia, hyperkalaemia, hypokalaemia,   hypomagnesaemia, hyponatraemia", "ParentId": "bf5b8931-0b43-456f-a732-3e01f14e31fb"}, {"Element": "<sup>b</sup>", "ID": "d0134823-6ca5-45c3-a505-dbf30089b9c8", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "5868762b-81f4-4a39-b1ad-a259bd2c496f", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b </sup>", "ID": "a5899fa9-6055-4110-9035-2cc5dcbf2d07", "Styles": "None", "Classes": "None", "Text": "b ", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "9979ba09-281e-44df-a5dd-7057d51ce60e", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "5f97fed1-03dd-4dbb-9d66-120cafe012a8", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "83c8c3e0-76ad-4a5f-88dc-4851f1baf334", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "9d51fc52-7b8c-45eb-84fc-438d2bc8e9c1", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "884af716-6ccb-43a1-9bd5-f244084f3d10", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<sup>b</sup>", "ID": "2dbf3982-74db-42df-bf70-d760a166b4a9", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "9e60cbc1-1975-4547-b3e2-7760c5fb5261"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span></p>\n</td>\n</tr>", "ID": "815cc1ff-b9d5-47e2-996c-bc2201355ed5", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>\n</td>", "ID": "d5939df4-eb1c-487a-9c97-b712499c44c6", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "815cc1ff-b9d5-47e2-996c-bc2201355ed5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common</span></p>", "ID": "2d54d77f-ab7a-4a3a-a2f7-def62af9cf92", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "d5939df4-eb1c-487a-9c97-b712499c44c6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Common</span>", "ID": "e0e9898f-ce7a-4ad7-8f9a-b5aa2e852675", "Styles": "color:black", "Classes": "None", "Text": "Common", "ParentId": "2d54d77f-ab7a-4a3a-a2f7-def62af9cf92"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span></p>\n</td>", "ID": "26e79c52-34c7-43e7-8d1c-57da8646e0af", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "815cc1ff-b9d5-47e2-996c-bc2201355ed5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span><sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span><span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span></p>", "ID": "c62d2e27-c7df-4b6e-8e69-b54974171bd4", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "26e79c52-34c7-43e7-8d1c-57da8646e0af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">increased total bilirubin,</span>", "ID": "40825239-4adc-4652-bfe7-8196bf14a9fa", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "increased total bilirubin,", "ParentId": "c62d2e27-c7df-4b6e-8e69-b54974171bd4"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"color:black\">b</span></sup>", "ID": "c5844e9d-e5a4-4a61-8e01-5a2805b0f30f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c62d2e27-c7df-4b6e-8e69-b54974171bd4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">b</span>", "ID": "4b5119c7-2960-4b8a-8feb-0c23f20b6d01", "Styles": "color:black", "Classes": "None", "Text": "b", "ParentId": "c5844e9d-e5a4-4a61-8e01-5a2805b0f30f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\"> </span>", "ID": "9835a653-20bc-433c-80cf-219d34b81d81", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": " ", "ParentId": "c62d2e27-c7df-4b6e-8e69-b54974171bd4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,\n  </sup>hypernatraemia<sup>b</sup></span>", "ID": "78cda2ab-2b16-4e17-ae0e-1d89586e13fb", "Styles": "color:black", "Classes": "None", "Text": "decreased absolute neutrophil count,hypermagnesaemia,hypernatraemia", "ParentId": "c62d2e27-c7df-4b6e-8e69-b54974171bd4"}, {"Element": "<sup>b </sup>", "ID": "dbed056f-9856-4569-acea-54fdec4fca22", "Styles": "None", "Classes": "None", "Text": "b ", "ParentId": "78cda2ab-2b16-4e17-ae0e-1d89586e13fb"}, {"Element": "<sup>b,\n  </sup>", "ID": "c9431e11-fe9a-4146-839d-8183d16997e0", "Styles": "None", "Classes": "None", "Text": "b,   ", "ParentId": "78cda2ab-2b16-4e17-ae0e-1d89586e13fb"}, {"Element": "<sup>b</sup>", "ID": "fee0b400-9dbf-4aeb-a369-96cdc6b28f2a", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "78cda2ab-2b16-4e17-ae0e-1d89586e13fb"}, {"Element": "<tr style=\"height:13.45pt\">\n<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>\n<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span></p>\n</td>\n</tr>", "ID": "d5df0efb-5fec-4885-a8fd-1e0c417e08c4", "Styles": "height:13.45pt", "Classes": "None", "Text": "   ", "ParentId": "a3601124-59bd-4de9-ba79-eb73c6fae9a1"}, {"Element": "<td style=\"width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"138\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>\n</td>", "ID": "828174cf-4ee4-4564-8139-241e8e95bfd7", "Styles": "width:103.7pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "d5df0efb-5fec-4885-a8fd-1e0c417e08c4"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Uncommon</span></p>", "ID": "5b8480c9-c2c0-44e8-8323-7b6987ab7f53", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "828174cf-4ee4-4564-8139-241e8e95bfd7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Uncommon</span>", "ID": "74d6de54-c068-44a5-88c7-a55d9cfca549", "Styles": "color:black", "Classes": "None", "Text": "Uncommon", "ParentId": "5b8480c9-c2c0-44e8-8323-7b6987ab7f53"}, {"Element": "<td style=\"width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"485\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span></p>\n</td>", "ID": "70a559b4-5eaa-4791-bf1b-9bd196fab6a1", "Styles": "width:364.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt", "Classes": "None", "Text": "  ", "ParentId": "d5df0efb-5fec-4885-a8fd-1e0c417e08c4"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span></p>", "ID": "549eb7fa-fe98-48ec-9189-500e0e937b9d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "70a559b4-5eaa-4791-bf1b-9bd196fab6a1"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;letter-spacing:.15pt\">Increased lipase, increased amylase</span>", "ID": "68689123-4d9e-42b5-ad3b-b83dc5270f53", "Styles": "color:black;letter-spacing:.15pt", "Classes": "None", "Text": "Increased lipase, increased amylase", "ParentId": "549eb7fa-fe98-48ec-9189-500e0e937b9d"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\">a</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Musculoskeletal\npain is a composite term which includes back pain, bone pain, musculoskeletal\nchest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity,\npain in jaw, spinal pain.</span></p>", "ID": "dd6ab079-c706-4f47-bcfb-acd07c94eab1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\">a</span></span>", "ID": "9ffbd33c-4bf9-4411-86a2-ed50e3d57846", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "dd6ab079-c706-4f47-bcfb-acd07c94eab1"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "b327a323-7621-4924-9bdc-a7e5325f6067", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "9ffbd33c-4bf9-4411-86a2-ed50e3d57846"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Musculoskeletal\npain is a composite term which includes back pain, bone pain, musculoskeletal\nchest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity,\npain in jaw, spinal pain.</span>", "ID": "2a0baab2-06ab-4bcd-b2a2-20ad221d683e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, pain in jaw, spinal pain.", "ParentId": "dd6ab079-c706-4f47-bcfb-acd07c94eab1"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid\"><span class=\"EMEASuperscript\"><span lang=\"EN-GB\">b</span></span><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Frequencies\nreflect the proportion of patients who experienced a worsening from baseline in\nlaboratory measurements. See \u201cDescription of selected adverse reactions;\nlaboratory abnormalities\u201d below.</span></p>", "ID": "00ce91ee-31d1-47ad-88a5-addd2d5a90a1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\npage-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\">b</span></span>", "ID": "aab2119d-9ee1-453c-b28a-6f4ce3bd924b", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "00ce91ee-31d1-47ad-88a5-addd2d5a90a1"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "51eefbf4-0b95-4432-805a-7d639bb88716", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "aab2119d-9ee1-453c-b28a-6f4ce3bd924b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Frequencies\nreflect the proportion of patients who experienced a worsening from baseline in\nlaboratory measurements. See \u201cDescription of selected adverse reactions;\nlaboratory abnormalities\u201d below.</span>", "ID": "648da173-d5f8-47f8-9e63-c1860db30495", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Frequencies reflect the proportion of patients who experienced a worsening from baseline in laboratory measurements. See \u201cDescription of selected adverse reactions; laboratory abnormalities\u201d below.", "ParentId": "00ce91ee-31d1-47ad-88a5-addd2d5a90a1"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "3b4030a2-5090-44ca-9668-973f198bb88d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "50bd7118-9fe0-4f53-a2e0-90347228d548", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3b4030a2-5090-44ca-9668-973f198bb88d"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "86ca0ae4-ca2f-43d1-95d0-5bb9c15ce371", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "50bd7118-9fe0-4f53-a2e0-90347228d548"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "73799054-a1f1-4319-8529-2e4391c08692", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "86ca0ae4-ca2f-43d1-95d0-5bb9c15ce371"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u></p>", "ID": "790f6794-8076-4a12-84d5-77ef3c838381", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Description\nof selected adverse reactions</span></u>", "ID": "c0771c29-bc2a-48c8-a58c-e0d26d0429a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "790f6794-8076-4a12-84d5-77ef3c838381"}, {"Element": "<span lang=\"EN-GB\">Description\nof selected adverse reactions</span>", "ID": "d2c9d312-f3a5-46a6-9bb7-4f5eb20f8b1f", "Styles": "None", "Classes": "None", "Text": "Description of selected adverse reactions", "ParentId": "c0771c29-bc2a-48c8-a58c-e0d26d0429a5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Data for the following immune\u2011related\nadverse reactions are based on patients who received\nnivolumab\u00a03\u00a0mg/kg in two NSCLC studies (CA209017 and CA209063, see\nsection\u00a05.1). The management guidelines for these adverse reactions are\ndescribed in section\u00a04.4.</span></p>", "ID": "9d64316d-f03c-4ee0-98b9-3eeaed2ba46e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Data for the following immune\u2011related\nadverse reactions are based on patients who received\nnivolumab\u00a03\u00a0mg/kg in two NSCLC studies (CA209017 and CA209063, see\nsection\u00a05.1). The management guidelines for these adverse reactions are\ndescribed in section\u00a04.4.</span>", "ID": "b98f0f19-3344-4e0b-a2cf-346896f444cd", "Styles": "None", "Classes": "None", "Text": "Data for the following immune\u2011related adverse reactions are based on patients who received nivolumab\u00a03\u00a0mg/kg in two NSCLC studies (CA209017 and CA209063, see section\u00a05.1). The management guidelines for these adverse reactions are described in section\u00a04.4.", "ParentId": "9d64316d-f03c-4ee0-98b9-3eeaed2ba46e"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "43f508e4-5fc8-4cf3-80b2-725ebf67debb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "262839c5-ba85-4a71-9b58-707191cdbee0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "43f508e4-5fc8-4cf3-80b2-725ebf67debb"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "cf070524-d1c4-400a-b24b-ede444f0d640", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "262839c5-ba85-4a71-9b58-707191cdbee0"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "acfd6fc0-d22c-47ac-8ab9-bdd2c9dc5269", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "cf070524-d1c4-400a-b24b-ede444f0d640"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune-related\npneumonitis</span></u></i></p>", "ID": "c2f5977c-4bd3-494a-97cc-2da498ed9df4", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune-related\npneumonitis</span></u></i>", "ID": "1ade0169-b8fb-466c-b1fe-0ecceea283c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c2f5977c-4bd3-494a-97cc-2da498ed9df4"}, {"Element": "<u><span lang=\"EN-GB\">Immune-related\npneumonitis</span></u>", "ID": "487bb62a-90a7-48d0-a41e-fc5f41f831b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1ade0169-b8fb-466c-b1fe-0ecceea283c1"}, {"Element": "<span lang=\"EN-GB\">Immune-related\npneumonitis</span>", "ID": "85731477-de4c-48e5-9f65-7102436db2f1", "Styles": "None", "Classes": "None", "Text": "Immune-related pneumonitis", "ParentId": "487bb62a-90a7-48d0-a41e-fc5f41f831b1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof pneumonitis, including interstitial lung disease, was 5.2%\u00a0(13/248).\nGrade 2\u00a0and Grade\u00a03 cases were reported in 2.8% (7/248) and 1.6% (4/248)\nof patients, respectively. No Grade\u00a04 or\u00a05 cases reported in these\nstudies. In the phase 1 study MDX1106-03, pneumonitis, including a Grade 4 case\nin 1 patient, was reported in 3/37 patients (8.1%) with NSCLC receiving\nnivolumab </span><span lang=\"EN-GB\">3\u00a0mg/kg.</span></p>", "ID": "5debee72-93c5-4989-88f2-27a2dc079b81", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof pneumonitis, including interstitial lung disease, was 5.2%\u00a0(13/248).\nGrade 2\u00a0and Grade\u00a03 cases were reported in 2.8% (7/248) and 1.6% (4/248)\nof patients, respectively. No Grade\u00a04 or\u00a05 cases reported in these\nstudies. In the phase 1 study MDX1106-03, pneumonitis, including a Grade 4 case\nin 1 patient, was reported in 3/37 patients (8.1%) with NSCLC receiving\nnivolumab </span>", "ID": "687f487c-8e40-445f-827e-1eb756d587c8", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of pneumonitis, including interstitial lung disease, was 5.2%\u00a0(13/248). Grade 2\u00a0and Grade\u00a03 cases were reported in 2.8% (7/248) and 1.6% (4/248) of patients, respectively. No Grade\u00a04 or\u00a05 cases reported in these studies. In the phase 1 study MDX1106-03, pneumonitis, including a Grade 4 case in 1 patient, was reported in 3/37 patients (8.1%) with NSCLC receiving nivolumab ", "ParentId": "5debee72-93c5-4989-88f2-27a2dc079b81"}, {"Element": "<span lang=\"EN-GB\">3\u00a0mg/kg.</span>", "ID": "366e8f99-bf1a-436d-8af4-c7eeb7f49add", "Styles": "None", "Classes": "None", "Text": "3\u00a0mg/kg.", "ParentId": "5debee72-93c5-4989-88f2-27a2dc079b81"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "fe690df1-f401-46cc-b2b4-bb58d2019fd1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "ced7ab88-5613-4968-a020-00792e7323b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe690df1-f401-46cc-b2b4-bb58d2019fd1"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "dfcc75cc-68f8-4872-90ca-942cd5cdbcc2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ced7ab88-5613-4968-a020-00792e7323b3"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "4e70f7e1-066e-4f3e-b50e-82217c097967", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "dfcc75cc-68f8-4872-90ca-942cd5cdbcc2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 11.6\u00a0weeks\n(range: 2.6-85.1). Eleven patients received high-dose corticosteroids (at least\n40\u00a0mg prednisone equivalents) at a median initial dose of 1.1\u00a0mg/kg\n(range:\u00a00.5-4.0) for a median total duration of 4.3 weeks (range:\u00a00.6-13.1).\nEight patients, including the 4 patients with a Grade 3 case, required\npermanent discontinuation of nivolumab due to pneumonitis. Resolution occurred\nin all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).</span></p>", "ID": "afc78abe-c8b1-4f1b-8bd5-3d123fe81f53", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset was 11.6\u00a0weeks\n(range: 2.6-85.1). Eleven patients received high-dose corticosteroids (at least\n40\u00a0mg prednisone equivalents) at a median initial dose of 1.1\u00a0mg/kg\n(range:\u00a00.5-4.0) for a median total duration of 4.3 weeks (range:\u00a00.6-13.1).\nEight patients, including the 4 patients with a Grade 3 case, required\npermanent discontinuation of nivolumab due to pneumonitis. Resolution occurred\nin all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).</span>", "ID": "ca4a0f75-5772-4daa-95a7-d3a0f542e7af", "Styles": "None", "Classes": "None", "Text": "Median time to onset was 11.6\u00a0weeks (range: 2.6-85.1). Eleven patients received high-dose corticosteroids (at least 40\u00a0mg prednisone equivalents) at a median initial dose of 1.1\u00a0mg/kg (range:\u00a00.5-4.0) for a median total duration of 4.3 weeks (range:\u00a00.6-13.1). Eight patients, including the 4 patients with a Grade 3 case, required permanent discontinuation of nivolumab due to pneumonitis. Resolution occurred in all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).", "ParentId": "afc78abe-c8b1-4f1b-8bd5-3d123fe81f53"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "d0a2f78b-ff58-4719-ba14-1f1f20555e03", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "c002cefd-9bbc-4000-8b65-96af9d94a50e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0a2f78b-ff58-4719-ba14-1f1f20555e03"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "907ac82b-6fe6-48f5-a1e8-a08feada2ff5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c002cefd-9bbc-4000-8b65-96af9d94a50e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b04a56a2-7b62-4b97-85c1-d5c249362c24", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "907ac82b-6fe6-48f5-a1e8-a08feada2ff5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u></i></p>", "ID": "31868674-cd82-427d-b244-a5a197ab8eda", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u></i>", "ID": "07179bad-3513-4a2a-8c44-538ddb3a71ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "31868674-cd82-427d-b244-a5a197ab8eda"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\ncolitis</span></u>", "ID": "421d084c-0f67-40a9-9f7f-25f94f21e2c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "07179bad-3513-4a2a-8c44-538ddb3a71ef"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\ncolitis</span>", "ID": "fa14b3ba-7667-46ea-9b58-fc48ff0a24f5", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related colitis", "ParentId": "421d084c-0f67-40a9-9f7f-25f94f21e2c0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof diarrhoea or colitis was\u00a09.3% (23/248). Grade\u00a02 and Grade\u00a03\u00a0cases\nwere reported in\u00a02% (5/248) and 1.6% (4/248)\u00a0of patients,\nrespectively. No Grade\u00a04\u00a0or\u00a05\u00a0cases were reported in these\nstudies.</span></p>", "ID": "d3690ad8-c8b0-435b-baed-089c78863ab7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof diarrhoea or colitis was\u00a09.3% (23/248). Grade\u00a02 and Grade\u00a03\u00a0cases\nwere reported in\u00a02% (5/248) and 1.6% (4/248)\u00a0of patients,\nrespectively. No Grade\u00a04\u00a0or\u00a05\u00a0cases were reported in these\nstudies.</span>", "ID": "a1d85710-9501-4865-a2d4-a88fe12f7bd9", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of diarrhoea or colitis was\u00a09.3% (23/248). Grade\u00a02 and Grade\u00a03\u00a0cases were reported in\u00a02% (5/248) and 1.6% (4/248)\u00a0of patients, respectively. No Grade\u00a04\u00a0or\u00a05\u00a0cases were reported in these studies.", "ParentId": "d3690ad8-c8b0-435b-baed-089c78863ab7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "373280b6-5157-472e-bbe2-6f3a6f040d73", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6876d8e2-9add-4d60-8e6f-7d644dc21126", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "373280b6-5157-472e-bbe2-6f3a6f040d73"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was\u00a05.6\u00a0weeks\n(range:\u00a00.1\u201191.0). Three patients, </span><span lang=\"EN-GB\">including\u00a02\u00a0patients\nwith a Grade\u00a03\u00a0case,</span><span lang=\"EN-GB\"> received high\u2011dose\ncorticosteroids (at least\u00a040\u00a0mg prednisone equivalents) at a median\ninitial dose of 0.6\u00a0mg/kg (range: 0.4-1.3) for a median duration of 2.0\u00a0weeks\n(range: 1.4-14.1). One patient required permanent discontinuation of nivolumab\ndue to Grade 3 diarrhoea. Resolution occurred in 19\u00a0patients (83%) with a\nmedian time to resolution of 2.0\u00a0weeks (range:\u00a00.1\u201131.0).</span></p>", "ID": "f18f9ea1-f72f-4ee2-a65d-97a85d5d348f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset was\u00a05.6\u00a0weeks\n(range:\u00a00.1\u201191.0). Three patients, </span>", "ID": "bed75856-643a-4142-bbf4-4c61eb23b7d4", "Styles": "None", "Classes": "None", "Text": "Median time to onset was\u00a05.6\u00a0weeks (range:\u00a00.1\u201191.0). Three patients, ", "ParentId": "f18f9ea1-f72f-4ee2-a65d-97a85d5d348f"}, {"Element": "<span lang=\"EN-GB\">including\u00a02\u00a0patients\nwith a Grade\u00a03\u00a0case,</span>", "ID": "07e175e2-fcf6-425b-8c7c-9719ce139f8e", "Styles": "None", "Classes": "None", "Text": "including\u00a02\u00a0patients with a Grade\u00a03\u00a0case,", "ParentId": "f18f9ea1-f72f-4ee2-a65d-97a85d5d348f"}, {"Element": "<span lang=\"EN-GB\"> received high\u2011dose\ncorticosteroids (at least\u00a040\u00a0mg prednisone equivalents) at a median\ninitial dose of 0.6\u00a0mg/kg (range: 0.4-1.3) for a median duration of 2.0\u00a0weeks\n(range: 1.4-14.1). One patient required permanent discontinuation of nivolumab\ndue to Grade 3 diarrhoea. Resolution occurred in 19\u00a0patients (83%) with a\nmedian time to resolution of 2.0\u00a0weeks (range:\u00a00.1\u201131.0).</span>", "ID": "1f79cea5-1545-4e88-af91-d66d6335b165", "Styles": "None", "Classes": "None", "Text": " received high\u2011dose corticosteroids (at least\u00a040\u00a0mg prednisone equivalents) at a median initial dose of 0.6\u00a0mg/kg (range: 0.4-1.3) for a median duration of 2.0\u00a0weeks (range: 1.4-14.1). One patient required permanent discontinuation of nivolumab due to Grade 3 diarrhoea. Resolution occurred in 19\u00a0patients (83%) with a median time to resolution of 2.0\u00a0weeks (range:\u00a00.1\u201131.0).", "ParentId": "f18f9ea1-f72f-4ee2-a65d-97a85d5d348f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b0b2dcfd-56e1-417a-a059-263d84bf6f11", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65ca673e-d0b8-43a5-8104-8bd7a04540c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0b2dcfd-56e1-417a-a059-263d84bf6f11"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u></i></p>", "ID": "0725da98-2a05-432d-9e8b-3158cad4a9a5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u></i>", "ID": "1577ca38-3b14-4419-b8a4-4a0f2b94bc22", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0725da98-2a05-432d-9e8b-3158cad4a9a5"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span></u>", "ID": "d0035dac-7e7f-4500-b0b4-e5fe25dbc1d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1577ca38-3b14-4419-b8a4-4a0f2b94bc22"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\nhepatitis</span>", "ID": "ddb9700b-764d-411d-aa5c-b70114059454", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related hepatitis", "ParentId": "d0035dac-7e7f-4500-b0b4-e5fe25dbc1d8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof liver function test abnormalities was 1.2% (3/248). Grade\u00a02 cases were\nreported in 0.4% (1/248) of patients. No Grade\u00a03-5 cases were reported in\nthese studies. </span></p>", "ID": "9107ac9b-afe2-4bd0-b84b-ad39fc9c210e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof liver function test abnormalities was 1.2% (3/248). Grade\u00a02 cases were\nreported in 0.4% (1/248) of patients. No Grade\u00a03-5 cases were reported in\nthese studies. </span>", "ID": "749933e6-0f7d-410e-815c-2e2e090fb6fb", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of liver function test abnormalities was 1.2% (3/248). Grade\u00a02 cases were reported in 0.4% (1/248) of patients. No Grade\u00a03-5 cases were reported in these studies. ", "ParentId": "9107ac9b-afe2-4bd0-b84b-ad39fc9c210e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aad45b8e-3034-4be6-86a5-0efd4cb07097", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e663195-6aae-4647-a6fc-0443ae4c14fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aad45b8e-3034-4be6-86a5-0efd4cb07097"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 25.1 weeks\n(range: 4.1-31.1). None of these patients received high-dose corticosteroids. One\npatient required permanent discontinuation of nivolumab due to Grade 2 increases\nin transaminases. Resolution occurred in 2\u00a0patients (67%) with a median\ntime to resolution of 4.1\u00a0weeks (range:\u00a02.9\u201122.3<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>", "ID": "beb20973-ac8b-4529-8b4c-85fc1dc979f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset was 25.1 weeks\n(range: 4.1-31.1). None of these patients received high-dose corticosteroids. One\npatient required permanent discontinuation of nivolumab due to Grade 2 increases\nin transaminases. Resolution occurred in 2\u00a0patients (67%) with a median\ntime to resolution of 4.1\u00a0weeks (range:\u00a02.9\u201122.3<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span>", "ID": "8f689b2c-235e-46a3-bcb5-04d387de1a31", "Styles": "None", "Classes": "None", "Text": "Median time to onset was 25.1 weeks (range: 4.1-31.1). None of these patients received high-dose corticosteroids. One patient required permanent discontinuation of nivolumab due to Grade 2 increases in transaminases. Resolution occurred in 2\u00a0patients (67%) with a median time to resolution of 4.1\u00a0weeks (range:\u00a02.9\u201122.3);  denotes a censored observation.", "ParentId": "beb20973-ac8b-4529-8b4c-85fc1dc979f9"}, {"Element": "<sup>+</sup>", "ID": "441256c0-3c5b-4903-8b0f-f593c14f6e9c", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "8f689b2c-235e-46a3-bcb5-04d387de1a31"}, {"Element": "<span class=\"EMEASuperscript\">+</span>", "ID": "dccda1d0-4fb3-484c-9f9e-d0d775f3eeb6", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "+", "ParentId": "8f689b2c-235e-46a3-bcb5-04d387de1a31"}, {"Element": "<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>", "ID": "1679b6c8-aa45-4ab6-9960-2e0e0de867dc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "053962d6-fe47-4113-9b27-77525c4d8eb7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1679b6c8-aa45-4ab6-9960-2e0e0de867dc"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "0f414f3b-3caa-4949-92d9-413e90bd7c9c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "053962d6-fe47-4113-9b27-77525c4d8eb7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "76472fd7-3716-4dbd-be2e-8bf5bddd6ab7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f414f3b-3caa-4949-92d9-413e90bd7c9c"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "4c975594-26ed-428e-a6fa-ac7b37143e8e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "76472fd7-3716-4dbd-be2e-8bf5bddd6ab7"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune\u2011related\nnephritis and renal dysfunction</span></u></i></p>", "ID": "936dee29-689a-45d0-9a96-a38b9518e506", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune\u2011related\nnephritis and renal dysfunction</span></u></i>", "ID": "2a7e8826-616a-4350-89bc-0c5cdee3eb25", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "936dee29-689a-45d0-9a96-a38b9518e506"}, {"Element": "<u><span lang=\"EN-GB\">Immune\u2011related\nnephritis and renal dysfunction</span></u>", "ID": "6f021e56-2938-4722-b03c-3f6f5290bd15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a7e8826-616a-4350-89bc-0c5cdee3eb25"}, {"Element": "<span lang=\"EN-GB\">Immune\u2011related\nnephritis and renal dysfunction</span>", "ID": "36b3cdb6-591a-4962-a1f9-a579e128c5f0", "Styles": "None", "Classes": "None", "Text": "Immune\u2011related nephritis and renal dysfunction", "ParentId": "6f021e56-2938-4722-b03c-3f6f5290bd15"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof nephritis or renal dysfunction was 3.2%\u00a0(8/248). Grade\u00a02 and Grade\u00a03\ncases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively.\nNo Grade\u00a04\u00a0or\u00a05 nephritis or renal dysfunction was reported in\nthese studies.</span></p>", "ID": "ba02caf7-f843-4f5a-acc0-f9badbfe5866", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof nephritis or renal dysfunction was 3.2%\u00a0(8/248). Grade\u00a02 and Grade\u00a03\ncases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively.\nNo Grade\u00a04\u00a0or\u00a05 nephritis or renal dysfunction was reported in\nthese studies.</span>", "ID": "3a0d7ca2-7caf-41a5-8bac-fd872063c859", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of nephritis or renal dysfunction was 3.2%\u00a0(8/248). Grade\u00a02 and Grade\u00a03 cases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively. No Grade\u00a04\u00a0or\u00a05 nephritis or renal dysfunction was reported in these studies.", "ParentId": "ba02caf7-f843-4f5a-acc0-f9badbfe5866"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6657022d-ed95-44b8-b31f-fb73528a88c4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c2644779-2f73-4b68-b6d2-ba1564a51958", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6657022d-ed95-44b8-b31f-fb73528a88c4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was\u00a010.5 weeks\n(range:\u00a02.1\u201127.0). Two patients, including the one patient with a Grade\u00a03\u00a0case\n(tubulointerstitial nephritis), received high\u2011dose corticosteroids (at\nleast 40\u00a0mg prednisone equivalents) at a median initial dose of 0.8\u00a0mg/kg\n(range: 0.5-1.2) for a median duration of 5.3\u00a0weeks (range: 0.9-9.7).\nResolution occurred in 5 patients (71%), including the Grade\u00a03 case, with\na median time to resolution of 5.9\u00a0weeks (range: 0.7- 37.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>", "ID": "09ed00b5-b836-4262-828c-6cd572b744cc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset was\u00a010.5 weeks\n(range:\u00a02.1\u201127.0). Two patients, including the one patient with a Grade\u00a03\u00a0case\n(tubulointerstitial nephritis), received high\u2011dose corticosteroids (at\nleast 40\u00a0mg prednisone equivalents) at a median initial dose of 0.8\u00a0mg/kg\n(range: 0.5-1.2) for a median duration of 5.3\u00a0weeks (range: 0.9-9.7).\nResolution occurred in 5 patients (71%), including the Grade\u00a03 case, with\na median time to resolution of 5.9\u00a0weeks (range: 0.7- 37.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span>", "ID": "4a6a80f3-54db-4154-9d96-283bc6792d42", "Styles": "None", "Classes": "None", "Text": "Median time to onset was\u00a010.5 weeks (range:\u00a02.1\u201127.0). Two patients, including the one patient with a Grade\u00a03\u00a0case (tubulointerstitial nephritis), received high\u2011dose corticosteroids (at least 40\u00a0mg prednisone equivalents) at a median initial dose of 0.8\u00a0mg/kg (range: 0.5-1.2) for a median duration of 5.3\u00a0weeks (range: 0.9-9.7). Resolution occurred in 5 patients (71%), including the Grade\u00a03 case, with a median time to resolution of 5.9\u00a0weeks (range: 0.7- 37.6);  denotes a censored observation.", "ParentId": "09ed00b5-b836-4262-828c-6cd572b744cc"}, {"Element": "<sup>+</sup>", "ID": "f7b611a8-8c4b-4898-ac68-fca783cfc535", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "4a6a80f3-54db-4154-9d96-283bc6792d42"}, {"Element": "<span class=\"EMEASuperscript\">+</span>", "ID": "324838b6-dc67-4522-a451-9e744c702fc6", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "+", "ParentId": "4a6a80f3-54db-4154-9d96-283bc6792d42"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a7a56c2-1f73-4e8b-9ea7-a55182c28bbe", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "328860a3-2f62-4953-a37b-89925d46cbbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a7a56c2-1f73-4e8b-9ea7-a55182c28bbe"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immune-related\nendocrinopathies</span></u></i></p>", "ID": "ab9a796b-e41a-4929-abb2-1280f0713f09", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune-related\nendocrinopathies</span></u></i>", "ID": "0acb5343-fd06-4f93-ba72-cd3f764a5a3d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ab9a796b-e41a-4929-abb2-1280f0713f09"}, {"Element": "<u><span lang=\"EN-GB\">Immune-related\nendocrinopathies</span></u>", "ID": "35ad63b1-642c-4234-817d-5a3c8efa0bf2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0acb5343-fd06-4f93-ba72-cd3f764a5a3d"}, {"Element": "<span lang=\"EN-GB\">Immune-related\nendocrinopathies</span>", "ID": "d70e990f-718c-4f86-9e92-4d81d790f5ef", "Styles": "None", "Classes": "None", "Text": "Immune-related endocrinopathies", "ParentId": "35ad63b1-642c-4234-817d-5a3c8efa0bf2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof thyroid disorders, including hypothyroidism or thyroiditis, was\u00a04.4%\u00a0(11/248).\nGrade\u00a02 cases were reported in 3.6% (9/248) of patients. No Grade 3\u20115\nthyroid disorders were reported. The incidence of adrenal insufficiency was 0.4%\n(1/248; Grade\u00a03). There were no reports of hypophysitis, diabetes\nmellitus, or diabetic ketoacidosis in these studies.</span></p>", "ID": "d109ed95-3f10-4ce9-9692-b6ce480a34e6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof thyroid disorders, including hypothyroidism or thyroiditis, was\u00a04.4%\u00a0(11/248).\nGrade\u00a02 cases were reported in 3.6% (9/248) of patients. No Grade 3\u20115\nthyroid disorders were reported. The incidence of adrenal insufficiency was 0.4%\n(1/248; Grade\u00a03). There were no reports of hypophysitis, diabetes\nmellitus, or diabetic ketoacidosis in these studies.</span>", "ID": "93594834-4e9b-4767-8424-e378a8bc6309", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of thyroid disorders, including hypothyroidism or thyroiditis, was\u00a04.4%\u00a0(11/248). Grade\u00a02 cases were reported in 3.6% (9/248) of patients. No Grade 3\u20115 thyroid disorders were reported. The incidence of adrenal insufficiency was 0.4% (1/248; Grade\u00a03). There were no reports of hypophysitis, diabetes mellitus, or diabetic ketoacidosis in these studies.", "ParentId": "d109ed95-3f10-4ce9-9692-b6ce480a34e6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a9486e30-798c-40fb-a035-689cf2facf84", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a5971dc-f8fa-4535-9435-dfe9db403385", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9486e30-798c-40fb-a035-689cf2facf84"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset of these\nendocrinopathies was\u00a017.8\u00a0weeks (range: 6.1\u201133.1). Three\npatients, including the one patient with Grade\u00a03 adrenal insufficiency,\nreceived high\u2011dose corticosteroids (at least 40\u00a0mg prednisone\nequivalents) at a median initial dose of 1.1\u00a0mg/kg (range: 0.5-1.3) for 2.7\u00a0weeks\n(range: 0.6-4.6). The Grade\u00a03 case required permanent discontinuation of\nnivolumab. Resolution occurred in 6\u00a0patients (50%) with a median time to\nresolution of 20.6\u00a0weeks (0.4-47.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation. </span></p>", "ID": "07140eb2-28a3-49a1-8885-053e48284a5c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset of these\nendocrinopathies was\u00a017.8\u00a0weeks (range: 6.1\u201133.1). Three\npatients, including the one patient with Grade\u00a03 adrenal insufficiency,\nreceived high\u2011dose corticosteroids (at least 40\u00a0mg prednisone\nequivalents) at a median initial dose of 1.1\u00a0mg/kg (range: 0.5-1.3) for 2.7\u00a0weeks\n(range: 0.6-4.6). The Grade\u00a03 case required permanent discontinuation of\nnivolumab. Resolution occurred in 6\u00a0patients (50%) with a median time to\nresolution of 20.6\u00a0weeks (0.4-47.6<sup>+</sup>); <span class=\"EMEASuperscript\">+</span> denotes a censored observation. </span>", "ID": "8e7a3f5b-47fa-41fe-8256-493de370bd13", "Styles": "None", "Classes": "None", "Text": "Median time to onset of these endocrinopathies was\u00a017.8\u00a0weeks (range: 6.1\u201133.1). Three patients, including the one patient with Grade\u00a03 adrenal insufficiency, received high\u2011dose corticosteroids (at least 40\u00a0mg prednisone equivalents) at a median initial dose of 1.1\u00a0mg/kg (range: 0.5-1.3) for 2.7\u00a0weeks (range: 0.6-4.6). The Grade\u00a03 case required permanent discontinuation of nivolumab. Resolution occurred in 6\u00a0patients (50%) with a median time to resolution of 20.6\u00a0weeks (0.4-47.6);  denotes a censored observation. ", "ParentId": "07140eb2-28a3-49a1-8885-053e48284a5c"}, {"Element": "<sup>+</sup>", "ID": "b6d368b8-d756-4380-8960-f28627c7d663", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "8e7a3f5b-47fa-41fe-8256-493de370bd13"}, {"Element": "<span class=\"EMEASuperscript\">+</span>", "ID": "276e4f46-1d6b-4c6a-9047-5ed67d1dbc68", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "+", "ParentId": "8e7a3f5b-47fa-41fe-8256-493de370bd13"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcfcb98a-bc50-4ce4-93f7-c6dbf3c56477", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9060d3c8-2018-4fb2-b9d5-ab30a461e2f3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcfcb98a-bc50-4ce4-93f7-c6dbf3c56477"}, {"Element": "<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\">Immune-related rash </span></u></i></p>", "ID": "03ba5b54-e982-4ce0-a183-d29164f0b634", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immune-related rash </span></u></i>", "ID": "44c63e5a-4a64-4029-8bff-0875faea4612", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "03ba5b54-e982-4ce0-a183-d29164f0b634"}, {"Element": "<u><span lang=\"EN-GB\">Immune-related rash </span></u>", "ID": "13dbe07b-3e5e-462a-ba7d-1433bc79ca85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44c63e5a-4a64-4029-8bff-0875faea4612"}, {"Element": "<span lang=\"EN-GB\">Immune-related rash </span>", "ID": "a12e4f49-b698-4717-86b1-57124374fda3", "Styles": "None", "Classes": "None", "Text": "Immune-related rash ", "ParentId": "13dbe07b-3e5e-462a-ba7d-1433bc79ca85"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof rash was 12.1%\u00a0(30/248). Grade\u00a02 and Grade\u00a03 cases were\nreported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively. No\nGrade\u00a04\u00a0or\u00a05 rash was reported in these studies.</span></p>", "ID": "fb8c1c5c-c1ae-4ca2-8e34-de4957186583", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof rash was 12.1%\u00a0(30/248). Grade\u00a02 and Grade\u00a03 cases were\nreported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively. No\nGrade\u00a04\u00a0or\u00a05 rash was reported in these studies.</span>", "ID": "a5bbf3e3-043d-47f1-a31a-6492c64734bb", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of rash was 12.1%\u00a0(30/248). Grade\u00a02 and Grade\u00a03 cases were reported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively. No Grade\u00a04\u00a0or\u00a05 rash was reported in these studies.", "ParentId": "fb8c1c5c-c1ae-4ca2-8e34-de4957186583"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5e2c16f-2cb6-49a0-8f6f-4210abe122b5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c3ff8ef-4e0d-417d-8812-f86ce97c6d85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5e2c16f-2cb6-49a0-8f6f-4210abe122b5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Median time to onset was 8.1\u00a0weeks\n(range:\u00a00.3\u201151.9). None of these patients received high-dose\ncorticosteroids. Two patients (1 with Grade\u00a02 rash and 1 with Grade\u00a03\nrash) required permanent discontinuation of nivolumab. Resolution occurred in\n24\u00a0patients (83%), including the 2\u00a0patients with a Grade\u00a03 case,\nwith a median time to resolution of 5.7\u00a0weeks (range: 0.1- 46.9<sup>+</sup>);\n<span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span></p>", "ID": "18665dfb-d2c1-48e4-b779-ecbccc8f1007", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Median time to onset was 8.1\u00a0weeks\n(range:\u00a00.3\u201151.9). None of these patients received high-dose\ncorticosteroids. Two patients (1 with Grade\u00a02 rash and 1 with Grade\u00a03\nrash) required permanent discontinuation of nivolumab. Resolution occurred in\n24\u00a0patients (83%), including the 2\u00a0patients with a Grade\u00a03 case,\nwith a median time to resolution of 5.7\u00a0weeks (range: 0.1- 46.9<sup>+</sup>);\n<span class=\"EMEASuperscript\">+</span> denotes a censored observation.</span>", "ID": "44b24376-da4f-4c02-bf8a-198b2b8b48a7", "Styles": "None", "Classes": "None", "Text": "Median time to onset was 8.1\u00a0weeks (range:\u00a00.3\u201151.9). None of these patients received high-dose corticosteroids. Two patients (1 with Grade\u00a02 rash and 1 with Grade\u00a03 rash) required permanent discontinuation of nivolumab. Resolution occurred in 24\u00a0patients (83%), including the 2\u00a0patients with a Grade\u00a03 case, with a median time to resolution of 5.7\u00a0weeks (range: 0.1- 46.9);  denotes a censored observation.", "ParentId": "18665dfb-d2c1-48e4-b779-ecbccc8f1007"}, {"Element": "<sup>+</sup>", "ID": "f40d4304-c78e-4930-b7fe-c8e942ae8af6", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "44b24376-da4f-4c02-bf8a-198b2b8b48a7"}, {"Element": "<span class=\"EMEASuperscript\">+</span>", "ID": "d9c43aa5-75e2-4eb6-b1c7-edcab020de4d", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "+", "ParentId": "44b24376-da4f-4c02-bf8a-198b2b8b48a7"}, {"Element": "<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "ce5fc913-2056-4f48-8cdd-9540b40b6607", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "7cdf99da-a690-4b03-ad94-f6c3087774c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ce5fc913-2056-4f48-8cdd-9540b40b6607"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ec0ffb0-5e65-44cd-a57a-a3beb54f76d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cdf99da-a690-4b03-ad94-f6c3087774c7"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Infusion\nreactions</span></u></i></p>", "ID": "8418eb5e-4ff0-4012-ab09-cb7ae7c02982", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Infusion\nreactions</span></u></i>", "ID": "e9d6db39-b9a5-481b-9fab-aec51b3d87f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8418eb5e-4ff0-4012-ab09-cb7ae7c02982"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nreactions</span></u>", "ID": "80132580-517d-4b57-9364-f7b9343389cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9d6db39-b9a5-481b-9fab-aec51b3d87f8"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions</span>", "ID": "8a2895e9-76f8-4a18-b9cb-b039fae5344a", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "80132580-517d-4b57-9364-f7b9343389cc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof hypersensitivity/infusion reactions was 1.6% (4/248). Grade\u00a03\nanaphylactic reaction and Grade\u00a04 hypersensitivity were each reported in 1\u00a0patient;\nboth of these cases led to discontinuation and resolved with treatment.</span></p>", "ID": "76b3201a-18c9-4b1d-8271-df5587aa7850", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In CA209017 and CA209063, the incidence\nof hypersensitivity/infusion reactions was 1.6% (4/248). Grade\u00a03\nanaphylactic reaction and Grade\u00a04 hypersensitivity were each reported in 1\u00a0patient;\nboth of these cases led to discontinuation and resolved with treatment.</span>", "ID": "c487edb8-3d63-4778-ac8a-737712a91400", "Styles": "None", "Classes": "None", "Text": "In CA209017 and CA209063, the incidence of hypersensitivity/infusion reactions was 1.6% (4/248). Grade\u00a03 anaphylactic reaction and Grade\u00a04 hypersensitivity were each reported in 1\u00a0patient; both of these cases led to discontinuation and resolved with treatment.", "ParentId": "76b3201a-18c9-4b1d-8271-df5587aa7850"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f5f1f14-7052-408f-8e74-66d1eef004fd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c4fde70-992a-4a39-b33f-4318a8837e81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f5f1f14-7052-408f-8e74-66d1eef004fd"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Laboratory\nabnormalities</span></u></i></p>", "ID": "d823a9f3-6947-4182-bd4c-fb6606a6a3ac", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Laboratory\nabnormalities</span></u></i>", "ID": "0872e6cd-a34e-4f20-8140-aeffc2083253", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d823a9f3-6947-4182-bd4c-fb6606a6a3ac"}, {"Element": "<u><span lang=\"EN-GB\">Laboratory\nabnormalities</span></u>", "ID": "7d485f78-116a-4514-a500-524861722598", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0872e6cd-a34e-4f20-8140-aeffc2083253"}, {"Element": "<span lang=\"EN-GB\">Laboratory\nabnormalities</span>", "ID": "44e88440-297b-4bf6-909b-6b4886ba14e7", "Styles": "None", "Classes": "None", "Text": "Laboratory abnormalities", "ParentId": "7d485f78-116a-4514-a500-524861722598"}, {"Element": "<p align=\"left\" class=\"BMSBodyText\" style=\"margin-bottom:0in;text-align:left;\nline-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">In\nCA209017 and CA209063, the proportion of patients who experienced a shift from\nbaseline to a Grade\u00a03\u00a0or\u00a04 laboratory abnormality was as\nfollows: 13.2% for decreased lymphocytes, 9% for hyponatraemia, 2.9% for\nhypercalcaemia and hyperkalaemia, 2.5% for decreased haemoglobin (all\nGrade\u00a03), 2.0% for hypokalaemia, 1.6% for decreased neutrophil count, 1.3%\nfor hypomagnesaemia, 1.2% for hypocalcaemia, 0.8% for increased total bilirubin,\nand 0.4% for increased AST, decreased platelet, hypermagnesaemia, and\nhypernatraemia. There was no worsening to Grade\u00a03\u00a0or\u00a04 in increased\nALT, increased alkaline phosphatase, and increased creatinine</span><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:windowtext\">.</span></p>", "ID": "f20a63ea-98ae-4073-9774-b3f7b36402e7", "Styles": "margin-bottom:0in;text-align:left;\nline-height:normal", "Classes": "['BMSBodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">In\nCA209017 and CA209063, the proportion of patients who experienced a shift from\nbaseline to a Grade\u00a03\u00a0or\u00a04 laboratory abnormality was as\nfollows: 13.2% for decreased lymphocytes, 9% for hyponatraemia, 2.9% for\nhypercalcaemia and hyperkalaemia, 2.5% for decreased haemoglobin (all\nGrade\u00a03), 2.0% for hypokalaemia, 1.6% for decreased neutrophil count, 1.3%\nfor hypomagnesaemia, 1.2% for hypocalcaemia, 0.8% for increased total bilirubin,\nand 0.4% for increased AST, decreased platelet, hypermagnesaemia, and\nhypernatraemia. There was no worsening to Grade\u00a03\u00a0or\u00a04 in increased\nALT, increased alkaline phosphatase, and increased creatinine</span>", "ID": "b2d95456-0def-4a1e-a51c-83cec80cf82c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "In CA209017 and CA209063, the proportion of patients who experienced a shift from baseline to a Grade\u00a03\u00a0or\u00a04 laboratory abnormality was as follows: 13.2% for decreased lymphocytes, 9% for hyponatraemia, 2.9% for hypercalcaemia and hyperkalaemia, 2.5% for decreased haemoglobin (all Grade\u00a03), 2.0% for hypokalaemia, 1.6% for decreased neutrophil count, 1.3% for hypomagnesaemia, 1.2% for hypocalcaemia, 0.8% for increased total bilirubin, and 0.4% for increased AST, decreased platelet, hypermagnesaemia, and hypernatraemia. There was no worsening to Grade\u00a03\u00a0or\u00a04 in increased ALT, increased alkaline phosphatase, and increased creatinine", "ParentId": "f20a63ea-98ae-4073-9774-b3f7b36402e7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:windowtext\">.</span>", "ID": "d78b54cb-0187-47ef-8304-3fe008cc83fe", "Styles": "font-size:10.0pt;color:windowtext", "Classes": "None", "Text": ".", "ParentId": "f20a63ea-98ae-4073-9774-b3f7b36402e7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bef6eca1-3569-4030-9df9-ea5ea4fe99d0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3553b8e1-42b6-4672-878e-b72fd49e75d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bef6eca1-3569-4030-9df9-ea5ea4fe99d0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In study CA209017, hypercalcaemia was more\nfrequently reported in the nivolumab group (31/130, 24%) than in the docetaxel\ngroup (9/124, 7%). The exact cause is not known. Although hyperparathyroidism\nwas not reported in CA209017, immune-related hyperparathyroidism might be\nconsidered especially if associated with hypophosphataemia (reported in\n6\u00a0hypercalcemic patients in this study).</span></p>", "ID": "4c888e1c-5c09-4eee-8892-1889c7f73fb7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In study CA209017, hypercalcaemia was more\nfrequently reported in the nivolumab group (31/130, 24%) than in the docetaxel\ngroup (9/124, 7%). The exact cause is not known. Although hyperparathyroidism\nwas not reported in CA209017, immune-related hyperparathyroidism might be\nconsidered especially if associated with hypophosphataemia (reported in\n6\u00a0hypercalcemic patients in this study).</span>", "ID": "92b3b9d2-4635-42fc-b2c1-f449641766bd", "Styles": "None", "Classes": "None", "Text": "In study CA209017, hypercalcaemia was more frequently reported in the nivolumab group (31/130, 24%) than in the docetaxel group (9/124, 7%). The exact cause is not known. Although hyperparathyroidism was not reported in CA209017, immune-related hyperparathyroidism might be considered especially if associated with hypophosphataemia (reported in 6\u00a0hypercalcemic patients in this study).", "ParentId": "4c888e1c-5c09-4eee-8892-1889c7f73fb7"}, {"Element": "<p class=\"EMEABodyText\">\u00a0</p>", "ID": "6afc7da0-464c-4ac2-8f6b-b020e82dece1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "\u00a0", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Immunogenicity</span></u></i></p>", "ID": "025a2bde-104b-4a43-a1e0-a5764f745533", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Immunogenicity</span></u></i>", "ID": "20945ecb-3ebe-404d-b2c1-4ca6f3fc1627", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "025a2bde-104b-4a43-a1e0-a5764f745533"}, {"Element": "<u><span lang=\"EN-GB\">Immunogenicity</span></u>", "ID": "47aa5244-6039-4ea7-b519-11ff7c51b34c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20945ecb-3ebe-404d-b2c1-4ca6f3fc1627"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "6c2776ae-fa5c-4b3e-8952-345bdaa6bfff", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "47aa5244-6039-4ea7-b519-11ff7c51b34c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with all therapeutic proteins, there\nis a potential for an immune response to nivolumab. Of the 497\u00a0patients\nwho were treated with nivolumab 3\u00a0mg/kg every 2\u00a0weeks and evaluable\nfor the presence of anti\u2011product\u2011antibodies, 51\u00a0(10.3%)\npatients tested positive for treatment-emergent anti-product antibodies by an\nelectrochemiluminescent (ECL) assay. Only 4\u00a0(0.8%)\u00a0patients were\npersistent positive. Neutralising antibodies were detected in only 5\u00a0(1.0%\nof the total) of the positive anti\u2011product\u2011antibody patients. There\nwas no evidence of altered pharmacokinetic or toxicity profile associated with\nanti\u2011product\u2011antibody development.</span></p>", "ID": "ccac2449-6bcf-446d-a432-fc6bf6bc638e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">As with all therapeutic proteins, there\nis a potential for an immune response to nivolumab. Of the 497\u00a0patients\nwho were treated with nivolumab 3\u00a0mg/kg every 2\u00a0weeks and evaluable\nfor the presence of anti\u2011product\u2011antibodies, 51\u00a0(10.3%)\npatients tested positive for treatment-emergent anti-product antibodies by an\nelectrochemiluminescent (ECL) assay. Only 4\u00a0(0.8%)\u00a0patients were\npersistent positive. Neutralising antibodies were detected in only 5\u00a0(1.0%\nof the total) of the positive anti\u2011product\u2011antibody patients. There\nwas no evidence of altered pharmacokinetic or toxicity profile associated with\nanti\u2011product\u2011antibody development.</span>", "ID": "2d20c75b-1e4e-47f0-9257-2d2a9f519b6c", "Styles": "None", "Classes": "None", "Text": "As with all therapeutic proteins, there is a potential for an immune response to nivolumab. Of the 497\u00a0patients who were treated with nivolumab 3\u00a0mg/kg every 2\u00a0weeks and evaluable for the presence of anti\u2011product\u2011antibodies, 51\u00a0(10.3%) patients tested positive for treatment-emergent anti-product antibodies by an electrochemiluminescent (ECL) assay. Only 4\u00a0(0.8%)\u00a0patients were persistent positive. Neutralising antibodies were detected in only 5\u00a0(1.0% of the total) of the positive anti\u2011product\u2011antibody patients. There was no evidence of altered pharmacokinetic or toxicity profile associated with anti\u2011product\u2011antibody development.", "ParentId": "ccac2449-6bcf-446d-a432-fc6bf6bc638e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c8b86b6-676a-4b3a-829e-be49be4cafff", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81ef2d3b-6688-459f-a9e2-50515eadc1b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c8b86b6-676a-4b3a-829e-be49be4cafff"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting\nof suspected adverse reactions</span></u></p>", "ID": "91d738d6-9e3f-4748-ba09-e44e626e65f0", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Reporting\nof suspected adverse reactions</span></u>", "ID": "c409a9ca-e309-46d9-9720-3520c998f5cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91d738d6-9e3f-4748-ba09-e44e626e65f0"}, {"Element": "<span lang=\"EN-GB\">Reporting\nof suspected adverse reactions</span>", "ID": "bb55dfcc-d1f3-4c6f-a6c1-2c80fa560ce0", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "c409a9ca-e309-46d9-9720-3520c998f5cc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\nafter authorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\" style=\"background:silver\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span><span lang=\"EN-GB\" style=\"background:silver\">.</span></p>", "ID": "d81d9162-6bb5-485d-904a-054946b83fa0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions\nafter authorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in </span></span>", "ID": "4234bcd8-d3a5-48d5-88c6-a0dd1427a7cd", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "d81d9162-6bb5-485d-904a-054946b83fa0"}, {"Element": "<span style=\"background:silver\">the national reporting system listed in </span>", "ID": "ecb60459-efc1-4a7b-8716-4dfd1f62da7b", "Styles": "background:silver", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "4234bcd8-d3a5-48d5-88c6-a0dd1427a7cd"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>", "ID": "9100a67a-7316-4112-8b8d-761010140b7b", "Styles": "background:silver", "Classes": "None", "Text": "", "ParentId": "d81d9162-6bb5-485d-904a-054946b83fa0"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a>", "ID": "b4591721-b1fc-4f8b-a7eb-7bd3cff995e5", "Styles": "None", "Classes": "None", "Text": "Appendix V", "ParentId": "9100a67a-7316-4112-8b8d-761010140b7b"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">.</span>", "ID": "185773ea-9bb8-4429-8b75-177196814da6", "Styles": "background:silver", "Classes": "None", "Text": ".", "ParentId": "d81d9162-6bb5-485d-904a-054946b83fa0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb511903-d388-45b6-b1f6-53e694ecf680", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "05390eee-1442-4677-a075-c08ab831781c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb511903-d388-45b6-b1f6-53e694ecf680"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></p>", "ID": "829a4214-e341-49d6-bd0d-cec4e901d848", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "615dea0f-9b83-4935-b969-5a1de7a55e89", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "829a4214-e341-49d6-bd0d-cec4e901d848"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c03f4d4-7f44-4068-bb2e-a3fa90744dbb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d74b7dcb-cbc7-4bd1-a508-b8dd9ec9ef79", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c03f4d4-7f44-4068-bb2e-a3fa90744dbb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No cases of overdose have been reported\nin clinical trials. In case of overdose, patients should be closely monitored\nfor signs or symptoms of adverse reactions, and appropriate symptomatic\ntreatment instituted immediately.</span></p>", "ID": "526e5b94-d044-4ef3-8feb-dcd756ea5edd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">No cases of overdose have been reported\nin clinical trials. In case of overdose, patients should be closely monitored\nfor signs or symptoms of adverse reactions, and appropriate symptomatic\ntreatment instituted immediately.</span>", "ID": "23d91cd9-7e2d-4fa9-b697-3566838a76c4", "Styles": "None", "Classes": "None", "Text": "No cases of overdose have been reported in clinical trials. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.", "ParentId": "526e5b94-d044-4ef3-8feb-dcd756ea5edd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "25badd2a-4ac2-4f52-b3fd-8b49b752a6b3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ccd67eef-3dec-4623-a614-7b06201bc853", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25badd2a-4ac2-4f52-b3fd-8b49b752a6b3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c3b019e-6d8f-407e-89d0-1e7f1e6e21f5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "76f60011-2ff6-453d-9640-228f575ffe09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c3b019e-6d8f-407e-89d0-1e7f1e6e21f5"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></p>", "ID": "993f05aa-a873-490e-8827-636dcb5e49f1", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span>", "ID": "c77d415b-cdd5-4335-9af0-9c2bca10b107", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "993f05aa-a873-490e-8827-636dcb5e49f1"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a6a133c-8c40-43ee-bed8-a071c8911aef", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79f08067-69d4-4b79-9baf-a5adc7c90ea5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a6a133c-8c40-43ee-bed8-a071c8911aef"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1 \u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></p>", "ID": "dce735b5-e689-4369-b701-7ec477b3041a", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.1 \u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span>", "ID": "44727a96-533b-4e3f-9fed-ca82ff7f16bd", "Styles": "None", "Classes": "None", "Text": "5.1 \u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "dce735b5-e689-4369-b701-7ec477b3041a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "772e1451-2a18-4a78-b678-7e7f28978bee", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "384cf920-1282-4415-b08e-e9fa9500bc2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "772e1451-2a18-4a78-b678-7e7f28978bee"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Antineoplastic\nagents, monoclonal antibodies. ATC code: </span><span lang=\"EN-GB\">L01XC17.</span></p>", "ID": "3802f963-f5b1-42d2-8c9c-e3311cd9965f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Pharmacotherapeutic group: Antineoplastic\nagents, monoclonal antibodies. ATC code: </span>", "ID": "6e6647a6-a33c-4a3c-9202-fa586d9009d4", "Styles": "None", "Classes": "None", "Text": "Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: ", "ParentId": "3802f963-f5b1-42d2-8c9c-e3311cd9965f"}, {"Element": "<span lang=\"EN-GB\">L01XC17.</span>", "ID": "d4f9a118-2100-4ff9-9189-2ec1a8329448", "Styles": "None", "Classes": "None", "Text": "L01XC17.", "ParentId": "3802f963-f5b1-42d2-8c9c-e3311cd9965f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d66b385-d7df-40be-bdaa-ab612bb5530a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dfc631d6-5dca-4327-8320-d457ce5be4d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d66b385-d7df-40be-bdaa-ab612bb5530a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></p>", "ID": "22717614-ab5b-4673-9436-92df10ab9346", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Mechanism\nof action</span></u>", "ID": "3ee7e227-c085-42a8-bb08-807ac17e6c49", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "22717614-ab5b-4673-9436-92df10ab9346"}, {"Element": "<span lang=\"EN-GB\">Mechanism\nof action</span>", "ID": "8d567903-5e3e-4232-b3c4-4668e178e9a7", "Styles": "None", "Classes": "None", "Text": "Mechanism of action", "ParentId": "3ee7e227-c085-42a8-bb08-807ac17e6c49"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is a human immunoglobulin G4\n(IgG4) monoclonal antibody (HuMAb), which binds to the programmed death\u20111\n(PD\u20111) receptor and blocks its interaction with PD\u2011L1 and PD\u2011L2.\nThe PD\u20111 receptor is a negative regulator of T\u2011cell activity that\nhas been shown to be involved in the control of T\u2011cell immune responses.\nEngagement of PD\u20111 with the ligands PD\u2011L1 and PD\u2011L2, which are\nexpressed in antigen presenting cells and may be expressed by tumours or other\ncells in the tumour microenvironment, results in inhibition of T\u2011cell\nproliferation and cytokine secretion. Nivolumab potentiates T\u2011cell\nresponses, including anti-tumour responses, through blockade of PD\u20111\nbinding to PD\u2011L1 and PD\u2011L2 ligands. In syngeneic mouse models,\nblocking PD\u20111 activity resulted in decreased tumour growth.</span></p>", "ID": "d188e1c4-a537-4fac-ba3e-faaf8b42db20", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is a human immunoglobulin G4\n(IgG4) monoclonal antibody (HuMAb), which binds to the programmed death\u20111\n(PD\u20111) receptor and blocks its interaction with PD\u2011L1 and PD\u2011L2.\nThe PD\u20111 receptor is a negative regulator of T\u2011cell activity that\nhas been shown to be involved in the control of T\u2011cell immune responses.\nEngagement of PD\u20111 with the ligands PD\u2011L1 and PD\u2011L2, which are\nexpressed in antigen presenting cells and may be expressed by tumours or other\ncells in the tumour microenvironment, results in inhibition of T\u2011cell\nproliferation and cytokine secretion. Nivolumab potentiates T\u2011cell\nresponses, including anti-tumour responses, through blockade of PD\u20111\nbinding to PD\u2011L1 and PD\u2011L2 ligands. In syngeneic mouse models,\nblocking PD\u20111 activity resulted in decreased tumour growth.</span>", "ID": "390a7921-4b32-4667-af00-162d74e33b17", "Styles": "None", "Classes": "None", "Text": "Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death\u20111 (PD\u20111) receptor and blocks its interaction with PD\u2011L1 and PD\u2011L2. The PD\u20111 receptor is a negative regulator of T\u2011cell activity that has been shown to be involved in the control of T\u2011cell immune responses. Engagement of PD\u20111 with the ligands PD\u2011L1 and PD\u2011L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T\u2011cell proliferation and cytokine secretion. Nivolumab potentiates T\u2011cell responses, including anti-tumour responses, through blockade of PD\u20111 binding to PD\u2011L1 and PD\u2011L2 ligands. In syngeneic mouse models, blocking PD\u20111 activity resulted in decreased tumour growth.", "ParentId": "d188e1c4-a537-4fac-ba3e-faaf8b42db20"}, {"Element": "<p class=\"EMEABodyText\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "5670100b-b8cd-4364-b8c9-86ddf7b07f03", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "46cc6d90-f0b0-4bfe-be64-a60862b34fe1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5670100b-b8cd-4364-b8c9-86ddf7b07f03"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "a006fd90-29d5-4631-a007-a7394703f9d3", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "46cc6d90-f0b0-4bfe-be64-a60862b34fe1"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></p>", "ID": "b8b3f6e9-1c3a-4281-83ba-d4e05cc45cda", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u>", "ID": "ce369feb-c9d8-44b5-91b5-b0ce6318debc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8b3f6e9-1c3a-4281-83ba-d4e05cc45cda"}, {"Element": "<span lang=\"EN-GB\">Clinical\nefficacy and safety</span>", "ID": "4dcf8bf0-059c-4e58-8f11-cac6b53d897e", "Styles": "None", "Classes": "None", "Text": "Clinical efficacy and safety", "ParentId": "ce369feb-c9d8-44b5-91b5-b0ce6318debc"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "c7d23741-966e-45f8-9043-d08703ce1b40", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "6bcfb4ba-a57c-446d-8da7-e0f0600c4cbe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7d23741-966e-45f8-9043-d08703ce1b40"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "b7aae623-8ff8-4a2b-8dbf-e89de5817838", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6bcfb4ba-a57c-446d-8da7-e0f0600c4cbe"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "daa02c33-7c33-449f-a761-db9e31132772", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b7aae623-8ff8-4a2b-8dbf-e89de5817838"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Randomised\nphase\u00a03 study vs. docetaxel (CA209017)</span></u></i></p>", "ID": "2307eac5-a36d-4ae4-9372-82d7dce83893", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Randomised\nphase\u00a03 study vs. docetaxel (CA209017)</span></u></i>", "ID": "787247ef-af24-4314-b896-75fb296b6096", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2307eac5-a36d-4ae4-9372-82d7dce83893"}, {"Element": "<u><span lang=\"EN-GB\">Randomised\nphase\u00a03 study vs. docetaxel (CA209017)</span></u>", "ID": "627ad4bf-ea26-49aa-b4d9-f236f86b0323", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "787247ef-af24-4314-b896-75fb296b6096"}, {"Element": "<span lang=\"EN-GB\">Randomised\nphase\u00a03 study vs. docetaxel (CA209017)</span>", "ID": "88dbfe9e-0955-4804-b568-456895560da7", "Styles": "None", "Classes": "None", "Text": "Randomised phase\u00a03 study vs. docetaxel (CA209017)", "ParentId": "627ad4bf-ea26-49aa-b4d9-f236f86b0323"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of\nnivolumab\u00a03\u00a0mg/kg as a single agent for the treatment of advanced or\nmetastatic squamous NSCLC were evaluated in a phase\u00a03, randomised,\nopen-label study (CA209017). The study included patients (18\u00a0years or\nolder) who have experienced disease progression during or after one prior\nplatinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology\nGroup (ECOG) performance status score of 0 or 1. Patients were enrolled\nregardless of their PD-L1 status. Patients with active autoimmune disease,\nsymptomatic interstitial lung disease, or untreated brain metastasis were\nexcluded from the study. Patients with treated brain metastases were eligible\nif neurologically returned to baseline at least 2\u00a0weeks prior to\nenrolment, and either off corticosteroids, or on a stable or decreasing dose of\n&lt;10 mg daily prednisone equivalents.</span></p>", "ID": "3586e167-c337-4729-8d46-0792d2292e1e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of\nnivolumab\u00a03\u00a0mg/kg as a single agent for the treatment of advanced or\nmetastatic squamous NSCLC were evaluated in a phase\u00a03, randomised,\nopen-label study (CA209017). The study included patients (18\u00a0years or\nolder) who have experienced disease progression during or after one prior\nplatinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology\nGroup (ECOG) performance status score of 0 or 1. Patients were enrolled\nregardless of their PD-L1 status. Patients with active autoimmune disease,\nsymptomatic interstitial lung disease, or untreated brain metastasis were\nexcluded from the study. Patients with treated brain metastases were eligible\nif neurologically returned to baseline at least 2\u00a0weeks prior to\nenrolment, and either off corticosteroids, or on a stable or decreasing dose of\n&lt;10 mg daily prednisone equivalents.</span>", "ID": "820a0bba-55b5-4fc9-987f-e7fa567559df", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of nivolumab\u00a03\u00a0mg/kg as a single agent for the treatment of advanced or metastatic squamous NSCLC were evaluated in a phase\u00a03, randomised, open-label study (CA209017). The study included patients (18\u00a0years or older) who have experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Patients were enrolled regardless of their PD-L1 status. Patients with active autoimmune disease, symptomatic interstitial lung disease, or untreated brain metastasis were excluded from the study. Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2\u00a0weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents.", "ParentId": "3586e167-c337-4729-8d46-0792d2292e1e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e6f022bd-69f1-458a-907f-79e4928022c7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6177f2f-76e8-4b80-8d96-faad1c2ecfec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6f022bd-69f1-458a-907f-79e4928022c7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">A total of 272 patients were randomised\nto receive either nivolumab 3\u00a0mg/kg (N\u00a0=\u00a0135) administered\nintravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks or docetaxel (n\u00a0=\u00a0137)\n75\u00a0mg/m<sup>2</sup> every 3\u00a0weeks. Treatment was continued as long as\nclinical benefit was observed or until treatment was no longer tolerated. </span><span lang=\"EN-GB\">T</span><span lang=\"EN-GB\">umour assessments,</span><span lang=\"EN-GB\"> according\nto the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, </span><span lang=\"EN-GB\">were conducted\u00a09 weeks after randomisation and continued every\u00a06\u00a0weeks\nthereafter. The primary efficacy outcome measure was overall survival (OS). Key\nsecondary efficacy outcome measures were investigator-assessed objective\nresponse rate (ORR) and progression-free survival (PFS). In addition, symptom\nimprovement and overall health status were assessed using the Lung Cancer\nSymptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue\nScale (EQ-VAS), respectively. </span></p>", "ID": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">A total of 272 patients were randomised\nto receive either nivolumab 3\u00a0mg/kg (N\u00a0=\u00a0135) administered\nintravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks or docetaxel (n\u00a0=\u00a0137)\n75\u00a0mg/m<sup>2</sup> every 3\u00a0weeks. Treatment was continued as long as\nclinical benefit was observed or until treatment was no longer tolerated. </span>", "ID": "8c0ae880-ac60-454e-9b25-03c6509787a1", "Styles": "None", "Classes": "None", "Text": "A total of 272 patients were randomised to receive either nivolumab 3\u00a0mg/kg (N\u00a0=\u00a0135) administered intravenously over\u00a060\u00a0minutes every\u00a02\u00a0weeks or docetaxel (n\u00a0=\u00a0137) 75\u00a0mg/m every 3\u00a0weeks. Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. ", "ParentId": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af"}, {"Element": "<sup>2</sup>", "ID": "adc864b3-911c-49c6-9bb9-bbe754a1299a", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "8c0ae880-ac60-454e-9b25-03c6509787a1"}, {"Element": "<span lang=\"EN-GB\">T</span>", "ID": "c548d91d-09ab-4d51-b1b6-0911baee3717", "Styles": "None", "Classes": "None", "Text": "T", "ParentId": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af"}, {"Element": "<span lang=\"EN-GB\">umour assessments,</span>", "ID": "2890783d-f20e-4a6e-88a8-60ccfc07083b", "Styles": "None", "Classes": "None", "Text": "umour assessments,", "ParentId": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af"}, {"Element": "<span lang=\"EN-GB\"> according\nto the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, </span>", "ID": "a8674f90-5353-4481-bead-e4d0d408776d", "Styles": "None", "Classes": "None", "Text": " according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, ", "ParentId": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af"}, {"Element": "<span lang=\"EN-GB\">were conducted\u00a09 weeks after randomisation and continued every\u00a06\u00a0weeks\nthereafter. The primary efficacy outcome measure was overall survival (OS). Key\nsecondary efficacy outcome measures were investigator-assessed objective\nresponse rate (ORR) and progression-free survival (PFS). In addition, symptom\nimprovement and overall health status were assessed using the Lung Cancer\nSymptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue\nScale (EQ-VAS), respectively. </span>", "ID": "b63c165a-1a29-4526-bdbe-59ee69904d78", "Styles": "None", "Classes": "None", "Text": "were conducted\u00a09 weeks after randomisation and continued every\u00a06\u00a0weeks thereafter. The primary efficacy outcome measure was overall survival (OS). Key secondary efficacy outcome measures were investigator-assessed objective response rate (ORR) and progression-free survival (PFS). In addition, symptom improvement and overall health status were assessed using the Lung Cancer Symptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue Scale (EQ-VAS), respectively. ", "ParentId": "feb3675e-7b4b-4bf5-a7b9-2ae5add4d2af"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eaeaae76-bac2-4070-8ddd-bf98538efdc3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a0304e42-d574-4add-9ab3-003b04488489", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eaeaae76-bac2-4070-8ddd-bf98538efdc3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Baseline characteristics were generally balanced\nbetween the two groups. The median age was\u00a063\u00a0years (range:\u00a039\u201185)\nwith 44% </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">65\u00a0years of age and 11% </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span><span lang=\"EN-GB\">75\u00a0years of age. The\nmajority of patients were white (93%) and male (76%). Thirty-one percent had\nprogressive disease reported as the best response to their most recent prior\nregimen and 45% received nivolumab within 3\u00a0months of completing their\nmost recent prior regimen. Baseline ECOG performance status score was 0\u00a0(24%)\nor 1\u00a0(76%). </span></p>", "ID": "4458f4d2-b625-4931-b8f7-1e0060461569", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Baseline characteristics were generally balanced\nbetween the two groups. The median age was\u00a063\u00a0years (range:\u00a039\u201185)\nwith 44% </span>", "ID": "42df0a51-d47f-4335-9449-8fc17f6c48c8", "Styles": "None", "Classes": "None", "Text": "Baseline characteristics were generally balanced between the two groups. The median age was\u00a063\u00a0years (range:\u00a039\u201185) with 44% ", "ParentId": "4458f4d2-b625-4931-b8f7-1e0060461569"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span>", "ID": "c6f8774c-ae0e-4190-8a8a-727acbf56d95", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "4458f4d2-b625-4931-b8f7-1e0060461569"}, {"Element": "<span lang=\"EN-GB\">65\u00a0years of age and 11% </span>", "ID": "0929fb43-583f-4548-8e6a-837b955bc5cc", "Styles": "None", "Classes": "None", "Text": "65\u00a0years of age and 11% ", "ParentId": "4458f4d2-b625-4931-b8f7-1e0060461569"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b3</span>", "ID": "4dd883e0-0fe2-4f23-b6c2-a3b37b5435f1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "4458f4d2-b625-4931-b8f7-1e0060461569"}, {"Element": "<span lang=\"EN-GB\">75\u00a0years of age. The\nmajority of patients were white (93%) and male (76%). Thirty-one percent had\nprogressive disease reported as the best response to their most recent prior\nregimen and 45% received nivolumab within 3\u00a0months of completing their\nmost recent prior regimen. Baseline ECOG performance status score was 0\u00a0(24%)\nor 1\u00a0(76%). </span>", "ID": "7e57b9cc-6cb6-4005-b1d5-fa64b1b8ba6a", "Styles": "None", "Classes": "None", "Text": "75\u00a0years of age. The majority of patients were white (93%) and male (76%). Thirty-one percent had progressive disease reported as the best response to their most recent prior regimen and 45% received nivolumab within 3\u00a0months of completing their most recent prior regimen. Baseline ECOG performance status score was 0\u00a0(24%) or 1\u00a0(76%). ", "ParentId": "4458f4d2-b625-4931-b8f7-1e0060461569"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff3f2695-6522-48dd-ba17-73ee70afcaa3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "559d1a5e-5a7c-460e-8d2a-56fbe26d4078", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff3f2695-6522-48dd-ba17-73ee70afcaa3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The Kaplan-Meier curves for OS are shown\nin Figure\u00a01.</span></p>", "ID": "a533c302-4d11-433c-832a-2a0f87a7272d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The Kaplan-Meier curves for OS are shown\nin Figure\u00a01.</span>", "ID": "8b525700-2211-4f3d-ab01-57ba050cc206", "Styles": "None", "Classes": "None", "Text": "The Kaplan-Meier curves for OS are shown in Figure\u00a01.", "ParentId": "a533c302-4d11-433c-832a-2a0f87a7272d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2bf9b33-e752-4cdc-b522-91064ba23d39", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5296476a-97d7-4244-bf5b-60834bea9b14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2bf9b33-e752-4cdc-b522-91064ba23d39"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b>Figure 1:\u00a0\u00a0\u00a0 Kaplan-Meier\ncurves of OS (CA209017) </b></p>", "ID": "08633326-5d3e-422e-8f54-d9a8cd304256", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b>Figure 1:\u00a0\u00a0\u00a0 Kaplan-Meier\ncurves of OS (CA209017) </b>", "ID": "e399a55f-7b48-44f5-9591-f3064421775f", "Styles": "None", "Classes": "None", "Text": "Figure 1:\u00a0\u00a0\u00a0 Kaplan-Meier curves of OS (CA209017) ", "ParentId": "08633326-5d3e-422e-8f54-d9a8cd304256"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "2b58eb52-3230-46d9-acfa-7d5b95afc86c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b>\u00a0</b>", "ID": "cbb010c0-fbdf-4c34-8a3f-b4d2d0214511", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b58eb52-3230-46d9-acfa-7d5b95afc86c"}, {"Element": "<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center;page-break-after:\navoid\"><span style=\"position:absolute;z-index:251657728;left:0px;margin-left:\n1px;margin-top:17px;width:39px;height:336px\"><img alt=\"Text Box: Probability of Survival\" height=\"336\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image002.gif\" width=\"39\"/></span><span lang=\"EN-GB\"><img border=\"0\" height=\"377\" id=\"Picture 4\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image003.jpg\" width=\"527\"/></span></p>", "ID": "e94920a7-9909-4aed-ae34-fa3a1a73a416", "Styles": "text-align:center;page-break-after:\navoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span style=\"position:absolute;z-index:251657728;left:0px;margin-left:\n1px;margin-top:17px;width:39px;height:336px\"><img alt=\"Text Box: Probability of Survival\" height=\"336\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image002.gif\" width=\"39\"/></span>", "ID": "297dfe23-008d-4886-9676-ffdd9b5fa80b", "Styles": "position:absolute;z-index:251657728;left:0px;margin-left:\n1px;margin-top:17px;width:39px;height:336px", "Classes": "None", "Text": "", "ParentId": "e94920a7-9909-4aed-ae34-fa3a1a73a416"}, {"Element": "<img alt=\"Text Box: Probability of Survival\" height=\"336\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image002.gif\" width=\"39\"/>", "ID": "4f388e49-b20e-4866-9640-9bce9dbc1a0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "297dfe23-008d-4886-9676-ffdd9b5fa80b"}, {"Element": "<span lang=\"EN-GB\"><img border=\"0\" height=\"377\" id=\"Picture 4\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image003.jpg\" width=\"527\"/></span>", "ID": "cb6c4851-db00-42ca-83e9-cc895f53e8bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e94920a7-9909-4aed-ae34-fa3a1a73a416"}, {"Element": "<img border=\"0\" height=\"377\" id=\"Picture 4\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image003.jpg\" width=\"527\"/>", "ID": "a065ea06-9b77-4b19-8ce0-b1ddc5a57638", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cb6c4851-db00-42ca-83e9-cc895f53e8bb"}, {"Element": "<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center;page-break-after:\navoid\"><span lang=\"EN-GB\">Overall Survival (Months)</span></p>", "ID": "21d4e668-bda2-4bb3-9432-2b3c9ec10f2b", "Styles": "text-align:center;page-break-after:\navoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Overall Survival (Months)</span>", "ID": "aa9277e1-753a-4511-a1fe-cff5bba25dfe", "Styles": "None", "Classes": "None", "Text": "Overall Survival (Months)", "ParentId": "21d4e668-bda2-4bb3-9432-2b3c9ec10f2b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\nSubjects at Risk</span></p>", "ID": "bdac5683-9c8f-4869-a64f-25f67a8bd6ee", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Number of\nSubjects at Risk</span>", "ID": "2740f9f3-48ae-4747-814c-aed3e4f7f4f7", "Styles": "None", "Classes": "None", "Text": "Number of Subjects at Risk", "ParentId": "bdac5683-9c8f-4869-a64f-25f67a8bd6ee"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse\" width=\"567\">\n<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">135</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">113</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">86</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">69</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Docetaxel</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">137</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">103</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">45</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">30</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>\n</table>", "ID": "209acf12-46d8-4c4a-b320-e556cb4ef2e1", "Styles": "margin-left:5.4pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "     ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span></p>\n</td>\n</tr>", "ID": "a6c19836-e64f-4f97-93cd-de619463e236", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "209acf12-46d8-4c4a-b320-e556cb4ef2e1"}, {"Element": "<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span></p>\n</td>", "ID": "93ef01aa-8139-4ba1-a248-3369916afa71", "Styles": "width:425.25pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a6c19836-e64f-4f97-93cd-de619463e236"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span></p>", "ID": "bacb5efd-9807-493d-8672-ce3d751ff75a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "93ef01aa-8139-4ba1-a248-3369916afa71"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\n  3 mg/kg</span>", "ID": "4f27c469-d9c1-4f2d-9a00-29a077dfe25c", "Styles": "None", "Classes": "None", "Text": "Nivolumab   3 mg/kg", "ParentId": "bacb5efd-9807-493d-8672-ce3d751ff75a"}, {"Element": "<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">135</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">113</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">86</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">69</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>", "ID": "1433c3f7-860e-4c42-9636-7896ee9d36f6", "Styles": "None", "Classes": "None", "Text": "          ", "ParentId": "209acf12-46d8-4c4a-b320-e556cb4ef2e1"}, {"Element": "<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">135</span></p>\n</td>", "ID": "31969728-aeff-4b2f-9b92-d0b2ae1322da", "Styles": "width:63.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">135</span></p>", "ID": "07b5a7de-c454-4052-a923-fa341ad2c2fe", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "31969728-aeff-4b2f-9b92-d0b2ae1322da"}, {"Element": "<span lang=\"EN-GB\">135</span>", "ID": "02a8e62a-e7b2-4cb6-ad87-21b144d76356", "Styles": "None", "Classes": "None", "Text": "135", "ParentId": "07b5a7de-c454-4052-a923-fa341ad2c2fe"}, {"Element": "<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">113</span></p>\n</td>", "ID": "5766c22a-b13c-4cd0-ae04-d610f6da2593", "Styles": "width:44.1pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">113</span></p>", "ID": "116c20c6-6f2f-4860-ada2-3c0ace926c63", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "5766c22a-b13c-4cd0-ae04-d610f6da2593"}, {"Element": "<span lang=\"EN-GB\">113</span>", "ID": "b0be84d2-8305-4237-b7b4-d46136cb26f3", "Styles": "None", "Classes": "None", "Text": "113", "ParentId": "116c20c6-6f2f-4860-ada2-3c0ace926c63"}, {"Element": "<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">86</span></p>\n</td>", "ID": "612f1a35-1f6f-4c0c-bcf5-d9ae71cc1809", "Styles": "width:44.1pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">86</span></p>", "ID": "9f6e843f-ed0d-493d-823c-5bdfc1b0e26d", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "612f1a35-1f6f-4c0c-bcf5-d9ae71cc1809"}, {"Element": "<span lang=\"EN-GB\">86</span>", "ID": "e22b3564-9080-4921-bd59-638b41cabf77", "Styles": "None", "Classes": "None", "Text": "86", "ParentId": "9f6e843f-ed0d-493d-823c-5bdfc1b0e26d"}, {"Element": "<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">69</span></p>\n</td>", "ID": "7d5a8710-0d67-4909-ba28-882ba6835911", "Styles": "width:46.45pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">69</span></p>", "ID": "e6580ced-d4ac-4dea-b5f1-2e1a9c05cfa3", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "7d5a8710-0d67-4909-ba28-882ba6835911"}, {"Element": "<span lang=\"EN-GB\">69</span>", "ID": "9b2f6d8a-f4e3-445d-9ef9-0adf3d393d65", "Styles": "None", "Classes": "None", "Text": "69", "ParentId": "e6580ced-d4ac-4dea-b5f1-2e1a9c05cfa3"}, {"Element": "<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">52</span></p>\n</td>", "ID": "76390310-bf8e-480c-99f8-1f6ddeb29999", "Styles": "width:42.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">52</span></p>", "ID": "ff816ae1-77f9-412e-8bac-3e5928756d5d", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "76390310-bf8e-480c-99f8-1f6ddeb29999"}, {"Element": "<span lang=\"EN-GB\">52</span>", "ID": "0dae9e4c-5d4b-4577-93a7-c21fe0c2fad3", "Styles": "None", "Classes": "None", "Text": "52", "ParentId": "ff816ae1-77f9-412e-8bac-3e5928756d5d"}, {"Element": "<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>", "ID": "22ad7ccb-2891-4bc7-95bd-2f7f407b72f7", "Styles": "width:49.6pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>", "ID": "970caf05-0a55-4af0-90d6-f9c40fb9fcd7", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "22ad7ccb-2891-4bc7-95bd-2f7f407b72f7"}, {"Element": "<span lang=\"EN-GB\">31</span>", "ID": "3ad3ae65-cfea-4cd5-86d1-321349686b39", "Styles": "None", "Classes": "None", "Text": "31", "ParentId": "970caf05-0a55-4af0-90d6-f9c40fb9fcd7"}, {"Element": "<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15</span></p>\n</td>", "ID": "1c0f82de-70ba-4359-ab6e-98264879c6cd", "Styles": "width:42.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">15</span></p>", "ID": "d596073d-0491-4e04-a5a4-9728b338e16b", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "1c0f82de-70ba-4359-ab6e-98264879c6cd"}, {"Element": "<span lang=\"EN-GB\">15</span>", "ID": "0ea12d51-08df-41a2-a8f2-996321690567", "Styles": "None", "Classes": "None", "Text": "15", "ParentId": "d596073d-0491-4e04-a5a4-9728b338e16b"}, {"Element": "<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>", "ID": "8196cac3-eba4-40c7-a131-a11163f74c50", "Styles": "width:42.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>", "ID": "c631e29e-6de9-4018-9984-7aa138588787", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8196cac3-eba4-40c7-a131-a11163f74c50"}, {"Element": "<span lang=\"EN-GB\">7</span>", "ID": "b219beb5-49ec-4ae6-9f7c-a70fcf470659", "Styles": "None", "Classes": "None", "Text": "7", "ParentId": "c631e29e-6de9-4018-9984-7aa138588787"}, {"Element": "<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>", "ID": "17d871b2-7a19-4e97-bad2-7b0e27f52f17", "Styles": "width:49.6pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1433c3f7-860e-4c42-9636-7896ee9d36f6"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>", "ID": "72184e65-0ad8-4be1-967d-38f5c639a83a", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "17d871b2-7a19-4e97-bad2-7b0e27f52f17"}, {"Element": "<span lang=\"EN-GB\">0</span>", "ID": "d61431ca-bb1c-4a51-8239-b18107b1d7b6", "Styles": "None", "Classes": "None", "Text": "0", "ParentId": "72184e65-0ad8-4be1-967d-38f5c639a83a"}, {"Element": "<tr>\n<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Docetaxel</span></p>\n</td>\n</tr>", "ID": "b2a47ccd-5451-4895-a7ad-1e1011e26a58", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "209acf12-46d8-4c4a-b320-e556cb4ef2e1"}, {"Element": "<td colspan=\"9\" style=\"width:425.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"567\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Docetaxel</span></p>\n</td>", "ID": "2f91ce5f-3469-4871-ad24-c3795bc05be8", "Styles": "width:425.25pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a47ccd-5451-4895-a7ad-1e1011e26a58"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Docetaxel</span></p>", "ID": "b069dd6a-65a6-4107-9532-3d435ad5298c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "2f91ce5f-3469-4871-ad24-c3795bc05be8"}, {"Element": "<span lang=\"EN-GB\">Docetaxel</span>", "ID": "e41f75b5-5c88-4960-ad30-4b1709748197", "Styles": "None", "Classes": "None", "Text": "Docetaxel", "ParentId": "b069dd6a-65a6-4107-9532-3d435ad5298c"}, {"Element": "<tr>\n<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">137</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">103</span></p>\n</td>\n<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">45</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">30</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14</span></p>\n</td>\n<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>\n<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2</span></p>\n</td>\n<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>\n</tr>", "ID": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3", "Styles": "None", "Classes": "None", "Text": "          ", "ParentId": "209acf12-46d8-4c4a-b320-e556cb4ef2e1"}, {"Element": "<td style=\"width:63.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">137</span></p>\n</td>", "ID": "76237bb8-1c11-449e-82d0-6c4030a3768c", "Styles": "width:63.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">137</span></p>", "ID": "717b5f11-5201-430a-b91d-a052914ac39d", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "76237bb8-1c11-449e-82d0-6c4030a3768c"}, {"Element": "<span lang=\"EN-GB\">137</span>", "ID": "347e744e-d0f1-4c06-b974-622b497864dc", "Styles": "None", "Classes": "None", "Text": "137", "ParentId": "717b5f11-5201-430a-b91d-a052914ac39d"}, {"Element": "<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">103</span></p>\n</td>", "ID": "3dc7700a-063e-4bf9-8142-3af9da35dc54", "Styles": "width:44.1pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">103</span></p>", "ID": "b215a17d-224b-4ad0-891e-04c92fcc9f9a", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3dc7700a-063e-4bf9-8142-3af9da35dc54"}, {"Element": "<span lang=\"EN-GB\">103</span>", "ID": "182825d5-ea31-45ea-b4d5-1e213aa18070", "Styles": "None", "Classes": "None", "Text": "103", "ParentId": "b215a17d-224b-4ad0-891e-04c92fcc9f9a"}, {"Element": "<td style=\"width:44.1pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">68</span></p>\n</td>", "ID": "123ff2d9-5249-4ce1-bf53-5a3ba1408a38", "Styles": "width:44.1pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">68</span></p>", "ID": "16a0abc8-4a6a-4c93-b395-0b6f5023289e", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "123ff2d9-5249-4ce1-bf53-5a3ba1408a38"}, {"Element": "<span lang=\"EN-GB\">68</span>", "ID": "3a327170-a011-4c01-8786-42b70a1ac672", "Styles": "None", "Classes": "None", "Text": "68", "ParentId": "16a0abc8-4a6a-4c93-b395-0b6f5023289e"}, {"Element": "<td style=\"width:46.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">45</span></p>\n</td>", "ID": "5866f210-d736-443e-bdb2-6238931213c2", "Styles": "width:46.45pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">45</span></p>", "ID": "d1469ff2-7274-4fab-87c1-0d03e022a3f1", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "5866f210-d736-443e-bdb2-6238931213c2"}, {"Element": "<span lang=\"EN-GB\">45</span>", "ID": "4fec86f4-8891-4a94-b794-2cafb79bf76b", "Styles": "None", "Classes": "None", "Text": "45", "ParentId": "d1469ff2-7274-4fab-87c1-0d03e022a3f1"}, {"Element": "<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">30</span></p>\n</td>", "ID": "aa37f124-6193-43ee-b5ae-308009b30481", "Styles": "width:42.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">30</span></p>", "ID": "905c71aa-5fa3-4d3b-b887-8fcfbd6dbbe1", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "aa37f124-6193-43ee-b5ae-308009b30481"}, {"Element": "<span lang=\"EN-GB\">30</span>", "ID": "62f9f1c2-c21d-432f-8485-77fe76a5f69b", "Styles": "None", "Classes": "None", "Text": "30", "ParentId": "905c71aa-5fa3-4d3b-b887-8fcfbd6dbbe1"}, {"Element": "<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14</span></p>\n</td>", "ID": "b24f014e-e992-4e6e-8d92-02b79331d5a3", "Styles": "width:49.6pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">14</span></p>", "ID": "4e87592e-6bd1-4aa9-80a6-4e83ab341127", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "b24f014e-e992-4e6e-8d92-02b79331d5a3"}, {"Element": "<span lang=\"EN-GB\">14</span>", "ID": "1fbe396b-3584-4a27-bece-e121de18f02c", "Styles": "None", "Classes": "None", "Text": "14", "ParentId": "4e87592e-6bd1-4aa9-80a6-4e83ab341127"}, {"Element": "<td style=\"width:42.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>\n</td>", "ID": "e3c5e5cb-3403-466b-ba41-b6157201040b", "Styles": "width:42.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7</span></p>", "ID": "f1320dfa-94b3-448e-aa5f-f6ebf1ada18a", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e3c5e5cb-3403-466b-ba41-b6157201040b"}, {"Element": "<span lang=\"EN-GB\">7</span>", "ID": "c0b18510-cfbe-48df-b52d-01fe6546d746", "Styles": "None", "Classes": "None", "Text": "7", "ParentId": "f1320dfa-94b3-448e-aa5f-f6ebf1ada18a"}, {"Element": "<td style=\"width:42.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"57\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2</span></p>\n</td>", "ID": "f7d53812-d306-4624-95eb-17fed5737c4b", "Styles": "width:42.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2</span></p>", "ID": "b1b75977-e3a0-4ff5-a9f2-fd5bd523d16c", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f7d53812-d306-4624-95eb-17fed5737c4b"}, {"Element": "<span lang=\"EN-GB\">2</span>", "ID": "8dd75996-997c-4653-b80f-1de03b3f9d22", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "b1b75977-e3a0-4ff5-a9f2-fd5bd523d16c"}, {"Element": "<td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\">\n<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>\n</td>", "ID": "08640417-8c0b-4571-a6d1-6ba1067c2ab9", "Styles": "width:49.6pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ebd01844-4f82-4bc4-b78a-771c3b98f6a3"}, {"Element": "<p align=\"right\" class=\"EMEABodyText\" style=\"text-align:right;page-break-after:\n  avoid\"><span lang=\"EN-GB\">0</span></p>", "ID": "f65f9532-5eda-4125-9461-f542643b82df", "Styles": "text-align:right;page-break-after:\n  avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "08640417-8c0b-4571-a6d1-6ba1067c2ab9"}, {"Element": "<span lang=\"EN-GB\">0</span>", "ID": "53e66405-2189-4f8d-8384-fe8aba30ab8d", "Styles": "None", "Classes": "None", "Text": "0", "ParentId": "f65f9532-5eda-4125-9461-f542643b82df"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image004.jpg\" width=\"49\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nivolumab\n3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)</span></p>", "ID": "88c48dfb-268c-45d6-9f3d-42f2a5276d6b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image004.jpg\" width=\"49\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nivolumab\n3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)</span>", "ID": "7e696a74-cbda-46a5-8998-288fcad05a35", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nivolumab 3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)", "ParentId": "88c48dfb-268c-45d6-9f3d-42f2a5276d6b"}, {"Element": "<img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image004.jpg\" width=\"49\"/>", "ID": "e68af3fe-7ed8-4323-a28c-85d45703b141", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e696a74-cbda-46a5-8998-288fcad05a35"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image005.jpg\" width=\"45\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Docetaxel\n(events : 113/137), median and 95% CI : 6.01 (5.13, 7.33)</span></p>", "ID": "1a2c0923-1217-4efc-ac56-507939cd12b4", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\"><img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image005.jpg\" width=\"45\"/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Docetaxel\n(events : 113/137), median and 95% CI : 6.01 (5.13, 7.33)</span>", "ID": "d8c0db46-4b91-4262-82f2-67d95a8a6072", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Docetaxel (events : 113/137), median and 95% CI : 6.01 (5.13, 7.33)", "ParentId": "1a2c0923-1217-4efc-ac56-507939cd12b4"}, {"Element": "<img border=\"0\" height=\"21\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image005.jpg\" width=\"45\"/>", "ID": "807222e9-e4c0-42b5-bd2d-2b57d6e433be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8c0db46-4b91-4262-82f2-67d95a8a6072"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2c589bd8-cada-4501-8a03-cd308927f9ea", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee5fe08b-e606-4c1e-8c0c-25dec7e48813", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c589bd8-cada-4501-8a03-cd308927f9ea"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The observed OS benefit was consistently\ndemonstrated across subgroups of patients. Survival benefit was observed\nregardless of whether patients had tumours that were designated PD-L1 negative\nor PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%).\nHowever, the role of this biomarker (PD-L1 expression) has not been fully\nelucidated.</span></p>", "ID": "917e1faf-eacd-4118-99b6-1a97146e4931", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The observed OS benefit was consistently\ndemonstrated across subgroups of patients. Survival benefit was observed\nregardless of whether patients had tumours that were designated PD-L1 negative\nor PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%).\nHowever, the role of this biomarker (PD-L1 expression) has not been fully\nelucidated.</span>", "ID": "20a568a2-b67a-41ea-b5ed-49e8e28d48a5", "Styles": "None", "Classes": "None", "Text": "The observed OS benefit was consistently demonstrated across subgroups of patients. Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%). However, the role of this biomarker (PD-L1 expression) has not been fully elucidated.", "ParentId": "917e1faf-eacd-4118-99b6-1a97146e4931"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b2555ef-4732-4678-9ea8-09e02c131c5f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "31ef2f07-523f-4d2e-9ec8-eb6d74cd603f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b2555ef-4732-4678-9ea8-09e02c131c5f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Study CA209017 included a limited number\nof patients \u2265 75\u00a0years (11\u00a0in the nivolumab group and 18\u00a0in\nthe docetaxel group). Nivolumab showed numerically less effect on OS (HR\u00a01.85;\n95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05 ) and ORR (9.1% vs\n16.7%). Because of the small sample size, no definitive conclusions can be\ndrawn from these data.</span></p>", "ID": "fa372ee5-4945-4dda-a81d-2f48670a8c3e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Study CA209017 included a limited number\nof patients \u2265 75\u00a0years (11\u00a0in the nivolumab group and 18\u00a0in\nthe docetaxel group). Nivolumab showed numerically less effect on OS (HR\u00a01.85;\n95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05 ) and ORR (9.1% vs\n16.7%). Because of the small sample size, no definitive conclusions can be\ndrawn from these data.</span>", "ID": "d8f2e5b2-a44e-4011-8464-da0c06c63cb6", "Styles": "None", "Classes": "None", "Text": "Study CA209017 included a limited number of patients \u2265 75\u00a0years (11\u00a0in the nivolumab group and 18\u00a0in the docetaxel group). Nivolumab showed numerically less effect on OS (HR\u00a01.85; 95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05 ) and ORR (9.1% vs 16.7%). Because of the small sample size, no definitive conclusions can be drawn from these data.", "ParentId": "fa372ee5-4945-4dda-a81d-2f48670a8c3e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2c518e9-e2cb-4f47-93ef-f35cd745dbfa", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1892be6-c8e8-4bbc-a946-a281e58e0216", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2c518e9-e2cb-4f47-93ef-f35cd745dbfa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Efficacy results are shown in Table\u00a03.</span></p>", "ID": "1e0bcea5-a815-4673-9c9e-de821aaba6af", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Efficacy results are shown in Table\u00a03.</span>", "ID": "a458fd12-de4b-4a41-a3da-7293848663bd", "Styles": "None", "Classes": "None", "Text": "Efficacy results are shown in Table\u00a03.", "ParentId": "1e0bcea5-a815-4673-9c9e-de821aaba6af"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d5795ba-d685-42ae-981f-e89cd0cee06f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c99ffb6-e01a-4ff6-b5bc-7f680080f107", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d5795ba-d685-42ae-981f-e89cd0cee06f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\n3</span></b><span lang=\"EN-GB\">:\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Efficacy\nresults (CA209017)</b></span></p>", "ID": "c8607744-a55c-4f1d-88f0-21f37a4ea132", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Table\n3</span></b>", "ID": "be28160d-cc5c-4a65-af97-d4141f240895", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8607744-a55c-4f1d-88f0-21f37a4ea132"}, {"Element": "<span lang=\"EN-GB\">Table\n3</span>", "ID": "1b9e897a-a7f1-44a2-b5cd-f83c61886ca0", "Styles": "None", "Classes": "None", "Text": "Table 3", "ParentId": "be28160d-cc5c-4a65-af97-d4141f240895"}, {"Element": "<span lang=\"EN-GB\">:\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Efficacy\nresults (CA209017)</b></span>", "ID": "157443bd-0320-4414-ae1c-c5e0ef00d84e", "Styles": "None", "Classes": "None", "Text": ":\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c8607744-a55c-4f1d-88f0-21f37a4ea132"}, {"Element": "<b>Efficacy\nresults (CA209017)</b>", "ID": "be3ff73c-625c-461c-ba80-a3a07d92b0c2", "Styles": "None", "Classes": "None", "Text": "Efficacy results (CA209017)", "ParentId": "157443bd-0320-4414-ae1c-c5e0ef00d84e"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr>\n<td style=\"width:151.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b></p>\n</td>\n<td style=\"width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p class=\"BMSTableText\">9.23 (7.33, 13.27)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p class=\"BMSTableText\">6.01 (5.13, 7.33)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">3.48 (2.14, 4.86)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">2.83 (2.10, 3.52)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:151.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\">20.8 (14.0, 28.4)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"margin-top:0in\">6.4 (2.9, 11.8)</p>\n</td>\n</tr>\n</table>", "ID": "2538fe13-67ef-42f6-9ede-4f11608866fc", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                                ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<tr>\n<td style=\"width:151.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b></p>\n</td>\n</tr>", "ID": "fd7c1037-8a70-458e-8ae9-8c6015e03048", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "87bca0db-4b6a-4a9f-a052-d8bf6b187ca3", "Styles": "width:151.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fd7c1037-8a70-458e-8ae9-8c6015e03048"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "9dd4c3c2-f7b2-4cff-bcb7-eec48c616deb", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "87bca0db-4b6a-4a9f-a052-d8bf6b187ca3"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a7364e4a-4aaf-4a07-b471-0e2c4449975c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9dd4c3c2-f7b2-4cff-bcb7-eec48c616deb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0029ce7c-7d18-4525-9e84-d21be65d2f26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7364e4a-4aaf-4a07-b471-0e2c4449975c"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b></p>\n</td>", "ID": "095d29b0-d21d-4676-b298-850eb1376f52", "Styles": "width:168.8pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fd7c1037-8a70-458e-8ae9-8c6015e03048"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b></p>", "ID": "fe1ef1a3-ad62-471e-88b0-0d8e5c3fabc6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "095d29b0-d21d-4676-b298-850eb1376f52"}, {"Element": "<b><span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span></b>", "ID": "30bf7c50-eaae-4950-87b2-37b11734575d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe1ef1a3-ad62-471e-88b0-0d8e5c3fabc6"}, {"Element": "<span lang=\"EN-GB\">nivolumab<br/>\n  (n\u00a0=\u00a0135)</span>", "ID": "c88255d4-2449-465a-b975-ba7f897d5b51", "Styles": "None", "Classes": "None", "Text": "nivolumab   (n\u00a0=\u00a0135)", "ParentId": "30bf7c50-eaae-4950-87b2-37b11734575d"}, {"Element": "<br/>", "ID": "6bf187da-81e4-474c-a68f-04750aba6561", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c88255d4-2449-465a-b975-ba7f897d5b51"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b></p>\n</td>", "ID": "67e677e7-77a8-4cf6-b099-5b5d44af2c74", "Styles": "width:2.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fd7c1037-8a70-458e-8ae9-8c6015e03048"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b></p>", "ID": "471d9e55-d0ab-46d9-abeb-36439ae7420c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67e677e7-77a8-4cf6-b099-5b5d44af2c74"}, {"Element": "<b><span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span></b>", "ID": "0ca07c3e-17f0-4cd6-9ef2-aeb916c55aaf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "471d9e55-d0ab-46d9-abeb-36439ae7420c"}, {"Element": "<span lang=\"EN-GB\">docetaxel<br/>\n  (n\u00a0=\u00a0137)</span>", "ID": "e3183811-5db8-434a-ada1-66534cef6e84", "Styles": "None", "Classes": "None", "Text": "docetaxel   (n\u00a0=\u00a0137)", "ParentId": "0ca07c3e-17f0-4cd6-9ef2-aeb916c55aaf"}, {"Element": "<br/>", "ID": "ea7df7fb-dd67-4551-b907-8fbf95b6fa9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3183811-5db8-434a-ada1-66534cef6e84"}, {"Element": "<tr>\n<td style=\"width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b></p>\n</td>\n<td style=\"width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d616a7bb-f9a0-466b-988f-edafb60dbd6c", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b></p>\n</td>", "ID": "2a0edf44-73b8-41d6-b937-1cf95c54ccc3", "Styles": "width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d616a7bb-f9a0-466b-988f-edafb60dbd6c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b></p>", "ID": "05ce9c5f-2e0f-4f22-8045-a6b9e7ddb115", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2a0edf44-73b8-41d6-b937-1cf95c54ccc3"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span></b>", "ID": "8ef53d40-ab55-4652-81a6-b045e3c9ecda", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "05ce9c5f-2e0f-4f22-8045-a6b9e7ddb115"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Overall survival </span>", "ID": "1d73bd3c-1e2d-4842-8aa2-be9c7e78b30e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Overall survival ", "ParentId": "8ef53d40-ab55-4652-81a6-b045e3c9ecda"}, {"Element": "<td style=\"width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "c3b2aaef-c764-414a-bc32-ddf0a365445f", "Styles": "width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d616a7bb-f9a0-466b-988f-edafb60dbd6c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d62997cd-192c-4fba-912a-7332116a0f8c", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c3b2aaef-c764-414a-bc32-ddf0a365445f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "0ab1fe16-4950-4c37-8ff1-919b160e4ced", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d62997cd-192c-4fba-912a-7332116a0f8c"}, {"Element": "<td style=\"width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "68afb8fd-1a62-464a-81c4-30cab0807349", "Styles": "width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d616a7bb-f9a0-466b-988f-edafb60dbd6c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "825775eb-8023-4a5f-9742-8dd95c41d31a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "68afb8fd-1a62-464a-81c4-30cab0807349"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "d92d3c74-8b0d-4b24-8607-75f6d87ede1e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "825775eb-8023-4a5f-9742-8dd95c41d31a"}, {"Element": "<td style=\"width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "f47a2f68-457a-43bd-926b-f497e0466417", "Styles": "width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d616a7bb-f9a0-466b-988f-edafb60dbd6c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "5f45bea2-4758-4b1e-9aae-f2db66697542", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f47a2f68-457a-43bd-926b-f497e0466417"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "2f77408f-e0db-4c87-b26a-b9c87e45f250", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "5f45bea2-4758-4b1e-9aae-f2db66697542"}, {"Element": "<td style=\"width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "cc1cdaa0-5f8b-4823-97f6-005192e5c97d", "Styles": "width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d616a7bb-f9a0-466b-988f-edafb60dbd6c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "33fb7fef-00b7-4ef9-9df3-115cc5b206bb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc1cdaa0-5f8b-4823-97f6-005192e5c97d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "7b52290e-a11e-434b-9e3e-6ee11c83ae36", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "33fb7fef-00b7-4ef9-9df3-115cc5b206bb"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span></p>\n</td>\n</tr>", "ID": "8b4e9930-68e3-4bee-98d1-4e8ca500e1c9", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>", "ID": "7f32fde0-d8d1-479d-b614-3a2915dd2891", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b4e9930-68e3-4bee-98d1-4e8ca500e1c9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>", "ID": "9e6055c1-beff-45c8-b659-666ac60eb7dd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f32fde0-d8d1-479d-b614-3a2915dd2891"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span>", "ID": "93485f72-e922-4fb9-8d1d-e8ba8d015005", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Events", "ParentId": "9e6055c1-beff-45c8-b659-666ac60eb7dd"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span></p>\n</td>", "ID": "6b9d42d0-e0e7-4e32-90e1-2f53aad6f023", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b4e9930-68e3-4bee-98d1-4e8ca500e1c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span></p>", "ID": "9672cbc9-c9bc-4298-9573-341aa9012530", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b9d42d0-e0e7-4e32-90e1-2f53aad6f023"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">86 (63.7)</span>", "ID": "7305f911-ffce-4613-a5cc-7ea1854074f5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "86 (63.7)", "ParentId": "9672cbc9-c9bc-4298-9573-341aa9012530"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span></p>\n</td>", "ID": "18884100-f41d-4cf3-a3a9-235eb10945ef", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b4e9930-68e3-4bee-98d1-4e8ca500e1c9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span></p>", "ID": "95e4ae9c-1f0e-41b8-8be5-0ee16b576ac8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18884100-f41d-4cf3-a3a9-235eb10945ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">113 (82.5)</span>", "ID": "cb6042eb-ae43-4855-8227-97f800094002", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "113 (82.5)", "ParentId": "95e4ae9c-1f0e-41b8-8be5-0ee16b576ac8"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span></p>\n</td>\n</tr>", "ID": "542b91ff-1f1d-4690-8c33-09fc082692c4", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>", "ID": "4e7b8f86-1515-47a9-ad78-87ce5ffc7f33", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "542b91ff-1f1d-4690-8c33-09fc082692c4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>", "ID": "1f65ce88-3f69-4bc8-9962-f7d4773a9e35", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4e7b8f86-1515-47a9-ad78-87ce5ffc7f33"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span>", "ID": "633ea591-c85c-4ba8-84be-1cd0fbf36d2d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Hazard ratio ", "ParentId": "1f65ce88-3f69-4bc8-9962-f7d4773a9e35"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span></p>\n</td>", "ID": "7cd3e1ad-a8c9-4c46-8513-da6bd7dc4baf", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "542b91ff-1f1d-4690-8c33-09fc082692c4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span></p>", "ID": "2c54e4db-3a10-4ab7-b3a0-bd58e8e23abe", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7cd3e1ad-a8c9-4c46-8513-da6bd7dc4baf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.59</span>", "ID": "3b17c2a5-f6a9-4bff-a658-1e321a39572c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.59", "ParentId": "2c54e4db-3a10-4ab7-b3a0-bd58e8e23abe"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span></p>\n</td>\n</tr>", "ID": "05d34d6b-4b41-4ae1-8f40-33d83d49a050", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span></p>\n</td>", "ID": "1f333ea0-6e02-4404-b8da-961448c80bb6", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "05d34d6b-4b41-4ae1-8f40-33d83d49a050"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span></p>", "ID": "4c9b73cf-595b-4d3a-9302-4c919aa34c7c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1f333ea0-6e02-4404-b8da-961448c80bb6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">96.85% CI</span>", "ID": "02155e1c-e454-4dbe-9dc0-16cd8bdfdf50", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "96.85% CI", "ParentId": "4c9b73cf-595b-4d3a-9302-4c919aa34c7c"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span></p>\n</td>", "ID": "605b3343-0048-482b-bca1-b8b4b5411be2", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "05d34d6b-4b41-4ae1-8f40-33d83d49a050"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span></p>", "ID": "396127d1-16e9-47ce-9c74-cfece8e8334e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "605b3343-0048-482b-bca1-b8b4b5411be2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.43, 0.81)</span>", "ID": "91b46cca-a7e9-4111-96a9-716aaad39181", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(0.43, 0.81)", "ParentId": "396127d1-16e9-47ce-9c74-cfece8e8334e"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span></p>\n</td>\n</tr>", "ID": "c5db1056-44d9-45f1-885f-87bf474d4683", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>", "ID": "b4107022-5d7e-46bf-ba6c-802f806873be", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c5db1056-44d9-45f1-885f-87bf474d4683"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>", "ID": "4d9b2def-fb22-4807-84af-c476bea11fa7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b4107022-5d7e-46bf-ba6c-802f806873be"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span>", "ID": "1b707342-6100-4291-ae56-319be689dd5a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p\u2011value", "ParentId": "4d9b2def-fb22-4807-84af-c476bea11fa7"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span></p>\n</td>", "ID": "abe63e09-a05a-4a23-909c-b3f70fd67a5e", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c5db1056-44d9-45f1-885f-87bf474d4683"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span></p>", "ID": "cd369663-b1f2-40e4-9d1d-7bd51e0cdf77", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abe63e09-a05a-4a23-909c-b3f70fd67a5e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0002</span>", "ID": "0ced4d9a-92b6-4cb7-934f-712fc21782dd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0002", "ParentId": "cd369663-b1f2-40e4-9d1d-7bd51e0cdf77"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "8e89a12c-8952-4ad9-9dda-9edf19c4190d", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "b12dbb42-7276-42ea-b771-f217d4d79b70", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e89a12c-8952-4ad9-9dda-9edf19c4190d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "23f2edb6-77e4-4d5b-adc2-4fd4c329d772", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "b12dbb42-7276-42ea-b771-f217d4d79b70"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "60275205-7fc6-44c1-81a5-81271cd1b6b8", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "310ee047-98c2-4977-9380-bbd43a6df256", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60275205-7fc6-44c1-81a5-81271cd1b6b8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e0c7991a-6ae3-4788-8ca5-7ca75c556c0b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "310ee047-98c2-4977-9380-bbd43a6df256"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "097e7ca0-fef7-433e-bd3d-e6f1349e7d70", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "337c266e-2f3e-45bd-9bec-5b31d3776a73", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "097e7ca0-fef7-433e-bd3d-e6f1349e7d70"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "522b8290-725a-4c0b-bde1-f6ddaf1e72f8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "337c266e-2f3e-45bd-9bec-5b31d3776a73"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "a930b264-a416-482f-8412-48388f4c667b", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "e89661b2-fc4d-4da7-95c1-405545bb5bbb", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a930b264-a416-482f-8412-48388f4c667b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "a840e524-de68-455e-a573-abd6db9ddfcc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "e89661b2-fc4d-4da7-95c1-405545bb5bbb"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "5517b197-4741-433d-b502-09603524f955", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "76af9a5b-9d93-46ba-baf1-3aaa96fb20e0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "e485553d-58d4-4d58-a0bb-e019c37e1a31", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5517b197-4741-433d-b502-09603524f955"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "f35bc7ff-9ee0-4f51-9a8f-2c5b00a9b6bb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "e485553d-58d4-4d58-a0bb-e019c37e1a31"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p class=\"BMSTableText\">9.23 (7.33, 13.27)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p class=\"BMSTableText\">6.01 (5.13, 7.33)</p>\n</td>\n</tr>", "ID": "f76d3d09-ddc7-46c3-9da6-e0072b3961b1", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span></p>\n</td>", "ID": "9a039de7-f374-4cd8-9a3d-585ba735f36e", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f76d3d09-ddc7-46c3-9da6-e0072b3961b1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span></p>", "ID": "50906585-e9dd-43ca-bff3-7cfc3afe0dfd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9a039de7-f374-4cd8-9a3d-585ba735f36e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) months</span>", "ID": "4a61cb72-e29b-4923-850a-1d9ad8216d94", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Median (95% CI) months", "ParentId": "50906585-e9dd-43ca-bff3-7cfc3afe0dfd"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p class=\"BMSTableText\">9.23 (7.33, 13.27)</p>\n</td>", "ID": "e722cc3c-6302-46a4-9035-eb2def265812", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f76d3d09-ddc7-46c3-9da6-e0072b3961b1"}, {"Element": "<p class=\"BMSTableText\">9.23 (7.33, 13.27)</p>", "ID": "f8172913-14b1-4951-8631-8a1d7c356a1c", "Styles": "None", "Classes": "['BMSTableText']", "Text": "9.23 (7.33, 13.27)", "ParentId": "e722cc3c-6302-46a4-9035-eb2def265812"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p class=\"BMSTableText\">6.01 (5.13, 7.33)</p>\n</td>", "ID": "4c0b50e3-e0c8-4f55-b1b2-124b3f172ae8", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f76d3d09-ddc7-46c3-9da6-e0072b3961b1"}, {"Element": "<p class=\"BMSTableText\">6.01 (5.13, 7.33)</p>", "ID": "609aeae8-5504-41e5-939c-36163679b72d", "Styles": "None", "Classes": "['BMSTableText']", "Text": "6.01 (5.13, 7.33)", "ParentId": "4c0b50e3-e0c8-4f55-b1b2-124b3f172ae8"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span></p>\n</td>\n</tr>", "ID": "1cd3fc38-d71e-4a81-af69-ac13cf3a6184", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>", "ID": "6e0a9a0b-5ae7-47c0-998c-190b1b5f497a", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1cd3fc38-d71e-4a81-af69-ac13cf3a6184"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>", "ID": "8c5e057a-5ebb-47a2-8d2a-9f93d7ee8f7c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6e0a9a0b-5ae7-47c0-998c-190b1b5f497a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span>", "ID": "a0491dfb-0fb1-4e99-a787-7ad5b06b8191", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months", "ParentId": "8c5e057a-5ebb-47a2-8d2a-9f93d7ee8f7c"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span></p>\n</td>", "ID": "379107de-1963-42c3-97a7-c8d4b0c82698", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1cd3fc38-d71e-4a81-af69-ac13cf3a6184"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span></p>", "ID": "d44329fb-56ff-4588-9c5c-02f04ef3523c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "379107de-1963-42c3-97a7-c8d4b0c82698"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">42.1 (33.7, 50.3)</span>", "ID": "57974f42-10e9-46d2-9e99-d8c001b5d974", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "42.1 (33.7, 50.3)", "ParentId": "d44329fb-56ff-4588-9c5c-02f04ef3523c"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span></p>\n</td>", "ID": "7f98b95f-a27e-4dc1-acb5-b0c69c914e8a", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1cd3fc38-d71e-4a81-af69-ac13cf3a6184"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span></p>", "ID": "d8bf92a3-20b2-4e12-9b8c-e961e6c2c7c9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f98b95f-a27e-4dc1-acb5-b0c69c914e8a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">23.7 (16.9, 31.1)</span>", "ID": "d878fecf-99ae-47e1-a62d-6c7510ceaa9e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "23.7 (16.9, 31.1)", "ParentId": "d8bf92a3-20b2-4e12-9b8c-e961e6c2c7c9"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>", "ID": "1d57e90d-e505-45f2-a66a-fa9d6104be45", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b></p>\n</td>", "ID": "99c42214-0b00-4dc5-893a-9c81b91e6d49", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d57e90d-e505-45f2-a66a-fa9d6104be45"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b></p>", "ID": "a513da12-2f47-4095-87fe-686f28fd44ab", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "99c42214-0b00-4dc5-893a-9c81b91e6d49"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span></b>", "ID": "4f99270b-b63d-4942-9bea-bdb55021feee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a513da12-2f47-4095-87fe-686f28fd44ab"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Confirmed objective response </span>", "ID": "94f09abf-05e1-4db7-a98a-3ed612ac53b8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Confirmed objective response ", "ParentId": "4f99270b-b63d-4942-9bea-bdb55021feee"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span></p>\n</td>", "ID": "cee4c527-207f-4a7b-9fd8-7b09719d6307", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d57e90d-e505-45f2-a66a-fa9d6104be45"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span></p>", "ID": "3a5c51aa-e20c-44c8-8c17-775e12644a30", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cee4c527-207f-4a7b-9fd8-7b09719d6307"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">27</span>", "ID": "a5265a0c-7433-4809-baa5-1067fcfb9170", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "27", "ParentId": "3a5c51aa-e20c-44c8-8c17-775e12644a30"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span></p>\n</td>", "ID": "098650b9-b3c9-49cc-aa5e-1352b727f60d", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d57e90d-e505-45f2-a66a-fa9d6104be45"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span></p>", "ID": "e01187c7-eb4a-4440-b907-1fdcc1b42ed2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "098650b9-b3c9-49cc-aa5e-1352b727f60d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20.0%)</span>", "ID": "b296a2bd-74ab-4de7-b2a8-84890d6a098f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(20.0%)", "ParentId": "e01187c7-eb4a-4440-b907-1fdcc1b42ed2"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span></p>\n</td>", "ID": "0214da3b-df16-4f0b-a73e-092211538711", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d57e90d-e505-45f2-a66a-fa9d6104be45"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span></p>", "ID": "1ab21c81-b618-4350-ac11-89bd134333d6", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0214da3b-df16-4f0b-a73e-092211538711"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">12</span>", "ID": "9c68529d-1e62-494b-aaea-82390026c8c3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "12", "ParentId": "1ab21c81-b618-4350-ac11-89bd134333d6"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>", "ID": "9c38f051-d72e-4e75-920a-0b34d555ca67", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1d57e90d-e505-45f2-a66a-fa9d6104be45"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>", "ID": "98044cd9-0d91-426b-885d-d52539f47758", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9c38f051-d72e-4e75-920a-0b34d555ca67"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span>", "ID": "6ff89948-1482-4357-95fc-06d306ba6d92", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(8.8%)", "ParentId": "98044cd9-0d91-426b-885d-d52539f47758"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span></p>\n</td>\n</tr>", "ID": "6d0e737b-e7ef-4efe-a943-55cb2fa2964e", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span></p>\n</td>", "ID": "a23efbb0-6906-4f7c-8fbf-9560bad0777e", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6d0e737b-e7ef-4efe-a943-55cb2fa2964e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span></p>", "ID": "3c258ead-3bd2-4454-84b3-c448b3fd8c5f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a23efbb0-6906-4f7c-8fbf-9560bad0777e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(95% CI)</span>", "ID": "3b6a9572-3e4a-4001-b912-3f86ccfa1b50", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(95% CI)", "ParentId": "3c258ead-3bd2-4454-84b3-c448b3fd8c5f"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span></p>\n</td>", "ID": "09525ea0-3907-4970-b1d3-16eef41eb84c", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6d0e737b-e7ef-4efe-a943-55cb2fa2964e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span></p>", "ID": "fa29b52b-24c8-42c5-816b-be5ef1c0d999", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09525ea0-3907-4970-b1d3-16eef41eb84c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(13.6, 27.7)</span>", "ID": "c01eef52-e260-4680-bee9-cfb82bb01809", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(13.6, 27.7)", "ParentId": "fa29b52b-24c8-42c5-816b-be5ef1c0d999"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span></p>\n</td>", "ID": "5c16617a-70c3-4559-aed5-8b54195ba895", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6d0e737b-e7ef-4efe-a943-55cb2fa2964e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span></p>", "ID": "9ec0e0c0-358b-4b3d-8aa7-b4a92ae3bb99", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c16617a-70c3-4559-aed5-8b54195ba895"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(4.6, 14.8)</span>", "ID": "bd854f22-de4a-43c6-9952-771381541b86", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(4.6, 14.8)", "ParentId": "9ec0e0c0-358b-4b3d-8aa7-b4a92ae3bb99"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span></p>\n</td>\n</tr>", "ID": "8c8f468e-d3c0-438e-9e00-6684441a946c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span></p>\n</td>", "ID": "b974d176-90d5-4fe8-afdf-2bd07dcb5019", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8c8f468e-d3c0-438e-9e00-6684441a946c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span></p>", "ID": "0300724b-d2c6-4a0a-8546-6e8d59697725", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b974d176-90d5-4fe8-afdf-2bd07dcb5019"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Odds ratio (95% CI)</span>", "ID": "24cddc08-d027-4351-8b4d-cd98366aa529", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Odds ratio (95% CI)", "ParentId": "0300724b-d2c6-4a0a-8546-6e8d59697725"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span></p>\n</td>", "ID": "c949043c-235b-4edd-ba72-3c0130314974", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8c8f468e-d3c0-438e-9e00-6684441a946c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span></p>", "ID": "6dd7606e-84e0-425d-bcc4-48d8293b627b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c949043c-235b-4edd-ba72-3c0130314974"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.64 (1.27, 5.49)</span>", "ID": "2fba659e-db07-4d1e-a799-90e27086f65f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.64 (1.27, 5.49)", "ParentId": "6dd7606e-84e0-425d-bcc4-48d8293b627b"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span></p>\n</td>\n</tr>", "ID": "c436c0c8-45e2-4aaf-bf51-1a63d49e8a81", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>", "ID": "6f602179-fb85-4a47-84db-688edba10aa3", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c436c0c8-45e2-4aaf-bf51-1a63d49e8a81"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>", "ID": "ec420f33-cbb0-419b-9edd-096b853d9f0b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6f602179-fb85-4a47-84db-688edba10aa3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span>", "ID": "bba6cf78-e1b0-4159-a729-4174e2ed2978", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p\u2011value", "ParentId": "ec420f33-cbb0-419b-9edd-096b853d9f0b"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span></p>\n</td>", "ID": "fd470e5f-03d4-47f0-8444-8542b3108fcf", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c436c0c8-45e2-4aaf-bf51-1a63d49e8a81"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span></p>", "ID": "baf56902-c25e-4c0f-8bb2-bca873ec0a1e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd470e5f-03d4-47f0-8444-8542b3108fcf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0083</span>", "ID": "cd944ba0-48ea-4520-bc09-18e05789735e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0083", "ParentId": "baf56902-c25e-4c0f-8bb2-bca873ec0a1e"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "28a1cbe7-73da-4074-b33b-0afa30a55757", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "a739d2d0-da9f-4fe5-90dd-271c09a5c751", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "28a1cbe7-73da-4074-b33b-0afa30a55757"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "dbc5c0f7-d1b1-4304-ba3e-0216f12a4e5a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "a739d2d0-da9f-4fe5-90dd-271c09a5c751"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "dd42ae4b-e775-4494-a124-2aa6772d89f4", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "6c5588c2-c738-4eea-90c7-79742b5d6c44", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dd42ae4b-e775-4494-a124-2aa6772d89f4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "7834c442-1ea3-4789-8094-bc20bbe9db89", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "6c5588c2-c738-4eea-90c7-79742b5d6c44"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "428a1e40-f11d-41da-8cb7-4f9ff2f35415", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "dc3a327f-aace-4a53-b971-0d65e14a184d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "428a1e40-f11d-41da-8cb7-4f9ff2f35415"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "6d6c0a7b-561d-4ba5-aff3-a6af5e1c6775", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "dc3a327f-aace-4a53-b971-0d65e14a184d"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "76ecc24b-b2cb-40d5-aada-54ba4a7400c5", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1a505b50-59df-43b3-b756-09be8f8af490", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "76ecc24b-b2cb-40d5-aada-54ba4a7400c5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "a18a1548-e4e4-48cb-a82e-e716ce05b297", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1a505b50-59df-43b3-b756-09be8f8af490"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "2604214b-b1cc-46dd-b651-3ff4347c4ed8", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "18db1fd9-714f-4a97-ae4e-b6aaf8a4e1a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "bc8c276a-3057-481a-a4b7-09428a4023d7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2604214b-b1cc-46dd-b651-3ff4347c4ed8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "5fb2eeda-7fd3-431e-90eb-7dd200c5f918", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "bc8c276a-3057-481a-a4b7-09428a4023d7"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "11bb01c0-1083-4077-9065-d94cde3fc8bf", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span></p>\n</td>", "ID": "bb221087-91ca-4502-81f3-317f4865494c", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11bb01c0-1083-4077-9065-d94cde3fc8bf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span></p>", "ID": "6034ac97-9c55-4d55-af0b-f1c0bb5bf1bb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb221087-91ca-4502-81f3-317f4865494c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Complete response (CR)</span>", "ID": "548dab53-fcf8-47a1-bb08-6cebacb2ffc0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Complete response (CR)", "ParentId": "6034ac97-9c55-4d55-af0b-f1c0bb5bf1bb"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span></p>\n</td>", "ID": "52259fd4-4a96-4633-bd03-f4ba0cf0af75", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11bb01c0-1083-4077-9065-d94cde3fc8bf"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span></p>", "ID": "ce32a991-d9b5-4e4e-8351-8b0254e4ab69", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52259fd4-4a96-4633-bd03-f4ba0cf0af75"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1</span>", "ID": "409b32b7-e077-4444-9870-ae7159e93b09", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1", "ParentId": "ce32a991-d9b5-4e4e-8351-8b0254e4ab69"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span></p>\n</td>", "ID": "b18f3744-886d-411c-b44d-728a9311525b", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11bb01c0-1083-4077-9065-d94cde3fc8bf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span></p>", "ID": "621991af-ba43-4602-b111-cf0c01da02e3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b18f3744-886d-411c-b44d-728a9311525b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.7%)</span>", "ID": "5d60df55-be57-4608-abaa-cbc33bd37302", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(0.7%)", "ParentId": "621991af-ba43-4602-b111-cf0c01da02e3"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span></p>\n</td>", "ID": "ec194113-48e9-4556-b6e9-bd7af6922ccb", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11bb01c0-1083-4077-9065-d94cde3fc8bf"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span></p>", "ID": "c34f6a8f-6edf-4fa4-8245-3cd185681bc6", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec194113-48e9-4556-b6e9-bd7af6922ccb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0 </span>", "ID": "c260dab7-0ebf-418d-aaee-b60284287605", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0 ", "ParentId": "c34f6a8f-6edf-4fa4-8245-3cd185681bc6"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "0177b988-08fc-4a3b-8f7f-62e378541913", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "11bb01c0-1083-4077-9065-d94cde3fc8bf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "3378a21e-1a69-453d-ad1a-251071146269", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0177b988-08fc-4a3b-8f7f-62e378541913"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e9c58611-fb2e-4ae6-b58a-1940155d1537", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "3378a21e-1a69-453d-ad1a-251071146269"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>\n</tr>", "ID": "592c4060-f42f-4f84-a50b-98c251b3145c", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span></p>\n</td>", "ID": "1014ff70-1202-46d5-a4dd-d00b0d0e0052", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "592c4060-f42f-4f84-a50b-98c251b3145c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span></p>", "ID": "fea52163-025f-4cef-9a65-de535869c26a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1014ff70-1202-46d5-a4dd-d00b0d0e0052"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Partial response (PR)</span>", "ID": "a965e0f8-f6a4-40a3-a086-98a2d05cdcc0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Partial response (PR)", "ParentId": "fea52163-025f-4cef-9a65-de535869c26a"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span></p>\n</td>", "ID": "64b9ceec-e482-4e67-950b-aa0a9d836a09", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "592c4060-f42f-4f84-a50b-98c251b3145c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span></p>", "ID": "b40ad8a8-148e-4d2f-8997-75ba1eb0819e", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64b9ceec-e482-4e67-950b-aa0a9d836a09"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">26</span>", "ID": "67bdffc3-9015-4009-a624-65df3248f921", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "26", "ParentId": "b40ad8a8-148e-4d2f-8997-75ba1eb0819e"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span></p>\n</td>", "ID": "cf6e8ef4-94f3-4b5e-8330-d08b33329749", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "592c4060-f42f-4f84-a50b-98c251b3145c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span></p>", "ID": "ec81c03c-f24c-4ec9-beda-549ba48c86c1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf6e8ef4-94f3-4b5e-8330-d08b33329749"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(19.3%)</span>", "ID": "92dccb7b-3a94-4775-b314-a7e05f3cd9de", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(19.3%)", "ParentId": "ec81c03c-f24c-4ec9-beda-549ba48c86c1"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span></p>\n</td>", "ID": "8eaa10db-564b-4c87-8541-636f7d997bb6", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "592c4060-f42f-4f84-a50b-98c251b3145c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span></p>", "ID": "b77e401a-f91b-4e49-9973-1cef272ad89b", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8eaa10db-564b-4c87-8541-636f7d997bb6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 </span>", "ID": "78b6eb29-1033-45ca-b3f2-48be0791021b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "12 ", "ParentId": "b77e401a-f91b-4e49-9973-1cef272ad89b"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>\n</td>", "ID": "0890481a-7be7-4058-8019-346ca1f98f56", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "592c4060-f42f-4f84-a50b-98c251b3145c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span></p>", "ID": "b0d250ac-1de3-4709-a820-77a8c6e9df1c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0890481a-7be7-4058-8019-346ca1f98f56"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(8.8%)</span>", "ID": "cefab6fd-c7e2-420b-b1b6-8d58968f5fe7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(8.8%)", "ParentId": "b0d250ac-1de3-4709-a820-77a8c6e9df1c"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span></p>\n</td>\n</tr>", "ID": "2fb019a2-2dff-4158-a17e-111515d77cec", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span></p>\n</td>", "ID": "08d10b58-6547-455d-809c-c34fe3a1b6ed", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2fb019a2-2dff-4158-a17e-111515d77cec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span></p>", "ID": "b14fc73e-226c-4b2a-adf8-a3cbb546382f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08d10b58-6547-455d-809c-c34fe3a1b6ed"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Stable disease (SD)</span>", "ID": "5f9720fe-e7cb-4d76-9521-62dcbe09c21b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Stable disease (SD)", "ParentId": "b14fc73e-226c-4b2a-adf8-a3cbb546382f"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span></p>\n</td>", "ID": "dde5a16f-4efb-4c19-be55-60f8b43abb5e", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2fb019a2-2dff-4158-a17e-111515d77cec"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span></p>", "ID": "845bff78-0c68-47f6-9e25-8e198d24163c", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dde5a16f-4efb-4c19-be55-60f8b43abb5e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">39</span>", "ID": "ea573d8e-8d9e-44b3-9a78-14726909dbaf", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "39", "ParentId": "845bff78-0c68-47f6-9e25-8e198d24163c"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span></p>\n</td>", "ID": "e880abd0-f29f-4aa6-b639-e7bb11d75736", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2fb019a2-2dff-4158-a17e-111515d77cec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span></p>", "ID": "7910734c-90b5-4600-86c8-d223d441fca5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e880abd0-f29f-4aa6-b639-e7bb11d75736"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(28.9%)</span>", "ID": "e734a5ff-91b2-4572-9567-4d681db72945", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(28.9%)", "ParentId": "7910734c-90b5-4600-86c8-d223d441fca5"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span></p>\n</td>", "ID": "0a6731fd-419f-4cbd-9a2e-0b0a10be45ab", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2fb019a2-2dff-4158-a17e-111515d77cec"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span></p>", "ID": "3ae09781-5bff-45a8-a20b-533a78892c9c", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a6731fd-419f-4cbd-9a2e-0b0a10be45ab"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">47 </span>", "ID": "1a1ec9b5-26e8-439d-bf8b-2dfb35357e42", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "47 ", "ParentId": "3ae09781-5bff-45a8-a20b-533a78892c9c"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span></p>\n</td>", "ID": "66b64601-6e8a-4f1c-b107-cad63060ea03", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2fb019a2-2dff-4158-a17e-111515d77cec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span></p>", "ID": "3036c386-99e0-4ce4-9c5b-146cc9cc38ec", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66b64601-6e8a-4f1c-b107-cad63060ea03"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(34.3%)</span>", "ID": "f42b7287-1727-4f97-a994-444b20f95dbd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(34.3%)", "ParentId": "3036c386-99e0-4ce4-9c5b-146cc9cc38ec"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "13253cc6-ed6d-4891-b889-99edb9f5241d", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "6a25a1de-7d82-43ba-a09d-8e71f74b0a42", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13253cc6-ed6d-4891-b889-99edb9f5241d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "2f664aaf-6c9f-401b-b58c-0454eb40b2b5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "6a25a1de-7d82-43ba-a09d-8e71f74b0a42"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "a6d6df70-9226-4cee-922e-deed8c46f944", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "f6472bad-9d15-48c6-b10a-0eac40e441fe", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a6d6df70-9226-4cee-922e-deed8c46f944"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "51e438b1-79ef-40b2-ba48-16033016d876", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f6472bad-9d15-48c6-b10a-0eac40e441fe"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "4bccfeff-0fd4-40a4-9cd2-d69836b1c28f", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "0d1864c5-6ad8-40f4-8aff-8c703573ef16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4bccfeff-0fd4-40a4-9cd2-d69836b1c28f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e0013173-ed08-4e78-8cad-7544f96a4cdf", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "0d1864c5-6ad8-40f4-8aff-8c703573ef16"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "6c54a82e-9d85-4393-9e61-4d5b2a4370f2", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "a7adb607-0d68-46bd-a48a-e00d8e382673", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c54a82e-9d85-4393-9e61-4d5b2a4370f2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "a5c61608-242f-4658-973f-eb3f844128ad", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "a7adb607-0d68-46bd-a48a-e00d8e382673"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "f4ced4ec-c5ca-47b9-a9a9-bf16b7f3bf30", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6bd91a64-e6f1-4294-864a-be1bbaa9eef6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "bf16245f-0340-47d8-bcfa-322f6d0d4d09", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f4ced4ec-c5ca-47b9-a9a9-bf16b7f3bf30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "3a4183c3-e715-413d-b49b-26bc6452668e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "bf16245f-0340-47d8-bcfa-322f6d0d4d09"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "37a344cb-b0a4-4ad2-8ee1-14928cdc2368", "Styles": "None", "Classes": "None", "Text": "     ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b></p>\n</td>", "ID": "e62ec1b4-0279-4618-94bd-70ca30b90047", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37a344cb-b0a4-4ad2-8ee1-14928cdc2368"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b></p>", "ID": "f460f39d-9ba2-4054-8ab8-6b1509bef139", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e62ec1b4-0279-4618-94bd-70ca30b90047"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span></b>", "ID": "79870c17-ca75-4a53-a316-23d129f8c5c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f460f39d-9ba2-4054-8ab8-6b1509bef139"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median duration of response </span>", "ID": "fb22eb4c-b694-4cb0-bce5-de8d020b1c48", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Median duration of response ", "ParentId": "79870c17-ca75-4a53-a316-23d129f8c5c3"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "5bf0c98f-d030-4972-908f-1598bcb0011f", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37a344cb-b0a4-4ad2-8ee1-14928cdc2368"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "dcd9847f-ec84-43b1-8a81-3582924beaa3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5bf0c98f-d030-4972-908f-1598bcb0011f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "8d28453c-5c1f-4d9b-82aa-f272d7f84f88", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "dcd9847f-ec84-43b1-8a81-3582924beaa3"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "550826b3-05b6-41d5-b3df-2a9402292fea", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37a344cb-b0a4-4ad2-8ee1-14928cdc2368"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "327ce291-1b64-41ec-af95-fd43d9ae8e10", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "550826b3-05b6-41d5-b3df-2a9402292fea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "d0fbcb75-6fdf-420e-a324-a3cc42cae648", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "327ce291-1b64-41ec-af95-fd43d9ae8e10"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "e80959ce-3f79-402c-9382-b16ecd2002db", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37a344cb-b0a4-4ad2-8ee1-14928cdc2368"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1e67ce3a-202c-4856-ace8-9206dac46b1f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e80959ce-3f79-402c-9382-b16ecd2002db"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "4f3e2beb-c9de-4c8d-b056-6552a798370e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1e67ce3a-202c-4856-ace8-9206dac46b1f"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>\n</td>\n</tr>", "ID": "fc497294-8ea2-4f93-89e9-736d337052d6", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>", "ID": "666f6475-369b-4e24-b780-aee2405c8c76", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc497294-8ea2-4f93-89e9-736d337052d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>", "ID": "bc66a46f-6cf5-4759-a14e-17f9420e01b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "666f6475-369b-4e24-b780-aee2405c8c76"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span>", "ID": "7e65a599-fc46-4067-a98f-0cffd1ee494d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Months (range)", "ParentId": "bc66a46f-6cf5-4759-a14e-17f9420e01b5"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span></p>\n</td>", "ID": "1adb6422-786e-421a-a44f-4e05912c51e8", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc497294-8ea2-4f93-89e9-736d337052d6"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span></p>", "ID": "48bc36fc-5a88-40d8-9b8b-fd5f4e88e561", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1adb6422-786e-421a-a44f-4e05912c51e8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Not reached</span>", "ID": "cfc8f62d-869a-412e-a1c4-a87e950f9cdc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Not reached", "ParentId": "48bc36fc-5a88-40d8-9b8b-fd5f4e88e561"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span></p>\n</td>", "ID": "5c6642ab-1018-4ba4-85ac-c295d6d46744", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc497294-8ea2-4f93-89e9-736d337052d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span></p>", "ID": "58f140ab-060c-48e5-9bd8-677501102573", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c6642ab-1018-4ba4-85ac-c295d6d46744"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(2.9 - 20.5<sup>+</sup>)</span>", "ID": "746f0491-dbe0-4bf7-9d3c-e18475b33890", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(2.9 - 20.5)", "ParentId": "58f140ab-060c-48e5-9bd8-677501102573"}, {"Element": "<sup>+</sup>", "ID": "96c57fe3-2943-46c6-b082-46ba5058e81f", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "746f0491-dbe0-4bf7-9d3c-e18475b33890"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span></p>\n</td>", "ID": "46b33da7-f762-49a2-98b9-7ce7a7a7d501", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc497294-8ea2-4f93-89e9-736d337052d6"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span></p>", "ID": "7054c050-d418-4edc-92cf-77f7ee96bf36", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46b33da7-f762-49a2-98b9-7ce7a7a7d501"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">8.4</span>", "ID": "49dcf9ec-9773-4674-afe3-16825b530efb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "8.4", "ParentId": "7054c050-d418-4edc-92cf-77f7ee96bf36"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>\n</td>", "ID": "d0327ffb-44d4-4343-91dd-b099c1e1703f", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc497294-8ea2-4f93-89e9-736d337052d6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>", "ID": "17051cef-7ad9-44fd-8fcf-0a682dcf7d62", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d0327ffb-44d4-4343-91dd-b099c1e1703f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span>", "ID": "a9884a98-ea99-4d78-b77e-f4dc556039f5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(1.4 - 15.2)", "ParentId": "17051cef-7ad9-44fd-8fcf-0a682dcf7d62"}, {"Element": "<sup>+</sup>", "ID": "a5b206cf-9767-45ff-a406-76a1eed50019", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "a9884a98-ea99-4d78-b77e-f4dc556039f5"}, {"Element": "<sup>+</sup>", "ID": "dbb59844-05bf-4623-994d-c0ab78ab5005", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "a9884a98-ea99-4d78-b77e-f4dc556039f5"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "027474e3-cc98-4a60-bddb-4cadb626f119", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "eda977e2-e927-4c81-85bc-17ce328826d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "027474e3-cc98-4a60-bddb-4cadb626f119"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "1f56db0a-5688-4e8e-894e-fea5c4d6baa2", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "eda977e2-e927-4c81-85bc-17ce328826d3"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "ecbe6865-db11-47d6-8a54-4e3bb367625e", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d7718b1e-7bc9-4edf-bae8-92e12e465962", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ecbe6865-db11-47d6-8a54-4e3bb367625e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "ddb02547-1a56-4e97-8697-4c24da4d1df6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d7718b1e-7bc9-4edf-bae8-92e12e465962"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "bc54d050-88c2-4809-accc-eebb64dec9ba", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "089cce19-0f26-4948-9415-53fda86be641", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc54d050-88c2-4809-accc-eebb64dec9ba"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "ecbc0825-025e-4710-818e-9b6fb7cc5b9d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "089cce19-0f26-4948-9415-53fda86be641"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "48fe5aad-dc59-4b64-be5d-3a9220e55bd4", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d190f616-171e-4b07-b550-9773cd5a2713", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "48fe5aad-dc59-4b64-be5d-3a9220e55bd4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "3583ca50-081b-4f02-899b-b40f1978df91", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d190f616-171e-4b07-b550-9773cd5a2713"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "6b5030d9-300b-432d-b02d-d967c7b45bdb", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0d07b5f-3c9e-459c-aeb0-86d5f8a511b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "62f3ef0f-999f-4b9d-b68f-13a34df5aa10", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b5030d9-300b-432d-b02d-d967c7b45bdb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "9224e26f-bfda-430f-9f26-1205bf06aac6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "62f3ef0f-999f-4b9d-b68f-13a34df5aa10"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "324d41b9-f82e-4cdf-8af8-2d824e724c33", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b></p>\n</td>", "ID": "a10302e9-f594-4673-9a0c-610645663f14", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "324d41b9-f82e-4cdf-8af8-2d824e724c33"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b></p>", "ID": "bc427a46-2dd4-4690-850e-3196cbfe026d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a10302e9-f594-4673-9a0c-610645663f14"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span></b>", "ID": "dfe2f3b7-4099-4f19-97bf-95c96703bc6d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bc427a46-2dd4-4690-850e-3196cbfe026d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median time to response</span>", "ID": "20ec70c6-73c1-4635-88ee-c2d203bbbaab", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Median time to response", "ParentId": "dfe2f3b7-4099-4f19-97bf-95c96703bc6d"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "0a03f8ff-dd23-46cb-a08b-a8ab626676c2", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "324d41b9-f82e-4cdf-8af8-2d824e724c33"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d0a93f4a-497a-42e9-84c0-e96ba01dbcb5", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a03f8ff-dd23-46cb-a08b-a8ab626676c2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "71248f56-6bbc-4123-9fb8-26141328b098", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d0a93f4a-497a-42e9-84c0-e96ba01dbcb5"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "adf62c32-668d-4e24-bd51-e2485eb7a640", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "324d41b9-f82e-4cdf-8af8-2d824e724c33"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "200bdd1a-fa86-4b14-bd84-22474c01e7ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf62c32-668d-4e24-bd51-e2485eb7a640"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e0f8caa5-f361-4432-a6f9-7a8431f3b323", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "200bdd1a-fa86-4b14-bd84-22474c01e7ba"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "5a6d8e7b-d836-4d46-b0c8-bcf211f526bc", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "324d41b9-f82e-4cdf-8af8-2d824e724c33"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "f8aaa933-b598-4eb0-960b-7b77e4a73fc5", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a6d8e7b-d836-4d46-b0c8-bcf211f526bc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "f0a981fd-5a21-48ab-93a7-708cd6947209", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f8aaa933-b598-4eb0-960b-7b77e4a73fc5"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "d9f91016-d5f6-41eb-8bc7-ac9932f72df8", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "324d41b9-f82e-4cdf-8af8-2d824e724c33"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "5de9bea6-cf96-44c8-85a2-9eed12b193b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d9f91016-d5f6-41eb-8bc7-ac9932f72df8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "32bfd42a-b724-4e0f-8658-ba9088b809cd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "5de9bea6-cf96-44c8-85a2-9eed12b193b5"}, {"Element": "<tr style=\"height:13.05pt\">\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span></p>\n</td>\n</tr>", "ID": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066", "Styles": "height:13.05pt", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>\n</td>", "ID": "89afe5c2-c596-4be5-ab0b-eaf3091065d8", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span></p>", "ID": "0e8056dd-8393-4957-a0fa-284c32d2c43a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89afe5c2-c596-4be5-ab0b-eaf3091065d8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Months (range)</span>", "ID": "18e91e37-8770-4bce-ae0d-a5fb3292a412", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Months (range)", "ParentId": "0e8056dd-8393-4957-a0fa-284c32d2c43a"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span></p>\n</td>", "ID": "3c8ff6cb-9610-4abe-8cbd-23cb274db9a8", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span></p>", "ID": "e9cd19e2-8f47-459c-8bb0-2f0dc4f3ca96", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3c8ff6cb-9610-4abe-8cbd-23cb274db9a8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2</span>", "ID": "80722c27-a4ab-4529-91ef-1b316ddb5236", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.2", "ParentId": "e9cd19e2-8f47-459c-8bb0-2f0dc4f3ca96"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span></p>\n</td>", "ID": "853cb558-1c1f-4878-bc54-193aab279ac9", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span></p>", "ID": "49f0a2a9-dd3c-41a3-a8c9-032865a33940", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "853cb558-1c1f-4878-bc54-193aab279ac9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.6 - 11.8)</span>", "ID": "93f7514b-4eab-4e94-b6f8-3d3ff04f66a0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(1.6 - 11.8)", "ParentId": "49f0a2a9-dd3c-41a3-a8c9-032865a33940"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span></p>\n</td>", "ID": "7f87130c-e82d-41f2-ae3d-eff58109f296", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span></p>", "ID": "c90bb4dc-efb0-4c81-bd22-f6900f847240", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f87130c-e82d-41f2-ae3d-eff58109f296"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1</span>", "ID": "8273eef3-6547-477c-9428-b1dafad562f7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.1", "ParentId": "c90bb4dc-efb0-4c81-bd22-f6900f847240"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span></p>\n</td>", "ID": "28af6c0f-bc4e-4b0e-9d60-a59f05eba7e4", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt;\n  height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "acea7f4c-c98c-4d95-9ba1-7cae6feb8066"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span></p>", "ID": "f12825d4-7fda-446f-ae4f-b0185ab03574", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "28af6c0f-bc4e-4b0e-9d60-a59f05eba7e4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(1.8 - 9.5)</span>", "ID": "c4c87e92-9cc4-4f13-b5ce-d0891a32ffad", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(1.8 - 9.5)", "ParentId": "f12825d4-7fda-446f-ae4f-b0185ab03574"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "4476e692-3834-48ce-8b39-3e890c549614", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b></p>\n</td>", "ID": "680a9081-e20d-410a-8bb9-f5012aece27f", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4476e692-3834-48ce-8b39-3e890c549614"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b></p>", "ID": "b0301dc6-87c4-467f-9115-a562b15d0879", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "680a9081-e20d-410a-8bb9-f5012aece27f"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span></b>", "ID": "27ace670-64cb-4fa2-a39b-a0db8c8d181d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0301dc6-87c4-467f-9115-a562b15d0879"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Progression-free survival</span>", "ID": "076e8ebe-0d91-4e39-93f5-99d0823423e2", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Progression-free survival", "ParentId": "27ace670-64cb-4fa2-a39b-a0db8c8d181d"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "fc6163a6-bd28-4fac-b26f-574753e39fb2", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4476e692-3834-48ce-8b39-3e890c549614"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "8159d356-32cd-4931-a716-8283499c6efe", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fc6163a6-bd28-4fac-b26f-574753e39fb2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "7047b9c5-2341-4fc9-966e-0dfbf1f2cfc8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "8159d356-32cd-4931-a716-8283499c6efe"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "3b8f1160-90d1-468d-85b3-356d08ae428f", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4476e692-3834-48ce-8b39-3e890c549614"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "6d578aa4-24a7-4835-8c3a-253cc5e277e2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b8f1160-90d1-468d-85b3-356d08ae428f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "291f93d3-ba21-4ac0-aea6-9712d2594928", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "6d578aa4-24a7-4835-8c3a-253cc5e277e2"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "cd7fd10d-5a0f-49bb-a595-1f74e4723def", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4476e692-3834-48ce-8b39-3e890c549614"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1887b5b8-e5ed-42e2-a49d-10863cba9510", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cd7fd10d-5a0f-49bb-a595-1f74e4723def"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "3950af50-7d98-4b49-b55c-a7246d683c44", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1887b5b8-e5ed-42e2-a49d-10863cba9510"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "84954a87-c86b-4345-b96d-989eddbda482", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4476e692-3834-48ce-8b39-3e890c549614"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "52edd2fb-3d54-4c22-9521-7a83229d8a4c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "84954a87-c86b-4345-b96d-989eddbda482"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e81be060-f0e6-4091-be97-057645884753", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "52edd2fb-3d54-4c22-9521-7a83229d8a4c"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span></p>\n</td>\n</tr>", "ID": "3815bd0b-c368-4aff-9569-cb0625da1b29", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>\n</td>", "ID": "674d1616-0cfb-46f1-bb0f-4d277e51fecb", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3815bd0b-c368-4aff-9569-cb0625da1b29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span></p>", "ID": "d5174616-226b-4638-b993-fb82f1edc8d6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "674d1616-0cfb-46f1-bb0f-4d277e51fecb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Events</span>", "ID": "0c7ebf44-bfdc-4d0c-8c03-3cfd30e323fe", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Events", "ParentId": "d5174616-226b-4638-b993-fb82f1edc8d6"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" width=\"225\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span></p>\n</td>", "ID": "b746d11b-3bd0-4a8c-8240-16c418ac74aa", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3815bd0b-c368-4aff-9569-cb0625da1b29"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span></p>", "ID": "72e4d62d-2819-4dd0-8037-2b8a18cf1d01", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b746d11b-3bd0-4a8c-8240-16c418ac74aa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">105 (77.8)</span>", "ID": "6ff0a91e-79be-4817-ab6c-0c9ff3552c72", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "105 (77.8)", "ParentId": "72e4d62d-2819-4dd0-8037-2b8a18cf1d01"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" width=\"192\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span></p>\n</td>", "ID": "1dbf8d1a-ab49-4ee0-aa82-3e14ab7c6673", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3815bd0b-c368-4aff-9569-cb0625da1b29"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span></p>", "ID": "534f2a10-040c-44ed-a871-2d4f6aac84e3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dbf8d1a-ab49-4ee0-aa82-3e14ab7c6673"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">122 (89.1)</span>", "ID": "725129ab-e0ee-44c5-b432-426aa3e16ac8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "122 (89.1)", "ParentId": "534f2a10-040c-44ed-a871-2d4f6aac84e3"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span></p>\n</td>\n</tr>", "ID": "54fca283-eaf5-4db8-b5c5-f55e1bbb5c5b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>\n</td>", "ID": "b0640afa-9a65-498e-880f-263e38a4067a", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54fca283-eaf5-4db8-b5c5-f55e1bbb5c5b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span></p>", "ID": "938ac093-aa6d-4e75-937d-2b690cd73d35", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0640afa-9a65-498e-880f-263e38a4067a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Hazard ratio </span>", "ID": "cc4b6979-8bf7-4770-9cb5-1168f23c8647", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Hazard ratio ", "ParentId": "938ac093-aa6d-4e75-937d-2b690cd73d35"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span></p>\n</td>", "ID": "7494677f-872b-4def-a3bb-4725daf067ce", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "54fca283-eaf5-4db8-b5c5-f55e1bbb5c5b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span></p>", "ID": "6c5d719e-1ae5-4716-93d6-71fd52b7e939", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7494677f-872b-4def-a3bb-4725daf067ce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.62 </span>", "ID": "1770a523-1c7a-4d03-a9b7-23b7010afb6e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.62 ", "ParentId": "6c5d719e-1ae5-4716-93d6-71fd52b7e939"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span></p>\n</td>\n</tr>", "ID": "f4abe320-d948-4194-b4a3-2ed090d0caef", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span></p>\n</td>", "ID": "f23c0f4b-083d-4e42-9afd-e42ddb36d009", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f4abe320-d948-4194-b4a3-2ed090d0caef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span></p>", "ID": "9b34e97d-2fb8-45fd-ae43-29740b962610", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f23c0f4b-083d-4e42-9afd-e42ddb36d009"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;color:black\">95% CI</span>", "ID": "82c52c94-76b8-40f8-a51a-1dcac5ba5268", "Styles": "font-size:10.0pt;color:black", "Classes": "None", "Text": "95% CI", "ParentId": "9b34e97d-2fb8-45fd-ae43-29740b962610"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span></p>\n</td>", "ID": "b25ede72-4f25-4e3e-bf01-a0b8ec08b5df", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f4abe320-d948-4194-b4a3-2ed090d0caef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span></p>", "ID": "cfa1d64b-1f52-4a82-955f-d6cd92181fd3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b25ede72-4f25-4e3e-bf01-a0b8ec08b5df"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.47, 0.81)</span>", "ID": "f8af6d1f-7b56-41b4-8bcd-3c1c0d9851f4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(0.47, 0.81)", "ParentId": "cfa1d64b-1f52-4a82-955f-d6cd92181fd3"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>\n<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span></p>\n</td>\n</tr>", "ID": "6292b673-3664-4785-9f7b-edb40e9f720b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>\n</td>", "ID": "45053d44-124c-4d9a-90a3-5ccba929f8f1", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6292b673-3664-4785-9f7b-edb40e9f720b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span></p>", "ID": "8fdf6ce9-2e91-4f22-93ce-c79e228c113a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45053d44-124c-4d9a-90a3-5ccba929f8f1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">p\u2011value</span>", "ID": "cb36a212-67be-4c2c-91a7-409e80811e47", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p\u2011value", "ParentId": "8fdf6ce9-2e91-4f22-93ce-c79e228c113a"}, {"Element": "<td colspan=\"4\" style=\"width:312.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"417\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span></p>\n</td>", "ID": "d3706232-51fe-4818-998e-a5214a6e8c68", "Styles": "width:312.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6292b673-3664-4785-9f7b-edb40e9f720b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span></p>", "ID": "304f5482-2b0e-40b5-8d17-e764bf72f86c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3706232-51fe-4818-998e-a5214a6e8c68"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">&lt; 0.0004</span>", "ID": "77b0fbad-7260-44df-8241-875d931ac77c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "< 0.0004", "ParentId": "304f5482-2b0e-40b5-8d17-e764bf72f86c"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "be5f259b-6e36-48e0-afd2-d81fe9f3698c", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "044c748d-a318-4805-85f6-3d7954d1c468", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be5f259b-6e36-48e0-afd2-d81fe9f3698c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "62d2e9c2-ccbc-457b-b9c1-f638edbf24eb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "044c748d-a318-4805-85f6-3d7954d1c468"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "37d9a947-3e62-4110-98d4-fd2667aa193c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "62d2e9c2-ccbc-457b-b9c1-f638edbf24eb"}, {"Element": "<td style=\"width:79.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "82b6b6b4-b530-4a9b-b805-894d25eb2951", "Styles": "width:79.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be5f259b-6e36-48e0-afd2-d81fe9f3698c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "297ea79f-3b48-4c62-a817-52e7e0f64dbf", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82b6b6b4-b530-4a9b-b805-894d25eb2951"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "6b247c2b-e407-4948-b842-aa9ba27f1aa8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "297ea79f-3b48-4c62-a817-52e7e0f64dbf"}, {"Element": "<td style=\"width:89.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "c7372672-5f4f-47b2-acdb-e3c44547a015", "Styles": "width:89.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be5f259b-6e36-48e0-afd2-d81fe9f3698c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d0734582-f035-416c-a38b-91c6f296a978", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7372672-5f4f-47b2-acdb-e3c44547a015"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "e8411a61-dd27-4cbd-9892-5088e1c1f387", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d0734582-f035-416c-a38b-91c6f296a978"}, {"Element": "<td style=\"width:60.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "1023415f-e065-4c51-b323-885e78f5a735", "Styles": "width:60.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be5f259b-6e36-48e0-afd2-d81fe9f3698c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "0324aef2-19bc-4d46-a211-47af5fad462d", "Styles": "text-align:right;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1023415f-e065-4c51-b323-885e78f5a735"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "b83e67bf-4482-401c-bcce-ca430c781fc7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "0324aef2-19bc-4d46-a211-47af5fad462d"}, {"Element": "<td style=\"width:83.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"111\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "a9dbcc71-54fa-4d89-8f84-87b789512972", "Styles": "width:83.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be5f259b-6e36-48e0-afd2-d81fe9f3698c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "63881399-afd3-433b-868f-7b3e1be5508c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9dbcc71-54fa-4d89-8f84-87b789512972"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "cf17e69a-deef-42b4-adce-a75eb205c49e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "63881399-afd3-433b-868f-7b3e1be5508c"}, {"Element": "<tr>\n<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">3.48 (2.14, 4.86)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">2.83 (2.10, 3.52)</p>\n</td>\n</tr>", "ID": "7cc2a8b1-a22a-4c2f-8ccc-e645cab09d36", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span></p>\n</td>", "ID": "a275c69d-529b-4186-8175-42dddbfa3719", "Styles": "width:151.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7cc2a8b1-a22a-4c2f-8ccc-e645cab09d36"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span></p>", "ID": "91079c23-5a68-40a4-bb3b-c6db8d0d7bf6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a275c69d-529b-4186-8175-42dddbfa3719"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Median (95% CI) (months)</span>", "ID": "6169cd23-6e04-42e6-aec3-c9dfab6d87ee", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Median (95% CI) (months)", "ParentId": "91079c23-5a68-40a4-bb3b-c6db8d0d7bf6"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">3.48 (2.14, 4.86)</p>\n</td>", "ID": "32dfb1d5-5d21-4079-a6f0-48e5e9d38014", "Styles": "width:168.8pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7cc2a8b1-a22a-4c2f-8ccc-e645cab09d36"}, {"Element": "<p class=\"BMSTableText\" style=\"page-break-after:avoid\">3.48 (2.14, 4.86)</p>", "ID": "5078d199-12de-4c76-8c51-854649447ab7", "Styles": "page-break-after:avoid", "Classes": "['BMSTableText']", "Text": "3.48 (2.14, 4.86)", "ParentId": "32dfb1d5-5d21-4079-a6f0-48e5e9d38014"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"page-break-after:avoid\">2.83 (2.10, 3.52)</p>\n</td>", "ID": "fb047ea9-21c8-4708-b9af-5ce22c49d859", "Styles": "width:2.0in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7cc2a8b1-a22a-4c2f-8ccc-e645cab09d36"}, {"Element": "<p class=\"BMSTableText\" style=\"page-break-after:avoid\">2.83 (2.10, 3.52)</p>", "ID": "76025929-1e86-4807-8948-8ee4e727403e", "Styles": "page-break-after:avoid", "Classes": "['BMSTableText']", "Text": "2.83 (2.10, 3.52)", "ParentId": "fb047ea9-21c8-4708-b9af-5ce22c49d859"}, {"Element": "<tr>\n<td style=\"width:151.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>\n<td colspan=\"2\" style=\"width:168.8pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\">20.8 (14.0, 28.4)</p>\n</td>\n<td colspan=\"2\" style=\"width:2.0in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"margin-top:0in\">6.4 (2.9, 11.8)</p>\n</td>\n</tr>", "ID": "39c819f2-6910-408e-9c7b-65bcc3dcfe6a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "2538fe13-67ef-42f6-9ede-4f11608866fc"}, {"Element": "<td style=\"width:151.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>\n</td>", "ID": "6028dfb1-6e90-450b-8a85-60b3a794be93", "Styles": "width:151.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39c819f2-6910-408e-9c7b-65bcc3dcfe6a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span></p>", "ID": "aabfb533-8350-4382-b321-5d6fadc6da28", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6028dfb1-6e90-450b-8a85-60b3a794be93"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months</span>", "ID": "d036ed05-4de0-476c-9eda-6356bcf123b9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Rate (95% CI) at 12\u00a0months", "ParentId": "aabfb533-8350-4382-b321-5d6fadc6da28"}, {"Element": "<td colspan=\"2\" style=\"width:168.8pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\">\n<p class=\"BMSTableText\">20.8 (14.0, 28.4)</p>\n</td>", "ID": "5303a115-9c66-46c7-af05-6f6fcc2b1a68", "Styles": "width:168.8pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39c819f2-6910-408e-9c7b-65bcc3dcfe6a"}, {"Element": "<p class=\"BMSTableText\">20.8 (14.0, 28.4)</p>", "ID": "e0d2d18c-f209-44f7-8b30-ed657f3861fe", "Styles": "None", "Classes": "['BMSTableText']", "Text": "20.8 (14.0, 28.4)", "ParentId": "5303a115-9c66-46c7-af05-6f6fcc2b1a68"}, {"Element": "<td colspan=\"2\" style=\"width:2.0in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"192\">\n<p class=\"BMSTableText\" style=\"margin-top:0in\">6.4 (2.9, 11.8)</p>\n</td>", "ID": "42151b48-0f1b-42f6-a98a-24e1eec4e679", "Styles": "width:2.0in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "39c819f2-6910-408e-9c7b-65bcc3dcfe6a"}, {"Element": "<p class=\"BMSTableText\" style=\"margin-top:0in\">6.4 (2.9, 11.8)</p>", "ID": "0b2caa99-c9b4-4135-9c76-dd625f027f55", "Styles": "margin-top:0in", "Classes": "['BMSTableText']", "Text": "6.4 (2.9, 11.8)", "ParentId": "42151b48-0f1b-42f6-a98a-24e1eec4e679"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "19f91b10-3a4c-4b0d-84de-d651946f2fa8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55dec1c7-acad-491e-96e1-e9a00be49c32", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19f91b10-3a4c-4b0d-84de-d651946f2fa8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The rate of disease-related symptom\nimprovement, as measured by LCSS, was similar between the nivolumab group\n(18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time\nfor both treatment groups, indicating better overall health status for patients\nremaining on treatment.</span></p>", "ID": "e92aa154-3e96-46f3-bc4f-b148a512c218", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The rate of disease-related symptom\nimprovement, as measured by LCSS, was similar between the nivolumab group\n(18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time\nfor both treatment groups, indicating better overall health status for patients\nremaining on treatment.</span>", "ID": "f416d974-ccd3-4010-a568-4e2b191280b9", "Styles": "None", "Classes": "None", "Text": "The rate of disease-related symptom improvement, as measured by LCSS, was similar between the nivolumab group (18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time for both treatment groups, indicating better overall health status for patients remaining on treatment.", "ParentId": "e92aa154-3e96-46f3-bc4f-b148a512c218"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8289966f-157e-4313-ab93-f4839178c1f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55541218-1681-43b5-9867-bd2c041aab3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8289966f-157e-4313-ab93-f4839178c1f9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Single-arm\nphase\u00a02\u00a0study (CA209063)</span></u></i></p>", "ID": "27e362de-1c09-4773-a535-5971cd216621", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Single-arm\nphase\u00a02\u00a0study (CA209063)</span></u></i>", "ID": "2451f016-2425-4b60-a7de-a2087e556d2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27e362de-1c09-4773-a535-5971cd216621"}, {"Element": "<u><span lang=\"EN-GB\">Single-arm\nphase\u00a02\u00a0study (CA209063)</span></u>", "ID": "b4be3039-426a-4bb2-a465-c7f9c9b8ca27", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2451f016-2425-4b60-a7de-a2087e556d2a"}, {"Element": "<span lang=\"EN-GB\">Single-arm\nphase\u00a02\u00a0study (CA209063)</span>", "ID": "02a7d53a-5de5-47fa-a11f-dec345771e65", "Styles": "None", "Classes": "None", "Text": "Single-arm phase\u00a02\u00a0study (CA209063)", "ParentId": "b4be3039-426a-4bb2-a465-c7f9c9b8ca27"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Study CA209063 was a single-arm, open-label\nstudy conducted in 117\u00a0patients with locally advanced or metastatic\nsquamous-NSCLC after two or more lines of therapy; otherwise similar inclusion\ncriteria as study CA209017 were applied. Nivolumab 3\u00a0mg/kg showed an\noverall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of\n8.21\u00a0months (95% CI: 6.05-10.9\u00a0months ), and a median PFS of 1.87\u00a0months\n(95% CI 1.77-3.15\u00a0months. The PFS was measured by RECIST version 1.1. The\nestimated 1-year survival rate was 41%.</span></p>", "ID": "bb499950-9bee-42b9-902b-165c08119605", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Study CA209063 was a single-arm, open-label\nstudy conducted in 117\u00a0patients with locally advanced or metastatic\nsquamous-NSCLC after two or more lines of therapy; otherwise similar inclusion\ncriteria as study CA209017 were applied. Nivolumab 3\u00a0mg/kg showed an\noverall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of\n8.21\u00a0months (95% CI: 6.05-10.9\u00a0months ), and a median PFS of 1.87\u00a0months\n(95% CI 1.77-3.15\u00a0months. The PFS was measured by RECIST version 1.1. The\nestimated 1-year survival rate was 41%.</span>", "ID": "a27b2349-192f-4597-a438-984c3dc844f5", "Styles": "None", "Classes": "None", "Text": "Study CA209063 was a single-arm, open-label study conducted in 117\u00a0patients with locally advanced or metastatic squamous-NSCLC after two or more lines of therapy; otherwise similar inclusion criteria as study CA209017 were applied. Nivolumab 3\u00a0mg/kg showed an overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of 8.21\u00a0months (95% CI: 6.05-10.9\u00a0months ), and a median PFS of 1.87\u00a0months (95% CI 1.77-3.15\u00a0months. The PFS was measured by RECIST version 1.1. The estimated 1-year survival rate was 41%.", "ParentId": "bb499950-9bee-42b9-902b-165c08119605"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3d1d1fe-342b-4409-8499-c86cc570beb5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "394ae579-61b7-418f-b6fb-1ac58f876f73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3d1d1fe-342b-4409-8499-c86cc570beb5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u>Safety and efficacy in\nelderly patients</u></p>", "ID": "7347db11-32c3-4865-ba56-2269a3bfc2ee", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u>Safety and efficacy in\nelderly patients</u>", "ID": "53caf555-92b1-42b2-8f2d-c99dbae7ddb8", "Styles": "None", "Classes": "None", "Text": "Safety and efficacy in elderly patients", "ParentId": "7347db11-32c3-4865-ba56-2269a3bfc2ee"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No overall differences in safety or\nefficacy were reported between elderly (\u2265\u00a065\u00a0years) and younger\npatients (&lt;\u00a065\u00a0years). </span><span lang=\"EN-GB\">Data from patients\n75\u00a0years of age or older are too limited to draw conclusions on this\npopulation.</span></p>", "ID": "27cee99d-478e-426e-a8b4-e94a2a2bd1a8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">No overall differences in safety or\nefficacy were reported between elderly (\u2265\u00a065\u00a0years) and younger\npatients (&lt;\u00a065\u00a0years). </span>", "ID": "fbfd520c-4485-47a0-bc79-556a14d596df", "Styles": "None", "Classes": "None", "Text": "No overall differences in safety or efficacy were reported between elderly (\u2265\u00a065\u00a0years) and younger patients (<\u00a065\u00a0years). ", "ParentId": "27cee99d-478e-426e-a8b4-e94a2a2bd1a8"}, {"Element": "<span lang=\"EN-GB\">Data from patients\n75\u00a0years of age or older are too limited to draw conclusions on this\npopulation.</span>", "ID": "af64a38b-3ac8-4607-a552-bf76f21b8c12", "Styles": "None", "Classes": "None", "Text": "Data from patients 75\u00a0years of age or older are too limited to draw conclusions on this population.", "ParentId": "27cee99d-478e-426e-a8b4-e94a2a2bd1a8"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "cfcb658a-bf20-458c-9031-1e6ce089edc7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "b97849b8-d3b7-43bd-9ce8-4d6828149d68", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cfcb658a-bf20-458c-9031-1e6ce089edc7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "7b464e32-8f75-45e8-9814-df885bec5a91", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b97849b8-d3b7-43bd-9ce8-4d6828149d68"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e7a38b8f-7ff3-4798-b89d-9377570b56b5", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "7b464e32-8f75-45e8-9814-df885bec5a91"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></p>", "ID": "f758c606-ca7a-42ad-b440-69de2deb1ecd", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\npopulation</span></u>", "ID": "1992725a-fb48-43ab-b2b4-efcdd78e16c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f758c606-ca7a-42ad-b440-69de2deb1ecd"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "2a6a8041-e30b-40ed-b401-3337e33f70b1", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "1992725a-fb48-43ab-b2b4-efcdd78e16c2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The European Medicines Agency has\ndeferred the obligation to submit the results of studies with nivolumab in all\nsubsets of the paediatric population in the treatment of malignant solid\ntumours (see section\u00a04.2 for information on paediatric use).</span></p>", "ID": "43a25b74-92b5-4851-840e-db29a317980f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The European Medicines Agency has\ndeferred the obligation to submit the results of studies with nivolumab in all\nsubsets of the paediatric population in the treatment of malignant solid\ntumours (see section\u00a04.2 for information on paediatric use).</span>", "ID": "95dd5dbe-3ed8-4be1-8866-8a4bf3a3dcb4", "Styles": "None", "Classes": "None", "Text": "The European Medicines Agency has deferred the obligation to submit the results of studies with nivolumab in all subsets of the paediatric population in the treatment of malignant solid tumours (see section\u00a04.2 for information on paediatric use).", "ParentId": "43a25b74-92b5-4851-840e-db29a317980f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9939479e-55fa-42c0-8d06-aa4188de0b72", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4bef8652-e3bc-4c44-9939-897f6de72adb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9939479e-55fa-42c0-8d06-aa4188de0b72"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span></p>", "ID": "cde1a37f-f430-4cb7-9c47-5544b93918eb", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span>", "ID": "4f0dabb1-2c3e-4f0c-ab29-93161cff3151", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "cde1a37f-f430-4cb7-9c47-5544b93918eb"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>", "ID": "b3218b30-9dc3-46a6-9f8e-f1746f65bd62", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "cc73d76a-f253-4565-af5e-086ca71555d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b3218b30-9dc3-46a6-9f8e-f1746f65bd62"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "3197a3da-da7e-47c9-b850-38f90884d145", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc73d76a-f253-4565-af5e-086ca71555d1"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "50099883-ec25-41b2-9446-d0635828f254", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3197a3da-da7e-47c9-b850-38f90884d145"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "7762d213-e7e7-471a-991d-690f71eec697", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "50099883-ec25-41b2-9446-d0635828f254"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics (PK) of nivolumab\nis linear in the dose range of\u00a00.1\u00a0to\u00a010\u00a0mg/kg. The\ngeometric mean clearance (CL), terminal half\u2011life, and average exposure\nat steady state at 3\u00a0mg/kg every\u00a02\u00a0weeks of nivolumab\nwere\u00a09.5\u00a0mL/h,\u00a026.7\u00a0days, and 75.3\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/mL,\nrespectively, based on a population PK analysis.</span></p>", "ID": "c35d46f5-9b5f-4320-b13f-41de22a50607", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The pharmacokinetics (PK) of nivolumab\nis linear in the dose range of\u00a00.1\u00a0to\u00a010\u00a0mg/kg. The\ngeometric mean clearance (CL), terminal half\u2011life, and average exposure\nat steady state at 3\u00a0mg/kg every\u00a02\u00a0weeks of nivolumab\nwere\u00a09.5\u00a0mL/h,\u00a026.7\u00a0days, and 75.3\u00a0</span>", "ID": "eaa945f6-704c-4476-b4c5-801565d14a37", "Styles": "None", "Classes": "None", "Text": "The pharmacokinetics (PK) of nivolumab is linear in the dose range of\u00a00.1\u00a0to\u00a010\u00a0mg/kg. The geometric mean clearance (CL), terminal half\u2011life, and average exposure at steady state at 3\u00a0mg/kg every\u00a02\u00a0weeks of nivolumab were\u00a09.5\u00a0mL/h,\u00a026.7\u00a0days, and 75.3\u00a0", "ParentId": "c35d46f5-9b5f-4320-b13f-41de22a50607"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span>", "ID": "a0e164dc-be09-40b2-82e7-d5486f82b600", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "c35d46f5-9b5f-4320-b13f-41de22a50607"}, {"Element": "<span lang=\"EN-GB\">g/mL,\nrespectively, based on a population PK analysis.</span>", "ID": "28413bfd-fdcf-46cd-9eb6-67958cfa57f4", "Styles": "None", "Classes": "None", "Text": "g/mL, respectively, based on a population PK analysis.", "ParentId": "c35d46f5-9b5f-4320-b13f-41de22a50607"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8b58d94-a818-4a34-8b48-49d815dc5936", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fafef653-35a3-42a6-91c7-076997905736", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8b58d94-a818-4a34-8b48-49d815dc5936"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab CL increased with increasing\nbody weight. Body weight normalised dosing produced approximately uniform\nsteady\u2011state trough concentration over a wide range of body weights (34\u2011162\u00a0kg).\n</span></p>", "ID": "9812899e-a8f8-48d5-979a-1e659ba89b01", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab CL increased with increasing\nbody weight. Body weight normalised dosing produced approximately uniform\nsteady\u2011state trough concentration over a wide range of body weights (34\u2011162\u00a0kg).\n</span>", "ID": "2e34e4f3-756c-4e34-b2ec-5d81d4594ac9", "Styles": "None", "Classes": "None", "Text": "Nivolumab CL increased with increasing body weight. Body weight normalised dosing produced approximately uniform steady\u2011state trough concentration over a wide range of body weights (34\u2011162\u00a0kg). ", "ParentId": "9812899e-a8f8-48d5-979a-1e659ba89b01"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8bde0d16-097d-490e-90c3-9d830fad5a9d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d403fd0-569a-4b89-95bc-218bd895853d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8bde0d16-097d-490e-90c3-9d830fad5a9d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The metabolic pathway of nivolumab has\nnot been characterised. Nivolumab is expected to be degraded into small\npeptides and amino acids via catabolic pathways in the same manner as\nendogenous IgG.</span></p>", "ID": "7ac131eb-51e4-4377-a346-c2a00cacff4c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The metabolic pathway of nivolumab has\nnot been characterised. Nivolumab is expected to be degraded into small\npeptides and amino acids via catabolic pathways in the same manner as\nendogenous IgG.</span>", "ID": "c7877495-bfe7-4da7-b39f-f81dd3f6aed8", "Styles": "None", "Classes": "None", "Text": "The metabolic pathway of nivolumab has not been characterised. Nivolumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.", "ParentId": "7ac131eb-51e4-4377-a346-c2a00cacff4c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7987f319-e520-4fb4-b63d-dc1f2d5c2c35", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4ab3848-bcf6-4ecf-a6ab-efeaeaa17ea3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7987f319-e520-4fb4-b63d-dc1f2d5c2c35"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>", "ID": "d59a69f6-2a99-490d-8536-f1bb5712bec9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations</span></u>", "ID": "f021d41e-46c5-447d-ae98-8e8ffbd98686", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d59a69f6-2a99-490d-8536-f1bb5712bec9"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations</span>", "ID": "ee7df58b-c26e-4b54-b65e-64df0ff6b5ab", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "f021d41e-46c5-447d-ae98-8e8ffbd98686"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e07e125-93af-4dfa-97ff-d87c79915452", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a16aa59-9017-49fb-b153-4cdd71971d74", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e07e125-93af-4dfa-97ff-d87c79915452"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">A population PK analysis suggested no difference\nin CL of nivolumab based on age, gender, race, tumour type, tumour size, and\nhepatic impairment. Although ECOG status, baseline glomerular filtration rate\n(GFR), albumin, body weight, and mild hepatic impairment had an effect on\nnivolumab CL, the effect was not clinically meaningful.</span></p>", "ID": "2a4f5c16-08eb-4386-9bd9-b209ac8e994c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">A population PK analysis suggested no difference\nin CL of nivolumab based on age, gender, race, tumour type, tumour size, and\nhepatic impairment. Although ECOG status, baseline glomerular filtration rate\n(GFR), albumin, body weight, and mild hepatic impairment had an effect on\nnivolumab CL, the effect was not clinically meaningful.</span>", "ID": "547c948a-73ca-49b1-acc9-6d435cea7f5c", "Styles": "None", "Classes": "None", "Text": "A population PK analysis suggested no difference in CL of nivolumab based on age, gender, race, tumour type, tumour size, and hepatic impairment. Although ECOG status, baseline glomerular filtration rate (GFR), albumin, body weight, and mild hepatic impairment had an effect on nivolumab CL, the effect was not clinically meaningful.", "ParentId": "2a4f5c16-08eb-4386-9bd9-b209ac8e994c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc07ce57-52f5-4866-85f9-aeb5d2e14d7c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ffdfbb5a-10de-40d3-9d08-4f15f4820a32", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc07ce57-52f5-4866-85f9-aeb5d2e14d7c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Renal\nimpairment</span></u></i></p>", "ID": "f10f4c50-c309-4a9b-9457-e0f944f4c169", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Renal\nimpairment</span></u></i>", "ID": "1b6f053d-95e1-4702-8ad0-2e80ffbecc93", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f10f4c50-c309-4a9b-9457-e0f944f4c169"}, {"Element": "<u><span lang=\"EN-GB\">Renal\nimpairment</span></u>", "ID": "62beda65-e035-457c-95f7-440dd9a7db9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b6f053d-95e1-4702-8ad0-2e80ffbecc93"}, {"Element": "<span lang=\"EN-GB\">Renal\nimpairment</span>", "ID": "8e9bc4a3-f08d-4817-aef2-dee9aaa7c9a5", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "62beda65-e035-457c-95f7-440dd9a7db9b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The effect of renal impairment on the CL\nof nivolumab was evaluated in patients with mild (GFR\u00a0&lt;\u00a090\nand\u00a0\u2265\u00a060\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0379), moderate (GFR\u00a0&lt;\u00a060\nand\u00a0\u2265\u00a030\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0179), or severe (GFR\u00a0&lt;\u00a030\nand\u00a0\u2265\u00a015\u00a0mL/min/1.73\u00a0m<sup>2</sup>; n\u00a0=\u00a02)\nrenal impairment compared to patients with normal renal function\n(GFR\u00a0\u2265\u00a090\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0342) in population PK analyses. No clinically important\ndifferences in the CL of nivolumab were found between patients with mild or\nmoderate renal impairment and patients with normal renal function. Data from\npatients with severe renal impairment are too limited to draw conclusions on\nthis population (see section\u00a04.2). </span></p>", "ID": "751281e8-3006-4cc8-8fc6-c5f17dfab6a2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The effect of renal impairment on the CL\nof nivolumab was evaluated in patients with mild (GFR\u00a0&lt;\u00a090\nand\u00a0\u2265\u00a060\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0379), moderate (GFR\u00a0&lt;\u00a060\nand\u00a0\u2265\u00a030\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0179), or severe (GFR\u00a0&lt;\u00a030\nand\u00a0\u2265\u00a015\u00a0mL/min/1.73\u00a0m<sup>2</sup>; n\u00a0=\u00a02)\nrenal impairment compared to patients with normal renal function\n(GFR\u00a0\u2265\u00a090\u00a0mL/min/1.73\u00a0m<sup>2</sup>;\nn\u00a0=\u00a0342) in population PK analyses. No clinically important\ndifferences in the CL of nivolumab were found between patients with mild or\nmoderate renal impairment and patients with normal renal function. Data from\npatients with severe renal impairment are too limited to draw conclusions on\nthis population (see section\u00a04.2). </span>", "ID": "c51191ea-e5ce-418d-84c9-4d2695bc9194", "Styles": "None", "Classes": "None", "Text": "The effect of renal impairment on the CL of nivolumab was evaluated in patients with mild (GFR\u00a0<\u00a090 and\u00a0\u2265\u00a060\u00a0mL/min/1.73\u00a0m; n\u00a0=\u00a0379), moderate (GFR\u00a0<\u00a060 and\u00a0\u2265\u00a030\u00a0mL/min/1.73\u00a0m; n\u00a0=\u00a0179), or severe (GFR\u00a0<\u00a030 and\u00a0\u2265\u00a015\u00a0mL/min/1.73\u00a0m; n\u00a0=\u00a02) renal impairment compared to patients with normal renal function (GFR\u00a0\u2265\u00a090\u00a0mL/min/1.73\u00a0m; n\u00a0=\u00a0342) in population PK analyses. No clinically important differences in the CL of nivolumab were found between patients with mild or moderate renal impairment and patients with normal renal function. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see section\u00a04.2). ", "ParentId": "751281e8-3006-4cc8-8fc6-c5f17dfab6a2"}, {"Element": "<sup>2</sup>", "ID": "ad1a6332-f5fc-45fe-beb3-93b65f536524", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "c51191ea-e5ce-418d-84c9-4d2695bc9194"}, {"Element": "<sup>2</sup>", "ID": "a2be44ec-cf0d-413b-83b0-9dbf856f4d0a", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "c51191ea-e5ce-418d-84c9-4d2695bc9194"}, {"Element": "<sup>2</sup>", "ID": "cf104179-26f2-4d13-ada0-56437eee60d5", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "c51191ea-e5ce-418d-84c9-4d2695bc9194"}, {"Element": "<sup>2</sup>", "ID": "c87e3860-df60-4506-ad3a-7a4b7031a4f1", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "c51191ea-e5ce-418d-84c9-4d2695bc9194"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "41735b38-4cbd-4bd9-b4b9-cd85537d59c3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ead8086b-0725-4814-99dc-89df9cae75d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "41735b38-4cbd-4bd9-b4b9-cd85537d59c3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Hepatic\nimpairment</span></u></i></p>", "ID": "a26a4cdf-25cb-423f-8713-320662fa0802", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Hepatic\nimpairment</span></u></i>", "ID": "0bf255ad-e427-49df-bd5a-926599934043", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a26a4cdf-25cb-423f-8713-320662fa0802"}, {"Element": "<u><span lang=\"EN-GB\">Hepatic\nimpairment</span></u>", "ID": "98c90159-16da-4882-98d8-e8bcb349ba62", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0bf255ad-e427-49df-bd5a-926599934043"}, {"Element": "<span lang=\"EN-GB\">Hepatic\nimpairment</span>", "ID": "a7c5a391-e8ef-44e3-afc7-ffdc3b8e7e5f", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "98c90159-16da-4882-98d8-e8bcb349ba62"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The effect of hepatic impairment on the\nCL of nivolumab was evaluated in patients with mild hepatic impairment (total\nbilirubin\u00a01.0\u00a0\u00d7\u00a0to\u00a01.5\u00a0\u00d7\u00a0ULN or AST\u00a0&gt;\u00a0ULN\nas defined using the National Cancer Institute criteria of hepatic dysfunction;\nn\u00a0=\u00a092) compared to patients with normal hepatic function (total\nbilirubin and AST\u00a0\u2264\u00a0ULN; n\u00a0=\u00a0804) in the population\nPK analyses. No clinically important differences in the CL of nivolumab were\nfound between patients with mild hepatic impairment and normal hepatic\nfunction. Nivolumab has not been studied in patients with moderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) or severe hepatic impairment (total bilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) (see section\u00a04.2).</span></p>", "ID": "c9e28075-29d9-482f-a198-a1f538f726d6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The effect of hepatic impairment on the\nCL of nivolumab was evaluated in patients with mild hepatic impairment (total\nbilirubin\u00a01.0\u00a0\u00d7\u00a0to\u00a01.5\u00a0\u00d7\u00a0ULN or AST\u00a0&gt;\u00a0ULN\nas defined using the National Cancer Institute criteria of hepatic dysfunction;\nn\u00a0=\u00a092) compared to patients with normal hepatic function (total\nbilirubin and AST\u00a0\u2264\u00a0ULN; n\u00a0=\u00a0804) in the population\nPK analyses. No clinically important differences in the CL of nivolumab were\nfound between patients with mild hepatic impairment and normal hepatic\nfunction. Nivolumab has not been studied in patients with moderate (total\nbilirubin\u00a0&gt;\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) or severe hepatic impairment (total bilirubin\u00a0&gt;\u00a03\u00a0\u00d7\u00a0ULN\nand any AST) (see section\u00a04.2).</span>", "ID": "fd9e23ec-da00-48e6-af38-da80eb149e75", "Styles": "None", "Classes": "None", "Text": "The effect of hepatic impairment on the CL of nivolumab was evaluated in patients with mild hepatic impairment (total bilirubin\u00a01.0\u00a0\u00d7\u00a0to\u00a01.5\u00a0\u00d7\u00a0ULN or AST\u00a0>\u00a0ULN as defined using the National Cancer Institute criteria of hepatic dysfunction; n\u00a0=\u00a092) compared to patients with normal hepatic function (total bilirubin and AST\u00a0\u2264\u00a0ULN; n\u00a0=\u00a0804) in the population PK analyses. No clinically important differences in the CL of nivolumab were found between patients with mild hepatic impairment and normal hepatic function. Nivolumab has not been studied in patients with moderate (total bilirubin\u00a0>\u00a01.5\u00a0\u00d7\u00a0to\u00a03\u00a0\u00d7\u00a0ULN and any AST) or severe hepatic impairment (total bilirubin\u00a0>\u00a03\u00a0\u00d7\u00a0ULN and any AST) (see section\u00a04.2).", "ParentId": "c9e28075-29d9-482f-a198-a1f538f726d6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3494db4a-0d32-410f-a134-e6b92df63bf1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39bd42ca-c163-4a7b-b7c5-5efe4baa4ae1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3494db4a-0d32-410f-a134-e6b92df63bf1"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</span></p>", "ID": "f5e45046-98b9-4c61-ae49-3ebadfe016d9", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</span>", "ID": "40984484-a7bc-4ec6-b82b-db81501752b6", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "f5e45046-98b9-4c61-ae49-3ebadfe016d9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec7bc9a7-e8b4-455e-8728-571dc06bf162", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d3f1a25-9b14-4799-812c-428ffd6a7683", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec7bc9a7-e8b4-455e-8728-571dc06bf162"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.5pt;color:black\">Blockade\nof PD\u2011L1 signalling has been shown in murine models of pregnancy to\ndisrupt tolerance to the foetus and to increase foetal loss. </span><span lang=\"EN-GB\">The effects of nivolumab on prenatal and postnatal development were\nevaluated in monkeys that received nivolumab twice weekly from the onset of\norganogenesis in the first trimester through delivery, at exposure levels\neither\u00a08\u00a0or\u00a035\u00a0times higher than those observed at the\nclinical dose of\u00a03\u00a0mg/kg of nivolumab (based on AUC). </span><span lang=\"EN-GB\">There was a </span><span lang=\"EN-GB\">dose\u2011dependent increase in\nfoetal losses and increased neonatal mortality </span><span lang=\"EN-GB\">beginning\nin the third trimester</span><span lang=\"EN-GB\">.</span></p>", "ID": "8d5f54b1-1f96-436d-97b2-2a856e396eb5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.5pt;color:black\">Blockade\nof PD\u2011L1 signalling has been shown in murine models of pregnancy to\ndisrupt tolerance to the foetus and to increase foetal loss. </span>", "ID": "15564155-c626-4a4e-bb6d-f604acba41c2", "Styles": "font-size:11.5pt;color:black", "Classes": "None", "Text": "Blockade of PD\u2011L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to increase foetal loss. ", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<span lang=\"EN-GB\">The effects of nivolumab on prenatal and postnatal development were\nevaluated in monkeys that received nivolumab twice weekly from the onset of\norganogenesis in the first trimester through delivery, at exposure levels\neither\u00a08\u00a0or\u00a035\u00a0times higher than those observed at the\nclinical dose of\u00a03\u00a0mg/kg of nivolumab (based on AUC). </span>", "ID": "866d5b55-1a53-495c-9b00-448b5b8e9afb", "Styles": "None", "Classes": "None", "Text": "The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab twice weekly from the onset of organogenesis in the first trimester through delivery, at exposure levels either\u00a08\u00a0or\u00a035\u00a0times higher than those observed at the clinical dose of\u00a03\u00a0mg/kg of nivolumab (based on AUC). ", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<span lang=\"EN-GB\">There was a </span>", "ID": "37fcdec8-743a-4cc8-9a87-c76ed0ea4559", "Styles": "None", "Classes": "None", "Text": "There was a ", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<span lang=\"EN-GB\">dose\u2011dependent increase in\nfoetal losses and increased neonatal mortality </span>", "ID": "89b64873-7891-4792-b4f2-cfa1fb7c95d8", "Styles": "None", "Classes": "None", "Text": "dose\u2011dependent increase in foetal losses and increased neonatal mortality ", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<span lang=\"EN-GB\">beginning\nin the third trimester</span>", "ID": "7e3d8931-028e-4be9-8e0f-9d46b35ac462", "Styles": "None", "Classes": "None", "Text": "beginning in the third trimester", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "0b3fe25f-0962-4dba-851d-4be3e0465554", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "8d5f54b1-1f96-436d-97b2-2a856e396eb5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "664b1e58-1af5-4f39-8827-836bb89cbe0a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f77c796-a370-49d3-820e-0650e10971fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "664b1e58-1af5-4f39-8827-836bb89cbe0a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The remaining offspring of nivolumab\u2011treated\nfemales survived to scheduled termination, with no treatment\u2011related\nclinical signs, alterations to normal development, organ\u2011weight effects,\nor gross and microscopic pathology changes. Results for growth indices, as well\nas teratogenic, neurobehavioral, immunological, and clinical pathology\nparameters throughout the 6\u2011month postnatal period were comparable to the\ncontrol group. However, b</span><span lang=\"EN-GB\" style=\"font-size:11.5pt;\ncolor:black\">ased on its mechanism of action, foetal exposure to nivolumab may\nincrease the risk of developing immune\u2011related disorders or altering the\nnormal immune response and immune\u2011related disorders have been reported in\nPD\u20111 knockout mice.</span></p>", "ID": "e69f04eb-3e29-4410-8cd1-9090f4df16d7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The remaining offspring of nivolumab\u2011treated\nfemales survived to scheduled termination, with no treatment\u2011related\nclinical signs, alterations to normal development, organ\u2011weight effects,\nor gross and microscopic pathology changes. Results for growth indices, as well\nas teratogenic, neurobehavioral, immunological, and clinical pathology\nparameters throughout the 6\u2011month postnatal period were comparable to the\ncontrol group. However, b</span>", "ID": "f76c471b-55dc-40f8-8c8f-1f183a2e2732", "Styles": "None", "Classes": "None", "Text": "The remaining offspring of nivolumab\u2011treated females survived to scheduled termination, with no treatment\u2011related clinical signs, alterations to normal development, organ\u2011weight effects, or gross and microscopic pathology changes. Results for growth indices, as well as teratogenic, neurobehavioral, immunological, and clinical pathology parameters throughout the 6\u2011month postnatal period were comparable to the control group. However, b", "ParentId": "e69f04eb-3e29-4410-8cd1-9090f4df16d7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.5pt;\ncolor:black\">ased on its mechanism of action, foetal exposure to nivolumab may\nincrease the risk of developing immune\u2011related disorders or altering the\nnormal immune response and immune\u2011related disorders have been reported in\nPD\u20111 knockout mice.</span>", "ID": "c2647cbe-d19d-4967-8847-f47d6de3015a", "Styles": "font-size:11.5pt;\ncolor:black", "Classes": "None", "Text": "ased on its mechanism of action, foetal exposure to nivolumab may increase the risk of developing immune\u2011related disorders or altering the normal immune response and immune\u2011related disorders have been reported in PD\u20111 knockout mice.", "ParentId": "e69f04eb-3e29-4410-8cd1-9090f4df16d7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f69a4b9-b5c6-49e4-b2b4-c38f53c85674", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b45e93b-a808-4138-97c0-80f168cd76df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f69a4b9-b5c6-49e4-b2b4-c38f53c85674"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility studies have not been\nperformed with </span><span lang=\"EN-GB\">nivolumab</span><span lang=\"EN-GB\">.</span></p>", "ID": "e38d745a-3b2c-4511-a950-d844df40d82f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Fertility studies have not been\nperformed with </span>", "ID": "6db8eb18-736e-436a-b552-f626d9abf1cc", "Styles": "None", "Classes": "None", "Text": "Fertility studies have not been performed with ", "ParentId": "e38d745a-3b2c-4511-a950-d844df40d82f"}, {"Element": "<span lang=\"EN-GB\">nivolumab</span>", "ID": "9bcdcb2e-7504-4698-a4bc-1041f1e491ec", "Styles": "None", "Classes": "None", "Text": "nivolumab", "ParentId": "e38d745a-3b2c-4511-a950-d844df40d82f"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f736d64c-a0c4-4308-b549-81525325d743", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "e38d745a-3b2c-4511-a950-d844df40d82f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66639757-704b-49ab-a39e-da1fd1ca6adf", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5715472c-0140-4088-b2d7-e70c2c8cd8ce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66639757-704b-49ab-a39e-da1fd1ca6adf"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c360c730-ce55-4b72-8286-ca51cafba609", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eefc390e-abfb-42f9-927f-99a2dffc2a1a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c360c730-ce55-4b72-8286-ca51cafba609"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></p>", "ID": "6e83286f-6092-4444-9fc1-717a1dbef5c0", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span>", "ID": "1ff496f7-7595-4d11-b5b7-feda710cb383", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "6e83286f-6092-4444-9fc1-717a1dbef5c0"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "39529a41-880f-4591-81a1-635d324f3c16", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7bbbfeb9-3355-4950-a993-6f743d52b28b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "39529a41-880f-4591-81a1-635d324f3c16"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of\nexcipients</span></p>", "ID": "535c5304-bbbf-4c28-8459-becb9f5aa060", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of\nexcipients</span>", "ID": "8db75c77-ce60-4a91-a3f4-5d5dafd1fabd", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "535c5304-bbbf-4c28-8459-becb9f5aa060"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1ec49e1f-3eae-4819-9670-72d72c89ab46", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e2ec1395-867a-423a-a5b9-3aef23046984", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1ec49e1f-3eae-4819-9670-72d72c89ab46"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium citrate dihydrate</span></p>", "ID": "b65ac3e9-e11f-4a36-8c06-22d8d0b4bb81", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Sodium citrate dihydrate</span>", "ID": "feac0293-058a-4342-9b03-036991cd1cf3", "Styles": "None", "Classes": "None", "Text": "Sodium citrate dihydrate", "ParentId": "b65ac3e9-e11f-4a36-8c06-22d8d0b4bb81"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium chloride</span></p>", "ID": "b519bef5-f024-4c1e-914d-e6a3cf44fefa", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Sodium chloride</span>", "ID": "39f38fec-3f9c-4be7-9e07-5d97eff897c5", "Styles": "None", "Classes": "None", "Text": "Sodium chloride", "ParentId": "b519bef5-f024-4c1e-914d-e6a3cf44fefa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mannitol (E421)</span></p>", "ID": "6249d393-e5af-457f-af8d-0ce3d5703365", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Mannitol (E421)</span>", "ID": "256812a7-9ae4-4330-8d44-5f709da0821a", "Styles": "None", "Classes": "None", "Text": "Mannitol (E421)", "ParentId": "6249d393-e5af-457f-af8d-0ce3d5703365"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pentetic acid (diethylenetriaminepentaacetic\nacid)</span></p>", "ID": "2a4613d9-4167-41f3-8273-699bccf9b450", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Pentetic acid (diethylenetriaminepentaacetic\nacid)</span>", "ID": "c7ce4991-899b-470c-8528-f80295a0c7b3", "Styles": "None", "Classes": "None", "Text": "Pentetic acid (diethylenetriaminepentaacetic acid)", "ParentId": "2a4613d9-4167-41f3-8273-699bccf9b450"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Polysorbate\u00a080</span></p>", "ID": "8192c6d6-090d-4c83-834a-1b3641685df3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Polysorbate\u00a080</span>", "ID": "12e2bc3b-265f-4f13-ae84-d6e0fa8366a5", "Styles": "None", "Classes": "None", "Text": "Polysorbate\u00a080", "ParentId": "8192c6d6-090d-4c83-834a-1b3641685df3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)</span></p>", "ID": "ce23ff54-d950-4c97-a6ab-f67fdaf7d244", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)</span>", "ID": "9efbbdbf-2189-496f-8776-66862ae8768b", "Styles": "None", "Classes": "None", "Text": "Sodium hydroxide (for pH adjustment)", "ParentId": "ce23ff54-d950-4c97-a6ab-f67fdaf7d244"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)</span></p>", "ID": "917cbe46-dd72-4518-9dad-a88c539f1a89", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)</span>", "ID": "3a0343cc-292d-4217-b2e7-75fb2d094e87", "Styles": "None", "Classes": "None", "Text": "Hydrochloric acid (for pH adjustment)", "ParentId": "917cbe46-dd72-4518-9dad-a88c539f1a89"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Water for injections</span></p>", "ID": "6929d8f2-7b53-4bb9-b13e-67b2139f2220", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Water for injections</span>", "ID": "f2b29a06-a44e-44e9-879e-cc41f7d051be", "Styles": "None", "Classes": "None", "Text": "Water for injections", "ParentId": "6929d8f2-7b53-4bb9-b13e-67b2139f2220"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b89fbcb-b790-43cc-83da-9095a05d731d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2a0fe77-bd10-4f12-84d9-a5f8aac53974", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b89fbcb-b790-43cc-83da-9095a05d731d"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></p>", "ID": "aff77392-7f7c-47e5-b202-447c94dcf01d", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "f6a76a64-05ba-4a91-b848-15eafc0022e6", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "aff77392-7f7c-47e5-b202-447c94dcf01d"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb1b2354-232f-48e3-a3e1-572528725484", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d4f1657-8fe9-4aa4-a3b8-3da6f5870df2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb1b2354-232f-48e3-a3e1-572528725484"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products. Nivolumab\u00a0BMS\nshould not be infused concomitantly in the same intravenous line with other\nmedicinal products.</span></p>", "ID": "708117e5-e793-492a-b2b6-063eb2136b19", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products. Nivolumab\u00a0BMS\nshould not be infused concomitantly in the same intravenous line with other\nmedicinal products.</span>", "ID": "27bdf869-df28-446b-b008-6216ae26816f", "Styles": "None", "Classes": "None", "Text": "In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Nivolumab\u00a0BMS should not be infused concomitantly in the same intravenous line with other medicinal products.", "ParentId": "708117e5-e793-492a-b2b6-063eb2136b19"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54688831-70ff-42a9-8105-688092568d3c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91136c9f-0129-41db-8f35-fd4d20dbfc3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54688831-70ff-42a9-8105-688092568d3c"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></p>", "ID": "34fe2b31-fc94-452c-b225-8544722acd13", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "29f89fd6-3f58-4e3d-b996-ad886bdae2b5", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "34fe2b31-fc94-452c-b225-8544722acd13"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5693f246-174c-48bd-bbe8-a5769cbbe8ff", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ebcd624d-e19a-440e-b679-45d0822eca98", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5693f246-174c-48bd-bbe8-a5769cbbe8ff"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened\nvial</span></u></p>", "ID": "9c8b4b42-fb0e-4899-979b-cfc1e1d25bd2", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Unopened\nvial</span></u>", "ID": "4d945248-e6c0-48d8-a717-2b1c725f84a2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c8b4b42-fb0e-4899-979b-cfc1e1d25bd2"}, {"Element": "<span lang=\"EN-GB\">Unopened\nvial</span>", "ID": "8633b68f-3ef6-4c4a-8988-c12cc0577789", "Styles": "None", "Classes": "None", "Text": "Unopened vial", "ParentId": "4d945248-e6c0-48d8-a717-2b1c725f84a2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">2\u00a0years.</span></p>", "ID": "8a00a5b4-36fc-48ba-809f-f5e380dcffdd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">2\u00a0years.</span>", "ID": "b8bc63c8-fd92-4841-ac2a-9ddc6c8ba90b", "Styles": "None", "Classes": "None", "Text": "2\u00a0years.", "ParentId": "8a00a5b4-36fc-48ba-809f-f5e380dcffdd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a381e581-20ea-4e61-a8d7-ae5a47bf7967", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b190c3fd-fa5a-4b83-af27-bdde0bc12dcc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a381e581-20ea-4e61-a8d7-ae5a47bf7967"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">After opening</span></u></p>", "ID": "896fffdb-0e79-4238-a780-5b0e64975f49", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">After opening</span></u>", "ID": "338cc667-0273-4e0a-976e-c275b514cf23", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "896fffdb-0e79-4238-a780-5b0e64975f49"}, {"Element": "<span lang=\"EN-GB\">After opening</span>", "ID": "97a5b135-dcc1-4d0e-bd9a-102afb2d3281", "Styles": "None", "Classes": "None", "Text": "After opening", "ParentId": "338cc667-0273-4e0a-976e-c275b514cf23"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">From a microbiological point of view, once opened, the medicinal\nproduct should be infused or diluted and infused immediately.</span></p>", "ID": "83a64808-4e93-4d6e-9ffd-5b9a7474051d", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">From a microbiological point of view, once opened, the medicinal\nproduct should be infused or diluted and infused immediately.</span>", "ID": "1f6a9290-7f67-4765-aca4-2a1684e9032f", "Styles": "None", "Classes": "None", "Text": "From a microbiological point of view, once opened, the medicinal product should be infused or diluted and infused immediately.", "ParentId": "83a64808-4e93-4d6e-9ffd-5b9a7474051d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e7348350-0aee-4aa2-b9ef-fb4981031636", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a7fc576-a5b6-42e0-b20b-8109de4b4bf2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e7348350-0aee-4aa2-b9ef-fb4981031636"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:0in;text-indent:0in\"><u><span lang=\"EN-GB\">After preparation of infusion</span></u><span lang=\"EN-GB\"> </span></p>", "ID": "a8191e0d-4b8e-4903-afbc-a5ed60c12fc1", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">After preparation of infusion</span></u>", "ID": "05cddb10-54ec-47ee-bb04-f75d1a4041a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8191e0d-4b8e-4903-afbc-a5ed60c12fc1"}, {"Element": "<span lang=\"EN-GB\">After preparation of infusion</span>", "ID": "937a61c7-e15b-464f-9233-acd4a99649cb", "Styles": "None", "Classes": "None", "Text": "After preparation of infusion", "ParentId": "05cddb10-54ec-47ee-bb04-f75d1a4041a9"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "13ad6861-8665-4b87-8609-2b18a25f81aa", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "a8191e0d-4b8e-4903-afbc-a5ed60c12fc1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">From a microbiological point of view,\nthe product should be used immediately.</span></p>", "ID": "afd7fcc5-72d8-4f49-9181-b84fa693f7b7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">From a microbiological point of view,\nthe product should be used immediately.</span>", "ID": "9c32c556-3ee8-4de6-bb0b-4d9a3b2876e2", "Styles": "None", "Classes": "None", "Text": "From a microbiological point of view, the product should be used immediately.", "ParentId": "afd7fcc5-72d8-4f49-9181-b84fa693f7b7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If not used immediately, chemical and\nphysical in-use stability of Nivolumab\u00a0BMS has been demonstrated for\n24\u00a0hours at\u00a02\u00baC to\u00a08\u00baC protected from light and a\nmaximum of 4\u00a0hours at 20\u00b0C-25\u00b0C and room light (this 4-hour period\nof the total 24\u00a0hours should be inclusive of the product administration\nperiod).</span></p>", "ID": "b3876c58-f1b2-4388-9025-c1940c763b64", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If not used immediately, chemical and\nphysical in-use stability of Nivolumab\u00a0BMS has been demonstrated for\n24\u00a0hours at\u00a02\u00baC to\u00a08\u00baC protected from light and a\nmaximum of 4\u00a0hours at 20\u00b0C-25\u00b0C and room light (this 4-hour period\nof the total 24\u00a0hours should be inclusive of the product administration\nperiod).</span>", "ID": "7e4781df-9681-4120-9165-e1a03f8f5fdc", "Styles": "None", "Classes": "None", "Text": "If not used immediately, chemical and physical in-use stability of Nivolumab\u00a0BMS has been demonstrated for 24\u00a0hours at\u00a02\u00baC to\u00a08\u00baC protected from light and a maximum of 4\u00a0hours at 20\u00b0C-25\u00b0C and room light (this 4-hour period of the total 24\u00a0hours should be inclusive of the product administration period).", "ParentId": "b3876c58-f1b2-4388-9025-c1940c763b64"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "adb52440-65ae-44bb-b2d4-e50c95dc8b9c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2446b112-e73b-4bfb-a532-8287de321353", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "adb52440-65ae-44bb-b2d4-e50c95dc8b9c"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</span></p>", "ID": "45f8cb8b-5660-4064-a11c-b736b859eaa2", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</span>", "ID": "ee2b0fb9-c004-457c-8c91-e9d3e3a359eb", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "45f8cb8b-5660-4064-a11c-b736b859eaa2"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf134b99-b22d-4001-aa01-c09dff099e07", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f4164e9-f972-42c7-9d2e-63c2e4e5a3c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf134b99-b22d-4001-aa01-c09dff099e07"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C\u20118\u00b0C).</span></p>", "ID": "5622b9d8-fd69-4854-8772-868b7f93c201", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C\u20118\u00b0C).</span>", "ID": "5cf7724d-2b1e-4e94-85a4-7ae3609eab01", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator (2\u00b0C\u20118\u00b0C).", "ParentId": "5622b9d8-fd69-4854-8772-868b7f93c201"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>", "ID": "6e2575e9-0cc1-499b-8e2c-e5f2400c350d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not freeze.</span>", "ID": "1bae8c28-7739-4775-abff-a5b790c6e640", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "6e2575e9-0cc1-499b-8e2c-e5f2400c350d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>", "ID": "bb4b4ca6-a31e-4b36-b8dd-13d20e95ad01", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span>", "ID": "772c57a5-26e2-4e85-bbdf-d3e07b24a046", "Styles": "None", "Classes": "None", "Text": "Store in the original package in order to protect from light.", "ParentId": "bb4b4ca6-a31e-4b36-b8dd-13d20e95ad01"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "97269764-d22a-4659-88a6-79434fe22ca1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b1da3131-75ac-4bdb-818c-9f7ca0d49367", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97269764-d22a-4659-88a6-79434fe22ca1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For storage conditions after preparation\nof the infusion, see section\u00a06.3.</span></p>", "ID": "dca8aeb9-a6a9-4365-9d98-b4f418cebe7b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For storage conditions after preparation\nof the infusion, see section\u00a06.3.</span>", "ID": "b26b338e-9073-4b69-97f0-be9bcfc0d2ab", "Styles": "None", "Classes": "None", "Text": "For storage conditions after preparation of the infusion, see section\u00a06.3.", "ParentId": "dca8aeb9-a6a9-4365-9d98-b4f418cebe7b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e7559f4-fb84-450b-ac49-b56882aa1486", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "357b5fef-ac85-40c6-bbf1-f7d22fed821d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e7559f4-fb84-450b-ac49-b56882aa1486"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and\ncontents of container</span></p>", "ID": "fda7280f-2c6b-493e-ad3a-22cd27e7106d", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and\ncontents of container</span>", "ID": "8a823bf7-48e2-4413-8f66-e4223aa5b75d", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "fda7280f-2c6b-493e-ad3a-22cd27e7106d"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f652ca80-e15f-45ab-a6c7-d1fd515f3902", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "695f4269-244b-4fcd-b2da-8a09cdd712c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f652ca80-e15f-45ab-a6c7-d1fd515f3902"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">4\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a dark\nblue flip\u2011off seal (aluminium). Pack size of\u00a01\u00a0vial.</span></p>", "ID": "0127e415-7e1b-4007-891e-501e0dd7e464", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a dark\nblue flip\u2011off seal (aluminium). Pack size of\u00a01\u00a0vial.</span>", "ID": "e3b899f8-c952-4f5f-bf9d-c9ab945eb6d8", "Styles": "None", "Classes": "None", "Text": "4\u00a0mL of concentrate in a\u00a010\u00a0mL vial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a dark blue flip\u2011off seal (aluminium). Pack size of\u00a01\u00a0vial.", "ParentId": "0127e415-7e1b-4007-891e-501e0dd7e464"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">10\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a grey flip\u2011off\nseal (aluminium). Pack size of 1\u00a0vial.</span></p>", "ID": "00e1d313-c8b3-4ed0-9815-55804565e34f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">10\u00a0mL of concentrate in a\u00a010\u00a0mL\nvial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a grey flip\u2011off\nseal (aluminium). Pack size of 1\u00a0vial.</span>", "ID": "7ea010cb-c674-4028-a841-a5fc48967a7d", "Styles": "None", "Classes": "None", "Text": "10\u00a0mL of concentrate in a\u00a010\u00a0mL vial (Type\u00a0I\u00a0glass) with a stopper (coated butyl rubber) and a grey flip\u2011off seal (aluminium). Pack size of 1\u00a0vial.", "ParentId": "00e1d313-c8b3-4ed0-9815-55804565e34f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91c3ae33-f6bf-499b-9ad0-92f6b74f9edb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b572fc8c-555b-450c-8dae-c16bf58c2aad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91c3ae33-f6bf-499b-9ad0-92f6b74f9edb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>", "ID": "0e4f0b28-7dee-40a9-8c92-3642d984764d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Not all pack sizes may be marketed.</span>", "ID": "2c2cc12c-b500-4689-8006-9e112ec9f105", "Styles": "None", "Classes": "None", "Text": "Not all pack sizes may be marketed.", "ParentId": "0e4f0b28-7dee-40a9-8c92-3642d984764d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd3ac804-dce9-4a75-a84a-10de8c49c67e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "065df696-2643-4e99-81c4-62e9db081fab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd3ac804-dce9-4a75-a84a-10de8c49c67e"}, {"Element": "<p class=\"EMEAHeading2\"><a name=\"OLE_LINK1\"><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</span></a></p>", "ID": "a30bed9e-5d05-4686-874c-72de16c196d8", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<a name=\"OLE_LINK1\"><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</span></a>", "ID": "8b3832a9-11d7-46bf-a63e-c0ae44645ce6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a30bed9e-5d05-4686-874c-72de16c196d8"}, {"Element": "<span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</span>", "ID": "c3955a7b-5ca6-42d3-930e-1863c38630f6", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling", "ParentId": "8b3832a9-11d7-46bf-a63e-c0ae44645ce6"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49089340-1de8-4a8e-8a9a-aa35991f6f75", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "599fab6d-e629-4f42-aea1-97aa1a77d5a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49089340-1de8-4a8e-8a9a-aa35991f6f75"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span></p>", "ID": "704dc46b-89ca-43d0-9aa1-ddda3dc22d8a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span>", "ID": "d0be807f-0b49-463f-930d-a218b9e46bf8", "Styles": "None", "Classes": "None", "Text": "Preparation should be performed by trained personnel in accordance with good practices rules, especially with respect to asepsis.", "ParentId": "704dc46b-89ca-43d0-9aa1-ddda3dc22d8a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "770ec42b-826a-4be1-b8f2-0db16ca058ed", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "835c88eb-1703-4b40-83a7-ea5e06474f14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "770ec42b-826a-4be1-b8f2-0db16ca058ed"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparation\nand administration</span></u></p>", "ID": "c9f38ddf-f395-44d0-98d6-b00d38841cd3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Preparation\nand administration</span></u>", "ID": "9348c54a-7eee-4061-8c76-a0273b76097b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9f38ddf-f395-44d0-98d6-b00d38841cd3"}, {"Element": "<span lang=\"EN-GB\">Preparation\nand administration</span>", "ID": "b3b1b805-e196-4ced-bf82-f29810f9d2c3", "Styles": "None", "Classes": "None", "Text": "Preparation and administration", "ParentId": "9348c54a-7eee-4061-8c76-a0273b76097b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6bfbf472-05a5-41c0-831f-b85e5b426b9c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fb40fb1-0555-4ab1-aae3-2e87d11cb6e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6bfbf472-05a5-41c0-831f-b85e5b426b9c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Calculating\nthe dose</span></u></i></p>", "ID": "df15c2b0-7d86-44f4-bf85-c71e6a5ba51a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Calculating\nthe dose</span></u></i>", "ID": "6d5cb509-f222-4536-8d06-15ef3e180577", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df15c2b0-7d86-44f4-bf85-c71e6a5ba51a"}, {"Element": "<u><span lang=\"EN-GB\">Calculating\nthe dose</span></u>", "ID": "62900dfb-7e35-45b5-aad9-d2da6601cad8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6d5cb509-f222-4536-8d06-15ef3e180577"}, {"Element": "<span lang=\"EN-GB\">Calculating\nthe dose</span>", "ID": "625b9aa4-3a40-48df-8b0f-07fa07c43bae", "Styles": "None", "Classes": "None", "Text": "Calculating the dose", "ParentId": "62900dfb-7e35-45b5-aad9-d2da6601cad8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The prescribed dose for the patient is\ngiven in mg/kg. Based on this prescribed dose, calculate the total dose to be\ngiven. More than one vial of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">concentrate may be needed to give the total dose for the patient.</span></p>", "ID": "f2b333ce-b55c-4be1-81b1-c99c020b761b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The prescribed dose for the patient is\ngiven in mg/kg. Based on this prescribed dose, calculate the total dose to be\ngiven. More than one vial of </span>", "ID": "922ec9ab-2fd6-46a4-a1f8-8d5b1ae56df5", "Styles": "None", "Classes": "None", "Text": "The prescribed dose for the patient is given in mg/kg. Based on this prescribed dose, calculate the total dose to be given. More than one vial of ", "ParentId": "f2b333ce-b55c-4be1-81b1-c99c020b761b"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS </span>", "ID": "31206a98-50ea-4c36-b102-26c246ed4f5c", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS ", "ParentId": "f2b333ce-b55c-4be1-81b1-c99c020b761b"}, {"Element": "<span lang=\"EN-GB\">concentrate may be needed to give the total dose for the patient.</span>", "ID": "e74fbf46-0256-48b0-beaa-df2a6893dfc1", "Styles": "None", "Classes": "None", "Text": "concentrate may be needed to give the total dose for the patient.", "ParentId": "f2b333ce-b55c-4be1-81b1-c99c020b761b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f5f761e-0e38-4808-84e2-b0a5ce575082", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e674ce4-c17f-437c-9089-80a22177b229", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f5f761e-0e38-4808-84e2-b0a5ce575082"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">The\ntotal nivolumab dose in mg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span></p>", "ID": "18a1708c-f2c1-4295-9b7a-010aefa53431", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "8609643f-a7a0-4fdb-9a13-e8591bfde022", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "18a1708c-f2c1-4295-9b7a-010aefa53431"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "00ad4131-727e-4d46-85a4-0d23d070a97b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "8609643f-a7a0-4fdb-9a13-e8591bfde022"}, {"Element": "<span lang=\"EN-GB\">The\ntotal nivolumab dose in mg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span>", "ID": "28c4edae-0098-4b83-85b8-7ab82da12aa9", "Styles": "None", "Classes": "None", "Text": "The total nivolumab dose in mg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the prescribed dose in mg/kg. ", "ParentId": "18a1708c-f2c1-4295-9b7a-010aefa53431"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">The\nvolume of Nivolumab\u00a0BMS concentrate to prepare the dose (mL)\u00a0=\u00a0the\ntotal dose in mg, divided by\u00a010 (the Nivolumab\u00a0BMS concentrate\nstrength is\u00a010\u00a0mg/mL). </span></p>", "ID": "23e82b9a-f28c-472a-91fd-28997001adaa", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "59b5a866-75b5-42f9-abde-59e3558390d9", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "23e82b9a-f28c-472a-91fd-28997001adaa"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "94a4a89e-c31a-4c8b-bfb4-e1e3489d031c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "59b5a866-75b5-42f9-abde-59e3558390d9"}, {"Element": "<span lang=\"EN-GB\">The\nvolume of Nivolumab\u00a0BMS concentrate to prepare the dose (mL)\u00a0=\u00a0the\ntotal dose in mg, divided by\u00a010 (the Nivolumab\u00a0BMS concentrate\nstrength is\u00a010\u00a0mg/mL). </span>", "ID": "4fb0a79d-ef62-4f76-9d4d-a970c3120f45", "Styles": "None", "Classes": "None", "Text": "The volume of Nivolumab\u00a0BMS concentrate to prepare the dose (mL)\u00a0=\u00a0the total dose in mg, divided by\u00a010 (the Nivolumab\u00a0BMS concentrate strength is\u00a010\u00a0mg/mL). ", "ParentId": "23e82b9a-f28c-472a-91fd-28997001adaa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8c131ac-ecff-43c2-880b-ad0c77304772", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "429a52b9-37e7-423e-9347-87a159e9ef6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8c131ac-ecff-43c2-880b-ad0c77304772"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Preparing\nthe infusion</span></u></i></p>", "ID": "7b3c7cd5-a57a-41d4-b418-d95c43ffbcb7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Preparing\nthe infusion</span></u></i>", "ID": "655cfde1-f06e-4745-a7e0-4a1cb5607014", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b3c7cd5-a57a-41d4-b418-d95c43ffbcb7"}, {"Element": "<u><span lang=\"EN-GB\">Preparing\nthe infusion</span></u>", "ID": "1e437f04-bbea-409f-82e8-cdaf4d2edfe4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "655cfde1-f06e-4745-a7e0-4a1cb5607014"}, {"Element": "<span lang=\"EN-GB\">Preparing\nthe infusion</span>", "ID": "06642a79-c7ff-4048-914e-b65c54a8950e", "Styles": "None", "Classes": "None", "Text": "Preparing the infusion", "ParentId": "1e437f04-bbea-409f-82e8-cdaf4d2edfe4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Take care to ensure aseptic handling\nwhen you prepare the infusion. The infusion should be prepared in a laminar\nflow hood or safety cabinet using standard precautions for the safe handling of\nintravenous agents.</span></p>", "ID": "e3dffbf5-3ddd-4454-a64b-36c8ebeb3cc9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Take care to ensure aseptic handling\nwhen you prepare the infusion. The infusion should be prepared in a laminar\nflow hood or safety cabinet using standard precautions for the safe handling of\nintravenous agents.</span>", "ID": "2556d502-98c8-4f82-9cef-1a198dfc984a", "Styles": "None", "Classes": "None", "Text": "Take care to ensure aseptic handling when you prepare the infusion. The infusion should be prepared in a laminar flow hood or safety cabinet using standard precautions for the safe handling of intravenous agents.", "ParentId": "e3dffbf5-3ddd-4454-a64b-36c8ebeb3cc9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60c8fe55-3eb7-43ff-825a-f97e476cb7b8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e36b6d13-2a9a-4f38-a51d-2ba77d47deb3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60c8fe55-3eb7-43ff-825a-f97e476cb7b8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> can be used for intravenous administration either:</span></p>", "ID": "99597b4c-6cd8-4667-a845-64e28fd25efb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "64ce21ed-8715-487d-82ce-f5f30ce24dbd", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "99597b4c-6cd8-4667-a845-64e28fd25efb"}, {"Element": "<span lang=\"EN-GB\"> can be used for intravenous administration either:</span>", "ID": "cec1a33a-1588-47e1-839a-589c3b8fb1c6", "Styles": "None", "Classes": "None", "Text": " can be used for intravenous administration either:", "ParentId": "99597b4c-6cd8-4667-a845-64e28fd25efb"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:27.0pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">without\ndilution, after transfer to an infusion container using an appropriate sterile\nsyringe;</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">or</span></p>", "ID": "c8da9869-8307-4b55-a664-4bacefd72306", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;\ntext-autospace:none", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "6dc2d317-52df-478c-b326-2e3ce1f5ec71", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "c8da9869-8307-4b55-a664-4bacefd72306"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "0b79df0f-0d6e-435a-afff-a1dc1dbab4a4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "6dc2d317-52df-478c-b326-2e3ce1f5ec71"}, {"Element": "<span lang=\"EN-GB\">without\ndilution, after transfer to an infusion container using an appropriate sterile\nsyringe;</span>", "ID": "6a70c967-6594-4081-a5d3-2ee038d72b4f", "Styles": "None", "Classes": "None", "Text": "without dilution, after transfer to an infusion container using an appropriate sterile syringe;", "ParentId": "c8da9869-8307-4b55-a664-4bacefd72306"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "e4f49cf7-ee83-4c7b-ad32-e6b8802356b6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c8da9869-8307-4b55-a664-4bacefd72306"}, {"Element": "<span lang=\"EN-GB\">or</span>", "ID": "9fdb55ef-6503-4fba-b988-752121db99a3", "Styles": "None", "Classes": "None", "Text": "or", "ParentId": "c8da9869-8307-4b55-a664-4bacefd72306"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\n</span></span><span lang=\"EN-GB\">after diluting to concentrations as low as\u00a01\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">. The final infusion concentration should\nrange between\u00a01\u00a0and\u00a010\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">. </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">concentrate may be diluted with either:</span><span lang=\"EN-GB\"> </span></p>", "ID": "690c764b-f0f9-455a-aeea-80cb36db8d90", "Styles": "text-autospace:none", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\n</span></span>", "ID": "3b30bbd0-1e8c-467a-b01d-32316193861e", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\n</span>", "ID": "1e198d76-eecc-4570-8202-3318869feee9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "3b30bbd0-1e8c-467a-b01d-32316193861e"}, {"Element": "<span lang=\"EN-GB\">after diluting to concentrations as low as\u00a01\u00a0mg/</span>", "ID": "a1a8c40b-fafc-4bcf-a9e2-0ebdaf49d024", "Styles": "None", "Classes": "None", "Text": "after diluting to concentrations as low as\u00a01\u00a0mg/", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">mL</span>", "ID": "a7ab8ec3-9abc-4543-8047-778c3c575d34", "Styles": "None", "Classes": "None", "Text": "mL", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">. The final infusion concentration should\nrange between\u00a01\u00a0and\u00a010\u00a0mg/</span>", "ID": "8def5a2f-80dc-41e3-96ff-51c978709bab", "Styles": "None", "Classes": "None", "Text": ". The final infusion concentration should range between\u00a01\u00a0and\u00a010\u00a0mg/", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">mL</span>", "ID": "3a50aec8-e634-43e1-873a-7f0a944077dd", "Styles": "None", "Classes": "None", "Text": "mL", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "a72b702e-c1a9-495c-923b-b9429e61cda0", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS </span>", "ID": "703ea8bf-207a-4341-bcb8-4d86cff4b346", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS ", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\">concentrate may be diluted with either:</span>", "ID": "f941b996-69c0-49fc-a1a8-d075cb66ef89", "Styles": "None", "Classes": "None", "Text": "concentrate may be diluted with either:", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "46aef3f1-a9af-439e-92b0-51981d0b02ad", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "690c764b-f0f9-455a-aeea-80cb36db8d90"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">sodium\nchloride\u00a09\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\">\n(0.9%) solution for injection; or</span></p>", "ID": "e1d7baaa-f0e3-4992-a01f-e30b2cfe4b33", "Styles": "margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "7340c4ae-0d37-4564-bb3f-3a780ac71fe3", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "e1d7baaa-f0e3-4992-a01f-e30b2cfe4b33"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "27d3a3b7-1943-4bcd-aeb2-70ebf1190a6f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "7340c4ae-0d37-4564-bb3f-3a780ac71fe3"}, {"Element": "<span lang=\"EN-GB\">sodium\nchloride\u00a09\u00a0mg/</span>", "ID": "c694f11f-63d3-48f2-9d93-1f9f579a718d", "Styles": "None", "Classes": "None", "Text": "sodium chloride\u00a09\u00a0mg/", "ParentId": "e1d7baaa-f0e3-4992-a01f-e30b2cfe4b33"}, {"Element": "<span lang=\"EN-GB\">mL</span>", "ID": "e8775c25-a809-433d-8612-0e16ce6d1889", "Styles": "None", "Classes": "None", "Text": "mL", "ParentId": "e1d7baaa-f0e3-4992-a01f-e30b2cfe4b33"}, {"Element": "<span lang=\"EN-GB\">\n(0.9%) solution for injection; or</span>", "ID": "f182fcc1-8be2-4d7b-9708-55f717bda168", "Styles": "None", "Classes": "None", "Text": " (0.9%) solution for injection; or", "ParentId": "e1d7baaa-f0e3-4992-a01f-e30b2cfe4b33"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">50\u00a0mg/</span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\"> (5%) glucose solution for injection.</span><span lang=\"EN-GB\"> </span></p>", "ID": "c2e11304-ebc0-46d2-8e35-26b991d823fb", "Styles": "margin-left:55.35pt;text-indent:-27.0pt;\ntext-autospace:none", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "08881508-e9e8-48e6-9b0c-ef3cace6bf01", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "c2e11304-ebc0-46d2-8e35-26b991d823fb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "4aa98715-610c-4094-9365-83460e87bfcd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "08881508-e9e8-48e6-9b0c-ef3cace6bf01"}, {"Element": "<span lang=\"EN-GB\">50\u00a0mg/</span>", "ID": "b5306a11-4572-4a2d-b498-a4b99396fae9", "Styles": "None", "Classes": "None", "Text": "50\u00a0mg/", "ParentId": "c2e11304-ebc0-46d2-8e35-26b991d823fb"}, {"Element": "<span lang=\"EN-GB\">mL</span>", "ID": "3974be3f-983c-4b62-bfaa-272323a9c66e", "Styles": "None", "Classes": "None", "Text": "mL", "ParentId": "c2e11304-ebc0-46d2-8e35-26b991d823fb"}, {"Element": "<span lang=\"EN-GB\"> (5%) glucose solution for injection.</span>", "ID": "3c266ebe-e73a-40f8-a5f4-169a8d63a2cd", "Styles": "None", "Classes": "None", "Text": " (5%) glucose solution for injection.", "ParentId": "c2e11304-ebc0-46d2-8e35-26b991d823fb"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "3d449d69-712d-40e0-a788-c1f6a254489d", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c2e11304-ebc0-46d2-8e35-26b991d823fb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38f51c9e-6fa6-4129-ab56-d1d00e8284ee", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9af87ee3-4cec-4015-983c-3cd72331a0f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38f51c9e-6fa6-4129-ab56-d1d00e8284ee"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">STEP 1</span></p>", "ID": "bb678a98-a516-4471-9707-e9a2ea0a85f8", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">STEP 1</span>", "ID": "d0240964-422e-499b-96b1-74ed3dfeb4ff", "Styles": "None", "Classes": "None", "Text": "STEP 1", "ParentId": "bb678a98-a516-4471-9707-e9a2ea0a85f8"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Inspect\nthe Nivolumab\u00a0BMS concentrate for particulate matter or discoloration. Do\nnot shake the vial. Nivolumab\u00a0BMS concentrate is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles. </span></p>", "ID": "a1b04a0b-487d-4ba2-9205-b6591e7c2a66", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "f55517dc-e21d-4eed-8a07-00c3c14ba14c", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "a1b04a0b-487d-4ba2-9205-b6591e7c2a66"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "640ac495-cb62-4d78-b2bc-24c5c4fab66a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "f55517dc-e21d-4eed-8a07-00c3c14ba14c"}, {"Element": "<span lang=\"EN-GB\">Inspect\nthe Nivolumab\u00a0BMS concentrate for particulate matter or discoloration. Do\nnot shake the vial. Nivolumab\u00a0BMS concentrate is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles. </span>", "ID": "326e712a-8bcf-4a2d-9223-99c27edff5e1", "Styles": "None", "Classes": "None", "Text": "Inspect the Nivolumab\u00a0BMS concentrate for particulate matter or discoloration. Do not shake the vial. Nivolumab\u00a0BMS concentrate is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles. ", "ParentId": "a1b04a0b-487d-4ba2-9205-b6591e7c2a66"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Withdraw\nthe required volume of Nivolumab\u00a0BMS concentrate using an appropriate\nsterile syringe. </span></p>", "ID": "d6f2c9b7-a449-4642-bafb-cb25e98f5215", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "41092db0-f163-4b11-8b67-212087e2863a", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "d6f2c9b7-a449-4642-bafb-cb25e98f5215"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "81e5b0a3-9a30-4df3-8cc2-76af26acddac", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "41092db0-f163-4b11-8b67-212087e2863a"}, {"Element": "<span lang=\"EN-GB\">Withdraw\nthe required volume of Nivolumab\u00a0BMS concentrate using an appropriate\nsterile syringe. </span>", "ID": "24c960bd-dd82-4bef-93e9-1f0bdd47db05", "Styles": "None", "Classes": "None", "Text": "Withdraw the required volume of Nivolumab\u00a0BMS concentrate using an appropriate sterile syringe. ", "ParentId": "d6f2c9b7-a449-4642-bafb-cb25e98f5215"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a268c824-26ac-463c-9aed-474d496104b4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11e1876b-a2ab-455c-b041-61a4f0843dfc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a268c824-26ac-463c-9aed-474d496104b4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">STEP 2</span></p>", "ID": "9a5959a5-1494-4280-a3a7-dbc237548053", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">STEP 2</span>", "ID": "8acc5d8c-e6b9-4cb2-ab72-96c1e514deb9", "Styles": "None", "Classes": "None", "Text": "STEP 2", "ParentId": "9a5959a5-1494-4280-a3a7-dbc237548053"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Transfer\nthe concentrate into a sterile, evacuated glass bottle or intravenous container\n(PVC or polyolefin). </span></p>", "ID": "a7481edc-8e9d-49f2-affc-b5b386e91674", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "c1864625-ac8f-4b76-a8e1-fff9ca5e586f", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "a7481edc-8e9d-49f2-affc-b5b386e91674"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "7c7401a6-97d9-4ed0-9a1c-45b3242f2781", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "c1864625-ac8f-4b76-a8e1-fff9ca5e586f"}, {"Element": "<span lang=\"EN-GB\">Transfer\nthe concentrate into a sterile, evacuated glass bottle or intravenous container\n(PVC or polyolefin). </span>", "ID": "7975dd49-3609-409f-974a-246b7ad924c0", "Styles": "None", "Classes": "None", "Text": "Transfer the concentrate into a sterile, evacuated glass bottle or intravenous container (PVC or polyolefin). ", "ParentId": "a7481edc-8e9d-49f2-affc-b5b386e91674"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">If\napplicable, dilute with the required volume of sodium chloride\u00a09\u00a0mg/mL\n(0.9%) solution for injection or\u00a050\u00a0mg/mL (5%) glucose solution for\ninjection. Gently mix the infusion by manual rotation. Do not shake.</span></p>", "ID": "935c01fa-4314-46bd-8612-7068c89c2e08", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "7c8f92ad-ccda-40ae-ba0b-21b7c984480b", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "935c01fa-4314-46bd-8612-7068c89c2e08"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "ef6ffb02-c23c-4dd0-aed6-49e7fc13d386", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "7c8f92ad-ccda-40ae-ba0b-21b7c984480b"}, {"Element": "<span lang=\"EN-GB\">If\napplicable, dilute with the required volume of sodium chloride\u00a09\u00a0mg/mL\n(0.9%) solution for injection or\u00a050\u00a0mg/mL (5%) glucose solution for\ninjection. Gently mix the infusion by manual rotation. Do not shake.</span>", "ID": "24f0745d-2ebe-4ba4-8d7f-ff5dfb8c8635", "Styles": "None", "Classes": "None", "Text": "If applicable, dilute with the required volume of sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for injection or\u00a050\u00a0mg/mL (5%) glucose solution for injection. Gently mix the infusion by manual rotation. Do not shake.", "ParentId": "935c01fa-4314-46bd-8612-7068c89c2e08"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c831a368-2242-405b-8209-98d163e072b1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff738010-2813-45c0-b9a8-b3974db62c00", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c831a368-2242-405b-8209-98d163e072b1"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Administration</span></u></i></p>", "ID": "0d5cbf16-3b09-4c40-92a3-27f287d6b6e1", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Administration</span></u></i>", "ID": "69fc9b46-986c-465a-8f31-1e846f0c26b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d5cbf16-3b09-4c40-92a3-27f287d6b6e1"}, {"Element": "<u><span lang=\"EN-GB\">Administration</span></u>", "ID": "ef8bb1a6-eca5-4757-947a-d7c3b6160162", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69fc9b46-986c-465a-8f31-1e846f0c26b7"}, {"Element": "<span lang=\"EN-GB\">Administration</span>", "ID": "38eb326d-01e1-4f62-9b89-b5d8d2fc851f", "Styles": "None", "Classes": "None", "Text": "Administration", "ParentId": "ef8bb1a6-eca5-4757-947a-d7c3b6160162"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion must not be administered as an intravenous push or bolus\ninjection.</span></p>", "ID": "8a8e21c4-8bda-41fe-8e45-91fce218994e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS </span>", "ID": "231cc326-326b-4c85-a52f-cb122af8755f", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS ", "ParentId": "8a8e21c4-8bda-41fe-8e45-91fce218994e"}, {"Element": "<span lang=\"EN-GB\">infusion must not be administered as an intravenous push or bolus\ninjection.</span>", "ID": "9f6ab482-1a64-476e-9cfc-e380c02b1bb5", "Styles": "None", "Classes": "None", "Text": "infusion must not be administered as an intravenous push or bolus injection.", "ParentId": "8a8e21c4-8bda-41fe-8e45-91fce218994e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS infusion\nintravenously over a period of\u00a060\u00a0minutes.</span></p>", "ID": "771b7138-0b48-4c76-b11b-32d3b19a2074", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS infusion\nintravenously over a period of\u00a060\u00a0minutes.</span>", "ID": "53777aef-1a3b-41d8-84f3-5bdee8c8e5f8", "Styles": "None", "Classes": "None", "Text": "Administer the Nivolumab\u00a0BMS infusion intravenously over a period of\u00a060\u00a0minutes.", "ParentId": "771b7138-0b48-4c76-b11b-32d3b19a2074"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span></p>", "ID": "e21581fd-221d-431d-904f-26a6c3fdaad1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS </span>", "ID": "054b9d63-3c74-42ed-b82a-31e43835f96c", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS ", "ParentId": "e21581fd-221d-431d-904f-26a6c3fdaad1"}, {"Element": "<span lang=\"EN-GB\">infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span>", "ID": "f71c76a5-93da-42ca-a96d-96a2f803c644", "Styles": "None", "Classes": "None", "Text": "infusion should not be infused at the same time in the same intravenous line with other agents. Use a separate infusion line for the infusion.", "ParentId": "e21581fd-221d-431d-904f-26a6c3fdaad1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "532b873a-8d40-4260-b1f5-0e2b9c9bb90e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0348d09c-6c70-4b1f-9ad1-dcac22e36738", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "532b873a-8d40-4260-b1f5-0e2b9c9bb90e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm to\u00a01.2 \u03bcm).</span></p>", "ID": "ad6fcf63-5e93-4525-b308-c9e12ca2639d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm to\u00a01.2 \u03bcm).</span>", "ID": "6cf5c306-e632-4d6c-b8d6-0f38d23b06c4", "Styles": "None", "Classes": "None", "Text": "Use an infusion set and an in\u2011line, sterile, non\u2011pyrogenic, low protein binding filter (pore size of\u00a00.2\u00a0\u03bcm to\u00a01.2 \u03bcm).", "ParentId": "ad6fcf63-5e93-4525-b308-c9e12ca2639d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6313036b-ff53-427f-b268-87f8d10a3101", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aaf0afe3-8168-4898-9b3e-8ef73a76743b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6313036b-ff53-427f-b268-87f8d10a3101"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS </span><span lang=\"EN-GB\">infusion is compatible with PVC and polyolefin containers, glass\nbottles, PVC</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">infusion sets and\nin-line filters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to 1.2\u00a0\u00b5m.</span></p>", "ID": "fcf44147-b357-40ba-aae5-b1b935b4a4dc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS </span>", "ID": "702168e2-df6c-40e2-a94c-f123d475e8a5", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS ", "ParentId": "fcf44147-b357-40ba-aae5-b1b935b4a4dc"}, {"Element": "<span lang=\"EN-GB\">infusion is compatible with PVC and polyolefin containers, glass\nbottles, PVC</span>", "ID": "2d18ceb4-5278-476e-89ba-58523b5dd1cb", "Styles": "None", "Classes": "None", "Text": "infusion is compatible with PVC and polyolefin containers, glass bottles, PVC", "ParentId": "fcf44147-b357-40ba-aae5-b1b935b4a4dc"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "ad81c903-12fb-4de6-a082-3db8d5d14210", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fcf44147-b357-40ba-aae5-b1b935b4a4dc"}, {"Element": "<span lang=\"EN-GB\">infusion sets and\nin-line filters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to 1.2\u00a0\u00b5m.</span>", "ID": "ac0df53b-8fab-468f-ac5a-6ce110d782c3", "Styles": "None", "Classes": "None", "Text": "infusion sets and in-line filters with polyethersulfone membranes with pore sizes of\u00a00.2\u00a0\u00b5m to 1.2\u00a0\u00b5m.", "ParentId": "fcf44147-b357-40ba-aae5-b1b935b4a4dc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea88738b-5a17-4704-a590-5a2aba72b571", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50806119-4b32-4835-a5af-76766163fbc4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea88738b-5a17-4704-a590-5a2aba72b571"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">After administration of the nivolumab dose,\nflush the line with sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for\ninjection or\u00a050\u00a0mg/mL (5%) glucose solution for injection.</span></p>", "ID": "df02aa49-8911-4c9e-b265-c712b3ddb44d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">After administration of the nivolumab dose,\nflush the line with sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for\ninjection or\u00a050\u00a0mg/mL (5%) glucose solution for injection.</span>", "ID": "b3d4ac8f-8895-481a-8f64-a4662af8f533", "Styles": "None", "Classes": "None", "Text": "After administration of the nivolumab dose, flush the line with sodium chloride\u00a09\u00a0mg/mL (0.9%) solution for injection or\u00a050\u00a0mg/mL (5%) glucose solution for injection.", "ParentId": "df02aa49-8911-4c9e-b265-c712b3ddb44d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "69eb53d0-3fb5-4fcd-8fc5-94633f091cc9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c04821b-3942-4e3f-8582-32f80a894dfe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "69eb53d0-3fb5-4fcd-8fc5-94633f091cc9"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Disposal</span></u></i></p>", "ID": "82a2a676-266a-4833-9740-7d3680e8c47b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><u><span lang=\"EN-GB\">Disposal</span></u></i>", "ID": "e3dd623b-b12d-4a12-9951-c5d63a0a123e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82a2a676-266a-4833-9740-7d3680e8c47b"}, {"Element": "<u><span lang=\"EN-GB\">Disposal</span></u>", "ID": "8d47b697-aad7-4b85-add8-3f47cf549ba1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3dd623b-b12d-4a12-9951-c5d63a0a123e"}, {"Element": "<span lang=\"EN-GB\">Disposal</span>", "ID": "0651c3d3-c0ac-4480-b235-3c55d6ec449b", "Styles": "None", "Classes": "None", "Text": "Disposal", "ParentId": "8d47b697-aad7-4b85-add8-3f47cf549ba1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. </span><span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span></p>", "ID": "8d0d73a6-6e74-4785-8630-a307dc8a44e4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. </span>", "ID": "af6b8209-a603-4516-88be-c696147fad66", "Styles": "None", "Classes": "None", "Text": "Do not store any unused portion of the infusion solution for reuse. ", "ParentId": "8d0d73a6-6e74-4785-8630-a307dc8a44e4"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span>", "ID": "de4c8034-7a8a-47e6-84c2-eb46f84acb9f", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "8d0d73a6-6e74-4785-8630-a307dc8a44e4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c473afa-27fa-48e7-a9a1-3741c40da77e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d33463d4-ce44-47f5-9cc8-3329bd584be8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c473afa-27fa-48e7-a9a1-3741c40da77e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef91ed97-6050-4a02-a7b4-79770293a48d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a597fc3a-9dc4-44e5-a4e3-3c47572d2138", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef91ed97-6050-4a02-a7b4-79770293a48d"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></p>", "ID": "0fbaf0f8-b020-48c1-8c62-63fd6d90540b", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span>", "ID": "3ed3fda9-73a1-4099-a0a5-6cb631e886f4", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "0fbaf0f8-b020-48c1-8c62-63fd6d90540b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5841b1d1-5a1e-4fb1-aa50-a7e09e8c4f29", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37d43e93-7f7e-4b23-b0a9-dfbe119e4041", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5841b1d1-5a1e-4fb1-aa50-a7e09e8c4f29"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG<br/>\nUxbridge Business Park<br/>\nSanderson Road<br/>\nUxbridge UB8\u00a01DH<br/>\nUnited Kingdom<br/>\n<br/>\n</span></p>", "ID": "6aa85d89-6d74-47cd-a657-d8addb325999", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG<br/>\nUxbridge Business Park<br/>\nSanderson Road<br/>\nUxbridge UB8\u00a01DH<br/>\nUnited Kingdom<br/>\n<br/>\n</span>", "ID": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8\u00a01DH United Kingdom  ", "ParentId": "6aa85d89-6d74-47cd-a657-d8addb325999"}, {"Element": "<br/>", "ID": "c86ec14c-89fd-4786-9874-939778abfbd3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<br/>", "ID": "c7368c95-1743-4161-a8a6-37faee067c17", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<br/>", "ID": "1ea48425-bf5b-4db8-9358-2f04c2f878a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<br/>", "ID": "0e3a4eed-756c-4214-bff2-49db40426071", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<br/>", "ID": "3e96cf45-e68f-417a-83c0-54f3221887dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<br/>", "ID": "38d9d01b-c152-40a6-a5f7-0313b45ea871", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fdab553-8ff3-49cd-8cf0-6916eecba0c3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "68d01958-db27-4a57-b97e-f95f66a29b4b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "40ce21bc-d246-44a5-b851-85f429049348", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68d01958-db27-4a57-b97e-f95f66a29b4b"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></p>", "ID": "4048f9b0-2bea-40fe-85b3-1f6b2e78b08a", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "3075155b-5430-4845-be57-5608726038bd", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "4048f9b0-2bea-40fe-85b3-1f6b2e78b08a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ade3163-2416-43fe-9181-293c8cebc6ce", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e24e668-5ef3-41c1-a2e0-8ceb061b5628", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ade3163-2416-43fe-9181-293c8cebc6ce"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EU/1/15/1026/001-002</span></p>", "ID": "61c31533-8b37-483b-8f0c-c4ef2ca91924", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">EU/1/15/1026/001-002</span>", "ID": "1529598e-008f-44a8-9750-5cff941b66ae", "Styles": "None", "Classes": "None", "Text": "EU/1/15/1026/001-002", "ParentId": "61c31533-8b37-483b-8f0c-c4ef2ca91924"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa818078-c419-4607-a195-088418cb0724", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1df16277-fb7e-42d9-80c6-d2cfaf093b80", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa818078-c419-4607-a195-088418cb0724"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>", "ID": "8ce52648-9bd8-430a-8a69-aa8d6331ddc2", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span>", "ID": "981353bf-7b0b-4755-9445-7ee0132491f8", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "8ce52648-9bd8-430a-8a69-aa8d6331ddc2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a581c4f-6a26-4251-a963-5d17d7b0bb58", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7518a664-76ee-4bd9-9460-439d2adeee9c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a581c4f-6a26-4251-a963-5d17d7b0bb58"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "992c682b-4187-44fb-a3ec-fa18151b2c72", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b0f59978-a6a6-498c-b2ae-1a3cfeca54e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "992c682b-4187-44fb-a3ec-fa18151b2c72"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF\nREVISION OF THE TEXT</span></p>", "ID": "be2dd2d5-be38-4c22-9575-9c0836835a7c", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF\nREVISION OF THE TEXT</span>", "ID": "ec64a9e5-1337-47e2-9773-debb3646e9b8", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "be2dd2d5-be38-4c22-9575-9c0836835a7c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4fe49ce1-0b02-463a-ab8b-3dbc131875bc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c8204d3-c20c-4e87-9727-444705976a09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4fe49ce1-0b02-463a-ab8b-3dbc131875bc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b9e3fd70-621a-4126-a6cc-d2b55eba0c20", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae3611db-c968-4781-8a4c-4b93a9c2edd7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9e3fd70-621a-4126-a6cc-d2b55eba0c20"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\nproduct is available on the website of the European Medicines Agency </span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>", "ID": "9f95b8b9-44c9-4329-bb06-fdd55e34f420", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Detailed information on this medicinal\nproduct is available on the website of the European Medicines Agency </span>", "ID": "8c5edbb7-e982-4215-8206-c9c6adec9303", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency ", "ParentId": "9f95b8b9-44c9-4329-bb06-fdd55e34f420"}, {"Element": "<span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span>", "ID": "66705614-3885-4d35-a7ae-dfba935e6683", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f95b8b9-44c9-4329-bb06-fdd55e34f420"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "4642e143-9525-42be-ba97-806a7c011861", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "66705614-3885-4d35-a7ae-dfba935e6683"}, {"Element": "<span class=\"MsoHyperlink\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span></b></span>", "ID": "0402f968-c4e3-4c1a-9eea-078a731b1a29", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span></b>", "ID": "931971de-aa23-41a0-8044-6b2401b29d03", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0402f968-c4e3-4c1a-9eea-078a731b1a29"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span>", "ID": "ea062a0f-0ebb-4cee-a3a9-a3596fdb8c1b", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "931971de-aa23-41a0-8044-6b2401b29d03"}, {"Element": "<br clear=\"all\" style=\"page-break-before:\nalways\"/>", "ID": "d2fd0f62-1d8a-4f41-a831-c7350c43b93c", "Styles": "page-break-before:\nalways", "Classes": "None", "Text": "", "ParentId": "ea062a0f-0ebb-4cee-a3a9-a3596fdb8c1b"}, {"Element": "<p class=\"EMEATitle\"><a name=\"_GoBack\"></a><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "491ee495-4001-4f74-ae77-f8c8ba4fa309", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<a name=\"_GoBack\"></a>", "ID": "7e5dbeb1-ebc4-49a3-8a65-f725fb6d5b07", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "491ee495-4001-4f74-ae77-f8c8ba4fa309"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "45819267-e15e-4c45-aa1c-cb75c2559526", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "491ee495-4001-4f74-ae77-f8c8ba4fa309"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "e7a42e86-2c99-44b5-aabe-b3265a5ef1b9", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "45819267-e15e-4c45-aa1c-cb75c2559526"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "f0a7befe-bbca-440d-918e-5f1e15e49b02", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "e7a42e86-2c99-44b5-aabe-b3265a5ef1b9"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "348f418f-3bd1-4cfb-9086-fb1ea843080f", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "707e32bb-9647-4978-a9cd-df626e1cfa74", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "348f418f-3bd1-4cfb-9086-fb1ea843080f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "80057dcb-eddc-46b6-84e6-47a44f3932be", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "707e32bb-9647-4978-a9cd-df626e1cfa74"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e344c62c-a86d-4561-bff9-59339aa0931f", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "80057dcb-eddc-46b6-84e6-47a44f3932be"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "e32e9b79-0f1e-4477-bc75-fc4acdb9b749", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "cebb0a77-1fec-4c7f-9413-80742b28db4d", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "e32e9b79-0f1e-4477-bc75-fc4acdb9b749"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "f32234f2-d2c1-4a55-9253-90cc26f15f2f", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "cebb0a77-1fec-4c7f-9413-80742b28db4d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b36c9063-da2c-4f43-aad4-0dc672994279", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "f32234f2-d2c1-4a55-9253-90cc26f15f2f"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "6d13e6f1-6729-4ad8-8707-e9162e4bb59d", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "708600a4-dd41-4e94-9569-06e683e34241", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "6d13e6f1-6729-4ad8-8707-e9162e4bb59d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "1ae3542d-11b3-4432-961a-4d5dc07285ea", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "708600a4-dd41-4e94-9569-06e683e34241"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "7bf6f915-b324-4caf-91c4-472ddcd72a6d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "1ae3542d-11b3-4432-961a-4d5dc07285ea"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "6f4803dc-2cab-4ec6-a4c8-653639c3b792", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "676f7f5a-3d9a-42fb-91c0-e83340f76573", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "6f4803dc-2cab-4ec6-a4c8-653639c3b792"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "041d5b9b-ac32-41a6-9bba-40177fa56326", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "676f7f5a-3d9a-42fb-91c0-e83340f76573"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c9977b68-616f-4817-824c-b2dfe17540a2", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "041d5b9b-ac32-41a6-9bba-40177fa56326"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "23184098-497c-4a8a-8bb3-965cde4e6004", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "0014d9da-c3c6-44e9-b81a-75832e97631e", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "23184098-497c-4a8a-8bb3-965cde4e6004"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "b6e90b5f-50eb-40c5-a8b6-0fb1f218684d", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "0014d9da-c3c6-44e9-b81a-75832e97631e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "91525921-4aa1-444f-a9e7-600aade32e82", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b6e90b5f-50eb-40c5-a8b6-0fb1f218684d"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "219c25a9-4c1f-404a-8a69-9baca25b3e8e", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "457193e1-bd8e-461c-94be-d8580d1eca51", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "219c25a9-4c1f-404a-8a69-9baca25b3e8e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "af257acd-3693-4843-99b5-e2bb8cf999e8", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "457193e1-bd8e-461c-94be-d8580d1eca51"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "abf7ea35-0361-495f-b75a-74c1be22c077", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "af257acd-3693-4843-99b5-e2bb8cf999e8"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "47b43af3-06ea-4f1b-b191-14ad88032a27", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "14c70fe4-a36b-426a-8b46-77654bda5c2c", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "47b43af3-06ea-4f1b-b191-14ad88032a27"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "14d6c216-c445-448b-a54e-18219541c21a", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "14c70fe4-a36b-426a-8b46-77654bda5c2c"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "abd8b0eb-503a-4ba1-9db0-8fe21faf6075", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "14d6c216-c445-448b-a54e-18219541c21a"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "b2f6e54f-8531-450b-9ea7-035fc20905c9", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "435fada8-0f00-41b2-9293-7ad25df50e3c", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "b2f6e54f-8531-450b-9ea7-035fc20905c9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "2601b04d-4a91-4116-a021-ffb3fa0cea95", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "435fada8-0f00-41b2-9293-7ad25df50e3c"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "6fdcac4a-f3f6-4eec-970a-006b9d125c6d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2601b04d-4a91-4116-a021-ffb3fa0cea95"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "3fe5d677-72a0-4c2c-a9ab-8efcbe7ed739", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "3842e195-4637-47da-b5a0-c2151ea52505", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "3fe5d677-72a0-4c2c-a9ab-8efcbe7ed739"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "699e8718-e959-4967-88d2-c52f2efe2a76", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "3842e195-4637-47da-b5a0-c2151ea52505"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "8557ed45-34c7-451f-81ef-48bd13f8dc1d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "699e8718-e959-4967-88d2-c52f2efe2a76"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "369c35d0-6d92-4fcf-88ac-0e01daa9a195", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "1b12ded6-bec4-4936-88a0-9c8a43abe39a", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "369c35d0-6d92-4fcf-88ac-0e01daa9a195"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "5ae31ac2-1bcb-43a4-bc72-d7d34af0a132", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "1b12ded6-bec4-4936-88a0-9c8a43abe39a"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "9236c3db-9440-4009-80dc-b34ec0c37fae", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "5ae31ac2-1bcb-43a4-bc72-d7d34af0a132"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "5a767b26-6187-4bea-9ebf-2450e4d5c0b2", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "1503cfab-a296-41d1-8072-29f9a9bb2657", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "5a767b26-6187-4bea-9ebf-2450e4d5c0b2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "3ea96516-2cf7-40a5-81f3-15149e5cfe83", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "1503cfab-a296-41d1-8072-29f9a9bb2657"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "6d6ab5c5-58af-4ad4-a4e2-8f0e7f1f23aa", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "3ea96516-2cf7-40a5-81f3-15149e5cfe83"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "e99f4a00-3b6b-435c-a03f-a325a316d6c5", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "36a8edd8-f2dd-4524-9676-0083f822c22b", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "e99f4a00-3b6b-435c-a03f-a325a316d6c5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "0b65e8a9-ac4b-480f-8645-0693ce2ae912", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "36a8edd8-f2dd-4524-9676-0083f822c22b"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "dade1848-d453-43a0-9388-ce882544a4a3", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "0b65e8a9-ac4b-480f-8645-0693ce2ae912"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "46c43e9b-36c8-4364-8a18-81eaeb617f6e", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "8102e5fe-552b-4e38-9d99-91d0a269ca2f", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "46c43e9b-36c8-4364-8a18-81eaeb617f6e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "62037d3f-c2f5-47ae-a677-a3f4c57dda9c", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "8102e5fe-552b-4e38-9d99-91d0a269ca2f"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "8a62de33-ea03-4928-b89e-3a8cbfcc63ef", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "62037d3f-c2f5-47ae-a677-a3f4c57dda9c"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "eb80e538-6821-46a0-b311-3910a9c7fcc5", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "77bc4cb0-b1e0-4c0a-a135-d10d7c16fc9e", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "eb80e538-6821-46a0-b311-3910a9c7fcc5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "be8ac46c-5ed4-4468-85f1-42021fc6cb69", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "77bc4cb0-b1e0-4c0a-a135-d10d7c16fc9e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "ade2b6e9-e909-443f-b898-fd7d0653c2f8", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "be8ac46c-5ed4-4468-85f1-42021fc6cb69"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "01f8a470-912f-4583-bc61-28d431a7e618", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "f139f40a-ce7a-48fa-a4c0-39a6c1776e4c", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "01f8a470-912f-4583-bc61-28d431a7e618"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "c90a41cc-acb1-4894-a057-777b7efb9c90", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "f139f40a-ce7a-48fa-a4c0-39a6c1776e4c"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "025f2625-50ae-4725-b5b5-024774f71294", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "c90a41cc-acb1-4894-a057-777b7efb9c90"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "080e76c2-22f8-4a44-be24-d10d788907e7", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "888b1d5f-bc18-4895-b5e0-bd8c6a673e0d", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "080e76c2-22f8-4a44-be24-d10d788907e7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "05f9b867-fb77-409b-a048-6d720db0cf93", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "888b1d5f-bc18-4895-b5e0-bd8c6a673e0d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "ef805244-64d6-4c16-af39-efeaa8b2a5a6", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "05f9b867-fb77-409b-a048-6d720db0cf93"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "32b77c1c-0da1-49d7-bf14-a3d65ad04268", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "bf825ee2-5ece-47a0-bae9-0fed9dce71a2", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "32b77c1c-0da1-49d7-bf14-a3d65ad04268"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "4594a2dd-5859-411c-829c-9efbe784c7ea", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "bf825ee2-5ece-47a0-bae9-0fed9dce71a2"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "a22eaea7-ed4a-4885-8be2-32cbe2ccac6d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "4594a2dd-5859-411c-829c-9efbe784c7ea"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "4d7bf10c-2449-4fa7-9872-f50f06b59374", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "0120d7fd-56ca-4bef-9614-69c5a3f26e32", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "4d7bf10c-2449-4fa7-9872-f50f06b59374"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "16aa1eb2-c0be-47e7-aadd-e3fad61a555b", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "0120d7fd-56ca-4bef-9614-69c5a3f26e32"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b4d454df-9b50-4779-8020-4d012674fb52", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "16aa1eb2-c0be-47e7-aadd-e3fad61a555b"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "34d01f2b-2106-4b70-949a-3506bf142165", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "8fda47a3-1d86-4542-9ad6-bd55a4e07155", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "34d01f2b-2106-4b70-949a-3506bf142165"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "6f55817b-0f6a-46ef-be4a-7d06d76dc9f5", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "8fda47a3-1d86-4542-9ad6-bd55a4e07155"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "2f145027-3326-4423-b799-3a8d4bc2c764", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6f55817b-0f6a-46ef-be4a-7d06d76dc9f5"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "92dfa9c5-e9cf-4b65-98a3-317bbedbbc09", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "d12ce8c1-1a43-4637-8fbc-b38f7eeb8a64", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "92dfa9c5-e9cf-4b65-98a3-317bbedbbc09"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "85af2a1d-fb33-4cac-bb79-2a6e47bd0eb3", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "d12ce8c1-1a43-4637-8fbc-b38f7eeb8a64"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e9ebd633-ea18-48d0-b237-664fe04b5b81", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "85af2a1d-fb33-4cac-bb79-2a6e47bd0eb3"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "402f8c39-596c-4e6b-8894-2bdcb44ec6a7", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "5b51ad1c-300e-4fc2-9f84-96f847396ab9", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "402f8c39-596c-4e6b-8894-2bdcb44ec6a7"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "285642ee-7f46-4e77-b994-a09e35f8e8af", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "5b51ad1c-300e-4fc2-9f84-96f847396ab9"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "232df10c-191a-41a8-96a5-6737a2280d2e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "285642ee-7f46-4e77-b994-a09e35f8e8af"}, {"Element": "<p class=\"EMEATitle\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "72316e76-5c59-4713-bd4e-87de7be0b425", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "8a4352a8-8942-4541-869b-e26645786f00", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "72316e76-5c59-4713-bd4e-87de7be0b425"}, {"Element": "<span lang=\"EN-GB\" style=\"color:windowtext\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "cc7846c3-f11f-4217-844d-12b10a2150ef", "Styles": "color:windowtext", "Classes": "None", "Text": "", "ParentId": "8a4352a8-8942-4541-869b-e26645786f00"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "0b0aaaa1-c6e8-4a48-891f-d84d7fe295b5", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "cc7846c3-f11f-4217-844d-12b10a2150ef"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX II</span></p>", "ID": "b1087a5c-617b-4ee3-92d0-12425d01f36a", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">ANNEX II</span>", "ID": "225a4b94-44c1-4243-acf6-4c4a7128073f", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "b1087a5c-617b-4ee3-92d0-12425d01f36a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8a1d97d8-c42f-4f05-933c-d4b382ffed6f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1681da5e-c7b9-4665-a00d-2cf1ad24715e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8a1d97d8-c42f-4f05-933c-d4b382ffed6f"}, {"Element": "<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span></p>", "ID": "904d2efa-ca24-430c-93ed-6e2908cc6176", "Styles": "margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "31e4e26c-8b8b-4221-8e2a-d901027e8d08", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "904d2efa-ca24-430c-93ed-6e2908cc6176"}, {"Element": "<span lang=\"EN-GB\">MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span>", "ID": "3107d1ad-2747-4d23-89b8-87925804b389", "Styles": "None", "Classes": "None", "Text": "MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE", "ParentId": "904d2efa-ca24-430c-93ed-6e2908cc6176"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ca656afb-3509-49ad-94b1-32259c501bca", "Styles": "margin-left:85.05pt;text-indent:-35.4pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1dff23e7-d9bf-46ee-9d0d-3c7da9c97a2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ca656afb-3509-49ad-94b1-32259c501bca"}, {"Element": "<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>", "ID": "b1076bbf-7c29-44ad-a82e-d1503062220f", "Styles": "margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span>", "ID": "f973fbe3-5f4b-4ed6-b2bc-93f88d4c7536", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "b1076bbf-7c29-44ad-a82e-d1503062220f"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37195913-7a7d-416d-900b-5ebe74b7bbee", "Styles": "margin-left:85.05pt;text-indent:-35.4pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed9b9304-e57d-45c2-919b-7d94b91ab8d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37195913-7a7d-416d-900b-5ebe74b7bbee"}, {"Element": "<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>", "ID": "0af1c66c-b7e8-4f11-8c6b-95874dfd4145", "Styles": "margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span>", "ID": "95f0e84d-8106-4e15-820f-49832cbff641", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "0af1c66c-b7e8-4f11-8c6b-95874dfd4145"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4db8625c-064a-40de-b1c1-c4c4eb411cc4", "Styles": "margin-left:85.05pt;text-indent:-35.4pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a97d4a45-10dd-476a-8ef2-2b064ddf55b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4db8625c-064a-40de-b1c1-c4c4eb411cc4"}, {"Element": "<p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span></p>", "ID": "61cf8bf5-0c7d-4627-b31b-89f32d8e2721", "Styles": "margin-left:85.05pt;text-align:left;\ntext-indent:-35.4pt", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span>", "ID": "1a49fe38-8731-4e5d-8669-c70fe123fd13", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "61cf8bf5-0c7d-4627-b31b-89f32d8e2721"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:85.05pt;text-indent:-35.4pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "546951bc-8729-4bd6-ae4f-5fe936adc589", "Styles": "margin-left:85.05pt;text-indent:-35.4pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68c13ad7-a7b5-4af7-9418-cbeb68f84daa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "546951bc-8729-4bd6-ae4f-5fe936adc589"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "9071a9bb-cf5f-4c9e-85c9-a6ad3050f992", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "eb58dc42-52eb-402a-9c00-38235ca93487", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase", "Classes": "None", "Text": " ", "ParentId": "9071a9bb-cf5f-4c9e-85c9-a6ad3050f992"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "667acb26-1183-411f-a21f-5e04f8ef6b23", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "eb58dc42-52eb-402a-9c00-38235ca93487"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER\n</span><span lang=\"EN-GB\">OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span></p>", "ID": "6ee8f0d8-6fea-441c-9d5a-a821ce718519", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER\n</span>", "ID": "5f4a829e-24ec-42f6-916e-615fc81e2363", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER ", "ParentId": "6ee8f0d8-6fea-441c-9d5a-a821ce718519"}, {"Element": "<span lang=\"EN-GB\">OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER\nRESPONSIBLE FOR BATCH RELEASE</span>", "ID": "bb0f096b-56a2-403f-aa0f-fee8bd2ab719", "Styles": "None", "Classes": "None", "Text": "OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE", "ParentId": "6ee8f0d8-6fea-441c-9d5a-a821ce718519"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "69b15bd7-f3e1-42f2-b6b8-a17160d93c6d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5777bb1a-8195-4027-8e41-78bae0c848bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "69b15bd7-f3e1-42f2-b6b8-a17160d93c6d"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Name and address of the manufacturer of\nthe biological active substance</span></u></p>", "ID": "c02bebe3-b9f0-479e-9252-b25167c00066", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer of\nthe biological active substance</span></u>", "ID": "831b0084-6cf1-4cd8-a4c1-da357dfe6b3d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c02bebe3-b9f0-479e-9252-b25167c00066"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer of\nthe biological active substance</span>", "ID": "6339e0af-2904-487b-946f-6737ec8219aa", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer of the biological active substance", "ParentId": "831b0084-6cf1-4cd8-a4c1-da357dfe6b3d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c1e4020f-15c7-49c5-a02a-ec3cbf2b79cc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73382587-581d-4fc1-b54a-1f739cabdc71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1e4020f-15c7-49c5-a02a-ec3cbf2b79cc"}, {"Element": "<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lonza\nBiologics, Inc.</span></p>", "ID": "5207fce9-2d11-4b97-adb1-d1f812b2e366", "Styles": "page-break-after:avoid", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Lonza\nBiologics, Inc.</span>", "ID": "aa5ebd78-5308-41b6-abc5-0425f2587ad2", "Styles": "None", "Classes": "None", "Text": "Lonza Biologics, Inc.", "ParentId": "5207fce9-2d11-4b97-adb1-d1f812b2e366"}, {"Element": "<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">101\nInternational Drive</span></p>", "ID": "659bb63a-0033-4008-b219-239f59460536", "Styles": "page-break-after:avoid", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">101\nInternational Drive</span>", "ID": "3de7dc26-6176-4215-bcce-bfda881a6917", "Styles": "None", "Classes": "None", "Text": "101 International Drive", "ParentId": "659bb63a-0033-4008-b219-239f59460536"}, {"Element": "<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Portsmouth,\nNew Hampshire</span></p>", "ID": "6ca74e3c-4057-426f-a166-60d9c8ac0100", "Styles": "page-break-after:avoid", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Portsmouth,\nNew Hampshire</span>", "ID": "cf3b8b59-70a0-481c-8f4a-93b5a95c81c5", "Styles": "None", "Classes": "None", "Text": "Portsmouth, New Hampshire", "ParentId": "6ca74e3c-4057-426f-a166-60d9c8ac0100"}, {"Element": "<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">03801</span></p>", "ID": "9353a808-5b28-4abf-9c52-1eaf636d53c0", "Styles": "page-break-after:avoid", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">03801</span>", "ID": "31869bff-8270-4b9e-ae5c-951ac0f378f3", "Styles": "None", "Classes": "None", "Text": "03801", "ParentId": "9353a808-5b28-4abf-9c52-1eaf636d53c0"}, {"Element": "<p class=\"EMEAAddress\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">USA</span></p>", "ID": "37a47eca-75de-420c-8251-ab80878731ed", "Styles": "page-break-after:avoid", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">USA</span>", "ID": "b6ab4b5b-07c3-4480-be55-d3877e0dfb61", "Styles": "None", "Classes": "None", "Text": "USA", "ParentId": "37a47eca-75de-420c-8251-ab80878731ed"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "92f46a3d-f06a-440c-9773-1b653bd9af65", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de6011db-9cf7-4031-9787-e061d3b44aef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92f46a3d-f06a-440c-9773-1b653bd9af65"}, {"Element": "<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u></p>", "ID": "32b6304b-eca5-4e8a-bcdc-a9c535cba1c7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u>", "ID": "b5efb8f8-1e8d-4fc7-9948-0ac2b8a083e6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32b6304b-eca5-4e8a-bcdc-a9c535cba1c7"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span>", "ID": "592974e1-35c8-4530-a7b5-9b784d3babee", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer responsible for batch release", "ParentId": "b5efb8f8-1e8d-4fc7-9948-0ac2b8a083e6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5fe060a9-7122-41c5-9cee-328912e68444", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cef88222-b4fd-4bbd-8124-63423e29c8d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5fe060a9-7122-41c5-9cee-328912e68444"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span></p>", "ID": "6c3fe51e-4dac-4acf-9602-36720867b257", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span>", "ID": "16e7632a-3b29-48e8-bcae-f1d14f35cbcb", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb S.r.l.", "ParentId": "6c3fe51e-4dac-4acf-9602-36720867b257"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Loc. Fontana del Ceraso</span></p>", "ID": "6f9d9e90-022c-4177-8f3c-0baafa9f1aa8", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Loc. Fontana del Ceraso</span>", "ID": "ed8fcacd-61e8-4848-88be-df5a97afa45c", "Styles": "None", "Classes": "None", "Text": "Loc. Fontana del Ceraso", "ParentId": "6f9d9e90-022c-4177-8f3c-0baafa9f1aa8"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">03012\u00a0Anagni (FR)</span></p>", "ID": "7ba6e881-8cc2-453f-8166-1817d22aa4e1", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">03012\u00a0Anagni (FR)</span>", "ID": "7315ad05-4155-4c4d-b7bb-05703bc4caef", "Styles": "None", "Classes": "None", "Text": "03012\u00a0Anagni (FR)", "ParentId": "7ba6e881-8cc2-453f-8166-1817d22aa4e1"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Italy</span></p>", "ID": "7868d543-1f8d-4d2f-ad0b-db5681f60e6e", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Italy</span>", "ID": "1eb7a92f-1554-40fa-a7bb-c6f9c28fa3a0", "Styles": "None", "Classes": "None", "Text": "Italy", "ParentId": "7868d543-1f8d-4d2f-ad0b-db5681f60e6e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f39795e3-25b0-48d1-9ddc-adf93373d954", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87a84330-e30f-46ee-bbfe-ac4d1aefa20f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f39795e3-25b0-48d1-9ddc-adf93373d954"}, {"Element": "<p class=\"EMEAHeading1\"><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">B.</span></a><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE </span></p>", "ID": "2456c22f-b8f1-4391-a90f-81dbbae281ce", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<a name=\"OLE_LINK2\"><span lang=\"EN-GB\">B.</span></a>", "ID": "cb7cec93-ec73-4370-9779-da33b0b3e655", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2456c22f-b8f1-4391-a90f-81dbbae281ce"}, {"Element": "<span lang=\"EN-GB\">B.</span>", "ID": "c9ea1cff-9d7a-4d8f-b11b-eaa6f257791e", "Styles": "None", "Classes": "None", "Text": "B.", "ParentId": "cb7cec93-ec73-4370-9779-da33b0b3e655"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING\nSUPPLY AND USE </span>", "ID": "7cccc152-cea7-4e22-8e7e-74c7afac05e2", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE ", "ParentId": "2456c22f-b8f1-4391-a90f-81dbbae281ce"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bab2bc11-c171-4aa2-9fd2-3d0b41b84e88", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7245c193-257d-44ec-b5bb-c1d55c9064a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bab2bc11-c171-4aa2-9fd2-3d0b41b84e88"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span></p>", "ID": "112f3ec4-a80a-4cf0-ab9d-8fb33d433743", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\n4.2).</span>", "ID": "91dfc533-cd9a-4b1b-b3f5-6a914c842a07", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).", "ParentId": "112f3ec4-a80a-4cf0-ab9d-8fb33d433743"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53565276-a270-4bfb-8957-f4dff7ee9c7b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b389d710-6e14-4424-bb01-0c937b33a5a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53565276-a270-4bfb-8957-f4dff7ee9c7b"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>", "ID": "51b31b27-b7ec-4eb6-b3c4-9a363a97e9c2", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span>", "ID": "ba81f5ea-735b-4be5-89af-90f568ead453", "Styles": "None", "Classes": "None", "Text": "C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "51b31b27-b7ec-4eb6-b3c4-9a363a97e9c2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d84a1334-5847-4cef-bc42-326293893821", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ec82264-9328-4f1c-957e-8c27a73e1c6f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d84a1334-5847-4cef-bc42-326293893821"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic safety update reports</span></b></p>", "ID": "870141b2-a410-4040-9dac-562df856699c", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f6dd5829-728d-4a7b-beb2-2b1324b4956d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "870141b2-a410-4040-9dac-562df856699c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "bdeaf71e-5507-4152-ae4d-d91a98eaac89", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f6dd5829-728d-4a7b-beb2-2b1324b4956d"}, {"Element": "<b><span lang=\"EN-GB\">Periodic safety update reports</span></b>", "ID": "d66c9e0d-0887-437e-b03b-5c00c5222d2f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "870141b2-a410-4040-9dac-562df856699c"}, {"Element": "<span lang=\"EN-GB\">Periodic safety update reports</span>", "ID": "8ede34ad-b5de-4e00-86b8-a8bc4a991933", "Styles": "None", "Classes": "None", "Text": "Periodic safety update reports", "ParentId": "d66c9e0d-0887-437e-b03b-5c00c5222d2f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4825758-18b1-46ff-a958-b914eec154d9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa3312fa-51d2-4502-9ea0-36d6e73f57c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4825758-18b1-46ff-a958-b914eec154d9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The marketing authorisation holder shall\nsubmit the first periodic safety update report for this product within 6 months\nfollowing authorisation. Subsequently, the marketing authorisation holder shall\nsubmit periodic safety update reports for this product in accordance with the\nrequirements set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and published on the European\nmedicines web-portal.</span></p>", "ID": "aa7392c0-8b35-4e32-9722-117c760c2d14", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The marketing authorisation holder shall\nsubmit the first periodic safety update report for this product within 6 months\nfollowing authorisation. Subsequently, the marketing authorisation holder shall\nsubmit periodic safety update reports for this product in accordance with the\nrequirements set out in the list of Union reference dates (EURD list) provided\nfor under Article 107c(7) of Directive 2001/83/EC and published on the European\nmedicines web-portal.</span>", "ID": "1b35697a-f46b-4e3b-a321-6d5e4c776dc3", "Styles": "None", "Classes": "None", "Text": "The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.", "ParentId": "aa7392c0-8b35-4e32-9722-117c760c2d14"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66993ebd-2920-4683-ab2d-078814833512", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36d2c1b7-a4d7-44f3-899c-1a9648720d2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66993ebd-2920-4683-ab2d-078814833512"}, {"Element": "<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span></p>", "ID": "42865ae7-da6c-4971-bc59-bdc148d160d9", "Styles": "None", "Classes": "['EMEAHeading1']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span>", "ID": "f44f924b-4051-4cb4-9f12-246d7f9cd10d", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0 ", "ParentId": "42865ae7-da6c-4971-bc59-bdc148d160d9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1d0829a-0e29-41ab-9557-139f4f511187", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bfabcd60-e5a1-4e60-ad9c-6defaf313ea4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1d0829a-0e29-41ab-9557-139f4f511187"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>", "ID": "497cabd1-1023-4d0b-ab41-a998d7963f51", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c01c92ed-84a6-4232-a6e9-b2725182080d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "497cabd1-1023-4d0b-ab41-a998d7963f51"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "29ba6c59-3281-4969-839d-121f132708de", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c01c92ed-84a6-4232-a6e9-b2725182080d"}, {"Element": "<b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b>", "ID": "e52cfbf3-aae6-4054-8e02-b96e6af4c180", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "497cabd1-1023-4d0b-ab41-a998d7963f51"}, {"Element": "<span lang=\"EN-GB\">Risk Management Plan (RMP)</span>", "ID": "44d368be-2830-4f69-8578-df2af1ce1bb8", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "e52cfbf3-aae6-4054-8e02-b96e6af4c180"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "148df003-2b4a-4d9b-80c6-16d11352f7d3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18517fd9-1e9d-467c-9585-a0e0f2cc42f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "148df003-2b4a-4d9b-80c6-16d11352f7d3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span></p>", "ID": "7dbc0f8c-4691-48ce-965f-3bd8bd4ef9ed", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The MAH shall perform the required\npharmacovigilance activities and interventions detailed in the agreed RMP\npresented in Module 1.8.2 of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</span>", "ID": "cd1fecc3-b4c1-4051-a836-7663cb02e220", "Styles": "None", "Classes": "None", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.", "ParentId": "7dbc0f8c-4691-48ce-965f-3bd8bd4ef9ed"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "74630656-46a6-4058-9e76-e82e9c5b70a1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3d852f9-b640-40b8-a392-db2f0dbc84fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "74630656-46a6-4058-9e76-e82e9c5b70a1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>", "ID": "4391f67b-6ccf-4528-89ee-4e56835ef0a3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">An updated RMP should be submitted:</span>", "ID": "74454cd8-6367-421c-8cf4-e7f8cb1c5220", "Styles": "None", "Classes": "None", "Text": "An updated RMP should be submitted:", "ParentId": "4391f67b-6ccf-4528-89ee-4e56835ef0a3"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>", "ID": "3c042bc9-9660-4007-afe1-1faa4ba9b82e", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2063e535-bebb-462a-954e-bb472ccb0a0f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3c042bc9-9660-4007-afe1-1faa4ba9b82e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "444af6a4-9eb6-4023-b67e-fb2e59d82f18", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2063e535-bebb-462a-954e-bb472ccb0a0f"}, {"Element": "<span lang=\"EN-GB\">At the request of the European Medicines Agency;</span>", "ID": "2b60920d-694c-43c2-85c5-105cc48cbb2c", "Styles": "None", "Classes": "None", "Text": "At the request of the European Medicines Agency;", "ParentId": "3c042bc9-9660-4007-afe1-1faa4ba9b82e"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>", "ID": "39702f69-8a91-417c-ada9-efaefda5f01a", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7891b39e-9f71-451c-b0df-267947e791a8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "39702f69-8a91-417c-ada9-efaefda5f01a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0a14576e-fe72-476d-b44c-ed38534ca6ac", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7891b39e-9f71-451c-b0df-267947e791a8"}, {"Element": "<span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span>", "ID": "a4e09958-d38d-46ab-8cb5-6c699719d7c3", "Styles": "None", "Classes": "None", "Text": "Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "39702f69-8a91-417c-ada9-efaefda5f01a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81e5fada-45ec-4854-b349-e72ec48dcd6b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "295917d3-c5b6-4531-a30a-a4c146f4de26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81e5fada-45ec-4854-b349-e72ec48dcd6b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If the dates for submission of a PSUR\nand the update of a RMP coincide, they can be submitted at the same time.</span></p>", "ID": "af0f962f-da58-45ab-adb7-910905239e9b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If the dates for submission of a PSUR\nand the update of a RMP coincide, they can be submitted at the same time.</span>", "ID": "68156072-279b-4736-924e-887158093aab", "Styles": "None", "Classes": "None", "Text": "If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.", "ParentId": "af0f962f-da58-45ab-adb7-910905239e9b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "885cc910-e151-4af4-8468-cf30724c9a9b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ce8f9fb-994e-47fe-ba54-c8174f72a11b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "885cc910-e151-4af4-8468-cf30724c9a9b"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Additional risk minimisation measures </span></b></p>", "ID": "a6c84d9b-9f20-48b2-b864-3e5f26030ae2", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e59c6516-20e0-4253-81eb-3cd4a12b310e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a6c84d9b-9f20-48b2-b864-3e5f26030ae2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9cc67f64-54c6-4870-b1bc-ccc5a2f1f03c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e59c6516-20e0-4253-81eb-3cd4a12b310e"}, {"Element": "<b><span lang=\"EN-GB\">Additional risk minimisation measures </span></b>", "ID": "6939111e-4f71-4163-8129-270eb7c791c6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6c84d9b-9f20-48b2-b864-3e5f26030ae2"}, {"Element": "<span lang=\"EN-GB\">Additional risk minimisation measures </span>", "ID": "705b870e-6f67-430b-ad6e-d374c37ded08", "Styles": "None", "Classes": "None", "Text": "Additional risk minimisation measures ", "ParentId": "6939111e-4f71-4163-8129-270eb7c791c6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e05a9644-c5b9-4a01-aeb8-6d05d1e5a1ff", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae8a5841-bd50-47cb-a3c9-911312fe2169", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e05a9644-c5b9-4a01-aeb8-6d05d1e5a1ff"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Prior to launch of Nivolumab\u00a0BMS in\neach Member State the Marketing Authorisation Holder (MAH) must agree about the\ncontent and format of the educational programme, including communication media,\ndistribution modalities, and any other aspects of the programme, with the\nNational Competent Authority. </span></p>", "ID": "59960a9d-8cc6-46cd-a045-f2003e82afe7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Prior to launch of Nivolumab\u00a0BMS in\neach Member State the Marketing Authorisation Holder (MAH) must agree about the\ncontent and format of the educational programme, including communication media,\ndistribution modalities, and any other aspects of the programme, with the\nNational Competent Authority. </span>", "ID": "d29e34c7-1e77-4b7d-b83c-b3790d666c06", "Styles": "None", "Classes": "None", "Text": "Prior to launch of Nivolumab\u00a0BMS in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. ", "ParentId": "59960a9d-8cc6-46cd-a045-f2003e82afe7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The educational programme is aimed at\nincreasing the awareness about the potential immune mediated adverse events\nassociated with Nivolumab\u00a0BMS use, how to manage them and to enhance the awareness\nof patients or their caregivers on the signs and symptoms relevant to the early\nthose adverse events.</span></p>", "ID": "81035f4b-2b37-4db5-80a3-f16d173e62fc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The educational programme is aimed at\nincreasing the awareness about the potential immune mediated adverse events\nassociated with Nivolumab\u00a0BMS use, how to manage them and to enhance the awareness\nof patients or their caregivers on the signs and symptoms relevant to the early\nthose adverse events.</span>", "ID": "74668d9c-4e12-4c57-aab1-2a039163316c", "Styles": "None", "Classes": "None", "Text": "The educational programme is aimed at increasing the awareness about the potential immune mediated adverse events associated with Nivolumab\u00a0BMS use, how to manage them and to enhance the awareness of patients or their caregivers on the signs and symptoms relevant to the early those adverse events.", "ParentId": "81035f4b-2b37-4db5-80a3-f16d173e62fc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The MAH shall ensure that in each Member\nState where Nivolumab\u00a0BMS is marketed, all healthcare professionals and\npatients/carers who are expected to prescribe and use Nivolumab\u00a0BMS have\naccess to/are provided with the following educational package:</span></p>", "ID": "4df77a30-bc00-4e12-a1ae-a2fcf033f02a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The MAH shall ensure that in each Member\nState where Nivolumab\u00a0BMS is marketed, all healthcare professionals and\npatients/carers who are expected to prescribe and use Nivolumab\u00a0BMS have\naccess to/are provided with the following educational package:</span>", "ID": "5d476032-b04a-45b6-a0c9-532bf22bb1c4", "Styles": "None", "Classes": "None", "Text": "The MAH shall ensure that in each Member State where Nivolumab\u00a0BMS is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Nivolumab\u00a0BMS have access to/are provided with the following educational package:", "ParentId": "4df77a30-bc00-4e12-a1ae-a2fcf033f02a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "021c68ed-5fe4-4582-a1c8-e6d9eaa36ee9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63610ad4-8728-4d7e-962d-a91839b1f139", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "021c68ed-5fe4-4582-a1c8-e6d9eaa36ee9"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Physician educational material</span></p>", "ID": "82dc2341-2d18-47e4-8cb0-e2460f51e107", "Styles": "margin-left:35.45pt;text-indent:-21.25pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "028d53a5-706c-4f3c-ab0f-a0e0701e4a94", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "82dc2341-2d18-47e4-8cb0-e2460f51e107"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "74500b1e-21fd-4ddd-8899-a7b1d9dd326b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "028d53a5-706c-4f3c-ab0f-a0e0701e4a94"}, {"Element": "<span lang=\"EN-GB\">Physician educational material</span>", "ID": "16e42558-765f-4320-909a-2e159d4a4282", "Styles": "None", "Classes": "None", "Text": "Physician educational material", "ParentId": "82dc2341-2d18-47e4-8cb0-e2460f51e107"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patient alert card</span></p>", "ID": "c0e7c811-4478-4acd-aed9-e58d34b64fbb", "Styles": "margin-left:35.45pt;text-indent:-21.25pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7021d475-e0c6-4bab-bcf9-68bb8c802439", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c0e7c811-4478-4acd-aed9-e58d34b64fbb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "03a97b35-2254-4b2d-aa66-93e3c31aa745", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7021d475-e0c6-4bab-bcf9-68bb8c802439"}, {"Element": "<span lang=\"EN-GB\">Patient alert card</span>", "ID": "5c1efa2f-8aa6-47c8-9647-49fc8767d4a7", "Styles": "None", "Classes": "None", "Text": "Patient alert card", "ParentId": "c0e7c811-4478-4acd-aed9-e58d34b64fbb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "040a4a44-da42-42a7-b038-3f4888e629a2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d5252d41-e3d1-4833-82c2-2381f8bbdcda", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "040a4a44-da42-42a7-b038-3f4888e629a2"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">The physician educational material</span></b><span lang=\"EN-GB\"> should contain:</span></p>", "ID": "14642088-992a-45ae-be9e-24b62970106f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">The physician educational material</span></b>", "ID": "2cc1a872-a13e-4296-8368-3266f5dc2f2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "14642088-992a-45ae-be9e-24b62970106f"}, {"Element": "<span lang=\"EN-GB\">The physician educational material</span>", "ID": "a456510e-2313-4887-a2f2-a6d7483959a1", "Styles": "None", "Classes": "None", "Text": "The physician educational material", "ParentId": "2cc1a872-a13e-4296-8368-3266f5dc2f2a"}, {"Element": "<span lang=\"EN-GB\"> should contain:</span>", "ID": "ad47cf1e-8d2f-42d5-ae9d-9cc4814886b7", "Styles": "None", "Classes": "None", "Text": " should contain:", "ParentId": "14642088-992a-45ae-be9e-24b62970106f"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The Summary of Product Characteristics</span></p>", "ID": "02a88780-ec73-4f2c-bbb3-75818393446d", "Styles": "margin-left:35.45pt;text-indent:-21.25pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "47d39d58-3ca7-4999-8ab8-e6bedbba796f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "02a88780-ec73-4f2c-bbb3-75818393446d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c6c1c7d8-96a1-4886-b087-a3b984c0330d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "47d39d58-3ca7-4999-8ab8-e6bedbba796f"}, {"Element": "<span lang=\"EN-GB\">The Summary of Product Characteristics</span>", "ID": "96e08884-9b59-43ef-b1f4-ab1dc0a95180", "Styles": "None", "Classes": "None", "Text": "The Summary of Product Characteristics", "ParentId": "02a88780-ec73-4f2c-bbb3-75818393446d"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:35.45pt;text-indent:-21.25pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Adverse Reaction Management Guide</span></p>", "ID": "225d9c30-066c-4aad-a8d3-e9051b3b41a8", "Styles": "margin-left:35.45pt;text-indent:-21.25pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f1fdbc26-5c4b-4dec-9137-3e2fd3bf1ec5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "225d9c30-066c-4aad-a8d3-e9051b3b41a8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6a276e2d-4141-4fe6-bd1d-9fee1dcc3d29", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f1fdbc26-5c4b-4dec-9137-3e2fd3bf1ec5"}, {"Element": "<span lang=\"EN-GB\">Adverse Reaction Management Guide</span>", "ID": "ea3725bf-631f-4481-a7e4-9d72ee1ae81e", "Styles": "None", "Classes": "None", "Text": "Adverse Reaction Management Guide", "ParentId": "225d9c30-066c-4aad-a8d3-e9051b3b41a8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d4f01bac-61af-469c-b522-e16193bdc465", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d5e1818-984b-4d0b-a2bb-a5a7a2d46a5a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d4f01bac-61af-469c-b522-e16193bdc465"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The </span><span lang=\"EN-GB\">Adverse\nReaction Management Guide shall contain the following key elements:</span></p>", "ID": "cab026db-5506-4e2f-a313-482d9ae18156", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The </span>", "ID": "ba10d7d7-8d77-417b-b922-8ea66f58446f", "Styles": "None", "Classes": "None", "Text": "The ", "ParentId": "cab026db-5506-4e2f-a313-482d9ae18156"}, {"Element": "<span lang=\"EN-GB\">Adverse\nReaction Management Guide shall contain the following key elements:</span>", "ID": "3b7cb68d-7d4b-4b15-86ab-4a21322cf339", "Styles": "None", "Classes": "None", "Text": "Adverse Reaction Management Guide shall contain the following key elements:", "ParentId": "cab026db-5506-4e2f-a313-482d9ae18156"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:#1D1B11\">\u00a0</span></p>", "ID": "3c893c5e-a609-486f-bdd4-f40e8101ad37", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:#1D1B11\">\u00a0</span>", "ID": "77527fc6-c75b-4fb6-b4ab-32cc0ed30ce5", "Styles": "color:#1D1B11", "Classes": "None", "Text": "\u00a0", "ParentId": "3c893c5e-a609-486f-bdd4-f40e8101ad37"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Relevant information (e.g. seriousness,\nseverity, frequency, time to onset, reversibility of the AE as applicable) for\nthe following safety concerns:</span></p>", "ID": "e38ef82d-2550-44e4-aad6-7afd0ac7c056", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "263fa837-a896-4c4e-821f-290c686eac9f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e38ef82d-2550-44e4-aad6-7afd0ac7c056"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "518af9eb-ad8f-4f27-8825-b18920251ae2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "263fa837-a896-4c4e-821f-290c686eac9f"}, {"Element": "<span lang=\"EN-GB\">Relevant information (e.g. seriousness,\nseverity, frequency, time to onset, reversibility of the AE as applicable) for\nthe following safety concerns:</span>", "ID": "1fa32e78-af04-40f0-9c4b-65766940c4cc", "Styles": "None", "Classes": "None", "Text": "Relevant information (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable) for the following safety concerns:", "ParentId": "e38ef82d-2550-44e4-aad6-7afd0ac7c056"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related pneumonitis</span></p>", "ID": "0d774258-3aaa-478d-9f5e-0c033f9d4200", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "d79de93a-103b-4347-a63a-0d0f6c0f1485", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "0d774258-3aaa-478d-9f5e-0c033f9d4200"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "38f40c56-945a-4f20-bba4-733af4cf036b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d79de93a-103b-4347-a63a-0d0f6c0f1485"}, {"Element": "<span lang=\"EN-GB\">Immune-related pneumonitis</span>", "ID": "fb56fb93-2bb7-4325-9754-edfad67f7e52", "Styles": "None", "Classes": "None", "Text": "Immune-related pneumonitis", "ParentId": "0d774258-3aaa-478d-9f5e-0c033f9d4200"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related colitis</span></p>", "ID": "b2a57f1b-3bf9-4a24-9f9b-762de4e7e188", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "4d2fcb69-44af-4839-97f0-24d5f4f52a9a", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "b2a57f1b-3bf9-4a24-9f9b-762de4e7e188"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "ec3f25c3-4c72-4531-b204-ad2e7f652e90", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "4d2fcb69-44af-4839-97f0-24d5f4f52a9a"}, {"Element": "<span lang=\"EN-GB\">Immune-related colitis</span>", "ID": "eaf3547a-5dfc-413a-a985-82901b01c837", "Styles": "None", "Classes": "None", "Text": "Immune-related colitis", "ParentId": "b2a57f1b-3bf9-4a24-9f9b-762de4e7e188"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related hepatitis</span></p>", "ID": "9f23e6d6-3fbe-4915-a5b6-628603ad92bd", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "4a012277-791e-4e1c-bc95-365bd763240d", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "9f23e6d6-3fbe-4915-a5b6-628603ad92bd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "aa54eb65-af39-439c-866d-5ba84deb37e4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "4a012277-791e-4e1c-bc95-365bd763240d"}, {"Element": "<span lang=\"EN-GB\">Immune-related hepatitis</span>", "ID": "baafdd43-dd3a-4fcc-b74d-e4ab66c81128", "Styles": "None", "Classes": "None", "Text": "Immune-related hepatitis", "ParentId": "9f23e6d6-3fbe-4915-a5b6-628603ad92bd"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span></p>", "ID": "de886d02-8d49-4494-8180-52743b762431", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "42f1407d-d801-411a-9280-84f9f0897cdc", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "de886d02-8d49-4494-8180-52743b762431"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "d73dd322-b7cf-47d3-b576-0fb6d1c35b5f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "42f1407d-d801-411a-9280-84f9f0897cdc"}, {"Element": "<span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span>", "ID": "57efb073-2600-4761-8e18-7785fa2dd415", "Styles": "None", "Classes": "None", "Text": "Immune-related nephritis or renal dysfunction", "ParentId": "de886d02-8d49-4494-8180-52743b762431"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related endocrinopathies </span></p>", "ID": "ac908c45-2f66-4385-a105-9951301b0410", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "08d4a795-b68b-4970-9002-3cfdf0ac2846", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "ac908c45-2f66-4385-a105-9951301b0410"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "f94aad3e-5ae0-4ab5-a7a3-702500142473", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "08d4a795-b68b-4970-9002-3cfdf0ac2846"}, {"Element": "<span lang=\"EN-GB\">Immune-related endocrinopathies </span>", "ID": "6e586128-b9b5-47df-aabc-53e5af02ed0b", "Styles": "None", "Classes": "None", "Text": "Immune-related endocrinopathies ", "ParentId": "ac908c45-2f66-4385-a105-9951301b0410"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune related rash</span></p>", "ID": "abcc6440-7325-4867-b150-979167c837dd", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "16dcc853-6c68-4f25-a591-ce6b44e2d6b2", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "abcc6440-7325-4867-b150-979167c837dd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "b7f93f31-cebf-4ce7-8053-5c954e7e538e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "16dcc853-6c68-4f25-a591-ce6b44e2d6b2"}, {"Element": "<span lang=\"EN-GB\">Immune related rash</span>", "ID": "155292d0-5939-401c-9664-31c5d0221f3a", "Styles": "None", "Classes": "None", "Text": "Immune related rash", "ParentId": "abcc6440-7325-4867-b150-979167c837dd"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other immune-related ARs</span></p>", "ID": "aeefe031-9d82-48e2-8b96-643f77938b86", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "e1611101-78dc-4ed4-8881-e7aee89966de", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "aeefe031-9d82-48e2-8b96-643f77938b86"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "692905ee-be68-4b61-8e44-fdefc30593c5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "e1611101-78dc-4ed4-8881-e7aee89966de"}, {"Element": "<span lang=\"EN-GB\">Other immune-related ARs</span>", "ID": "61e03025-566d-4246-8da3-e070061a6cf8", "Styles": "None", "Classes": "None", "Text": "Other immune-related ARs", "ParentId": "aeefe031-9d82-48e2-8b96-643f77938b86"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c6e88f2a-60fe-446a-ba28-95d5f59ec3f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "10d02d2a-eeeb-4346-acdb-1a43143b1f68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6e88f2a-60fe-446a-ba28-95d5f59ec3f9"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Details on how to minimise the safety concern\nthrough appropriate monitoring and management</span></p>", "ID": "ea4a5a6e-526a-4a42-84d9-10e9b9f1afcb", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d43fc5b5-61d0-4b42-b6d8-965d05c71278", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ea4a5a6e-526a-4a42-84d9-10e9b9f1afcb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "298e90a1-9663-46db-8f7c-bc52934d5ad8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d43fc5b5-61d0-4b42-b6d8-965d05c71278"}, {"Element": "<span lang=\"EN-GB\">Details on how to minimise the safety concern\nthrough appropriate monitoring and management</span>", "ID": "17d81a58-25de-4762-926f-b50024c566b8", "Styles": "None", "Classes": "None", "Text": "Details on how to minimise the safety concern through appropriate monitoring and management", "ParentId": "ea4a5a6e-526a-4a42-84d9-10e9b9f1afcb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b1be711-2f41-44e3-9b0c-86ad3d0c4698", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "373dd9d0-c48b-4a5e-b56d-9042c61f6a07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b1be711-2f41-44e3-9b0c-86ad3d0c4698"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The patient alert card</span></b><span lang=\"EN-GB\"> shall contain the following key messages: </span></p>", "ID": "c868d669-d446-445e-98e2-5589a8faef57", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c5399005-1fb9-4f09-b227-0a62098bd821", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c868d669-d446-445e-98e2-5589a8faef57"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c91e7859-d287-4fb9-9504-68b76b9b337c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c5399005-1fb9-4f09-b227-0a62098bd821"}, {"Element": "<b><span lang=\"EN-GB\">The patient alert card</span></b>", "ID": "acf976f6-5a8e-4808-9cc5-c7c3553cf768", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c868d669-d446-445e-98e2-5589a8faef57"}, {"Element": "<span lang=\"EN-GB\">The patient alert card</span>", "ID": "c752a956-619e-4ab9-a12e-1d1b74e53c88", "Styles": "None", "Classes": "None", "Text": "The patient alert card", "ParentId": "acf976f6-5a8e-4808-9cc5-c7c3553cf768"}, {"Element": "<span lang=\"EN-GB\"> shall contain the following key messages: </span>", "ID": "399fe617-0b5f-4791-a04b-bf377034bf37", "Styles": "None", "Classes": "None", "Text": " shall contain the following key messages: ", "ParentId": "c868d669-d446-445e-98e2-5589a8faef57"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45af07eb-eebd-4eab-a7bd-32bf74b5b5cd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12090d05-0753-4142-81cc-ca765c6391fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45af07eb-eebd-4eab-a7bd-32bf74b5b5cd"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">That Nivolumab\u00a0BMS treatment may increase\nthe risk of: </span></p>", "ID": "ee767ddc-d94d-4511-983b-6db2811f223e", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8ebd39f0-ed0d-454f-a392-b0d2d27a881f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ee767ddc-d94d-4511-983b-6db2811f223e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9b0a4d5d-b4a1-451c-910f-e73ce2c44126", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8ebd39f0-ed0d-454f-a392-b0d2d27a881f"}, {"Element": "<span lang=\"EN-GB\">That Nivolumab\u00a0BMS treatment may increase\nthe risk of: </span>", "ID": "e395aa35-836d-466c-af11-d626c7eba4b0", "Styles": "None", "Classes": "None", "Text": "That Nivolumab\u00a0BMS treatment may increase the risk of: ", "ParentId": "ee767ddc-d94d-4511-983b-6db2811f223e"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related pneumonitis</span></p>", "ID": "679b3f22-bc82-45c0-a53d-e14cc3e039db", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "041e940d-aa18-4323-94a8-f9e71ebe3ed7", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "679b3f22-bc82-45c0-a53d-e14cc3e039db"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "0169a993-a74b-44bb-a392-4dd1b9e1eb8d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "041e940d-aa18-4323-94a8-f9e71ebe3ed7"}, {"Element": "<span lang=\"EN-GB\">Immune-related pneumonitis</span>", "ID": "ac09be4d-52d2-48a8-bc6e-6c2d60ddc000", "Styles": "None", "Classes": "None", "Text": "Immune-related pneumonitis", "ParentId": "679b3f22-bc82-45c0-a53d-e14cc3e039db"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related colitis</span></p>", "ID": "7fb0a949-6de3-4166-a52e-490985cf4fcc", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "03774462-fa5d-423e-ae99-2eff025b1962", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "7fb0a949-6de3-4166-a52e-490985cf4fcc"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "95585922-a612-4d7d-aeec-5c7ad6d07f0c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "03774462-fa5d-423e-ae99-2eff025b1962"}, {"Element": "<span lang=\"EN-GB\">Immune-related colitis</span>", "ID": "08aa4696-e734-4347-ae15-967b2345b283", "Styles": "None", "Classes": "None", "Text": "Immune-related colitis", "ParentId": "7fb0a949-6de3-4166-a52e-490985cf4fcc"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related hepatitis</span></p>", "ID": "752bb79a-ce21-457f-a35d-155d709a8f45", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "bbe51fe8-ec81-42e1-9331-72ff2eee2835", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "752bb79a-ce21-457f-a35d-155d709a8f45"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "4d4c06fc-7d72-4293-9c4f-39056fcdc100", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "bbe51fe8-ec81-42e1-9331-72ff2eee2835"}, {"Element": "<span lang=\"EN-GB\">Immune-related hepatitis</span>", "ID": "07c38004-af56-48eb-83a6-fc7e1f0066bf", "Styles": "None", "Classes": "None", "Text": "Immune-related hepatitis", "ParentId": "752bb79a-ce21-457f-a35d-155d709a8f45"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span></p>", "ID": "679d0135-a4a7-4962-811d-b5223b83b6db", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "0e5da1bb-abe7-4d47-8f63-23652dbb2ae0", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "679d0135-a4a7-4962-811d-b5223b83b6db"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "eee94a4f-d3e7-46f4-961c-c1e969d2d60c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "0e5da1bb-abe7-4d47-8f63-23652dbb2ae0"}, {"Element": "<span lang=\"EN-GB\">Immune-related nephritis or renal dysfunction</span>", "ID": "9e781117-18cc-4eae-831d-00e6b1f80963", "Styles": "None", "Classes": "None", "Text": "Immune-related nephritis or renal dysfunction", "ParentId": "679d0135-a4a7-4962-811d-b5223b83b6db"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune-related endocrinopathies </span></p>", "ID": "a911d5f9-7ea9-40e0-810d-eb8c94ce3631", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "476e5de8-15e8-466a-9edb-0069ec9e6a15", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "a911d5f9-7ea9-40e0-810d-eb8c94ce3631"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "deb9c836-d80e-440e-b606-6126e4062d9e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "476e5de8-15e8-466a-9edb-0069ec9e6a15"}, {"Element": "<span lang=\"EN-GB\">Immune-related endocrinopathies </span>", "ID": "8f975a24-3a70-4d5f-8850-6fa702e7de0b", "Styles": "None", "Classes": "None", "Text": "Immune-related endocrinopathies ", "ParentId": "a911d5f9-7ea9-40e0-810d-eb8c94ce3631"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune related rash</span></p>", "ID": "444a5508-ee1a-42a1-b97b-66fafdcc72d0", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "708a98b4-efb5-4933-b17a-0dcfa31e1646", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "444a5508-ee1a-42a1-b97b-66fafdcc72d0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "c51b5ce6-3b57-4bae-8808-383477498d3e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "708a98b4-efb5-4933-b17a-0dcfa31e1646"}, {"Element": "<span lang=\"EN-GB\">Immune related rash</span>", "ID": "6bab79ed-54fa-43ed-a28f-a21c9380e1ff", "Styles": "None", "Classes": "None", "Text": "Immune related rash", "ParentId": "444a5508-ee1a-42a1-b97b-66fafdcc72d0"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:63.8pt;text-indent:-27.8pt\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other immune-related ARs</span></p>", "ID": "3d28f0b7-82b5-4ae1-8572-344192bb42f1", "Styles": "margin-left:63.8pt;text-indent:-27.8pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "148fd923-9544-4ed0-8773-82f94818f7ea", "Styles": "font-family:\"Courier New\"", "Classes": "None", "Text": "o", "ParentId": "3d28f0b7-82b5-4ae1-8572-344192bb42f1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "e5829b31-4512-4db2-b288-bc39cccef0b7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "148fd923-9544-4ed0-8773-82f94818f7ea"}, {"Element": "<span lang=\"EN-GB\">Other immune-related ARs</span>", "ID": "9c626d5d-b0d3-47dd-95a9-eff2275a1cf9", "Styles": "None", "Classes": "None", "Text": "Other immune-related ARs", "ParentId": "3d28f0b7-82b5-4ae1-8572-344192bb42f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c2d5dbc3-9c36-41d7-964e-843d055e993b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d3a5feb-923a-42fc-94c9-732cf3f6fabc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c2d5dbc3-9c36-41d7-964e-843d055e993b"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Signs or symptoms of the safety concern and when\nto seek attention from a HCP</span></p>", "ID": "6aa1e9d8-d039-4e4a-a97b-68d27e9e3536", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5b5bb8c1-77ea-4420-ad28-7b7ddefa12fc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6aa1e9d8-d039-4e4a-a97b-68d27e9e3536"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "131cdf71-c056-4e40-8a90-bc9859bbc7a8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5b5bb8c1-77ea-4420-ad28-7b7ddefa12fc"}, {"Element": "<span lang=\"EN-GB\">Signs or symptoms of the safety concern and when\nto seek attention from a HCP</span>", "ID": "bb4087aa-083f-4281-9c48-424c4d0aa346", "Styles": "None", "Classes": "None", "Text": "Signs or symptoms of the safety concern and when to seek attention from a HCP", "ParentId": "6aa1e9d8-d039-4e4a-a97b-68d27e9e3536"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da4814be-5c12-495b-b7a7-c11e330f9bd7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a434329e-bfa8-4d8e-82c5-0c8ac94c4521", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da4814be-5c12-495b-b7a7-c11e330f9bd7"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-14.15pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Contact details of the Nivolumab\u00a0BMS prescriber\n</span></p>", "ID": "2cb4c45e-bdf6-4e40-8fab-2a512dfedf91", "Styles": "margin-left:28.35pt;text-indent:-14.15pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "65cb806c-50e8-4d49-90f9-9f9b589807e4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2cb4c45e-bdf6-4e40-8fab-2a512dfedf91"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3c26d9be-71b3-4c0e-af69-af51601a3b41", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "65cb806c-50e8-4d49-90f9-9f9b589807e4"}, {"Element": "<span lang=\"EN-GB\">Contact details of the Nivolumab\u00a0BMS prescriber\n</span>", "ID": "218586ec-f15a-401f-ad27-88b0c3a3161b", "Styles": "None", "Classes": "None", "Text": "Contact details of the Nivolumab\u00a0BMS prescriber ", "ParentId": "2cb4c45e-bdf6-4e40-8fab-2a512dfedf91"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5f5f7af-c165-4948-830d-1989247fe241", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "205a7e15-7c79-4643-9818-515cecb9ae24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5f5f7af-c165-4948-830d-1989247fe241"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Obligation to conduct post-authorisation\nmeasures </span></b></p>", "ID": "f5b6e8b4-c87a-4888-aedf-37178d6e631f", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f7e813c-9f83-4d2c-b0d5-c4a31dbb1aab", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f5b6e8b4-c87a-4888-aedf-37178d6e631f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c63a3322-205a-4b3b-be4f-f37772679b6c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4f7e813c-9f83-4d2c-b0d5-c4a31dbb1aab"}, {"Element": "<b><span lang=\"EN-GB\">Obligation to conduct post-authorisation\nmeasures </span></b>", "ID": "a7ffc36a-965c-46ee-ae70-8ecce9420e17", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5b6e8b4-c87a-4888-aedf-37178d6e631f"}, {"Element": "<span lang=\"EN-GB\">Obligation to conduct post-authorisation\nmeasures </span>", "ID": "9ac40cdf-aa7a-4291-8ee1-29bc5f1dd683", "Styles": "None", "Classes": "None", "Text": "Obligation to conduct post-authorisation measures ", "ParentId": "a7ffc36a-965c-46ee-ae70-8ecce9420e17"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59fba14a-5792-4c62-a09a-7151464e83ed", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4867d6e7-519e-4182-a6c5-2586ac767edf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59fba14a-5792-4c62-a09a-7151464e83ed"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The MAH\nshall complete, within the stated timeframe, the below measures:</span></p>", "ID": "82b099fb-165a-43b1-85c4-2fa7429a6c40", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The MAH\nshall complete, within the stated timeframe, the below measures:</span>", "ID": "f7b80052-4f34-4f55-85d0-cf5fc69bdc64", "Styles": "None", "Classes": "None", "Text": "The MAH shall complete, within the stated timeframe, the below measures:", "ParentId": "82b099fb-165a-43b1-85c4-2fa7429a6c40"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42c1d75f-3eca-4ccf-9a8f-6a037164a655", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd9304b4-72d9-40e2-94c7-9f04d881b44a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42c1d75f-3eca-4ccf-9a8f-6a037164a655"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:1.2pt;border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid;height:21.5pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;background:white;\n  padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"462\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:106.3pt;border:solid black 1.0pt;border-left:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Due date</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:63.25pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">1. </span><span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span><span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span><span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span><span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:303.7pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2015</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> March 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> December 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "ed76d937-9617-4c5a-a78d-adf044a965b0", "Styles": "margin-left:1.2pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "    ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<tr style=\"page-break-inside:avoid;height:21.5pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;background:white;\n  padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"462\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>\n<td style=\"width:106.3pt;border:solid black 1.0pt;border-left:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Due date</span></p>\n</td>\n</tr>", "ID": "dc61c453-9142-42e1-a19a-bea4c2601051", "Styles": "page-break-inside:avoid;height:21.5pt", "Classes": "None", "Text": "   ", "ParentId": "ed76d937-9617-4c5a-a78d-adf044a965b0"}, {"Element": "<td style=\"width:346.35pt;border:solid black 1.0pt;background:white;\n  padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"462\">\n<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Description</span></b></p>\n</td>", "ID": "3e9f1de9-49ce-4269-8c1c-23ab91d11eeb", "Styles": "width:346.35pt;border:solid black 1.0pt;background:white;\n  padding:0in 4.25pt 0in 4.25pt;height:21.5pt", "Classes": "None", "Text": "  ", "ParentId": "dc61c453-9142-42e1-a19a-bea4c2601051"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Description</span></b></p>", "ID": "e2cc8124-ad48-4013-91d7-4a03c95cdb69", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3e9f1de9-49ce-4269-8c1c-23ab91d11eeb"}, {"Element": "<b><span lang=\"EN-GB\">Description</span></b>", "ID": "a7435c28-eba9-466d-85b7-482388d87571", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2cc8124-ad48-4013-91d7-4a03c95cdb69"}, {"Element": "<span lang=\"EN-GB\">Description</span>", "ID": "863b96c0-b064-47db-9d90-d993a6b89f87", "Styles": "None", "Classes": "None", "Text": "Description", "ParentId": "a7435c28-eba9-466d-85b7-482388d87571"}, {"Element": "<td style=\"width:106.3pt;border:solid black 1.0pt;border-left:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Due date</span></p>\n</td>", "ID": "eb2152fe-31d9-40d4-9193-e4ba277877c2", "Styles": "width:106.3pt;border:solid black 1.0pt;border-left:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt", "Classes": "None", "Text": "  ", "ParentId": "dc61c453-9142-42e1-a19a-bea4c2601051"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Due date</span></p>", "ID": "c1b6c87e-23e7-41b0-b218-cd052b842b1e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "eb2152fe-31d9-40d4-9193-e4ba277877c2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Due date</span>", "ID": "fa5563c7-4b43-40d6-958d-3761e18128c7", "Styles": "color:black", "Classes": "None", "Text": "Due date", "ParentId": "c1b6c87e-23e7-41b0-b218-cd052b842b1e"}, {"Element": "<tr style=\"page-break-inside:avoid;height:63.25pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">1. </span><span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span><span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span><span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span><span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span></p>\n</td>\n</tr>", "ID": "fee2fe0b-049e-452e-b392-41913d1857c7", "Styles": "page-break-inside:avoid;height:63.25pt", "Classes": "None", "Text": "   ", "ParentId": "ed76d937-9617-4c5a-a78d-adf044a965b0"}, {"Element": "<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">1. </span><span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span><span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span><span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>\n</td>", "ID": "d44b90ed-59d9-4dbe-8a42-9bf299a7c9bd", "Styles": "width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt", "Classes": "None", "Text": "  ", "ParentId": "fee2fe0b-049e-452e-b392-41913d1857c7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">1. </span><span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span><span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span><span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span><span lang=\"EN-GB\" style=\"color:black\">. </span></p>", "ID": "8ff5436a-49f5-4261-84b7-da507ccc28d2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "d44b90ed-59d9-4dbe-8a42-9bf299a7c9bd"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">1. </span>", "ID": "704d3272-c9f3-4901-a43c-18289ecc7306", "Styles": "color:black", "Classes": "None", "Text": "1. ", "ParentId": "8ff5436a-49f5-4261-84b7-da507ccc28d2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Post-authorisation efficacy study (PAES): </span>", "ID": "f1646f05-3505-42b7-8c60-f593021d1f84", "Styles": "color:black", "Classes": "None", "Text": "Post-authorisation efficacy study (PAES): ", "ParentId": "8ff5436a-49f5-4261-84b7-da507ccc28d2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The MAH should submit an updated OS data for\n  Study CA209017: </span>", "ID": "59bafd19-20d4-4def-8ae3-9de1daf9466f", "Styles": "color:black", "Classes": "None", "Text": "The MAH should submit an updated OS data for   Study CA209017: ", "ParentId": "8ff5436a-49f5-4261-84b7-da507ccc28d2"}, {"Element": "<span style=\"color:black\">a Phase\u00a03, randomized\n  study of nivolumab vs docetaxel in subjects with advanced or metastatic\n  squamous NSCLC who have experienced disease progression during or after one\n  prior platinum doublet-based chemotherapy regimen</span>", "ID": "8b0f4b9b-1b61-4003-92c5-9cab1ddf2018", "Styles": "color:black", "Classes": "None", "Text": "a Phase\u00a03, randomized   study of nivolumab vs docetaxel in subjects with advanced or metastatic   squamous NSCLC who have experienced disease progression during or after one   prior platinum doublet-based chemotherapy regimen", "ParentId": "8ff5436a-49f5-4261-84b7-da507ccc28d2"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">. </span>", "ID": "566fa0a6-7f4f-4fc3-bdb7-33b9ebcccf17", "Styles": "color:black", "Classes": "None", "Text": ". ", "ParentId": "8ff5436a-49f5-4261-84b7-da507ccc28d2"}, {"Element": "<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span><span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span></p>\n</td>", "ID": "640db23a-52c8-461a-a491-bfac94232166", "Styles": "width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt", "Classes": "None", "Text": "  ", "ParentId": "fee2fe0b-049e-452e-b392-41913d1857c7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span><span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span></p>", "ID": "856543e0-f496-4999-af67-16dfab60f2eb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "640db23a-52c8-461a-a491-bfac94232166"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The updated data\n  should be submitted by 31</span>", "ID": "4f12b6a1-7cd0-403c-8fb8-8b37f970c7e7", "Styles": "color:black", "Classes": "None", "Text": "The updated data   should be submitted by 31", "ParentId": "856543e0-f496-4999-af67-16dfab60f2eb"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st </span></span>", "ID": "9efd453f-5566-47b8-ae5f-e4e362cf221e", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "856543e0-f496-4999-af67-16dfab60f2eb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">st </span>", "ID": "4d75487a-2574-4620-9f5a-ffe69cf18c8d", "Styles": "color:black", "Classes": "None", "Text": "st ", "ParentId": "9efd453f-5566-47b8-ae5f-e4e362cf221e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">December\n  2015</span>", "ID": "b9b6d0f9-ca59-4e87-8cc3-dcf66c0fa713", "Styles": "color:black", "Classes": "None", "Text": "December   2015", "ParentId": "856543e0-f496-4999-af67-16dfab60f2eb"}, {"Element": "<tr style=\"page-break-inside:avoid;height:303.7pt\">\n<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2015</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> March 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> December 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a6fe66fd-24e4-43f0-9463-70e4a25b977b", "Styles": "page-break-inside:avoid;height:303.7pt", "Classes": "None", "Text": "   ", "ParentId": "ed76d937-9617-4c5a-a78d-adf044a965b0"}, {"Element": "<td style=\"width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"462\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>\n<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "177374f9-2426-44bb-b1b8-eb54564ad426", "Styles": "width:346.35pt;border:solid black 1.0pt;border-top:none;\n  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt", "Classes": "None", "Text": "        ", "ParentId": "a6fe66fd-24e4-43f0-9463-70e4a25b977b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span></p>", "ID": "61e28dbf-56c2-4921-9a88-625e8c84c556", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">2. The value of\n  biomarkers to predict the efficacy of nivolumab should be further explored,\n  specifically:</span>", "ID": "4c68b688-3179-40e1-9b39-2e78e7aa8fff", "Styles": "color:black", "Classes": "None", "Text": "2. The value of   biomarkers to predict the efficacy of nivolumab should be further explored,   specifically:", "ParentId": "61e28dbf-56c2-4921-9a88-625e8c84c556"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span></p>", "ID": "5ff4ee3e-7d12-4378-84f2-590dcdc00077", "Styles": "margin-left:27.4pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "890a5d73-301b-447b-9e7f-3c6364dcc12f", "Styles": "None", "Classes": "None", "Text": "1.", "ParentId": "5ff4ee3e-7d12-4378-84f2-590dcdc00077"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "7e7bcd13-074a-4d57-a45f-2c73d8aa2820", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "890a5d73-301b-447b-9e7f-3c6364dcc12f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">To continue the exploration of the optimal\n  cut-off for PD-L1 positivity based on current assay method used to further\n  elucidate its value as predictive of nivolumab efficacy. These analyses will\n  be conducted in Studies CA 209037 and CA209066 in patients with advanced\n  melanoma.</span>", "ID": "5429d836-b19e-434e-ab98-72fba4d0dbdd", "Styles": "color:black", "Classes": "None", "Text": "To continue the exploration of the optimal   cut-off for PD-L1 positivity based on current assay method used to further   elucidate its value as predictive of nivolumab efficacy. These analyses will   be conducted in Studies CA 209037 and CA209066 in patients with advanced   melanoma.", "ParentId": "5ff4ee3e-7d12-4378-84f2-590dcdc00077"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span></p>", "ID": "38b27e85-730e-4bfc-9ca3-55fc83d2f740", "Styles": "margin-left:27.4pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">2.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "9dda9c10-d308-4511-b163-1a356d890d99", "Styles": "None", "Classes": "None", "Text": "2.", "ParentId": "38b27e85-730e-4bfc-9ca3-55fc83d2f740"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "492a6dbc-d16c-4266-a815-b935c6f0cbbc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "9dda9c10-d308-4511-b163-1a356d890d99"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">To further investigate the value biomarkers\n  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,\n  other methods / assays, and associated cut-offs, that might prove more\n  sensitive and specific in predicting response to treatment based on PD-L1,\n  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA\n  signature, etc.) as predictive of nivolumab efficacy. These additional\n  biomarker analyses are occurring in the context of Study CA209-038 and Study\n  CA209-066. </span>", "ID": "ce557f54-f6e7-434c-a5d6-ffdd0452b889", "Styles": "color:black", "Classes": "None", "Text": "To further investigate the value biomarkers   other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,   other methods / assays, and associated cut-offs, that might prove more   sensitive and specific in predicting response to treatment based on PD-L1,   PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA   signature, etc.) as predictive of nivolumab efficacy. These additional   biomarker analyses are occurring in the context of Study CA209-038 and Study   CA209-066. ", "ParentId": "38b27e85-730e-4bfc-9ca3-55fc83d2f740"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span></p>", "ID": "90706067-be4f-4294-9960-7073a0811258", "Styles": "margin-left:27.4pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "3eab8695-04db-4998-afca-0d546f60f48f", "Styles": "None", "Classes": "None", "Text": "3.", "ParentId": "90706067-be4f-4294-9960-7073a0811258"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "7805052b-2e74-4b00-8b9f-945020ba54b9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "3eab8695-04db-4998-afca-0d546f60f48f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038\n  and CA209064).</span>", "ID": "a5f991c8-b5d3-4299-8428-33d4d41f6c8b", "Styles": "color:black", "Classes": "None", "Text": "To further investigate at post-approval the   relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038   and CA209064).", "ParentId": "90706067-be4f-4294-9960-7073a0811258"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>", "ID": "f81df977-8b8b-44dc-86ab-782a7ec9b2ef", "Styles": "margin-left:27.4pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "3776036b-590f-4baa-a774-071ad1d34e56", "Styles": "None", "Classes": "None", "Text": "4.", "ParentId": "f81df977-8b8b-44dc-86ab-782a7ec9b2ef"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "51209450-efb5-4a01-bfb0-65f066764c76", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "3776036b-590f-4baa-a774-071ad1d34e56"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">To further investigate the associative\n  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span>", "ID": "77dd44fc-56a5-4ea5-8042-89e1b4b43e94", "Styles": "color:black", "Classes": "None", "Text": "To further investigate the associative   analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.", "ParentId": "f81df977-8b8b-44dc-86ab-782a7ec9b2ef"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:27.4pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>", "ID": "03e5a0a0-db29-41e6-9546-735a109e007c", "Styles": "margin-left:27.4pt;text-indent:-14.15pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "1c6c213c-88d5-4441-afb7-f3bf07466704", "Styles": "None", "Classes": "None", "Text": "5.", "ParentId": "03e5a0a0-db29-41e6-9546-735a109e007c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "687947f0-0866-4fa9-bc97-57f1783dbdfd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "1c6c213c-88d5-4441-afb7-f3bf07466704"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">To further investigate at post-approval the\n  possible change in PD-L1 status of the tumour during treatment and/or tumour\n  progression in Studies CA209-009, CA209-038 and CA209-064. </span>", "ID": "91a0db57-5038-4e94-87ec-fc2800353ca6", "Styles": "color:black", "Classes": "None", "Text": "To further investigate at post-approval the   possible change in PD-L1 status of the tumour during treatment and/or tumour   progression in Studies CA209-009, CA209-038 and CA209-064. ", "ParentId": "03e5a0a0-db29-41e6-9546-735a109e007c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "210208fd-b09a-4f3a-9cfc-efffde34bbf9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "177374f9-2426-44bb-b1b8-eb54564ad426"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "735aa0a4-c442-49f1-918b-1497125049cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "210208fd-b09a-4f3a-9cfc-efffde34bbf9"}, {"Element": "<td style=\"width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt\" width=\"142\">\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2015</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> March 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> December 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8a7a4e89-f945-4096-a97b-da3d83245f38", "Styles": "width:106.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:\n  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt", "Classes": "None", "Text": "                     ", "ParentId": "a6fe66fd-24e4-43f0-9463-70e4a25b977b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2015</span></p>", "ID": "65e6a5d0-1fe6-48f2-a3ee-a7e663eb66cb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">30</span>", "ID": "75b67055-cfb1-47ef-b64e-e5d314fbbd9e", "Styles": "color:black", "Classes": "None", "Text": "30", "ParentId": "65e6a5d0-1fe6-48f2-a3ee-a7e663eb66cb"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span>", "ID": "a2918fb6-016b-416e-b86a-874d5c8689f6", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "65e6a5d0-1fe6-48f2-a3ee-a7e663eb66cb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">th</span>", "ID": "5d04b157-3be6-42ba-8ef9-1ac710d9ca65", "Styles": "color:black", "Classes": "None", "Text": "th", "ParentId": "a2918fb6-016b-416e-b86a-874d5c8689f6"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> September 2015</span>", "ID": "46ea3703-f72b-401e-a825-3b39fb18b6fc", "Styles": "color:black", "Classes": "None", "Text": " September 2015", "ParentId": "65e6a5d0-1fe6-48f2-a3ee-a7e663eb66cb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91a675dc-c46f-4e16-ab4e-901021ab2711", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "28ce8d36-1b8f-4841-a316-f9c59fc2bf16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91a675dc-c46f-4e16-ab4e-901021ab2711"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "78a75812-cf05-463a-b040-b9b9fc1ea6b1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff8bb871-1273-43c6-8909-de5d347d0173", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "78a75812-cf05-463a-b040-b9b9fc1ea6b1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c1341358-e5ab-4d6c-ac88-6849f487c810", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8743116c-ba88-4794-9f66-324f07546942", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1341358-e5ab-4d6c-ac88-6849f487c810"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23bf923a-c688-410b-9c1d-d15df87bc49e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d3d490e-620f-4696-83b2-346536e55369", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23bf923a-c688-410b-9c1d-d15df87bc49e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>", "ID": "0d7cc36d-fff8-47a7-83d8-8810554bc4fb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">30</span>", "ID": "4f64a6af-7c4e-452e-a4ae-35607f7de6a4", "Styles": "color:black", "Classes": "None", "Text": "30", "ParentId": "0d7cc36d-fff8-47a7-83d8-8810554bc4fb"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span>", "ID": "a33e04c7-5176-404e-a3b1-c3a7dc593e16", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "0d7cc36d-fff8-47a7-83d8-8810554bc4fb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">th</span>", "ID": "d478307d-5cd7-4851-ba91-70cec5b7120f", "Styles": "color:black", "Classes": "None", "Text": "th", "ParentId": "a33e04c7-5176-404e-a3b1-c3a7dc593e16"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> September 2017</span>", "ID": "e2361bd5-ed34-413f-b318-c6595b37a6ad", "Styles": "color:black", "Classes": "None", "Text": " September 2017", "ParentId": "0d7cc36d-fff8-47a7-83d8-8810554bc4fb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "864716e4-5871-4202-82ed-602a3bfa8c84", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd930940-9ce9-4e47-9ec5-b538b5fad9c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "864716e4-5871-4202-82ed-602a3bfa8c84"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fac232f-d583-4e2b-a156-20c0abdb61c4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a60add0-a1b6-425c-b1cb-1355f5b086ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fac232f-d583-4e2b-a156-20c0abdb61c4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb3596c8-de60-485e-9e2e-5309c92d9521", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0256cb77-eed5-4cc1-9a03-0b998f2ee888", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb3596c8-de60-485e-9e2e-5309c92d9521"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "84b7e013-6b32-44cf-bb5e-d245e34dbc0b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1deb1ba6-98c4-4eb6-a7d7-bff5cda2f397", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84b7e013-6b32-44cf-bb5e-d245e34dbc0b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "727fcd01-941b-484c-9450-e038e1f667b3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1950d72-b2a4-4685-ab6a-0deb83734c3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "727fcd01-941b-484c-9450-e038e1f667b3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f54d0f6-bfd5-468d-ba14-dff851214cfa", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66b120e0-1fd4-4e5d-9d91-ff2f01ae4d78", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f54d0f6-bfd5-468d-ba14-dff851214cfa"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30c6ff7e-6f8d-4a35-97bf-706da9ad925a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37375602-9076-45ca-8bc0-ea1e6ccb3ed0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30c6ff7e-6f8d-4a35-97bf-706da9ad925a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> March 2017</span></p>", "ID": "3ebc2973-cbec-47b2-84f5-9f90c18639c5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">31</span>", "ID": "093867cf-8358-49af-b8b5-ca4843b92df9", "Styles": "color:black", "Classes": "None", "Text": "31", "ParentId": "3ebc2973-cbec-47b2-84f5-9f90c18639c5"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span>", "ID": "e1093a87-7433-4031-a935-123902a2a313", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "3ebc2973-cbec-47b2-84f5-9f90c18639c5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">st</span>", "ID": "ff7a2eed-6e79-4a30-a72d-9366de683df9", "Styles": "color:black", "Classes": "None", "Text": "st", "ParentId": "e1093a87-7433-4031-a935-123902a2a313"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> March 2017</span>", "ID": "150510f1-f7b8-42ad-92f3-f49929b283cb", "Styles": "color:black", "Classes": "None", "Text": " March 2017", "ParentId": "3ebc2973-cbec-47b2-84f5-9f90c18639c5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "16759421-bc59-4ab1-a61b-88e17aa3612d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "31057b45-5cf0-40fc-80dc-ed08e37c9a78", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "16759421-bc59-4ab1-a61b-88e17aa3612d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52ee6ab3-f1a6-4abc-af46-3b2aa51b38dc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4fd6a5a-1b2a-4206-9dd4-3b1c4e92842a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52ee6ab3-f1a6-4abc-af46-3b2aa51b38dc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">31</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span><span lang=\"EN-GB\" style=\"color:black\"> December 2017</span></p>", "ID": "0387a734-57f9-4a5b-8820-52bc796fb750", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">31</span>", "ID": "dc862261-30e5-4837-a706-cef70d7dec58", "Styles": "color:black", "Classes": "None", "Text": "31", "ParentId": "0387a734-57f9-4a5b-8820-52bc796fb750"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">st</span></span>", "ID": "1173916c-ec05-457f-a2ef-d1b30fa73e30", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "0387a734-57f9-4a5b-8820-52bc796fb750"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">st</span>", "ID": "50d9f0da-fb32-4781-b53c-36c1ffe35cc9", "Styles": "color:black", "Classes": "None", "Text": "st", "ParentId": "1173916c-ec05-457f-a2ef-d1b30fa73e30"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> December 2017</span>", "ID": "9ba284a3-0470-4097-8743-6f6aa5cad25a", "Styles": "color:black", "Classes": "None", "Text": " December 2017", "ParentId": "0387a734-57f9-4a5b-8820-52bc796fb750"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "187221ef-9ac7-4650-bfbc-107d84e8394d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2abae616-5656-46e1-b55c-e132951589b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "187221ef-9ac7-4650-bfbc-107d84e8394d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">30</span><span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span><span lang=\"EN-GB\" style=\"color:black\"> September 2017</span></p>", "ID": "9f24d5c1-8303-4c80-a7e4-a1c890eaf823", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">30</span>", "ID": "99f3f26b-4c6f-4511-8f02-ab001eb781b8", "Styles": "color:black", "Classes": "None", "Text": "30", "ParentId": "9f24d5c1-8303-4c80-a7e4-a1c890eaf823"}, {"Element": "<span class=\"EMEASuperscript\"><span lang=\"EN-GB\" style=\"color:black\">th</span></span>", "ID": "8d1d100a-baab-4e12-a914-36daae0a5e38", "Styles": "None", "Classes": "['EMEASuperscript']", "Text": "", "ParentId": "9f24d5c1-8303-4c80-a7e4-a1c890eaf823"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">th</span>", "ID": "ce1e1eb1-2d91-4098-a9ee-f7ca18c2597a", "Styles": "color:black", "Classes": "None", "Text": "th", "ParentId": "8d1d100a-baab-4e12-a914-36daae0a5e38"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> September 2017</span>", "ID": "540aab83-ce3f-4515-a517-f46020ab6ed5", "Styles": "color:black", "Classes": "None", "Text": " September 2017", "ParentId": "9f24d5c1-8303-4c80-a7e4-a1c890eaf823"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59102fe4-f012-49a1-8aae-db3a9f984452", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "8a7a4e89-f945-4096-a97b-da3d83245f38"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9eba364b-94c9-4fce-8e82-9f398f454a27", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59102fe4-f012-49a1-8aae-db3a9f984452"}, {"Element": "<p class=\"EMEABodyText\"><span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></span></p>", "ID": "f56a75da-13a7-4753-909f-687f16d2ae20", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span></span>", "ID": "55426813-78d6-48a4-b6a8-18c1bb9e3800", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "f56a75da-13a7-4753-909f-687f16d2ae20"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "1c690059-c897-4bfb-9097-d48726ab6b46", "Styles": "color:black", "Classes": "None", "Text": "", "ParentId": "55426813-78d6-48a4-b6a8-18c1bb9e3800"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "9887fe2c-9618-4efc-9cba-678906f4cef7", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "1c690059-c897-4bfb-9097-d48726ab6b46"}, {"Element": "<span class=\"MsoHyperlink\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\n\"Times New Roman\",serif;color:black'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span></span>", "ID": "70d5f2f1-b5c0-4154-a34b-552156b0be70", "Styles": "None", "Classes": "['MsoHyperlink']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\n\"Times New Roman\",serif;color:black'><br clear=\"all\" style=\"page-break-before:\nalways\"/>\n</span>", "ID": "df94433d-b7ee-4741-8ca8-afa77475940f", "Styles": "font-size:11.0pt;font-family:\n\"Times New Roman\",serif;color:black", "Classes": "None", "Text": " ", "ParentId": "70d5f2f1-b5c0-4154-a34b-552156b0be70"}, {"Element": "<br clear=\"all\" style=\"page-break-before:\nalways\"/>", "ID": "f879b9f0-158e-487c-825a-161a2ea28412", "Styles": "page-break-before:\nalways", "Classes": "None", "Text": "", "ParentId": "df94433d-b7ee-4741-8ca8-afa77475940f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b73e3c7-e993-4838-8452-776afe59d3cb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdf8d863-e5cc-4418-a370-63b56f51e80f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b73e3c7-e993-4838-8452-776afe59d3cb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "77a2f96a-0a27-4834-b996-4c2a85ab5c1f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fac52b6b-a7c4-4b6f-ab4d-956e0ed2bf75", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "77a2f96a-0a27-4834-b996-4c2a85ab5c1f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5939c20-84a4-4a2c-a18a-9338d51e7e05", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1f286f4-7c28-4ae2-8e78-fd5d65b69c34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5939c20-84a4-4a2c-a18a-9338d51e7e05"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00b9529c-3f44-4b39-b416-bc0b7bd5ce71", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2bc69a2f-3dc6-4cda-853b-e308f119722d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00b9529c-3f44-4b39-b416-bc0b7bd5ce71"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1df1ab05-fd5f-406d-a9d5-c222aa83d45a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27737973-2c56-4e48-aca0-3221e470230c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1df1ab05-fd5f-406d-a9d5-c222aa83d45a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fd31270a-3321-4569-962c-017e1f7b84c6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ca82357-0667-45b6-8b9b-f45a3331dac3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd31270a-3321-4569-962c-017e1f7b84c6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46eb2bc3-af44-467c-ae97-8102c3beb061", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1d2e6f0-1d91-49a8-a936-e0f93380ce59", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46eb2bc3-af44-467c-ae97-8102c3beb061"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "088f9f0a-b324-45cc-8f2a-54b6759bb20b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b753ebdd-18ed-4b53-9b1a-367bcb731040", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "088f9f0a-b324-45cc-8f2a-54b6759bb20b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59f1405c-f172-4722-912c-ae1099248bb6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9991e7ca-4588-4c0c-b1af-bac144f0601b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59f1405c-f172-4722-912c-ae1099248bb6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4aeebcf7-7a9b-460a-ba6c-739aacb5d699", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddb45983-2758-469b-bd3c-95100a8dcd33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4aeebcf7-7a9b-460a-ba6c-739aacb5d699"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b0dadf52-acc8-42a9-aa5f-8f615bad29f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c42acb21-9db1-42c4-87b2-0dcb7d829ef7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0dadf52-acc8-42a9-aa5f-8f615bad29f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0559edfa-6949-4cc5-a023-73583d7470df", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb7edb34-4235-429b-bec6-0a103b4a9074", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0559edfa-6949-4cc5-a023-73583d7470df"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0fc61cee-c2a2-4ca2-8861-a2921ea24c11", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7577f64d-cdee-47c3-99be-b2306fef0b15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0fc61cee-c2a2-4ca2-8861-a2921ea24c11"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "494fefcc-8db6-4ca5-864a-9f1b5b0919a4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "40757d04-235b-42b9-b675-6d2113f5dc3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "494fefcc-8db6-4ca5-864a-9f1b5b0919a4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5ae2e49-ad2f-49be-b359-a2959e5a53a2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a4efc8a-077e-483d-9872-7d03934a31a9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5ae2e49-ad2f-49be-b359-a2959e5a53a2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9273d984-f5da-4c7d-adb2-1dcbec00f9fc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ec713e1-1c48-4834-b93c-06d505f81bb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9273d984-f5da-4c7d-adb2-1dcbec00f9fc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d70f95d4-bff2-4f7d-a2ce-c3dcb1f386bf", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e565a1f4-2e19-4feb-972a-a18e086e4e3f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d70f95d4-bff2-4f7d-a2ce-c3dcb1f386bf"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2c9fefae-e136-4bd2-978a-b530dafc2c59", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9d0ebf7-cdb7-4142-8edc-82e14c2b243d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c9fefae-e136-4bd2-978a-b530dafc2c59"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fb012033-0ebc-4f7f-add1-1d0ec6e67694", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1903eb9b-8e42-470c-bd8f-c115352ba95f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fb012033-0ebc-4f7f-add1-1d0ec6e67694"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e572044-6048-4fd1-a10a-9db60accc95b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "698d874f-563c-4003-9975-634589bb2b20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e572044-6048-4fd1-a10a-9db60accc95b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ffd00550-d7c2-47e9-bab0-561700a7568c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f49557fd-ee4a-4dd3-b3a4-935cb379f250", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ffd00550-d7c2-47e9-bab0-561700a7568c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2feae82c-2938-446b-824f-f42ff100636f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a5b6aca-c840-4caf-ac12-9a1a81ea304a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2feae82c-2938-446b-824f-f42ff100636f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8e581fe8-949e-46c0-a34b-b0647d514519", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ea217d3-636a-4d10-919e-da5b9b199cc7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e581fe8-949e-46c0-a34b-b0647d514519"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">III</span></p>", "ID": "ad9f2b0e-919d-4f2e-bd72-967a61bf981a", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">ANNEX</span>", "ID": "48076b55-24bc-4af4-ba8f-727f8b2c63a6", "Styles": "None", "Classes": "None", "Text": "ANNEX", "ParentId": "ad9f2b0e-919d-4f2e-bd72-967a61bf981a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-weight:normal\"> </span>", "ID": "ab63d320-1dbf-4dc5-998d-dc22cf1e1083", "Styles": "font-weight:normal", "Classes": "None", "Text": " ", "ParentId": "ad9f2b0e-919d-4f2e-bd72-967a61bf981a"}, {"Element": "<span lang=\"EN-GB\">III</span>", "ID": "0f0f92c0-fb47-472e-b033-cbe836d6ae3e", "Styles": "None", "Classes": "None", "Text": "III", "ParentId": "ad9f2b0e-919d-4f2e-bd72-967a61bf981a"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5b0e2982-1ead-488f-b01b-5a62bfbc69d7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "440efc9d-f1a4-4736-9618-d774fbd69072", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b0e2982-1ead-488f-b01b-5a62bfbc69d7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65a1d02e-3bcc-45a6-bf9b-19ef6e8e0881", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "440efc9d-f1a4-4736-9618-d774fbd69072"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">LABELLING</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">AND</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">PACKAGE</span><span lang=\"EN-GB\" style=\"font-weight:normal\"> </span><span lang=\"EN-GB\">LEAFLET</span></p>", "ID": "6dd4e310-6941-408c-86c5-0e5164635c30", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">LABELLING</span>", "ID": "52f3a534-78aa-4d2c-952a-dfd4b49e7e48", "Styles": "None", "Classes": "None", "Text": "LABELLING", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-weight:normal\"> </span>", "ID": "08a7e664-a6a7-4c0b-9fbe-a5fca9771e82", "Styles": "font-weight:normal", "Classes": "None", "Text": " ", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\">AND</span>", "ID": "a42228ea-f0c1-4c02-8d70-cf7ada9029d2", "Styles": "None", "Classes": "None", "Text": "AND", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-weight:normal\"> </span>", "ID": "62bd5974-4033-4514-b9e1-6f4eba04ceb7", "Styles": "font-weight:normal", "Classes": "None", "Text": " ", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\">PACKAGE</span>", "ID": "39ccc242-5379-44ab-b4d8-faef90206e5e", "Styles": "None", "Classes": "None", "Text": "PACKAGE", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-weight:normal\"> </span>", "ID": "75011cb3-a742-4770-9111-28ad5e6d3e71", "Styles": "font-weight:normal", "Classes": "None", "Text": " ", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<span lang=\"EN-GB\">LEAFLET</span>", "ID": "2cffa515-8205-4cba-9645-50c4069d031a", "Styles": "None", "Classes": "None", "Text": "LEAFLET", "ParentId": "6dd4e310-6941-408c-86c5-0e5164635c30"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "2eea7975-8efb-48e0-98f9-7d61eb4d0ce3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2a3e89ef-e6e5-4c2f-8b30-f8e1de63a1fc", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "2eea7975-8efb-48e0-98f9-7d61eb4d0ce3"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "80cf8930-a02d-4bdb-9f33-c1609088b4ae", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2a3e89ef-e6e5-4c2f-8b30-f8e1de63a1fc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4261ea97-a794-48a3-ae81-98979c085781", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff686d6d-13f2-437d-8f2e-beaed097187c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4261ea97-a794-48a3-ae81-98979c085781"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ac230e4-8f2f-4ae8-b288-80f191010754", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c79d6a5-f87f-4bac-8ed2-9d34830e4536", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ac230e4-8f2f-4ae8-b288-80f191010754"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32050274-442c-4a14-b5ca-8ed607e5f322", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34eccb93-fef8-4f0c-8f87-aa8ca412e420", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32050274-442c-4a14-b5ca-8ed607e5f322"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ecad3fb5-7fd3-418f-8f07-ac0245c3c9ce", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4cc5419-634f-42c7-9ec7-164685bb2329", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ecad3fb5-7fd3-418f-8f07-ac0245c3c9ce"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42241b80-4594-4369-94fd-89b75f3b9144", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a026590b-4314-460a-8f09-04f65343115b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42241b80-4594-4369-94fd-89b75f3b9144"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8afe0492-d5fd-4e0f-b20d-108166f5039b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1123950a-c9cf-4b2e-836e-57dbe929efcd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8afe0492-d5fd-4e0f-b20d-108166f5039b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "47cd12f1-1d9a-435d-b8ad-6833e4ae1996", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e2c520d8-1b24-47c5-98d5-6cd1e3fafcc9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47cd12f1-1d9a-435d-b8ad-6833e4ae1996"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f264cad-c4d4-4783-a20a-8e62b3b3c6c7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "586dced8-8867-4a19-b162-964b3adee23a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f264cad-c4d4-4783-a20a-8e62b3b3c6c7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ed543a9-8fc4-4126-8d61-5dc6fe4deb54", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8b89e2a-c116-498b-b1eb-c96b61cf2826", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ed543a9-8fc4-4126-8d61-5dc6fe4deb54"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f3fcfe20-1e77-4114-ab67-c4f45a15a477", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "653297ec-e9aa-444f-8185-bb727a6b1024", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f3fcfe20-1e77-4114-ab67-c4f45a15a477"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7854a584-ee23-41c3-b46e-11e370c1554a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f0d67b6-fa2e-4989-ade8-b11f8986c708", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7854a584-ee23-41c3-b46e-11e370c1554a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f1209c6-9218-40e0-bd6f-93a5e3b4c126", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb4a2b7f-ab3a-46b3-8354-5cdc14d4dd04", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f1209c6-9218-40e0-bd6f-93a5e3b4c126"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5dee2a0e-2c20-46dd-a539-a9754e1c9957", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7aa94b46-9b7e-4b05-8b12-8b4921a4e66f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5dee2a0e-2c20-46dd-a539-a9754e1c9957"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6983cc95-8311-47e5-8ae5-0caf41f55cbe", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "19ea961f-efe1-47e6-8365-6f50dda37bdf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6983cc95-8311-47e5-8ae5-0caf41f55cbe"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd674b1e-f6b6-42b2-8808-da6f30802a43", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ceb6917-e71d-4ae7-82ed-c1f0a963bd4e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd674b1e-f6b6-42b2-8808-da6f30802a43"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f45bbcb-2cd0-4620-8d7c-2cfe869b699c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55299f76-c563-42f1-91ac-4e7aa4aff598", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f45bbcb-2cd0-4620-8d7c-2cfe869b699c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f9554ac-3c55-453e-a134-e6fb939f0c76", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d68447c-b7e0-46cb-8d6c-a683948369bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f9554ac-3c55-453e-a134-e6fb939f0c76"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f08d8a41-3aba-4e8a-94cd-95b64b748764", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5474f83e-32d8-4160-ab3e-bc96013f7f34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f08d8a41-3aba-4e8a-94cd-95b64b748764"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4bf2be3a-7cf2-401f-8d4d-ceaf586dc664", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4a2b562-51a2-4aa8-9bb3-c4b876e40275", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4bf2be3a-7cf2-401f-8d4d-ceaf586dc664"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "19c01708-29d0-41f4-97e5-028e52374a87", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c587b119-b648-4359-9bfd-3ca4d90d0eed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19c01708-29d0-41f4-97e5-028e52374a87"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed35ac2a-abba-46de-a908-00f781dace3a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "358fa203-e60b-4b6b-8b43-7565881867d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed35ac2a-abba-46de-a908-00f781dace3a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce6c48bc-8609-45d7-a53c-47610e0e783f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe765632-5c01-454f-9c1a-95829de9e38b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce6c48bc-8609-45d7-a53c-47610e0e783f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e6d1161b-0ae6-43be-8675-46da33e90d68", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6dd37725-0570-43f2-bc75-5203fe3df7c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6d1161b-0ae6-43be-8675-46da33e90d68"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">A. LABELLING</span></p>", "ID": "596e203c-7710-4015-b04b-63ee2803ba88", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">A. LABELLING</span>", "ID": "74ecc25e-8efd-46c1-8009-20782bc74827", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "596e203c-7710-4015-b04b-63ee2803ba88"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "a4c11d46-9fdc-45a7-af9d-2bd6a01368a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "e54030a1-317e-49c7-8b79-09da77970d98", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ntext-transform:uppercase", "Classes": "None", "Text": " ", "ParentId": "a4c11d46-9fdc-45a7-af9d-2bd6a01368a8"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "d191c895-8050-4cc8-aa36-a9af35e41da5", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "e54030a1-317e-49c7-8b79-09da77970d98"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\nPACKAGING</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON</span></p>\n</div>", "ID": "e8115048-c5b8-465d-b70a-209461336246", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\nPACKAGING</span></p>", "ID": "5ec72984-5188-4bbd-840b-f089229d128c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e8115048-c5b8-465d-b70a-209461336246"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\nPACKAGING</span>", "ID": "9455b690-30c1-49b6-a91a-bc867d69f062", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "5ec72984-5188-4bbd-840b-f089229d128c"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3bf1e27e-abf1-4e3b-9ecf-e352170fbf44", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e8115048-c5b8-465d-b70a-209461336246"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a89ca109-9355-4b80-9fa3-1c4151f48058", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3bf1e27e-abf1-4e3b-9ecf-e352170fbf44"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON</span></p>", "ID": "7ab6ab53-ad5a-44e2-a05f-c61e4da206ea", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e8115048-c5b8-465d-b70a-209461336246"}, {"Element": "<span lang=\"EN-GB\">OUTER CARTON</span>", "ID": "7f4c0f81-0b90-4c8b-aa91-0d7e3a464db7", "Styles": "None", "Classes": "None", "Text": "OUTER CARTON", "ParentId": "7ab6ab53-ad5a-44e2-a05f-c61e4da206ea"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17111497-ee56-4b6d-862c-a6a5fd310f41", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f0418434-826f-450c-a92f-5f26338a3dec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17111497-ee56-4b6d-862c-a6a5fd310f41"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fa10c1e-28ec-417b-b9ac-f76a60da2a50", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2ad3a23-ebf3-4912-b495-c9a52b5acdcc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fa10c1e-28ec-417b-b9ac-f76a60da2a50"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</div>", "ID": "148a2cdd-5658-4d4b-a84a-c205d41f279f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "41611bf6-c972-4840-8e81-975a6878bfbf", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "148a2cdd-5658-4d4b-a84a-c205d41f279f"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "6528f101-f558-4c24-ae97-7a100b943dc9", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "41611bf6-c972-4840-8e81-975a6878bfbf"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "018cbbf1-6c41-412f-afd9-21b29e52dca7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "db8674b5-b481-475e-aa57-e83b7c9cbbe3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "018cbbf1-6c41-412f-afd9-21b29e52dca7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span></p>", "ID": "0935376b-fdd3-4fb8-82c4-4097864c636b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span>", "ID": "3a6ece4d-1bb4-472b-9073-6073fdfeb7b6", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate for solution for infusion", "ParentId": "0935376b-fdd3-4fb8-82c4-4097864c636b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">nivolumab</span></p>", "ID": "b1714714-4b07-411c-9c51-535d961812d1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">nivolumab</span>", "ID": "04ed1b7a-6d3b-4c4f-8556-954431a8ce8f", "Styles": "None", "Classes": "None", "Text": "nivolumab", "ParentId": "b1714714-4b07-411c-9c51-535d961812d1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa38652d-3dec-430f-a5f7-fae8bb3ac1f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3945d2d8-02a4-4365-8c62-8fef9ae7c75c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa38652d-3dec-430f-a5f7-fae8bb3ac1f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c2f09ab0-16ce-4cf2-9481-9c4928c100ef", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7578a246-b37c-43fd-a008-8b4ba8415dc3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c2f09ab0-16ce-4cf2-9481-9c4928c100ef"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></p>\n</div>", "ID": "25128cc2-55af-4e87-a7c3-635938f0ce65", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></p>", "ID": "66c1390f-bd08-4165-a52a-56927fd12f75", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "25128cc2-55af-4e87-a7c3-635938f0ce65"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "3a9c8ca4-ee12-484d-b463-58d9e7dd3645", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "66c1390f-bd08-4165-a52a-56927fd12f75"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b6cea3a-ff45-4ae9-bd56-113757760ca4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67020d6e-e8ba-4a8b-a98d-c1ce54eac516", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b6cea3a-ff45-4ae9-bd56-113757760ca4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span></p>", "ID": "a2e39955-4290-40b3-b708-ab701a0f9cf4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each mL of concentrate contains\u00a010\u00a0mg\nof nivolumab.</span>", "ID": "f10c1eab-77bf-439d-98a9-38362dd1e3e7", "Styles": "None", "Classes": "None", "Text": "Each mL of concentrate contains\u00a010\u00a0mg of nivolumab.", "ParentId": "a2e39955-4290-40b3-b708-ab701a0f9cf4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each vial of 4\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span></p>", "ID": "39570c9a-3756-4409-8e81-27254471e823", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each vial of 4\u00a0mL contains\u00a040\u00a0mg\nof nivolumab.</span>", "ID": "6530187d-5d08-4e24-a92f-af58108d9b37", "Styles": "None", "Classes": "None", "Text": "Each vial of 4\u00a0mL contains\u00a040\u00a0mg of nivolumab.", "ParentId": "39570c9a-3756-4409-8e81-27254471e823"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">Each vial of\n10\u00a0mL contains\u00a0100\u00a0mg of nivolumab.</span></p>", "ID": "c40e1989-6b0d-44be-9a44-a6c9240de96a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">Each vial of\n10\u00a0mL contains\u00a0100\u00a0mg of nivolumab.</span>", "ID": "4575ae6e-87f4-4b9b-a2c8-4f54d0a61f55", "Styles": "background:silver", "Classes": "None", "Text": "Each vial of 10\u00a0mL contains\u00a0100\u00a0mg of nivolumab.", "ParentId": "c40e1989-6b0d-44be-9a44-a6c9240de96a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "90c887c1-6d25-4bae-bc8c-0ae089b89cbf", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1798ebec-8d71-4708-9df3-a19f0b6c624f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90c887c1-6d25-4bae-bc8c-0ae089b89cbf"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f89fa62e-f201-4050-9ff3-e690249f997f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce13d081-abf7-4409-a4bd-488bcfd5da8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f89fa62e-f201-4050-9ff3-e690249f997f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></p>\n</div>", "ID": "9e4b734d-ede7-46b6-bc0a-c3cc96af476b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></p>", "ID": "ed3b8330-e6d8-4896-a584-d6124c029a2a", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "9e4b734d-ede7-46b6-bc0a-c3cc96af476b"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "f3e65085-7d9b-480c-9e90-25c43e45a4db", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "ed3b8330-e6d8-4896-a584-d6124c029a2a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71c3f0cf-3cac-43ca-8af6-8a5e001747e3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ca247dc-17bd-44c4-80ed-d22cf6f4f83a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71c3f0cf-3cac-43ca-8af6-8a5e001747e3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Excipients: sodium citrate dihydrate,\nsodium chloride, mannitol\u00a0(E421), pentetic acid, polysorbate\u00a080,\nsodium hydroxide, hydrochloric acid, water for injections.</span></p>", "ID": "b9750a39-2c14-4006-9d98-687cb0a1bee2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Excipients: sodium citrate dihydrate,\nsodium chloride, mannitol\u00a0(E421), pentetic acid, polysorbate\u00a080,\nsodium hydroxide, hydrochloric acid, water for injections.</span>", "ID": "5f826428-5178-4e79-89df-bfdb37e6ce4a", "Styles": "None", "Classes": "None", "Text": "Excipients: sodium citrate dihydrate, sodium chloride, mannitol\u00a0(E421), pentetic acid, polysorbate\u00a080, sodium hydroxide, hydrochloric acid, water for injections.", "ParentId": "b9750a39-2c14-4006-9d98-687cb0a1bee2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b404a90-9bc0-4289-9790-cd051f5ff388", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a2ab3ba-41da-47b4-b07b-4964d7780b81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b404a90-9bc0-4289-9790-cd051f5ff388"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">See leaflet\nfor further information.</span></p>", "ID": "5f7bcf7d-18c8-4256-8050-34186fc6e6b2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">See leaflet\nfor further information.</span>", "ID": "8cc79eb7-c093-4edd-854f-72a8d89ac8e2", "Styles": "background:silver", "Classes": "None", "Text": "See leaflet for further information.", "ParentId": "5f7bcf7d-18c8-4256-8050-34186fc6e6b2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span></p>", "ID": "9680b3af-41fa-4c15-af2a-e3e29c8163ee", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span>", "ID": "c7f221d5-70cf-43bc-b376-8846d5b36f3f", "Styles": "background:silver", "Classes": "None", "Text": "\u00a0", "ParentId": "9680b3af-41fa-4c15-af2a-e3e29c8163ee"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3bba17c5-8253-43f2-8bd9-bbefae28a41e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0321480a-53a2-4829-be36-5c809757d3b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3bba17c5-8253-43f2-8bd9-bbefae28a41e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></p>\n</div>", "ID": "b208c208-3ca0-4044-a222-318d8ffb87c6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></p>", "ID": "25cab388-af26-4025-a0c6-c50ad37b1c42", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "b208c208-3ca0-4044-a222-318d8ffb87c6"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "f13a9e94-d886-4b57-b5fc-2b1be5551eee", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "25cab388-af26-4025-a0c6-c50ad37b1c42"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e7c781f-cdaf-418a-93ff-03a01a94c51e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24f3edb1-81ce-4485-b2f8-07fd2e7b2c0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e7c781f-cdaf-418a-93ff-03a01a94c51e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">Concentrate\nfor solution for infusion.</span></p>", "ID": "511f3652-4169-41cd-97d6-6ae7662c29f1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">Concentrate\nfor solution for infusion.</span>", "ID": "8b76b434-eaed-4052-8a32-734760d2163a", "Styles": "background:silver", "Classes": "None", "Text": "Concentrate for solution for infusion.", "ParentId": "511f3652-4169-41cd-97d6-6ae7662c29f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c52084c3-4625-4e17-bb51-ee33db8a2d03", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0069148a-e65d-470f-8d32-73302cb3d278", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c52084c3-4625-4e17-bb51-ee33db8a2d03"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span></p>", "ID": "194a6406-156d-4a3e-8182-cdf11c547ab0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span>", "ID": "6b771393-5110-4f35-a4f3-7f8eb7f15fff", "Styles": "None", "Classes": "None", "Text": "40\u00a0mg/4\u00a0mL", "ParentId": "194a6406-156d-4a3e-8182-cdf11c547ab0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span></p>", "ID": "6e885f01-affc-44d8-b3de-c221655fa7dd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span>", "ID": "80440c99-74d5-4561-938a-5622c6114f13", "Styles": "background:silver", "Classes": "None", "Text": "100\u00a0mg/10\u00a0mL", "ParentId": "6e885f01-affc-44d8-b3de-c221655fa7dd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd3d30bc-bcf3-4e18-bfbb-63f1049e6551", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d3b6529-213f-4f6a-9b78-b1b9f1036646", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd3d30bc-bcf3-4e18-bfbb-63f1049e6551"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">1\u00a0vial</span></p>", "ID": "27fbb4a2-c4e8-4356-90fa-d3fae717be53", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">1\u00a0vial</span>", "ID": "d537a736-f734-469d-b0a5-af670489f7f7", "Styles": "None", "Classes": "None", "Text": "1\u00a0vial", "ParentId": "27fbb4a2-c4e8-4356-90fa-d3fae717be53"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d022b9a8-5a9e-407b-9e7a-11174eb74bd7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c16196ca-0cc6-490e-ab3c-8350d6b42f0c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d022b9a8-5a9e-407b-9e7a-11174eb74bd7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0245f454-aed0-47c9-88e9-98c1c03c8b14", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b02ddbc1-43ca-45d4-80ee-b5615abbe3fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0245f454-aed0-47c9-88e9-98c1c03c8b14"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></p>\n</div>", "ID": "54ae2324-3716-48c2-8ade-8d49596316b0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></p>", "ID": "e000548d-07f8-45a8-9f88-cc4a8bb644e4", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "54ae2324-3716-48c2-8ade-8d49596316b0"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "82248077-ed07-42d1-9137-86c1fab7a4d7", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "e000548d-07f8-45a8-9f88-cc4a8bb644e4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ffb8c77-fcfb-4334-bec7-75a5af429eae", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43191fa5-561c-4812-a9c0-9af0ab7bed2f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ffb8c77-fcfb-4334-bec7-75a5af429eae"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>", "ID": "c423b86e-b631-4a64-870a-ce532525364f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use.</span>", "ID": "a6499dd9-5503-4f85-8e95-333dff92468a", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "c423b86e-b631-4a64-870a-ce532525364f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Intravenous use.</span></p>", "ID": "a21c6d1d-a308-4e53-8836-f6d11c4f8d15", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Intravenous use.</span>", "ID": "5fc128a3-8bc8-4038-91b0-cf9a8292adeb", "Styles": "None", "Classes": "None", "Text": "Intravenous use.", "ParentId": "a21c6d1d-a308-4e53-8836-f6d11c4f8d15"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22818e0e-f55c-4fd6-a412-9581253f60f1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4250c07-1d27-486d-8386-901e41d51cf6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22818e0e-f55c-4fd6-a412-9581253f60f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "338485a9-05e9-4af8-b429-0c72c9322c04", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4f3b677-f2eb-4bb5-a652-22ced339fb3a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "338485a9-05e9-4af8-b429-0c72c9322c04"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE\nMEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>\n</div>", "ID": "f4289cb0-647c-4451-bf4a-9937b5b80941", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE\nMEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>", "ID": "fc528ac0-9e57-457f-a4d6-477070a4a5de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "f4289cb0-647c-4451-bf4a-9937b5b80941"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE\nMEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span>", "ID": "09bf4743-7d06-4a5d-ba1b-1287044e7946", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "fc528ac0-9e57-457f-a4d6-477070a4a5de"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5bd012b1-0127-43f3-904c-e69290706ba3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8907f339-c97f-4ee4-8181-a9fa104949fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5bd012b1-0127-43f3-904c-e69290706ba3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span></p>", "ID": "c523c2a9-ecc5-4ead-8691-3fe495e1f66e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of\nchildren.</span>", "ID": "01cc9f14-1a4f-4629-83c0-5142ad8f6f35", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children.", "ParentId": "c523c2a9-ecc5-4ead-8691-3fe495e1f66e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c4d52a6-860b-453d-b4e4-ec3fa05ce99e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9eb6b6b2-a088-4eb1-9216-eee5519536db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c4d52a6-860b-453d-b4e4-ec3fa05ce99e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "484c08cf-a2bd-439a-8da9-533d07d5370a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e805e3b5-20cc-42e5-89c3-5d813b420dd7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "484c08cf-a2bd-439a-8da9-533d07d5370a"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></p>\n</div>", "ID": "37d2e61a-f4ef-47c9-a770-5dbd8e0a8bda", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></p>", "ID": "fccbe4fc-4398-4ce9-8d1b-39c3165e4d17", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "37d2e61a-f4ef-47c9-a770-5dbd8e0a8bda"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "0e644562-f13d-42b1-9193-dfaef92011f5", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "fccbe4fc-4398-4ce9-8d1b-39c3165e4d17"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "717f35c4-cdc3-45b2-8003-5562a3445a80", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e81769c-0c8c-4aca-9c20-24ff031a86ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "717f35c4-cdc3-45b2-8003-5562a3445a80"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For single use only.</span></p>", "ID": "cd4bdca4-d3a6-4e54-af42-4ae6848e01d2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For single use only.</span>", "ID": "455f92dc-1a35-417a-87d1-8cec04a6a9ab", "Styles": "None", "Classes": "None", "Text": "For single use only.", "ParentId": "cd4bdca4-d3a6-4e54-af42-4ae6848e01d2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12da3ee7-6aae-4bc1-9e2c-126aee00a600", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ca81c86-50f4-447f-8742-68cad4fc3067", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12da3ee7-6aae-4bc1-9e2c-126aee00a600"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fb7faabf-22c2-4b48-8850-bfbad3ff6ca7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be3be344-16b9-4677-8a74-a1289ff5632b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fb7faabf-22c2-4b48-8850-bfbad3ff6ca7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>\n</div>", "ID": "b2883fc7-746c-4f9b-b77b-60e5c6b0d3db", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>", "ID": "3dae54b6-b945-47c2-bfdd-cedec6e6962c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "b2883fc7-746c-4f9b-b77b-60e5c6b0d3db"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "4a918b3b-ac6e-4332-a41b-02f7025c3c9a", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "3dae54b6-b945-47c2-bfdd-cedec6e6962c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dc2e3fd-33c5-4eac-8e76-343d463b92f3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83bbe1e4-e5ad-4f06-b9f7-0cd7428e7fa6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dc2e3fd-33c5-4eac-8e76-343d463b92f3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "56c40e14-2ca3-4f19-bbcb-8d2437a038ea", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "709988ca-40fa-4e8a-9457-522af62608a1", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "56c40e14-2ca3-4f19-bbcb-8d2437a038ea"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ede047cd-d941-4730-bb9d-aca6513cba34", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88916650-7e2e-4bed-b6cd-0c59a54a2eb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ede047cd-d941-4730-bb9d-aca6513cba34"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c244d849-06d6-4aac-9721-e48f6c213172", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3cee2139-21d6-43fa-80f7-bf19d2e0a892", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c244d849-06d6-4aac-9721-e48f6c213172"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></p>\n</div>", "ID": "0b2f5ef9-246f-440c-b435-e4635a37725c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></p>", "ID": "0c530560-46fc-4938-bae4-fd8b7e98bed8", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "0b2f5ef9-246f-440c-b435-e4635a37725c"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span>", "ID": "d18d92ca-e786-4739-b31c-f6ab182273f9", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "0c530560-46fc-4938-bae4-fd8b7e98bed8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c32ad87d-db4a-4364-a845-ec9150bba6be", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "791c1e67-3d74-4e78-a0e1-bcb6580445a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c32ad87d-db4a-4364-a845-ec9150bba6be"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator.</span></p>", "ID": "c828e7a7-ef02-458a-b6bb-b450f1d676d3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator.</span>", "ID": "e0c287fd-3913-4271-ac06-c0fcf6b1bbbe", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator.", "ParentId": "c828e7a7-ef02-458a-b6bb-b450f1d676d3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>", "ID": "a794c71a-684f-4de1-9afc-5d34c57cff68", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not freeze.</span>", "ID": "4df5f64b-3afc-4c54-a855-fd980186177d", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "a794c71a-684f-4de1-9afc-5d34c57cff68"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>", "ID": "73cb7779-b448-4b1d-b6a4-282d753774cb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span>", "ID": "ec687cb3-2461-446a-8851-3c30e8bd80c7", "Styles": "None", "Classes": "None", "Text": "Store in the original package in order to protect from light.", "ParentId": "73cb7779-b448-4b1d-b6a4-282d753774cb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "893a5104-4ff1-48d3-8f51-4b451f6e47f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "edbfdd0b-7b00-4b64-a71c-1293db32deb7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "893a5104-4ff1-48d3-8f51-4b451f6e47f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0615d69c-b2a0-4de9-8926-5502c738610f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d8fdaac-5ed7-438f-8dbd-3b4a455ada3f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0615d69c-b2a0-4de9-8926-5502c738610f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></p>\n</div>", "ID": "f0cfaeb3-64c5-4135-8481-c4201b624a15", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span></p>", "ID": "019d88ae-a154-4654-9ef6-b71d36ccca1d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "f0cfaeb3-64c5-4135-8481-c4201b624a15"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF\nUNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL\nPRODUCTS, IF APPROPRIATE</span>", "ID": "fad2b11a-add9-4020-8722-37d866ce0c18", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "019d88ae-a154-4654-9ef6-b71d36ccca1d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "327e79a7-7c4f-4168-94bd-a0fdb2cbbd9b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a66d48e-8e41-4e47-a621-4db442ebdcac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "327e79a7-7c4f-4168-94bd-a0fdb2cbbd9b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f739347f-2899-4713-82c3-72b83e93c837", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ba7410f-6f4d-4435-b9a9-b954573ea6aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f739347f-2899-4713-82c3-72b83e93c837"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f6d875c-31e5-40e5-bd3d-3ba9fce5e0a4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "082a3765-2fcd-4d67-85ef-4a89cd7eeda3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f6d875c-31e5-40e5-bd3d-3ba9fce5e0a4"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND\nADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>\n</div>", "ID": "5420f2de-4273-4808-ba26-1cd5d15ce691", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND\nADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>", "ID": "d62fb64f-82ac-4d9f-8186-3d2673fccf8c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "5420f2de-4273-4808-ba26-1cd5d15ce691"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND\nADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "d0bf5d0d-879e-4cf2-9f84-b44ea1333da8", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "d62fb64f-82ac-4d9f-8186-3d2673fccf8c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac770557-fc78-4586-a9d8-ba59568b14c8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5f66a16-ce29-45bb-b09c-dca292d1744e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac770557-fc78-4586-a9d8-ba59568b14c8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span></p>", "ID": "e972f0a4-82cd-4cd2-9b19-51a236556cbc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span>", "ID": "c8e1fb49-d986-4758-8c5c-3749f1ad288e", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb Pharma EEIG", "ParentId": "e972f0a4-82cd-4cd2-9b19-51a236556cbc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uxbridge Business Park</span></p>", "ID": "6e6c2516-cf20-47b5-b757-6370ce28a275", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Uxbridge Business Park</span>", "ID": "f6216149-57ac-4f76-b473-b730240c8c27", "Styles": "None", "Classes": "None", "Text": "Uxbridge Business Park", "ParentId": "6e6c2516-cf20-47b5-b757-6370ce28a275"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Sanderson Road</span></p>", "ID": "8df61c87-6f30-437b-b1f5-e842b63acf1a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Sanderson Road</span>", "ID": "eb84f082-d582-4dc9-87e8-4467bef45061", "Styles": "None", "Classes": "None", "Text": "Sanderson Road", "ParentId": "8df61c87-6f30-437b-b1f5-e842b63acf1a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span></p>", "ID": "56d506d5-94c4-47e2-814b-d92a3a824aa3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span>", "ID": "aae4de00-ba5e-42a7-8485-ff2f10747534", "Styles": "None", "Classes": "None", "Text": "Uxbridge UB8\u00a01DH", "ParentId": "56d506d5-94c4-47e2-814b-d92a3a824aa3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">United Kingdom<i><br/>\n<br/>\n</i></span></p>", "ID": "55a78314-8dfc-49bf-8628-8aa40656403a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">United Kingdom<i><br/>\n<br/>\n</i></span>", "ID": "c951fbaa-bd77-4425-9997-f6c7628f14ad", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "55a78314-8dfc-49bf-8628-8aa40656403a"}, {"Element": "<i><br/>\n<br/>\n</i>", "ID": "dc891720-12bd-4ab5-a9a7-12bf8e47a7f3", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c951fbaa-bd77-4425-9997-f6c7628f14ad"}, {"Element": "<br/>", "ID": "f1fbed54-0472-4142-bde6-4b3bdb8e3fb6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc891720-12bd-4ab5-a9a7-12bf8e47a7f3"}, {"Element": "<br/>", "ID": "41cab921-0a79-4308-8588-ee6596eaf247", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc891720-12bd-4ab5-a9a7-12bf8e47a7f3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae73be0d-fbc4-48bf-aa64-dff1fcdf0526", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62d1389c-6207-466b-b82c-6db447eecc34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae73be0d-fbc4-48bf-aa64-dff1fcdf0526"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></p>\n</div>", "ID": "3ebb123d-29ee-41a6-b664-26a5304a62bd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span></p>", "ID": "3dc84005-971b-41fa-9274-3697ea790a0c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "3ebb123d-29ee-41a6-b664-26a5304a62bd"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S) </span>", "ID": "c1bff50f-a446-4f45-bdc4-b661d9fed826", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S) ", "ParentId": "3dc84005-971b-41fa-9274-3697ea790a0c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cebb607b-1331-469c-80f5-b83aa4a74fc2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "32179ad5-576e-4f88-95cb-aadd39df8ab1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cebb607b-1331-469c-80f5-b83aa4a74fc2"}, {"Element": "<p class=\"EMEABodyText\">EU/1/15/1026/001\u00a0<span style=\"background:silver\">40\u00a0mg\nvial</span></p>", "ID": "62cc5fba-7d89-4312-8c1e-99881f037135", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "EU/1/15/1026/001\u00a0", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span style=\"background:silver\">40\u00a0mg\nvial</span>", "ID": "779711a2-7472-471f-af48-06fcca461241", "Styles": "background:silver", "Classes": "None", "Text": "40\u00a0mg vial", "ParentId": "62cc5fba-7d89-4312-8c1e-99881f037135"}, {"Element": "<p class=\"EMEABodyText\"><span style=\"background:silver\">EU/1/15/1026/002\u00a0100\u00a0mg\nvial</span></p>", "ID": "e9b06e45-b978-45bb-8aa5-fe9c0434649b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span style=\"background:silver\">EU/1/15/1026/002\u00a0100\u00a0mg\nvial</span>", "ID": "d4e4e27f-8d6a-4297-b84a-d17c3d49afc8", "Styles": "background:silver", "Classes": "None", "Text": "EU/1/15/1026/002\u00a0100\u00a0mg vial", "ParentId": "e9b06e45-b978-45bb-8aa5-fe9c0434649b"}, {"Element": "<p class=\"EMEABodyText\">\u00a0</p>", "ID": "1169f075-eb27-4cd3-a03c-4ee746490f63", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "\u00a0", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEABodyText\">\u00a0</p>", "ID": "3bc09a9f-22fb-4c37-873a-7d41aecc83cd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "\u00a0", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></p>\n</div>", "ID": "4a291d3d-7ac5-49f0-9e2b-ad61fb3888f5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></p>", "ID": "32781ec5-0eec-4b83-a82d-3e7eb49ba1ae", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "4a291d3d-7ac5-49f0-9e2b-ad61fb3888f5"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span>", "ID": "9e1080a1-51d5-4972-b71e-4b2a31cbf161", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "32781ec5-0eec-4b83-a82d-3e7eb49ba1ae"}, {"Element": "<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "5576e44b-72c2-4da5-b7df-44e64f1f291d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "c750b2ef-0335-493a-9e58-be5e5a6bc339", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5576e44b-72c2-4da5-b7df-44e64f1f291d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "049baeb4-f89a-47bf-8dee-d9d9ca8a2d8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c750b2ef-0335-493a-9e58-be5e5a6bc339"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "7d1a9782-d595-4e46-8779-64a049c53a78", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "63da57da-aac9-4d0e-87f3-d7abb2b6de11", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "7d1a9782-d595-4e46-8779-64a049c53a78"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12641a6d-75ae-45d9-89e0-cd47f6d8f63c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3f7bcb4-000e-4764-8fb2-85cffbbb53fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12641a6d-75ae-45d9-89e0-cd47f6d8f63c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76fee970-047a-4782-8a0a-436b0ae0cacd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c22a4d5-4f8e-4cf8-9cca-6413123cb90b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76fee970-047a-4782-8a0a-436b0ae0cacd"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></p>\n</div>", "ID": "b22de535-6537-46e5-a2ed-e6e41b48fc77", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></p>", "ID": "6c78c982-1819-46d0-a179-2117b083b26c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "b22de535-6537-46e5-a2ed-e6e41b48fc77"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span>", "ID": "4d76b8d4-2b3a-4998-8ec9-8787d3bd7bf0", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "6c78c982-1819-46d0-a179-2117b083b26c"}, {"Element": "<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "3bd4cb0e-b748-4dd8-9fd4-127309122c49", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "c4a8ebb2-62f6-4214-a8bd-ec6cfb625723", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3bd4cb0e-b748-4dd8-9fd4-127309122c49"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b0b3004-d828-47d9-ad93-ef38fbf0a1bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4a8ebb2-62f6-4214-a8bd-ec6cfb625723"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de283664-e9f0-48e5-92a2-0751b9d49022", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d251706-4e61-49b5-912e-45be850bcd56", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de283664-e9f0-48e5-92a2-0751b9d49022"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b8c4d96-0d6a-4284-894c-830f5f3cbcb0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3db4020f-17a7-48d8-b62b-5e5f93c30b29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b8c4d96-0d6a-4284-894c-830f5f3cbcb0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></p>\n</div>", "ID": "a53a8114-ce1a-4b9b-aef2-aa95e94543b3", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></p>", "ID": "9d1dfaa2-d686-4580-9fbd-a40e2292ac3c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "a53a8114-ce1a-4b9b-aef2-aa95e94543b3"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "b64e141d-3054-471b-afb8-4e19082c4fb1", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "9d1dfaa2-d686-4580-9fbd-a40e2292ac3c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40f58b5d-3594-47c1-88d4-7585af4c8356", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93a0b243-f34c-4e4a-9982-6d42a9e613ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40f58b5d-3594-47c1-88d4-7585af4c8356"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2aaf02ad-439c-4a6c-a452-1dd95aa44485", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2892bdf-11c9-40ac-9d6d-da5b83620bee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2aaf02ad-439c-4a6c-a452-1dd95aa44485"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be828c0b-4963-4a91-8ea9-d60fc947840c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "90192ce3-2732-4243-a72b-c9cbefc029a3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be828c0b-4963-4a91-8ea9-d60fc947840c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></p>\n</div>", "ID": "e025d0e3-7177-48b6-9237-80b55cc6b83f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></p>", "ID": "7f517f0b-7da5-4804-a0e7-8cc744bc891c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e025d0e3-7177-48b6-9237-80b55cc6b83f"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span>", "ID": "04a23b87-4995-4ea5-b595-d79c972c5924", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "7f517f0b-7da5-4804-a0e7-8cc744bc891c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c65c2bbf-78d3-460d-8981-9890daefea91", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a60b548-15f1-4ecb-8735-4eb0adbee30f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c65c2bbf-78d3-460d-8981-9890daefea91"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification\nfor not including Braille accepted</span><span lang=\"EN-GB\" style=\"color:black;\nbackground:#CCCCCC\">.</span></p>", "ID": "3fe5badb-374d-4bf3-8192-f5654eb7dcdc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification\nfor not including Braille accepted</span>", "ID": "dd74feb9-8fdf-4973-a706-0c82a312b935", "Styles": "color:black;background:silver", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "3fe5badb-374d-4bf3-8192-f5654eb7dcdc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;\nbackground:#CCCCCC\">.</span>", "ID": "34fd4156-27b2-4292-87e7-1bff08f66e5d", "Styles": "color:black;\nbackground:#CCCCCC", "Classes": "None", "Text": ".", "ParentId": "3fe5badb-374d-4bf3-8192-f5654eb7dcdc"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;text-transform:uppercase;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "6b49555b-cf3a-43c1-b37b-74ab316902e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;text-transform:uppercase;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2d6ca5d7-6b05-41a7-9fb5-935a040d2b23", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black;text-transform:uppercase;background:#CCCCCC", "Classes": "None", "Text": " ", "ParentId": "6b49555b-cf3a-43c1-b37b-74ab316902e2"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "313bfd3c-a202-4af9-b023-d67ada10cdaf", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2d6ca5d7-6b05-41a7-9fb5-935a040d2b23"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">minimum PARTICULARS TO APPEAR ON small\nIMMEDIATE PACKAGING units</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">VIAL LABEL</span></p>\n</div>", "ID": "7f411752-62d9-4241-a690-8219b1264fcf", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">minimum PARTICULARS TO APPEAR ON small\nIMMEDIATE PACKAGING units</span></p>", "ID": "635e50f4-6ca1-4f22-a2d4-346c72735aa3", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "7f411752-62d9-4241-a690-8219b1264fcf"}, {"Element": "<span lang=\"EN-GB\">minimum PARTICULARS TO APPEAR ON small\nIMMEDIATE PACKAGING units</span>", "ID": "7c447730-4808-41c7-9494-27cd30110e29", "Styles": "None", "Classes": "None", "Text": "minimum PARTICULARS TO APPEAR ON small IMMEDIATE PACKAGING units", "ParentId": "635e50f4-6ca1-4f22-a2d4-346c72735aa3"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f92d651e-c516-429c-84a6-b66c3a518b8c", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "7f411752-62d9-4241-a690-8219b1264fcf"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "973d1f3c-2835-424c-b80f-2ada31cc2d29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f92d651e-c516-429c-84a6-b66c3a518b8c"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">VIAL LABEL</span></p>", "ID": "41906c26-ddad-400e-aed7-9b7bc578b94b", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "7f411752-62d9-4241-a690-8219b1264fcf"}, {"Element": "<span lang=\"EN-GB\">VIAL LABEL</span>", "ID": "0e3cb7a9-2cfc-41dd-b11e-239cdd98d896", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "41906c26-ddad-400e-aed7-9b7bc578b94b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e186853-94bc-44fb-b45e-18202cddd0ae", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ab38631-4512-4e52-9e9f-f3a263cca248", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e186853-94bc-44fb-b45e-18202cddd0ae"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8018606-66b9-4177-8e0f-859b0b9fd10b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b82ed31-e14b-4d1a-ab12-59b794952628", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8018606-66b9-4177-8e0f-859b0b9fd10b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>\n</div>", "ID": "cf02c99d-11b6-4cfc-8082-e357a2e73805", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>", "ID": "e32a8dca-6285-412f-b117-eff29e063517", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "cf02c99d-11b6-4cfc-8082-e357a2e73805"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span>", "ID": "7bfc7ca2-0cb3-4ded-98e1-debdad0857d2", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "e32a8dca-6285-412f-b117-eff29e063517"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7677ac26-2416-4bcc-b41c-318ae4d4e9bb", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a05b30e0-025f-4e35-ae52-386a0cf8ea85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7677ac26-2416-4bcc-b41c-318ae4d4e9bb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nsterile concentrate</span></p>", "ID": "c83a4b46-e0c3-4398-9844-eb3af319a44c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL\nsterile concentrate</span>", "ID": "5fb8c848-1c68-4e2b-ba99-47f63021e99f", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS\u00a010\u00a0mg/mL sterile concentrate", "ParentId": "c83a4b46-e0c3-4398-9844-eb3af319a44c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">nivolumab</span></p>", "ID": "81721dcf-bbf4-4442-bcc8-b59c72ad5409", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">nivolumab</span>", "ID": "b19b93c1-5573-452d-ab81-78ebdfc23723", "Styles": "None", "Classes": "None", "Text": "nivolumab", "ParentId": "81721dcf-bbf4-4442-bcc8-b59c72ad5409"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">IV use</span></p>", "ID": "5ac72df1-03a4-44a0-8e76-b35a9187cb79", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">IV use</span>", "ID": "c2c86ca9-6272-493c-9f5d-6664c688637f", "Styles": "None", "Classes": "None", "Text": "IV use", "ParentId": "5ac72df1-03a4-44a0-8e76-b35a9187cb79"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b3596c7-aa41-4b33-bfd2-3f3f87b51779", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b86523b4-2064-495c-a112-0d1d5d325e44", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b3596c7-aa41-4b33-bfd2-3f3f87b51779"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "36e0e748-43cd-450c-a4c6-cec47a6673c1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3430834-d7d3-44db-bf46-f812f1d07847", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36e0e748-43cd-450c-a4c6-cec47a6673c1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></p>\n</div>", "ID": "e606a1e1-6057-4a6b-8bca-3f625506d89f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span></p>", "ID": "f94ade3c-5012-4507-a4c8-4fa18132c570", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e606a1e1-6057-4a6b-8bca-3f625506d89f"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</span>", "ID": "e006cda0-9a65-4800-b051-ceb083789e35", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "f94ade3c-5012-4507-a4c8-4fa18132c570"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b37335ab-e319-49c0-b541-ee446ed14a4d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c0e1047-3f7b-4901-8b13-0b89f9dc3f83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b37335ab-e319-49c0-b541-ee446ed14a4d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>", "ID": "3b5b0690-c94b-495a-b2d5-388ad74e4fcc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use.</span>", "ID": "832b9bf2-8dd9-4fef-ad93-7ce288edb8b7", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "3b5b0690-c94b-495a-b2d5-388ad74e4fcc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aea062cd-5c64-4fc9-ba9d-70764c910c6e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0bc0bb51-f874-430b-8856-c07a0ba5f2d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aea062cd-5c64-4fc9-ba9d-70764c910c6e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38da4215-f620-4855-a11d-65f07b376520", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f851cdf-fab5-4a42-9c07-00fc7923c776", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38da4215-f620-4855-a11d-65f07b376520"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>\n</div>", "ID": "fddc16d9-fb72-4fe6-9d71-b806191e251b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></p>", "ID": "c0d1a1b7-1a39-44ac-ac1e-b3368eb31877", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "fddc16d9-fb72-4fe6-9d71-b806191e251b"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "f12abced-cb06-4114-910f-8f9cfc50ca81", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "c0d1a1b7-1a39-44ac-ac1e-b3368eb31877"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf36874c-9279-4ba5-8a00-94936985d1b7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "af3efec4-e2c0-40be-8ed2-93028fc6ed4c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf36874c-9279-4ba5-8a00-94936985d1b7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "7b1d6707-4f32-4f3a-b487-6505c71d087e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "fb23421b-375b-4f7c-aada-b7a2a330d5c4", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "7b1d6707-4f32-4f3a-b487-6505c71d087e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f426cbd-8901-4dfa-bb28-71372c4bec1a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93a1dd3c-b46d-4d29-9f21-149a9dcf6e59", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f426cbd-8901-4dfa-bb28-71372c4bec1a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f2f83cbb-dd1c-4043-8b36-3abb1403cf81", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83badeca-9854-49de-b7ba-2d97236c32fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f2f83cbb-dd1c-4043-8b36-3abb1403cf81"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></p>\n</div>", "ID": "cca1096b-8c5b-4b14-8101-a5a40d422e40", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></p>", "ID": "87aa9b3f-fb76-43f2-aa6c-a531576cf309", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "cca1096b-8c5b-4b14-8101-a5a40d422e40"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "875924ee-15a3-4af3-a722-52d98e49e0e5", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "87aa9b3f-fb76-43f2-aa6c-a531576cf309"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bbb0e6b7-b0c6-40d8-b793-231275c7d5e7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2f4a577-e927-419b-9725-a9e138d667ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bbb0e6b7-b0c6-40d8-b793-231275c7d5e7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "7ff23237-1999-478a-9567-83574c72fa99", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "2c711756-bc4b-4e63-8d73-e7925e86f9e5", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "7ff23237-1999-478a-9567-83574c72fa99"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cad1a670-7cf3-4db7-b0b9-4d8bff98f951", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5117abcc-ef1c-4a74-853d-406063216b60", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cad1a670-7cf3-4db7-b0b9-4d8bff98f951"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4412f954-aef9-4053-b729-81ce73111b3a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8516f113-5637-42f1-86bc-bbfa731a3049", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4412f954-aef9-4053-b729-81ce73111b3a"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></p>\n</div>", "ID": "16e1c8cf-0884-4cb3-b0a8-fbb9af29cf2c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span></p>", "ID": "80241f17-d263-460d-b0ca-d3f3a1670036", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "16e1c8cf-0884-4cb3-b0a8-fbb9af29cf2c"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</span>", "ID": "11c7d1b7-f8c0-4d26-bed7-e98e4c9d5209", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "80241f17-d263-460d-b0ca-d3f3a1670036"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "790d252d-df5e-40d1-9426-277e61b46423", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c6ea72fd-970d-40fe-b929-13148627f328", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "790d252d-df5e-40d1-9426-277e61b46423"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span></p>", "ID": "58e99399-e0fd-409d-b178-137c702416b3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">40\u00a0mg/4\u00a0mL</span>", "ID": "6ef67a26-6af6-44f3-a930-4317aebf2c44", "Styles": "None", "Classes": "None", "Text": "40\u00a0mg/4\u00a0mL", "ParentId": "58e99399-e0fd-409d-b178-137c702416b3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span></p>", "ID": "f2eb8e91-ba77-4b6b-a8d9-f7c7ccffd421", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">100\u00a0mg/10\u00a0mL</span>", "ID": "8d17ad56-5b66-4f97-b47c-e507bb84660e", "Styles": "background:silver", "Classes": "None", "Text": "100\u00a0mg/10\u00a0mL", "ParentId": "f2eb8e91-ba77-4b6b-a8d9-f7c7ccffd421"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "401d02fd-0eb2-48f1-9b5e-2cce68e0adba", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dfebcfdb-7dc7-45c4-92d9-d73f5fd92dbd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "401d02fd-0eb2-48f1-9b5e-2cce68e0adba"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cfa942e8-7ef7-4afb-8c03-bdb703cbcf1d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79c10673-91f6-4caa-bfc6-732e550d8d96", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cfa942e8-7ef7-4afb-8c03-bdb703cbcf1d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></p>\n</div>", "ID": "e89b6c18-fd4a-4895-9124-c39102c54871", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></p>", "ID": "5c6c19ff-2819-4000-947a-c4b5821fdd05", "Styles": "None", "Classes": "['EMEATitlePAC']", "Text": "", "ParentId": "e89b6c18-fd4a-4895-9124-c39102c54871"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span>", "ID": "71179fd4-f896-46d9-8dae-3866d782466c", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "5c6c19ff-2819-4000-947a-c4b5821fdd05"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ce9a738-ddc7-4655-a27d-379c6e632387", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9ae8e20-9d31-4fdd-820a-486e83fd0112", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ce9a738-ddc7-4655-a27d-379c6e632387"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For single use only.</span></p>", "ID": "00869350-7278-4154-8a22-7c0c33513eb5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For single use only.</span>", "ID": "d29b9928-d32f-4acb-911c-b9f11fe6711f", "Styles": "None", "Classes": "None", "Text": "For single use only.", "ParentId": "00869350-7278-4154-8a22-7c0c33513eb5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "e74b9f3b-f15c-4a59-b0e5-e5cd324d9c2a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span>", "ID": "bc5f7f26-bb5c-4fda-8fef-15cfd4ec6659", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "e74b9f3b-f15c-4a59-b0e5-e5cd324d9c2a"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "bed67fba-2350-4cf3-9e9b-bdcfb8ce4437", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "19a7e94b-1b36-4166-bec6-ea048c7692d3", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "bed67fba-2350-4cf3-9e9b-bdcfb8ce4437"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b858dae-7d0b-4a67-82fa-26f4bc22e018", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dacb65b1-6f1c-49aa-8d4b-3599080eeb9e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b858dae-7d0b-4a67-82fa-26f4bc22e018"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b311c5e-f8de-451e-b17d-aae8b5caa302", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dc1746b5-2536-416b-b286-882238c51379", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b311c5e-f8de-451e-b17d-aae8b5caa302"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d023cd6-ed25-486a-ad19-a6f3282a7d6b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a048f0e2-5606-4e4a-a652-1a2dbba05d9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d023cd6-ed25-486a-ad19-a6f3282a7d6b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8967f34a-636c-4a46-a233-37ef367b0e95", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e63795b-5d75-460c-a16c-a8da3b43f220", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8967f34a-636c-4a46-a233-37ef367b0e95"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff367a36-84a5-4709-9e29-0753f613b32d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5dcd56bd-2111-4e37-bf39-c876ae4e6f80", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff367a36-84a5-4709-9e29-0753f613b32d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2de966bc-8eb3-4aee-8f1e-c0fe65f79f71", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9fa7bf29-05d4-454c-b068-9aee7000554d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2de966bc-8eb3-4aee-8f1e-c0fe65f79f71"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b92f844f-69a1-4318-ba4e-8b4bf224985f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88f24abd-3ea1-448c-b9f2-f3f50fba8a89", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b92f844f-69a1-4318-ba4e-8b4bf224985f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1013cf46-7096-4836-a45d-b4edaf1ba4f9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6095bb5a-db21-4ff2-86ff-a7c311f5a44b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1013cf46-7096-4836-a45d-b4edaf1ba4f9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95faa394-44df-44a0-9b79-dfded9a2670d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63388826-7252-4119-a310-c78533032e2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95faa394-44df-44a0-9b79-dfded9a2670d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "abcb0be3-1c16-4568-a662-630cc43ba2e9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1234950-7e4a-46a0-9b67-2b461aaa5ebf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "abcb0be3-1c16-4568-a662-630cc43ba2e9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1869d511-7c89-40aa-b39b-e8eed73cd7d9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0443ef64-d736-4d62-97da-85cd52516a5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1869d511-7c89-40aa-b39b-e8eed73cd7d9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "841e0fa4-77a4-4d91-b8b9-1b31be39523e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a688383-b874-4a1c-81f2-39effed4d02d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "841e0fa4-77a4-4d91-b8b9-1b31be39523e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "947dff84-8207-459b-b341-70d6b76a09c3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01ac7ebd-0f82-4352-8a88-25f35fddc8ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "947dff84-8207-459b-b341-70d6b76a09c3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5a0641d5-213c-4acb-a08e-4d6260dc1d60", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "751c159a-0f4c-4c3f-bf48-55ed5590bba9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5a0641d5-213c-4acb-a08e-4d6260dc1d60"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c3f4fe1e-604b-4b61-9ea7-1e04cb0d857b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7b3a3c9-7bb2-4672-a280-246372131ca4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c3f4fe1e-604b-4b61-9ea7-1e04cb0d857b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3161aabc-61f3-4ce3-9f7c-6819599d6e20", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aee2ea2a-c514-4b01-8bb2-76cc3d9bec1f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3161aabc-61f3-4ce3-9f7c-6819599d6e20"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1237a575-c0b5-4215-ba90-06eb07937974", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34b6396f-d325-4e95-ae4d-f7e6de528fb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1237a575-c0b5-4215-ba90-06eb07937974"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8191cf87-e099-4835-b391-01e15c3c8fa4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6d020710-4818-49e2-8150-7c77a659e192", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8191cf87-e099-4835-b391-01e15c3c8fa4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55d5d714-2df2-4943-a441-adc02990a60e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88485b99-f5a7-4d84-a6c5-e74512373a70", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55d5d714-2df2-4943-a441-adc02990a60e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b984e752-3bd7-47fa-bb84-5bc9788dbf41", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9d315d8-11cd-4aaa-a798-ae0a81b69eb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b984e752-3bd7-47fa-bb84-5bc9788dbf41"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bc9d1f2-e575-48dd-9f56-bb6e8598ec00", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b2b428a-bf1e-4b20-9c34-f6a5258bef51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bc9d1f2-e575-48dd-9f56-bb6e8598ec00"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56240965-6e75-44bb-9c10-113a388f41d8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea5dbfe5-336d-4abe-9083-bb4929872130", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56240965-6e75-44bb-9c10-113a388f41d8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fedef7d1-fd38-4714-b19f-dfe98762e9d9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4614c960-3165-4b58-b7e2-7f053e440d6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fedef7d1-fd38-4714-b19f-dfe98762e9d9"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>", "ID": "239da3c6-8c8c-4f1f-b939-9e543175c857", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">B. PACKAGE LEAFLET</span>", "ID": "f075ee8d-554b-43a9-acf8-f2513d5a9df5", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "239da3c6-8c8c-4f1f-b939-9e543175c857"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "f92a1e37-95dc-430c-bd9f-90763fb5a4b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "6964f519-1a71-48ad-8d5b-c3290a8f3560", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "f92a1e37-95dc-430c-bd9f-90763fb5a4b5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "3e9a659a-221d-4963-978f-d879be6eb740", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "6964f519-1a71-48ad-8d5b-c3290a8f3560"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">Package leaflet: Information for the user</span></p>", "ID": "52bf4256-5faf-4dce-9f6a-28080a66dc72", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Package leaflet: Information for the user</span>", "ID": "7cc99455-a0eb-4443-8d1d-09ab7c925be1", "Styles": "None", "Classes": "None", "Text": "Package leaflet: Information for the user", "ParentId": "52bf4256-5faf-4dce-9f6a-28080a66dc72"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9eaaca54-f668-4d0b-9ef6-9bb549f0fb5b", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7193412-9f7b-49e3-bc47-4aba4f0196b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9eaaca54-f668-4d0b-9ef6-9bb549f0fb5b"}, {"Element": "<p class=\"EMEATitle\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span></p>", "ID": "3466cde5-242c-490f-b96d-3cbe3719494a", "Styles": "None", "Classes": "['EMEATitle']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate\nfor solution for infusion</span>", "ID": "3f191a30-76a6-4801-abdd-700ed93ea48d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS\u00a010\u00a0mg/mL concentrate for solution for infusion", "ParentId": "3466cde5-242c-490f-b96d-3cbe3719494a"}, {"Element": "<p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><span lang=\"EN-GB\">nivolumab</span></p>", "ID": "ab39b185-f926-4ae4-a62d-50028c8d090a", "Styles": "text-align:center", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">nivolumab</span>", "ID": "717627c9-a5e8-475e-affc-2925c101291f", "Styles": "None", "Classes": "None", "Text": "nivolumab", "ParentId": "ab39b185-f926-4ae4-a62d-50028c8d090a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ad4cce0-0aa5-4d42-af58-b2a1e604aac4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f4042ab-1593-4e87-9d73-1cf5717146b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ad4cce0-0aa5-4d42-af58-b2a1e604aac4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image006.gif\" width=\"21\"/></span><span lang=\"EN-GB\">This medicine is subject to\nadditional monitoring. This will allow quick identification of new safety\ninformation. You can help by reporting any side effects you may get. See the\nend of section\u00a04 for how to report side effects.</span></p>", "ID": "a197b161-6975-48f1-8ca1-ddf0890954b7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\"><img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image006.gif\" width=\"21\"/></span>", "ID": "371a365d-2336-44bb-93fb-b3ac2fde3e1b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a197b161-6975-48f1-8ca1-ddf0890954b7"}, {"Element": "<img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" src=\"Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image006.gif\" width=\"21\"/>", "ID": "18388e05-9008-467d-b74d-aa020c5e5d04", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "371a365d-2336-44bb-93fb-b3ac2fde3e1b"}, {"Element": "<span lang=\"EN-GB\">This medicine is subject to\nadditional monitoring. This will allow quick identification of new safety\ninformation. You can help by reporting any side effects you may get. See the\nend of section\u00a04 for how to report side effects.</span>", "ID": "55dcd81b-6bfc-429e-9e75-3d53ccdcb3e8", "Styles": "None", "Classes": "None", "Text": "This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section\u00a04 for how to report side effects.", "ParentId": "a197b161-6975-48f1-8ca1-ddf0890954b7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "313738b1-e812-490f-9ef3-77cd8d907c58", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e429e617-fb38-400a-86d9-1f37da369925", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "313738b1-e812-490f-9ef3-77cd8d907c58"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start using this medicine because it contains important information\nfor you.</span></b></p>", "ID": "e8a8c70c-eff6-4ca5-a1c4-6d645ade740b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start using this medicine because it contains important information\nfor you.</span></b>", "ID": "1558fcb3-00f0-405a-8b67-5d288788549a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8a8c70c-eff6-4ca5-a1c4-6d645ade740b"}, {"Element": "<span lang=\"EN-GB\">Read all of this leaflet carefully\nbefore you start using this medicine because it contains important information\nfor you.</span>", "ID": "aacc388f-506e-4c19-8b5f-e374a97c7ca8", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start using this medicine because it contains important information for you.", "ParentId": "1558fcb3-00f0-405a-8b67-5d288788549a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this leaflet. You may need to read\nit again. </span></p>", "ID": "53290804-5f5f-4b9c-852a-dc2d9270f742", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Keep this leaflet. You may need to read\nit again. </span>", "ID": "e973a88f-6612-4472-9d51-fac7be29e8a6", "Styles": "None", "Classes": "None", "Text": "Keep this leaflet. You may need to read it again. ", "ParentId": "53290804-5f5f-4b9c-852a-dc2d9270f742"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is important that you keep the Alert\nCard with you during treatment.</span></p>", "ID": "09085a66-f87f-4032-af70-1a74bae6ce9e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">It is important that you keep the Alert\nCard with you during treatment.</span>", "ID": "4f357432-1a35-4c83-a003-69c15edfcc90", "Styles": "None", "Classes": "None", "Text": "It is important that you keep the Alert Card with you during treatment.", "ParentId": "09085a66-f87f-4032-af70-1a74bae6ce9e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions, ask\nyour doctor.</span></p>", "ID": "ad23c189-1228-4eac-b894-b186942a0358", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions, ask\nyour doctor.</span>", "ID": "89dd6eba-33fe-4458-a062-0e5c97a3761b", "Styles": "None", "Classes": "None", "Text": "If you have any further questions, ask your doctor.", "ParentId": "ad23c189-1228-4eac-b894-b186942a0358"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\nyour doctor.</span><span lang=\"EN-GB\"> This includes any possible side effects\nnot listed in this leaflet. See section\u00a04.</span></p>", "ID": "bc69e6bf-bb92-4ff9-b256-8013c905d9bd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, talk to\nyour doctor.</span>", "ID": "18f058bd-a383-46f0-bd8d-51ead2e8e41d", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor.", "ParentId": "bc69e6bf-bb92-4ff9-b256-8013c905d9bd"}, {"Element": "<span lang=\"EN-GB\"> This includes any possible side effects\nnot listed in this leaflet. See section\u00a04.</span>", "ID": "480c2948-4146-4166-97a4-0a663c1f03c2", "Styles": "None", "Classes": "None", "Text": " This includes any possible side effects not listed in this leaflet. See section\u00a04.", "ParentId": "bc69e6bf-bb92-4ff9-b256-8013c905d9bd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f807efb6-f2d0-4113-9130-dd14b009b93d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f03c1738-6efc-4566-a452-27d431b81131", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f807efb6-f2d0-4113-9130-dd14b009b93d"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nis in this leaflet</span></b></p>", "ID": "b8a37d86-1583-4afd-837f-cc90945eb9cc", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">What\nis in this leaflet</span></b>", "ID": "6c3cdf92-cdaf-4697-a788-94bdc0aa1e77", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8a37d86-1583-4afd-837f-cc90945eb9cc"}, {"Element": "<span lang=\"EN-GB\">What\nis in this leaflet</span>", "ID": "a43dcfab-df5f-46d6-ae1b-7a1ccedf93f6", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet", "ParentId": "6c3cdf92-cdaf-4697-a788-94bdc0aa1e77"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "b94d6bf1-bc39-44b2-99ee-9f3e14a0ae51", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "3d46e06a-9844-4084-baaf-526f02bdd4ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b94d6bf1-bc39-44b2-99ee-9f3e14a0ae51"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2acd1d13-628c-4a34-bf5d-1329a37a2146", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d46e06a-9844-4084-baaf-526f02bdd4ce"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for </span></p>", "ID": "aec38df6-a966-4c95-9776-6212d5ef8dd5", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for </span>", "ID": "2390620a-e8d7-47a4-8e33-e2ff217fb1e8", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Nivolumab\u00a0BMS is and what it is used for ", "ParentId": "aec38df6-a966-4c95-9776-6212d5ef8dd5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span></p>", "ID": "a8f3b2d1-e601-4337-883d-54b5ae3fc293", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span>", "ID": "a4ed0bba-6429-4e73-b4e4-1f2430fbe02c", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you use Nivolumab\u00a0BMS", "ParentId": "a8f3b2d1-e601-4337-883d-54b5ae3fc293"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto use Nivolumab\u00a0BMS</span></p>", "ID": "94cb00b6-3b92-4a8f-b64d-e6db1c661ff1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto use Nivolumab\u00a0BMS</span>", "ID": "5636fa1c-2874-4fcb-b274-b39a51c17c13", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to use Nivolumab\u00a0BMS", "ParentId": "94cb00b6-3b92-4a8f-b64d-e6db1c661ff1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>", "ID": "5783a7f9-1e17-4ff5-99d0-68ba82cbed00", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "1bbc6798-895a-495f-be7d-3f56a1381366", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "5783a7f9-1e17-4ff5-99d0-68ba82cbed00"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span></p>", "ID": "3b04f6aa-be66-44f9-9524-3b6ae9647389", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span>", "ID": "230e04b2-8ca2-4186-a1cf-faea4a814a3d", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Nivolumab\u00a0BMS", "ParentId": "3b04f6aa-be66-44f9-9524-3b6ae9647389"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>", "ID": "10d7ab24-6400-4e33-b798-9f7f3bfa4d6f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span>", "ID": "be3aa241-c75f-4529-a796-a12d4d986b1c", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "10d7ab24-6400-4e33-b798-9f7f3bfa4d6f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b5e8ba41-872a-4385-b664-f77a46df4556", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfbf869f-52e3-4b15-ab3d-eb5db78ec165", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5e8ba41-872a-4385-b664-f77a46df4556"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e7bf784-4418-4b2a-9ff5-a447fab05751", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a59873a4-d96f-4700-9bb1-7ebcada53da4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e7bf784-4418-4b2a-9ff5-a447fab05751"}, {"Element": "<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for</span></p>", "ID": "decf5730-5bb9-40ee-a142-dc0d995579c0", "Styles": "None", "Classes": "['EMEAHeading3']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nNivolumab\u00a0BMS is and what it is used for</span>", "ID": "18da2a77-7920-4ae2-be2f-040f9d2d48fe", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Nivolumab\u00a0BMS is and what it is used for", "ParentId": "decf5730-5bb9-40ee-a142-dc0d995579c0"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d2d8408-8765-4b7e-a4e5-72506693122e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0808da0-5aa1-4cc4-9357-968ec1198a58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d2d8408-8765-4b7e-a4e5-72506693122e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS is a medicine used to\ntreat advanced non-small cell lung cancer (a type of lung cancer) in adults. It\ncontains the active substance nivolumab, which is a monoclonal antibody, a type\nof protein designed to recognise and attach to a specific target substance in\nthe body. </span></p>", "ID": "2e6e7da0-9ea0-4189-894f-f8ca726be2b1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS is a medicine used to\ntreat advanced non-small cell lung cancer (a type of lung cancer) in adults. It\ncontains the active substance nivolumab, which is a monoclonal antibody, a type\nof protein designed to recognise and attach to a specific target substance in\nthe body. </span>", "ID": "cdb79483-42cc-47de-80ed-40767db29398", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS is a medicine used to treat advanced non-small cell lung cancer (a type of lung cancer) in adults. It contains the active substance nivolumab, which is a monoclonal antibody, a type of protein designed to recognise and attach to a specific target substance in the body. ", "ParentId": "2e6e7da0-9ea0-4189-894f-f8ca726be2b1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "786a85ed-242e-4c80-b061-f820c8d75b40", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cc9297cd-7036-45d2-9a7b-4629fcbf7105", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "786a85ed-242e-4c80-b061-f820c8d75b40"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab attaches to a target protein\ncalled programmed death\u20111 receptor (PD\u20111) that can switch off the\nactivity of T cells (a type of white blood cell that forms part of the immune\nsystem, the body\u2019s natural defences). By attaching to PD-1, nivolumab\nblocks its action and prevents it from switching off your T cells. This helps\nincrease their activity against the lung cancer cells.</span></p>", "ID": "31bdf9f5-b851-47dc-a8cb-f1b4c3e6a871", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab attaches to a target protein\ncalled programmed death\u20111 receptor (PD\u20111) that can switch off the\nactivity of T cells (a type of white blood cell that forms part of the immune\nsystem, the body\u2019s natural defences). By attaching to PD-1, nivolumab\nblocks its action and prevents it from switching off your T cells. This helps\nincrease their activity against the lung cancer cells.</span>", "ID": "40ce1f9d-4283-40e3-aed6-2816709283b3", "Styles": "None", "Classes": "None", "Text": "Nivolumab attaches to a target protein called programmed death\u20111 receptor (PD\u20111) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body\u2019s natural defences). By attaching to PD-1, nivolumab blocks its action and prevents it from switching off your T cells. This helps increase their activity against the lung cancer cells.", "ParentId": "31bdf9f5-b851-47dc-a8cb-f1b4c3e6a871"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc36e3cf-4de4-4d6c-a100-f0249bec809a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72ba7117-ca97-49e6-9e30-b56b1b7ca261", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc36e3cf-4de4-4d6c-a100-f0249bec809a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed77b4a5-43c0-48d8-8580-49f611f0a3f3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5ce987c-8952-4dba-999e-d4493f7fc984", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed77b4a5-43c0-48d8-8580-49f611f0a3f3"}, {"Element": "<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span></p>", "ID": "1eb7a2f8-3fae-4ae5-a08c-3dd3f44123ea", "Styles": "None", "Classes": "['EMEAHeading3']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Nivolumab\u00a0BMS</span>", "ID": "ee740196-2dd8-4101-9e91-defcc116acf9", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you use Nivolumab\u00a0BMS", "ParentId": "1eb7a2f8-3fae-4ae5-a08c-3dd3f44123ea"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "d2244c40-cd79-443a-a8bd-513521ceff53", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "2757d3ee-40c3-43c2-b4dc-38bd65910809", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2244c40-cd79-443a-a8bd-513521ceff53"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "784ac38c-e3bc-4cb1-a4e1-0333b3850bac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2757d3ee-40c3-43c2-b4dc-38bd65910809"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You\nshould not be given Nivolumab\u00a0BMS</span></b></p>", "ID": "9890e186-12fd-4a27-bfa4-72beaf6faa3e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">You\nshould not be given Nivolumab\u00a0BMS</span></b>", "ID": "87a32e29-7ac3-468d-a263-dafd7772a38d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9890e186-12fd-4a27-bfa4-72beaf6faa3e"}, {"Element": "<span lang=\"EN-GB\">You\nshould not be given Nivolumab\u00a0BMS</span>", "ID": "07029578-045d-44e1-8f92-0babf2c494a4", "Styles": "None", "Classes": "None", "Text": "You should not be given Nivolumab\u00a0BMS", "ParentId": "87a32e29-7ac3-468d-a263-dafd7772a38d"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">if you are <b>allergic</b> to nivolumab or any\nof the other ingredients of this medicine (listed in section\u00a06\n\"Contents of the pack and other information\"). <b>Talk to your doctor</b>\nif you are not sure.</span></p>", "ID": "dc1106bf-b8f8-4ea2-93f9-eade1fda4e55", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "d44952cf-3ccd-4182-b4d3-9eb6dc808446", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "dc1106bf-b8f8-4ea2-93f9-eade1fda4e55"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "56354bd4-036b-4516-a806-f1ba83677113", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d44952cf-3ccd-4182-b4d3-9eb6dc808446"}, {"Element": "<span lang=\"EN-GB\">if you are <b>allergic</b> to nivolumab or any\nof the other ingredients of this medicine (listed in section\u00a06\n\"Contents of the pack and other information\"). <b>Talk to your doctor</b>\nif you are not sure.</span>", "ID": "1b9f5004-acd3-4215-97da-9fa93c374404", "Styles": "None", "Classes": "None", "Text": "if you are  to nivolumab or any of the other ingredients of this medicine (listed in section\u00a06 \"Contents of the pack and other information\").  if you are not sure.", "ParentId": "dc1106bf-b8f8-4ea2-93f9-eade1fda4e55"}, {"Element": "<b>allergic</b>", "ID": "616a8f69-3f9f-4790-87dc-4867354f6ea9", "Styles": "None", "Classes": "None", "Text": "allergic", "ParentId": "1b9f5004-acd3-4215-97da-9fa93c374404"}, {"Element": "<b>Talk to your doctor</b>", "ID": "b2d27709-9dcb-4d43-89f6-d911936eb997", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor", "ParentId": "1b9f5004-acd3-4215-97da-9fa93c374404"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aab1b58f-87a6-4201-b510-8b0f39c1d082", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f30fe5f8-4bdc-4eaa-abcd-9b4831158b0d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aab1b58f-87a6-4201-b510-8b0f39c1d082"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>", "ID": "61999b41-2e30-4090-b0d7-f0ce2dea2535", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Warnings\nand precautions</span></b>", "ID": "cdffb248-ad99-4d3a-8523-96e4f15d3f40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "61999b41-2e30-4090-b0d7-f0ce2dea2535"}, {"Element": "<span lang=\"EN-GB\">Warnings\nand precautions</span>", "ID": "ca43c883-d1c0-4b70-9eac-6124cc3e6265", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "cdffb248-ad99-4d3a-8523-96e4f15d3f40"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Talk to your doctor before using\nNivolumab\u00a0BMS as it may cause:</span></p>", "ID": "836ef934-e269-4f04-8d94-312d1e2dd74c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Talk to your doctor before using\nNivolumab\u00a0BMS as it may cause:</span>", "ID": "55ec4d9b-6796-4d75-906e-617761e99845", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor before using Nivolumab\u00a0BMS as it may cause:", "ParentId": "836ef934-e269-4f04-8d94-312d1e2dd74c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Problems with your lungs</span></b><span lang=\"EN-GB\"> such as breathing difficulties or cough. These may be signs of\ninflammation of the lungs (pneumonitis <span style=\"color:black\">or\ninterstitial lung disease).</span></span></p>", "ID": "3c52d00b-6f00-4c6c-bfb7-560c6e4d8fb9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "d805b9db-6aad-464e-a718-38641c9bb18c", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "3c52d00b-6f00-4c6c-bfb7-560c6e4d8fb9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "773aad12-8ba5-47c1-bc5f-e4c86f5e9e64", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d805b9db-6aad-464e-a718-38641c9bb18c"}, {"Element": "<b><span lang=\"EN-GB\">Problems with your lungs</span></b>", "ID": "76f479bb-92ed-4c4b-b7c8-d953c4eb3ae4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3c52d00b-6f00-4c6c-bfb7-560c6e4d8fb9"}, {"Element": "<span lang=\"EN-GB\">Problems with your lungs</span>", "ID": "f100eb3a-41bc-4aff-8a14-fab07d4273d1", "Styles": "None", "Classes": "None", "Text": "Problems with your lungs", "ParentId": "76f479bb-92ed-4c4b-b7c8-d953c4eb3ae4"}, {"Element": "<span lang=\"EN-GB\"> such as breathing difficulties or cough. These may be signs of\ninflammation of the lungs (pneumonitis <span style=\"color:black\">or\ninterstitial lung disease).</span></span>", "ID": "194c9903-8262-44d4-81ef-5690cf8bc844", "Styles": "None", "Classes": "None", "Text": " such as breathing difficulties or cough. These may be signs of inflammation of the lungs (pneumonitis ", "ParentId": "3c52d00b-6f00-4c6c-bfb7-560c6e4d8fb9"}, {"Element": "<span style=\"color:black\">or\ninterstitial lung disease).</span>", "ID": "241478ed-3160-4673-b71d-e9e985ec3ce7", "Styles": "color:black", "Classes": "None", "Text": "or interstitial lung disease).", "ParentId": "194c9903-8262-44d4-81ef-5690cf8bc844"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Diarrhoea</span></b><span lang=\"EN-GB\">\n(watery, loose or soft stools) or any symptoms of <b>inflammation of the\nintestines</b> (colitis), such as stomach pain and mucus or blood in stool.</span></p>", "ID": "70d94dad-47b6-4e8e-b73c-307b167fa9b5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "9ccb5141-b62b-4a6f-87bf-8de7512f9cfe", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "70d94dad-47b6-4e8e-b73c-307b167fa9b5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "e9116b45-e57e-42a0-bca6-2e8679e8e07f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "9ccb5141-b62b-4a6f-87bf-8de7512f9cfe"}, {"Element": "<b><span lang=\"EN-GB\">Diarrhoea</span></b>", "ID": "00f3d79f-a6d5-4a5a-bef0-3d35add1b5ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70d94dad-47b6-4e8e-b73c-307b167fa9b5"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea</span>", "ID": "ee73c8d5-db15-49b2-8e93-f2f825002d57", "Styles": "None", "Classes": "None", "Text": "Diarrhoea", "ParentId": "00f3d79f-a6d5-4a5a-bef0-3d35add1b5ea"}, {"Element": "<span lang=\"EN-GB\">\n(watery, loose or soft stools) or any symptoms of <b>inflammation of the\nintestines</b> (colitis), such as stomach pain and mucus or blood in stool.</span>", "ID": "df1a27a5-e9cb-4b12-9ed1-fde870fe19cf", "Styles": "None", "Classes": "None", "Text": " (watery, loose or soft stools) or any symptoms of  (colitis), such as stomach pain and mucus or blood in stool.", "ParentId": "70d94dad-47b6-4e8e-b73c-307b167fa9b5"}, {"Element": "<b>inflammation of the\nintestines</b>", "ID": "10852c7e-8196-4074-852e-c746be396a31", "Styles": "None", "Classes": "None", "Text": "inflammation of the intestines", "ParentId": "df1a27a5-e9cb-4b12-9ed1-fde870fe19cf"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation of the liver (hepatitis).</span></b><span lang=\"EN-GB\"> Signs and symptoms of hepatitis may include abnormal liver function\ntests, eye or skin yellowing (jaundice), pain on the right side of your stomach\narea, or tiredness.</span></p>", "ID": "0fb7ddb4-6982-412f-924d-500dd84057f5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "9af0c3af-6145-47c2-a313-d8e638a2bee2", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "0fb7ddb4-6982-412f-924d-500dd84057f5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "d41275e0-eb75-409f-ad52-4e42142700b2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "9af0c3af-6145-47c2-a313-d8e638a2bee2"}, {"Element": "<b><span lang=\"EN-GB\">Inflammation of the liver (hepatitis).</span></b>", "ID": "e7de7c60-4e2a-465f-b057-e22f23a8eafb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0fb7ddb4-6982-412f-924d-500dd84057f5"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the liver (hepatitis).</span>", "ID": "3cfa1512-13c8-495f-9f86-7faf7beaa7f8", "Styles": "None", "Classes": "None", "Text": "Inflammation of the liver (hepatitis).", "ParentId": "e7de7c60-4e2a-465f-b057-e22f23a8eafb"}, {"Element": "<span lang=\"EN-GB\"> Signs and symptoms of hepatitis may include abnormal liver function\ntests, eye or skin yellowing (jaundice), pain on the right side of your stomach\narea, or tiredness.</span>", "ID": "ec7731fc-20a4-4afb-b8df-b045a524b5c1", "Styles": "None", "Classes": "None", "Text": " Signs and symptoms of hepatitis may include abnormal liver function tests, eye or skin yellowing (jaundice), pain on the right side of your stomach area, or tiredness.", "ParentId": "0fb7ddb4-6982-412f-924d-500dd84057f5"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation or problems with your kidneys. </span></b><span lang=\"EN-GB\">Signs and symptoms may include abnormal kidney function tests, or\ndecreased volume of urine.</span></p>", "ID": "8371f7d8-73c9-4f5c-ae14-4cfc73534c2c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "0dc63e17-93d1-4561-bd3f-ab0e41cc4bb6", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "8371f7d8-73c9-4f5c-ae14-4cfc73534c2c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "02d2b2ae-e2e5-4699-91ed-111f2472aedf", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "0dc63e17-93d1-4561-bd3f-ab0e41cc4bb6"}, {"Element": "<b><span lang=\"EN-GB\">Inflammation or problems with your kidneys. </span></b>", "ID": "4a6bc181-ca9f-453b-a67c-48bb8f50cb88", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8371f7d8-73c9-4f5c-ae14-4cfc73534c2c"}, {"Element": "<span lang=\"EN-GB\">Inflammation or problems with your kidneys. </span>", "ID": "029f892e-e686-4956-9473-ece00f96f3f7", "Styles": "None", "Classes": "None", "Text": "Inflammation or problems with your kidneys. ", "ParentId": "4a6bc181-ca9f-453b-a67c-48bb8f50cb88"}, {"Element": "<span lang=\"EN-GB\">Signs and symptoms may include abnormal kidney function tests, or\ndecreased volume of urine.</span>", "ID": "1c4fccdc-6208-43c8-87f4-c8eb50a20cc6", "Styles": "None", "Classes": "None", "Text": "Signs and symptoms may include abnormal kidney function tests, or decreased volume of urine.", "ParentId": "8371f7d8-73c9-4f5c-ae14-4cfc73534c2c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Problems with your hormone producing glands</span></b><span lang=\"EN-GB\"> (including the pituitary, the thyroid and adrenal glands) that may\naffect how these glands work. Signs and symptoms that these glands are not\nworking properly may include fatigue (extreme tiredness), weight change or\nheadache and visual disturbances.</span></p>", "ID": "6839fdd6-4942-4978-af1f-c378fa118f5c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "c34adbbc-8eb1-49da-b1e7-7c8d47ae4ef8", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "6839fdd6-4942-4978-af1f-c378fa118f5c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "0697e003-d57d-42d9-9b99-e41d68c55e90", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "c34adbbc-8eb1-49da-b1e7-7c8d47ae4ef8"}, {"Element": "<b><span lang=\"EN-GB\">Problems with your hormone producing glands</span></b>", "ID": "0d9fb0fb-b605-4000-bb01-1c589420bddd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6839fdd6-4942-4978-af1f-c378fa118f5c"}, {"Element": "<span lang=\"EN-GB\">Problems with your hormone producing glands</span>", "ID": "b2cd911d-197d-4351-9650-6718dd3a4283", "Styles": "None", "Classes": "None", "Text": "Problems with your hormone producing glands", "ParentId": "0d9fb0fb-b605-4000-bb01-1c589420bddd"}, {"Element": "<span lang=\"EN-GB\"> (including the pituitary, the thyroid and adrenal glands) that may\naffect how these glands work. Signs and symptoms that these glands are not\nworking properly may include fatigue (extreme tiredness), weight change or\nheadache and visual disturbances.</span>", "ID": "bbe74d4b-f3a9-4b24-8241-f5c747d98807", "Styles": "None", "Classes": "None", "Text": " (including the pituitary, the thyroid and adrenal glands) that may affect how these glands work. Signs and symptoms that these glands are not working properly may include fatigue (extreme tiredness), weight change or headache and visual disturbances.", "ParentId": "6839fdd6-4942-4978-af1f-c378fa118f5c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Diabetes </span></b><span lang=\"EN-GB\">(symptoms\ninclude excessive thirst, the passing of a greatly increased amount of urine,\nincrease in appetite with a loss of weight, feeling tired, drowsy, weak,\ndepressed, irritable and generally unwell) or <b>diabetic ketoacidosis </b>(acid\nin the blood produced from diabetes).</span></p>", "ID": "206f9392-2c1b-4e31-a10d-6f8159d35dbf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "dabb27e3-f07a-4bbf-81ab-ed1d639ef38d", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "206f9392-2c1b-4e31-a10d-6f8159d35dbf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "9c91e8eb-db29-4c37-91c4-6b5df76377bb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "dabb27e3-f07a-4bbf-81ab-ed1d639ef38d"}, {"Element": "<b><span lang=\"EN-GB\">Diabetes </span></b>", "ID": "cd9dba82-35c2-4680-a7b5-7cc27357a99a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "206f9392-2c1b-4e31-a10d-6f8159d35dbf"}, {"Element": "<span lang=\"EN-GB\">Diabetes </span>", "ID": "9a4d6516-d0ca-48ae-996d-2eaa95bd901f", "Styles": "None", "Classes": "None", "Text": "Diabetes ", "ParentId": "cd9dba82-35c2-4680-a7b5-7cc27357a99a"}, {"Element": "<span lang=\"EN-GB\">(symptoms\ninclude excessive thirst, the passing of a greatly increased amount of urine,\nincrease in appetite with a loss of weight, feeling tired, drowsy, weak,\ndepressed, irritable and generally unwell) or <b>diabetic ketoacidosis </b>(acid\nin the blood produced from diabetes).</span>", "ID": "645be59a-ffb8-4048-bd61-e9262cc16124", "Styles": "None", "Classes": "None", "Text": "(symptoms include excessive thirst, the passing of a greatly increased amount of urine, increase in appetite with a loss of weight, feeling tired, drowsy, weak, depressed, irritable and generally unwell) or (acid in the blood produced from diabetes).", "ParentId": "206f9392-2c1b-4e31-a10d-6f8159d35dbf"}, {"Element": "<b>diabetic ketoacidosis </b>", "ID": "adbea567-3030-4c1a-b152-3fe21732ce8f", "Styles": "None", "Classes": "None", "Text": "diabetic ketoacidosis ", "ParentId": "645be59a-ffb8-4048-bd61-e9262cc16124"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Inflammation of the skin </span></b><span lang=\"EN-GB\">that can lead to rash and itching.</span></p>", "ID": "2eae8bd0-5598-41f4-abf6-50d6f18db4dd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "47e3d027-e14e-4935-8973-b2e952548823", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "2eae8bd0-5598-41f4-abf6-50d6f18db4dd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "cfdade85-2a25-4b75-814f-424419fd2c54", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "47e3d027-e14e-4935-8973-b2e952548823"}, {"Element": "<b><span lang=\"EN-GB\">Inflammation of the skin </span></b>", "ID": "593b7419-076a-4042-a109-e3fc1213951f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2eae8bd0-5598-41f4-abf6-50d6f18db4dd"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the skin </span>", "ID": "eeb69f8f-e40b-456f-babd-fe9802f069c3", "Styles": "None", "Classes": "None", "Text": "Inflammation of the skin ", "ParentId": "593b7419-076a-4042-a109-e3fc1213951f"}, {"Element": "<span lang=\"EN-GB\">that can lead to rash and itching.</span>", "ID": "273e9e06-a955-4db6-af85-6b88457fab0f", "Styles": "None", "Classes": "None", "Text": "that can lead to rash and itching.", "ParentId": "2eae8bd0-5598-41f4-abf6-50d6f18db4dd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">\u00a0</span></p>", "ID": "99c70d14-92c7-4ca4-9a48-cd876a43d330", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">\u00a0</span>", "ID": "bac95c32-6963-40bf-93a6-898c170c9e86", "Styles": "color:black", "Classes": "None", "Text": "\u00a0", "ParentId": "99c70d14-92c7-4ca4-9a48-cd876a43d330"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor\nimmediately</span></b><span lang=\"EN-GB\" style=\"color:black\"> if you have any of\nthese signs or symptoms or if they get worse. <b>Do not try to treat your\nsymptoms with other medicines on your own. </b>Your doctor may</span></p>", "ID": "28ab6272-c2c2-4d7f-a44a-b8838da74b6b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Tell your doctor\nimmediately</span></b>", "ID": "4ffd069b-b1d6-4509-86d9-cf7df8efa499", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28ab6272-c2c2-4d7f-a44a-b8838da74b6b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Tell your doctor\nimmediately</span>", "ID": "c8e3b4ff-56cb-4260-a14e-cac9b71a66c2", "Styles": "color:black", "Classes": "None", "Text": "Tell your doctor immediately", "ParentId": "4ffd069b-b1d6-4509-86d9-cf7df8efa499"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\"> if you have any of\nthese signs or symptoms or if they get worse. <b>Do not try to treat your\nsymptoms with other medicines on your own. </b>Your doctor may</span>", "ID": "54499298-972d-4e50-90f1-171238438a03", "Styles": "color:black", "Classes": "None", "Text": " if you have any of these signs or symptoms or if they get worse. Your doctor may", "ParentId": "28ab6272-c2c2-4d7f-a44a-b8838da74b6b"}, {"Element": "<b>Do not try to treat your\nsymptoms with other medicines on your own. </b>", "ID": "75042fab-89a4-42b0-a033-bdb130e960ae", "Styles": "None", "Classes": "None", "Text": "Do not try to treat your symptoms with other medicines on your own. ", "ParentId": "54499298-972d-4e50-90f1-171238438a03"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">give you other medicines in order to prevent complications\nand reduce your symptoms,</span></p>", "ID": "cd7822d8-2f0d-4be2-ac73-2daaeb69dec7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "dc44a05d-a8a2-4688-92ed-0a01127f3cf9", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "cd7822d8-2f0d-4be2-ac73-2daaeb69dec7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "4851bdcc-ecc0-4e55-9697-40e4161250e4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "dc44a05d-a8a2-4688-92ed-0a01127f3cf9"}, {"Element": "<span lang=\"EN-GB\">give you other medicines in order to prevent complications\nand reduce your symptoms,</span>", "ID": "8857ddb0-529a-460c-8625-d10a9842e176", "Styles": "None", "Classes": "None", "Text": "give you other medicines in order to prevent complications and reduce your symptoms,", "ParentId": "cd7822d8-2f0d-4be2-ac73-2daaeb69dec7"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">withhold the next dose of Nivolumab\u00a0BMS,</span></p>", "ID": "a42d3013-13a2-4e17-a6e8-d03fad240b5f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f37368b-0b92-405e-9da6-9682f7aa3aa1", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "a42d3013-13a2-4e17-a6e8-d03fad240b5f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "4575f16e-dde6-4cf4-b88a-9d5718ed865c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "4f37368b-0b92-405e-9da6-9682f7aa3aa1"}, {"Element": "<span lang=\"EN-GB\">withhold the next dose of Nivolumab\u00a0BMS,</span>", "ID": "099d8d27-db21-46bb-895c-39db2e1eddc1", "Styles": "None", "Classes": "None", "Text": "withhold the next dose of Nivolumab\u00a0BMS,", "ParentId": "a42d3013-13a2-4e17-a6e8-d03fad240b5f"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">or stop your treatment with Nivolumab\u00a0BMS\naltogether.</span></p>", "ID": "84c50666-b6b3-48a4-9a9c-09805fefa5e4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "612bf730-c71f-4426-bde3-6172e810dbe8", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "84c50666-b6b3-48a4-9a9c-09805fefa5e4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "96a7d554-9dba-4eff-a1c7-de173a161b01", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "612bf730-c71f-4426-bde3-6172e810dbe8"}, {"Element": "<span lang=\"EN-GB\">or stop your treatment with Nivolumab\u00a0BMS\naltogether.</span>", "ID": "382ae171-e0fd-4072-8ee9-b2ec32a844ca", "Styles": "None", "Classes": "None", "Text": "or stop your treatment with Nivolumab\u00a0BMS altogether.", "ParentId": "84c50666-b6b3-48a4-9a9c-09805fefa5e4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">Please note that\nthese signs and symptoms are <b>sometimes delayed</b>, and may develop weeks or\nmonths after your last dose. Before treatment, your doctor will check your\ngeneral health. You will also have <b>blood tests</b> during your treatment.</span></p>", "ID": "96f1f420-9255-4868-b306-833ad484d53c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Please note that\nthese signs and symptoms are <b>sometimes delayed</b>, and may develop weeks or\nmonths after your last dose. Before treatment, your doctor will check your\ngeneral health. You will also have <b>blood tests</b> during your treatment.</span>", "ID": "d3066e25-b6c2-4013-b66a-ee4b0ecb82b7", "Styles": "color:black", "Classes": "None", "Text": "Please note that these signs and symptoms are , and may develop weeks or months after your last dose. Before treatment, your doctor will check your general health. You will also have  during your treatment.", "ParentId": "96f1f420-9255-4868-b306-833ad484d53c"}, {"Element": "<b>sometimes delayed</b>", "ID": "e06a9748-2957-4152-a108-a2fc89c6622e", "Styles": "None", "Classes": "None", "Text": "sometimes delayed", "ParentId": "d3066e25-b6c2-4013-b66a-ee4b0ecb82b7"}, {"Element": "<b>blood tests</b>", "ID": "b75b8396-ca83-4f4e-a086-2cf2008ff86c", "Styles": "None", "Classes": "None", "Text": "blood tests", "ParentId": "d3066e25-b6c2-4013-b66a-ee4b0ecb82b7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8391ff61-3c9d-4bfd-8f52-8058b7030f95", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e1cc6ab-5707-43c3-87f8-4c7307de13f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8391ff61-3c9d-4bfd-8f52-8058b7030f95"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Check\nwith your doctor or nurse before you are given Nivolumab\u00a0BMS if:</span></b></p>", "ID": "53bf5f43-79c9-4424-befb-a9a4ad4e6543", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Check\nwith your doctor or nurse before you are given Nivolumab\u00a0BMS if:</span></b>", "ID": "8bd4622e-9e09-4687-82ba-5c1e55ec3b06", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53bf5f43-79c9-4424-befb-a9a4ad4e6543"}, {"Element": "<span lang=\"EN-GB\">Check\nwith your doctor or nurse before you are given Nivolumab\u00a0BMS if:</span>", "ID": "1a06f62f-65df-4b12-b934-3dc405fc168b", "Styles": "None", "Classes": "None", "Text": "Check with your doctor or nurse before you are given Nivolumab\u00a0BMS if:", "ParentId": "8bd4622e-9e09-4687-82ba-5c1e55ec3b06"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have been told that your <b>cancer has\nspread to your brain</b></span></p>", "ID": "e94fc7eb-6d42-470d-87c1-a9ef184e39d2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "836c9066-8498-4c62-882c-d94f93303276", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "e94fc7eb-6d42-470d-87c1-a9ef184e39d2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "177aaae2-03a2-4c73-9302-37c00f6c2d90", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "836c9066-8498-4c62-882c-d94f93303276"}, {"Element": "<span lang=\"EN-GB\">you have been told that your <b>cancer has\nspread to your brain</b></span>", "ID": "5f6e4d8a-e0c9-4e87-aa3e-528ca9ff348b", "Styles": "None", "Classes": "None", "Text": "you have been told that your ", "ParentId": "e94fc7eb-6d42-470d-87c1-a9ef184e39d2"}, {"Element": "<b>cancer has\nspread to your brain</b>", "ID": "dcb0d022-5136-4294-96ec-7c7c11f14904", "Styles": "None", "Classes": "None", "Text": "cancer has spread to your brain", "ParentId": "5f6e4d8a-e0c9-4e87-aa3e-528ca9ff348b"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have an <b>autoimmune disease</b> (a\ncondition where the body attacks its own cells);</span></p>", "ID": "4da3ce7e-d359-47fe-8f6a-dd16ad9419f6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "93d7f62a-bfca-43f3-b29e-e8126a593542", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "4da3ce7e-d359-47fe-8f6a-dd16ad9419f6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "3086e08f-6c77-48d9-904b-59b408384ecb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "93d7f62a-bfca-43f3-b29e-e8126a593542"}, {"Element": "<span lang=\"EN-GB\">you have an <b>autoimmune disease</b> (a\ncondition where the body attacks its own cells);</span>", "ID": "db5a18e1-b396-46c7-98d7-49e77d7669c8", "Styles": "None", "Classes": "None", "Text": "you have an  (a condition where the body attacks its own cells);", "ParentId": "4da3ce7e-d359-47fe-8f6a-dd16ad9419f6"}, {"Element": "<b>autoimmune disease</b>", "ID": "177effdb-aa6b-43fa-a751-acabdf6c57b0", "Styles": "None", "Classes": "None", "Text": "autoimmune disease", "ParentId": "db5a18e1-b396-46c7-98d7-49e77d7669c8"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have any history of <b>inflammation of the\nlungs</b>;</span></p>", "ID": "4a1013ac-90a4-4c3d-9ec1-47217bda036d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "df990a89-74ae-496c-b00d-fd03becf790c", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "4a1013ac-90a4-4c3d-9ec1-47217bda036d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "c090b858-7821-4dcb-8cf0-65e0d8510db0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "df990a89-74ae-496c-b00d-fd03becf790c"}, {"Element": "<span lang=\"EN-GB\">you have any history of <b>inflammation of the\nlungs</b>;</span>", "ID": "06cf1205-7ec3-4ec3-9ee9-ea07514addb0", "Styles": "None", "Classes": "None", "Text": "you have any history of ;", "ParentId": "4a1013ac-90a4-4c3d-9ec1-47217bda036d"}, {"Element": "<b>inflammation of the\nlungs</b>", "ID": "4aee0b20-a68e-40a4-8e32-5c1d8ce38d5e", "Styles": "None", "Classes": "None", "Text": "inflammation of the lungs", "ParentId": "06cf1205-7ec3-4ec3-9ee9-ea07514addb0"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">you have been taken <b>medicines to suppress\nyour immune system.</b></span></p>", "ID": "82d5e9e6-8884-41e9-8bfb-06badbf4afe4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "429f5dab-00fa-4e9c-b0ca-e27ad196a575", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "82d5e9e6-8884-41e9-8bfb-06badbf4afe4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "776bce46-2460-4c04-b520-fe36170f8a6c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "429f5dab-00fa-4e9c-b0ca-e27ad196a575"}, {"Element": "<span lang=\"EN-GB\">you have been taken <b>medicines to suppress\nyour immune system.</b></span>", "ID": "1bd3c1c5-0955-4de4-90d6-e3f9b160b7d5", "Styles": "None", "Classes": "None", "Text": "you have been taken ", "ParentId": "82d5e9e6-8884-41e9-8bfb-06badbf4afe4"}, {"Element": "<b>medicines to suppress\nyour immune system.</b>", "ID": "4ff97a88-1416-4ec1-a0f9-573533ce4d37", "Styles": "None", "Classes": "None", "Text": "medicines to suppress your immune system.", "ParentId": "1bd3c1c5-0955-4de4-90d6-e3f9b160b7d5"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5e8f243d-46fd-4397-bf8d-669b5da180c2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7705d00-7285-4353-af0c-119313e068dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5e8f243d-46fd-4397-bf8d-669b5da180c2"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Children\nand adolescents</span></b></p>", "ID": "8b954ed3-c900-4596-9d7a-1d5c7f28bc96", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Children\nand adolescents</span></b>", "ID": "31c0e6dd-86a8-40ff-ad00-fbcbab6e85f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8b954ed3-c900-4596-9d7a-1d5c7f28bc96"}, {"Element": "<span lang=\"EN-GB\">Children\nand adolescents</span>", "ID": "f18ed8d3-6b03-4b93-9fa6-13dabd9fa321", "Styles": "None", "Classes": "None", "Text": "Children and adolescents", "ParentId": "31c0e6dd-86a8-40ff-ad00-fbcbab6e85f8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS should not be used in\nchildren and adolescents below\u00a018\u00a0years of age.</span></p>", "ID": "571237bd-86e1-4c1a-8db3-f3f49c6fbb1a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS should not be used in\nchildren and adolescents below\u00a018\u00a0years of age.</span>", "ID": "c39922b7-d236-460f-ba55-d6e380a3aad3", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS should not be used in children and adolescents below\u00a018\u00a0years of age.", "ParentId": "571237bd-86e1-4c1a-8db3-f3f49c6fbb1a"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "60604980-5ddf-4edf-be3c-e25c4cd5cbe3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2aa44a1b-10b2-4b90-9e44-1506009eacc8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "60604980-5ddf-4edf-be3c-e25c4cd5cbe3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f31f325e-aa3d-4421-b5dc-de971e30a2a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2aa44a1b-10b2-4b90-9e44-1506009eacc8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Nivolumab\u00a0BMS</span></b></p>", "ID": "53d18faf-66f4-4a55-814c-f3cd4b174fb3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Other\nmedicines and Nivolumab\u00a0BMS</span></b>", "ID": "bf017701-32ca-4cd9-8653-227a40e4e1a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53d18faf-66f4-4a55-814c-f3cd4b174fb3"}, {"Element": "<span lang=\"EN-GB\">Other\nmedicines and Nivolumab\u00a0BMS</span>", "ID": "cb07ba02-eaa1-416b-b447-08a9ec74bc32", "Styles": "None", "Classes": "None", "Text": "Other medicines and Nivolumab\u00a0BMS", "ParentId": "bf017701-32ca-4cd9-8653-227a40e4e1a3"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Before you are given </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b><b><span lang=\"EN-GB\">, tell your doctor </span></b><span lang=\"EN-GB\">if you are taking any medicines that suppress your immune system,\nsuch as corticosteroids, since these medicines may interfere with the effect of\n</span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. However,\nonce you are treated with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">, your doctor may give you corticosteroids to reduce any possible\nside\u2011effects that you may have during your treatment and this will not\nimpact the effect of the medicine.</span></p>", "ID": "afbbe7db-0277-484f-bfb8-8d98044d437a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Before you are given </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b>", "ID": "1d2f7f99-31f6-4841-8c25-3687ec7e8368", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">Before you are given </span>", "ID": "04168f43-7212-4827-a655-50088353ab8f", "Styles": "None", "Classes": "None", "Text": "Before you are given ", "ParentId": "1d2f7f99-31f6-4841-8c25-3687ec7e8368"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "2d65d689-bd70-48a6-8550-aeb62b8b2082", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "1d2f7f99-31f6-4841-8c25-3687ec7e8368"}, {"Element": "<b><span lang=\"EN-GB\">, tell your doctor </span></b>", "ID": "2e02ca97-4e57-42f9-b56e-8056df47ef12", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">, tell your doctor </span>", "ID": "1f0fe4ff-ea1e-400c-8696-2bd88b25da21", "Styles": "None", "Classes": "None", "Text": ", tell your doctor ", "ParentId": "2e02ca97-4e57-42f9-b56e-8056df47ef12"}, {"Element": "<span lang=\"EN-GB\">if you are taking any medicines that suppress your immune system,\nsuch as corticosteroids, since these medicines may interfere with the effect of\n</span>", "ID": "3e1a6277-cb40-45ed-b655-5ccb9124105c", "Styles": "None", "Classes": "None", "Text": "if you are taking any medicines that suppress your immune system, such as corticosteroids, since these medicines may interfere with the effect of ", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "0b5caaed-06b9-43d2-88c0-06b1eeb0c23d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">. However,\nonce you are treated with </span>", "ID": "1cb7d5e4-9ed3-412f-b7f6-6e99ba4a522c", "Styles": "None", "Classes": "None", "Text": ". However, once you are treated with ", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "f3781e05-3516-4247-903e-a3d21d8996de", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<span lang=\"EN-GB\">, your doctor may give you corticosteroids to reduce any possible\nside\u2011effects that you may have during your treatment and this will not\nimpact the effect of the medicine.</span>", "ID": "865a071d-5708-4a39-8cb2-746a0aa601ff", "Styles": "None", "Classes": "None", "Text": ", your doctor may give you corticosteroids to reduce any possible side\u2011effects that you may have during your treatment and this will not impact the effect of the medicine.", "ParentId": "afbbe7db-0277-484f-bfb8-8d98044d437a"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor </span></b><span lang=\"EN-GB\">if you are taking or have recently taken any other medicines. </span><b><span lang=\"EN-GB\">Do not take any other medicines </span></b><span lang=\"EN-GB\">during\nyour treatment without talking to your doctor first.</span></p>", "ID": "54a96c34-9ed4-4ac0-88ce-cce545dccd47", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor </span></b>", "ID": "5e6096de-c2fc-4f1b-ac6f-2f91bb05b76f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54a96c34-9ed4-4ac0-88ce-cce545dccd47"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor </span>", "ID": "53888c82-6269-4f77-ae64-18c3ac5c5b24", "Styles": "None", "Classes": "None", "Text": "Tell your doctor ", "ParentId": "5e6096de-c2fc-4f1b-ac6f-2f91bb05b76f"}, {"Element": "<span lang=\"EN-GB\">if you are taking or have recently taken any other medicines. </span>", "ID": "dffae0fd-1ff1-4f42-a511-f110534946a1", "Styles": "None", "Classes": "None", "Text": "if you are taking or have recently taken any other medicines. ", "ParentId": "54a96c34-9ed4-4ac0-88ce-cce545dccd47"}, {"Element": "<b><span lang=\"EN-GB\">Do not take any other medicines </span></b>", "ID": "c4244d25-e684-4d18-bb19-b5526cebdeed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54a96c34-9ed4-4ac0-88ce-cce545dccd47"}, {"Element": "<span lang=\"EN-GB\">Do not take any other medicines </span>", "ID": "fbc1052b-cc1c-4d5f-8d3b-cbad1340f63c", "Styles": "None", "Classes": "None", "Text": "Do not take any other medicines ", "ParentId": "c4244d25-e684-4d18-bb19-b5526cebdeed"}, {"Element": "<span lang=\"EN-GB\">during\nyour treatment without talking to your doctor first.</span>", "ID": "13374e20-773b-4ede-89e7-c1f0d58f5fe7", "Styles": "None", "Classes": "None", "Text": "during your treatment without talking to your doctor first.", "ParentId": "54a96c34-9ed4-4ac0-88ce-cce545dccd47"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a7b01c8-3f89-4474-950d-a54d9fc0aef3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3079527-4e43-450d-90ee-85afa7421013", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a7b01c8-3f89-4474-950d-a54d9fc0aef3"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast\u2011feeding</span></b></p>", "ID": "c3ced11b-6cce-4501-8f46-4a2631af25af", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy\nand breast\u2011feeding</span></b>", "ID": "1a94f936-ad4c-4f9a-a76a-0fb58e1464d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3ced11b-6cce-4501-8f46-4a2631af25af"}, {"Element": "<span lang=\"EN-GB\">Pregnancy\nand breast\u2011feeding</span>", "ID": "aecc4869-3f96-4fbc-92da-24e76eb12da9", "Styles": "None", "Classes": "None", "Text": "Pregnancy and breast\u2011feeding", "ParentId": "1a94f936-ad4c-4f9a-a76a-0fb58e1464d2"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor</span></b><span lang=\"EN-GB\"> if you are pregnant or think you might be, if you are planning to\nbecome pregnant, or if you are breast\u2011feeding.</span></p>", "ID": "f5a358b0-d1de-421f-8196-69899767d80f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor</span></b>", "ID": "c73b7b94-c0ad-431e-aeee-e81d68241108", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5a358b0-d1de-421f-8196-69899767d80f"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor</span>", "ID": "7b351a19-0582-4155-a9f4-399ca9f86e88", "Styles": "None", "Classes": "None", "Text": "Tell your doctor", "ParentId": "c73b7b94-c0ad-431e-aeee-e81d68241108"}, {"Element": "<span lang=\"EN-GB\"> if you are pregnant or think you might be, if you are planning to\nbecome pregnant, or if you are breast\u2011feeding.</span>", "ID": "c81c9054-57d8-4bd5-b895-abd51d256cda", "Styles": "None", "Classes": "None", "Text": " if you are pregnant or think you might be, if you are planning to become pregnant, or if you are breast\u2011feeding.", "ParentId": "f5a358b0-d1de-421f-8196-69899767d80f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d9ec475-5b56-44f5-80ca-c4f9dc1929bd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdd4037e-190a-4f1f-8bd6-658a3af38dc7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d9ec475-5b56-44f5-80ca-c4f9dc1929bd"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS if you\nare pregnant</span></b><span lang=\"EN-GB\"> unless your doctor specifically tells\nyou to. The effects of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> in pregnant women are not known, but it is possible that the active\nsubstance, nivolumab, could harm an unborn baby.</span></p>", "ID": "081a0daa-a879-4482-ac2d-b42dc961115c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS if you\nare pregnant</span></b>", "ID": "087fc5ed-0f15-4087-838b-792ca8f918b8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "081a0daa-a879-4482-ac2d-b42dc961115c"}, {"Element": "<span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS if you\nare pregnant</span>", "ID": "7d9f2f78-37ad-4e65-b7d4-8a4d34e9aa08", "Styles": "None", "Classes": "None", "Text": "Do not use Nivolumab\u00a0BMS if you are pregnant", "ParentId": "087fc5ed-0f15-4087-838b-792ca8f918b8"}, {"Element": "<span lang=\"EN-GB\"> unless your doctor specifically tells\nyou to. The effects of </span>", "ID": "d2ca096d-9fad-48a4-8ef1-f6da24b7d9a1", "Styles": "None", "Classes": "None", "Text": " unless your doctor specifically tells you to. The effects of ", "ParentId": "081a0daa-a879-4482-ac2d-b42dc961115c"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "5ed40775-4ef3-4fe1-8406-3903e20f472c", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "081a0daa-a879-4482-ac2d-b42dc961115c"}, {"Element": "<span lang=\"EN-GB\"> in pregnant women are not known, but it is possible that the active\nsubstance, nivolumab, could harm an unborn baby.</span>", "ID": "953b0b22-0280-438f-a6dd-e5db67de2d92", "Styles": "None", "Classes": "None", "Text": " in pregnant women are not known, but it is possible that the active substance, nivolumab, could harm an unborn baby.", "ParentId": "081a0daa-a879-4482-ac2d-b42dc961115c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You must use <b>effective contraception</b>\nwhile you are being treated with Nivolumab\u00a0BMS and for at least 5\u00a0months\nfollowing the last dose of Nivolumab\u00a0BMS, if you are a woman who could\nbecome pregnant.</span></p>", "ID": "315e9b0c-e71c-43a1-8a93-137cc7ed69ff", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "ca5cc82b-7023-4997-bed7-70c9447a00e8", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "315e9b0c-e71c-43a1-8a93-137cc7ed69ff"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "c14843c2-1ae5-40f8-873a-cb3da9f023db", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "ca5cc82b-7023-4997-bed7-70c9447a00e8"}, {"Element": "<span lang=\"EN-GB\">You must use <b>effective contraception</b>\nwhile you are being treated with Nivolumab\u00a0BMS and for at least 5\u00a0months\nfollowing the last dose of Nivolumab\u00a0BMS, if you are a woman who could\nbecome pregnant.</span>", "ID": "e166cb48-afe1-4fe9-a0f5-460cea656b85", "Styles": "None", "Classes": "None", "Text": "You must use  while you are being treated with Nivolumab\u00a0BMS and for at least 5\u00a0months following the last dose of Nivolumab\u00a0BMS, if you are a woman who could become pregnant.", "ParentId": "315e9b0c-e71c-43a1-8a93-137cc7ed69ff"}, {"Element": "<b>effective contraception</b>", "ID": "432cdecf-8c7b-44a5-b424-6c4be4eb69c6", "Styles": "None", "Classes": "None", "Text": "effective contraception", "ParentId": "e166cb48-afe1-4fe9-a0f5-460cea656b85"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you become pregnant while using Nivolumab\u00a0BMS\n<b>tell your doctor</b>.</span></p>", "ID": "d353cc48-4956-4d5e-8c3d-8f19c1698e97", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "064701aa-90f6-4f7e-851a-6ee201bd1ee6", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "d353cc48-4956-4d5e-8c3d-8f19c1698e97"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "ed5a9017-d059-4f0f-90f8-63891a2f2b83", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "064701aa-90f6-4f7e-851a-6ee201bd1ee6"}, {"Element": "<span lang=\"EN-GB\">If you become pregnant while using Nivolumab\u00a0BMS\n<b>tell your doctor</b>.</span>", "ID": "6a394833-87e1-40c7-a48f-1447c0627b85", "Styles": "None", "Classes": "None", "Text": "If you become pregnant while using Nivolumab\u00a0BMS .", "ParentId": "d353cc48-4956-4d5e-8c3d-8f19c1698e97"}, {"Element": "<b>tell your doctor</b>", "ID": "b0be5658-01d7-4dfd-a495-e9ab9c80a752", "Styles": "None", "Classes": "None", "Text": "tell your doctor", "ParentId": "6a394833-87e1-40c7-a48f-1447c0627b85"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f13e7e1-f842-4b54-83d7-96eaef239109", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24dffbab-2aa4-45ee-9eaa-a351cca75fef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f13e7e1-f842-4b54-83d7-96eaef239109"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is not known whether nivolumab gets\ninto breast milk. A risk to the breast\u2011fed infant cannot be excluded. <b>Ask\nyour doctor</b> if you can breast\u2011feed during or after treatment with Nivolumab\u00a0BMS.</span></p>", "ID": "115826a0-5092-4933-b0b1-2be439279ab4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">It is not known whether nivolumab gets\ninto breast milk. A risk to the breast\u2011fed infant cannot be excluded. <b>Ask\nyour doctor</b> if you can breast\u2011feed during or after treatment with Nivolumab\u00a0BMS.</span>", "ID": "401da206-1426-4b8a-bae9-de080b3576ff", "Styles": "None", "Classes": "None", "Text": "It is not known whether nivolumab gets into breast milk. A risk to the breast\u2011fed infant cannot be excluded.  if you can breast\u2011feed during or after treatment with Nivolumab\u00a0BMS.", "ParentId": "115826a0-5092-4933-b0b1-2be439279ab4"}, {"Element": "<b>Ask\nyour doctor</b>", "ID": "19a82c57-f597-4afe-9def-032dce31f474", "Styles": "None", "Classes": "None", "Text": "Ask your doctor", "ParentId": "401da206-1426-4b8a-bae9-de080b3576ff"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b114f02b-7c2a-43f8-83ff-318c4c91cc90", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d60520a5-36c1-4fef-af6e-b2dfc8036f24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b114f02b-7c2a-43f8-83ff-318c4c91cc90"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>", "ID": "b2296243-8cee-492c-a8ed-729fb7ca2cc8", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Driving\nand using machines</span></b>", "ID": "167b14a6-e271-453f-98d9-adcd1b211ec9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b2296243-8cee-492c-a8ed-729fb7ca2cc8"}, {"Element": "<span lang=\"EN-GB\">Driving\nand using machines</span>", "ID": "65e4f697-146e-438e-a1c9-fc5788f4ce7c", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "167b14a6-e271-453f-98d9-adcd1b211ec9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab is unlikely to affect your\nability to drive or use machines; however, use caution when performing these\nactivities until you are sure that nivolumab does not adversely affect you.</span></p>", "ID": "60a4ee39-d2ee-411b-851e-9d10b5943145", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab is unlikely to affect your\nability to drive or use machines; however, use caution when performing these\nactivities until you are sure that nivolumab does not adversely affect you.</span>", "ID": "11bf2324-80bf-4902-bdff-d91a4ff74691", "Styles": "None", "Classes": "None", "Text": "Nivolumab is unlikely to affect your ability to drive or use machines; however, use caution when performing these activities until you are sure that nivolumab does not adversely affect you.", "ParentId": "60a4ee39-d2ee-411b-851e-9d10b5943145"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b9aef74-bc45-4752-97c1-28d4a6511d08", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a7651f8-b61d-412f-b0dd-08bbca43963b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b9aef74-bc45-4752-97c1-28d4a6511d08"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> contains sodium</span></b></p>", "ID": "c1471cf2-516d-45cc-a2ea-3c5b43671e7d", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> contains sodium</span></b>", "ID": "38fa2e99-ab5d-45d7-8dfe-cad8f48b73dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1471cf2-516d-45cc-a2ea-3c5b43671e7d"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "963e0872-8646-4b80-afc4-03e274b93024", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "38fa2e99-ab5d-45d7-8dfe-cad8f48b73dc"}, {"Element": "<span lang=\"EN-GB\"> contains sodium</span>", "ID": "0b76b819-2276-49ba-8bf5-878775f9e95d", "Styles": "None", "Classes": "None", "Text": " contains sodium", "ParentId": "38fa2e99-ab5d-45d7-8dfe-cad8f48b73dc"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor </span></b><span lang=\"EN-GB\">if you are on a low\u2011sodium (low\u2011salt) diet before you\nare given </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. This\nmedicine contains\u00a02.5\u00a0mg sodium per </span><span lang=\"EN-GB\">mL</span><span lang=\"EN-GB\"> of concentrate.</span></p>", "ID": "e05372c6-1a15-4ca3-bdd9-02182e42899a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor </span></b>", "ID": "e0a7ffb4-c270-4353-b7e7-63b443483c19", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor </span>", "ID": "3377aa89-f2e5-4dd6-b7bd-62939b83c76e", "Styles": "None", "Classes": "None", "Text": "Tell your doctor ", "ParentId": "e0a7ffb4-c270-4353-b7e7-63b443483c19"}, {"Element": "<span lang=\"EN-GB\">if you are on a low\u2011sodium (low\u2011salt) diet before you\nare given </span>", "ID": "47f8391f-29d5-4687-a3b8-5cad10e0f3e9", "Styles": "None", "Classes": "None", "Text": "if you are on a low\u2011sodium (low\u2011salt) diet before you are given ", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "d20f2112-f6cc-4126-81d9-c601d8d3583a", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<span lang=\"EN-GB\">. This\nmedicine contains\u00a02.5\u00a0mg sodium per </span>", "ID": "2390ed21-7d93-4883-9c7c-b4e54b92608e", "Styles": "None", "Classes": "None", "Text": ". This medicine contains\u00a02.5\u00a0mg sodium per ", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<span lang=\"EN-GB\">mL</span>", "ID": "02d0884f-37fb-4c98-a598-0ed02514a58d", "Styles": "None", "Classes": "None", "Text": "mL", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<span lang=\"EN-GB\"> of concentrate.</span>", "ID": "a67e6af7-a874-490a-82a3-83a23e8d8129", "Styles": "None", "Classes": "None", "Text": " of concentrate.", "ParentId": "e05372c6-1a15-4ca3-bdd9-02182e42899a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e003114e-a7c1-474a-a696-5672eb45da00", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc797db8-ac7f-4a64-b8cf-9556265996c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e003114e-a7c1-474a-a696-5672eb45da00"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">You will also find this information in\nthe Patient Alert Card you have been given by your doctor. It is important that\nyou keep this Alert Card and show it to your partner or caregivers.</span></p>", "ID": "3e0994d7-c27a-4181-a1d9-98872148b908", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">You will also find this information in\nthe Patient Alert Card you have been given by your doctor. It is important that\nyou keep this Alert Card and show it to your partner or caregivers.</span>", "ID": "f2c4b2d8-39a5-45c2-9d7f-4b4d6f4e1353", "Styles": "None", "Classes": "None", "Text": "You will also find this information in the Patient Alert Card you have been given by your doctor. It is important that you keep this Alert Card and show it to your partner or caregivers.", "ParentId": "3e0994d7-c27a-4181-a1d9-98872148b908"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1e9881e-0385-4113-92db-f18a3573551c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "933674ea-4141-4801-8449-cf88628016c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1e9881e-0385-4113-92db-f18a3573551c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bfee1d3d-e94a-41d5-834d-b45ecf6baf1f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0948c4c1-9ed9-44c8-a709-39569ab322ab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bfee1d3d-e94a-41d5-834d-b45ecf6baf1f"}, {"Element": "<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 H</span><span lang=\"EN-GB\">ow to use Nivolumab\u00a0BMS</span></p>", "ID": "dc7fd142-826a-4983-9653-bca8b903bf6c", "Styles": "None", "Classes": "['EMEAHeading3']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 H</span>", "ID": "a7a2cbb8-b26e-4968-a1c9-45b86b90036c", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 H", "ParentId": "dc7fd142-826a-4983-9653-bca8b903bf6c"}, {"Element": "<span lang=\"EN-GB\">ow to use Nivolumab\u00a0BMS</span>", "ID": "b4729e3b-2701-4019-b85d-92be50332917", "Styles": "None", "Classes": "None", "Text": "ow to use Nivolumab\u00a0BMS", "ParentId": "dc7fd142-826a-4983-9653-bca8b903bf6c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "255ba09e-240c-4bf7-b909-655d6fd2ed2e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d393f7e3-97f0-4810-a3a2-54b2209bd0ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "255ba09e-240c-4bf7-b909-655d6fd2ed2e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nmuch </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b><b><span lang=\"EN-GB\">\nis given</span></b></p>", "ID": "53b4d780-5c2b-4fdc-b962-7bc905aeb356", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">How\nmuch </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></b>", "ID": "32830170-6ffb-427c-b019-c0bedcad5609", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53b4d780-5c2b-4fdc-b962-7bc905aeb356"}, {"Element": "<span lang=\"EN-GB\">How\nmuch </span>", "ID": "24450e7c-57ba-4665-9a85-a83eccfa7143", "Styles": "None", "Classes": "None", "Text": "How much ", "ParentId": "32830170-6ffb-427c-b019-c0bedcad5609"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "8c29e7eb-a4ee-437d-a416-71ccf5c37a31", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "32830170-6ffb-427c-b019-c0bedcad5609"}, {"Element": "<b><span lang=\"EN-GB\">\nis given</span></b>", "ID": "0e488ae0-5be6-4109-95aa-70b05bcbe8f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53b4d780-5c2b-4fdc-b962-7bc905aeb356"}, {"Element": "<span lang=\"EN-GB\">\nis given</span>", "ID": "c31bc181-9a30-4b78-bfbe-95ee1eb0f0de", "Styles": "None", "Classes": "None", "Text": " is given", "ParentId": "0e488ae0-5be6-4109-95aa-70b05bcbe8f6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The amount of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> you will be given will be calculated based on your body weight. The\n</span><span lang=\"EN-GB\">recommended</span><span lang=\"EN-GB\"> dose\nis\u00a03\u00a0mg of nivolumab per kilogram of your body weight.</span></p>", "ID": "5d113d8a-7547-49ae-8414-721f2334edf2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The amount of </span>", "ID": "ae4068ac-cf42-4eed-bf72-f752626e7bab", "Styles": "None", "Classes": "None", "Text": "The amount of ", "ParentId": "5d113d8a-7547-49ae-8414-721f2334edf2"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "046100b6-07ff-4b0c-b18d-ebe3310756d6", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "5d113d8a-7547-49ae-8414-721f2334edf2"}, {"Element": "<span lang=\"EN-GB\"> you will be given will be calculated based on your body weight. The\n</span>", "ID": "a5d39e90-f9aa-424f-845a-8cb0e72418f0", "Styles": "None", "Classes": "None", "Text": " you will be given will be calculated based on your body weight. The ", "ParentId": "5d113d8a-7547-49ae-8414-721f2334edf2"}, {"Element": "<span lang=\"EN-GB\">recommended</span>", "ID": "e48f68dc-6ce0-484a-bd53-ecdf6cb46362", "Styles": "None", "Classes": "None", "Text": "recommended", "ParentId": "5d113d8a-7547-49ae-8414-721f2334edf2"}, {"Element": "<span lang=\"EN-GB\"> dose\nis\u00a03\u00a0mg of nivolumab per kilogram of your body weight.</span>", "ID": "ade06e45-52da-48ff-88df-6496cee64aef", "Styles": "None", "Classes": "None", "Text": " dose is\u00a03\u00a0mg of nivolumab per kilogram of your body weight.", "ParentId": "5d113d8a-7547-49ae-8414-721f2334edf2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Depending on your dose, the appropriate\namount of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> will\nbe diluted with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for\ninjection or\u00a0glucose 50\u00a0mg/mL\u00a0(5%) solution for injection before\nuse. More than one vial of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> may be necessary to obtain the required dose.</span></p>", "ID": "cac6e06c-7981-41be-8574-5468f2d0bbe9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Depending on your dose, the appropriate\namount of </span>", "ID": "cf4f32df-3e3b-49f7-b8fa-ea8200b59259", "Styles": "None", "Classes": "None", "Text": "Depending on your dose, the appropriate amount of ", "ParentId": "cac6e06c-7981-41be-8574-5468f2d0bbe9"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "881b37b4-a077-40b9-95ae-383d17851d10", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "cac6e06c-7981-41be-8574-5468f2d0bbe9"}, {"Element": "<span lang=\"EN-GB\"> will\nbe diluted with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for\ninjection or\u00a0glucose 50\u00a0mg/mL\u00a0(5%) solution for injection before\nuse. More than one vial of </span>", "ID": "cbf64f48-b674-412e-b0ce-5b2934eff2b1", "Styles": "None", "Classes": "None", "Text": " will be diluted with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection or\u00a0glucose 50\u00a0mg/mL\u00a0(5%) solution for injection before use. More than one vial of ", "ParentId": "cac6e06c-7981-41be-8574-5468f2d0bbe9"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "0cd568d2-1a66-4989-83e5-065fdb56b96c", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "cac6e06c-7981-41be-8574-5468f2d0bbe9"}, {"Element": "<span lang=\"EN-GB\"> may be necessary to obtain the required dose.</span>", "ID": "6b3d03a7-0ba0-414a-9ad6-97d04ef727e7", "Styles": "None", "Classes": "None", "Text": " may be necessary to obtain the required dose.", "ParentId": "cac6e06c-7981-41be-8574-5468f2d0bbe9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab7d5f23-46bf-487e-a663-beed36a5b14c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da2a6cc5-20ca-48ac-b1f5-8e73bc0f7a6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab7d5f23-46bf-487e-a663-beed36a5b14c"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nNivolumab\u00a0BMS is given</span></b></p>", "ID": "2a273500-c73c-495d-bb74-bd50c0a5bbb2", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">How\nNivolumab\u00a0BMS is given</span></b>", "ID": "e279f449-5d57-4d2f-b306-cb584a82c27e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a273500-c73c-495d-bb74-bd50c0a5bbb2"}, {"Element": "<span lang=\"EN-GB\">How\nNivolumab\u00a0BMS is given</span>", "ID": "aba94873-384a-4683-8cc0-5346ae24aad5", "Styles": "None", "Classes": "None", "Text": "How Nivolumab\u00a0BMS is given", "ParentId": "e279f449-5d57-4d2f-b306-cb584a82c27e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">You will receive treatment with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> in a hospital or clinic,\nunder the supervision of an experienced doctor.</span></p>", "ID": "6d9f5499-a311-4f65-a4e2-41e1529aa633", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">You will receive treatment with </span>", "ID": "0e0a9889-0818-4ffe-a74a-59b13c635d1a", "Styles": "None", "Classes": "None", "Text": "You will receive treatment with ", "ParentId": "6d9f5499-a311-4f65-a4e2-41e1529aa633"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "d2fbfc13-3f4f-4e42-95c9-7e6dfe501181", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "6d9f5499-a311-4f65-a4e2-41e1529aa633"}, {"Element": "<span lang=\"EN-GB\"> in a hospital or clinic,\nunder the supervision of an experienced doctor.</span>", "ID": "70cd27eb-ac6e-48b3-9d9d-f8794e413499", "Styles": "None", "Classes": "None", "Text": " in a hospital or clinic, under the supervision of an experienced doctor.", "ParentId": "6d9f5499-a311-4f65-a4e2-41e1529aa633"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "136e3b6a-36b1-4544-b2fd-edda0324260f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a7f3596-521f-48bf-ae40-b5762e8a8b23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "136e3b6a-36b1-4544-b2fd-edda0324260f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> will be given to you as an infusion (a drip) into a vein\n(intravenously) over a period of\u00a060\u00a0minutes, every\u00a02\u00a0weeks.\nYour doctor will continue giving you </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> for as long as you keep benefitting from it or until you no longer\ntolerate the treatment.</span></p>", "ID": "3c650503-a419-4485-94b2-9ab6608e71f0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "46143ba4-287c-4bd2-8858-33710d03ab1d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "3c650503-a419-4485-94b2-9ab6608e71f0"}, {"Element": "<span lang=\"EN-GB\"> will be given to you as an infusion (a drip) into a vein\n(intravenously) over a period of\u00a060\u00a0minutes, every\u00a02\u00a0weeks.\nYour doctor will continue giving you </span>", "ID": "5e62b249-6513-495e-8f35-23c2b7096a4a", "Styles": "None", "Classes": "None", "Text": " will be given to you as an infusion (a drip) into a vein (intravenously) over a period of\u00a060\u00a0minutes, every\u00a02\u00a0weeks. Your doctor will continue giving you ", "ParentId": "3c650503-a419-4485-94b2-9ab6608e71f0"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "75228161-6f56-4c09-8ca6-d582a1b4f1de", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "3c650503-a419-4485-94b2-9ab6608e71f0"}, {"Element": "<span lang=\"EN-GB\"> for as long as you keep benefitting from it or until you no longer\ntolerate the treatment.</span>", "ID": "77a7c312-a656-4349-8924-4e6635473336", "Styles": "None", "Classes": "None", "Text": " for as long as you keep benefitting from it or until you no longer tolerate the treatment.", "ParentId": "3c650503-a419-4485-94b2-9ab6608e71f0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "947c7d35-1629-4804-b5f2-ebef37bba4d8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16e3f07f-f467-4e61-ba37-d7cbc2981536", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "947c7d35-1629-4804-b5f2-ebef37bba4d8"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nmiss a dose of Nivolumab\u00a0BMS</span></b></p>", "ID": "40531791-1712-408d-9036-d0161ce334ff", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">If you\nmiss a dose of Nivolumab\u00a0BMS</span></b>", "ID": "263f76cd-533d-4375-871b-19f14714df20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40531791-1712-408d-9036-d0161ce334ff"}, {"Element": "<span lang=\"EN-GB\">If you\nmiss a dose of Nivolumab\u00a0BMS</span>", "ID": "e02b7bf5-2f14-42b5-be11-4548aeab50f5", "Styles": "None", "Classes": "None", "Text": "If you miss a dose of Nivolumab\u00a0BMS", "ParentId": "263f76cd-533d-4375-871b-19f14714df20"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is very important for you to keep all\nyour appointments to receive </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\">. If you miss an appointment, ask your doctor when to schedule your\nnext dose.</span></p>", "ID": "ed07fb5c-3930-4b10-9970-593ee8034668", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">It is very important for you to keep all\nyour appointments to receive </span>", "ID": "eca6dac4-f1af-4288-8199-36eda54a788e", "Styles": "None", "Classes": "None", "Text": "It is very important for you to keep all your appointments to receive ", "ParentId": "ed07fb5c-3930-4b10-9970-593ee8034668"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "2df51854-2163-45b0-b90c-ba909a4573ea", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "ed07fb5c-3930-4b10-9970-593ee8034668"}, {"Element": "<span lang=\"EN-GB\">. If you miss an appointment, ask your doctor when to schedule your\nnext dose.</span>", "ID": "a173f905-bc0a-4b9e-907d-c5def64c560d", "Styles": "None", "Classes": "None", "Text": ". If you miss an appointment, ask your doctor when to schedule your next dose.", "ParentId": "ed07fb5c-3930-4b10-9970-593ee8034668"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "134d7562-c5eb-4254-892e-aa1c8fdc7949", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "76bd07ae-a6ec-471f-b764-e3522eb17d9c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "134d7562-c5eb-4254-892e-aa1c8fdc7949"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nstop using Nivolumab\u00a0BMS</span></b></p>", "ID": "9b39397e-761b-4e83-97ea-a5328cd04b22", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">If you\nstop using Nivolumab\u00a0BMS</span></b>", "ID": "705e4671-f2f4-4c8b-bd20-cdc3a90f60cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9b39397e-761b-4e83-97ea-a5328cd04b22"}, {"Element": "<span lang=\"EN-GB\">If you\nstop using Nivolumab\u00a0BMS</span>", "ID": "d8e2e94f-19e4-4cd8-bcbd-cbe308d706cf", "Styles": "None", "Classes": "None", "Text": "If you stop using Nivolumab\u00a0BMS", "ParentId": "705e4671-f2f4-4c8b-bd20-cdc3a90f60cb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Stopping your treatment may stop the\neffect of the medicine. Do not stop treatment with </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> unless you have discussed this with your doctor.</span></p>", "ID": "b39d6a84-d1f6-432a-81c5-69ac77540801", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Stopping your treatment may stop the\neffect of the medicine. Do not stop treatment with </span>", "ID": "59cc38a8-75dc-44f6-8b3d-4f3c44cf2b9d", "Styles": "None", "Classes": "None", "Text": "Stopping your treatment may stop the effect of the medicine. Do not stop treatment with ", "ParentId": "b39d6a84-d1f6-432a-81c5-69ac77540801"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "bf6e03c5-81ac-48f3-b8ca-5538488a0244", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "b39d6a84-d1f6-432a-81c5-69ac77540801"}, {"Element": "<span lang=\"EN-GB\"> unless you have discussed this with your doctor.</span>", "ID": "71dda327-5d37-4c04-a961-7c7967bb96e4", "Styles": "None", "Classes": "None", "Text": " unless you have discussed this with your doctor.", "ParentId": "b39d6a84-d1f6-432a-81c5-69ac77540801"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f3eae28-f8b4-4b1e-9e34-b1dc045b9047", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f94969ef-7787-4006-915f-d5cffb647089", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f3eae28-f8b4-4b1e-9e34-b1dc045b9047"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions about\nyour treatment or on the use of this medicine, ask your doctor.</span></p>", "ID": "0ca0bb6b-090f-4b6d-8de0-7310a70476ca", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions about\nyour treatment or on the use of this medicine, ask your doctor.</span>", "ID": "dd18fc00-8056-40b2-b4de-2cbc3d036b1f", "Styles": "None", "Classes": "None", "Text": "If you have any further questions about your treatment or on the use of this medicine, ask your doctor.", "ParentId": "0ca0bb6b-090f-4b6d-8de0-7310a70476ca"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ebcce22d-609a-49a7-9898-85c89e7d4bce", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f025d6c9-f9f0-4334-8751-1e97b2042f2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ebcce22d-609a-49a7-9898-85c89e7d4bce"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "62f94e8f-c409-4b24-adac-fa648eacad26", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "807e7a15-47a5-4955-bad4-d86190dc69dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "62f94e8f-c409-4b24-adac-fa648eacad26"}, {"Element": "<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>", "ID": "5d4e97d5-76e8-42f9-bc1f-2223954f43eb", "Styles": "None", "Classes": "['EMEAHeading3']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "12b0cd72-25a9-463f-a6dc-ae401b5f25f5", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "5d4e97d5-76e8-42f9-bc1f-2223954f43eb"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de41c8db-38f4-4ef7-b908-cc4f5af3c772", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c739adc-b431-46be-bac1-28b207a87cc0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de41c8db-38f4-4ef7-b908-cc4f5af3c772"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\ncause side effects, although not everybody gets them. Your doctor will discuss\nthese with you and will explain the risks and benefits of your treatment.</span></p>", "ID": "6191b083-27a1-4889-aa65-659af4a44fe0", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Like all medicines, this medicine can\ncause side effects, although not everybody gets them. Your doctor will discuss\nthese with you and will explain the risks and benefits of your treatment.</span>", "ID": "372082d6-1706-402e-924e-9b85d754bbfc", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the risks and benefits of your treatment.", "ParentId": "6191b083-27a1-4889-aa65-659af4a44fe0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82dfc07f-5066-425b-8625-f50faacb4192", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "083df758-2f0c-4010-ba18-5d20251780c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82dfc07f-5066-425b-8625-f50faacb4192"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Be aware of important symptoms of\ninflammation.</span></b><span lang=\"EN-GB\"> Nivolumab\u00a0BMS acts on your\nimmune system and may cause inflammation in parts of your body. Inflammation\nmay cause serious damage to your body and some inflammatory conditions may be\nlife\u2011threatening and need treatment or withdrawal of nivolumab.</span></p>", "ID": "706a4dcb-302c-4a98-9db4-32bfde6449b3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Be aware of important symptoms of\ninflammation.</span></b>", "ID": "9a35d682-e9ae-46fb-9d28-33396a72d365", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "706a4dcb-302c-4a98-9db4-32bfde6449b3"}, {"Element": "<span lang=\"EN-GB\">Be aware of important symptoms of\ninflammation.</span>", "ID": "6ddedcf3-b888-4395-9e7f-5ea6f22a4606", "Styles": "None", "Classes": "None", "Text": "Be aware of important symptoms of inflammation.", "ParentId": "9a35d682-e9ae-46fb-9d28-33396a72d365"}, {"Element": "<span lang=\"EN-GB\"> Nivolumab\u00a0BMS acts on your\nimmune system and may cause inflammation in parts of your body. Inflammation\nmay cause serious damage to your body and some inflammatory conditions may be\nlife\u2011threatening and need treatment or withdrawal of nivolumab.</span>", "ID": "40591d7c-7dd1-41be-9506-61cd3cd78402", "Styles": "None", "Classes": "None", "Text": " Nivolumab\u00a0BMS acts on your immune system and may cause inflammation in parts of your body. Inflammation may cause serious damage to your body and some inflammatory conditions may be life\u2011threatening and need treatment or withdrawal of nivolumab.", "ParentId": "706a4dcb-302c-4a98-9db4-32bfde6449b3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "21462c42-79bc-4ebe-8d3c-7dbb0d7fa792", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7deefeca-24eb-4bbb-9e48-7338c033bcf3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "21462c42-79bc-4ebe-8d3c-7dbb0d7fa792"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following side effects have been\nreported in clinical trials with nivolumab:</span></p>", "ID": "480429cf-2a4c-4afc-9613-8b5c5d5b7107", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The following side effects have been\nreported in clinical trials with nivolumab:</span>", "ID": "5a1374eb-0c76-4e22-b84a-85497fe001b0", "Styles": "None", "Classes": "None", "Text": "The following side effects have been reported in clinical trials with nivolumab:", "ParentId": "480429cf-2a4c-4afc-9613-8b5c5d5b7107"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7d8cfb67-cb8d-4f77-b489-39c7eb76ce90", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ecf94efa-a210-4a05-b959-42b21e2abb41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7d8cfb67-cb8d-4f77-b489-39c7eb76ce90"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon (may affect more than\u00a01\u00a0in\u00a010\u00a0people)</span></b></p>", "ID": "afc7e0e4-6f41-4988-a9a1-b718db080324", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Very\ncommon (may affect more than\u00a01\u00a0in\u00a010\u00a0people)</span></b>", "ID": "91e4f499-d5bb-4ba9-a69b-f39685452ca3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afc7e0e4-6f41-4988-a9a1-b718db080324"}, {"Element": "<span lang=\"EN-GB\">Very\ncommon (may affect more than\u00a01\u00a0in\u00a010\u00a0people)</span>", "ID": "480814d7-cb6b-4910-b390-46dcbbdb0c77", "Styles": "None", "Classes": "None", "Text": "Very common (may affect more than\u00a01\u00a0in\u00a010\u00a0people)", "ParentId": "91e4f499-d5bb-4ba9-a69b-f39685452ca3"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Decreased appetite</span></p>", "ID": "f9de60c0-063f-4596-b296-35f3a3312e47", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "429e0f58-7832-4e65-9217-d90d9accf7f1", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "f9de60c0-063f-4596-b296-35f3a3312e47"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "d3a74a01-d8d9-4171-bfae-00c4416fabfd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "429e0f58-7832-4e65-9217-d90d9accf7f1"}, {"Element": "<span lang=\"EN-GB\">Decreased appetite</span>", "ID": "48441268-1241-4166-b6d5-14802a5fe455", "Styles": "None", "Classes": "None", "Text": "Decreased appetite", "ParentId": "f9de60c0-063f-4596-b296-35f3a3312e47"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Nausea</span></p>", "ID": "3e056cd2-f94f-41e4-8d13-99d5839a1f3c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "5a141dec-7d3c-40a8-85ec-8e9bc6bcafe0", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "3e056cd2-f94f-41e4-8d13-99d5839a1f3c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "4edb913d-2a5b-48ee-b489-888e523f4e68", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "5a141dec-7d3c-40a8-85ec-8e9bc6bcafe0"}, {"Element": "<span lang=\"EN-GB\">Nausea</span>", "ID": "a21ccd7d-dbea-402e-8056-d3c401fd7c88", "Styles": "None", "Classes": "None", "Text": "Nausea", "ParentId": "3e056cd2-f94f-41e4-8d13-99d5839a1f3c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling tired or weak</span></p>", "ID": "1d5dc391-6e6c-4e3c-9471-769c617072ec", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "edcf0aa4-1785-4c7c-9e52-21b07b18362e", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "1d5dc391-6e6c-4e3c-9471-769c617072ec"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "bc1a4784-9916-4aa7-8d11-a883f6aec3bc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "edcf0aa4-1785-4c7c-9e52-21b07b18362e"}, {"Element": "<span lang=\"EN-GB\">Feeling tired or weak</span>", "ID": "2eee5da3-a793-44ce-8974-28f4cf91cceb", "Styles": "None", "Classes": "None", "Text": "Feeling tired or weak", "ParentId": "1d5dc391-6e6c-4e3c-9471-769c617072ec"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d1867367-a6ee-42ac-8c8f-bae4e803a74b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "69b2a251-3c83-4a6e-954f-f140ff447852", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d1867367-a6ee-42ac-8c8f-bae4e803a74b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Common\n(may affect up to\u00a01\u00a0in\u00a010\u00a0people)</span></b></p>", "ID": "e0410dc1-a73d-493d-b252-2c0269afcf37", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Common\n(may affect up to\u00a01\u00a0in\u00a010\u00a0people)</span></b>", "ID": "84b80bc5-09d2-4ab9-945c-ff4fa7a565ba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e0410dc1-a73d-493d-b252-2c0269afcf37"}, {"Element": "<span lang=\"EN-GB\">Common\n(may affect up to\u00a01\u00a0in\u00a010\u00a0people)</span>", "ID": "e482147d-31c3-47e1-bd0c-de13d21e3dc1", "Styles": "None", "Classes": "None", "Text": "Common (may affect up to\u00a01\u00a0in\u00a010\u00a0people)", "ParentId": "84b80bc5-09d2-4ab9-945c-ff4fa7a565ba"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Underactive thyroid gland which can cause\ntiredness or weight gain</span></p>", "ID": "cd6f3aa3-0ba6-4878-b681-38c4c9e3e2db", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "ceaa3db1-61da-47cd-94d9-c7bfd377155c", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "cd6f3aa3-0ba6-4878-b681-38c4c9e3e2db"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "ebdb70d7-0403-437b-8382-2fc796120412", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "ceaa3db1-61da-47cd-94d9-c7bfd377155c"}, {"Element": "<span lang=\"EN-GB\">Underactive thyroid gland which can cause\ntiredness or weight gain</span>", "ID": "af2ac1f7-8715-457c-838f-1898a6e99bac", "Styles": "None", "Classes": "None", "Text": "Underactive thyroid gland which can cause tiredness or weight gain", "ParentId": "cd6f3aa3-0ba6-4878-b681-38c4c9e3e2db"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the nerves causing numbness,\nweakness, tingling or burning pain of the arms and legs, headache, dizziness</span></p>", "ID": "206ce20c-b2c3-4a23-ba47-a00ae5275339", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "eb30b6d5-9636-45e0-ac1b-f36f1af78db0", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "206ce20c-b2c3-4a23-ba47-a00ae5275339"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "a67efc99-e109-4aee-b813-a42f7e75b3b2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "eb30b6d5-9636-45e0-ac1b-f36f1af78db0"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the nerves causing numbness,\nweakness, tingling or burning pain of the arms and legs, headache, dizziness</span>", "ID": "595b953d-a5d6-4354-9ff1-2289fc2fe6ab", "Styles": "None", "Classes": "None", "Text": "Inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs, headache, dizziness", "ParentId": "206ce20c-b2c3-4a23-ba47-a00ae5275339"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the lungs (pneumonitis),\ncharacterised by coughing and difficulty breathing, shortness of breath\n(dyspnoea), cough</span></p>", "ID": "1ba6a7e0-040e-420a-bb8a-acef0756e2c5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "28864d54-1922-4a3d-9225-28e3d3e24cc9", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "1ba6a7e0-040e-420a-bb8a-acef0756e2c5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "20966273-f6ce-497e-babd-ab42f7dbed09", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "28864d54-1922-4a3d-9225-28e3d3e24cc9"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the lungs (pneumonitis),\ncharacterised by coughing and difficulty breathing, shortness of breath\n(dyspnoea), cough</span>", "ID": "ef4540c9-66c4-4607-97e1-772a637ea366", "Styles": "None", "Classes": "None", "Text": "Inflammation of the lungs (pneumonitis), characterised by coughing and difficulty breathing, shortness of breath (dyspnoea), cough", "ParentId": "1ba6a7e0-040e-420a-bb8a-acef0756e2c5"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Diarrhoea (watery, loose or soft stools), mouth\nulcers and cold sores (stomatitis), vomiting, stomach pain, constipation, dry\nmouth</span></p>", "ID": "31215a6f-4256-4454-9712-5cc2aaccd88e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "beafbaa8-2450-44a9-b2cd-363c7a858b10", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "31215a6f-4256-4454-9712-5cc2aaccd88e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "bb10881d-3384-4f16-8b93-d783474e7656", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "beafbaa8-2450-44a9-b2cd-363c7a858b10"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea (watery, loose or soft stools), mouth\nulcers and cold sores (stomatitis), vomiting, stomach pain, constipation, dry\nmouth</span>", "ID": "2c73144f-dc51-4a88-8cc0-9a413124af0d", "Styles": "None", "Classes": "None", "Text": "Diarrhoea (watery, loose or soft stools), mouth ulcers and cold sores (stomatitis), vomiting, stomach pain, constipation, dry mouth", "ParentId": "31215a6f-4256-4454-9712-5cc2aaccd88e"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Skin rash, itching</span></p>", "ID": "623af008-dd90-485f-bb50-27756ff3370d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "93957184-151e-4cce-a052-0563209952bc", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "623af008-dd90-485f-bb50-27756ff3370d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "cce7261d-beef-430a-9834-90f67dca38e9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "93957184-151e-4cce-a052-0563209952bc"}, {"Element": "<span lang=\"EN-GB\">Skin rash, itching</span>", "ID": "daf5c956-2e8b-491b-baec-afb894d3ca2e", "Styles": "None", "Classes": "None", "Text": "Skin rash, itching", "ParentId": "623af008-dd90-485f-bb50-27756ff3370d"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;letter-spacing:.15pt\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Pain in the muscles, bones and joints</span></p>", "ID": "bcb15120-4eab-4dde-aeff-a34f9736f21c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings;letter-spacing:.15pt\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span></span>", "ID": "cc48b8e5-d0b3-4a81-90a6-7a450206bf87", "Styles": "font-family:Wingdings;letter-spacing:.15pt", "Classes": "None", "Text": "\u00a7", "ParentId": "bcb15120-4eab-4dde-aeff-a34f9736f21c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0 </span>", "ID": "b6f870fd-9f79-4990-8f52-f8869c4d8631", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "cc48b8e5-d0b3-4a81-90a6-7a450206bf87"}, {"Element": "<span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Pain in the muscles, bones and joints</span>", "ID": "6ace972f-c315-4520-b996-9c09feac24c5", "Styles": "letter-spacing:.15pt", "Classes": "None", "Text": "Pain in the muscles, bones and joints", "ParentId": "bcb15120-4eab-4dde-aeff-a34f9736f21c"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Fever, oedema\n(swelling)</span></p>", "ID": "cfa35d4e-6ac6-4602-9161-8f3b96acfcc8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "cdcb1109-fbe0-4e6b-9caf-f84706811a20", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "cfa35d4e-6ac6-4602-9161-8f3b96acfcc8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "a05c0c60-443c-444d-a2cc-fa8d4f623c03", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "cdcb1109-fbe0-4e6b-9caf-f84706811a20"}, {"Element": "<span lang=\"EN-GB\" style=\"letter-spacing:.15pt\">Fever, oedema\n(swelling)</span>", "ID": "7e0596e2-8572-435f-b0aa-c13623f7eae8", "Styles": "letter-spacing:.15pt", "Classes": "None", "Text": "Fever, oedema (swelling)", "ParentId": "cfa35d4e-6ac6-4602-9161-8f3b96acfcc8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d20a942-1771-4bf7-943b-edc5c8a7dc2f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42e229f9-d91d-454f-8e2f-6728e55ebefe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d20a942-1771-4bf7-943b-edc5c8a7dc2f"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon\n(may affect up to\u00a01\u00a0in\u00a0100\u00a0people)</span></b></p>", "ID": "8f7c6d12-2cd6-4e19-8171-9b2b6eca854c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Uncommon\n(may affect up to\u00a01\u00a0in\u00a0100\u00a0people)</span></b>", "ID": "efefe794-64dc-42cf-99ee-a3aab8076738", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8f7c6d12-2cd6-4e19-8171-9b2b6eca854c"}, {"Element": "<span lang=\"EN-GB\">Uncommon\n(may affect up to\u00a01\u00a0in\u00a0100\u00a0people)</span>", "ID": "b3b46954-6690-45a3-aaad-13d0ad6b15ce", "Styles": "None", "Classes": "None", "Text": "Uncommon (may affect up to\u00a01\u00a0in\u00a0100\u00a0people)", "ParentId": "efefe794-64dc-42cf-99ee-a3aab8076738"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bronchitis, infections of the upper respiratory\ntract</span></p>", "ID": "7a0a1e89-2a3c-4f0c-94e5-ac12da317fc2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "5887305c-2a20-4221-b1a2-5a3f5c3a9b00", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "7a0a1e89-2a3c-4f0c-94e5-ac12da317fc2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "eee1a12b-e8f9-43c6-a074-f988be858c4e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "5887305c-2a20-4221-b1a2-5a3f5c3a9b00"}, {"Element": "<span lang=\"EN-GB\">Bronchitis, infections of the upper respiratory\ntract</span>", "ID": "da88d84b-771d-45ee-bf7c-1fe447497020", "Styles": "None", "Classes": "None", "Text": "Bronchitis, infections of the upper respiratory tract", "ParentId": "7a0a1e89-2a3c-4f0c-94e5-ac12da317fc2"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A disease causing the inflammation or\nenlargement of a lymph node (Kikuchi lymphadenitis)</span></p>", "ID": "b4faf64c-9078-4834-b4fd-392467d4de55", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "4eea557e-8068-48e5-a864-28e8f8a4aadc", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "b4faf64c-9078-4834-b4fd-392467d4de55"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "108fc8a1-5a83-4770-b196-11084e9b80ba", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "4eea557e-8068-48e5-a864-28e8f8a4aadc"}, {"Element": "<span lang=\"EN-GB\">A disease causing the inflammation or\nenlargement of a lymph node (Kikuchi lymphadenitis)</span>", "ID": "cee3afe4-2d7d-40c6-ada4-6eaf7f4d6937", "Styles": "None", "Classes": "None", "Text": "A disease causing the inflammation or enlargement of a lymph node (Kikuchi lymphadenitis)", "ParentId": "b4faf64c-9078-4834-b4fd-392467d4de55"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Allergic reaction, reactions related to the\nadministration of the medicine </span></p>", "ID": "a9848fdf-b1e0-451f-a128-c2b05013e523", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "b1bb476a-1756-4179-a0ca-03ac458b4d6a", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "a9848fdf-b1e0-451f-a128-c2b05013e523"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "5f183399-19d0-4df9-985d-d780934e3c5d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b1bb476a-1756-4179-a0ca-03ac458b4d6a"}, {"Element": "<span lang=\"EN-GB\">Allergic reaction, reactions related to the\nadministration of the medicine </span>", "ID": "3ac60f78-f088-4b45-9e92-efed2878fe76", "Styles": "None", "Classes": "None", "Text": "Allergic reaction, reactions related to the administration of the medicine ", "ParentId": "a9848fdf-b1e0-451f-a128-c2b05013e523"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Adrenal glands not working properly,\ninflammation of the thyroid gland</span></p>", "ID": "d618082f-6dce-4f2f-8822-4ed9ba1c38be", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "eb7a6484-0622-4e41-9ba6-8b662b45c43a", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "d618082f-6dce-4f2f-8822-4ed9ba1c38be"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "a2503444-b730-4b5a-afde-251e415afc65", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "eb7a6484-0622-4e41-9ba6-8b662b45c43a"}, {"Element": "<span lang=\"EN-GB\">Adrenal glands not working properly,\ninflammation of the thyroid gland</span>", "ID": "36e7da67-01d9-4895-b25c-2cd9b45c5354", "Styles": "None", "Classes": "None", "Text": "Adrenal glands not working properly, inflammation of the thyroid gland", "ParentId": "d618082f-6dce-4f2f-8822-4ed9ba1c38be"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A condition in which the muscles become weak and\ntire easily (myasthenic syndrome), damage to the nerves in different parts of\nthe body that can cause decreased feeling or affect movement</span></p>", "ID": "72d15500-1edb-46e3-8788-90610375c878", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "c6dd8f31-dad1-45f9-b6e5-b6c878560c7b", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "72d15500-1edb-46e3-8788-90610375c878"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "e69498da-ba78-44bb-9db9-4a873d93bb66", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "c6dd8f31-dad1-45f9-b6e5-b6c878560c7b"}, {"Element": "<span lang=\"EN-GB\">A condition in which the muscles become weak and\ntire easily (myasthenic syndrome), damage to the nerves in different parts of\nthe body that can cause decreased feeling or affect movement</span>", "ID": "677dd79b-3594-48ce-88e4-3f0662896235", "Styles": "None", "Classes": "None", "Text": "A condition in which the muscles become weak and tire easily (myasthenic syndrome), damage to the nerves in different parts of the body that can cause decreased feeling or affect movement", "ParentId": "72d15500-1edb-46e3-8788-90610375c878"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fast heart rate</span></p>", "ID": "794a88fe-89e6-479d-9da1-9527be138912", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "995f4ed8-0ac9-416c-9ef5-9675edcc4278", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "794a88fe-89e6-479d-9da1-9527be138912"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "109c2140-cb9c-4680-b3c9-46644c6487c5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "995f4ed8-0ac9-416c-9ef5-9675edcc4278"}, {"Element": "<span lang=\"EN-GB\">Fast heart rate</span>", "ID": "6ec2e56a-49ed-4cf3-91af-1665755123d9", "Styles": "None", "Classes": "None", "Text": "Fast heart rate", "ParentId": "794a88fe-89e6-479d-9da1-9527be138912"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of blood vessels</span></p>", "ID": "41c61b03-5ec8-435f-a43a-28152b7d5ebb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "e468a25e-c307-498c-962e-d19b97242698", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "41c61b03-5ec8-435f-a43a-28152b7d5ebb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "92b0a810-db6d-41fe-a787-2eacd4e43d70", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "e468a25e-c307-498c-962e-d19b97242698"}, {"Element": "<span lang=\"EN-GB\">Inflammation of blood vessels</span>", "ID": "d198c764-b615-4214-bf30-8c49ee1be69e", "Styles": "None", "Classes": "None", "Text": "Inflammation of blood vessels", "ParentId": "41c61b03-5ec8-435f-a43a-28152b7d5ebb"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid in the lungs</span></p>", "ID": "eb510ab5-21fb-4ca8-8b8c-f21d2bd5f452", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "b3689611-a05b-4f59-bb68-e2d21219436a", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "eb510ab5-21fb-4ca8-8b8c-f21d2bd5f452"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "425ce72b-54c3-430c-b807-5c314c727644", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "b3689611-a05b-4f59-bb68-e2d21219436a"}, {"Element": "<span lang=\"EN-GB\">Fluid in the lungs</span>", "ID": "d9b5b53f-0a6d-4fc5-8334-c32b56e5b38b", "Styles": "None", "Classes": "None", "Text": "Fluid in the lungs", "ParentId": "eb510ab5-21fb-4ca8-8b8c-f21d2bd5f452"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the intestines (colitis), ulcer\nof the small intestines</span></p>", "ID": "3cce915d-5a75-4f62-ba79-450b72d7ba7e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "6107ff81-94f5-4d59-b65c-2ecdd2613518", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "3cce915d-5a75-4f62-ba79-450b72d7ba7e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "b447ae69-41e7-4000-8f8e-d40d87f73498", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "6107ff81-94f5-4d59-b65c-2ecdd2613518"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the intestines (colitis), ulcer\nof the small intestines</span>", "ID": "02336e12-a79a-426a-a6f7-16a446050116", "Styles": "None", "Classes": "None", "Text": "Inflammation of the intestines (colitis), ulcer of the small intestines", "ParentId": "3cce915d-5a75-4f62-ba79-450b72d7ba7e"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hives (itchy, bumpy rash)</span></p>", "ID": "aa38e127-0c9e-41cf-b063-3ac44ce97f88", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "fb4ee159-ff5f-4f3f-8132-021a863f1ee7", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "aa38e127-0c9e-41cf-b063-3ac44ce97f88"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "38ddd9ce-cd7c-4c59-8c55-60511200291b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "fb4ee159-ff5f-4f3f-8132-021a863f1ee7"}, {"Element": "<span lang=\"EN-GB\">Hives (itchy, bumpy rash)</span>", "ID": "c20e772e-8960-4542-ac2e-973a6a67c8c8", "Styles": "None", "Classes": "None", "Text": "Hives (itchy, bumpy rash)", "ParentId": "aa38e127-0c9e-41cf-b063-3ac44ce97f88"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of muscles causing pain or\nstiffness</span></p>", "ID": "e1b56fb3-8095-40a4-b8b4-dc47efe90060", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "dd7873c0-f280-4bd6-8947-5f3c37e8f962", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "e1b56fb3-8095-40a4-b8b4-dc47efe90060"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "ab81f7f4-aad0-40ef-884e-bf4014728f25", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "dd7873c0-f280-4bd6-8947-5f3c37e8f962"}, {"Element": "<span lang=\"EN-GB\">Inflammation of muscles causing pain or\nstiffness</span>", "ID": "bd7bf4ab-a13a-43c6-9f24-c5d7e706d816", "Styles": "None", "Classes": "None", "Text": "Inflammation of muscles causing pain or stiffness", "ParentId": "e1b56fb3-8095-40a4-b8b4-dc47efe90060"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney disease, kidney failure.</span></p>", "ID": "c3fd08d8-023e-4793-86d6-608f5e79132f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "78045d7a-1f9c-43f0-997e-712280ed6362", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "c3fd08d8-023e-4793-86d6-608f5e79132f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "74ed62ce-e9fc-48b9-858b-14eea910c25b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "78045d7a-1f9c-43f0-997e-712280ed6362"}, {"Element": "<span lang=\"EN-GB\">Kidney disease, kidney failure.</span>", "ID": "7a8eedf5-73ec-40af-b04a-ee4e017e5b18", "Styles": "None", "Classes": "None", "Text": "Kidney disease, kidney failure.", "ParentId": "c3fd08d8-023e-4793-86d6-608f5e79132f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c6ef3bd-0271-4d64-929e-0336b0e52895", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84db2d91-7462-47b2-8820-5d8d7467448d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c6ef3bd-0271-4d64-929e-0336b0e52895"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Tell your doctor immediately</span></b><span lang=\"EN-GB\"> if you get any of the side effects listed above. Do not try to\ntreat your symptoms with other medicines on your own.</span></p>", "ID": "20889ea5-d1c8-4b58-9af7-e5cf944174fd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor immediately</span></b>", "ID": "91f6f63b-9b9a-4919-9366-b0df13b95748", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20889ea5-d1c8-4b58-9af7-e5cf944174fd"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor immediately</span>", "ID": "c5df24e3-95a5-4ca0-ae0f-0133947515fc", "Styles": "None", "Classes": "None", "Text": "Tell your doctor immediately", "ParentId": "91f6f63b-9b9a-4919-9366-b0df13b95748"}, {"Element": "<span lang=\"EN-GB\"> if you get any of the side effects listed above. Do not try to\ntreat your symptoms with other medicines on your own.</span>", "ID": "5b7c6d8d-84f7-45ef-8364-4b999b9c2449", "Styles": "None", "Classes": "None", "Text": " if you get any of the side effects listed above. Do not try to treat your symptoms with other medicines on your own.", "ParentId": "20889ea5-d1c8-4b58-9af7-e5cf944174fd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>", "ID": "8b3c98d8-f9ea-46df-bc37-bbd6d1f7a289", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span>", "ID": "e57a5a8c-4469-4f83-8d31-abbf252344a9", "Styles": "font-family:TimesNewRoman", "Classes": "None", "Text": "\u00a0", "ParentId": "8b3c98d8-f9ea-46df-bc37-bbd6d1f7a289"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Changes\nin test results</span></b></p>", "ID": "34aef2df-fac2-42d9-bdb3-d3e8c4b6e953", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Changes\nin test results</span></b>", "ID": "dbc07d95-9010-467c-83dd-a6df9cf1d7b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34aef2df-fac2-42d9-bdb3-d3e8c4b6e953"}, {"Element": "<span lang=\"EN-GB\">Changes\nin test results</span>", "ID": "407ef479-fc88-440d-8564-bd5f0d5af4bb", "Styles": "None", "Classes": "None", "Text": "Changes in test results", "ParentId": "dbc07d95-9010-467c-83dd-a6df9cf1d7b4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> may cause changes in the results of tests carried out by your\ndoctor. These include:</span></p>", "ID": "49adec6b-b54e-4448-9091-c09d4fc7defe", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "9166ca3a-e477-489b-ab5a-fec13b6eb0b8", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "49adec6b-b54e-4448-9091-c09d4fc7defe"}, {"Element": "<span lang=\"EN-GB\"> may cause changes in the results of tests carried out by your\ndoctor. These include:</span>", "ID": "6f862029-a41b-4c76-90b8-8eb683c885cf", "Styles": "None", "Classes": "None", "Text": " may cause changes in the results of tests carried out by your doctor. These include:", "ParentId": "49adec6b-b54e-4448-9091-c09d4fc7defe"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A decreased number of red blood cells (which\ncarry oxygen), white blood cells (which are important in fighting infection) or\nplatelets (cells which help the blood to clot)</span></p>", "ID": "385ea7a3-979a-4a56-b1ef-67cbd86554da", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "20da42d2-4282-43bc-9d6b-d48691100e9b", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "385ea7a3-979a-4a56-b1ef-67cbd86554da"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "812b6f6a-a663-400a-acb8-8ccc4dcb2593", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "20da42d2-4282-43bc-9d6b-d48691100e9b"}, {"Element": "<span lang=\"EN-GB\">A decreased number of red blood cells (which\ncarry oxygen), white blood cells (which are important in fighting infection) or\nplatelets (cells which help the blood to clot)</span>", "ID": "5b9e2da8-2a24-4162-8ed0-cc42ea9b63d8", "Styles": "None", "Classes": "None", "Text": "A decreased number of red blood cells (which carry oxygen), white blood cells (which are important in fighting infection) or platelets (cells which help the blood to clot)", "ParentId": "385ea7a3-979a-4a56-b1ef-67cbd86554da"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal liver function tests (increased amounts\nof the liver enzymes aspartate aminotransferase, alanine aminotransferase or\nalkaline phosphatase in your blood, higher blood levels of bilirubin)</span></p>", "ID": "2fc51f41-35ef-4dd2-81db-a76e0f95a4e1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "a7cc88fe-0c47-4f45-ab13-a2bb814dd40b", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "2fc51f41-35ef-4dd2-81db-a76e0f95a4e1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "14a31317-e4f5-4bcf-a687-ec809576017d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "a7cc88fe-0c47-4f45-ab13-a2bb814dd40b"}, {"Element": "<span lang=\"EN-GB\">Abnormal liver function tests (increased amounts\nof the liver enzymes aspartate aminotransferase, alanine aminotransferase or\nalkaline phosphatase in your blood, higher blood levels of bilirubin)</span>", "ID": "2d56a0f9-4911-42a8-a611-837e03be0e85", "Styles": "None", "Classes": "None", "Text": "Abnormal liver function tests (increased amounts of the liver enzymes aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase in your blood, higher blood levels of bilirubin)", "ParentId": "2fc51f41-35ef-4dd2-81db-a76e0f95a4e1"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal kidney function tests (increased\namounts of creatinine in your blood)</span></p>", "ID": "c292f3d2-bd88-4152-a005-f8f73e6acd62", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "2c951186-90e0-4901-bf3e-9b24c7b2adec", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "c292f3d2-bd88-4152-a005-f8f73e6acd62"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "08cc8590-1509-41c9-9e12-c1bd55ff16a1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "2c951186-90e0-4901-bf3e-9b24c7b2adec"}, {"Element": "<span lang=\"EN-GB\">Abnormal kidney function tests (increased\namounts of creatinine in your blood)</span>", "ID": "f4080921-a22c-4ac4-b567-a2722484292c", "Styles": "None", "Classes": "None", "Text": "Abnormal kidney function tests (increased amounts of creatinine in your blood)", "ParentId": "c292f3d2-bd88-4152-a005-f8f73e6acd62"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal levels of calcium, potassium,\nmagnesium, or sodium in your blood</span></p>", "ID": "f3f77f41-e743-4090-8063-786062c395be", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "f800c29b-d638-4c88-b934-f8572296d0d1", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "f3f77f41-e743-4090-8063-786062c395be"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "287480db-b028-4dcd-9e33-621650cb9d9a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "f800c29b-d638-4c88-b934-f8572296d0d1"}, {"Element": "<span lang=\"EN-GB\">Abnormal levels of calcium, potassium,\nmagnesium, or sodium in your blood</span>", "ID": "5f6db05e-8e84-45a0-92ba-59f7d8ec5df2", "Styles": "None", "Classes": "None", "Text": "Abnormal levels of calcium, potassium, magnesium, or sodium in your blood", "ParentId": "f3f77f41-e743-4090-8063-786062c395be"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">An increased level of the enzyme that breaks\ndown lipids and of the enzyme that breaks down starch.</span></p>", "ID": "913d31e0-5452-40c3-9c8b-1648551150f2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "f492f340-564c-4c05-add4-a4cbcfdc93a5", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "913d31e0-5452-40c3-9c8b-1648551150f2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "dbb7188b-dd73-47a9-8c87-2860417607e7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "f492f340-564c-4c05-add4-a4cbcfdc93a5"}, {"Element": "<span lang=\"EN-GB\">An increased level of the enzyme that breaks\ndown lipids and of the enzyme that breaks down starch.</span>", "ID": "fcf2e268-d6f4-4b09-b7dc-9889308698e1", "Styles": "None", "Classes": "None", "Text": "An increased level of the enzyme that breaks down lipids and of the enzyme that breaks down starch.", "ParentId": "913d31e0-5452-40c3-9c8b-1648551150f2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "34f6dbcf-dbcd-4fca-9aef-7e3848192f50", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f47e0d19-61c9-470e-a5dd-48b310e90861", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "34f6dbcf-dbcd-4fca-9aef-7e3848192f50"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>", "ID": "a4359444-0e9e-4d5e-a828-f80052c21d2c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Reporting\nof side effects</span></b>", "ID": "8c5fb242-0eb7-4d26-85e0-e0b1d03a22d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4359444-0e9e-4d5e-a828-f80052c21d2c"}, {"Element": "<span lang=\"EN-GB\">Reporting\nof side effects</span>", "ID": "fe5d6a89-90b6-4102-ac66-a111bb9faa67", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "8c5fb242-0eb7-4d26-85e0-e0b1d03a22d8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, <b>talk to\nyour doctor</b>.</span><span lang=\"EN-GB\"> This includes any possible side\neffects not listed in this leaflet. You can also report side effects directly\nvia <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>. By reporting side effects you\ncan help provide more information on the safety of this medicine.</span></p>", "ID": "b9a2c3e2-1d66-42a3-b01c-b1f242946d99", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, <b>talk to\nyour doctor</b>.</span>", "ID": "962f21da-4a86-4d56-9d78-8465d8904050", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, .", "ParentId": "b9a2c3e2-1d66-42a3-b01c-b1f242946d99"}, {"Element": "<b>talk to\nyour doctor</b>", "ID": "fe646c86-88bd-4408-b6ed-8b5a65e4c062", "Styles": "None", "Classes": "None", "Text": "talk to your doctor", "ParentId": "962f21da-4a86-4d56-9d78-8465d8904050"}, {"Element": "<span lang=\"EN-GB\"> This includes any possible side\neffects not listed in this leaflet. You can also report side effects directly\nvia <span style=\"background:silver\">the national reporting system listed in </span></span>", "ID": "77f0f127-9b0a-494d-a1d3-2ec79d53c399", "Styles": "None", "Classes": "None", "Text": " This includes any possible side effects not listed in this leaflet. You can also report side effects directly via ", "ParentId": "b9a2c3e2-1d66-42a3-b01c-b1f242946d99"}, {"Element": "<span style=\"background:silver\">the national reporting system listed in </span>", "ID": "7033b87b-aa1d-4ffb-b11b-9807231d8182", "Styles": "background:silver", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "77f0f127-9b0a-494d-a1d3-2ec79d53c399"}, {"Element": "<span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>. By reporting side effects you\ncan help provide more information on the safety of this medicine.</span>", "ID": "a026c604-680c-48b5-b88e-0f7ade1e9c4b", "Styles": "None", "Classes": "None", "Text": ". By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "b9a2c3e2-1d66-42a3-b01c-b1f242946d99"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>", "ID": "295b2e32-7fa4-4edb-87b0-0c15541bf5f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a026c604-680c-48b5-b88e-0f7ade1e9c4b"}, {"Element": "<span style=\"background:silver\">Appendix V</span>", "ID": "28d9424c-8779-4bcc-8668-a69d017063ae", "Styles": "background:silver", "Classes": "None", "Text": "Appendix V", "ParentId": "295b2e32-7fa4-4edb-87b0-0c15541bf5f4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33656ef2-ac5f-4c72-8688-467b4bacd1b1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73a8eeb0-7ede-4257-84ca-6bced5f9fe85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33656ef2-ac5f-4c72-8688-467b4bacd1b1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f0182a63-59a7-47ad-afc3-c5dd8489672e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77b432ab-a68d-4c32-878c-52c8faef80e3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f0182a63-59a7-47ad-afc3-c5dd8489672e"}, {"Element": "<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span></p>", "ID": "cf46b49f-c75d-4009-9775-55727884a525", "Styles": "None", "Classes": "['EMEAHeading2']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Nivolumab\u00a0BMS</span>", "ID": "cdadac3e-9cd8-4e83-abd0-4e8f5219f8bc", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Nivolumab\u00a0BMS", "ParentId": "cf46b49f-c75d-4009-9775-55727884a525"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "143511c1-5824-41c6-9ef0-218d703885b3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "145543d6-6bf5-4688-a7c0-bede3c8984d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "143511c1-5824-41c6-9ef0-218d703885b3"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\nreach of children.</span></p>", "ID": "62b268d3-0ca2-480f-8e43-5f9752fcdfb6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Keep this medicine out of the sight and\nreach of children.</span>", "ID": "ff5d299c-ba92-4840-9a6d-0f8c86c5dd01", "Styles": "None", "Classes": "None", "Text": "Keep this medicine out of the sight and reach of children.", "ParentId": "62b268d3-0ca2-480f-8e43-5f9752fcdfb6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "50485e6f-31e8-48f2-aa5d-75934eaf6f12", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8baa37b4-66b3-48b8-ba99-d565110c3bca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "50485e6f-31e8-48f2-aa5d-75934eaf6f12"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\nexpiry date which is stated on the carton and the vial label </span><span lang=\"EN-GB\">after EXP. The expiry date refers to the last day of that month.</span></p>", "ID": "3d7d5ab3-1b5a-46ed-bdd9-30a05ff807bc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not use this medicine after the\nexpiry date which is stated on the carton and the vial label </span>", "ID": "2a9ad5af-1a32-49ad-b75b-920961ee9911", "Styles": "None", "Classes": "None", "Text": "Do not use this medicine after the expiry date which is stated on the carton and the vial label ", "ParentId": "3d7d5ab3-1b5a-46ed-bdd9-30a05ff807bc"}, {"Element": "<span lang=\"EN-GB\">after EXP. The expiry date refers to the last day of that month.</span>", "ID": "f29cc574-e8c5-4417-921e-58add5d6f078", "Styles": "None", "Classes": "None", "Text": "after EXP. The expiry date refers to the last day of that month.", "ParentId": "3d7d5ab3-1b5a-46ed-bdd9-30a05ff807bc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94400464-e87a-4f99-97b6-c732b86ccf49", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a902e19-d9df-4498-af51-5cb44dece54b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94400464-e87a-4f99-97b6-c732b86ccf49"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in a refrigerator\n(2\u00b0C\u00a0to\u00a08\u00b0C).</span></p>", "ID": "b80d73a1-f2fb-4631-92b0-dcb5709616b9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator\n(2\u00b0C\u00a0to\u00a08\u00b0C).</span>", "ID": "c740abff-3ea1-429f-9023-6fbbf48d660c", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator (2\u00b0C\u00a0to\u00a08\u00b0C).", "ParentId": "b80d73a1-f2fb-4631-92b0-dcb5709616b9"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not freeze.</span></p>", "ID": "ba62acac-7558-46b8-b5b3-f53e606f66d7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not freeze.</span>", "ID": "b2cbb965-6690-4e31-a952-195dc0112efc", "Styles": "None", "Classes": "None", "Text": "Do not freeze.", "ParentId": "ba62acac-7558-46b8-b5b3-f53e606f66d7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span></p>", "ID": "c02d4ad9-9aeb-47d3-82a0-fbbc067ba05d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Store in the original package in order\nto protect from light.</span>", "ID": "892b8ce0-8382-4b5f-95fb-7c6ecc46ef7a", "Styles": "None", "Classes": "None", "Text": "Store in the original package in order to protect from light.", "ParentId": "c02d4ad9-9aeb-47d3-82a0-fbbc067ba05d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4bae2fd-b966-4bc6-ae50-bdd5b656d8e2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ccde2c7e-4e4d-4abe-aff6-4981370ea545", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4bae2fd-b966-4bc6-ae50-bdd5b656d8e2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span></p>", "ID": "0c6eca2c-39e5-4e2b-8221-2a03c9687a5d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span>", "ID": "f81bccb3-0a55-4ba9-aee3-fceb921a5f9d", "Styles": "None", "Classes": "None", "Text": "Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.", "ParentId": "0c6eca2c-39e5-4e2b-8221-2a03c9687a5d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b977b21-6fe3-468f-bd1d-2230bf6e9159", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "467378e3-e869-4fc8-b6db-62241122803b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b977b21-6fe3-468f-bd1d-2230bf6e9159"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "61352821-f59a-4871-8924-619c13f512dd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2e3c3e5-525a-4a6c-b5de-c71d816e00b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "61352821-f59a-4871-8924-619c13f512dd"}, {"Element": "<p class=\"EMEAHeading3\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>", "ID": "f054b8af-4b21-4d28-815e-c5758d39d381", "Styles": "None", "Classes": "['EMEAHeading3']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span>", "ID": "eecb7bbb-20aa-44ec-9f29-141463f252d0", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "f054b8af-4b21-4d28-815e-c5758d39d381"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "295726ef-af0d-4ff6-8a86-2effefe0af3a", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f30c8fba-c834-41e2-8b07-b4c3f3b80985", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "295726ef-af0d-4ff6-8a86-2effefe0af3a"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS contains</span></b></p>", "ID": "9f83436e-b231-46a9-8e9c-d0eb14f2819c", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS contains</span></b>", "ID": "adc2d6eb-a1fd-4ec3-911b-105199084d01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f83436e-b231-46a9-8e9c-d0eb14f2819c"}, {"Element": "<span lang=\"EN-GB\">What\nNivolumab\u00a0BMS contains</span>", "ID": "055dc193-ea66-4280-9c43-fb70947920ff", "Styles": "None", "Classes": "None", "Text": "What Nivolumab\u00a0BMS contains", "ParentId": "adc2d6eb-a1fd-4ec3-911b-105199084d01"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is nivolumab.</span></p>", "ID": "87680772-a343-4d3e-b829-50d1c0e7a7e3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "7b88234d-8bce-4d7a-90a7-97c6a38f6ed9", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "87680772-a343-4d3e-b829-50d1c0e7a7e3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "7cdb3fe3-6ab3-4af5-8d45-66f90bdaa86e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "7b88234d-8bce-4d7a-90a7-97c6a38f6ed9"}, {"Element": "<span lang=\"EN-GB\">The active substance is nivolumab.</span>", "ID": "5fbdbee0-c808-416c-8ee2-2c9b4c3b7448", "Styles": "None", "Classes": "None", "Text": "The active substance is nivolumab.", "ParentId": "87680772-a343-4d3e-b829-50d1c0e7a7e3"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Each mL of\nconcentrate for solution for infusion contains\u00a010\u00a0mg of nivolumab.</span></p>", "ID": "9e2b4db0-fee1-431f-a52b-3a68864f0a53", "Styles": "margin-left:28.35pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each mL of\nconcentrate for solution for infusion contains\u00a010\u00a0mg of nivolumab.</span>", "ID": "85c9ba06-0ad5-4860-b299-c901db200549", "Styles": "None", "Classes": "None", "Text": "Each mL of concentrate for solution for infusion contains\u00a010\u00a0mg of nivolumab.", "ParentId": "9e2b4db0-fee1-431f-a52b-3a68864f0a53"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Each vial\ncontains either\u00a040\u00a0mg (in\u00a04\u00a0mL) or\u00a0100\u00a0mg\n(in\u00a010\u00a0mL) of nivolumab.</span></p>", "ID": "c08f260d-4cf2-4774-b733-f8488fe54860", "Styles": "margin-left:28.35pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Each vial\ncontains either\u00a040\u00a0mg (in\u00a04\u00a0mL) or\u00a0100\u00a0mg\n(in\u00a010\u00a0mL) of nivolumab.</span>", "ID": "f1f859d2-78f6-424f-a773-2c021de8f04a", "Styles": "None", "Classes": "None", "Text": "Each vial contains either\u00a040\u00a0mg (in\u00a04\u00a0mL) or\u00a0100\u00a0mg (in\u00a010\u00a0mL) of nivolumab.", "ParentId": "c08f260d-4cf2-4774-b733-f8488fe54860"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "506c97cf-0432-4e1a-b0a0-986de14528d4", "Styles": "margin-left:28.35pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04e5bbfd-1fd1-4037-9a45-d32758fa1107", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "506c97cf-0432-4e1a-b0a0-986de14528d4"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are sodium citrate\ndihydrate, sodium chloride (see section\u00a02\u00a0\"</span><span lang=\"EN-GB\"> Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> contains sodium\"),\nmannitol\u00a0(E421), pentetic acid, polysorbate\u00a080, sodium hydroxide,\nhydrochloric acid and water for injections.</span></p>", "ID": "3df50ea4-08d5-4099-8642-66d5aa4b879e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "04aaa899-a409-4693-b0cf-3a7e1eba0113", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "3df50ea4-08d5-4099-8642-66d5aa4b879e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "294a29b5-0975-4a8d-9970-11bcf5a62f74", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "04aaa899-a409-4693-b0cf-3a7e1eba0113"}, {"Element": "<span lang=\"EN-GB\">The other ingredients are sodium citrate\ndihydrate, sodium chloride (see section\u00a02\u00a0\"</span>", "ID": "90ed2eff-2262-427f-9f7d-9128481512c6", "Styles": "None", "Classes": "None", "Text": "The other ingredients are sodium citrate dihydrate, sodium chloride (see section\u00a02\u00a0\"", "ParentId": "3df50ea4-08d5-4099-8642-66d5aa4b879e"}, {"Element": "<span lang=\"EN-GB\"> Nivolumab\u00a0BMS</span>", "ID": "5856a0f0-45e9-44a2-a02f-7224e26e25e2", "Styles": "None", "Classes": "None", "Text": " Nivolumab\u00a0BMS", "ParentId": "3df50ea4-08d5-4099-8642-66d5aa4b879e"}, {"Element": "<span lang=\"EN-GB\"> contains sodium\"),\nmannitol\u00a0(E421), pentetic acid, polysorbate\u00a080, sodium hydroxide,\nhydrochloric acid and water for injections.</span>", "ID": "32cb6f02-675a-413d-92ab-2ee396a3d046", "Styles": "None", "Classes": "None", "Text": " contains sodium\"), mannitol\u00a0(E421), pentetic acid, polysorbate\u00a080, sodium hydroxide, hydrochloric acid and water for injections.", "ParentId": "3df50ea4-08d5-4099-8642-66d5aa4b879e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e0194f6c-b191-4dd7-a13e-432dc0aa93dd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04b568d1-238f-4e98-8a4f-ff21ddd6f3aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0194f6c-b191-4dd7-a13e-432dc0aa93dd"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS looks like and contents of the pack</span></b></p>", "ID": "5a48c43d-0a21-4ca8-a400-7a8e4aa72851", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">What\nNivolumab\u00a0BMS looks like and contents of the pack</span></b>", "ID": "f5f066a2-07c7-437e-926b-aab1bddeb46e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5a48c43d-0a21-4ca8-a400-7a8e4aa72851"}, {"Element": "<span lang=\"EN-GB\">What\nNivolumab\u00a0BMS looks like and contents of the pack</span>", "ID": "75a99eb8-c759-4af5-9851-817434bfce93", "Styles": "None", "Classes": "None", "Text": "What Nivolumab\u00a0BMS looks like and contents of the pack", "ParentId": "f5f066a2-07c7-437e-926b-aab1bddeb46e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS concentrate for\nsolution for infusion (sterile concentrate) is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles.</span></p>", "ID": "6059e610-2467-43fa-8d69-0642f9cbe309", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS concentrate for\nsolution for infusion (sterile concentrate) is a clear to opalescent,\ncolourless to pale yellow liquid that may contain few light particles.</span>", "ID": "c0ba932f-bc64-4c29-8e32-c2567cc555d2", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS concentrate for solution for infusion (sterile concentrate) is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.", "ParentId": "6059e610-2467-43fa-8d69-0642f9cbe309"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd3e715c-fd76-4bc6-8f69-efeb777921ff", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1fd8907-df2d-4ac4-8146-eb3a33062397", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd3e715c-fd76-4bc6-8f69-efeb777921ff"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is available in packs containing\neither\u00a01\u00a0vial of\u00a04\u00a0mL or\u00a01\u00a0vial of\u00a010\u00a0mL.</span></p>", "ID": "f84341c5-3bef-4489-b74c-e3987b8a3530", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">It is available in packs containing\neither\u00a01\u00a0vial of\u00a04\u00a0mL or\u00a01\u00a0vial of\u00a010\u00a0mL.</span>", "ID": "cefec4f1-fce7-44ce-9e2e-1224792daa3e", "Styles": "None", "Classes": "None", "Text": "It is available in packs containing either\u00a01\u00a0vial of\u00a04\u00a0mL or\u00a01\u00a0vial of\u00a010\u00a0mL.", "ParentId": "f84341c5-3bef-4489-b74c-e3987b8a3530"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6310c3d4-eacf-4453-8259-e23b9bf12113", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "480a4518-1a39-472c-bd0a-4d56183ceee9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6310c3d4-eacf-4453-8259-e23b9bf12113"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>", "ID": "8910a5e0-4227-49ee-b4c7-4a77a3a85a81", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Not all pack sizes may be marketed.</span>", "ID": "1e25976a-7108-41be-ad30-769525fc775f", "Styles": "None", "Classes": "None", "Text": "Not all pack sizes may be marketed.", "ParentId": "8910a5e0-4227-49ee-b4c7-4a77a3a85a81"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0ff6b8da-96e3-4367-8487-ac9e45cb0fc5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6948857-d84b-4356-a00a-f36ad6c45578", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0ff6b8da-96e3-4367-8487-ac9e45cb0fc5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b></p>", "ID": "6aaf9bf7-c5ea-4dbc-8ecc-bececa3fff95", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span></b>", "ID": "9322da9f-9db7-42ab-bd76-f22117884626", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6aaf9bf7-c5ea-4dbc-8ecc-bececa3fff95"}, {"Element": "<span lang=\"EN-GB\">Marketing\nAuthorisation Holder</span>", "ID": "e1e2f29c-5dfe-42a4-962a-805f10031ce8", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder", "ParentId": "9322da9f-9db7-42ab-bd76-f22117884626"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span></p>", "ID": "84840e28-211d-4b1c-9867-170cf413de8e", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb Pharma EEIG</span>", "ID": "b9717171-2c00-42f1-9ca2-4fc33932eeda", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb Pharma EEIG", "ParentId": "84840e28-211d-4b1c-9867-170cf413de8e"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Uxbridge Business Park</span></p>", "ID": "1f939334-9f6d-4d72-b3ba-5c5bf29e31c6", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Uxbridge Business Park</span>", "ID": "ab7310ab-a0b9-4a15-8581-4be88fff712e", "Styles": "None", "Classes": "None", "Text": "Uxbridge Business Park", "ParentId": "1f939334-9f6d-4d72-b3ba-5c5bf29e31c6"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Sanderson Road</span></p>", "ID": "3ba0af0f-136c-4636-a394-8201727e8777", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Sanderson Road</span>", "ID": "5a79bc39-e2b3-4583-a2a3-323f147ac69c", "Styles": "None", "Classes": "None", "Text": "Sanderson Road", "ParentId": "3ba0af0f-136c-4636-a394-8201727e8777"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span></p>", "ID": "98ec4546-8708-4d55-ad77-be8b92270321", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Uxbridge UB8\u00a01DH</span>", "ID": "4a18a443-4fa5-4516-b8c6-8d18bdcbff4a", "Styles": "None", "Classes": "None", "Text": "Uxbridge UB8\u00a01DH", "ParentId": "98ec4546-8708-4d55-ad77-be8b92270321"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">United Kingdom</span></p>", "ID": "b19a65a2-9d7a-4c3c-811b-3c8e07b8f8d7", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "9682bfd4-6776-4c74-87b1-11c1fe8b996d", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "b19a65a2-9d7a-4c3c-811b-3c8e07b8f8d7"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff5886f3-3228-4e3b-a95b-9ebf1ce08e37", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2c12e142-04ee-49f5-8591-93ba87842d21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff5886f3-3228-4e3b-a95b-9ebf1ce08e37"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>", "ID": "3e489d99-2703-4a48-af7e-fa42720e4985", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Manufacturer</span></b>", "ID": "8827f6b4-ff39-4662-8ee3-a06134233485", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e489d99-2703-4a48-af7e-fa42720e4985"}, {"Element": "<span lang=\"EN-GB\">Manufacturer</span>", "ID": "9d57f40b-2e01-4f7a-8dac-35c7be0539f6", "Styles": "None", "Classes": "None", "Text": "Manufacturer", "ParentId": "8827f6b4-ff39-4662-8ee3-a06134233485"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span></p>", "ID": "f90d382d-1d0b-4a6d-9580-a5b176da4380", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb S.r.l.</span>", "ID": "44d05de7-e616-468a-adba-debf8d70dee3", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb S.r.l.", "ParentId": "f90d382d-1d0b-4a6d-9580-a5b176da4380"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"ES\">Loc. Fontana del Ceraso</span></p>", "ID": "9e0d022d-161b-4924-90cf-ad4c435f3a46", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"ES\">Loc. Fontana del Ceraso</span>", "ID": "163ff1b3-9d3b-4221-b8cb-bbe49b0f2a33", "Styles": "None", "Classes": "None", "Text": "Loc. Fontana del Ceraso", "ParentId": "9e0d022d-161b-4924-90cf-ad4c435f3a46"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"ES\">03012\u00a0Anagni (FR)</span></p>", "ID": "734ebd2e-8cfd-4312-804d-5e72cd505fd8", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"ES\">03012\u00a0Anagni (FR)</span>", "ID": "8961c4c1-ae06-4acd-a24a-dbae5dab49b1", "Styles": "None", "Classes": "None", "Text": "03012\u00a0Anagni (FR)", "ParentId": "734ebd2e-8cfd-4312-804d-5e72cd505fd8"}, {"Element": "<p class=\"EMEAAddress\"><span lang=\"EN-GB\">Italy</span></p>", "ID": "65517e94-a4d5-4a6b-8c72-fc9f69b60890", "Styles": "None", "Classes": "['EMEAAddress']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Italy</span>", "ID": "56979ea5-3eb1-458e-933a-51a211f28bb6", "Styles": "None", "Classes": "None", "Text": "Italy", "ParentId": "65517e94-a4d5-4a6b-8c72-fc9f69b60890"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c80cd546-c92a-4d46-bf2e-ad738eb16b0e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a545a0e4-ab70-46ce-9b2f-39878a5071a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c80cd546-c92a-4d46-bf2e-ad738eb16b0e"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For </span><span lang=\"EN-GB\">any</span><span lang=\"EN-GB\"> information about this medicine, please\ncontact the local representative of the Marketing Authorisation Holder.</span></p>", "ID": "76544b0b-5003-46e1-970a-d03b7fe08228", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">For </span>", "ID": "e7af871b-54ab-4d34-b8a8-3a248f55e9c3", "Styles": "None", "Classes": "None", "Text": "For ", "ParentId": "76544b0b-5003-46e1-970a-d03b7fe08228"}, {"Element": "<span lang=\"EN-GB\">any</span>", "ID": "bd17fd5b-0996-49b2-aad0-8290f355f54e", "Styles": "None", "Classes": "None", "Text": "any", "ParentId": "76544b0b-5003-46e1-970a-d03b7fe08228"}, {"Element": "<span lang=\"EN-GB\"> information about this medicine, please\ncontact the local representative of the Marketing Authorisation Holder.</span>", "ID": "505c2a17-2cce-4588-8daa-92d124012b1b", "Styles": "None", "Classes": "None", "Text": " information about this medicine, please contact the local representative of the Marketing Authorisation Holder.", "ParentId": "76544b0b-5003-46e1-970a-d03b7fe08228"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "122bd40d-a174-406e-b2c6-5b7baa367749", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6157f2e-f107-4096-a60d-c082800029c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "122bd40d-a174-406e-b2c6-5b7baa367749"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.4pt;border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.0pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 372 6827 400</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:47.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:55.55pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"ES\">Portugal</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Vistor\n  hf.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"EN-GB\">: + 354 535 7000</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:38.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:60.95pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "9eed6c34-a020-4eee-9480-81781e1e3d55", "Styles": "margin-left:.4pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "016deb92-f90a-4e19-8d2d-2dc3c5c46686", "Styles": "page-break-inside:avoid;height:45.2pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "752e2b6a-4752-4341-ad95-369ffe1c4a7c", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "016deb92-f90a-4e19-8d2d-2dc3c5c46686"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b></p>", "ID": "5808a589-7207-4e54-b2df-23840a43ed7e", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "752e2b6a-4752-4341-ad95-369ffe1c4a7c"}, {"Element": "<b><span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span></b>", "ID": "ce592bc9-7d7b-45bf-8b88-ed4fc3325734", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5808a589-7207-4e54-b2df-23840a43ed7e"}, {"Element": "<span lang=\"EN-GB\">Belgique/Belgi\u00eb/Belgien</span>", "ID": "3c6f9c5b-f13f-4c05-bc2e-534145170da3", "Styles": "None", "Classes": "None", "Text": "Belgique/Belgi\u00eb/Belgien", "ParentId": "ce592bc9-7d7b-45bf-8b88-ed4fc3325734"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>", "ID": "dbc3f742-c677-4219-8f51-807dbe17cf7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "752e2b6a-4752-4341-ad95-369ffe1c4a7c"}, {"Element": "<span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span>", "ID": "5975da15-51ca-4c1f-9d70-10a482bd3fd4", "Styles": "None", "Classes": "None", "Text": "N.V. Bristol\u2011Myers Squibb Belgium   S.A.", "ParentId": "dbc3f742-c677-4219-8f51-807dbe17cf7a"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>", "ID": "be7214db-acfc-499f-b752-e9635f1af9a1", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "752e2b6a-4752-4341-ad95-369ffe1c4a7c"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span>", "ID": "8b65cf2d-6b37-481e-89a9-0e506fd279dc", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel:   + 32 2 352 76 11", "ParentId": "be7214db-acfc-499f-b752-e9635f1af9a1"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c4337b01-c904-41a9-ade1-0f9d9fb6dd3b", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "752e2b6a-4752-4341-ad95-369ffe1c4a7c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65976048-0f1b-4e49-804e-cc33842bb4a3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4337b01-c904-41a9-ade1-0f9d9fb6dd3b"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "f7659fba-bd03-43e4-9e9d-046b44c88f55", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "016deb92-f90a-4e19-8d2d-2dc3c5c46686"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>", "ID": "143f1e63-2daa-4550-83fb-4d0839e2d730", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "f7659fba-bd03-43e4-9e9d-046b44c88f55"}, {"Element": "<b><span lang=\"EN-GB\">Lietuva</span></b>", "ID": "c0450037-d476-4803-ac9a-d3535e75bcb8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "143f1e63-2daa-4550-83fb-4d0839e2d730"}, {"Element": "<span lang=\"EN-GB\">Lietuva</span>", "ID": "57dc19e7-f7c8-4720-9e35-d57d1690954f", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "c0450037-d476-4803-ac9a-d3535e75bcb8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "d8eea54c-faf1-440b-8747-cf83b419613b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "f7659fba-bd03-43e4-9e9d-046b44c88f55"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "2cccf233-f2c2-48ca-95f5-b1e803bd0bdd", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "d8eea54c-faf1-440b-8747-cf83b419613b"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span></p>", "ID": "b8464d96-fc1a-4b61-bae3-7a12c50df643", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "f7659fba-bd03-43e4-9e9d-046b44c88f55"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  370 5 2790 762</span>", "ID": "a255b4ec-71c7-448c-a6b9-653a762433e9", "Styles": "None", "Classes": "None", "Text": "Tel: +   370 5 2790 762", "ParentId": "b8464d96-fc1a-4b61-bae3-7a12c50df643"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa33ad22-8485-474f-9679-0ac38e532331", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "f7659fba-bd03-43e4-9e9d-046b44c88f55"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5eba121-e691-4ae9-beef-f4e9b78d0aba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa33ad22-8485-474f-9679-0ac38e532331"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5e40d93c-712a-4cfe-86ff-d51909417e56", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>\n</td>", "ID": "e349fcfc-c241-4915-9c7d-934fedfa872c", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "5e40d93c-712a-4cfe-86ff-d51909417e56"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "9b2952f4-3588-4deb-9bd5-67b76dc7d97a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e349fcfc-c241-4915-9c7d-934fedfa872c"}, {"Element": "<b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "4f5bdaf5-a259-4ed6-81f6-d90e54e89933", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9b2952f4-3588-4deb-9bd5-67b76dc7d97a"}, {"Element": "<span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "5871b44b-8cf5-44de-bf9e-ec470cf22df6", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "4f5bdaf5-a259-4ed6-81f6-d90e54e89933"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "9d22c806-292f-48cc-b6f5-716c84974bbc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "e349fcfc-c241-4915-9c7d-934fedfa872c"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "8b336a6b-65a4-4025-ac03-316f2a298b21", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "9d22c806-292f-48cc-b6f5-716c84974bbc"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span></p>", "ID": "5583ae1f-4c59-4619-ab7a-f2ff8d1de2a3", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "e349fcfc-c241-4915-9c7d-934fedfa872c"}, {"Element": "<span lang=\"EN-GB\">Te\u043b.:\n  + 359 800 12 400</span>", "ID": "24525bc3-44ab-4907-bace-97d6272f5f92", "Styles": "None", "Classes": "None", "Text": "Te\u043b.:   + 359 800 12 400", "ParentId": "5583ae1f-4c59-4619-ab7a-f2ff8d1de2a3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span></p>", "ID": "5d7a7b03-338c-459b-9e0f-f66f8f1215f6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e349fcfc-c241-4915-9c7d-934fedfa872c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:TimesNewRoman\">\u00a0</span>", "ID": "ff52e2fa-e00e-466c-9eec-c13864cbbe5a", "Styles": "font-family:TimesNewRoman", "Classes": "None", "Text": "\u00a0", "ParentId": "5d7a7b03-338c-459b-9e0f-f66f8f1215f6"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d545a46f-8ce2-48a8-a7db-1315aa0905a3", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "5e40d93c-712a-4cfe-86ff-d51909417e56"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>", "ID": "4b960beb-095c-4408-a3f3-352a6142f4f8", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "d545a46f-8ce2-48a8-a7db-1315aa0905a3"}, {"Element": "<b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b>", "ID": "e52feefd-0cce-4f1a-be61-ce9dd3b1303c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b960beb-095c-4408-a3f3-352a6142f4f8"}, {"Element": "<span lang=\"EN-GB\">Luxembourg/Luxemburg</span>", "ID": "a91ff05d-2b69-4c0a-80dd-f17fd218e9a3", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "e52feefd-0cce-4f1a-be61-ce9dd3b1303c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span></p>", "ID": "bd02c0fc-8565-4266-b577-67a649479c5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d545a46f-8ce2-48a8-a7db-1315aa0905a3"}, {"Element": "<span lang=\"EN-GB\">N.V. Bristol\u2011Myers Squibb Belgium\n  S.A.</span>", "ID": "649d46d8-a830-45b2-b277-dace25287b34", "Styles": "None", "Classes": "None", "Text": "N.V. Bristol\u2011Myers Squibb Belgium   S.A.", "ParentId": "bd02c0fc-8565-4266-b577-67a649479c5f"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span></p>", "ID": "68e7afc7-6b99-48d6-afed-7ea95d0a8da9", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "d545a46f-8ce2-48a8-a7db-1315aa0905a3"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel:\n  + 32 2 352 76 11</span>", "ID": "1cbd85f3-04ad-4d3c-bfb1-260a7c61b30a", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel:   + 32 2 352 76 11", "ParentId": "68e7afc7-6b99-48d6-afed-7ea95d0a8da9"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a72495cc-6a58-43a2-82a5-9e042cd029d3", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "d545a46f-8ce2-48a8-a7db-1315aa0905a3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2f62f7f7-b5df-4463-83d6-d4723ca37236", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a72495cc-6a58-43a2-82a5-9e042cd029d3"}, {"Element": "<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "54afca50-b671-48db-a621-9505b92eddec", "Styles": "page-break-inside:avoid;height:45.2pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6110d5f7-4182-4ab9-9fef-7b87001f3cf4", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "54afca50-b671-48db-a621-9505b92eddec"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>", "ID": "0c120cd3-643c-4a5d-a1a1-57435f4d9675", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "6110d5f7-4182-4ab9-9fef-7b87001f3cf4"}, {"Element": "<b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b>", "ID": "d57913d0-8266-4f43-8ad7-9fe417f78444", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0c120cd3-643c-4a5d-a1a1-57435f4d9675"}, {"Element": "<span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span>", "ID": "edb0d5c9-4184-47f2-90e8-46ade2998ab7", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1   republika", "ParentId": "d57913d0-8266-4f43-8ad7-9fe417f78444"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>", "ID": "7c1bb4dc-48a8-413e-b01d-93f6043f7df8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "6110d5f7-4182-4ab9-9fef-7b87001f3cf4"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span>", "ID": "59d3eb3c-4bfe-4322-9be3-ccc260aaee2e", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb spol. s   r.o.", "ParentId": "7c1bb4dc-48a8-413e-b01d-93f6043f7df8"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span></p>", "ID": "16bdbf5a-474b-478d-bfb7-d7bf5bcc3aee", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "6110d5f7-4182-4ab9-9fef-7b87001f3cf4"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  420 221 016 111</span>", "ID": "a280896d-2278-4a60-81b4-7a842e5fc5f6", "Styles": "None", "Classes": "None", "Text": "Tel: +   420 221 016 111", "ParentId": "16bdbf5a-474b-478d-bfb7-d7bf5bcc3aee"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c5ce784-f768-490c-9f7c-f30cc1810bb1", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "6110d5f7-4182-4ab9-9fef-7b87001f3cf4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29ec8236-781f-4f7b-8e19-c9f10ddcfa1a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c5ce784-f768-490c-9f7c-f30cc1810bb1"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "eddab19d-d20f-4a00-a0c4-ccf20488a859", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "54afca50-b671-48db-a621-9505b92eddec"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>", "ID": "dcc8f582-f55d-4ae6-8f7b-6aa1593f1299", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "eddab19d-d20f-4a00-a0c4-ccf20488a859"}, {"Element": "<b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b>", "ID": "a1cb7db0-7d63-41e1-9cac-00247dcad1ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dcc8f582-f55d-4ae6-8f7b-6aa1593f1299"}, {"Element": "<span lang=\"EN-GB\">Magyarorsz\u00e1g</span>", "ID": "9bda09d9-9308-4ed1-ad5f-f3aeee6f7a70", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "a1cb7db0-7d63-41e1-9cac-00247dcad1ac"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "8620b31e-787d-42a3-80ea-0a066400767b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "eddab19d-d20f-4a00-a0c4-ccf20488a859"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "63f85e31-b5e4-48a8-a9a4-d7d52594496f", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "8620b31e-787d-42a3-80ea-0a066400767b"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span></p>", "ID": "be97c053-6014-4584-a706-d3098d4abc51", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "eddab19d-d20f-4a00-a0c4-ccf20488a859"}, {"Element": "<span lang=\"EN-GB\">Tel.: +\n  36 1 301 9700</span>", "ID": "1fb5b6ec-23aa-46e3-91a9-9ed390c422d8", "Styles": "None", "Classes": "None", "Text": "Tel.: +   36 1 301 9700", "ParentId": "be97c053-6014-4584-a706-d3098d4abc51"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a229c9d-c0f8-435d-87ed-01d0765c2ea7", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "eddab19d-d20f-4a00-a0c4-ccf20488a859"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ee6c45e-3462-4680-b94d-c787a4240ac6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a229c9d-c0f8-435d-87ed-01d0765c2ea7"}, {"Element": "<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "821684cf-1dbf-45bb-922b-dd925ff47fcb", "Styles": "page-break-inside:avoid;height:45.2pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9fd117b7-5d34-499e-8ac7-1cf54c68e5ca", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "821684cf-1dbf-45bb-922b-dd925ff47fcb"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Danmark</span></b></p>", "ID": "228ce419-9468-4ab6-b23a-1b285a887cb2", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "9fd117b7-5d34-499e-8ac7-1cf54c68e5ca"}, {"Element": "<b><span lang=\"EN-GB\">Danmark</span></b>", "ID": "44881f59-2bf7-4353-9826-84ff2d48f64d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "228ce419-9468-4ab6-b23a-1b285a887cb2"}, {"Element": "<span lang=\"EN-GB\">Danmark</span>", "ID": "a4917126-9f2e-4562-820a-691274e5f757", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "44881f59-2bf7-4353-9826-84ff2d48f64d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span></p>", "ID": "726f6568-e2d8-4ae3-8456-0040f5f76324", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "9fd117b7-5d34-499e-8ac7-1cf54c68e5ca"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb</span>", "ID": "77ba34ef-b20a-4e03-9331-eadb8ca83926", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb", "ParentId": "726f6568-e2d8-4ae3-8456-0040f5f76324"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span></p>", "ID": "47ebcae2-23d2-4292-b5ea-9365bc559a1f", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "9fd117b7-5d34-499e-8ac7-1cf54c68e5ca"}, {"Element": "<span lang=\"EN-GB\">Tlf: +\n  45 45 93 05 06</span>", "ID": "e229c7a8-9550-4aa0-baf2-31852684f02b", "Styles": "None", "Classes": "None", "Text": "Tlf: +   45 45 93 05 06", "ParentId": "47ebcae2-23d2-4292-b5ea-9365bc559a1f"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "87d49489-2705-4746-b079-fb8d9fd3e0dd", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "9fd117b7-5d34-499e-8ac7-1cf54c68e5ca"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1acb5176-07f4-461e-84bd-96992c50944a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "87d49489-2705-4746-b079-fb8d9fd3e0dd"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ec636fc7-c840-4af3-b261-3c40f6b99d47", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "821684cf-1dbf-45bb-922b-dd925ff47fcb"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Malta</span></b></p>", "ID": "606ae741-5d43-4aec-a7ad-f24691ddefaa", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "ec636fc7-c840-4af3-b261-3c40f6b99d47"}, {"Element": "<b><span lang=\"EN-GB\">Malta</span></b>", "ID": "8c588a24-bd5a-4ec2-b248-c923c6ef9df6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "606ae741-5d43-4aec-a7ad-f24691ddefaa"}, {"Element": "<span lang=\"EN-GB\">Malta</span>", "ID": "c0bebeed-cefe-4821-a470-9afa48786c11", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "8c588a24-bd5a-4ec2-b248-c923c6ef9df6"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>", "ID": "6457e81d-2fc7-4e3b-85ce-b433c367927a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "ec636fc7-c840-4af3-b261-3c40f6b99d47"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span>", "ID": "407e8289-b84e-4628-987e-be1b7e3c23a5", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb S.r.l.", "ParentId": "6457e81d-2fc7-4e3b-85ce-b433c367927a"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>", "ID": "d389458d-4cb8-4206-851d-1f5230346519", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "ec636fc7-c840-4af3-b261-3c40f6b99d47"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span>", "ID": "92db1bda-f8e4-477c-9843-6d0fce9da4bd", "Styles": "None", "Classes": "None", "Text": "Tel: +   39 06 50 39 61", "ParentId": "d389458d-4cb8-4206-851d-1f5230346519"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42b23bd4-ca90-420a-975d-648679ca70b2", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "ec636fc7-c840-4af3-b261-3c40f6b99d47"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "876bfcf3-0c45-4cb6-a1de-d626c657e1ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42b23bd4-ca90-420a-975d-648679ca70b2"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "68817358-5cd7-4ff6-adc5-23c7d2c790c1", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "514472e2-1053-403a-9495-9e348baa5aa2", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "68817358-5cd7-4ff6-adc5-23c7d2c790c1"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>", "ID": "41b9ce11-8f69-4779-ad3e-6dcff33c49ea", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "514472e2-1053-403a-9495-9e348baa5aa2"}, {"Element": "<b><span lang=\"EN-GB\">Deutschland</span></b>", "ID": "555fc4b8-ded9-4376-97bb-04cbbb652a99", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41b9ce11-8f69-4779-ad3e-6dcff33c49ea"}, {"Element": "<span lang=\"EN-GB\">Deutschland</span>", "ID": "127bde34-e112-403c-8bb3-9b0b9d082e76", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "555fc4b8-ded9-4376-97bb-04cbbb652a99"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span></p>", "ID": "ed4f1c6b-b82a-4519-a03f-0ad0adfd4aa4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "514472e2-1053-403a-9495-9e348baa5aa2"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb GmbH &amp;\n  Co. KGaA</span>", "ID": "d02789fa-2334-433d-b2d2-0afd35c3f5cc", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb GmbH &   Co. KGaA", "ParentId": "ed4f1c6b-b82a-4519-a03f-0ad0adfd4aa4"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span></p>", "ID": "5a927849-e56c-4ec8-a50e-57c23037a24c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "514472e2-1053-403a-9495-9e348baa5aa2"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  49 89 121 42\u20110</span>", "ID": "66786b7a-a0e7-425f-bf96-9676b2bc0ea9", "Styles": "None", "Classes": "None", "Text": "Tel: +   49 89 121 42\u20110", "ParentId": "5a927849-e56c-4ec8-a50e-57c23037a24c"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53a84b5d-6cbf-43cf-acd8-d11f3993e570", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "514472e2-1053-403a-9495-9e348baa5aa2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65d3fa77-ecb9-48e8-9158-56c420bedf18", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53a84b5d-6cbf-43cf-acd8-d11f3993e570"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "65fd0078-f3c5-4d4b-a161-c9b025a6117c", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "68817358-5cd7-4ff6-adc5-23c7d2c790c1"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Nederland</span></b></p>", "ID": "911a43b2-d12e-4437-8e17-a5272ebf37fe", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "65fd0078-f3c5-4d4b-a161-c9b025a6117c"}, {"Element": "<b><span lang=\"EN-GB\">Nederland</span></b>", "ID": "899f4f72-69db-4083-9e45-3aa49f9792fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "911a43b2-d12e-4437-8e17-a5272ebf37fe"}, {"Element": "<span lang=\"EN-GB\">Nederland</span>", "ID": "7b358f66-0dde-41c4-865f-9ab39b1112c2", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "899f4f72-69db-4083-9e45-3aa49f9792fd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span></p>", "ID": "467a2412-accd-40df-ac04-05bb83763bdc", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "65fd0078-f3c5-4d4b-a161-c9b025a6117c"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb B.V.</span>", "ID": "a1b9c87c-d5fb-473d-9245-3842c2282a56", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb B.V.", "ParentId": "467a2412-accd-40df-ac04-05bb83763bdc"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span></p>", "ID": "8c9a2c90-f991-4489-9887-22273735b5ff", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "65fd0078-f3c5-4d4b-a161-c9b025a6117c"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  31 (0)30 300 2222</span>", "ID": "39e6d66b-f3bd-458f-93bb-0bbac0647a1b", "Styles": "None", "Classes": "None", "Text": "Tel: +   31 (0)30 300 2222", "ParentId": "8c9a2c90-f991-4489-9887-22273735b5ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce08c497-40f2-4ee0-bf81-3e7a0890de01", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "65fd0078-f3c5-4d4b-a161-c9b025a6117c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d4bfd40-a5ef-44be-a0cd-211abf33f06d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce08c497-40f2-4ee0-bf81-3e7a0890de01"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.0pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 372 6827 400</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "57c54bd6-c244-451d-b2a2-32a17f37208b", "Styles": "page-break-inside:avoid;height:44.0pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 372 6827 400</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "12e54373-85fa-4165-99d7-85df4169d7f6", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt", "Classes": "None", "Text": "     ", "ParentId": "57c54bd6-c244-451d-b2a2-32a17f37208b"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Eesti</span></b></p>", "ID": "39250cdb-9ef9-49f0-be5c-79ccc0d45c4d", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "12e54373-85fa-4165-99d7-85df4169d7f6"}, {"Element": "<b><span lang=\"EN-GB\">Eesti</span></b>", "ID": "08888dd8-8d88-4670-8767-2e2a1cea9722", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "39250cdb-9ef9-49f0-be5c-79ccc0d45c4d"}, {"Element": "<span lang=\"EN-GB\">Eesti</span>", "ID": "7baffc4a-9852-42db-9696-8510598af5e0", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "08888dd8-8d88-4670-8767-2e2a1cea9722"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "a874cdfb-91fc-4957-8055-646e9a499c31", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "12e54373-85fa-4165-99d7-85df4169d7f6"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "d6d89b48-f0cc-44b8-a74d-c214793c15b4", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "a874cdfb-91fc-4957-8055-646e9a499c31"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 372 6827 400</span></p>", "ID": "ffa56446-9e5f-403c-8d86-8adbec23be14", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "12e54373-85fa-4165-99d7-85df4169d7f6"}, {"Element": "<span lang=\"EN-GB\">Tel: </span>", "ID": "d3752938-f1d4-467a-91f1-d124200e9f88", "Styles": "None", "Classes": "None", "Text": "Tel: ", "ParentId": "ffa56446-9e5f-403c-8d86-8adbec23be14"}, {"Element": "<span lang=\"EN-GB\">+ 372 6827 400</span>", "ID": "7e4576d8-c525-4c2a-b401-f10a2962dcf0", "Styles": "None", "Classes": "None", "Text": "+ 372 6827 400", "ParentId": "ffa56446-9e5f-403c-8d86-8adbec23be14"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88c9cf58-5669-4251-99e9-0794ef92e7f8", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "12e54373-85fa-4165-99d7-85df4169d7f6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dc054ef5-8617-420a-b030-50fc357887fe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88c9cf58-5669-4251-99e9-0794ef92e7f8"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "89148509-f882-480c-8f8f-66198c42d061", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.0pt", "Classes": "None", "Text": "     ", "ParentId": "57c54bd6-c244-451d-b2a2-32a17f37208b"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Norge</span></b></p>", "ID": "c8f904df-fb4d-4faa-ad8c-4447311294ca", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "89148509-f882-480c-8f8f-66198c42d061"}, {"Element": "<b><span lang=\"EN-GB\">Norge</span></b>", "ID": "b52adc64-7141-4115-845b-6ebfbd5993c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8f904df-fb4d-4faa-ad8c-4447311294ca"}, {"Element": "<span lang=\"EN-GB\">Norge</span>", "ID": "ca590e64-6d14-4547-88d7-8c95b0ac1663", "Styles": "None", "Classes": "None", "Text": "Norge", "ParentId": "b52adc64-7141-4115-845b-6ebfbd5993c8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span></p>", "ID": "5b3aaa70-9fe2-4728-a889-caaf77600ff5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "89148509-f882-480c-8f8f-66198c42d061"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb Norway Ltd</span>", "ID": "ca1a7bfd-b461-49f0-a672-4fb318317334", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb Norway Ltd", "ParentId": "5b3aaa70-9fe2-4728-a889-caaf77600ff5"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span></p>", "ID": "fea98297-cd07-4a85-b89b-291b9261bc88", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "89148509-f882-480c-8f8f-66198c42d061"}, {"Element": "<span lang=\"EN-GB\">Tlf: +\n  47 67 55 53 50</span>", "ID": "9e8c8043-eb79-4238-9419-32c7fa4236e3", "Styles": "None", "Classes": "None", "Text": "Tlf: +   47 67 55 53 50", "ParentId": "fea98297-cd07-4a85-b89b-291b9261bc88"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0dcba296-2efe-4f13-b5b3-616f4f7cff1c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "89148509-f882-480c-8f8f-66198c42d061"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "636b9edd-c73c-4033-989b-b83fbb6441cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0dcba296-2efe-4f13-b5b3-616f4f7cff1c"}, {"Element": "<tr style=\"page-break-inside:avoid;height:47.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "3b869fa2-51f1-4472-a2fe-403ca55b5ede", "Styles": "page-break-inside:avoid;height:47.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "62c32e03-2f48-47ed-b0b2-cab27a282ed4", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt", "Classes": "None", "Text": "     ", "ParentId": "3b869fa2-51f1-4472-a2fe-403ca55b5ede"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "46eba5a2-2df1-4b61-9e67-493ced47ccda", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "62c32e03-2f48-47ed-b0b2-cab27a282ed4"}, {"Element": "<b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "d68cae7c-227d-4e36-8513-a7e15d1818d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46eba5a2-2df1-4b61-9e67-493ced47ccda"}, {"Element": "<span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "9275da5d-5fa8-4003-bf83-9b4dcd478ab5", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "d68cae7c-227d-4e36-8513-a7e15d1818d0"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>", "ID": "fd8b0f9a-71e7-403e-b783-0ba270e2be22", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "62c32e03-2f48-47ed-b0b2-cab27a282ed4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span>", "ID": "ec9452e5-ed6c-4b8d-a43b-8b1511afe4e8", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb A.E.", "ParentId": "fd8b0f9a-71e7-403e-b783-0ba270e2be22"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span></p>", "ID": "0ea31c12-7ec0-42ef-97c1-8507abffc989", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "62c32e03-2f48-47ed-b0b2-cab27a282ed4"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 6074300</span>", "ID": "3190bbf5-73da-4df7-9000-53a5e91334f2", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb:   + 30 210 6074300", "ParentId": "0ea31c12-7ec0-42ef-97c1-8507abffc989"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "021fad7d-9a1b-4b0c-92b8-81eb7b67ca9d", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "62c32e03-2f48-47ed-b0b2-cab27a282ed4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59bc0350-28f6-47d2-b884-1b8afd84df69", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "021fad7d-9a1b-4b0c-92b8-81eb7b67ca9d"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "678b50b6-4b62-4e2c-a34b-3a11352cc20b", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:47.6pt", "Classes": "None", "Text": "     ", "ParentId": "3b869fa2-51f1-4472-a2fe-403ca55b5ede"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>", "ID": "d6193339-bad5-4138-9d19-16ca79ba4581", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "678b50b6-4b62-4e2c-a34b-3a11352cc20b"}, {"Element": "<b><span lang=\"EN-GB\">\u00d6sterreich</span></b>", "ID": "8e8a2f2c-5b88-49c0-9110-e4c8e9d09afd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6193339-bad5-4138-9d19-16ca79ba4581"}, {"Element": "<span lang=\"EN-GB\">\u00d6sterreich</span>", "ID": "c97ba701-a84e-4af6-ae85-a275f7ec6e1b", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "8e8a2f2c-5b88-49c0-9110-e4c8e9d09afd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span></p>", "ID": "b4dcb1fc-1e92-4f96-b327-f32cf1d34256", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "678b50b6-4b62-4e2c-a34b-3a11352cc20b"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb GesmbH</span>", "ID": "09e2c778-60be-4a17-bd09-765e0925c1b9", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb GesmbH", "ParentId": "b4dcb1fc-1e92-4f96-b327-f32cf1d34256"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span></p>", "ID": "41e065df-7c88-4a91-af58-223093d0553d", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "678b50b6-4b62-4e2c-a34b-3a11352cc20b"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  43 1 60 14 30</span>", "ID": "19f15201-b2a2-49e2-8c8a-593e6879d371", "Styles": "None", "Classes": "None", "Text": "Tel: +   43 1 60 14 30", "ParentId": "41e065df-7c88-4a91-af58-223093d0553d"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12db28e7-aae9-430a-bdb9-03d9fbf8cc15", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "678b50b6-4b62-4e2c-a34b-3a11352cc20b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2257d0e7-0c0d-4e11-a585-7fb7096d21cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12db28e7-aae9-430a-bdb9-03d9fbf8cc15"}, {"Element": "<tr style=\"page-break-inside:avoid;height:55.55pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d28bd5a8-8efe-46d3-b4d0-af4251ab6f36", "Styles": "page-break-inside:avoid;height:55.55pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3b820429-ac45-4c5c-8c4a-fdd4d1c79b65", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt", "Classes": "None", "Text": "     ", "ParentId": "d28bd5a8-8efe-46d3-b4d0-af4251ab6f36"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>", "ID": "407b00aa-5d77-4f51-a26b-1c41d8bd8688", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3b820429-ac45-4c5c-8c4a-fdd4d1c79b65"}, {"Element": "<b><span lang=\"EN-GB\">Espa\u00f1a</span></b>", "ID": "0295d583-c465-4cad-a1f2-14e8ee142189", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "407b00aa-5d77-4f51-a26b-1c41d8bd8688"}, {"Element": "<span lang=\"EN-GB\">Espa\u00f1a</span>", "ID": "05907300-0639-45f1-b7fb-064cd002324a", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "0295d583-c465-4cad-a1f2-14e8ee142189"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span></p>", "ID": "44402032-78ef-4060-9225-3661dd957d95", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3b820429-ac45-4c5c-8c4a-fdd4d1c79b65"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb, S.A.</span>", "ID": "b8eb3e64-c8ce-483d-89ec-7509052744a8", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb, S.A.", "ParentId": "44402032-78ef-4060-9225-3661dd957d95"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span></p>", "ID": "33a4a038-ca76-4950-9839-014ea7b48bd0", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3b820429-ac45-4c5c-8c4a-fdd4d1c79b65"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  34 91 456 53 00</span>", "ID": "b299d4b8-62a3-419f-8578-626142c19c50", "Styles": "None", "Classes": "None", "Text": "Tel: +   34 91 456 53 00", "ParentId": "33a4a038-ca76-4950-9839-014ea7b48bd0"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20ffeba1-0038-4ae2-96b1-1fb6e2f0bc9f", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3b820429-ac45-4c5c-8c4a-fdd4d1c79b65"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "785d2200-c2e1-4497-a57d-b735ffd1b472", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20ffeba1-0038-4ae2-96b1-1fb6e2f0bc9f"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "55102277-5ce8-4a3a-8e16-09b91353651f", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:55.55pt", "Classes": "None", "Text": "     ", "ParentId": "d28bd5a8-8efe-46d3-b4d0-af4251ab6f36"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Polska</span></b></p>", "ID": "02c5ffc9-5803-458b-a01c-f428a60d9f81", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "55102277-5ce8-4a3a-8e16-09b91353651f"}, {"Element": "<b><span lang=\"EN-GB\">Polska</span></b>", "ID": "33a04d40-7324-4931-bdab-9a884d9d90c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02c5ffc9-5803-458b-a01c-f428a60d9f81"}, {"Element": "<span lang=\"EN-GB\">Polska</span>", "ID": "aa262af3-6b27-4e36-8c07-37e9002d5232", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "33a04d40-7324-4931-bdab-9a884d9d90c8"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span></p>", "ID": "078df910-e6a9-458d-b3b6-0bca6a0f536c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "55102277-5ce8-4a3a-8e16-09b91353651f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb Polska Sp. z o.o.</span>", "ID": "aa993cc9-e6b3-403e-ba99-8fdb147b5ae2", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb Polska Sp. z o.o.", "ParentId": "078df910-e6a9-458d-b3b6-0bca6a0f536c"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span></p>", "ID": "5eb85038-1a59-41fe-97b6-18b2bd86de44", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "55102277-5ce8-4a3a-8e16-09b91353651f"}, {"Element": "<span lang=\"EN-GB\">Tel.: +\n  48 22 5796666</span>", "ID": "c7a71c4b-8029-4dba-ad02-2dad77577382", "Styles": "None", "Classes": "None", "Text": "Tel.: +   48 22 5796666", "ParentId": "5eb85038-1a59-41fe-97b6-18b2bd86de44"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "280724be-b9eb-47f3-b824-ec2d2de4c36c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "55102277-5ce8-4a3a-8e16-09b91353651f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c13bfed-cbc3-4bef-9b84-1b7c1c73f840", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "280724be-b9eb-47f3-b824-ec2d2de4c36c"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"ES\">Portugal</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2d473de3-9c8f-4b93-aa8a-f5480555b0f8", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span></p>\n</td>", "ID": "4fe67463-f27e-4a03-a066-3dfcbebb0d99", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "2d473de3-9c8f-4b93-aa8a-f5480555b0f8"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">France</span></b></p>", "ID": "857fdbd2-7070-47e2-a07b-a70ad172acdd", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "4fe67463-f27e-4a03-a066-3dfcbebb0d99"}, {"Element": "<b><span lang=\"EN-GB\">France</span></b>", "ID": "8af2a334-2205-4623-a732-c974f45c0693", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "857fdbd2-7070-47e2-a07b-a70ad172acdd"}, {"Element": "<span lang=\"EN-GB\">France</span>", "ID": "7220c82b-da2c-4c1e-a25f-44c675912120", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "8af2a334-2205-4623-a732-c974f45c0693"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span></p>", "ID": "998efde1-d0c7-4098-8c34-f1b3325a01fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4fe67463-f27e-4a03-a066-3dfcbebb0d99"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb SARL</span>", "ID": "3e4fa08e-72ad-4cba-8ecf-c2ce2ed42aa9", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb SARL", "ParentId": "998efde1-d0c7-4098-8c34-f1b3325a01fa"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span></p>", "ID": "fd854be6-ef59-4975-91f9-cde574735793", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "4fe67463-f27e-4a03-a066-3dfcbebb0d99"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l:\n  + 33 (0)810 410 500</span>", "ID": "f7a4ac5d-5541-4a34-9d97-ae20317036dd", "Styles": "None", "Classes": "None", "Text": "T\u00e9l:   + 33 (0)810 410 500", "ParentId": "fd854be6-ef59-4975-91f9-cde574735793"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span></p>", "ID": "6803b382-ad79-447c-b111-80fe684c371b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "4fe67463-f27e-4a03-a066-3dfcbebb0d99"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">\u00a0</span>", "ID": "b07b78ad-94dd-4fab-a930-ea367999b043", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "\u00a0", "ParentId": "6803b382-ad79-447c-b111-80fe684c371b"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"ES\">Portugal</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "936db706-20db-4998-a483-00d985ff41ac", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "2d473de3-9c8f-4b93-aa8a-f5480555b0f8"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"ES\">Portugal</span></b></p>", "ID": "e8f3597f-46c7-46d6-b1f0-3cc0a73b0921", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "936db706-20db-4998-a483-00d985ff41ac"}, {"Element": "<b><span lang=\"ES\">Portugal</span></b>", "ID": "be33bdc9-8db2-42b4-a163-41eff698eb41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8f3597f-46c7-46d6-b1f0-3cc0a73b0921"}, {"Element": "<span lang=\"ES\">Portugal</span>", "ID": "5744bc64-3af9-4f97-83dc-2c8ccde7e6dd", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "be33bdc9-8db2-42b4-a163-41eff698eb41"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span></p>", "ID": "710cba86-6776-47dd-8f3e-311e60b0a3fd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "936db706-20db-4998-a483-00d985ff41ac"}, {"Element": "<span lang=\"ES\">Bristol\u2011Myers Squibb\n  Farmac\u00eautica Portuguesa, S.A.</span>", "ID": "49ca46ef-1eac-4fa2-8e0f-c93c227912ab", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Farmac\u00eautica Portuguesa, S.A.", "ParentId": "710cba86-6776-47dd-8f3e-311e60b0a3fd"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span></p>", "ID": "6901275b-6386-401d-8a25-88188636215c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "936db706-20db-4998-a483-00d985ff41ac"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  351 21 440 70 00</span>", "ID": "cfd596d4-777d-4f01-98a1-1b780c5bbb13", "Styles": "None", "Classes": "None", "Text": "Tel: +   351 21 440 70 00", "ParentId": "6901275b-6386-401d-8a25-88188636215c"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45f2f611-8edb-425c-a381-891ce4c9e68c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "936db706-20db-4998-a483-00d985ff41ac"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f981c34-0b4b-4361-ad1d-4fffa1d66bd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45f2f611-8edb-425c-a381-891ce4c9e68c"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a4799d4e-8fee-4612-927e-8334da96d137", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "ec6352b2-c823-4547-81de-bb29c257fe3d", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "a4799d4e-8fee-4612-927e-8334da96d137"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>", "ID": "f7207ac4-dd31-412c-9ac9-f2f8a6e81cec", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "ec6352b2-c823-4547-81de-bb29c257fe3d"}, {"Element": "<b><span lang=\"EN-GB\">Hrvatska</span></b>", "ID": "3cee73cc-1a2b-4bfd-8d6d-3d7105689935", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f7207ac4-dd31-412c-9ac9-f2f8a6e81cec"}, {"Element": "<span lang=\"EN-GB\">Hrvatska</span>", "ID": "7e343b2a-1d54-4c22-b6c3-9ecf0a86b92d", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "3cee73cc-1a2b-4bfd-8d6d-3d7105689935"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>", "ID": "da65bcaf-0815-4c8e-8720-f89721973015", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "ec6352b2-c823-4547-81de-bb29c257fe3d"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span>", "ID": "cc842654-2c40-4e59-94bc-49b8fa4a2796", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb spol. s   r.o.", "ParentId": "da65bcaf-0815-4c8e-8720-f89721973015"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span></p>", "ID": "0e45fdda-3521-4240-a5f3-d19b5473613e", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "ec6352b2-c823-4547-81de-bb29c257fe3d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Tel:\n  +385 (1) 6311\u2011833</span>", "ID": "df3c7955-5520-4e61-811d-e304a4928e84", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Tel:   +385 (1) 6311\u2011833", "ParentId": "0e45fdda-3521-4240-a5f3-d19b5473613e"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "87538417-171d-48db-be8a-5379b8c000c9", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "ec6352b2-c823-4547-81de-bb29c257fe3d"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "48fec792-cedc-4890-80b9-5607ad27a6c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87538417-171d-48db-be8a-5379b8c000c9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "667d29e2-fa86-4656-a5c6-ca8aecbe3a84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48fec792-cedc-4890-80b9-5607ad27a6c0"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5fdaef11-c5d1-4e5e-8f10-dc8ba937e94e", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "a4799d4e-8fee-4612-927e-8334da96d137"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>", "ID": "a897038e-a458-4295-ad30-f727275fd030", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "5fdaef11-c5d1-4e5e-8f10-dc8ba937e94e"}, {"Element": "<b><span lang=\"EN-GB\">Rom\u00e2nia</span></b>", "ID": "bdf6467b-1d15-4440-b44d-e84a4ea371d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a897038e-a458-4295-ad30-f727275fd030"}, {"Element": "<span lang=\"EN-GB\">Rom\u00e2nia</span>", "ID": "326ff1cf-a94a-40af-9339-ada76f83f4cd", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "bdf6467b-1d15-4440-b44d-e84a4ea371d2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "fd8b7881-8dff-47eb-8b68-7427f7d3b533", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "5fdaef11-c5d1-4e5e-8f10-dc8ba937e94e"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "83219f60-35a1-4833-851e-9b209d971c38", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "fd8b7881-8dff-47eb-8b68-7427f7d3b533"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span></p>", "ID": "a0856f3e-49cb-4ebf-b794-72b392abbe66", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "5fdaef11-c5d1-4e5e-8f10-dc8ba937e94e"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  40 (0)21 272 16 00</span>", "ID": "64bd6ca9-8144-4997-b77d-f67941f3ec1d", "Styles": "None", "Classes": "None", "Text": "Tel: +   40 (0)21 272 16 00", "ParentId": "a0856f3e-49cb-4ebf-b794-72b392abbe66"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b712252-f7f7-4038-a2e5-6016b19bcb59", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "5fdaef11-c5d1-4e5e-8f10-dc8ba937e94e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f980bebe-a81c-409c-9b10-66bfbf0489b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b712252-f7f7-4038-a2e5-6016b19bcb59"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8255e4b8-4e58-4810-85e0-00b5d21c8584", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3c2ebb68-ed94-4363-b2df-c9ff47d4a01e", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "8255e4b8-4e58-4810-85e0-00b5d21c8584"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "d2728c05-fed6-4030-9cd8-89005020c55e", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3c2ebb68-ed94-4363-b2df-c9ff47d4a01e"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "5bb8914f-da80-4dfc-9de0-1b822d92d175", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2728c05-fed6-4030-9cd8-89005020c55e"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "6e27f0d0-1e02-4067-bb39-0e35d3bf7667", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "5bb8914f-da80-4dfc-9de0-1b822d92d175"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>", "ID": "e3fc6aeb-fc66-40f5-b307-4c7228d7ada7", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "3c2ebb68-ed94-4363-b2df-c9ff47d4a01e"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span>", "ID": "61a993f9-f1b8-414c-b445-26ec4f147039", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Pharmaceuticals Ltd", "ParentId": "e3fc6aeb-fc66-40f5-b307-4c7228d7ada7"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span></p>", "ID": "bc964729-efda-4d9e-9581-60b346d120d2", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3c2ebb68-ed94-4363-b2df-c9ff47d4a01e"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  353 (1 800) 749 749</span>", "ID": "d4d8e181-7ab8-4cab-9bc2-01c31bdb23ad", "Styles": "None", "Classes": "None", "Text": "Tel: +   353 (1 800) 749 749", "ParentId": "bc964729-efda-4d9e-9581-60b346d120d2"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "637631b6-7bc2-47b0-8215-c4dbb1176113", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "3c2ebb68-ed94-4363-b2df-c9ff47d4a01e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7666e44-2113-486c-84fa-c9b280656ba8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "637631b6-7bc2-47b0-8215-c4dbb1176113"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a9e6655e-7cf7-4c95-88c3-393b5e220f23", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "8255e4b8-4e58-4810-85e0-00b5d21c8584"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>", "ID": "94024118-2ae5-44de-a0a1-5509bd6dd21d", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "a9e6655e-7cf7-4c95-88c3-393b5e220f23"}, {"Element": "<b><span lang=\"EN-GB\">Slovenija</span></b>", "ID": "22d2a2f4-202c-45c4-b732-51982a147858", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "94024118-2ae5-44de-a0a1-5509bd6dd21d"}, {"Element": "<span lang=\"EN-GB\">Slovenija</span>", "ID": "525b81bc-a547-4a36-b631-00525b822746", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "22d2a2f4-202c-45c4-b732-51982a147858"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>", "ID": "a0502551-0e0b-4ed5-bed5-60f090146a5c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a9e6655e-7cf7-4c95-88c3-393b5e220f23"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span>", "ID": "a4897c2f-afe7-4e45-916c-d23f2b9d8437", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb spol. s   r.o.", "ParentId": "a0502551-0e0b-4ed5-bed5-60f090146a5c"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span></p>", "ID": "0d5c89d0-89ee-474f-8408-bdbd453c1a46", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "a9e6655e-7cf7-4c95-88c3-393b5e220f23"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  386 1 236 47 00</span>", "ID": "f5bc3ad5-f3e2-4e76-a47f-e074ba35a8f5", "Styles": "None", "Classes": "None", "Text": "Tel: +   386 1 236 47 00", "ParentId": "0d5c89d0-89ee-474f-8408-bdbd453c1a46"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37cdff8d-caed-42fe-9595-1e7d05e6715c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "a9e6655e-7cf7-4c95-88c3-393b5e220f23"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3bb2eb8-4d03-4f21-80e5-cd7f45589a28", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37cdff8d-caed-42fe-9595-1e7d05e6715c"}, {"Element": "<tr style=\"page-break-inside:avoid;height:45.2pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Vistor\n  hf.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"EN-GB\">: + 354 535 7000</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "248571ff-9840-4837-ad69-6f2ca30cb8c7", "Styles": "page-break-inside:avoid;height:45.2pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Vistor\n  hf.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"EN-GB\">: + 354 535 7000</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "82218472-2e7d-4f9f-b073-d4a2ec47e392", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "248571ff-9840-4837-ad69-6f2ca30cb8c7"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>", "ID": "5dbd5ed7-968d-4ca2-9d09-77a7709dabbf", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "82218472-2e7d-4f9f-b073-d4a2ec47e392"}, {"Element": "<b><span lang=\"EN-GB\">\u00cdsland</span></b>", "ID": "0df5fe6e-4d66-4eb3-95d9-544c38e18869", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5dbd5ed7-968d-4ca2-9d09-77a7709dabbf"}, {"Element": "<span lang=\"EN-GB\">\u00cdsland</span>", "ID": "0b116f53-abcd-4369-b564-9e359fb70121", "Styles": "None", "Classes": "None", "Text": "\u00cdsland", "ParentId": "0df5fe6e-4d66-4eb3-95d9-544c38e18869"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Vistor\n  hf.</span></p>", "ID": "cf097842-4c4c-4ce4-9e22-4d2e9a59cdf2", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "82218472-2e7d-4f9f-b073-d4a2ec47e392"}, {"Element": "<span lang=\"EN-GB\">Vistor\n  hf.</span>", "ID": "70bc6c63-b7f1-4758-bcf7-7a71cbe2dcb8", "Styles": "None", "Classes": "None", "Text": "Vistor   hf.", "ParentId": "cf097842-4c4c-4ce4-9e22-4d2e9a59cdf2"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">S\u00edmi</span><span lang=\"EN-GB\">: + 354 535 7000</span></p>", "ID": "73be98cf-c0c8-4841-9b24-ba6ab8ca6735", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "82218472-2e7d-4f9f-b073-d4a2ec47e392"}, {"Element": "<span lang=\"EN-GB\">S\u00edmi</span>", "ID": "1a6b4fcf-08d5-43a0-a332-40a715b6043a", "Styles": "None", "Classes": "None", "Text": "S\u00edmi", "ParentId": "73be98cf-c0c8-4841-9b24-ba6ab8ca6735"}, {"Element": "<span lang=\"EN-GB\">: + 354 535 7000</span>", "ID": "accc1eb5-bd85-4280-a788-0941715a685f", "Styles": "None", "Classes": "None", "Text": ": + 354 535 7000", "ParentId": "73be98cf-c0c8-4841-9b24-ba6ab8ca6735"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "303b2117-3376-4747-ad4d-4d88d80a4b49", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "82218472-2e7d-4f9f-b073-d4a2ec47e392"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e3a0a87-ec50-4809-a3bb-83fd559c6d66", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "303b2117-3376-4747-ad4d-4d88d80a4b49"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c7c90672-8336-4fc1-a3dd-403f6899ec06", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:45.2pt", "Classes": "None", "Text": "     ", "ParentId": "248571ff-9840-4837-ad69-6f2ca30cb8c7"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>", "ID": "940025ce-997f-4aab-b541-2da36275bb0a", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c7c90672-8336-4fc1-a3dd-403f6899ec06"}, {"Element": "<b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b>", "ID": "1eb5a937-c901-45c3-9153-a04a33faaaac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "940025ce-997f-4aab-b541-2da36275bb0a"}, {"Element": "<span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span>", "ID": "f7a0a9ce-e70d-4ba9-ac23-c01c7e9ef0f0", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1   republika", "ParentId": "1eb5a937-c901-45c3-9153-a04a33faaaac"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span></p>", "ID": "93db578d-7abd-4f31-9f02-28c4685c38c2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c7c90672-8336-4fc1-a3dd-403f6899ec06"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb spol. s\n  r.o.</span>", "ID": "6b3c727b-48b0-4f32-b3ed-a1d9616f86c4", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb spol. s   r.o.", "ParentId": "93db578d-7abd-4f31-9f02-28c4685c38c2"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span></p>", "ID": "554c22ad-48aa-4be4-b302-e5bbfe2d48d9", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c7c90672-8336-4fc1-a3dd-403f6899ec06"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  421 2 59298411</span>", "ID": "5ad0b2e8-a5c3-445a-9875-0015509a283e", "Styles": "None", "Classes": "None", "Text": "Tel: +   421 2 59298411", "ParentId": "554c22ad-48aa-4be4-b302-e5bbfe2d48d9"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f1ce33e7-cfbe-4b5b-b4bb-6daacca77ea3", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c7c90672-8336-4fc1-a3dd-403f6899ec06"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7141940-1fb3-4fb2-a3bd-61e9c849e7b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f1ce33e7-cfbe-4b5b-b4bb-6daacca77ea3"}, {"Element": "<tr style=\"page-break-inside:avoid;height:44.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7a75346d-14ac-459d-b8cb-d86db520c770", "Styles": "page-break-inside:avoid;height:44.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c5df364c-17f5-4e6d-90db-72be0236248f", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "7a75346d-14ac-459d-b8cb-d86db520c770"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Italia</span></b></p>", "ID": "8c77d1cc-8740-47d7-aa74-f8fbe43a9899", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c5df364c-17f5-4e6d-90db-72be0236248f"}, {"Element": "<b><span lang=\"EN-GB\">Italia</span></b>", "ID": "7d14e2a5-3d1b-4892-a641-58cabb2f098a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c77d1cc-8740-47d7-aa74-f8fbe43a9899"}, {"Element": "<span lang=\"EN-GB\">Italia</span>", "ID": "f524661a-52cc-4a80-9895-f6fb7af0ce43", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "7d14e2a5-3d1b-4892-a641-58cabb2f098a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span></p>", "ID": "0ca3372a-d974-46c9-a760-19fe87fc6df3", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "c5df364c-17f5-4e6d-90db-72be0236248f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb S.r.l.</span>", "ID": "c506ab7e-e7ba-4ece-adae-d8d3a87fa935", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb S.r.l.", "ParentId": "0ca3372a-d974-46c9-a760-19fe87fc6df3"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span></p>", "ID": "a82ae146-0205-4b4c-8840-ab274d744450", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c5df364c-17f5-4e6d-90db-72be0236248f"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  39 06 50 39 61</span>", "ID": "6b5834ac-1b2a-4ac0-92d9-466ae542ae46", "Styles": "None", "Classes": "None", "Text": "Tel: +   39 06 50 39 61", "ParentId": "a82ae146-0205-4b4c-8840-ab274d744450"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b67bd72-ddde-44b2-ac4c-991435fbc9dc", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "c5df364c-17f5-4e6d-90db-72be0236248f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "82f1febc-0ab7-4b96-8e74-bfca30048299", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b67bd72-ddde-44b2-ac4c-991435fbc9dc"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "09e0434d-6604-4d78-b27c-3c69983c75c3", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:44.6pt", "Classes": "None", "Text": "     ", "ParentId": "7a75346d-14ac-459d-b8cb-d86db520c770"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>", "ID": "3faed86d-c72e-48b6-a3c4-e6192909e6a8", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "09e0434d-6604-4d78-b27c-3c69983c75c3"}, {"Element": "<b><span lang=\"EN-GB\">Suomi/Finland</span></b>", "ID": "c9e272c8-1088-48ee-962b-ad453ab86c57", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3faed86d-c72e-48b6-a3c4-e6192909e6a8"}, {"Element": "<span lang=\"EN-GB\">Suomi/Finland</span>", "ID": "89e373c2-5d3e-4486-a0cd-5862ff6117dd", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "c9e272c8-1088-48ee-962b-ad453ab86c57"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span></p>", "ID": "8f57c4c0-5208-4848-9ad4-07feb54a9602", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "09e0434d-6604-4d78-b27c-3c69983c75c3"}, {"Element": "<span lang=\"EN-GB\">Oy Bristol\u2011Myers Squibb\n  (Finland) Ab</span>", "ID": "1851cd96-9c0e-4db7-ad19-d8eac7254fb9", "Styles": "None", "Classes": "None", "Text": "Oy Bristol\u2011Myers Squibb   (Finland) Ab", "ParentId": "8f57c4c0-5208-4848-9ad4-07feb54a9602"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span></p>", "ID": "5354cd6c-4f95-40bb-8114-8f14b63e466f", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "09e0434d-6604-4d78-b27c-3c69983c75c3"}, {"Element": "<span lang=\"EN-GB\">Puh/Tel:\n  + 358 9 251 21 230</span>", "ID": "ddb4d93d-2298-4c64-9457-6396242db2cb", "Styles": "None", "Classes": "None", "Text": "Puh/Tel:   + 358 9 251 21 230", "ParentId": "5354cd6c-4f95-40bb-8114-8f14b63e466f"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "617bdd37-2c3f-446b-bd05-16d8a2ccf3ba", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "09e0434d-6604-4d78-b27c-3c69983c75c3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ece11d77-8a17-4bbd-adfb-9cc33c8b0a25", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "617bdd37-2c3f-446b-bd05-16d8a2ccf3ba"}, {"Element": "<tr style=\"page-break-inside:avoid;height:38.6pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "25cb031a-7d07-46ae-afcf-0921fa60a4e1", "Styles": "page-break-inside:avoid;height:38.6pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "10f766c7-fc5f-4c32-9f44-0aec8cc3d11e", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt", "Classes": "None", "Text": "     ", "ParentId": "25cb031a-7d07-46ae-afcf-0921fa60a4e1"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>", "ID": "53d98fa4-b4b0-4033-8e94-616313e8012a", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "10f766c7-fc5f-4c32-9f44-0aec8cc3d11e"}, {"Element": "<b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "5fb8d1cb-2b29-4409-85dc-575621d50123", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53d98fa4-b4b0-4033-8e94-616313e8012a"}, {"Element": "<span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "6d495aaf-636e-4de2-8204-a7ee5d0b2ccd", "Styles": "None", "Classes": "None", "Text": "\u039a\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "5fb8d1cb-2b29-4409-85dc-575621d50123"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span></p>", "ID": "cc07165e-b330-4301-90d3-33fbad3fd1d4", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "10f766c7-fc5f-4c32-9f44-0aec8cc3d11e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-variant:small-caps\">Bristol\u2011Myers\n  Squibb A.E.</span>", "ID": "bf4ccb00-8402-40fa-b104-db357e9d98e6", "Styles": "font-variant:small-caps", "Classes": "None", "Text": "Bristol\u2011Myers   Squibb A.E.", "ParentId": "cc07165e-b330-4301-90d3-33fbad3fd1d4"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span></p>", "ID": "2ff7b0c5-3547-4c75-824c-8315f8560d1c", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "10f766c7-fc5f-4c32-9f44-0aec8cc3d11e"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 357 800 92666</span>", "ID": "c36c44b3-f6cb-49c9-a21b-3d3807b3800a", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb:   + 357 800 92666", "ParentId": "2ff7b0c5-3547-4c75-824c-8315f8560d1c"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3704ca23-4f26-4b15-ba15-2e31aacbcdc7", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "10f766c7-fc5f-4c32-9f44-0aec8cc3d11e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e3355e2-d41d-4464-af3b-b7d03faade3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3704ca23-4f26-4b15-ba15-2e31aacbcdc7"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "06f25db1-8e4f-43a5-9613-7917c102db35", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:38.6pt", "Classes": "None", "Text": "     ", "ParentId": "25cb031a-7d07-46ae-afcf-0921fa60a4e1"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Sverige</span></b></p>", "ID": "eedb0237-80bb-4140-a03e-b53226ece6e6", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "06f25db1-8e4f-43a5-9613-7917c102db35"}, {"Element": "<b><span lang=\"EN-GB\">Sverige</span></b>", "ID": "b9104159-7846-4cf8-ad18-1d400bc48adc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eedb0237-80bb-4140-a03e-b53226ece6e6"}, {"Element": "<span lang=\"EN-GB\">Sverige</span>", "ID": "79effbd3-7a19-4eb6-8c5e-4a19d394c60a", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "b9104159-7846-4cf8-ad18-1d400bc48adc"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span></p>", "ID": "8cf34999-dd20-4b4d-8759-23b1bfe26e10", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "06f25db1-8e4f-43a5-9613-7917c102db35"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb AB</span>", "ID": "d37c0c14-321e-4e2d-8efa-d171766b9a15", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb AB", "ParentId": "8cf34999-dd20-4b4d-8759-23b1bfe26e10"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span></p>", "ID": "774bda55-cf97-44db-8a66-059b23ef93f9", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "06f25db1-8e4f-43a5-9613-7917c102db35"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  46 8 704 71 00</span>", "ID": "32e2aa8a-0a25-48c6-b85a-5dc759829722", "Styles": "None", "Classes": "None", "Text": "Tel: +   46 8 704 71 00", "ParentId": "774bda55-cf97-44db-8a66-059b23ef93f9"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b1cf2e5-c702-49c8-a4e7-f9e2c283b045", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "06f25db1-8e4f-43a5-9613-7917c102db35"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8031fa9d-92fa-4c46-a1fa-341f9de22653", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b1cf2e5-c702-49c8-a4e7-f9e2c283b045"}, {"Element": "<tr style=\"page-break-inside:avoid;height:60.95pt\">\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "34c8ab83-a064-4221-ae2d-b5f0845e8097", "Styles": "page-break-inside:avoid;height:60.95pt", "Classes": "None", "Text": "   ", "ParentId": "9eed6c34-a020-4eee-9480-81781e1e3d55"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4d969a20-aaad-4efb-bd10-5cf60c90686f", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt", "Classes": "None", "Text": "     ", "ParentId": "34c8ab83-a064-4221-ae2d-b5f0845e8097"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">Latvija</span></b></p>", "ID": "be550de0-5565-4f1e-b584-8ffd2ba030b6", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "4d969a20-aaad-4efb-bd10-5cf60c90686f"}, {"Element": "<b><span lang=\"EN-GB\">Latvija</span></b>", "ID": "e998b9ca-3b56-4590-8de8-969e10b81ff4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be550de0-5565-4f1e-b584-8ffd2ba030b6"}, {"Element": "<span lang=\"EN-GB\">Latvija</span>", "ID": "f0e9df4f-ad41-410e-b821-520e69a47504", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "e998b9ca-3b56-4590-8de8-969e10b81ff4"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span></p>", "ID": "f32f254e-e03f-4364-b7a2-4dbe5ad87c91", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "4d969a20-aaad-4efb-bd10-5cf60c90686f"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Gy\u00f3gyszerkereskedelmi Kft.</span>", "ID": "cf84c1cb-83a8-4cc7-8bfc-6ea5093ba63b", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Gy\u00f3gyszerkereskedelmi Kft.", "ParentId": "f32f254e-e03f-4364-b7a2-4dbe5ad87c91"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span></p>", "ID": "3182ecee-dd0a-4d1e-ac92-29cdfa78f106", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "4d969a20-aaad-4efb-bd10-5cf60c90686f"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  371 67 50 21 85</span>", "ID": "578658a5-3f73-4365-89d4-217db85fd7af", "Styles": "None", "Classes": "None", "Text": "Tel: +   371 67 50 21 85", "ParentId": "3182ecee-dd0a-4d1e-ac92-29cdfa78f106"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d1f51df5-c179-42c6-9bd1-9f87fcb45884", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "4d969a20-aaad-4efb-bd10-5cf60c90686f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "725605ff-39c7-4fce-a3db-9f0ff885fe01", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d1f51df5-c179-42c6-9bd1-9f87fcb45884"}, {"Element": "<td style=\"width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt\" valign=\"top\" width=\"302\">\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span></p>\n<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cf3c6ff6-043c-490b-8956-e0fc0441a3d3", "Styles": "width:3.15in;padding:0in 0in 0in 0in;\n  height:60.95pt", "Classes": "None", "Text": "     ", "ParentId": "34c8ab83-a064-4221-ae2d-b5f0845e8097"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>", "ID": "fc040caa-76b4-4233-ad30-510df7115df1", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "cf3c6ff6-043c-490b-8956-e0fc0441a3d3"}, {"Element": "<b><span lang=\"EN-GB\">United\n  Kingdom</span></b>", "ID": "42fe6720-e999-424e-b417-74abc063fd16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fc040caa-76b4-4233-ad30-510df7115df1"}, {"Element": "<span lang=\"EN-GB\">United\n  Kingdom</span>", "ID": "79b1e58c-5625-4948-a08c-1b0ff1baf6c2", "Styles": "None", "Classes": "None", "Text": "United   Kingdom", "ParentId": "42fe6720-e999-424e-b417-74abc063fd16"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span></p>", "ID": "1ef8670d-ed28-4344-bb27-9c3114abc3c9", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "cf3c6ff6-043c-490b-8956-e0fc0441a3d3"}, {"Element": "<span lang=\"EN-GB\">Bristol\u2011Myers Squibb\n  Pharmaceuticals Ltd</span>", "ID": "85a18e59-118f-4fc2-9626-586400427187", "Styles": "None", "Classes": "None", "Text": "Bristol\u2011Myers Squibb   Pharmaceuticals Ltd", "ParentId": "1ef8670d-ed28-4344-bb27-9c3114abc3c9"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span></p>", "ID": "ac82297d-d5ac-479a-9e1f-5ef796f4d891", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "cf3c6ff6-043c-490b-8956-e0fc0441a3d3"}, {"Element": "<span lang=\"EN-GB\">Tel: +\n  44 (0800) 731 1736</span>", "ID": "7692f242-b41c-4b4c-96c8-458ba4722bc6", "Styles": "None", "Classes": "None", "Text": "Tel: +   44 (0800) 731 1736", "ParentId": "ac82297d-d5ac-479a-9e1f-5ef796f4d891"}, {"Element": "<p class=\"EMEATableLeft\" style=\"page-break-after:auto\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35bcd90b-2eed-4f13-b614-771bd7c4babb", "Styles": "page-break-after:auto", "Classes": "['EMEATableLeft']", "Text": "", "ParentId": "cf3c6ff6-043c-490b-8956-e0fc0441a3d3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4811df5-b9e4-4f4a-81b6-d98e4d6ae684", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35bcd90b-2eed-4f13-b614-771bd7c4babb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac301adf-e09c-4836-b408-1cf40dfd2c50", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "357c5a5f-f7ec-459f-a47d-2813f2d42faf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac301adf-e09c-4836-b408-1cf40dfd2c50"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in</span></b></p>", "ID": "832b929c-f397-42de-96db-9e55eb05293a", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">This leaflet was last revised in</span></b>", "ID": "b0e1126d-6afe-4a40-aa58-43902530af9d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "832b929c-f397-42de-96db-9e55eb05293a"}, {"Element": "<span lang=\"EN-GB\">This leaflet was last revised in</span>", "ID": "3a54a76b-48cf-4124-8280-91fd70c82cea", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in", "ParentId": "b0e1126d-6afe-4a40-aa58-43902530af9d"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56470bc9-dc87-4644-8196-bd184f2284f1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3b7fbc3-c1a1-476a-8614-5501684503f9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56470bc9-dc87-4644-8196-bd184f2284f1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\navailable on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>", "ID": "13a198cb-8ba5-410a-9c5c-588a01275a34", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Detailed information on this medicine is\navailable on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span>", "ID": "11123435-1287-4104-b0b0-0d7ef0bab398", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site: ", "ParentId": "13a198cb-8ba5-410a-9c5c-588a01275a34"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "f2df4e74-9841-4686-b35a-9b365b5a07a5", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "11123435-1287-4104-b0b0-0d7ef0bab398"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b771f31-efb4-46f0-ae6c-74d51dc8d5fd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f55be89-e12d-4ebf-82db-ff966a33aedd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b771f31-efb4-46f0-ae6c-74d51dc8d5fd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">-------------------------------------------------------------------------------------------------------------------------</span></p>", "ID": "566ac42e-4c74-43ee-a811-fea863429568", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">-------------------------------------------------------------------------------------------------------------------------</span>", "ID": "601f2b2f-2c09-4875-862d-c5d4e9541df6", "Styles": "None", "Classes": "None", "Text": "-------------------------------------------------------------------------------------------------------------------------", "ParentId": "566ac42e-4c74-43ee-a811-fea863429568"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f20290a-2397-4c8b-9ac9-74bce9ccf88b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1825b311-29bb-47d9-810d-679ce4c6550a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f20290a-2397-4c8b-9ac9-74bce9ccf88b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">The\nfollowing information is intended for healthcare professionals only:</span></b></p>", "ID": "c7b20471-e11d-4e6b-98c6-6abb8397cd93", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">The\nfollowing information is intended for healthcare professionals only:</span></b>", "ID": "99e0752a-fecb-4da5-a8f4-de13d94133fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7b20471-e11d-4e6b-98c6-6abb8397cd93"}, {"Element": "<span lang=\"EN-GB\">The\nfollowing information is intended for healthcare professionals only:</span>", "ID": "647da477-f8e5-4d93-8ad0-42680aa587e8", "Styles": "None", "Classes": "None", "Text": "The following information is intended for healthcare professionals only:", "ParentId": "99e0752a-fecb-4da5-a8f4-de13d94133fc"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "600bba97-fa2c-4ab8-bc63-9e455913de5b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "902e0252-d59d-4341-9e11-5f28fe12f8d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "600bba97-fa2c-4ab8-bc63-9e455913de5b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Preparation\nand administration of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></u></b></p>", "ID": "c850d3db-a2dc-4665-812f-c797ef7a48e7", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><u><span lang=\"EN-GB\">Preparation\nand administration of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></u></b>", "ID": "aeeca6ed-6673-40d2-9dff-a9d3dae03504", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c850d3db-a2dc-4665-812f-c797ef7a48e7"}, {"Element": "<u><span lang=\"EN-GB\">Preparation\nand administration of </span><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span></u>", "ID": "4a0d8b34-b6f0-4561-a3d4-8d96d45e2424", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aeeca6ed-6673-40d2-9dff-a9d3dae03504"}, {"Element": "<span lang=\"EN-GB\">Preparation\nand administration of </span>", "ID": "f6f2c662-5eef-4688-9830-75f3fb2dc5bb", "Styles": "None", "Classes": "None", "Text": "Preparation and administration of ", "ParentId": "4a0d8b34-b6f0-4561-a3d4-8d96d45e2424"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "1fedc59a-f384-4163-b3e9-a4f243576292", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "4a0d8b34-b6f0-4561-a3d4-8d96d45e2424"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60cfd9e3-6aba-431a-a061-13a0509554fb", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4cd6ae23-9cb2-418b-978f-799b855fff6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60cfd9e3-6aba-431a-a061-13a0509554fb"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span></p>", "ID": "00250888-95c7-4050-a1b1-307374cc7e9f", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Preparation should be performed by\ntrained personnel in accordance with good practices rules, especially with\nrespect to asepsis.</span>", "ID": "381fc382-377c-4387-a9a8-00b2d6b14ec9", "Styles": "None", "Classes": "None", "Text": "Preparation should be performed by trained personnel in accordance with good practices rules, especially with respect to asepsis.", "ParentId": "00250888-95c7-4050-a1b1-307374cc7e9f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6233dba-26b4-4aad-9675-23d5dc25fde5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ae48ffa-57ab-4592-9a62-80ebfe51e2fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6233dba-26b4-4aad-9675-23d5dc25fde5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Calculating\nthe dose</span></b></p>", "ID": "3e5745f4-7e74-4c69-93de-8aae13ebd1b6", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Calculating\nthe dose</span></b>", "ID": "d738c499-7363-47af-aece-a851e46124bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e5745f4-7e74-4c69-93de-8aae13ebd1b6"}, {"Element": "<span lang=\"EN-GB\">Calculating\nthe dose</span>", "ID": "d66b44c9-ae34-4375-9457-21a2027dce4e", "Styles": "None", "Classes": "None", "Text": "Calculating the dose", "ParentId": "d738c499-7363-47af-aece-a851e46124bf"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The <b>prescribed dose</b> for the\npatient is given in mg/kg. Based on this prescribed dose, calculate the total\ndose to be given. More than one vial of Nivolumab\u00a0BMS concentrate may be\nneeded to give the total dose for the patient.</span></p>", "ID": "6038c558-6be6-46ac-bdde-618fc31b7d97", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">The <b>prescribed dose</b> for the\npatient is given in mg/kg. Based on this prescribed dose, calculate the total\ndose to be given. More than one vial of Nivolumab\u00a0BMS concentrate may be\nneeded to give the total dose for the patient.</span>", "ID": "5eb754db-92af-4ca1-a445-c5a73db34661", "Styles": "None", "Classes": "None", "Text": "The  for the patient is given in mg/kg. Based on this prescribed dose, calculate the total dose to be given. More than one vial of Nivolumab\u00a0BMS concentrate may be needed to give the total dose for the patient.", "ParentId": "6038c558-6be6-46ac-bdde-618fc31b7d97"}, {"Element": "<b>prescribed dose</b>", "ID": "0e3a1c72-0166-4041-9560-03af47b47a47", "Styles": "None", "Classes": "None", "Text": "prescribed dose", "ParentId": "5eb754db-92af-4ca1-a445-c5a73db34661"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a1a2d753-1079-4ab2-b850-c8bfa34b632d", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5e68dff-bcba-4882-9ed5-c1730d030fca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1a2d753-1079-4ab2-b850-c8bfa34b632d"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The <b>total nivolumab dose</b> in\nmg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span></p>", "ID": "5cd65a5c-63e4-4a59-a125-84102ad21774", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "957ce21d-c7cf-4229-93d7-60e2221e90aa", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "5cd65a5c-63e4-4a59-a125-84102ad21774"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "474259aa-9dea-4128-b916-7511465a44ab", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "957ce21d-c7cf-4229-93d7-60e2221e90aa"}, {"Element": "<span lang=\"EN-GB\">The <b>total nivolumab dose</b> in\nmg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the\nprescribed dose in mg/kg. </span>", "ID": "299c3287-fd23-4184-a31c-8e9867fd5ae7", "Styles": "None", "Classes": "None", "Text": "The  in mg\u00a0=\u00a0the patient\u2019s weight in kg\u00a0\u00d7\u00a0the prescribed dose in mg/kg. ", "ParentId": "5cd65a5c-63e4-4a59-a125-84102ad21774"}, {"Element": "<b>total nivolumab dose</b>", "ID": "30cdae6d-4933-44ad-b8d7-3c4c93d3f810", "Styles": "None", "Classes": "None", "Text": "total nivolumab dose", "ParentId": "299c3287-fd23-4184-a31c-8e9867fd5ae7"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The <b>volume of Nivolumab\u00a0BMS concentrate</b>\nto prepare the dose (mL)\u00a0=\u00a0the total dose in mg, divided by\u00a010\n(the Nivolumab\u00a0BMS concentrate strength is\u00a010\u00a0mg/mL). </span></p>", "ID": "81724de2-20c2-429c-85f0-74616bc1f8d9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "9d3a0a5c-6bd3-483d-ae6a-c42e3d40145c", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "81724de2-20c2-429c-85f0-74616bc1f8d9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "81d3726e-313c-4801-b802-36b61c343dee", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "9d3a0a5c-6bd3-483d-ae6a-c42e3d40145c"}, {"Element": "<span lang=\"EN-GB\">The <b>volume of Nivolumab\u00a0BMS concentrate</b>\nto prepare the dose (mL)\u00a0=\u00a0the total dose in mg, divided by\u00a010\n(the Nivolumab\u00a0BMS concentrate strength is\u00a010\u00a0mg/mL). </span>", "ID": "de75b39e-631e-430e-8d33-c203392289df", "Styles": "None", "Classes": "None", "Text": "The  to prepare the dose (mL)\u00a0=\u00a0the total dose in mg, divided by\u00a010 (the Nivolumab\u00a0BMS concentrate strength is\u00a010\u00a0mg/mL). ", "ParentId": "81724de2-20c2-429c-85f0-74616bc1f8d9"}, {"Element": "<b>volume of Nivolumab\u00a0BMS concentrate</b>", "ID": "b45669ec-4045-4bc9-bae8-01d04193dcd4", "Styles": "None", "Classes": "None", "Text": "volume of Nivolumab\u00a0BMS concentrate", "ParentId": "de75b39e-631e-430e-8d33-c203392289df"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33eb04ae-23e1-421d-8738-57b4bbbe7e03", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9cd6793-84a2-41e5-9950-85d6c64d97b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33eb04ae-23e1-421d-8738-57b4bbbe7e03"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Preparing\nthe infusion</span></b></p>", "ID": "08fdd988-37d2-40db-9fff-155002c5c2dc", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Preparing\nthe infusion</span></b>", "ID": "e5471e01-6ff6-479c-890e-5e393feafc94", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08fdd988-37d2-40db-9fff-155002c5c2dc"}, {"Element": "<span lang=\"EN-GB\">Preparing\nthe infusion</span>", "ID": "9f9b21fa-68f9-40db-bafd-ba3ede141b52", "Styles": "None", "Classes": "None", "Text": "Preparing the infusion", "ParentId": "e5471e01-6ff6-479c-890e-5e393feafc94"}, {"Element": "<p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Take care to ensure aseptic handling</span></b><span lang=\"EN-GB\"> when you prepare the infusion. The infusion should be prepared in a\nlaminar flow hood or safety cabinet using standard precautions for the safe\nhandling of intravenous agents.</span></p>", "ID": "7131804d-f17d-43d7-854b-b7c6ce89e18c", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Take care to ensure aseptic handling</span></b>", "ID": "242a0c58-ab17-48e4-8618-ffe3bebf3c47", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7131804d-f17d-43d7-854b-b7c6ce89e18c"}, {"Element": "<span lang=\"EN-GB\">Take care to ensure aseptic handling</span>", "ID": "4e419f2e-811a-46ae-943f-91bbabd62d53", "Styles": "None", "Classes": "None", "Text": "Take care to ensure aseptic handling", "ParentId": "242a0c58-ab17-48e4-8618-ffe3bebf3c47"}, {"Element": "<span lang=\"EN-GB\"> when you prepare the infusion. The infusion should be prepared in a\nlaminar flow hood or safety cabinet using standard precautions for the safe\nhandling of intravenous agents.</span>", "ID": "78999c3a-a8ed-49ba-ae25-3c0a77d26757", "Styles": "None", "Classes": "None", "Text": " when you prepare the infusion. The infusion should be prepared in a laminar flow hood or safety cabinet using standard precautions for the safe handling of intravenous agents.", "ParentId": "7131804d-f17d-43d7-854b-b7c6ce89e18c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c71a74db-8bf3-40fc-bc55-86008d89a747", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7d80e7d0-57d5-4590-ace9-f48e87e2d359", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c71a74db-8bf3-40fc-bc55-86008d89a747"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> can be used for intravenous administration either:</span></p>", "ID": "35762289-20a9-47ac-b88e-96daddc4d942", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "943a14dd-b530-467f-81a5-e221c848e739", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "35762289-20a9-47ac-b88e-96daddc4d942"}, {"Element": "<span lang=\"EN-GB\"> can be used for intravenous administration either:</span>", "ID": "c508a0ba-c80b-4814-8083-eb0228771151", "Styles": "None", "Classes": "None", "Text": " can be used for intravenous administration either:", "ParentId": "35762289-20a9-47ac-b88e-96daddc4d942"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">without dilution,</span></b><span lang=\"EN-GB\">\nafter transfer to an infusion container using an appropriate sterile syringe;</span></p>", "ID": "12e41757-03dc-4e28-beac-2f9a4a0d7208", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "2c9bc905-e9d2-41ad-9ffc-be973f6a7dc4", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "12e41757-03dc-4e28-beac-2f9a4a0d7208"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "4ae2b50b-2b14-4b28-ac82-2af3606032c1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "2c9bc905-e9d2-41ad-9ffc-be973f6a7dc4"}, {"Element": "<b><span lang=\"EN-GB\">without dilution,</span></b>", "ID": "0d57feb1-0fc7-4951-9bcd-51446a38311f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "12e41757-03dc-4e28-beac-2f9a4a0d7208"}, {"Element": "<span lang=\"EN-GB\">without dilution,</span>", "ID": "03a07c1a-789c-4257-b91b-083ffe8f3a6b", "Styles": "None", "Classes": "None", "Text": "without dilution,", "ParentId": "0d57feb1-0fc7-4951-9bcd-51446a38311f"}, {"Element": "<span lang=\"EN-GB\">\nafter transfer to an infusion container using an appropriate sterile syringe;</span>", "ID": "a0a72cbc-a292-4483-a87c-95307fdeabeb", "Styles": "None", "Classes": "None", "Text": " after transfer to an infusion container using an appropriate sterile syringe;", "ParentId": "12e41757-03dc-4e28-beac-2f9a4a0d7208"}, {"Element": "<p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">or</span></p>", "ID": "82373024-e16d-46d5-92e0-a767a9015e6b", "Styles": "margin-left:28.35pt", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">or</span>", "ID": "18bdb90c-e887-4473-a76d-1374bd97aa80", "Styles": "None", "Classes": "None", "Text": "or", "ParentId": "82373024-e16d-46d5-92e0-a767a9015e6b"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">after diluting</span></b><span lang=\"EN-GB\"> to\nconcentrations as low as\u00a01\u00a0mg/mL. The final infusion concentration\nshould range between\u00a01\u00a0and\u00a010\u00a0mg/mL. Nivolumab\u00a0BMS\nconcentrate may be diluted with either: </span></p>", "ID": "9da8d915-9157-4206-aebf-726c35e0be46", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "0c5e3947-a700-471e-88dd-2dc9dbc0a315", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "9da8d915-9157-4206-aebf-726c35e0be46"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "b16acfe1-bb28-4882-87ca-24017deefd2e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "0c5e3947-a700-471e-88dd-2dc9dbc0a315"}, {"Element": "<b><span lang=\"EN-GB\">after diluting</span></b>", "ID": "6a04bb3a-56a5-4506-99fd-c268579b21a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9da8d915-9157-4206-aebf-726c35e0be46"}, {"Element": "<span lang=\"EN-GB\">after diluting</span>", "ID": "bbd54332-999f-4f2e-8919-d385677d63eb", "Styles": "None", "Classes": "None", "Text": "after diluting", "ParentId": "6a04bb3a-56a5-4506-99fd-c268579b21a8"}, {"Element": "<span lang=\"EN-GB\"> to\nconcentrations as low as\u00a01\u00a0mg/mL. The final infusion concentration\nshould range between\u00a01\u00a0and\u00a010\u00a0mg/mL. Nivolumab\u00a0BMS\nconcentrate may be diluted with either: </span>", "ID": "9570b4e6-aa88-4558-a9ec-7d7dd1e4ac10", "Styles": "None", "Classes": "None", "Text": " to concentrations as low as\u00a01\u00a0mg/mL. The final infusion concentration should range between\u00a01\u00a0and\u00a010\u00a0mg/mL. Nivolumab\u00a0BMS concentrate may be diluted with either: ", "ParentId": "9da8d915-9157-4206-aebf-726c35e0be46"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:85.05pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection; or</span></p>", "ID": "3842c8ac-e524-4376-a67a-29022bb0cdab", "Styles": "margin-left:85.05pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "68094141-4c77-4395-bc0a-b65c286b2f4b", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "3842c8ac-e524-4376-a67a-29022bb0cdab"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "6ff699ad-2dda-4fee-a8d3-0559a306f1bf", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "68094141-4c77-4395-bc0a-b65c286b2f4b"}, {"Element": "<span lang=\"EN-GB\">sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection; or</span>", "ID": "15711121-adab-4ca5-9b81-098473a8c709", "Styles": "None", "Classes": "None", "Text": "sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection; or", "ParentId": "3842c8ac-e524-4376-a67a-29022bb0cdab"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:85.05pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">50\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection. </span></p>", "ID": "450a55d6-3b1b-4387-8314-2c2e9186ae1f", "Styles": "margin-left:85.05pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "233d0afd-9079-4826-8175-587ef28a9ac6", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "450a55d6-3b1b-4387-8314-2c2e9186ae1f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "e27c7b58-d244-4110-8652-a34700a80dcd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "233d0afd-9079-4826-8175-587ef28a9ac6"}, {"Element": "<span lang=\"EN-GB\">50\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection. </span>", "ID": "569ac590-0970-4d45-9a30-f01880786e52", "Styles": "None", "Classes": "None", "Text": "50\u00a0mg/mL\u00a0(5%) glucose solution for injection. ", "ParentId": "450a55d6-3b1b-4387-8314-2c2e9186ae1f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "239d547a-4cf4-4c0b-a581-1145376346c5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "441ea659-6da2-4c88-9c89-065015663c47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "239d547a-4cf4-4c0b-a581-1145376346c5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">STEP 1</span></b></p>", "ID": "87a6320e-c4d6-4d7e-bdf3-ce3a7868b936", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">STEP 1</span></b>", "ID": "5ef8813d-0d22-486f-8af2-0e5267651644", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87a6320e-c4d6-4d7e-bdf3-ce3a7868b936"}, {"Element": "<span lang=\"EN-GB\">STEP 1</span>", "ID": "8eab2499-d934-4311-b2ab-51f75ffc9473", "Styles": "None", "Classes": "None", "Text": "STEP 1", "ParentId": "5ef8813d-0d22-486f-8af2-0e5267651644"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inspect the Nivolumab\u00a0BMS concentrate for\nparticulate matter or discoloration. Do not shake the vial. Nivolumab\u00a0BMS\nconcentrate is a clear to opalescent, colourless to pale yellow liquid that may\ncontain few light particles. </span></p>", "ID": "b253a4ac-2886-41a3-b15f-eefc974ac63b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "6012f682-eaba-4ba3-b97b-c3de4a2ee434", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "b253a4ac-2886-41a3-b15f-eefc974ac63b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "7f2cc7c4-a6af-484d-af8d-9b7ee395b963", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "6012f682-eaba-4ba3-b97b-c3de4a2ee434"}, {"Element": "<span lang=\"EN-GB\">Inspect the Nivolumab\u00a0BMS concentrate for\nparticulate matter or discoloration. Do not shake the vial. Nivolumab\u00a0BMS\nconcentrate is a clear to opalescent, colourless to pale yellow liquid that may\ncontain few light particles. </span>", "ID": "279d97cb-8c55-493f-940c-0d9a68e074a3", "Styles": "None", "Classes": "None", "Text": "Inspect the Nivolumab\u00a0BMS concentrate for particulate matter or discoloration. Do not shake the vial. Nivolumab\u00a0BMS concentrate is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles. ", "ParentId": "b253a4ac-2886-41a3-b15f-eefc974ac63b"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Withdraw the required volume of Nivolumab\u00a0BMS\nconcentrate using an appropriate sterile syringe. </span></p>", "ID": "e3f3ebe1-aedf-4815-a55b-9a79c2800090", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "7f668148-1d03-4302-9ae7-3d0350136f16", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "e3f3ebe1-aedf-4815-a55b-9a79c2800090"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "42235ddc-2ce7-42ad-b318-9c8660a6920c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "7f668148-1d03-4302-9ae7-3d0350136f16"}, {"Element": "<span lang=\"EN-GB\">Withdraw the required volume of Nivolumab\u00a0BMS\nconcentrate using an appropriate sterile syringe. </span>", "ID": "3fcc27bd-a3ad-4f41-8abc-49e132731efa", "Styles": "None", "Classes": "None", "Text": "Withdraw the required volume of Nivolumab\u00a0BMS concentrate using an appropriate sterile syringe. ", "ParentId": "e3f3ebe1-aedf-4815-a55b-9a79c2800090"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de48c6c2-5245-4edf-98c2-7902f4453106", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "92182635-b794-47ce-a396-b109be85ffe5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de48c6c2-5245-4edf-98c2-7902f4453106"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">STEP 2</span></b></p>", "ID": "83267edf-7e82-412c-bee9-ddce5b680097", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">STEP 2</span></b>", "ID": "c687cbcb-a20b-4bcb-bdd2-47ef0e02cb9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83267edf-7e82-412c-bee9-ddce5b680097"}, {"Element": "<span lang=\"EN-GB\">STEP 2</span>", "ID": "13bad13e-c8b2-4dff-8583-4b83f160e885", "Styles": "None", "Classes": "None", "Text": "STEP 2", "ParentId": "c687cbcb-a20b-4bcb-bdd2-47ef0e02cb9e"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Transfer the concentrate into a sterile,\nevacuated glass bottle or intravenous container (PVC or polyolefin). </span></p>", "ID": "5aad31fe-ad19-424b-a4c3-90154f6601c9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "9d79445c-cc3f-48d3-80b9-996e1cf73832", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "5aad31fe-ad19-424b-a4c3-90154f6601c9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "3c6c5bba-8e6b-4b45-a69e-8271ee7df4c0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "9d79445c-cc3f-48d3-80b9-996e1cf73832"}, {"Element": "<span lang=\"EN-GB\">Transfer the concentrate into a sterile,\nevacuated glass bottle or intravenous container (PVC or polyolefin). </span>", "ID": "66cb06cb-296a-4246-8728-69a532ded119", "Styles": "None", "Classes": "None", "Text": "Transfer the concentrate into a sterile, evacuated glass bottle or intravenous container (PVC or polyolefin). ", "ParentId": "5aad31fe-ad19-424b-a4c3-90154f6601c9"}, {"Element": "<p class=\"EMEABodyTextIndent\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If applicable, dilute with the required volume\nof sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection\nor\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for injection. Gently mix the\ninfusion by manual rotation. Do not shake.</span></p>", "ID": "c02fbf9b-3da5-48f6-8818-a5f94a1ced57", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span></span>", "ID": "81dfe416-6cf0-4125-b972-37bdabafc882", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "c02fbf9b-3da5-48f6-8818-a5f94a1ced57"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\n</span>", "ID": "9b9f5b3c-990e-4219-ab76-3db2364ea5df", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "81dfe416-6cf0-4125-b972-37bdabafc882"}, {"Element": "<span lang=\"EN-GB\">If applicable, dilute with the required volume\nof sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection\nor\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for injection. Gently mix the\ninfusion by manual rotation. Do not shake.</span>", "ID": "0cd215af-cadb-4f90-8966-fff297987b64", "Styles": "None", "Classes": "None", "Text": "If applicable, dilute with the required volume of sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection or\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for injection. Gently mix the infusion by manual rotation. Do not shake.", "ParentId": "c02fbf9b-3da5-48f6-8818-a5f94a1ced57"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7a237991-0d68-4382-a7b1-ee1dfd513e38", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e27928b1-220a-4367-96ec-67dace186b43", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a237991-0d68-4382-a7b1-ee1dfd513e38"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Administration</span></b></p>", "ID": "d57d07a3-837c-4563-b03b-b5eea519772b", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Administration</span></b>", "ID": "037880ec-e742-4bf9-a747-b9ad8cdafd07", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d57d07a3-837c-4563-b03b-b5eea519772b"}, {"Element": "<span lang=\"EN-GB\">Administration</span>", "ID": "3da0ce03-439e-443d-8847-14d4a19e7685", "Styles": "None", "Classes": "None", "Text": "Administration", "ParentId": "037880ec-e742-4bf9-a747-b9ad8cdafd07"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion must not be administered as an intravenous push or bolus\ninjection.</span></p>", "ID": "40b26fdf-2d27-435a-a019-5cf83b99536b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "d0cfb109-16f4-4270-9d1e-9cc419c11d3d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "40b26fdf-2d27-435a-a019-5cf83b99536b"}, {"Element": "<span lang=\"EN-GB\"> infusion must not be administered as an intravenous push or bolus\ninjection.</span>", "ID": "33a413a2-69fb-419b-aa14-6ebc58f7ad1a", "Styles": "None", "Classes": "None", "Text": " infusion must not be administered as an intravenous push or bolus injection.", "ParentId": "40b26fdf-2d27-435a-a019-5cf83b99536b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS\ninfusion <b>intravenously over a period of 60\u00a0minutes</b>.</span></p>", "ID": "bbf6809f-2c51-41e7-9212-eedda5a7cfd8", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Administer the Nivolumab\u00a0BMS\ninfusion <b>intravenously over a period of 60\u00a0minutes</b>.</span>", "ID": "6ea94011-bf43-42d2-901f-6960a8f72b4c", "Styles": "None", "Classes": "None", "Text": "Administer the Nivolumab\u00a0BMS infusion .", "ParentId": "bbf6809f-2c51-41e7-9212-eedda5a7cfd8"}, {"Element": "<b>intravenously over a period of 60\u00a0minutes</b>", "ID": "93ce53a2-6b62-4880-bf4a-7f6ed4cdff0a", "Styles": "None", "Classes": "None", "Text": "intravenously over a period of 60\u00a0minutes", "ParentId": "6ea94011-bf43-42d2-901f-6960a8f72b4c"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f1dda71-4d6d-4722-9638-f154f7205bf2", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a33f4c9-0a93-4722-9385-1a9c65d4416b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f1dda71-4d6d-4722-9638-f154f7205bf2"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span></p>", "ID": "f74d9c5c-4ba1-47b8-afb8-b80b1a965f06", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "a4d281f4-7870-435a-a3bf-b156d6724964", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "f74d9c5c-4ba1-47b8-afb8-b80b1a965f06"}, {"Element": "<span lang=\"EN-GB\"> infusion should not be infused at the same time in the same\nintravenous line with other agents. Use a separate infusion line for the\ninfusion.</span>", "ID": "dc390de0-7a30-4d1a-82e2-175846e299b5", "Styles": "None", "Classes": "None", "Text": " infusion should not be infused at the same time in the same intravenous line with other agents. Use a separate infusion line for the infusion.", "ParentId": "f74d9c5c-4ba1-47b8-afb8-b80b1a965f06"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d270a5e9-e169-41b4-bd70-3e4b62547054", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d60750bf-576c-4f03-ab08-89eb9b1efb21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d270a5e9-e169-41b4-bd70-3e4b62547054"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm\u00a0to\u00a01.2\u00a0\u03bcm).</span></p>", "ID": "637b9774-88ba-4449-a7da-20b3d91fc45b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Use an infusion set and an in\u2011line,\nsterile, non\u2011pyrogenic, low protein binding filter (pore size\nof\u00a00.2\u00a0\u03bcm\u00a0to\u00a01.2\u00a0\u03bcm).</span>", "ID": "4be80cb4-de0a-4783-9a0d-a6fce952f338", "Styles": "None", "Classes": "None", "Text": "Use an infusion set and an in\u2011line, sterile, non\u2011pyrogenic, low protein binding filter (pore size of\u00a00.2\u00a0\u03bcm\u00a0to\u00a01.2\u00a0\u03bcm).", "ParentId": "637b9774-88ba-4449-a7da-20b3d91fc45b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "caf26b18-dd4c-4cf9-886e-8f2ba7caafa5", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b7a7952-63e2-4c28-8739-20c126bb3285", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "caf26b18-dd4c-4cf9-886e-8f2ba7caafa5"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion is compatible with:</span></p>", "ID": "f4fa17a5-0b8c-49f0-b0ee-e16c66de6e7e", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "66b83dd5-7428-4a37-9c81-baadf114d18a", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "f4fa17a5-0b8c-49f0-b0ee-e16c66de6e7e"}, {"Element": "<span lang=\"EN-GB\"> infusion is compatible with:</span>", "ID": "d7c7275a-9cd8-4ce3-97d1-d1aef1d8b5fd", "Styles": "None", "Classes": "None", "Text": " infusion is compatible with:", "ParentId": "f4fa17a5-0b8c-49f0-b0ee-e16c66de6e7e"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">PVC\ncontainers</span></p>", "ID": "bb142871-5a11-4429-9e72-ef007e1ebe93", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "b85a14d7-a921-42c2-aade-18a053f99d30", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "bb142871-5a11-4429-9e72-ef007e1ebe93"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "0168f7c3-3833-4e76-aeca-2ed08b9c949c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "b85a14d7-a921-42c2-aade-18a053f99d30"}, {"Element": "<span lang=\"EN-GB\">PVC\ncontainers</span>", "ID": "a853bd7c-9417-4f95-9bc3-fe9a0f76dc5a", "Styles": "None", "Classes": "None", "Text": "PVC containers", "ParentId": "bb142871-5a11-4429-9e72-ef007e1ebe93"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Polyolefin\ncontainers</span></p>", "ID": "696cdef8-ab77-44cb-911d-7d0329d41055", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "2c1dbf75-6c62-4242-96f1-f0b96e88e214", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "696cdef8-ab77-44cb-911d-7d0329d41055"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "d568a781-11ba-4388-af1f-c5e2aa4830c2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "2c1dbf75-6c62-4242-96f1-f0b96e88e214"}, {"Element": "<span lang=\"EN-GB\">Polyolefin\ncontainers</span>", "ID": "18532f1f-15b2-4903-b14d-2d339690526c", "Styles": "None", "Classes": "None", "Text": "Polyolefin containers", "ParentId": "696cdef8-ab77-44cb-911d-7d0329d41055"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">Glass\nbottles</span></p>", "ID": "d4b211f9-a00c-47c5-b427-9ed51bebebfe", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "804f6a48-e4e7-472e-bf68-0f553bb8c75d", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "d4b211f9-a00c-47c5-b427-9ed51bebebfe"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "642d1d76-23e8-48c8-b549-0f2dba306e38", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "804f6a48-e4e7-472e-bf68-0f553bb8c75d"}, {"Element": "<span lang=\"EN-GB\">Glass\nbottles</span>", "ID": "6e6158e5-1957-4f14-b2d6-e6563b5b7113", "Styles": "None", "Classes": "None", "Text": "Glass bottles", "ParentId": "d4b211f9-a00c-47c5-b427-9ed51bebebfe"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">PVC\ninfusion sets</span></p>", "ID": "f06c2b3f-14ad-4d4b-8280-4f42a47a2dd7", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "a6a8d117-02ea-4316-95e4-805c02e5c3a7", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "f06c2b3f-14ad-4d4b-8280-4f42a47a2dd7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "489d97cb-873c-4cbf-a80c-794fbaeb2b54", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "a6a8d117-02ea-4316-95e4-805c02e5c3a7"}, {"Element": "<span lang=\"EN-GB\">PVC\ninfusion sets</span>", "ID": "3dab046f-c4f3-4197-84f1-ef72881930c9", "Styles": "None", "Classes": "None", "Text": "PVC infusion sets", "ParentId": "f06c2b3f-14ad-4d4b-8280-4f42a47a2dd7"}, {"Element": "<p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span><span lang=\"EN-GB\">In\u2011line\nfilters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to\u00a01.2\u00a0\u00b5m.</span></p>", "ID": "49a3eac9-2e36-48f3-a068-b9b2682fe16f", "Styles": "None", "Classes": "['EMEABodyTextIndent']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span></span>", "ID": "f2674f6c-87dc-4b43-ad9c-5399f28763e5", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00a7", "ParentId": "49a3eac9-2e36-48f3-a068-b9b2682fe16f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0 </span>", "ID": "6434aea4-2ca1-412c-b814-30974141ddcb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0 ", "ParentId": "f2674f6c-87dc-4b43-ad9c-5399f28763e5"}, {"Element": "<span lang=\"EN-GB\">In\u2011line\nfilters with polyethersulfone membranes with pore sizes\nof\u00a00.2\u00a0\u00b5m to\u00a01.2\u00a0\u00b5m.</span>", "ID": "c8a0bcff-58ee-4f57-b80b-1d39e7390ee6", "Styles": "None", "Classes": "None", "Text": "In\u2011line filters with polyethersulfone membranes with pore sizes of\u00a00.2\u00a0\u00b5m to\u00a01.2\u00a0\u00b5m.", "ParentId": "49a3eac9-2e36-48f3-a068-b9b2682fe16f"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "62024898-df36-4fdf-aed2-0fa733f2288b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93096fde-ab20-4501-b991-19d1bf25a9eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "62024898-df36-4fdf-aed2-0fa733f2288b"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">After administration of the nivolumab\ndose, flush the line with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection or\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection.</span></p>", "ID": "0256dbf1-da3e-4b01-a596-bcdbf55963cd", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">After administration of the nivolumab\ndose, flush the line with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%)\nsolution for injection or\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for\ninjection.</span>", "ID": "4ce1109f-892c-4e7b-90c7-69a32a60e9d2", "Styles": "None", "Classes": "None", "Text": "After administration of the nivolumab dose, flush the line with sodium chloride\u00a09\u00a0mg/mL\u00a0(0.9%) solution for injection or\u00a050\u00a0mg/mL\u00a0(5%) glucose solution for injection.", "ParentId": "0256dbf1-da3e-4b01-a596-bcdbf55963cd"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32b46599-f344-4784-ac33-0c52b2af1371", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c6750363-0d4e-406a-a62c-7b87c996edc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32b46599-f344-4784-ac33-0c52b2af1371"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Storage\nconditions and shelf life</span></b></p>", "ID": "773757bc-8072-4cb2-93e9-48e271e88ce9", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Storage\nconditions and shelf life</span></b>", "ID": "38aed218-f1f8-47d3-92b2-e82d8622a796", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "773757bc-8072-4cb2-93e9-48e271e88ce9"}, {"Element": "<span lang=\"EN-GB\">Storage\nconditions and shelf life</span>", "ID": "63c23d50-5ce5-4ad7-993e-faee9caae033", "Styles": "None", "Classes": "None", "Text": "Storage conditions and shelf life", "ParentId": "38aed218-f1f8-47d3-92b2-e82d8622a796"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened\nvial</span></u></p>", "ID": "a69776d6-a9c9-4c84-a5b6-ba1a98a489fd", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Unopened\nvial</span></u>", "ID": "35f06448-3679-4702-a3f6-4e827245ce0e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a69776d6-a9c9-4c84-a5b6-ba1a98a489fd"}, {"Element": "<span lang=\"EN-GB\">Unopened\nvial</span>", "ID": "90fc01eb-a862-4558-af6d-f135f46ac9ac", "Styles": "None", "Classes": "None", "Text": "Unopened vial", "ParentId": "35f06448-3679-4702-a3f6-4e827245ce0e"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> must be <b>stored in a refrigerator</b>\n(2\u00b0C\u00a0to\u00a08\u00b0C). The vials must be kept in the original package\nin order to protect from light. Nivolumab\u00a0BMS should not be frozen.</span></p>", "ID": "44ed70ae-f199-463c-9c2c-f960a159a391", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "2ae0992a-b332-463d-8f76-998327c79b0d", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "44ed70ae-f199-463c-9c2c-f960a159a391"}, {"Element": "<span lang=\"EN-GB\"> must be <b>stored in a refrigerator</b>\n(2\u00b0C\u00a0to\u00a08\u00b0C). The vials must be kept in the original package\nin order to protect from light. Nivolumab\u00a0BMS should not be frozen.</span>", "ID": "06641945-0a5f-4d59-9c61-502473c09128", "Styles": "None", "Classes": "None", "Text": " must be  (2\u00b0C\u00a0to\u00a08\u00b0C). The vials must be kept in the original package in order to protect from light. Nivolumab\u00a0BMS should not be frozen.", "ParentId": "44ed70ae-f199-463c-9c2c-f960a159a391"}, {"Element": "<b>stored in a refrigerator</b>", "ID": "f4984aa1-1209-4e12-a63e-70bac40d45a4", "Styles": "None", "Classes": "None", "Text": "stored in a refrigerator", "ParentId": "06641945-0a5f-4d59-9c61-502473c09128"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "287155bf-9812-4bce-a122-094e1bdcb4a1", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ce5e2e0-9549-4b2a-a7ac-88950cbdba2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "287155bf-9812-4bce-a122-094e1bdcb4a1"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS after the\nexpiry date which is stated on the carton and on the vial label after EXP. The\nexpiry date refers to the last day of that month.</span></p>", "ID": "7c3d0fb8-d4d6-483a-990b-f9b6b2333fef", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not use Nivolumab\u00a0BMS after the\nexpiry date which is stated on the carton and on the vial label after EXP. The\nexpiry date refers to the last day of that month.</span>", "ID": "a7e4e98b-999b-4163-af03-13f534d8f1ee", "Styles": "None", "Classes": "None", "Text": "Do not use Nivolumab\u00a0BMS after the expiry date which is stated on the carton and on the vial label after EXP. The expiry date refers to the last day of that month.", "ParentId": "7c3d0fb8-d4d6-483a-990b-f9b6b2333fef"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dc1c9d1-925c-4b9f-b9bd-65070a9e335b", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9389ef3d-c3f4-43b7-b55f-b526b50110cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dc1c9d1-925c-4b9f-b9bd-65070a9e335b"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nivolumab\u00a0BMS\ninfusion</span></u></p>", "ID": "f01f4e61-4daa-4f55-9b29-08f2d59920d3", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<u><span lang=\"EN-GB\">Nivolumab\u00a0BMS\ninfusion</span></u>", "ID": "b846ccfa-9361-4b17-879b-c58d02062f96", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f01f4e61-4daa-4f55-9b29-08f2d59920d3"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS\ninfusion</span>", "ID": "e153ea55-b483-4168-9319-532eb6c11ebb", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS infusion", "ParentId": "b846ccfa-9361-4b17-879b-c58d02062f96"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Nivolumab\u00a0BMS</span><span lang=\"EN-GB\"> infusion must be completed within\u00a024\u00a0hours of\npreparation. If not used immediately, the solution may be stored under\nrefrigeration conditions (2\u00b0C\u20118\u00b0C) and protected from light for\nup to\u00a024\u00a0hours [a maximum of\u00a04\u00a0hours of the\ntotal\u00a024\u00a0hours can be at room temperature (20\u00b0C\u201125\u00b0C)\nand room light]. Other in\u2011use storage time and conditions are the\nresponsibility of the user.</span></p>", "ID": "594d8528-2709-46e9-b51a-7645f872c657", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Nivolumab\u00a0BMS</span>", "ID": "62b52172-578c-4d6d-8414-94a1796a0f04", "Styles": "None", "Classes": "None", "Text": "Nivolumab\u00a0BMS", "ParentId": "594d8528-2709-46e9-b51a-7645f872c657"}, {"Element": "<span lang=\"EN-GB\"> infusion must be completed within\u00a024\u00a0hours of\npreparation. If not used immediately, the solution may be stored under\nrefrigeration conditions (2\u00b0C\u20118\u00b0C) and protected from light for\nup to\u00a024\u00a0hours [a maximum of\u00a04\u00a0hours of the\ntotal\u00a024\u00a0hours can be at room temperature (20\u00b0C\u201125\u00b0C)\nand room light]. Other in\u2011use storage time and conditions are the\nresponsibility of the user.</span>", "ID": "7d332529-5b08-465d-84df-33bdc7e88902", "Styles": "None", "Classes": "None", "Text": " infusion must be completed within\u00a024\u00a0hours of preparation. If not used immediately, the solution may be stored under refrigeration conditions (2\u00b0C\u20118\u00b0C) and protected from light for up to\u00a024\u00a0hours [a maximum of\u00a04\u00a0hours of the total\u00a024\u00a0hours can be at room temperature (20\u00b0C\u201125\u00b0C) and room light]. Other in\u2011use storage time and conditions are the responsibility of the user.", "ParentId": "594d8528-2709-46e9-b51a-7645f872c657"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d47e22b3-f38c-466e-b434-f6fbe0f16dc6", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a23a5b6-7495-4190-b4d3-bd693279f3b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d47e22b3-f38c-466e-b434-f6fbe0f16dc6"}, {"Element": "<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disposal</span></b></p>", "ID": "16e036a2-e138-46ff-8236-c97cc766fe28", "Styles": "page-break-after:avoid", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<b><span lang=\"EN-GB\">Disposal</span></b>", "ID": "813daffc-a4bc-4862-9d03-a720f1c5717a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16e036a2-e138-46ff-8236-c97cc766fe28"}, {"Element": "<span lang=\"EN-GB\">Disposal</span>", "ID": "f491a579-b830-45dc-b9f2-38104d81386b", "Styles": "None", "Classes": "None", "Text": "Disposal", "ParentId": "813daffc-a4bc-4862-9d03-a720f1c5717a"}, {"Element": "<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span></p>", "ID": "e20f5b4a-ebee-4b0b-8bbc-d1730426ba49", "Styles": "None", "Classes": "['EMEABodyText']", "Text": "", "ParentId": "a320bbc2-23bc-44fe-8c66-044859926d59"}, {"Element": "<span lang=\"EN-GB\">Do not store any unused portion of the\ninfusion solution for reuse. Any unused medicine or waste material should be\ndisposed of in accordance with local requirements.</span>", "ID": "eb4515b2-1c4c-4257-bf04-337a9eb7a2d4", "Styles": "None", "Classes": "None", "Text": "Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.", "ParentId": "e20f5b4a-ebee-4b0b-8bbc-d1730426ba49"}]}